



Effective Health Care Program

Comparative Effectiveness Review
Number 125

Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment Appendixes



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Comparative Effectiveness Review

Number 125

Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2007-10055-I

Prepared by:

Tufts Evidence-based Practice Center
Boston, MA

Investigators:

Issa J. Dahabreh, M.D., M.S.
Denish Moorthy, M.B.B.S., M.S.
Jenny L. Lamont, M.S.
Minghua L. Chen, M.D., M.P.H.
David M. Kent, M.D., M.S.
Joseph Lau, M.D.

**AHRQ Publication No. 13-EHC117-EF
September 2013**

This report is based on research conducted by the Tufts Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10055-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EffectiveHealthCare@ahrq.hhs.gov.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation: Dahabreh IJ, Moorthy D, Lamont JL, Chen ML, Kent DM, Lau J. Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment. Comparative Effectiveness Review No. 125. (Prepared by Tufts Evidence-based Practice Center under Contract No. 290-2007-10055-I.) AHRQ Publication No. 13-EHC117-EF. Rockville, MD: Agency for Healthcare Research and Quality; September 2013. www.effectivehealthcare.ahrq.gov/reports/final/cfm.

Appendix A. Search Strategy

Search run on June 27, 2012:

Ovid MEDLINE(R) 1946 to June Week 2 2012, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations June 26, 2012, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to June 2012, EBM Reviews - Cochrane Central Register of Controlled Trials June 2012, Ovid MEDLINE(R) Daily Update June 26, 2012, Ovid OLDMEDLINE(R) 1946 to 1965

#		
1	((acute and coronary and syndrome\$) or ACS or myocardial infarction or ST elevation or non-ST elevation or percutaneous coronary intervention or (percutaneous and coronary and intervention) or PCI or stent\$ or implant\$ or CABG or (coronary and artery and bypass and graft\$) or coronary artery bypass graft\$ or stroke or TIA or (transient and isch?emic and attack) or (peripheral and arter\$ and disease\$) or (atrial and fibrillation) or (coronary and artery and disease) or (unstable and angina) or (angina and (ischemic or pectoris)) or ((cardiac or heart) and catheterization) or respond\$ or non-respon\$).af. or exp acute coronary syndrome/ or exp myocardial infarction/ or exp peripheral arterial disease/ or exp stent/ or exp atrial fibrillation/ or exp coronary artery bypass graft/ or exp stroke/ or exp transient ischemic attack/ or exp coronary artery disease/ or exp unstable angina/ or exp patient selection/ or exp coronary angiography/	1,348,184
2	(clopidogrel or plavix or prasugrel or effient or ticlopidine or ticlid or aggrenox or dipyridamole or ticagrelor or dipyridamole or persantine or (p2y12 and inhibitor) or antiplatelet\$ or anti-platelet\$ or "thienopyridine" or platelet inhibition).af. or (90055-48-4 or 55142-85-3 or 150322-43-3 or 58-32-2 or 274693-27-5).rn.	34,489
3	(cytochrome p450 or pharmacogenetics or cyp450 or cyp-450 or polymorph\$ or genetic\$ or cyp2c19 or 2c19 or genotype or p-450 or rs4244285 or rs28399504 or rs56337013 or rs12248560 or pharmacogenomics or allele\$ or varia\$ or ((platelet and activ\$) or (platelet and aggregation) or platelet reacti\$ or (platelet and function) or "thrombelastography" or "thromboelastography" or TEG or "pfa 100" or "pfa-100" or "pfa100" or ((optical or (light and transmission) or (light and transmittance) or (whole and blood) or impedance) and aggregometry) or (turbidimetric and optical and detection) or aggregometer or vasp or verifynow or p2y12 or ultegra or rpfa or (vasodilator and stimulated and phosphoprotein) or multiplate or "impact-R" or "Impact R")).af. or (exp cytochrome p450/ or exp Cytochrome P-450 Enzyme System/ OR Cytochrome P-450 CYP2c19/)	3,960,275
4	1 and 2 and 3	10,374

Appendix B. Excluded Studies

Studies are listed in alphabetical order by first author under each main reason for exclusion (bold headings): foreign language (not English), not population of interest (usually healthy volunteers, not patients), test not used for prognosis, prediction, or decisionmaking, insufficient sample size, no primary data, not study design of interest, not test of interest, not treatment of interest, not outcome of interest. PMIDs are given, when available, at the end of each reference.

Foreign Language

Ainetdinova DK, Udovichenko AE, Sulimov VA. [Resistance to antiplatelet drugs in patients with non ST elevation acute coronary syndrome]. *Kardiologiia* 2008;48(6):35-39. PMID: 18729834.

Averkov OV, Slavina NN, Gratsianskii NA. [Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel]. *Kardiologiia* 2003;43(10):50-59. PMID: 14593356.

Barbou F, Frere C, Hovasse T, et al. [Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty]. *Arch Mal Coeur Vaiss* 2006 Oct;99(10):894-99. PMID: 17100140.

Bochenek T, Wilczynski M, Wita K, et al. [Evaluation of platelet response to antiplatelet drugs. An important clue for cardiologists and cardiosurgeons]. *Kardiol Pol* 2007 Oct;65(10):1266-69. PMID: 17979060.

Bode C. [Therapy of acute myocardial infarction: COMMIT (Clopidogrel and Metoprolol Infarction Trial)]. *Internist (Berl)* 2006 Jul;47(7):764-66. PMID: 16794823.

Buriachkovskaia LI, Uchitel' IA, Sumarokov AV, et al. [Difficulties in evaluating the efficacy of antiplatelet therapy in clinical practice]. *Ter Arkh* 2009;81(5):41-47. PMID: 19537585.

Cai J, Wu Q, Fan L, et al. [Impact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation]. *Zhongguo Ying Yong Sheng Li Xue Za Zhi* 2010 Aug;26(3):266-69. PMID: 21038666.

Chen H, Yan W, Wu XY. [Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2010 Dec;30(12):1245-49. PMID: 21302482.

Chen ZQ, Hong L, Wang H. [Effect of danhong injection on platelet activation and inflammatory factors in patients of acute coronary syndrome after intervention therapy]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2009 Aug;29(8):692-94. PMID: 19848198.

Cuisset T, Frere C, Quilici J, et al. [Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome]. *Arch Mal Coeur Vaiss* 2006 Oct;99(10):889-93. PMID: 17100139.

Dankovtseva EN, Sidorenko BA. [The effectiveness of Ticagrelor does not depend on CYP2C19 gene polymorphism and ABCB1: results of a genetic analysis of the study PLATO]. *Kardiologiia* 2011;51(12):90-92. PMID: 22304323.

- De SS, Lettino M. [The TRITON-TIMI 38 trial]. *G Ital Cardiol (Rome)* 2008 Mar;9(3):149-54. PMID: 18422094.
- Eder C, Funke U, Schulze M, et al. [Modified platelet aggregation test in patients on ASA and/or clopidogrel]. *Hamostaseologie* 2007 Aug;27(3):163-76. PMID: 17694223.
- Feher G, Bagoly E, Kover F, et al. [The effect of carotid stenting on rheological parameters, free radical production and platelet aggregation]. *Orv Hetil* 2007 Dec 16;148(50):2365-70. PMID: 18055360.
- Frolova NS, Shakhnovich RM, Sirotkina OV, et al. [Clopidogrel resistance in patients with acute coronary syndrome]. *Ter Arkh* 2010;82(8):14-20. PMID: 20873239.
- Fukaya S, Iwamoto T, Kin K, et al. [Factors influencing platelet function in elderly patients with chronic phase thrombotic diseases]. *Nihon Ronen Igakkai Zasshi* 2000 Aug;37(8):619-26. PMID: 11086387.
- Galeote G, Lopez PA, Carcamo C, et al. [Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty]. *Rev Esp Cardiol* 2001 Nov;54(11):1256-63. PMID: 11707234.
- Galiavich AS, Valeeva DD, Minnetdinov RS, et al. [CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel]. *Kardiologiia* 2012;52(4):20-24. PMID: 22839512.
- Gao L, Wang PP, Liu Q. [Removing phlegm and dispelling stasis method combined with Western medicine for treatment of cerebrovascular stenosis]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2008 Jan;28(1):28-31. PMID: 18418965.
- Grajek S. [Letter to *Kardiologia Polska* concerning optimal treatment of myocardial infarction]. *Kardiol Pol* 2012;70(2):213-14. PMID: 22427099.
- Guan SY, Han YL, Li Y, et al. [Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2012 Jan;40(1):25-29. PMID: 22490629.
- Han YL, Su QF, Li Y, et al. [The effects of post coronary stenting triple antiplatelet therapies on platelet functions]. *Zhonghua Nei Ke Za Zhi* 2006 Aug;45(8):635-38. PMID: 17074146.
- Han YL, Li CY, Li Y, et al. [The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2007 Sep;35(9):788-92. PMID: 18070466.
- Haraguchi K, Miyachi S, Izumi T, et al. [Resistance to antiplatelet agents assessed by a point-of-care platelet function test and thromboembolic adverse events in neurointervention]. *No Shinkei Geka* 2012 May;40(5):399-406. PMID: 22538281.
- Izaguirre AR, de la PA, Gonzalez PH, et al. [Efficacy of clopidogrel as ADP-dependent platelet aggregation inhibitor. Study on individuals with coronary artery disease]. *Arch Inst Cardiol Mex* 2000 Sep;70(5):472-80. PMID: 11534098.
- Kawamura H, Kodama H, Takeuchi G, et al. [Antiplatelet therapy and platelet function studies in elderly patients with ischemic heart disease--evaluation of whole blood platelet aggregation]. *Rinsho Ketsueki* 1986 Oct;27(10):1815-22. PMID: 3820607.

Khaspekova SG, Ziuriaev IT, Iakushkin VV, et al. [Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome]. *Kardiologiya* 2011;51(7):4-7. PMID: 21878077.

Kin K, Iwamoto T, Takasaki M. [Evaluation of outcome based on platelet function in elderly patients with various diseases]. *Nihon Ronen Igakkai Zasshi* 2002 Jul;39(4):419-26. PMID: 12187807.

Komarov AL, Panchenko EP, Donnikov AE, et al. [Factors determining clinical effectiveness of clopidogrel and prognosis of patients with stable ischemic heart disease]. *Kardiologiya* 2011;51(2):8-18. PMID: 21627593.

Kum D, Kim M, Paik J, et al. [Clinical effects of additional cilostazol administration after drug-eluting stent insertion]. *Korean Circulation Journal* 2009;39(1):21-25.

Li Z, Liu F, Cui W, et al. [Impact of application time of aspirin and clopidogrel on platelet aggregation in patients with acute coronary syndrome]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2010 Apr;38(4):311-14. PMID: 20654074.

Liu F, Liu JC, Wang LJ, et al. [Effect of different duration of clopidogrel pretreatment on platelet activation in patients undergoing stenting]. *Zhonghua Wai Ke Za Zhi* 2009 Mar 15;47(6):411-14. PMID: 19595223.

Liu QZ, Hong T, Liu ZP, et al. [The effect of different loading doses of clopidogrel on platelet aggregation]. *Zhonghua Nei Ke Za Zhi* 2007 Feb;46(2):107-10. PMID: 17445432.

Loenko VB, Sorokina EA, Bobrov VS, et al. [Assessing clinical efficacy of the generic clopidogrel "Egutromb" in roentgenosurgical practice]. *Angiol Sosud Khir* 2010;16(4):193-97. PMID: 21389966.

Lu YL, Chen YD, Lu SZ. [Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2007 Sep;35(9):793-96. PMID: 18070468.

Martsevich SI, Tolpygina SN, Lukina I, et al. [Comparative evaluation of antiplatelet effectiveness drugs of original and reproduced enteric forms of acetylsalicylic acid (clinical study ICAR)]. *Kardiologiya* 2012;52(1):74-82. PMID: 22304357.

Mase K, Yanagihara F, Asada T, et al. [Evaluation of platelet aggregation test by grading curve]. *Rinsho Byori* 1992 Aug;40(8):857-62. PMID: 1404959.

Meves SH, Overbeck U, Kaiser A, et al. [Switching from clopidogrel hydrogen sulfate to clopidogrel besylate. Impaired antiplatelet effect in patients with ischemic stroke]. *Nervenarzt* 2010 Aug;81(8):992-97. PMID: 20517690.

Miziuk VM. [Effect of ivabradin and clopidogrel on platelet hemostasis indices in patients with acute coronary syndrome without ST-segment elevation and with concurrent cardiac insufficiency]. *Lik Sprava* 2008 Apr(3-4):71-75. PMID: 19145824.

Morel O, Viellard C, Faure A, et al. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation]. *Ann Cardiol Angeiol (Paris)* 2007 Jan;56(1):21-29. PMID: 17343035.

- Morofuji Y, So G, Hiu T, et al. [Preoperative analysis of platelet aggregability in carotid surgery]. *No Shinkei Geka* 2011 May;39(5):459-63. PMID: 21512195.
- Olszanska-Skorek T, Mazurowa A, Polczynska I, et al. [Platelet function in patients with acute myocardial infarct following administration of acetylsalicylic acid and dipyridamole]. *Pol Arch Med Wewn* 1979 Feb;61(2):135-42. PMID: 440980.
- Ono K, Arimoto H, Shirotani T. [Correlation between increased platelet ADP aggregability and silent brain infarcts]. *Brain Nerve* 2012 Feb;64(2):185-89. PMID: 22308263.
- Ouyang XL, Lin ZL, Wang HB, et al. [Slide platelet aggregation test used as a monitor for patient treated with anti-platelet drugs]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 2005 Apr;13(2):309-12. PMID: 15854298.
- Pakhomov I. [Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial]. *Kardiologiia* 2010;50(6):63-67. PMID: 20659030.
- Piedade PR, Gagliardi RJ, Damiani IT, et al. [Platelet aggregation test: application in the control of antiplatelet aggregation in the secondary prevention of stroke]. *Arq Neuropsiquiatr* 2003 Sep;61(3B):764-67. PMID: 14595479.
- Poponina TM, Kapilevich NA. [Choosing of disaggregants for the treatment of patients with instable angina without lifting the ST segment]. *Klin Lab Diagn* 2004 Oct(10):45-46. PMID: 15584401.
- Poponina TM, Kapilevich NA, Kisteneva IV, et al. [Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome]. *Ter Arkh* 2004;76(8):18-22. PMID: 15471389.
- Ren XN, Wang LF, Wang MS, et al. [Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2012 Feb;40(2):131-35. PMID: 22490713.
- Satoh T, Otsuka K, Sakurai I. [Method of quantitative measurement of human platelet aggregation in clinical practice]. *Nihon Ronen Igakkai Zasshi* 1998 Oct;35(10):748-56. PMID: 9893479.
- Serebruany VL, Malinin AI, Callahan KP, et al. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. *Atherosclerosis* 2001 Nov;159(1):239-41. PMID: 11689228.
- Shen J, Zhang RY, Zhang Q. [Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2008 Sep;36(9):807-11. PMID: 19102862.
- Shimizu H, Konohana A, Tajima S, et al. [Objective judgement on effects of medicine in patients with Raynaud's phenomenon--measurement of cutaneous blood flow using laser Doppler flowmeter and platelet aggregation activity]. *Nihon Hifuka Gakkai Zasshi* 1987 Jan;97(1):35-38. PMID: 2952821.

- Sirotkina OV, Zabortina AM, Berkovich OA, et al. [Genetic variants of platelet ADP receptor P2Y₁₂ associated with changed platelet functional activity and development of cardiovascular diseases]. *Genetika* 2009 Feb;45(2):247-53. PMID: 19334620.
- Slanar O, Drazd'akova M, Babiarova K, et al. [Genotyping of CYP2D6 and CYP2C19]. *Cas Lek Cesk* 2007;146(9):708-11. PMID: 17966194.
- Slavina NN, Averkov OV, Gratsianskii NA. [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. *Kardiologiia* 2005;45(12):11-16. PMID: 16353041.
- Tang XF, He C, Yuan JQ, et al. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2011 Jul;39(7):617-20. PMID: 22088240.
- Taniguchi N, Yamauchi K, Kondo T, et al. [Studies on antiplatelet therapy of low dosage of aspirin from the view point of its effect on platelet aggregation (author's transl)]. *Nihon Ronen Igakkai Zasshi* 1981 Nov;18(6):463-68. PMID: 7339085.
- Telejko B, Zak J, Bachorzewska-Gajewska H, et al. [Platelet-monocyte aggregate formation in patients with coronary heart disease and disorders of carbohydrate metabolism]. *Pol Arch Med Wewn* 2004 Sep;112(3):1067-73. PMID: 15727088.
- Uchiyama S, Yamazaki M, Maruyama S. [Antiplatelet effect of clopidogrel]. *Nihon Rinsho* 1992 Feb;50(2):372-78. PMID: 1613993.
- Voskoboi IV, Rebrov AP, Kirichuk VF, et al. [Lectin-induced platelet aggregation inpatients with unstable angina pectoris treated with anti-aggregation agents]. *Klin Med (Mosk)* 2001;79(4):21-25. PMID: 11496732.
- Wang YM, Cao YJ, Liu CF, et al. [The changes and effects of antiplatelet agents on platelet-leukocyte aggregation in patients with acute cerebral infarction]. *Zhonghua Nei Ke Za Zhi* 2007 Jul;46(7):562-65. PMID: 17959080.
- Xie Y, Liu T, Zhou YJ, et al. [Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2009 Jan;37(1):39-43. PMID: 19671350.
- Yasunaga K. [Inhibition of platelet aggregation by platelet inhibitory agents and its relation to their clinical effects]. *Rinsho Byori* 1979;Suppl 40:181-87. PMID: 551223.
- Zhang Y, Liang J, Zhou YJ, et al. [Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2005 Aug;33(8):695-99. PMID: 16188050.
- Zimmermann R, Lange D, Zeltsch C, et al. [Significance of thrombus structure for the antithrombotic effectiveness of thrombocyte aggregation inhibiting substances and anticoagulants]. *Verh Dtsch Ges Inn Med* 1977 Apr 17;83:1173-74. PMID: 347772.
- Zurn CS, Geisler T, Paterok M, et al. [Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention]. *Dtsch Med Wochenschr* 2008 Apr;133(16):817-22. PMID: 18398789.

Not Population of Interest

Altman R, Scazziotto A, DE Lourdes HM, et al. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. *J Thromb Haemost* 2006 Sep;4(9):2022-27. PMID: 16961610.

Babcock MJ, Sane AC, Eckman DM, et al. Persistent erythema with niacin is not attributable to aspirin resistance. *J Clin Lipidol* 2011 Mar;5(2):114-19. PMID: 21392725.

Bal Dit SC, Berge N, Boval B, et al. Functional variability of platelet response to clopidogrel correlates with P2Y₁₂ receptor occupancy. *Thromb Haemost* 2009 Jan;101(1):116-22. PMID: 19132197.

Bal Dit SC, Berge N, Boval B, et al. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. *Thromb Haemost* 2010 Sep;104(3):571-81. PMID: 20664906.

Bansal V, Fortlage D, Lee J, et al. A new clopidogrel (Plavix) point-of-care assay: rapid determination of antiplatelet activity in trauma patients. *J Trauma* 2011 Jan;70(1):65-69. PMID: 21217483.

Benzon HT, McCarthy RJ, Benzon HA, et al. Determination of residual antiplatelet activity of clopidogrel before neuraxial injections. *Br J Anaesth* 2011 Dec;107(6):966-71. PMID: 21968250.

Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. *J Thromb Haemost* 2007 Dec;5(12):2429-36. PMID: 17900275.

Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. *Br J Clin Pharmacol* 2010 Jul;70(1):65-77. PMID: 20642549.

Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. *Circulation* 2000 Jun 20;101(24):2823-28. PMID: 10859288.

Chen BL, Zhang W, Li Q, et al. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms. *Clin Exp Pharmacol Physiol* 2008 Aug;35(8):904-08. PMID: 18346178.

Chen F, Maridakis V, O'Neill EA, et al. A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel. *Platelets* 2012;23(4):249-58. PMID: 21919555.

Chen H, Yu G, Sun H, et al. Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution. *Evid Based Complement Alternat Med* 2011;2011:207034. PMID: 21423686.

Chung I, Choudhury A, Patel J, et al. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. *Ann Med* 2009;41(1):45-51. PMID: 18618353.

Depta JP, Fowler J, Novak E, et al. Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. *Stroke* 2012 Sep;43(9):2376-81. PMID: 22713488.

Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. *Am Heart J* 2004 Apr;147(4):E17. PMID: 15077100.

Djaffar J, I, Chamseddine N, Keleshian S, et al. Prevalence of CYP2C19 polymorphisms in the Lebanese population. *Mol Biol Rep* 2011 Nov;38(8):5449-52. PMID: 21380557.

Djukanovic N, Todorovic Z, Obradovic S, et al. Abrupt cessation of one-year clopidogrel treatment is not associated with thrombotic events. *J Pharmacol Sci* 2011;117(1):12-18. PMID: 21821970.

Dovlatova NL, Jakubowski JA, Sugidachi A, et al. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. *J Thromb Haemost* 2008 Jul;6(7):1153-59. PMID: 18485086.

Edwards A, Jakubowski JA, Rechner AR, et al. Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant. *Platelets* 2012;23(2):106-15. PMID: 21848368

Ferreiro JL, Ueno M, Capodanno D, et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. *Circ Cardiovasc Interv* 2010 Oct;3(5):436-41. PMID: 20858862.

Ferreiro JL, Ueno M, Tomasello SD, et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. *Circ Cardiovasc Interv* 2011 Jun;4(3):273-79. PMID: 21521834.

Flock A, Zobel A, Bauriedel G, et al. Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. *Thromb Res* 2010 Aug;126(2):e83-e87. PMID: 20553948.

Fontana P, Nolli S, Reber G, et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. *J Thromb Haemost* 2006 Apr;4(4):813-19. PMID: 16634751.

Frelinger AL, III, Li Y, Linden MD, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. *Circulation* 2009 Dec 22;120(25):2586-96. PMID: 19996015.

Frelinger AL, III, Barnard MR, Fox ML, et al. The Platelet Activity After Clopidogrel Termination (PACT) study. *Circ Cardiovasc Interv* 2010 Oct;3(5):442-49. PMID: 20736449.

Fuchs I, Frossard M, Spiel A, et al. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. *J Thromb Haemost* 2006 Dec;4(12):2547-52. PMID: 17002662.

Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. *Br J Clin Pharmacol* 2010 Sep;70(3):383-92. PMID: 20716239.

Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: comparison of methods. *Clin Chem* 2005 Jun;51(6):957-65. PMID: 15817818.

Gong IY, Crown N, Suen CM, et al. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. *Eur Heart J* 2012 Nov;33(22):2856-2464a. PMID: 22374717.

Hjorth ME, Christiansen MK, Schmidt EB, et al. Effect of exercise on platelet activation during aspirin or clopidogrel intake in healthy men. *Platelets* 2009 May;20(3):177-82. PMID: 19437335.

Hobson AR, Qureshi Z, Banks P, et al. Gender and responses to aspirin and clopidogrel: insights using short thrombelastography. *Cardiovasc Ther* 2009;27(4):246-52. PMID: 19903188.

Hobson AR, Qureshi Z, Banks P, et al. The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses. *Thrombosis* 2010;2010:908272. PMID: 22084661.

Homoncik M, Jilma B, Hergovich N, et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. *Thromb Haemost* 2000 Feb;83(2):316-21. PMID: 10739392.

Jakubowski JA, Payne CD, Li YG, et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. *Thromb Haemost* 2008 Feb;99(2):409-15. PMID: 18278193.

Jakubowski JA, Payne CD, Li YG, et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. *Thromb Haemost* 2008 Jan;99(1):215-22. PMID: 18217157.

Jakubowski JA, Li YG, Small DS, et al. A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. *J Cardiovasc Pharmacol* 2010 Jul;56(1):29-37. PMID: 20386460.

Jakubowski JA, Li YG, Small DS, et al. A Comparison of VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis. *J Cardiovasc Pharmacol* 2010 Mar 24 PMID: 20351563.

Jakubowski JA, Zhou C, Egan B, et al. Modification of the VerifyNow(R) P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism. *Platelets* 2011;22(8):619-25. PMID: 21639823.

Johnson GJ, Sharda AV, Rao GH, et al. Measurement of shear-activated platelet aggregate formation in non-anticoagulated blood: utility in detection of clopidogrel-aspirin-induced platelet dysfunction. *Clin Appl Thromb Hemost* 2012 Mar;18(2):140-49. PMID: 22009986.

Kaufman JS, Fiore L, Hasbargen JA, et al. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. *J Thromb Thrombolysis* 2000 Oct;10(2):127-31. PMID: 11005934.

Keating FK, Whitaker DA, Kabbani SS, et al. Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. *Am J Cardiol* 2004 Sep 15;94(6):725-28. PMID: 15374774.

Kenngott S, Olze R, Kollmer M, et al. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? *Eur J Med Res* 2010 May 18;15(5):220-24. PMID: 20562062.

Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. *Clin Pharmacol Ther* 2008 Aug;84(2):236-42. PMID: 18323861.

Labarthe B, Theroux P, Angioi M, et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. *J Am Coll Cardiol* 2005 Aug 16;46(4):638-45. PMID: 16098428.

Leadbeater PD, Kirkby NS, Thomas S, et al. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. *J Thromb Haemost* 2011 Oct;9(10):2050-56. PMID: 21794076.

Lee CC, McMillin GA, Babic N, et al. Evaluation of a CYP2C19 genotype panel on the GenMark eSensor(R) platform and the comparison to the Autogenomics Infiniti and Luminex CYP2C19 panels. *Clin Chim Acta* 2011 May 12;412(11-12):1133-37. PMID: 21385571.

Lee W, Suh JW, Yang HM, et al. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. *Korean Circ J* 2010 Jul;40(7):321-27. PMID: 20664740.

Lee YW, Cho YH, Kim YH, et al. Aspirin non-responsiveness in Korean subjects on dual anti-platelet treatment determined by two different platelet function assays. *Ann Clin Lab Sci* 2008;38(2):126-31. PMID: 18469357.

Li YG, Ni L, Brandt JT, et al. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. *Platelets* 2009 Aug;20(5):316-27. PMID: 19637095.

Lin PC, Jones SO, McGlasson DL. Effects of glucosamine and Celadrin on platelet function. *Clin Lab Sci* 2010;23(1):32-36. PMID: 20218092.

Litos IK, Emmanouilidou E, Glynou KM, et al. Rapid genotyping of CYP2D6, CYP2C19 and TPMT polymorphisms by primer extension reaction in a dipstick format. *Anal Bioanal Chem* 2007 Nov;389(6):1849-57. PMID: 17909762.

Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. *Eur J Clin Invest* 2005 Aug;35(8):476-81. PMID: 16101667.

Mahmud E, Cavendish JJ, Tsimikas S, et al. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. *J Am Coll Cardiol* 2007 Jun 5;49(22):2163-71. PMID: 17543636.

Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. *Eur Heart J* 1998 Oct;19(10):1538-46. PMID: 9820993.

Marton Z, Horvath B, Alexy T, et al. Follow-up of hemorheological parameters and platelet aggregation in patients with acute coronary syndromes. *Clin Hemorheol Microcirc* 2003;29(2):81-94. PMID: 14610303.

Muller A, Octavio J, Gonzalez MY, et al. Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: a clinical trial. *Am J Ther* 2010 May;17(3):351-56. PMID: 20019589.

Neubauer H, Kruger JC, Lask S, et al. Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. *Clin Res Cardiol* 2009 Sep;98(9):533-40. PMID: 19504141.

Ostrowsky J, Foes J, Warchol M, et al. Plateletworks platelet function test compared to the thromboelastograph for prediction of postoperative outcomes. *J Extra Corpor Technol* 2004 Jun;36(2):149-52. PMID: 15334755.

Orford JL, Kinlay S, Adams MR, et al. Clopidogrel inhibits shear-induced platelet function. *Platelets* 2002 May;13(3):187-89. PMID: 12180502.

Pasquali SK, Yow E, Jennings LK, et al. Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease. *Congenit Heart Dis* 2010 Nov;5(6):552-55. PMID: 21106014.

Patti G, Nusca A. Influence of platelet reactivity on outcome of patients with acute myocardial infarction undergoing primary angioplasty. *Circ J* 2011;75(9):2050-51. PMID: 21817805.

Penz SM, Bernlochner I, Toth O, et al. Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y₁₂ antagonists by using multiple electrode aggregometry. *Thromb J* 2010;8:9. PMID: 20465804.

Pittens CA, Bouman HJ, van Werkum JW, et al. Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y₁₂ receptor antagonists with different platelet function tests. *J Thromb Haemost* 2009 Nov;7(11):1929-32. PMID: 19691484.

Preisman S, Kogan A, Itzkovsky K, et al. Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. *Eur J Cardiothorac Surg* 2010 Jun;37(6):1367-74. PMID: 20181490.

Price MJ, Coleman JL, Steinhubl SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. *Am J Cardiol* 2006 Sep 1;98(5):681-84. PMID: 16923461.

Price MJ, Teirstein PS. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. *Am J Cardiol* 2008 Sep 15;102(6):790-95. PMID: 18774008.

Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. *Clin Pharmacol Ther* 2012 Jul;92(1):87-95. PMID: 22588608

Przyklenk K, Whittaker P. In vitro platelet responsiveness to adenosine-mediated “preconditioning” is age-dependent. *J Thromb Thrombolysis* 2005 Feb;19(1):5-10. PMID: 15976961.

Reece MJ, Klein AA, Salviz EA, et al. Near-patient platelet function testing in patients undergoing coronary artery surgery: a pilot study. *Anaesthesia* 2011 Feb;66(2):97-103. PMID: 21254984.

Roald HE, Barstad RM, Kierulf P, et al. Clopidogrel--a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. *Thromb Haemost* 1994 May;71(5):655-62. PMID: 8091395.

Saucedo JF, Lui HK, Garza L, et al. Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study. *J Thromb Thrombolysis* 2004 Oct;18(2):67-74. PMID: 15789173.

Schneider DJ, Baumann PQ, Whitaker DA, et al. Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen. *J Cardiovasc Pharmacol* 2005 Jul;46(1):41-45. PMID: 15965353.

Schwarz UR, Geiger J, Walter U, et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects. *Thromb Haemost* 1999 Sep;82(3):1145-52. PMID: 10494779.

Scott SA, Martis S, Peter I, et al. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. *Pharmacogenomics J* 2012 Aug;12(4):297-305. PMID: 21358751.

Serebruany VL, Malinin AI, Jerome SD, et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. *Am Heart J* 2003 Oct;146(4):713-20. PMID: 14564328.

Sevcikova H, Vojacek J, Bis J, et al. Good short-term but not long-term reproducibility of the antiplatelet efficacy laboratory assessment. *Clin Appl Thromb Hemost* 2012 Mar;18(2):174-80. PMID: 21949037.

Seyfert UT, Haubelt H, Vogt A, et al. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. *Platelets* 2007 May;18(3):199-206. PMID: 17497431.

Shaffer KE, Pearman DT, Galen RS, et al. A rapid platelet function assay used to regulate platelet transfusion prophylaxis following cardiopulmonary bypass surgery. *J Extra Corpor Technol* 2004 Jun;36(2):145-48. PMID: 15334754.

Shim CY, Park S, Song JW, et al. Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study. *Clin Ther* 2010 Aug;32(9):1664-73. PMID: 20974324.

Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. *Curr Med Res Opin* 2008 Aug;24(8):2251-57. PMID: 18786302.

Small DS, Wrishko RE, Ernest CS, et al. Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial. *Drugs Aging* 2009;26(9):781-90. PMID: 19728751.

Small DS, Payne CD, Kothare P, et al. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. *Clin Ther* 2010 Feb;32(2):365-79. PMID: 20206794.

Spiel AO, Frossard M, Mayr FB, et al. Pronounced platelet hyperfunction in patients with cardiac arrest achieving restoration of spontaneous circulation. *Crit Care Med* 2009 Mar;37(3):975-79. PMID: 19237906.

Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. *Circulation* 2001 May 29;103(21):2572-78. PMID: 11382726.

Strom CM, Goos D, Crossley B, et al. Testing for variants in CYP2C19: Population frequencies and testing experience in a clinical laboratory. *Genet Med* 2011 Oct 7 PMID: 21983594.

Strom CM, Goos D, Crossley B, et al. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. *Genet Med* 2012 Jan;14(1):95-100. PMID: 22237437.

Swallow RA, Agarwala RA, Dawkins KD, et al. Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? *Platelets* 2006 Sep;17(6):385-92. PMID: 16973499.

Tang YD, Rinder HM, Katz SD. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial. *Am Heart J* 2007 Sep;154(3):494-97. PMID: 17719296.

Tazaki J, Jinnai T, Tada T, et al. Prediction of clopidogrel low responders by a rapid CYP2C19 activity test. *J Atheroscler Thromb* 2012;19(2):186-93. PMID: 22166969.

Temesvari M, Paulik J, Kobori L, et al. High-resolution melting curve analysis to establish CYP2C19 *2 single nucleotide polymorphism: Comparison with hydrolysis SNP analysis. *Mol Cell Probes* 2011 Apr;25(2-3):130-33. PMID: 21315147.

Toth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. *Thromb Haemost* 2006 Dec;96(6):781-88. PMID: 17139373.

Uotani T, Sugimoto M, Nishino M, et al. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. *Clin Gastroenterol Hepatol* 2012 Aug;10(8):879-85. PMID: 22542748.

van Gestel MA, Heemskerk JW, Slaaf DW, et al. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. *Arterioscler Thromb Vasc Biol* 2003 Mar 1;23(3):518-23. PMID: 12615691.

Vilahur G, Choi BG, Zafar MU, et al. Normalization of platelet reactivity in clopidogrel-treated subjects. *J Thromb Haemost* 2007 Jan;5(1):82-90. PMID: 17239165.

Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. *J Cardiovasc Pharmacol Ther* 2007 Sep;12(3):205-12. PMID: 17875947.

Weerakkody GJ, Brandt JT, Payne CD, et al. Clopidogrel poor responders: an objective definition based on Bayesian classification. *Platelets* 2007 Sep;18(6):428-35. PMID: 17763152.

Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. *Am J Cardiol* 2007 Jul 15;100(2):331-36. PMID: 17631093.

Wheeler GL, Braden GA, Steinhubl SR, et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. *Am Heart J* 2002 Apr;143(4):602-11. PMID: 11923796.

Xie HG. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population. *Life Sci* 2000 Feb 25;66(14):L175-L181. PMID: 10755474.

Yamanouchi J, Hato T, Niiya T, et al. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol. *Platelets* 2011;22(2):135-42. PMID: 21158496.

Yeung J, Apopa PL, Vesci J, et al. Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation. *Mol Pharmacol* 2012 Mar;81(3):420-30. PMID: 22155783.

Yousef AM, Arafat T, Bulatova NR, et al. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. *J Clin Pharm Ther* 2008 Aug;33(4):439-49. PMID: 18613862.

Yun KH, Rhee SJ, Park HY, et al. Effects of omeprazole on the antiplatelet activity of clopidogrel. *Int Heart J* 2010 Jan;51(1):13-16. PMID: 20145345.

Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. *Br J Pharmacol* 2001 Sep;134(2):353-58. PMID: 11564653

Test Not Used for Prognosis, Prediction, or Decisionmaking

Abuzahra M, Pillai M, Caldera A, et al. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents. *Am J Cardiol* 2008 Aug 15;102(4):401-03. PMID: 18678295.

Addad F, Chakroune T, Asma A, et al. Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease. *Thromb Res* 2009 Feb;123(4):640-43. PMID: 18602138.

Ades PA, Savage PD, Toth MJ, et al. The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease. *Int J Obes (Lond)* 2008 Jun;32(6):967-74. PMID: 18268512.

Ahn SG, Lee SH, Sung JK, et al. Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention. *Platelets* 2011;22(4):305-07. PMID: 21480769.

Ahn SG, Lee SH, Sung JK, et al. Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention. *Platelets* 2011;22(4):305-07. PMID: 21480769.

Ajzenberg N, Aubry P, Huisse MG, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. *J Am Coll Cardiol* 2005 Jun 7;45(11):1753-56. PMID: 15936600.

Akowuah E, Shrivastava V, Jamnadas B, et al. Comparison of two strategies for the management of antiplatelet therapy during urgent surgery. *Ann Thorac Surg* 2005 Jul;80(1):149-52. PMID: 15975358.

Aleil B, Meyer N, Cazenave JP, et al. High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. *Thromb Haemost* 2005 Oct;94(4):886-87. PMID: 16270649.

Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. *J Thromb Haemost* 2005 Jan;3(1):85-92. PMID: 15634270.

Alexopoulos D, Xanthopoulou I, Tsigkas G, et al. Predictors of high on-treatment platelet reactivity early after clopidogrel loading in ST-elevation myocardial infarction. *Circ J* 2012;76(9):2183-87. PMID: 22664584.

Alstrom U, Tyden H, Oldgren J, et al. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. *Thromb Res* 2007;120(3):353-59. PMID: 17137616.

Althoff TF, Fischer M, Langer E, et al. Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. *Thromb Res* 2010 May;125(5):e190-e196. PMID: 20116087.

Altman R, Rivas AJ, Gonzalez CD. Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study. *Thromb J* 2012;10(1):3. PMID: 22236361.

Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. *Am J Cardiol* 2007 Aug 1;100(3):417-24. PMID: 17659921.

Ancrenaz V, Desmeules J, James R, et al. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. *Br J Pharmacol* 2012 Aug;166(8):2362-70. PMID: 22428615.

Ang L, Palakodeti V, Khalid A, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. *J Am Coll Cardiol* 2008 Sep 23;52(13):1052-59. PMID: 18848137.

Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. *Eur Heart J* 2011 Apr;32(7):838-46. PMID: 21252171.

Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. *J Am Coll Cardiol* 2010 Mar 16;55(11):1139-46. PMID: 20223369.

Angiolillo DJ, Bernardo E, Palazuelos J, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. *Thromb Haemost* 2008 Jan;99(1):161-68. PMID: 18217149.

Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. *J Am Coll Cardiol* 2006 Jul 18;48(2):298-304. PMID: 16843179.

Angiolillo DJ, Capranzano P, Ferreiro JL, et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. *Thromb Haemost* 2011 Aug;106(2):253-62. PMID: 21614414.

Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. *Eur Heart J* 2008 Sep;29(18):2202-11. PMID: 18567918.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. *Blood Coagul Fibrinolysis* 2004 Jul;15(5):427-33. PMID: 15205592.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. *Diabetes* 2006 Mar;55(3):780-84. PMID: 16505243.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. *Eur Heart J* 2004 Nov;25(21):1903-10. PMID: 15522469.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. *Thromb Res* 2005;115(1-2):101-08. PMID: 15567460.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. *Am J Cardiol* 2006 Jan 1;97(1):38-43. PMID: 16377281.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. *J Invasive Cardiol* 2004 Jun;16(6):325-29. PMID: 15156004.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. P1A polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. *Blood Coagul Fibrinolysis* 2004 Jan;15(1):89-93. PMID: 15166949.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? *J Invasive Cardiol* 2004 Apr;16(4):169-74. PMID: 15152138.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. *Diabetes* 2005 Aug;54(8):2430-35. PMID: 16046311.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. *Am J Cardiol* 2005 Oct 15;96(8):1095-99. PMID: 16214444.

Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. *JAMA* 2012 Jan 18;307(3):265-74. PMID: 22253393.

Angiolillo DJ, Saucedo JF, Deraad R, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. *J Am Coll Cardiol* 2010 Sep 21;56(13):1017-23. PMID: 20846599.

Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. *J Thromb Thrombolysis* 2012 Jul;34(1):44-55. PMID: 22569899.

Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. *Circulation* 2007 Feb 13;115(6):708-16. PMID: 17261652.

Angiolillo DJ, Welsh RC, Trenk D, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. *Circ Cardiovasc Interv* 2012 Jun;5(3):347-56. PMID: 22619259.

Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. *J Am Coll Cardiol* 2008 May 27;51(21):2028-33. PMID: 18498956.

Aradi D, Vorobcsuk A, Lenkey Z, et al. Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. *Platelets* 2010;21(1):1-10. PMID: 19929306.

Arai T, Kawamura A, Matsubara Y, et al. Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. *Heart Vessels* 2012 Sep;27(5):480-85. PMID: 21837496.

Arzamendi D, Dandachli F, Theoret JF, et al. An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis. *Clin Appl Thromb Hemost* 2011 Nov;17(6):E70-E78. PMID: 21078615.

- Ashraf T, Ahmed M, Talpur MS, et al. Competency profile of locally manufactured clopidogrel Lowplat and foreign manufactured clopidogrel Plavix in patients of suspected ischemic heart disease (CLAP-IHD). *J Pak Med Assoc* 2005 Oct;55(10):443-48. PMID: 16304854.
- Attar S, McLaughlin JS, Masaitis C. Clinical application of platelet aggregation. *South Med J* 1973 Apr;66(4):481-85. PMID: 4708247.
- Attisani M, Centofanti P, La TM, et al. Safety and effectiveness of low dosing of double antiplatelet therapy during long-term left ventricular support with the INCOR system. *J Artif Organs* 2010 Dec;13(4):202-06. PMID: 21127929.
- Awidi A, Saleh A, Dweik M, et al. Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study. *Heart Vessels* 2011 Sep;26(5):516-22. PMID: 21181173.
- Azcona L, Lopez Farre AJ, Jimenez Mateos-Caceres P, et al. Impact of clopidogrel and aspirin treatment on the expression of proteins in platelets from type-2 diabetic patients with stable coronary ischemia. *J Pharm Sci* 2012 Aug;101(8):2821-32. PMID: 22614874.
- Bal Dit SC, Crassard I, Simoneau G, et al. Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. *Cerebrovasc Dis* 2009;28(5):505-13. PMID: 19752552.
- Barilla F, Pulcinelli FM, Mangieri E, et al. Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. *Platelets* 2013;24(3):183-88. PMID: 22646157.
- Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. *Circulation* 2002 Sep 17;106(12):1470-76. PMID: 12234950.
- Bauriedel G, Skowasch D, Schneider M, et al. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. *Am Heart J* 2003 Feb;145(2):343-48. PMID: 12595854.
- Behan MW, Fox SC, Heptinstall S, et al. Inhibitory effects of P2Y₁₂ receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. *Platelets* 2005 Mar;16(2):73-80. PMID: 15823862.
- Beigel R, Hod H, Fefer P, et al. Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. *Am J Cardiol* 2011 Feb 1;107(3):339-42. PMID: 21256995.
- Beres BJ, Toth-Zsomboki E, Vargova K, et al. Analysis of platelet alpha₂-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. *Thromb Haemost* 2008 Nov;100(5):829-38. PMID: 18989527.
- Bernlochner I, Morath T, Brown PB, et al. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. *Platelets* 2013;24(1):15-25. PMID: 22372531.

Bernlochner I, Steinhubl S, Braun S, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. *Thromb Haemost* 2010 Dec;104(6):1193-200. PMID: 20838744.

Bigalke B, Geisler T, Stellos K, et al. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. *Am Heart J* 2008 Jul;156(1):193-200. PMID: 18585516.

Bilsel T, Akbulut T, Yesilcimen K, et al. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. *Heart Vessels* 2006 Mar;21(2):102-07. PMID: 16550311.

Bonello L, Berbis J, Laine M, et al. Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. *Thromb Haemost* 2012 Jul;108(1):101-06. PMID: 22535315.

Bonello L, Paganelli F, Gnat-George F, et al. Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention. *Thromb Res* 2008;122(2):285-88. PMID: 18093637.

Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. *Thromb Haemost* 1996 Dec;76(6):939-43. PMID: 8972014.

Borsiczky B, Sarszegi Z, Konyi A, et al. The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: a retrospective study. *Thromb Res* 2012 Jun;129(6):700-03. PMID: 21924759.

Bouman HJ, van Werkum JW, Hackeng CM, et al. Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects. *Neth Heart J* 2009 May;17(5):195-98. PMID: 19484155.

Brackbill ML, Kidd RS, Abdoo AD, et al. Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. *Heart Vessels* 2009 Mar;24(2):73-78. PMID: 19337788.

Braun OO, Amisten S, Wihlborg AK, et al. Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12). *Purinergic Signal* 2007 Jun;3(3):195-201. PMID: 18404433.

Braun OO, Johnell M, Varenhorst C, et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. *Thromb Haemost* 2008 Oct;100(4):626-33. PMID: 18841285.

Breet NJ, van Donkersgoed HE, van Werkum JW, et al. Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? *Neth Heart J* 2011 Jun;19(6):279-84. PMID: 21494888.

Brizzio ME, Shaw RE, Bosticco B, et al. Use of an objective tool to assess platelet inhibition prior to off-pump coronary surgery to reduce blood usage. *J Invasive Cardiol* 2012 Feb;24(2):49-52. PMID: 22294531.

Buch AN, Singh S, Roy P, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. *Am J Cardiol* 2007 Jun 1;99(11):1518-22. PMID: 17531573.

Burgstahler C, Geisler T, Lindemann S, et al. Elevated coronary calcium scores are associated with higher residual platelet aggregation after clopidogrel treatment in patients with stable angina pectoris. *Int J Cardiol* 2009 Jun 12;135(1):132-35. PMID: 18606468.

Campbell CL, Berger PB, Nuttall GA, et al. Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. *Am Heart J* 2005 Oct;150(4):796-99. PMID: 16209984.

Campo G, Ferraresi P, Marchesini J, et al. Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. *J Thromb Haemost* 2011 Oct;9(10):2106-08. PMID: 21819538.

Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. *J Am Coll Cardiol* 2006 Dec 5;48(11):2178-85. PMID: 17161242.

Cao YJ, Wang YM, Zhang J, et al. The effects of antiplatelet agents on platelet-leukocyte aggregations in patients with acute cerebral infarction. *J Thromb Thrombolysis* 2009 Feb;27(2):233-38. PMID: 18188511.

Cassar K, Bachoo P, Ford I, et al. Variability in responsiveness to clopidogrel in patients with intermittent claudication. *Eur J Vasc Endovasc Surg* 2006 Jul;32(1):71-75. PMID: 16549375.

Cassar K, Ford I, Greaves M, et al. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty. *Br J Surg* 2005 Feb;92(2):159-65. PMID: 15609386.

Casterella PJ, Kereiakes DJ, Steinhubl SR, et al. The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable. *Catheter Cardiovasc Interv* 2001 Dec;54(4):497-504. PMID: 11747189.

Cha JK, Jeong MH, Lee KM, et al. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. *J Thromb Thrombolysis* 2002 Oct;14(2):145-50. PMID: 12714834.

Cho JH, Jeong YH, Ahn YJ, et al. The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction. *Korean Circ J* 2010 Mar;40(3):119-24. PMID: 20339496.

Chyrchel B, Surdacki A, Chyrchel M, et al. Separate dosing of clopidogrel and omeprazole may improve platelet inhibition on dual antiplatelet therapy. *Int J Cardiol* 2011 May 19;149(1):124-25. PMID: 21345502.

Claeys MJ, Van der Planken MG, Bosmans JM, et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. *Eur Heart J* 2005 Mar;26(6):567-75. PMID: 15618034.

Claeys MJ, Van der Planken MG, Michiels JJ, et al. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. *Blood Coagul Fibrinolysis* 2002 Jun;13(4):283-88. PMID: 12032392.

Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. *Am Heart J* 2001 Mar;141(3):402-09. PMID: 11231437.

Craft RM, Chavez JJ, Snider CC, et al. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. *J Lab Clin Med* 2005 Jun;145(6):309-15. PMID: 15976759.

Cuisset T, Frere C, Moro PJ, et al. Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. *Thromb Res* 2010 Nov;126(5):e400-e402. PMID: 20828794.

Dalby M, Montalescot G, Bal Dit SC, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. *J Am Coll Cardiol* 2004 Jan 21;43(2):162-68. PMID: 14736431.

Danzi GB, Capuano C, Sesana M, et al. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. *Am J Cardiol* 2006 Feb 15;97(4):489-93. PMID: 16461043.

David JL, Limet R. Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients. *Thromb Haemost* 1999 Nov;82(5):1417-21. PMID: 10595630.

Denninger MH, Necciari J, Serre-Lacroix E, et al. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. *Semin Thromb Hemost* 1999;25 Suppl 2:41-45. PMID: 10440422.

Deray G, Bagnis C, Brouard R, et al. Clopidogrel activities in patients with renal function impairment. *Clin Drug Investig* 1998;16(4):319-28. PMID: 18370553.

Desch S, Siegemund A, Scholz U, et al. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction. *Clin Res Cardiol* 2012 Feb;101(2):117-24. PMID: 22015616.

Di SG, Patti G, Pasceri V, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. *J Am Coll Cardiol* 2010 Aug 10;56(7):550-57. PMID: 20688209.

Diego A, de Prado AP, Cuellas C, et al. P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction. *Thromb Res* 2012 Sep;130(3):e31-e36. PMID: 22704077.

Diehl P, Halscheid C, Olivier C, et al. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. *Clin Res Cardiol* 2011 Sep;100(9):765-71. PMID: 21479772.

Diehl P, Olivier C, Halscheid C, et al. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y₁₂ expressing leukocytes. *Basic Res Cardiol* 2010 May;105(3):379-87. PMID: 19943165.

Dorr G, Schmidt G, Grafe M, et al. Effects of combined therapy with clopidogrel and acetylsalicylic acid on platelet glycoprotein expression and aggregation. *J Cardiovasc Pharmacol* 2002 Apr;39(4):523-32. PMID: 11904526.

Drosch T, Brodoefel H, Geisler T, et al. Plaque distribution in clopidogrel responders and low responders as determined by multislice computed tomography. *Tex Heart Inst J* 2010;37(5):547-52. PMID: 20978565.

Duerschmied D, Ahrens I, Mauler M, et al. Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study. *PLoS One* 2012;7(2):e32656. PMID: 22384279.

Eikelboom JW, Hankey GJ, Thom J, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. *J Thromb Haemost* 2005 Dec;3(12):2649-55. PMID: 16359503.

Elsenberg EH, van Werkum JW, van de Wal RM, et al. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. *Thromb Haemost* 2009 Oct;102(4):719-27. PMID: 19806258.

Ernst NM, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2004 Sep 15;44(6):1187-93. PMID: 15364318.

Etz C, Welp H, Rothenburger M, et al. Analysis of platelet function during left ventricular support with the Incor and Excor system. *Heart Surg Forum* 2004;7(5):E423-E427. PMID: 15799917.

Fateh-Moghadam S, Htun P, Tomandl B, et al. Hyperresponsiveness of platelets in ischemic stroke. *Thromb Haemost* 2007 Jun;97(6):974-78. PMID: 17549300.

Fatini C, Sticchi E, Bolli P, et al. eNOS gene influences platelet phenotype in acute coronary syndrome patients on dual antiplatelet treatment. *Platelets* 2009 Dec;20(8):548-54. PMID: 19891529.

Fatini C, Sticchi E, Bolli P, et al. Platelet aggregability is modulated by eNOS locus in non-type 2 diabetic patients with acute coronary syndrome. *Nutr Metab Cardiovasc Dis* 2011 Jan;21(1):11-17. PMID: 19819117.

Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. *Int J Cardiol* 2007 Aug 21;120(2):188-92. PMID: 17169448.

Ferreiro JL, Ueno M, Desai B, et al. Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. *Rev Esp Cardiol (Engl Ed)* 2012 Jan;65(1):105-06. PMID: 21783310.

- Flierl U, Fraccarollo D, Lausenmeyer E, et al. Fractalkine activates a signal transduction pathway similar to P2Y₁₂ and is associated with impaired clopidogrel responsiveness. *Arterioscler Thromb Vasc Biol* 2012 Aug;32(8):1832-40. PMID: 22652599.
- Fong J, Cheng-Ching E, Hussain MS, et al. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. *J Stroke Cerebrovasc Dis* 2011 May;20(3):227-30. PMID: 20621513.
- Fontana P, Berdague P, Castelli C, et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. *J Thromb Haemost* 2010 Dec;8(12):2614-23. PMID: 20860677.
- Fontes-Carvalho R, Albuquerque A, Araujo C, et al. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. *Eur J Gastroenterol Hepatol* 2011 May;23(5):396-404. PMID: 21464720.
- Forbes CD, Lowe GD, MacLaren M, et al. Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist. *Semin Thromb Hemost* 1999;25 Suppl 2:55-60. PMID: 10440425.
- Fox SC, May JA, Shah A, et al. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. *Platelets* 2009 Jun;20(4):250-59. PMID: 19440925.
- Frelinger AL, III, Michelson AD, Wiviott SD, et al. Intrinsic platelet reactivity before P2Y₁₂ blockade contributes to residual platelet reactivity despite high-level P2Y₁₂ blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. *Thromb Haemost* 2011 Aug;106(2):219-26. PMID: 21713327.
- Freyenhofer MK, Bruno V, Willheim M, et al. Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter? *Thromb Haemost* 2012 Mar;107(3):538-44. PMID: 22274403.
- Fu Q, Yokoyama N, Takada K, et al. Comparison of platelet P2Y₁₂ ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting. *Int Heart J* 2010;51(5):303-07. PMID: 20966600.
- Fu XH, Hao QQ, Jia XW, et al. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. *Chin Med J (Engl)* 2008 Mar 20;121(6):522-27. PMID: 18364139.
- Fukuoka T, Furuya D, Takeda H, et al. Evaluation of clopidogrel resistance in ischemic stroke patients. *Intern Med* 2011;50(1):31-35. PMID: 21212570.
- Fukushima K, Kobayashi Y, Kitahara H, et al. Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study. *Heart Vessels* 2010 Jan;25(1):41-44. PMID: 20091397.
- Fukushima K, Kobayashi Y, Kitahara H, et al. Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement. *Circ J* 2008 Aug;72(8):1282-84. PMID: 18654014.

Fukushima K, Kobayashi Y, Kitahara H, et al. Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement. *Heart Vessels* 2010 May;25(3):182-86. PMID: 20512444.

Furman MI, Kereiakes DJ, Krueger LA, et al. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. *Am Heart J* 2001 Nov;142(5):790-98. PMID: 11685164.

Furman MI, Kereiakes DJ, Krueger LA, et al. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. *Am Heart J* 2003 Feb;145(2):e6. PMID: 12595861.

Gaglia MA, Jr., Torguson R, Pakala R, et al. Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity. *Am J Cardiol* 2011 Sep 15;108(6):766-71. PMID: 21752347.

Gajos G, Rostoff P, Undas A, et al. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. *J Am Coll Cardiol* 2010 Apr 20;55(16):1671-78. PMID: 20394870.

Gajos G, Rostoff P, Undas A, et al. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. *J Am Coll Cardiol* 2010 Apr 20;55(16):1671-78. PMID: 20394870.

Gao P, Xiong H, Zheng Z, et al. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing “one-stop” hybrid coronary revascularization. *Platelets* 2010;21(3):183-90. PMID: 20201634.

Garcia-Rinaldi R, Carro-Pagan C, Schaff HV, et al. Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses. *J Heart Valve Dis* 2009 Nov;18(6):617-25. PMID: 20099710.

Gawaz M, Seyfarth M, Muller I, et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. *Am J Cardiol* 2001 Feb 1;87(3):332-6, A9. PMID: 11165971.

Geara AS, Ayoub I, Abi RJ, et al. Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test? *Am J Cardiol* 2011 Apr 1;107(7):1103-04. PMID: 21419895.

Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. *Diabetes Care* 2007 Feb;30(2):372-74. PMID: 17259513.

Geisler T, Kapp M, Gohring-Frischholz K, et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. *Heart* 2008 Jun;94(6):743-47. PMID: 17567647.

Geisler T, Zurn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. *Eur Heart J* 2008 Jul;29(13):1635-43. PMID: 18503057.

Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. *J Am Coll Cardiol* 2008 Jan 22;51(3):256-60. PMID: 18206732.

Gilard M, Arnaud B, Le GG, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. *J Thromb Haemost* 2006 Nov;4(11):2508-09. PMID: 16898956.

Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. *JACC Cardiovasc Interv* 2008 Dec;1(6):612-19. PMID: 19463374.

Gorchakova O, von BN, Gawaz M, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. *Eur Heart J* 2004 Nov;25(21):1898-902. PMID: 15522468.

Gori AM, Cesari F, Marcucci R, et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. *Atherosclerosis* 2009 Jan;202(1):255-62. PMID: 18486134.

Graff J, Harder S, Wahl O, et al. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. *Clin Pharmacol Ther* 2005 Nov;78(5):468-76. PMID: 16321613.

Grdinic A, Vojvodic D, Djukanovic N, et al. PCI and clopidogrel: antiplatelet responsiveness and patient characteristics. *Acta Cardiol* 2011 Jun;66(3):333-40. PMID: 21744703.

Gremmel T, Kopp CW, Steiner S, et al. The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patients. *Atherosclerosis* 2011 Jul;217(1):135-38. PMID: 21497813.

Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. *Heart* 2010 Feb;96(3):186-89. PMID: 19687016.

Grossmann R, Sokolova O, Schnurr A, et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. *Thromb Haemost* 2004 Dec;92(6):1201-06. PMID: 15583724.

Guha S, Mookerjee S, Guha P, et al. Antiplatelet drug resistance in patients with recurrent acute coronary syndrome undergoing conservative management. *Indian Heart J* 2009 Jul;61(4):348-52. PMID: 20635737.

Guha S, Sardar P, Guha P, et al. Dual antiplatelet drug resistance in patients with acute coronary syndrome. *Indian Heart J* 2009 Jan;61(1):68-73. PMID: 19729693.

Guha S, Sardar P, Guha P, et al. Dual antiplatelet therapy in ACS: time-dependent variability in platelet aggregation during the first week. *Indian Heart J* 2009 Mar;61(2):173-77. PMID: 20039503.

Gurbel PA, Bliden KP, Etherington A, et al. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. *Thromb Res* 2007;121(1):107-15. PMID: 17400283.

Gurbel PA, Bliden KP, Guyer K, et al. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. *Thromb Res* 2007;119(5):563-70. PMID: 16806409.

Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. *J Am Coll Cardiol* 2005 May 3;45(9):1392-96. PMID: 15862408.

Gurbel PA, Bliden KP, Hiatt BL. The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition. *J Thromb Haemost* 2003 Jun;1(6):1319-21. PMID: 12871340.

Gurbel PA, Bliden KP, Saucedo JF, et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. *J Am Coll Cardiol* 2009 Feb 24;53(8):648-57. PMID: 19232896.

Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. *J Am Coll Cardiol* 2006 Dec 5;48(11):2186-91. PMID: 17161243.

Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. *Circulation* 2005 Mar 8;111(9):1153-59. PMID: 15738352.

Gurbel PA, Bliden KP. A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. *Platelets* 2003 Nov;14(7-8):481-83. PMID: 14713517.

Gurbel PA, Bliden KP. Interpretation of platelet inhibition by clopidogrel and the effect of non-responders. *J Thromb Haemost* 2003 Jun;1(6):1318-19. PMID: 12871339.

Gurbel PA, Cummings CC, Bell CR, et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. *Am Heart J* 2003 Feb;145(2):239-47. PMID: 12595840.

Gurbel PA, Malinin AI, Callahan KP, et al. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. *Am J Cardiol* 2002 Aug 1;90(3):312-15. PMID: 12127620.

Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. *J Am Coll Cardiol* 2008 Aug 26;52(9):743-49. PMID: 18718422.

Hafizullah M. Comparison of loading dose of 300mg versus 600mg of clopidogrel on platelet aggregation in patients with coronary artery disease. *Pakistan Heart Journal* 2006;39(3-4)

Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. *Thromb Haemost* 2010 May;103(5):920-25. PMID: 20352154.

Harmsze AM, van Werkum JW, Moral F, et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. *Platelets* 2011;22(2):98-102. PMID: 21142408.

Helft G, Osende JJ, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. *Arterioscler Thromb Vasc Biol* 2000 Oct;20(10):2316-21. PMID: 11031221.

Helgason CM, Grossi E, Pandey D, et al. Platelet aggregation and recruitment with aspirin-clopidogrel therapy. *Cerebrovasc Dis* 2008;25(5):392-400. PMID: 18349532.

Herrmann HC, Swierkosz TA, Kapoor S, et al. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. *Am J Cardiol* 2002 Jun 1;89(11):1293-97. PMID: 12031731.

Hezard N, Metz D, Garnotel R, et al. Platelet VASP phosphorylation assessment in clopidogrel-treated patients: lack of agreement between Western blot and flow cytometry. *Platelets* 2005 Dec;16(8):474-81. PMID: 16323337.

Hobson AR, Petley GW, Dawkins KD, et al. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. *Platelets* 2007 Nov;18(7):497-505. PMID: 17957565.

Hobson AR, Qureshi Z, Banks P, et al. Effects of clopidogrel on “aspirin specific” pathways of platelet inhibition. *Platelets* 2009 Sep;20(6):386-90. PMID: 19811222.

Hobson AR, Qureshi Z, Banks P, et al. The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses. *Thrombosis* 2010;2010:908272. PMID: 22084661.

Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. *Circulation* 2005 May 24;111(20):2560-64. PMID: 15809367.

Hogberg C, Gidlöf O, Deflorian F, et al. Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁(2) receptor-mediated platelet aggregation. *Thromb Haemost* 2012 Jul;108(1):119-32. PMID: 22628078.

Hong SJ, Park JY, Kim KA, et al. Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome. *Circ J* 2009 Jun;73(6):1111-18. PMID: 19372620.

Huczek Z, Filipiak KJ, Kochman J, et al. Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study. *Thromb Res* 2010 May;125(5):406-12. PMID: 19786298.

Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y₁₂ antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. *Eur Heart J* 2006 May;27(9):1038-47. PMID: 16476694.

Husted SE, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. *Clin Pharmacokinet* 2012 Jun 1;51(6):397-409. PMID: 22515556.

Ignjatovic VS, Petrovic N, Miloradovic V, et al. The influence of bisoprolol dose on ADP-induced platelet aggregability in patients on dual antiplatelet therapy. *Coron Artery Dis* 2010 Dec;21(8):472-76. PMID: 20861734.

Inami N, Nomura S, Kajiura T, et al. Significance of alpha(IIb)beta(3) in subacute stent thrombosis after percutaneous coronary intervention. *Clin Appl Thromb Hemost* 2005 Oct;11(4):455-59. PMID: 16244772.

Isordia-Salas I, Olalde-Roman MJ, Santiago-German D, et al. The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population. *Thromb Res* 2012 Sep;130(3):e67-e72. PMID: 22819265.

Ivandic BT, Giannitsis E, Schlick P, et al. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. *Clin Chem* 2007 Apr;53(4):614-19. PMID: 17332149.

Ivandic BT, Kurz K, Keck F, et al. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes. *Thromb Haemost* 2008 Oct;100(4):648-54. PMID: 18841288.

Ivandic BT, Schlick P, Staritz P, et al. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y₁₂ receptor. *Clin Chem* 2006 Mar;52(3):383-88. PMID: 16423907.

Izaguirre-Avila R, De IP-D, Barinagarrementeria-Aldatz F, et al. Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. *Clin Appl Thromb Hemost* 2002 Apr;8(2):169-77. PMID: 12121059.

Jagroop IA, Matsagas MI, Geroulakos G, et al. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. *Platelets* 2004 Mar;15(2):117-25. PMID: 15154604.

Jain R, Sood J. Antiplatelet therapy in patients with coronary artery stents for noncardiac surgery: Role of thromboelastography. *J Anaesthesiol Clin Pharmacol* 2011 Oct;27(4):537-40. PMID: 22096292.

Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. *J Intern Med* 2002 Sep;252(3):233-38. PMID: 12270003.

Jeon HW, Cha JK. Factors related to progression of middle cerebral artery stenosis determined using transcranial Doppler ultrasonography. *J Thromb Thrombolysis* 2008 Jun;25(3):265-69. PMID: 17541765.

Jeong YH, Bliden KP, Antonino MJ, et al. Usefulness of the VerifyNow P2Y₁₂ assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. *Am Heart J* 2012 Jul;164(1):35-42. PMID: 22795280.

Jeong YH, Cho JH, Kang MK, et al. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. *Thromb Res* 2010 Oct;126(4):e334-e338. PMID: 20451242.

Jeong YH, Hwang JY, Kim IS, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. *Circ Cardiovasc Interv* 2010 Feb 1;3(1):17-26. PMID: 20118150.

Jeong YH, Koh JS, Kang MK, et al. The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study. *Korean J Intern Med* 2010 Jun;25(2):154-61. PMID: 20526388.

Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. *J Am Coll Cardiol* 2009 Mar 31;53(13):1101-09. PMID: 19324253.

Jeong YH, Park Y, Bliden KP, et al. High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. *Heart* 2012 Feb;98(4):343-44. PMID: 22076014.

Jeong YH, Park Y, Kim IS, et al. Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions. *Thromb Haemost* 2010 Dec;104(6):1286-89. PMID: 20838742.

Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. *Eur Heart J* 2006 May;27(10):1166-73. PMID: 16621870.

Jin EZ, Yu LH, Li XQ. Loading effect of 200 mg cilostazol on platelet inhibition in patients undergoing percutaneous coronary intervention. *Int Heart J* 2012;53(1):1-4. PMID: 22398668.

Judge HM, Patil SB, Buckland RJ, et al. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y₁₂ receptor blockade and inhibition of platelet aggregation after clopidogrel. *J Thromb Haemost* 2010 Aug;8(8):1820-27. PMID: 20492465.

Kafian S, Mobarrez F, Kalani M, et al. Comparison of venous and arterial blood sampling for the assessment of platelet aggregation with whole blood impedance aggregometry. *Scand J Clin Lab Invest* 2011 Dec;71(8):637-40. PMID: 21870998.

Kamath S, Blann AD, Chin BS, et al. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. *J Am Coll Cardiol* 2002 Aug 7;40(3):484-90. PMID: 12142115.

Kar R, Meena A, Yadav BK, et al. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y₁ and P2Y₁₂ gene polymorphisms. *Platelets* 2013;24(4):297-302. PMID: 22721490.

Karlsson F, Modica A, Moos T. Association of level of kidney function and platelet aggregation in acute myocardial infarction. *Am J Kidney Dis* 2009 Aug;54(2):262-69. PMID: 19560852.

Kastrati A, von BN, Joost A, et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. *Circulation* 2004 Oct 5;110(14):1916-19. PMID: 15262828.

Khan NA, Peterson JF. A surveillance tool to support quality assurance and research in personalized medicine. *AMIA Annu Symp Proc* 2011;2011:701-08. PMID: 22195126.

Khan SB, Hameedullah, Noor L, et al. Comparison of effect of locally available brands of clopidogrel on platelet aggregation in patients with coronary artery disease. *J Ayub Med Coll Abbottabad* 2010 Jan;22(1):115-17. PMID: 21409920.

Kim GB, Kim JK, Park S, et al. Effect of atorvastatin and clopidogrel co-administration after coronary stenting in korean patients with stable angina. *Korean Circ J* 2011 Jan;41(1):28-33. PMID: 21359066.

Kim H, Lee HK, Han K, et al. Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. *Ann Clin Lab Sci* 2009;39(3):289-94. PMID: 19667414.

Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. *Circ J* 2007 Dec;71(12):1867-72. PMID: 18037738.

Kimmelstiel C, Badar J, Covic L, et al. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. *Thromb Res* 2005;116(1):55-66. PMID: 15850609.

Kimmelstiel C, Zhang P, Kapur NK, et al. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. *Circ Cardiovasc Interv* 2011 Apr 1;4(2):171-79. PMID: 21364148.

King A, Bath PM, Markus HS. Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial. *Stroke* 2011 Mar;42(3):650-55. PMID: 21257829.

Klinkhardt U, Bauersachs R, Adams J, et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. *Clin Pharmacol Ther* 2003 Mar;73(3):232-41. PMID: 12621388.

Konopka A, Spychalska J, Sitkiewicz D, et al. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone. *Am J Cardiovasc Drugs* 2007;7(6):433-39. PMID: 18076210.

Kottke-Marchant K, Powers JB, Brooks L, et al. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). *Clin Appl Thromb Hemost* 1999 Apr;5(2):122-30. PMID: 10725993.

Kotzailias N, Elwischger K, Sycha T, et al. Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. *J Stroke Cerebrovasc Dis* 2007 Sep;16(5):199-202. PMID: 17845916.

Kozinski M, Bielis L, Wisniewska-Szmyt J, et al. Diurnal variation in platelet inhibition by clopidogrel. *Platelets* 2011;22(8):579-87. PMID: 21627410.

Kozinski M, Bielis L, Wisniewska-Szmyt J, et al. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. *Cardiol J* 2008;15(6):530-36. PMID: 19039757.

Krischek B, Brannath W, Klinkhardt U, et al. Role of the retention test Homburg in evaluating platelet hyperactivity and in monitoring therapy with antiplatelet drugs. *Semin Thromb Hemost* 2005;31(4):458-63. PMID: 16149024.

Kuliczowski W, Greif M, Gasior M, et al. Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *Kardiol Pol* 2011;69(6):531-37. PMID: 21678284.

Kumar S, Saran RK, Puri A, et al. Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome. *Indian Heart J* 2007 Mar;59(2):152-56. PMID: 19122249.

Kwan J, Htun WW, Huang Y, et al. Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention. *Vasc Health Risk Manag* 2011;7:399-404. PMID: 21796254.

Labarthe B, Babin J, Bryckaert M, et al. Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel. *Br J Pharmacol* 2012 May;166(1):221-31. PMID: 21950486.

Labarthe B, Theroux P, Angioi M, et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. *J Am Coll Cardiol* 2005 Aug 16;46(4):638-45. PMID: 16098428.

Lahiri P, Roy S, Sardar P, et al. Platelet responsiveness to yohimbine hydrochloride and MRS2179 in the context of the interaction between collagen and epinephrine in acute coronary syndrome. *Blood Cells Mol Dis* 2009 Jul;43(1):105-10. PMID: 19272818.

Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. *Circulation* 2004 Jan 20;109(2):166-71. PMID: 14707025.

Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. *Circulation* 2003 Jan 7;107(1):32-37. PMID: 12515739.

Lee BK, Lee SW, Park SW, et al. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. *Am J Cardiol* 2007 Aug 15;100(4):610-14. PMID: 17697815.

Lee DH, Arat A, Morsi H, et al. Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. *AJNR Am J Neuroradiol* 2008 Aug;29(7):1389-94. PMID: 18483190.

Lee DH, Kim HS, Kim SM, et al. Change of Platelet Reactivity to Antiplatelet Therapy after Stenting Procedure for Cerebral Artery Stenosis: VerifyNow Antiplatelet Assay before and after Stenting. *Neurointervention* 2012 Feb;7(1):23-26. PMID: 22454781.

Lee J, Hwang Y, Kang W, et al. Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. *J Clin Pharmacol* 2012 Jul;52(7):985-95. PMID: 21617016.

Lee JM, Park S, Shin DJ, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. *Am J Cardiol* 2009 Jul 1;104(1):46-51. PMID: 19576320.

Lee K, Kim JY, Yoo BS, et al. Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. *J Thromb Haemost* 2010 Nov;8(11):2577-79. PMID: 20723027.

Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. *Eur Heart J* 2004 Mar;25(6):476-83. PMID: 15039127.

Lev EI, Arian ME, Vaduganathan M, et al. Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease. *Am Heart J* 2007 Oct;154(4):694-97. PMID: 17892993.

Li J, Jian Z, Huang L, et al. Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease. *Biomed Pharmacother* 2009 Sep;63(8):608-12. PMID: 19019624.

Li Y, Tai BC, Sia W, et al. Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention. *J Thromb Thrombolysis* 2012 Nov;34(4):499-505. PMID: 22855283.

Loreth RM, Klose G. Comparison of Two Different Blood Sample Tubes for Platelet Function Analysis with the Multiplate(R) System. *Transfus Med Hemother* 2010;37(5):289-92. PMID: 21113252.

Luchessi AD, Silbiger VN, Cerda A, et al. Increased clopidogrel response is associated with ABCC3 expression: a pilot study. *Clin Chim Acta* 2012 Feb 18;413(3-4):417-21. PMID: 22040781.

Madan M, Berkowitz SD, Christie DJ, et al. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. *Am Heart J* 2002 Jul;144(1):151-58. PMID: 12094202.

Madan M, Radhakrishnan S, Reis M, et al. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). *Am J Cardiol* 2005 Jun 1;95(11):1295-301. PMID: 15904632.

Madsen NJ, Holmes CE, Serrano FA, et al. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents. *Am J Cardiol* 2007 Aug 15;100(4):722-27. PMID: 17697836.

Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. *Circ Cardiovasc Interv* 2012 Apr;5(2):261-69. PMID: 22396581.

Malek LA, Bilinska ZT, Sitkiewicz D, et al. Platelet reactivity on aspirin, clopidogrel and abciximab in patients with acute coronary syndromes and reduced estimated glomerular filtration rate. *Thromb Res* 2010 Jan;125(1):67-71. PMID: 19443019.

Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. *Thromb Res* 2007;119(3):277-84. PMID: 16563469.

Malinin AI, Oshrine BR, Sane DC, et al. Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? *Blood Coagul Fibrinolysis* 2007 Mar;18(2):91-96. PMID: 17287623.

Malmstrom RE, Ostergren J, Jorgensen L, et al. Poor performance with a platelet counting technique to monitor clopidogrel inhibitory effects in the point-of-care setting. *Thromb Res* 2010 May;125(5):473-74. PMID: 19896705.

Marcucci R, Cesari F, Cinotti S, et al. ADAMTS-13 activity in the presence of elevated von Willebrand factor levels as a novel mechanism of residual platelet reactivity in high risk coronary patients on antiplatelet treatment. *Thromb Res* 2008;123(1):130-36. PMID: 18603284.

Mardikar HM, Hiremath MS, Moliterno DJ, et al. Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study. *Am Heart J* 2007 Aug;154(2):344-45. PMID: 17643586.

Maruyama H, Takeda H, Dembo T, et al. Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay. *Intern Med* 2011;50(7):695-98. PMID: 21467700.

Massberg S, Mueller I, Besta F, et al. Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. *Am Heart J* 2003 Nov;146(5):E19. PMID: 14597948.

Matetzky S, Fefer P, Shenkman B, et al. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. *Am J Cardiol* 2008 Sep 1;102(5):524-29. PMID: 18721506.

Matetzky S, Fefer P, Shenkman B, et al. Statins have an early antiplatelet effect in patients with acute myocardial infarction. *Platelets* 2011;22(2):103-10. PMID: 21171935.

Matsagas M, Jagroop IA, Geroulakos G, et al. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. *Clin Appl Thromb Hemost* 2003 Apr;9(2):115-20. PMID: 12812379.

Matsuyama N, Takano K, Miura A, et al. The effect of anti-platelet aggregation to prevent pressure ulcer development: a retrospective study of 132 elderly patients. *Gerontology* 2000 Nov;46(6):311-17. PMID: 11044785.

Mendolicchio GL, Zavalloni D, Bacci M, et al. Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood. *J Thromb Haemost* 2011 Feb;9(2):373-82. PMID: 21083646.

Meng K, Lu SZ, Zhu HG, et al. Use of tailored loading-dose clopidogrel in patients undergoing selected percutaneous coronary intervention based on adenosine diphosphate-mediated platelet aggregation. *Chin Med J (Engl)* 2010 Dec;123(24):3578-82. PMID: 22166634.

- Mengistu AM, Mayer J, Boldt J, et al. Usefulness of monitoring platelet function by multiple electrode aggregometry in primary coronary artery bypass surgery. *J Cardiothorac Vasc Anesth* 2011 Feb;25(1):42-47. PMID: 20427204.
- Metzler H, Pruller F, Munch A, et al. Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y₁₂ receptor monitoring. *Eur J Anaesthesiol* 2010 Feb;27(2):138-45. PMID: 19593147.
- Meuris B, Arnout J, Vlasselaers D, et al. Long-term management of an implantable left ventricular assist device using low molecular weight heparin and antiplatelet therapy: a possible alternative to oral anticoagulants. *Artif Organs* 2007 May;31(5):402-05. PMID: 17470211.
- Meves SH, Overbeck U, Endres HG, et al. Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke. *Thromb Haemost* 2012 Jan;107(1):69-79. PMID: 22159509.
- Michelson AD, Linden MD, Furman MI, et al. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. *J Thromb Haemost* 2007 Jan;5(1):75-81. PMID: 17002661.
- Milburn JA, Ford I, Cassar K, et al. Platelet activation, coagulation activation and C-reactive protein in simultaneous samples from the vascular access and peripheral veins of haemodialysis patients. *Int J Lab Hematol* 2012 Feb;34(1):52-58. PMID: 21722325.
- Mitsios JV, Papathanasiou AI, Elisaf M, et al. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. *Platelets* 2005 Aug;16(5):287-92. PMID: 16011979.
- Mitsios JV, Papathanasiou AI, Rodis FI, et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. *Circulation* 2004 Mar 23;109(11):1335-38. PMID: 15023882.
- Mizia-Stec K, Haberka M, Mizia M, et al. Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. *Pharmacol Rep* 2012;64(2):360-68. PMID: 22661187.
- Moceri P, Doyen D, Cerboni P, et al. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. *Thromb Res* 2011 Nov;128(5):458-62. PMID: 21777954.
- Mokhtar OA, Lemesle G, Armero S, et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. *Thromb Res* 2010 Aug;126(2):e147-e149. PMID: 20129650.
- Morel O, El GS, Hess S, et al. The extent of P2Y₁₂ inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. *Thromb Haemost* 2012 Aug;108(2):338-48. PMID: 22740070.
- Morel O, Faure A, Ohlmann P, et al. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis. *Thromb Haemost* 2007 Oct;98(4):896-99. PMID: 17938817.

Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. *J Am Coll Cardiol* 2000 Sep;36(3):699-705. PMID: 10987587.

Motovska Z, Odvodyova D, Fischerova M, et al. Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention. *Am J Cardiol* 2012 Mar 1;109(5):620-23. PMID: 22154314.

Motovska Z, Widimsky P, Petr R, et al. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". *J Cardiovasc Pharmacol* 2009 May;53(5):368-72. PMID: 19247187.

Motovska Z, Widimsky P, Petr R, et al. Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. *Int J Cardiol* 2010 Oct 8;144(2):255-57. PMID: 19232444.

Mrdovic I, Savic L, Krljanac G, et al. Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial. *Int J Cardiol* 2012 May 22 PMID: 22626838.

Mueller T, Dieplinger B, Poelz W, et al. Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease. *Clin Appl Thromb Hemost* 2009 Dec;15(6):652-59. PMID: 18805846.

Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer--comparison with two flow cytometric methods. *Thromb Res* 2007;121(2):249-58. PMID: 17482663.

Mueller T, Haltmayer M, Poelz W, et al. Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. *Vasc Endovascular Surg* 2003 Mar;37(2):117-23. PMID: 12669143.

Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. *Circulation* 2003 Nov 4;108(18):2195-97. PMID: 14568892.

Muller I, Massberg S, Zierhut W, et al. Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (CLAFIB). *Pathophysiol Haemost Thromb* 2002 Jan;32(1):16-24. PMID: 12214159.

Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. *Heart* 2001 Jan;85(1):92-93. PMID: 11119474.

Muller O, Hamilos M, Bartunek J, et al. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. *Am J Cardiol* 2010 Feb 1;105(3):333-38. PMID: 20102944.

Mylotte D, Peace AJ, Tedesco AT, et al. Clopidogrel discontinuation and platelet reactivity following coronary stenting. *J Thromb Haemost* 2011 Jan;9(1):24-32. PMID: 20961396.

Naidech AM, Bassin SL, Bernstein RA, et al. Reduced platelet activity is more common than reported anti-platelet medication use in patients with intracerebral hemorrhage. *Neurocrit Care* 2009 Dec;11(3):307-10. PMID: 19381881.

Naidech AM, Liebling SM, Rosenberg NF, et al. Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage. *Neurocrit Care* 2012 Feb;16(1):82-87. PMID: 21837536.

Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. *Eur Heart J* 2003 Oct;24(19):1744-49. PMID: 14522569.

Neubauer H, Lask S, Engelhardt A, et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. *Thromb Haemost* 2008 Feb;99(2):357-62. PMID: 18278186.

Nguyen TA, Lordkipanidze M, Diodati JG, et al. Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial. *J Interv Cardiol* 2009 Aug;22(4):368-77. PMID: 19689661.

Nielsen AB, Bochsén L, Steinbruchel DA. Hypercoagulability and platelet inhibition after OPCAB. Randomized intervention with clopidogrel. *Scand Cardiovasc J* 2007 Oct;41(5):325-30. PMID: 17852789.

Osmancik P, Jirmar R, Hulikova K, et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. *Catheter Cardiovasc Interv* 2010 Feb 1;75(2):158-66. PMID: 19902490.

Osmancik P, Paulu P, Tousek P, et al. High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. *J Thromb Thrombolysis* 2012 May;33(4):349-54. PMID: 22189756.

Osmancik PP, Bednar F, Mocikova H. Glycemia, triglycerides and disease severity are best associated with higher platelet activity in patients with stable coronary artery disease. *J Thromb Thrombolysis* 2007 Oct;24(2):105-07. PMID: 17308964.

Ostad MA, Nick E, Paixao-Gatinho V, et al. Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study. *Clin Res Cardiol* 2011 Jan;100(1):29-36. PMID: 20644943.

Pandya DJ, Fitzsimmons BF, Wolfe TJ, et al. Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose. *J Neuroimaging* 2010 Jan;20(1):64-69. PMID: 19018951.

Paniccia R, Antonucci E, Gori AM, et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. *Am J Clin Pathol* 2007 Jul;128(1):143-49. PMID: 17580282.

Papp E, Havasi V, Bene J, et al. Does glycoprotein IIIa gene (Pl(A)) polymorphism influence clopidogrel resistance? : a study in older patients. *Drugs Aging* 2007;24(4):345-50. PMID: 17432927.

Park KJ, Chung HS, Kim SR, et al. Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. *Korean J Lab Med* 2011 Apr;31(2):91-94. PMID: 21474982.

Park KW, Kang SH, Kang J, et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox'. *Heart* 2012 Jul;98(13):1000-06. PMID: 22572048.

Park KW, Park JJ, Jeon KH, et al. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. *Cardiovasc Ther* 2012 Feb;30(1):5-11. PMID: 21129165.

Park SH, Kim W, Park CS, et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. *Am J Cardiol* 2009 Nov 1;104(9):1292-95. PMID: 19840579.

Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. *JAMA* 2011 Sep 21;306(11):1215-23. PMID: 21934054.

Pasqualini L, Pirro M, Lombardini R, et al. A human model of platelet-leucocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease. *J Clin Pathol* 2002 Dec;55(12):946-50. PMID: 12461065.

Pattanaik S, Malhotra S, Sharma YP, et al. Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome. *Int J Clin Pharmacol Ther* 2010 Feb;48(2):93-102. PMID: 20137761.

Patti G, Chello M, Pasceri V, et al. Pretreatment with different loading doses of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) SELECT substudy. *J Cardiovasc Med (Hagerstown)* 2011 Mar;12(3):151-56. PMID: 21085001.

Patti G, Grieco D, Dicuonzo G, et al. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. *J Am Coll Cardiol* 2011 Feb 15;57(7):771-78. PMID: 21310311.

Payne DA, Jones CI, Hayes PD, et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. *Circulation* 2004 Mar 30;109(12):1476-81. PMID: 15007001.

Payne DA, Jones CI, Hayes PD, et al. Therapeutic benefit of low-dose clopidogrel in patients undergoing carotid surgery is linked to variability in the platelet adenosine diphosphate response and patients' weight. *Stroke* 2007 Sep;38(9):2464-69. PMID: 17656657.

Peace AJ, Tedesco AF, Foley DP, et al. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. *J Thromb Haemost* 2008 Dec;6(12):2027-34. PMID: 18823340.

Perneby C, Wallen NH, Hofman-Bang C, et al. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. *Thromb Haemost* 2007 Dec;98(6):1316-22. PMID: 18064330.

Petricevic M, Biocina B, Konosic S, et al. Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy. *Heart Vessels* 2013 Jan;28(1):57-65. PMID: 22203409.

Pham JP, Ueno M, Tello-Montoliu A, et al. Impact of gastric acid-suppressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study. *J Am Coll Cardiol* 2011 Sep 20;58(13):1396-98. PMID: 21920272.

Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? *J Am Coll Cardiol* 2007 Mar 13;49(10):1035-42. PMID: 17349882.

Piorkowski M, Priess J, Weikert U, et al. Abciximab therapy is associated with increased platelet activation and decreased heparin dosage in patients with acute myocardial infarction. *Thromb Haemost* 2005 Aug;94(2):422-26. PMID: 16113834.

Piorkowski M, Weikert U, Schwimmbeck PL, et al. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. *Thromb Haemost* 2004 Sep;92(3):614-20. PMID: 15351859.

Polena S, Gupta MP, Shaikh H, et al. Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4. *Proc West Pharmacol Soc* 2008;51:60-62. PMID: 19544679.

Pongracz E. Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke. *Clin Hemorheol Microcirc* 2004;30(3-4):237-42. PMID: 15258349.

Poyet R, Cuisset T, Frere C, et al. Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation). *Thromb Res* 2010 Nov;126(5):e397-e399. PMID: 20825983.

Prabhakaran S, Wells KR, Lee VH, et al. Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. *AJNR Am J Neuroradiol* 2008 Feb;29(2):281-85. PMID: 17989373.

Price MJ, Walder JS, Baker BA, et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. *J Am Coll Cardiol* 2012 Jun 19;59(25):2338-43. PMID: 22698488.

Quinn MJ, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. *Am J Cardiol* 2004 Mar 15;93(6):679-84. PMID: 15019868.

Qureshi AI, Siddiqui AM, Hanel RA, et al. Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: a prospective registry. *Neurosurgery* 2004 Feb;54(2):307-16. PMID: 14744276.

Raman S, Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. *J Thromb Haemost* 2004 Dec;2(12):2278-79. PMID: 15613054.

Ravn HB, Hjortdal VE, Stenbog EV, et al. Increased platelet reactivity and significant changes in coagulation markers after cavopulmonary connection. *Heart* 2001 Jan;85(1):61-65. PMID: 11119465.

Ray MJ, Juneja M, Bett N, et al. A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. *EuroIntervention* 2009 Aug;5(3):330-35. PMID: 19736157.

Ray MJ, Walters DL, Bett N, et al. Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2004 Jun;62(2):150-54. PMID: 15170702.

Ren YH, Yang TS, Wang Y, et al. Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome. *Chin Med J (Engl)* 2008 May 5;121(9):850-52. PMID: 18701053.

Riondino S, Petrini N, Donato L, et al. Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. *J Thromb Thrombolysis* 2009 Aug;28(2):151-55. PMID: 18636229.

Robier C, Neubauer M, Sternad H, et al. Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry. *Thromb Res* 2010 Sep;126(3):232-37. PMID: 20630570.

Sagcan A, Nalbantgil S, Omay SB, et al. The effect of type II diabetes mellitus on platelet aggregation in patients who underwent percutaneous transluminal coronary angioplasty. *Coron Artery Dis* 2002 Feb;13(1):45-48. PMID: 11917198.

Sairaku A, Nakano Y, Eno S, et al. Platelet function measured using a whole blood aggregometer can predict bleeding events. *J Atheroscler Thromb* 2011;18(1):16-23. PMID: 21060210.

Samara WM, Bliden KP, Tantry US, et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. *Thromb Res* 2005;115(1-2):89-94. PMID: 15567458.

Sambu N, Radhakrishnan A, Dent H, et al. Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry. *Heart* 2012 May;98(9):706-11. PMID: 22523055.

Sarafoff N, Neumann L, Morath T, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. *Am Heart J* 2011 Mar;161(3):605-10. PMID: 21392618.

Saucedo JF, Aude W, Pacheco R, et al. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The Pharmacodynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study). *Am J Cardiol* 2005 Jun 15;95(12):1453-56. PMID: 15950569.

Sbrana S, Della PF, Rizza A, et al. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation. *Cytometry B Clin Cytom* 2008 Jan;74(1):30-39. PMID: 17630652.

Schafer A, Flierl U, Pfortsch S, et al. The H(2)-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y(12) inhibition in platelets. *Pharmacol Res* 2010 Oct;62(4):352-56. PMID: 20595015.

Serebruany V, Cherala G, Williams C, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". *Am Heart J* 2009 Dec;158(6):925-32. PMID: 19958858.

Serebruany V, Pokov I, Kulickowski W, et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. *Thromb Haemost* 2008 Jul;100(1):76-82. PMID: 18612541.

Serebruany V, Rao SV, Silva MA, et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. *Eur Heart J* 2010 Jan;31(2):227-35. PMID: 19854728.

Serebruany VL, Kogushi M, stros-Pitei D, et al. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. *Thromb Haemost* 2009 Jul;102(1):111-19. PMID: 19572075.

Serebruany VL, Malinin AI, Atar D, et al. Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. *Am Heart J* 2007 Mar;153(3):371-77. PMID: 17307414.

Serebruany VL, Malinin AI, Atar D. Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients. *Cardiology* 2007;107(4):307-12. PMID: 17264511.

Serebruany VL, Malinin AI, Pokov A, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. *Am Heart J* 2008 Jan;155(1):93-97. PMID: 18082496.

Serebruany VL, Malinin AI, Pokov A, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. *Am Heart J* 2008 Jan;155(1):93-97. PMID: 18082496.

Serebruany VL, Malinin AI, Ziai W, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. *Stroke* 2005 Oct;36(10):2289-92. PMID: 16151033.

Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. *Arch Intern Med* 2004 Oct 11;164(18):2051-57. PMID: 15477442.

Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. *J Am Coll Cardiol* 2005 Jan 18;45(2):246-51. PMID: 15653023.

Serrano Junior CV, Soeiro AM, Araujo LF, et al. Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation. *Arq Bras Cardiol* 2010 Sep;95(3):321-27. PMID: 20721515.

Seyfarth HJ, Kokschi M, Roethig G, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. *Am Heart J* 2002 Jan;143(1):118-23. PMID: 11773921.

Shechter M, Shechter A, Hod H, et al. Brachial artery endothelial function predicts platelet function in control subjects and in patients with acute myocardial infarction. *Platelets* 2012;23(3):202-10. PMID: 21824040.

Shim CY, Yoon SJ, Park S, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. *Int J Cardiol* 2009 May 29;134(3):351-55. PMID: 18579227.

Shim JK, Choi YS, Oh YJ, et al. Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery. *J Thorac Cardiovasc Surg* 2007 Jul;134(1):59-64. PMID: 17599487.

Sibbing D, Busch G, Braun S, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. *Eur Heart J* 2008 Jun;29(12):1504-09. PMID: 18467322.

Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. *Thromb Haemost* 2009 Apr;101(4):714-19. PMID: 19350116.

Sibbing D, Stegherr J, Braun S, et al. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. *J Am Coll Cardiol* 2010 Feb 9;55(6):558-65. PMID: 20152561.

Sibbing D, von BN, Morath T, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. *Eur Heart J* 2010 May;31(10):1205-11. PMID: 20159881.

Sibbing D, von BO, Schomig A, et al. Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. *J Thromb Haemost* 2006 Dec;4(12):2566-68. PMID: 16938125.

Sibbing D, von BO, Schomig A, et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. *Am J Cardiol* 2007 Jul 15;100(2):203-05. PMID: 17631070.

Sibbing D, von BO, Schomig A, et al. Platelet function in clopidogrel-treated patients with acute coronary syndrome. *Blood Coagul Fibrinolysis* 2007 Jun;18(4):335-39. PMID: 17473574.

Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. *J Am Coll Cardiol* 2008 Nov 4;52(19):1557-63. PMID: 19007592.

Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. *Am Heart J* 2009 Jan;157(1):148-5. PMID: 19081411.

Skowasch D, Viktor A, Schneider-Schmitt M, et al. Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril. *Clin Res Cardiol* 2006 Apr;95(4):212-16. PMID: 16598590.

Slugg PH, Much DR, Smith WB, et al. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. *J Clin Pharmacol* 2000 Apr;40(4):396-401. PMID: 10761167.

Smith SM, Judge HM, Peters G, et al. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. *Platelets* 2004 Dec;15(8):465-74. PMID: 15763887.

Smout JD, Mikhailidis DP, Shenton BK, et al. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. *Clin Appl Thromb Hemost* 2004 Jan;10(1):9-18. PMID: 14979400.

Smout JD, Mikhailidis DP, Shenton BK, et al. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. *Clin Appl Thromb Hemost* 2004 Jan;10(1):9-18. PMID: 14979400.

Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? *Catheter Cardiovasc Interv* 2003 May;59(1):21-25. PMID: 12720236.

Solheim S, Pettersen AA, Arnesen H, et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. *Thromb Haemost* 2006 Nov;96(5):660-64. PMID: 17080224.

Solinas E, Gobbi G, Dangas G, et al. Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes. *J Thromb Thrombolysis* 2009 Jan;27(1):36-43. PMID: 18049795.

Staritz P, Kurz K, Stoll M, et al. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y₁₂-ADP receptor gene. *Int J Cardiol* 2009 Apr 17;133(3):341-45. PMID: 18485500.

Sternberg Z, Ching M, Sawyer RN, et al. Clopidogrel Responsiveness in Stroke Patients on a Chronic Aspirin Regimen. *J Stroke Cerebrovasc Dis* 2011 Dec 28 PMID: 22209644.

Sternberg Z, Ching M, Sawyer RN, et al. Clopidogrel Responsiveness in Stroke Patients on a Chronic Aspirin Regimen. *J Stroke Cerebrovasc Dis* 2011 Dec 28 PMID: 22209644.

Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATElet inhibition and patient Outcomes) PLATELET substudy. *J Am Coll Cardiol* 2010 Oct 26;56(18):1456-62. PMID: 20832963.

Storey RF, Bliden KP, Ecob R, et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. *J Thromb Haemost* 2011 Sep;9(9):1730-37. PMID: 21707911.

Storey RF, Judge HM, Wilcox RG, et al. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y₁₂ receptor antagonist AR-C69931MX but not aspirin. *Thromb Haemost* 2002 Sep;88(3):488-94. PMID: 12353080.

Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. *Platelets* 2002 Nov;13(7):407-13. PMID: 12487788.

Suh JW, Seung KB, Gwak CH, et al. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial. *Clin Ther* 2011 Aug;33(8):1057-68. PMID: 21816478.

Suryadevara S, Ueno M, Tello-Montoliu A, et al. Effects of pioglitazone on platelet P2Y₁₂-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. *Thromb Haemost* 2012 Nov;108(5):930-36. PMID: 22782352.

Szapary L, Bagoly E, Kover F, et al. The effect of carotid stenting on rheological parameters, free radical production and platelet aggregation. *Clin Hemorheol Microcirc* 2009;43(3):209-17. PMID: 19847055.

Talarico GP, Brancati M, Burzotta F, et al. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study. *J Cardiovasc Med (Hagerstown)* 2009 Mar;10(3):245-51. PMID: 19262211.

Talreja D, Lubbe D, Orford JL, et al. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study. *J Thromb Thrombolysis* 2004 Aug;18(1):25-30. PMID: 15744550.

Tang YD, Hasan F, Giordano FJ, et al. Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial. *Am Heart J* 2009 Dec;158(6):941-47. PMID: 19958860.

Taubert D, von BN, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. *Clin Pharmacol Ther* 2006 Nov;80(5):486-501. PMID: 17112805.

Tavassoli N, Voisin S, Carrie D, et al. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. *Am J Cardiovasc Drugs* 2010;10(1):29-35. PMID: 20104932.

Tekten T, Ceyhan C, Ercan E, et al. The effect of atorvastatin on platelet function in patients with coronary artery disease. *Acta Cardiol* 2004 Jun;59(3):311-15. PMID: 15255464.

Tetik S, Ak K, Isbir S, et al. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. *Clin Appl Thromb Hemost* 2010 Apr;16(2):189-98. PMID: 19703819.

Trenk D, Hochholzer W, Frundi D, et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. *Thromb Haemost* 2008 Jan;99(1):174-81. PMID: 18217151.

Trenk D, Hochholzer W, Muller B, et al. Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement. *EuroIntervention* 2008 Aug;4(2):214-21. PMID: 19110786.

Tsoumani ME, Kalantzi KI, Dimitriou AA, et al. Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate. *Angiology* 2012 Oct;63(7):547-51. PMID: 22144668.

Tsoumani ME, Kalantzi KI, Dimitriou AA, et al. Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. *Expert Opin Pharmacother* 2012 Feb;13(2):149-58. PMID: 22188544.

Tsukahara K, Kimura K, Morita S, et al. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. *J Cardiol* 2011 May;57(3):275-82. PMID: 21371863.

Tunggal P, Ng FH, Lam KF, et al. Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. *Am Heart J* 2011 Nov;162(5):870-74. PMID: 22093203.

Ueno M, Ferreira JL, Desai B, et al. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. *JACC Cardiovasc Interv* 2012 Mar;5(3):293-300. PMID: 22440495.

Ueno M, Ferreira JL, Tomasello SD, et al. Functional profile of the platelet P2Y₁(2) receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. *Thromb Haemost* 2011 Apr;105(4):730-32. PMID: 21225097.

Ueno M, Ferreira JL, Tomasello SD, et al. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. *JACC Cardiovasc Interv* 2011 Aug;4(8):905-12. PMID: 21851906.

Ural AU, Yilmaz MI, Avcu F, et al. Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components. *Int J Hematol* 2002 Oct;76(3):279-83. PMID: 12416740.

Valgimigli M, Tebaldi M, Campo G, et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. *JACC Cardiovasc Interv* 2012 Mar;5(3):268-77. PMID: 22440491.

van der Meijden PE, Feijge MA, Giesen PL, et al. Platelet P2Y₁₂ receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. *Thromb Haemost* 2005 Jun;93(6):1128-36. PMID: 15968399.

Van der Planken MG, Claeys MJ, Vertessen FJ, et al. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. *Thromb Res* 2003;111(3):159-64. PMID: 14678814.

van der Stelt CA, van Werkum JW, Seesing TH, et al. To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment. *Platelets* 2007 Nov;18(7):550-53. PMID: 17957573.

van Loon JE, de Jaegere PP, Ulrichs H, et al. The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. *Thromb Haemost* 2011 Jul;106(1):165-71. PMID: 21655675.

van Werkum JW, Gerritsen WB, Kelder JC, et al. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial. *Neth Heart J* 2007;15(11):375-81. PMID: 18176639.

van Werkum JW, Topcu Y, Postma S, et al. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. *Thromb Haemost* 2008 Mar;99(3):637-39. PMID: 18327417.

van Werkum JW, van der Stelt CA, Seesing TH, et al. The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. *J Thromb Haemost* 2007 Apr;5(4):881-83. PMID: 17263784.

Varon D, Lashevski I, Brenner B, et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. *Am Heart J* 1998 May;135(5 Pt 2 Su):S187-S193. PMID: 9588399.

Vasilieva E, Kasyanova O, Shpektor A. The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level. *Acute Card Care* 2008;10(3):181-84. PMID: 18608041.

Velik-Salchner C, Maier S, Innerhofer P, et al. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study. *Anesth Analg* 2009 Jun;108(6):1747-54. PMID: 19448196.

Vinholt P, Poulsen TS, Korsholm L, et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. *Thromb Haemost* 2005 Aug;94(2):438-43. PMID: 16113837.

Vogten JM, Gerritsen WB, Ackerstaff RG, et al. Perioperative microemboli and platelet aggregation in patients undergoing carotid endarterectomy. *Vascular* 2008 May;16(3):154-60. PMID: 18674464.

Volpi E, Giusti L, Ciregia F, et al. Platelet proteome and clopidogrel response in patients with stable angina undergoing percutaneous coronary intervention. *Clin Biochem* 2012 Jul;45(10-11):758-65. PMID: 22486984.

von BN, Kastrati A, Wiecek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. *Eur Heart J* 2007 Aug;28(15):1814-19. PMID: 17272357.

von BN, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolism, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. *Circulation* 2005 Nov 8;112(19):2946-50. PMID: 16260639.

von LF, Riggert J, Paulus W. Towards a rationale of platelet aggregation monitoring in stroke prophylaxis? *J Stroke Cerebrovasc Dis* 2009 Mar;18(2):111-15. PMID: 19251186.

Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y₁₂receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. *Eur Heart J* 2008 Jan;29(1):21-30. PMID: 18055486.

Walter T, Szabo S, Kazmaier S, et al. Effect of clopidogrel on adhesion molecules, hemostasis, and fibrinolysis in coronary heart disease. *J Cardiovasc Pharmacol* 2008 Jun;51(6):616-20. PMID: 18574391.

Walters DL, Ray MJ, Wood P, et al. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention. *Eur J Clin Invest* 2010 Feb;40(2):139-47. PMID: 20039931.

Wang XD, Zhang DF, Liu XB, et al. Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. *Eur J Intern Med* 2012 Jan;23(1):48-53. PMID: 22153531.

Warnholtz A, Ostad MA, Velich N, et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. *Atherosclerosis* 2008 Feb;196(2):689-95. PMID: 17214996.

Wenaweser P, Dorffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. *J Am Coll Cardiol* 2005 Jun 7;45(11):1748-52. PMID: 15936599.

Wenaweser P, Windecker S, Billinger M, et al. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. *Am J Cardiol* 2007 Feb 1;99(3):353-56. PMID: 17261397.

Wheeler GL, Braden GA, Bray PF, et al. Reduced inhibition by abciximab in platelets with the PLA2 polymorphism. *Am Heart J* 2002 Jan;143(1):76-82. PMID: 11773915.

Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. *Circulation* 2007 Dec 18;116(25):2923-32. PMID: 18056526.

Woo JS, Kim W, Lee SR, et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. *Am Heart J* 2011 Dec;162(6):1018-25. PMID: 22137075.

Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. *J Am Coll Cardiol* 2004 Jun 2;43(11):1982-88. PMID: 15172401.

Yang TH, Kim DI, Kim DK, et al. Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. *Korean J Intern Med* 2011 Jun;26(2):145-52. PMID: 21716590.

Yang TH, Kim DI, Kim JY, et al. Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation. *Korean Circ J* 2009 Nov;39(11):462-66. PMID: 19997541.

Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. *Clin Appl Thromb Hemost* 2010 Oct;16(5):579-83. PMID: 20460345.

Yedidya I, Netzer A, Vaduganathan M, et al. Clopidogrel tapering as a strategy to attenuate platelet rebound phenomenon in patients with bare-metal stents. *J Thromb Thrombolysis* 2012 Jan;33(1):16-21. PMID: 22081256.

Yong AS, Pennings GJ, Chang M, et al. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. *Blood* 2011 Jan 6;117(1):11-20. PMID: 20876457.

Zafar MU, Paz-Yepes M, Shimbo D, et al. Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. *Eur Heart J* 2010 Jul;31(13):1573-82. PMID: 20097703.

Zhang R, Ran HH, Zhu HL, et al. Differential effects of esomeprazole on the antiplatelet activity of clopidogrel in healthy individuals and patients after coronary stent implantation. *J Int Med Res* 2010 Sep;38(5):1617-25. PMID: 21309475.

Zhao L, Fletcher S, Weaver C, et al. Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. *Thromb Haemost* 2005 Mar;93(3):527-34. PMID: 15735805.

Ziegler S, Maca T, Alt E, et al. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. *Platelets* 2002 Dec;13(8):493-97. PMID: 12487783.

Zuern CS, Geisler T, Lutitsky N, et al. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. *Thromb Res* 2010 Feb;125(2):e51-e54. PMID: 19781742.

Insufficient Sample Size

Aktas B, Utz A, Hoenig-Liedl P, et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. *Stroke* 2003 Mar;34(3):764-69. PMID: 12624305.

Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. *J Thromb Haemost* 2005 Jan;3(1):85-92. PMID: 15634270.

Alstrom U, Granath F, Oldgren J, et al. Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery. *Thromb Res* 2009 Nov;124(5):572-77. PMID: 19631364.

Barone-Rochette G, Ormezzano O, Polack B, et al. Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases. *Arch Cardiovasc Dis* 2008 Feb;101(2):100-07. PMID: 18398394.

Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. *Catheter Cardiovasc Interv* 2003 Jul;59(3):295-302. PMID: 12822144.

Bonello L, Palot-Bonello N, Armero S, et al. Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism. *Int J Cardiol* 2010 Nov 5;145(1):165-66. PMID: 19712984.

Bouman HJ, Parlak E, van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. *J Thromb Haemost* 2010 Mar;8(3):482-88. PMID: 20040042.

Carville DG, Schleckser PA, Guyer KE, et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. *J Extra Corpor Technol* 1998 Dec;30(4):171-77. PMID: 10537577.

Fox SC, Behan MW, Heptinstall S. Inhibition of ADP-induced intracellular Ca²⁺ responses and platelet aggregation by the P2Y₁₂ receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E₁. *Cell Calcium* 2004 Jan;35(1):39-46. PMID: 14670370.

Freyenhofer MK, Bruno V, Brozovic I, et al. Is increased platelet turnover responsible for low responsiveness to different thienopyridines? A case report of recurrent stent thromboses. *Thromb Haemost* 2011 Jul;106(1):182-84. PMID: 21544319.

Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Y₁₂(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. *Arterioscler Thromb Vasc Biol* 1999 Aug;19(8):2007-11. PMID: 10446085.

Gerrits AJ, Koekman CA, van Haeften TW, et al. Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. *Diabetes* 2010 Jun;59(6):1487-95. PMID: 20200314.

Grau AJ, Reiners S, Lichy C, et al. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. *Stroke* 2003 Apr;34(4):849-54. PMID: 12637702.

Gremmel T, Steiner S, Seidinger D, et al. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. *J Thromb Haemost* 2010 Jan;8(1):37-42. PMID: 19818001.

Kidson-Gerber G, Weaver J, Gemmell R, et al. Serum thromboxane B₂ compared to five other platelet function tests for the evaluation of aspirin effect in stable cardiovascular disease. *Heart Lung Circ* 2010 Apr;19(4):234-42. PMID: 20144559.

Kuliczowski W, Rychlik B, Chizynski K, et al. Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y₁₂ receptor blockade. *Pol Arch Med Wewn* 2011 Apr;121(4):115-21. PMID: 21532533.

Lakkis NM, George S, Thomas E, et al. Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors. *Catheter Cardiovasc Interv* 2001 Jul;53(3):346-51. PMID: 11458412.

Lev EI, Osende JJ, Richard MF, et al. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function. *J Am Coll Cardiol* 2001 Mar 1;37(3):847-55. PMID: 11693761.

Lev EI, Alviar CL, Arikan ME, et al. Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction. *Am Heart J* 2007 Jan;153(1):41-46. PMID: 17174635.

Linnemann B, Schwonberg J, Rechner AR, et al. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. *Ann Hematol* 2010 Jun;89(6):597-605. PMID: 20049442.

Morel O, Bernhard N, Desprez D, et al. Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis? *Thromb Haemost* 2008 Feb;99(2):448-51. PMID: 18278200.

Morris A, Iprandi-Costa B, Brieger D. Platelet function analysis: a comparison of methods. *Int J Cardiol* 2010 Nov 5;145(1):167-68. PMID: 19897259.

Mukherjee D, Chew DP, Robbins M, et al. Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. *J Thromb Thrombolysis* 2001 Apr;11(2):151-54. PMID: 11406730.

Pena A, Collet JP, Hulot JS, et al. Can we override clopidogrel resistance? *Circulation* 2009 Jun 2;119(21):2854-57. PMID: 19487603.

Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. *Am J Cardiol* 2009 Aug 15;104(4):525-30. PMID: 19660606.

Saha S, Berglund M, Sylven C, et al. Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. *Int J Cardiol* 2008 Jan 11;123(2):195-96. PMID: 17320208.

Schuhmann CG, Sohn HY, Nagel J, et al. Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy--initial experiences. *Platelets* 2009 Nov;20(7):498-504. PMID: 19852689.

Serebruany VL, Midei MG, Meilman H, et al. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. *Postgrad Med J* 2006 Jun;82(968):404-10. PMID: 16754711.

Siller-Matula JM, Panzer S, Jilma B. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. *Platelets* 2008 Nov;19(7):551-54. PMID: 18979368.

Singla A, Antonino MJ, Bliden KP, et al. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. *Am Heart J* 2009 Nov;158(5):784-86. PMID: 19853698.

Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y₁₂ receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. *J Am Coll Cardiol* 2007 Nov 6;50(19):1852-56. PMID: 17980251.

Yokoi H, Kimura T, Isshiki T, et al. Pharmacodynamic assessment of a novel P2Y₁₂ receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. *Thromb Res* 2012 May;129(5):623-28. PMID: 22178576.

No Primary Data

Aalbers J. Obesity and platelet reactivity: the relationship remains uncertain. *Cardiovasc J Afr* 2011 Jul;22(4):223. PMID:21881696.

Akhlaghi A, Shirani S, Ziaie N, et al. Cytochrome P450 2C19 Polymorphism in Iranian Patients with Coronary Artery Disease. *ARYA Atheroscler* 2011;7(3):106-10. PMID:22577456.

Alexopoulos D. Regarding the “Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study”. *Am Heart J* 2012 May;163(5):e31. PMID:22607871.

Alexopoulos D, Xanthopoulou I. Clopidogrel dosing based on genotype. *JAMA* 2012 Mar 14;307(10):1024-25. PMID:22416093.

Angiolillo DJ, Ueno M. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations. *JACC Cardiovasc Interv* 2011 Apr;4(4):411-14. PMID:21511220.

Aradi D, Komocsi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. *Am Heart J* 2010 Sep;160(3):543-51. PMID:20826265.

Becker RC, Gurbel PA. Platelet P2Y₁₂ receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. *Thromb Haemost* 2010 Mar;103(3):535-44. PMID:20135066.

Beitelshees AL, Horenstein RB, Vesely MR, et al. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. *Clin Pharmacol Ther* 2011 Mar;89(3):455-59. PMID:21270785.

Bergmeijer TO, ten Berg JM. Value of CYP2C19 *2 and *17 genotyping in clinical practice. Promising but not ready yet. *Rev Esp Cardiol (Engl Ed)* 2012 Mar;65(3):205-07. PMID:22284726.

Bhattacharyya S, Rakhit R. Cytochrome P450 2C19 polymorphism and clopidogrel after MI. *Lancet* 2009 Apr 4;373(9670):1171-73. PMID:19345825.

Biondi-Zoccai G, Lotrionte M, Sheiban I. Overcoming “resistance” to aspirin and clopidogrel with tirofiban: fact or fiction? *Thromb Haemost* 2008 Oct;100(4):521-22. PMID:18841270.

Bisdas T, Haverich A, Teebken OE. The unknown effect of clopidogrel resistance in dual antiplatelet therapies after coronary artery bypass grafting. *J Am Coll Cardiol* 2011 Aug 30;58(10):1085-86. PMID:21867852.

Blann AD, Draper Z. Platelet activation as a marker of heart attack. *Clin Chim Acta* 2011 May 12;412(11-12):841-42. PMID:21338595.

Bonello L, Camoin-Jau L, Gnat-George F, et al. A threshold of platelet reactivity for ischaemic events? *Eur Heart J* 2008 Sep;29(17):2185-86. PMID:18617480.

Brar SS, ten BJ, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. *J Am Coll Cardiol* 2011 Nov 1;58(19):1945-54. PMID:22032704.

Braunwald E, Angiolillo D, Bates E, et al. Antiplatelet therapy and platelet function testing. *Clin Cardiol* 2008 Mar;31(3 Suppl 1):I36. PMID:18481821.

Broderick JP. Evidence against rapid reversal of antiplatelet medications in acute intracerebral hemorrhage. *Neurology* 2009 Apr 21;72(16):1376-77. PMID:19129503.

Cattaneo M. [Tailored treatment with clopidogrel based on the results of platelet function tests should not be implemented, in the absence of clear indications on the methodology to be used]. *G Ital Cardiol (Rome)* 2011 Mar;12(3):172-73. PMID:21560472.

Chin CT, Roe MT, Fox KA, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. *Am Heart J* 2010 Jul;160(1):16-22. PMID:20598967.

Collet JP, Cayla G, Cuisset T, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. *Am Heart J* 2011 Jan;161(1):5-12. PMID:21167334.

Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. *J Thromb Haemost* 2010 May;8(5):923-33. PMID:20156305.

Cuisset T, Frere C, Quilici J, et al. Adjusting clopidogrel loading doses according to vasodilator-stimulated phosphoprotein index: on time, too early, or too late? *J Am Coll Cardiol* 2008 Aug 26;52(9):790-91. PMID:18718431.

Cuisset T, Morange PE, Alessi MC. High residual platelet reactivity and thrombotic events. *JAMA* 2011 Dec 21;306(23):2561-62. PMID:22187272.

Curzen N, Sambu N. Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant? *Heart* 2011 Sep;97(17):1433-40. PMID:21821634.

Daniel A, Pinter T, Horvath IG, et al. Variability in response to clopidogrel: where is the threshold for 'low response'? *Eur Heart J* 2007 Feb;28(4):515-16. PMID:17289747.

De Miguel CA, Nieto AD, Perez de PA. Letter by De Miguel Castro et al regarding article, "Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on Thrombosis and Safety (GRAVITAS) trial". *Circulation* 2012 Apr 10;125(14):e570-e572. PMID:22492956.

Doraiswamy VA. Letter by Doraiswamy regarding article, "Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study". *Circulation* 2010 Mar 9;121(9):e235. PMID:20212290.

Drouet L. [Prescription, monitoring of antithrombotic treatment: 1--antiplatelet agents]. *Rev Prat* 2007 Nov 30;57(18):2045-50. PMID:18326440.

Fattorutto M. Measurement of the effect of ticlopidine with the platelet function analyser (PFA-100) during coronary stent implantation. *Am Heart J* 2003 Sep;146(3):E8. PMID:12947379.

Fileti L, Campo G, Valgimigli M. Latest clinical data on testing for high on-treatment platelet reactivity. *Rev Cardiovasc Med* 2011;12 Suppl 1:S14-S22. PMID:22080983.

Fontana P, de MP, Reny JL. Platelet hyperreactivity and dual antiplatelet therapy: can biases be avoided? *J Thromb Haemost* 2009 Feb;7(2):363-64. PMID:19036060.

Fosburgh D. Aspirin and clopidogrel resistance. *Mayo Clin Proc* 2006 Jul;81(7):989. PMID:16835978.

Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. *N Engl J Med* 2009 Jan 22;360(4):411-13. PMID:19164193.

Frelinger AL, III, Michelson AD. Clopidogrel linking evaluation of platelet response variability to mechanism of action. *J Am Coll Cardiol* 2005 Aug 16;46(4):646-47. PMID:16098429.

Fuster V, Sweeny JM. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. *JAMA* 2010 Oct 27;304(16):1839-40. PMID:20978263.

Gaborit B, Cuisset T, Frere C, et al. Glycemic control and clopidogrel response. *Am Heart J* 2010 Jun;159(6):e35. PMID:20569701.

Gasparovic H, Petricevic M, Biocina B. Reduction of thienopyridine-associated bleeding using multiple electrode whole-blood aggregometry. *Ann Thorac Surg* 2011 Aug;92(2):778-79. PMID:21801953.

Gawaz M, Geisler T. Coronary artery disease: Platelet activity: an obstacle for successful PCI. *Nat Rev Cardiol* 2009 Jun;6(6):391-92. PMID:19471282.

Ge J, Zhu J, Hong BK, et al. Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. *Curr Med Res Opin* 2010 Sep;26(9):2077-85. PMID:20629598.

Geisler T, Bigalke B, Schwab M. CYP2C19 genotype and outcomes of clopidogrel treatment. *N Engl J Med* 2011 Feb 3;364(5):481. PMID:21288102.

Gorelick PB, Hanley DF, Jr. Clopidogrel and its use in stroke patients. *Stroke* 1998 Aug;29(8):1737. PMID:9707220.

Granada JF, Price MJ, French PA, et al. Platelet-mediated thrombosis and drug-eluting stents. *Circ Cardiovasc Interv* 2011 Dec 1;4(6):629-37. PMID:22186107.

Grove EL, Hvas AM, Kristensen SD. Platelet function testing in atherothrombotic disease: steps forward in managing resistance to antiplatelet therapy. *Kardiol Pol* 2008 Apr;66(4):478-79. PMID:19496276.

Gurbel PA, Tantry US, Shuldiner AR. Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement". *Circulation* 2010 Oct 5;122(14):e478. PMID:20921447.

Guzauskas GF, Hughes DA, Bradley SM, et al. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. *Clin Pharmacol Ther* 2012 May;91(5):829-37. PMID:22453194.

Hall HM, Banerjee S, McGuire DK. Variability of clopidogrel response in patients with type 2 diabetes mellitus. *Diab Vasc Dis Res* 2011 Oct;8(4):245-53. PMID:21933840.

Hnid K, Chtioui M. Letter by Hnid and Chtioui regarding article, "Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry". *Circulation* 2011 Sep 13;124(11):e297. PMID:21911791.

Horowitz JD, Chirkov YY. Identifying clopidogrel resistance during chronic therapy: the case for a biochemical approach. *Thromb Haemost* 2008 Oct;100(4):519-20. PMID:18841269.

Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. *J Am Coll Cardiol* 2010 Jul 6;56(2):134-43. PMID:20620727.

Hulot JS, Collet JP, Montalescot G. Genetic substudy of the PLATO trial. *Lancet* 2011 Feb 19;377(9766):637, author-8. PMID:21334530.

Jagroop IA, Malley M, Mikhailidis DP. Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. *Clin Appl Thromb Hemost* 2002 Oct;8(4):381-82. PMID:12516689.

Jeong YH, Bliden KP, Tantry US, et al. The role of platelet function testing and genotyping in the stented patient treated with clopidogrel. *J Am Coll Cardiol* 2011 Dec 13;58(25):2701-02. PMID:22152965.

Jeremias A, Gruberg L. Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off? *J Invasive Cardiol* 2009 Jun;21(6):264-65. PMID:19494401.

Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. *J Lab Clin Med* 2001 Sep;138(3):152-63. PMID:11528368.

Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. *Stroke* 2003 Apr;34(4):849-54. PMID:12680383.

Jin B, Ni HC, Shen W, et al. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. *Mol Biol Rep* 2011 Mar;38(3):1697-702. PMID:20845077.

Kalyanasundaram A, Berger PB. Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention. *Circ Cardiovasc Interv* 2010 Jun 1;3(3):284-87. PMID:20551395.

Kamphuisen PW. Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment. *Eur Heart J* 2008 Jul;29(14):1699-700. PMID:18544543.

Kleiman NS. Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide? *Nat Clin Pract Cardiovasc Med* 2005 Jul;2(7):344-45. PMID:16265559.

Kuliczkowski W. [Pharmacogenetics of antiplatelet therapy- is it time for to evaluate polymorphism?]. *Kardiol Pol* 2009 Aug;67(8):835-36. PMID:19885980.

Lee SP, Suh JW, Park KW, et al. Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. *Trials* 2010;11:87. PMID:20735821.

Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. *J Thromb Haemost* 2012 Feb;10(2):199-206. PMID:22123356.

Lin GM, Li YH. Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. *Am J Cardiol* 2011 Feb 15;107(4):641. PMID:21295179.

Ma YT, Xie X. [Impact of genetic polymorphisms on efficacy of antiplatelet therapy]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2011 Jul;39(7):674-76. PMID:22088252.

Mahmud E, Ang L. Platelet function testing in practice: a case study. *Rev Cardiovasc Med* 2011;12 Suppl 1:S34-S39. PMID:22080985.

Mallouk N, Labruyere C, Reny JL, et al. Prevalence of poor biological response to clopidogrel: a systematic review. *Thromb Haemost* 2012 Mar;107(3):494-506. PMID:22273694.

Marian AJ. Cytochrome p-450 polymorphisms and response to clopidogrel. *Curr Atheroscler Rep* 2009 May;11(3):157-60. PMID:19361345.

Masood I. Comparative effect of antiplatelet therapy in retinal vein occlusion evaluated by the particle-counting method using light scattering. *Am J Ophthalmol* 2005 Jul;140(1):167. PMID:16038677.

McLean DS, Cannon CP. The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. *Crit Pathw Cardiol* 2006 Jun;5(2):103-13. PMID:18340222.

McLean DS, Cannon CP. A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. *Future Cardiol* 2006 May;2(3):255-67. PMID:19804082.

Mearns BM. Pharmacogenetics: Ticagrelor superior to clopidogrel in individuals predicted to be clopidogrel responders. *Nat Rev Cardiol* 2011 Jan;8(1):4. PMID:21218558.

Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. *JAMA* 2010 Oct 27;304(16):1821-30. PMID:20978260.

Mega JL, Topol EJ, Sabatine MS. CYP2C19 genotype and cardiovascular events. *JAMA* 2012 Apr 11;307(14):1482-83. PMID:22496256.

Miao J, Liu R, Li Z. Cytochrome P-450 polymorphisms and response to clopidogrel. *N Engl J Med* 2009 May 21;360(21):2250-51. PMID:19469033.

Miao J, Liu R, Li Z. Cytochrome P450 2C19 polymorphism and clopidogrel after MI. *Lancet* 2009 Apr 4;373(9670):1171-72. PMID:19345824.

Michelson AD. Platelet function testing in cardiovascular diseases. *Circulation* 2004 Nov 9;110(19):e489-e493. PMID:15533872.

Montalescot G, Bolognese L, Dudek D, et al. A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. *Am Heart J* 2011 Apr;161(4):650-56. PMID:21473962.

Mustard JF, Kinlough-Rathbone RL, Jenkins CS, et al. Modification of platelet function. *Ann N Y Acad Sci* 1972 Oct 27;201:343-59. PMID:4405310.

Nezami N, Nargabad ON, Ghorashi S. Letter by Nezami et al regarding article, "Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial". *Circulation* 2012 Apr 10;125(14):e569-2. PMID:22492955.

Nissen SE. Pharmacogenomics and clopidogrel: irrational exuberance? *JAMA* 2011 Dec 28;306(24):2727-28. PMID:22203545.

O'Connor SK, Ferreri SP, Michaels NM, et al. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. *Pharmacogenomics* 2012 Jun;13(8):955-62. PMID:22676199.

Osnabrugge RL, Kappetein AP, Janssens AC. Carriage of reduced-function CYP2C19 allele among patients treated with clopidogrel. *JAMA* 2011 Feb 2;305(5):467-68. PMID:21285422.

Palabrica TM, Burton PB. Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study". *Circulation* 2005 Oct 25;112(17):e282-e283. PMID:16250083.

Pare G, Eikelboom JW, Sibbing D, et al. Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. *Circ Cardiovasc Interv* 2011 Oct 1;4(5):514-21. PMID:22010190.

Perez de PA, Cuellas C, Diego A, et al. Platelet reactivity and stent thrombosis: still some issues to solve. *J Am Coll Cardiol* 2009 Aug 11;54(7):666-67. PMID:19660707.

Peters BJ, Harmsze AM, ten Berg JM, et al. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel. *Pharmacogenomics* 2011 Feb;12(2):141-44. PMID:21332306.

Petricevic M, Biocina B. Letter by Petricevic and Biocina regarding article, "Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study". *Circ Cardiovasc Interv* 2012 Jun;5(3):e47. PMID:22715457.

Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. *Am Heart J* 2009 May;157(5):818-24, 824. PMID:19376306.

Price MJ. The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention. *Circ Cardiovasc Interv* 2010 Jun 1;3(3):277-83. PMID:20551394.

Price MJ, Tantry US, Gurbel PA. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y₁₂ inhibitors. *Rev Cardiovasc Med* 2011;12(1):1-12. PMID:21546883.

Price MJ, Barker CM. Functional testing methods for the antiplatelet effect of P2Y₁₂ receptor antagonists. *Biomark Med* 2011 Feb;5(1):43-51. PMID:21319964.

Rajan L, Moliterno DJ. Options and outcomes with different antiplatelet strategies during primary percutaneous coronary intervention. *Eur Heart J* 2009 Jul;30(14):1687-89. PMID:19429914.

Ramaraj R. Cytochrome P450 2C19 polymorphism and clopidogrel after MI. *Lancet* 2009 Apr 4;373(9670):1172-73. PMID:19345827.

Ramirez AH, Delaney JT, Shuldiner AR. Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel. *Evid Based Med* 2011 Aug;16(4):124-25. PMID:21705400.

Rao GH. Need for a point-of-care assay for monitoring antiplatelet and antithrombotic therapies. *Stroke* 2009 Jun;40(6):2271-72. PMID:19407237.

Rechner AR. Platelet function testing in clinical diagnostics. *Hamostaseologie* 2011 May 2;31(2):79-87. PMID:21152677.

Ringelstein. Effect of the combination clopidogrel plus aspirin on silent cerebral microemboli and platelet activation, in patients with nonoperated symptomatic carotid stenosis (CARESS: clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis).

Schafer AI. Genetic and acquired determinants of individual variability of response to antiplatelet drugs. *Circulation* 2003 Aug 26;108(8):910-11. PMID:12939239.

Scheen AJ, Legrand D. Aspirin and clopidogrel resistance in patients with diabetes mellitus. *Eur Heart J* 2006 Dec;27(23):2900-01. PMID:17015405.

Schorr K, Weber AA, Hohlfeld T. Clopidogrel “resistance”. *Thromb Haemost* 2004 Aug;92(2):229-31. PMID:15269816.

Schorr K, Weber AA, Hohlfeld T. Clopidogrel “resistance” and statin cotreatment - significant for cardiocoronary prevention in real life? *Thromb Haemost* 2005 Aug;94(2):235-37. PMID:16113810.

Serebruany VL, Steinhubl SR, Hennekens CH. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. *Circulation* 2003 Apr 1;107(12):1568-69. PMID:12668486.

Serebruany VL. The “clopidogrel resistance” trap. *Am J Cardiol* 2007 Sep 15;100(6):1044-46. PMID:17826395.

Serebruany VL, Goto S. The challenge of monitoring platelet response after clopidogrel. *Eur Heart J* 2008 Dec;29(23):2833-34. PMID:18977768.

Serebruany VL. Current concepts targeting antiplatelet ‘resistance’. *Kardiol Pol* 2008 Apr;66(4):477. PMID:19496278.

Shantsila E, Lip GY. Beyond glucose levels in diabetic patients with coronary artery disease: platelet activity and non-responsiveness to antiplatelet therapy. *Thromb Haemost* 2008 Jul;100(1):7-8. PMID:18612528.

Shuldiner AR, Vesely MR, Fisch A. CYP2C19 genotype and cardiovascular events. *JAMA* 2012 Apr 11;307(14):1482-85. PMID:22496255.

Siasos G, Tousoulis D, Stefanadis C. CYP2C19 genotype and outcomes of clopidogrel treatment. *N Engl J Med* 2011 Feb 3;364(5):481-82. PMID:21288101.

Siasos G, Tousoulis D, Stefanadis C. CYP2C19 genotype and cardiovascular events. *JAMA* 2012 Apr 11;307(14):1483-84. PMID:22496257.

Silvain J, Cayla G, Hulot JS, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. *Eur Heart J* 2012 May;33(10):1241-49. PMID:22067090.

Sofi F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. *Thromb Haemost* 2010 Apr;103(4):841-48. PMID:20135063.

SoRelle R. Clopidogrel resistance marks recurrent risks. *Circulation* 2004 Jun 29;109(25):e9054-e9055. PMID:15226243.

Sorich MJ, Vitry A, Ward MB, et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. *J Thromb Haemost* 2010 Aug;8(8):1678-84. PMID:20492467.

Stegnar M. Platelet function tests and resistance to antiplatelet therapy. *Srp Arh Celok Lek* 2010 Jan;138 Suppl 1:59-63. PMID:20229685.

Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. *Circulation* 2010 Feb 2;121(4):481-83. PMID:20083686.

Steinhubl SR. The illusion of “optimal” platelet inhibition. *JACC Cardiovasc Interv* 2012 Mar;5(3):278-80. PMID:22440492.

Storey RF. Clopidogrel in acute coronary syndrome: to genotype or not? *Lancet* 2009 Jan 24;373(9660):276-78. PMID:19108882.

Tantry US, Jeong YH, Navarese EP, et al. Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y(1)(2) inhibitor therapeutic window. *JACC Cardiovasc Interv* 2012 Mar;5(3):290-92. PMID:22440494.

ten Berg JM, Deneer VH. Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome? *Nat Rev Cardiol* 2012 Apr;9(4):192-94. PMID:22411289.

Tricoci P, Harrington RA, Valgimigli M. Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study". *Circulation* 2005 Oct 25;112(17):e282. PMID:16246954.

Turgeon J, Pharand C, Michaud V. Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism. *CMAJ* 2006 Jun 6;174(12):1729. PMID:16754901.

van Werkum JW, Heestermans AA, Plokker HW, et al. Clinical, biochemical and genetical resistance to clopidogrel in a patient with recurrent stent thrombosis. *Int J Cardiol* 2007 Mar 2;116(1):136-37. PMID:16870279.

van Werkum JW, Harmsze AM, Elsenberg EH, et al. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. *Platelets* 2008 Nov;19(7):479-88. PMID:18979359.

Vassiliou V. Double-dose clopidogrel in patients undergoing PCI for ACS. *Lancet* 2011 Jan 22;377(9762):297. PMID:21256377.

Walter T. Influence of a therapy with Clopidogrel on the activation of platelet leukocytes and the endothelium in patients with stable angina pectoris. *Zeitschrift Fur Kardiologie* 2002;91(Supplement 1)

Warner TD, Mitchell JA, Kirkby NS. Short thromboelastography and the identification of high platelet reactivity while on and off therapy. *Heart* 2012 May;98(9):679-80. PMID:22523052.

Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). *Am Heart J* 2006 Oct;152(4):627-35. PMID:16996826.

Wiwantikit V. CYP2C19 gene variants cut-off levels for on-clopidogrel platelet aggregation. *Thromb Res* 2012 Feb;129(2):212. PMID:22030270.

Xydakis. The combination of clopidogrel (cl) and acetylsalicylic acid (asa) inhibits more effective the platelet activation in haemodialysis patients with acute coronary syndromes (acs) and high c reactive protein. 41st Congress European Renal Association European Dialysis and Transplantation Association. 2004 <[31] UNIQUE ID (DOI)>.

Yamazaki M, Uchiyama S. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. *Stroke* 2003 Dec;34(12):e227-e228. PMID:14631085.

Yang L, Valdes R, Jr., Taubert D, et al. A diagnostic informatics approach for stratifying risk outcome based on combined genotype effects. *Ther Drug Monit* 2012 Jun;34(3):283-88. PMID:22549497.

Zhao L, Fletcher S, Weaver C, et al. The effects of three anti-platelet drugs (aspirin, clopidogrel, dipyridamole) given singly or together on platelet and leukocyte function in healthy subjects and patients with previous ischemic stroke. *Journal of Thrombosis and Haemostasis* 2003;1(Supplement 1)

Zhu B, Effron MB, Kulkarni MP, et al. The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data. *J Cardiovasc Pharmacol* 2011 Mar;57(3):317-24. PMID:21266916.

Not Study Design of Interest

Benzon HT, Fragen R, Benzon HA, et al. Clopidogrel and neuraxial block: the role of the PFA II and P2Y12 assays. *Reg Anesth Pain Med* 2010 Jan;35(1):115. PMID: 20048663.

Bouman HJ, van Werkum JW, Breet NJ, et al. A case-control study on platelet reactivity in patients with coronary stent thrombosis. *J Thromb Haemost* 2011 May;9(5):909-16. PMID: 21382172.

Brar SS, ten BJ, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. *J Am Coll Cardiol* 2011 Nov 1;58(19):1945-54. PMID: 22032704.

Briongos FS, Salido-Tahoces L, de Juan-Baguda J, et al. [Multiple arterial thrombosis and resistance to conventional antiaggregation]. *Rev Esp Cardiol* 2011 Sep;64(9):836-37. PMID: 21497975.

Campo G, Valgimigli M, Carrescia C, et al. Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting. *Clin Appl Thromb Hemost* 2010 Oct;16(5):591-93. PMID: 19520678.

Capranzano P, Tamburino C, Capodanno D, et al. Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. *Thromb Haemost* 2011 Dec;106(6):1149-57. PMID: 22011914.

Dick RJ, Dear AE, Byron KA. Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. *Heart Lung Circ* 2011 Oct;20(10):657-58. PMID: 21215696.

Hobson AR, Petley G, Morton G, et al. Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. *Thromb J* 2008;6:1. PMID: 18312665.

Jung HJ, Sir JJ. Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance. *J Invasive Cardiol* 2011 Feb;23(2):E15-E18. PMID: 21297211.

Mazur P, Frolov M, Nizankowski R, et al. Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. *Platelets* 2013;24(2):151-55. PMID: 22497730.

Notarangelo MF, Marziliano N, Giacalone R, et al. [Stent thrombosis and clopidogrel response variability: is the genetic test useful in clinical practice?]. *G Ital Cardiol (Rome)* 2011 Oct;12(10):686-89. PMID: 21947114.

Nyiro G, Inczedy-Farkas G, Remenyi V, et al. The effect of the CYP 2C19*2 polymorphism on stroke care. *Acta Physiol Hung* 2012 Mar;99(1):33-39. PMID: 22425806.

Park SJ, Oh IY, Kim KH, et al. Minimal withdrawal of dual antiplatelet agents under the guidance of a point-of-care platelet activity assay early after drug-eluting stent implantation for surgical removal of renal cell carcinoma. *Int J Cardiol* 2011 Jun 2;149(2):e85-e87. PMID: 19477540.

Rajendran S, Parikh D, Shugman I, et al. High on treatment platelet reactivity and stent thrombosis. *Heart Lung Circ* 2011 Aug;20(8):525-31. PMID: 21592858.

Reese ES, Daniel MC, Beitelshes AL, et al. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. *Pharmacotherapy* 2012 Apr;32(4):323-32. PMID: 22461122.

Not Test of Interest

Ahn JC, Song WH, Kwon JA, et al. Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. *Korean J Intern Med* 2004 Dec;19(4):230-36. PMID: 15683111.

Ahnadi CE, Boughrassa FF, Chapman-Montgomery ES, et al. Comparison of two methods to assess variability of platelet response to anti-platelet therapies in patients with acute coronary syndrome undergoing angioplasty. *Thromb Haemost* 2004 Dec;92(6):1207-13. PMID: 15583725.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. *Thromb Res* 2005;116(6):491-97. PMID: 16181985.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. *Arterioscler Thromb Vasc Biol* 2006 Aug;26(8):1895-900. PMID: 16645157.

Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). *Am J Cardiol* 2001 Oct 15;88(8):884-6, A6. PMID: 11676953.

Azar RR, Kassab R, Zoghbi A, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. *Am Heart J* 2006 Feb;151(2):521. PMID: 16442924.

Bedard E, Rodes-Cabau J, Houde C, et al. Enhanced thrombogenesis but not platelet activation is associated with transcatheter closure of patent foramen ovale in patients with cryptogenic stroke. *Stroke* 2007 Jan;38(1):100-04. PMID: 17122434.

Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. *Am J Cardiol* 2002 Sep 15;90(6):625-28. PMID: 12231089.

Bi M, Ma Q, Zhang S, et al. Local mild hypothermia with thrombolysis for acute ischemic stroke within a 6-h window. *Clin Neurol Neurosurg* 2011 Nov;113(9):768-73. PMID: 21893379.

Bouman HJ, van Werkum JW, Rudez G, et al. The relevance of P2Y₁₂-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up. *Thromb Haemost* 2012 Jan;107(1):189-91. PMID:22159428

Breet NJ, van Werkum JW, Bouman HJ, et al. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. *J Thromb Haemost* 2010 Oct;8(10):2140-48. PMID: 20723029.

Burdess A, Nimmo AF, Campbell N, et al. Perioperative platelet and monocyte activation in patients with critical limb ischemia. *J Vasc Surg* 2010 Sep;52(3):697-703. PMID: 20816321.

Burdess A, Nimmo AF, Garden OJ, et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. *Ann Surg* 2010 Jul;252(1):37-42. PMID: 20562608.

Campo G, Valgimigli M, Frangione A, et al. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). *J Am Coll Cardiol* 2010 Jan 19;55(3):255-56. PMID: 20117406.

Cesari F, Marcucci R, Caporale R, et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. *Thromb Haemost* 2008 May;99(5):930-35. PMID: 18449424.

Cesari M, Kritchevsky SB, Nicklas B, et al. Oxidative damage, platelet activation, and inflammation to predict mobility disability and mortality in older persons: results from the health aging and body composition study. *J Gerontol A Biol Sci Med Sci* 2012 Jun;67(6):671-76. PMID: 22389462.

Cha JK, Jo WS, Shin HC, et al. Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke. *Platelets* 2004 Feb;15(1):3-7. PMID: 14985170.

Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. *J Am Coll Cardiol* 2004 Mar 17;43(6):1122-26. PMID: 15028378.

Chen WH, Lee PY, Ng W, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. *Am J Cardiol* 2005 Sep 15;96(6):760-63. PMID: 16169354.

Ciuffetti G, Lombardini R, Pirro M, et al. Clopidogrel: hemorheological effects in subjects with subclinical atherosclerosis. *Clin Hemorheol Microcirc* 2001;25(1):31-39. PMID: 11790868.

Cooke GE, Liu-Stratton Y, Ferketich AK, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. *J Am Coll Cardiol* 2006 Feb 7;47(3):541-46. PMID: 16458133.

Cuisset T, Hamilos M, Delrue M, et al. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome. *Thromb Haemost* 2010 Apr;103(4):774-79. PMID: 20135061.

Dalen M, van der LJ, Lindvall G, et al. Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery. *Scand Cardiovasc J* 2012 Feb;46(1):32-38. PMID: 21973169.

Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. *J Am Coll Cardiol* 2009 Oct 6;54(15):1438-46. PMID: 19796737.

Davlouros PA, Arseniou A, Hahalis G, et al. Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naïve patients with stable or unstable angina: a comparison of two strategies. *Am Heart J* 2009 Oct;158(4):585-91. PMID: 19781418.

Deliargyris EN, Upadhyia B, Melton LG, et al. Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI. *Clin Appl Thromb Hemost* 2006 Oct;12(4):458-64. PMID: 17000891.

Di NM, Bijsterveld NR, Meijers JC, et al. Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes. *J Am Coll Cardiol* 2005 Oct 18;46(8):1582-83. PMID: 16226189.

Douglas IJ, Evans SJ, Hingorani AD, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. *BMJ* 2012;345:e4388. PMID: 22782731.

Dropinski J, Musial J, Jakiela B, et al. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin. *Thromb Haemost* 2005 Dec;94(6):1300-05. PMID: 16411409.

Dropinski J, Jakiela B, Sanak M, et al. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. *Thromb Haemost* 2007 Jul;98(1):201-09. PMID: 17598014.

Egier DA, Keys JL, Hall SK, et al. Measurement of hemoglobin A1c from filter papers for population-based studies. *Clin Chem* 2011 Apr;57(4):577-85. PMID: 21296974.

Eikelboom JW, Weitz JI, Budaj A, et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. *Eur Heart J* 2002 Nov;23(22):1771-79. PMID: 12419297.

El-Atat F, Sarkar K, Kodali V, et al. A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention. *J Invasive Cardiol* 2011 Jan;23(1):9-13. PMID: 21183763.

Ercan E, Tengiz I, Duman C, et al. Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction. *Am Heart J* 2004 Jan;147(1):E1. PMID: 14691439.

Eriksson AC, Jonasson L, Lindahl TL, et al. Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. *J Transl Med* 2009;7:42. PMID: 19508722.

Frelinger AL, III, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. *Circulation* 2006 Jun 27;113(25):2888-96. PMID: 16785341.

Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. *Circulation* 2004 Sep 14;110(11):1392-97. PMID: 15313953.

Furman MI, Krueger LA, Linden MD, et al. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. *J Thromb Haemost* 2005 Feb;3(2):312-20. PMID: 15670038.

Furuta T, Iwaki T, Umemura K. [13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel. *Eur J Clin Pharmacol* 2010 May;66(5):457-63. PMID: 20349052.

Gibson CM, Ly HQ, Murphy SA, et al. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). *Am J Cardiol* 2006 Sep 15;98(6):761-63. PMID: 16950180.

Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. *Atherosclerosis* 2008 Jan;196(1):341-48. PMID: 17157856.

Goncalves SC, Labinaz M, Le MM, et al. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. *Am J Cardiol* 2011 Jan 15;107(2):204-09. PMID: 21129717.

Gremmel T, Steiner S, Seidinger D, et al. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. *Thromb Res* 2009 Nov;124(5):588-91. PMID: 19631365.

Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. *Platelets* 2011;22(3):188-95. PMID: 21231857.

Gulmez O, Yildirim A, Kaynar G, et al. Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. *J Thromb Thrombolysis* 2008 Jun;25(3):239-46. PMID: 17574519.

Hudzik B, Szkodzinski J, Danikiewicz A, et al. Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-beta1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention. *Eur Cytokine Netw* 2010 Dec;21(4):257-63. PMID: 21084246.

Husted S, Storey RF, Harrington RA, et al. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. *Clin Cardiol* 2010 Apr;33(4):206-12. PMID: 20394040.

Jaster M, Fuster V, Rosenthal P, et al. Catheter based intracoronary brachytherapy leads to increased platelet activation. *Heart* 2004 Feb;90(2):160-64. PMID: 14729786.

Jaumdally RJ, Varma C, Blann AD, et al. Platelet activation in coronary artery disease: intracardiac vs peripheral venous levels and the effects of angioplasty. *Chest* 2007 Nov;132(5):1532-39. PMID: 17908707.

Jin C, Lu L, Zhu ZB, et al. Increased serum vWF and sVCAM-1 levels are associated with late or very late angiographic stent thrombosis after sirolimus-eluting stent implantation. *Coron Artery Dis* 2010 Aug;21(5):273-77. PMID: 20508517.

Jung JH, Min PK, Lee SH, et al. Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). *Coron Artery Dis* 2009 Mar;20(2):150-54. PMID: 19301464.

Karlsson F, Modica A, Moos T. Dynamics of platelet activation in diabetic and non-diabetic subjects during the course of an acute myocardial infarction. *Thromb Res* 2007;121(2):269-73. PMID: 17543372.

Kasprzak M, Kozinski M, Bielis L, et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. *Cardiol J* 2009;16(6):535-44. PMID: 19950090.

Keating FK, Dauerman HL, Whitaker DA, et al. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. *Coron Artery Dis* 2005 Sep;16(6):401-05. PMID: 16118546.

Konopka A, Spychalska J, Piotrowski W, et al. Influence of some cardiovascular risk factors on the expression of platelet glycoprotein IIb/IIIa receptors in patients with myocardial infarction treated with antiplatelet drugs under primary percutaneous coronary intervention. *Mol Diagn Ther* 2009 Dec 1;13(6):375-82. PMID: 19925035.

Konstantinidis K, Gerasimidis T, Verdy E, et al. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood. *Thromb Haemost* 2007 Jan;97(1):109-18. PMID: 17200777.

Kopp CW, Steiner S, Nasel C, et al. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. *Stroke* 2003 Nov;34(11):2560-67. PMID: 14563968.

Lau WC, Welch TD, Shields T, et al. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. *J Cardiovasc Pharmacol* 2011 Jan;57(1):86-93. PMID: 20980920.

Lev EI, Patel RT, Guthikonda S, et al. Genetic polymorphisms of the platelet receptors P2Y₁₂, P2Y₁ and GP IIIa and response to aspirin and clopidogrel. *Thromb Res* 2007;119(3):355-60. PMID: 16581111.

Liu F, Li J, Wang DM, et al. Serial changes of circulating platelet activation markers after carotid artery stenting. *Angiology* 2009 Aug;60(4):427-30. PMID: 18796447.

Liu WH, Yang CH, Yeh KH, et al. Circulating levels of soluble P-selectin in patients in the early and recent phases of myocardial infarction. *Chang Gung Med J* 2005 Sep;28(9):613-20. PMID: 16323552.

Madsen EH, Gehr NR, Johannesen NL, et al. Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. *Platelets* 2011;22(7):537-46. PMID: 21591982.

Mahemuti A, Meneveau N, Seronde MF, et al. Early local intracoronary platelet activation after drug-eluting stent placement. *Chin Med J (Engl)* 2007 Nov 20;120(22):1986-91. PMID: 18067783.

Malmstrom RE, Ostergren J, Jorgensen L, et al. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. *J Intern Med* 2009 Nov;266(5):457-66. PMID: 19549094.

Mannini L, Marcucci R, Paniccia R, et al. Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. *Clin Hemorheol Microcirc* 2006;35(1-2):175-81. PMID: 16899924.

Marcucci R, Paniccia R, Antonucci E, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. *Am J Cardiol* 2006 Nov 1;98(9):1156-59. PMID: 17056317.

Mariani M, Mariani G, De SS. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. *Expert Rev Cardiovasc Ther* 2009 Jan;7(1):17-23. PMID: 19105763.

Marmur JD, Poludasu S, Agarwal A, et al. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention. *J Invasive Cardiol* 2008 Feb;20(2):53-58. PMID: 18252967.

McClung JA, Kruger AL, Ferraris A, et al. Usefulness of clopidogrel to protect against diabetes-induced vascular damage. *Am J Cardiol* 2010 Apr 1;105(7):1014-18. PMID: 20346323.

Mende A, Obata JE, Sano K, et al. Measurement of the platelet retention rate in a column of collagen-coated beads is useful for the assessment of efficacy of antiplatelet therapy. *Thromb Res* 2009 Apr;123(6):856-61. PMID: 19004478.

Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. *J Am Coll Cardiol* 2006 Sep 5;48(5):931-38. PMID: 16949482.

Moriau M, Lavenne-Pardonge E, Crasborn L, et al. The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. *Thromb Res* 1995 Jun 15;78(6):469-82. PMID: 15714749.

Motovska Z, Widimsky P, Kvasnicka J, et al. High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. *Blood Coagul Fibrinolysis* 2009 Jun;20(4):257-62. PMID: 19530321.

Naidech AM, Bendok BR, Garg RK, et al. Reduced platelet activity is associated with more intraventricular hemorrhage. *Neurosurgery* 2009 Oct;65(4):684-88. PMID: 19834372.

Norgard NB, Saya S, Hann CL, et al. Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization. *J Cardiovasc Pharmacol* 2008 Dec;52(6):536-39. PMID: 19034031.

O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. *J Am Coll Cardiol* 2009 Aug 18;54(8):678-85. PMID: 19679245.

Obradovic S, Subota V, Baskot B, et al. Changes in platelets and anticoagulant protein activity during adenosine-exercise single-photon emission computed tomography stress test. *Srp Arh Celok Lek* 2010 Jan;138 Suppl 1:28-32. PMID: 20229679.

Pamukcu B, Oflaz H, Oncul A, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. *J Thromb Thrombolysis* 2006 Oct;22(2):103-10. PMID: 17008975.

Pamukcu B, Oflaz H, Onur I, et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). *Blood Coagul Fibrinolysis* 2007 Mar;18(2):187-92. PMID: 17287637.

Paniccia R, Antonucci E, Gori AM, et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. *Am J Clin Pathol* 2007 Jul;128(1):143-49. PMID: 17580282.

Pearson L, Thom J, Adams M, et al. A rapid flow cytometric technique for the detection of platelet-monocyte complexes, activated platelets and platelet-derived microparticles. *Int J Lab Hematol* 2009 Aug;31(4):430-39. PMID: 18384393.

Pride YB, Wiviott SD, Buros JL, et al. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRIal to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. *Am Heart J* 2009 Sep;158(3):e21-e26. PMID: 19699846.

Rao AK, Vaidyula VR, Bagga S, et al. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. *Thromb Haemost* 2006 Dec;96(6):738-43. PMID: 17139367.

Reavey-Cantwell JF, Fox WC, Reichwage BD, et al. Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery. *Neurosurgery* 2009 May;64(5):890-95. PMID: 19287328.

Rudez G, Bouman HJ, van Werkum JW, et al. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. *Circ Cardiovasc Genet* 2009 Oct;2(5):515-21. PMID: 20031628.

Sacristan D, Lopez-Farre AJ, Zamorano-Leon JJ, et al. Effects of coronary preenting platelet inhibition on coronary poststenting inflammation. *J Cardiovasc Pharmacol* 2008 Mar;51(3):286-92. PMID: 18356694.

Saracini C, Vestrini A, Galora S, et al. Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing. *Genet Test Mol Biomarkers* 2012 Jun;16(6):500-03. PMID: 22239289.

Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. *Circulation* 2003 Aug 26;108(8):921-24. PMID: 12925453.

Schneider DJ, Sobel BE. Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin. *J Thromb Thrombolysis* 2009 Jul;28(1):6-9. PMID: 18607689.

Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. *Circulation* 2003 Aug 26;108(8):939-44. PMID: 12912814.

Shammas NW, Dippel EJ, Lemke JH, et al. Eptifibatide in peripheral vascular interventions: results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial. *J Invasive Cardiol* 2006 Jan;18(1):6-12. PMID: 16391376.

Sidhu JS, Cowan D, Tooze JA, et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. *Am Heart J* 2004 Jun;147(6):e25. PMID: 15199366.

Smith SM, Judge HM, Peters G, et al. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. *Platelets* 2005 Sep;16(6):340-45. PMID: 16194864.

Smith SM, Judge HM, Peters G, et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. *Platelets* 2006 Jun;17(4):250-58. PMID: 16769602.

Spiewak M, Malek LA, Kostrzewa G, et al. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. *Kardiol Pol* 2009 Aug;67(8):827-34. PMID: 19784880.

Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. *CMAJ* 2006 Jun 6;174(12):1715-22. PMID: 16754899.

Suh JW, Kim SY, Park JS, et al. Comparison of triple antiplatelet therapy including triflusal and conventional dual therapy in patients who underwent drug-eluting stent implantation. *Int Heart J* 2009 Nov;50(6):701-09. PMID: 19952467.

Syros G, Mehran R, Weisz G, et al. Role of PLA2 polymorphism on clinical events after percutaneous coronary intervention. *Acute Card Care* 2009;11(2):88-91. PMID: 19526385.

Szuk T, Nagy B, Jr., Bereczky Z, et al. Effects of ad hoc clopidogrel loading versus pre-treatment on P-selectin expression after coronary stent implantation. *Platelets* 2006 Aug;17(5):344-46. PMID: 16928609.

Tsai NW, Chang WN, Shaw CF, et al. Serial change in platelet activation markers with aspirin and clopidogrel after acute ischemic stroke. *Clin Neuropharmacol* 2010 Jan;33(1):40-45. PMID: 19855266.

Undas A, Stepien E, Branicka A, et al. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. *Kardiol Pol* 2009 Jun;67(6):591-98. PMID: 19618315.

van Zyl LT, Lesperance F, Frasure-Smith N, et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. *J Thromb Thrombolysis* 2009 Jan;27(1):48-56. PMID: 18188512.

Vavuranakis M, Latsios G, Aggelis D, et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. *Clin Ther* 2006 Jun;28(6):860-71. PMID: 16860169.

von BN, von BO, Koch W, et al. P2Y₁₂ gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. *Blood Coagul Fibrinolysis* 2005 Apr;16(3):199-204. PMID: 15795539.

Waehre T, Damas JK, Pedersen TM, et al. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. *J Thromb Haemost* 2006 Oct;4(10):2140-47. PMID: 16856976.

Wallaschofski H, Lohmann T, Hild E, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. *Thromb Haemost* 2006 Jul;96(1):38-44. PMID: 16807649.

Weber CF, Gorlinger K, Byhahn C, et al. Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy. *Eur J Anaesthesiol* 2011 Jan;28(1):57-62. PMID: 20962655.

Weltermann A, Fritsch P, Kyrle PA, et al. Effects of pretreatment with clopidogrel on platelet and coagulation activation in patients undergoing elective coronary stenting. *Thromb Res* 2003;112(1-2):19-24. PMID: 15013268.

Willerson JT, Cable G, Yeh ET. PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. *Tex Heart Inst J* 2009;36(6):530-39. PMID: 20069077.

Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. *Circulation* 2008 Oct 14;118(16):1626-36. PMID: 18757948.

Wong S, Morel-Kopp MC, Chen Q, et al. Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease. *Thromb Haemost* 2006 Jun;95(6):1042-43. PMID: 16732389.

Yasu T, Ikee R, Miyasaka Y, et al. [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. *Yakugaku Zasshi* 2010 Dec;130(12):1743-50. PMID: 21139402.

Yip HK, Chen SS, Liu JS, et al. Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. *Stroke* 2004 Jul;35(7):1683-87. PMID: 15155956.

Yip HK, Wu CJ, Hang CL, et al. Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effects of clopidogrel loading dose in inhibiting platelet activation. *Circ J* 2005 Oct;69(10):1208-11. PMID: 16195618.

Yip HK, Chang LT, Sun CK, et al. Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. *Am J Cardiol* 2006 Jan 15;97(2):192-94. PMID: 16442361.

Ziegler S, Schillinger M, Funk M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y₁₂, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. *Stroke* 2005 Jul;36(7):1394-99. PMID: 15933261.

Not Treatment of Interest

Abumiya T, Houkin K. Association of recurrent cerebral infarction with adenosine diphosphate- and collagen-induced platelet aggregation in patients treated with ticlopidine and/or aspirin. *J Stroke Cerebrovasc Dis* 2011 Jul;20(4):319-23. PMID: 20634093.

al-Mefty O, Marano G, Raiaraman S, et al. Transient ischemic attacks due to increased platelet aggregation and adhesiveness. Ultrastructural and functional correlation. *J Neurosurg* 1979 Apr;50(4):449-53. PMID: 422999.

Antolovic D, Reissfelder C, Rakow A, et al. A randomised controlled trial to evaluate and optimize the use of antiplatelet agents in the perioperative management in patients undergoing general and abdominal surgery--the APAP trial (ISRCTN45810007). *BMC Surg* 2011;11:7. PMID: 21371292.

Aradi D, Kulickowski W, Atar D, et al. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. *Thromb Haemost* 2012 Feb;107(2):338-45. PMID: 22186910.

Arpaia MR, Leonardo G, del GR. [Control of platelet antiaggregation therapy using an electronic aggregometer on whole blood]. *Minerva Cardioangiol* 1986 Apr;34(4):195-98. PMID: 3725023.

Atalar E, Haznedaroglu I, Aytemir K, et al. Effects of stent coating on platelets and endothelial cells after intracoronary stent implantation. *Clin Cardiol* 2001 Feb;24(2):159-64. PMID: 11214746.

Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. *J Am Coll Cardiol* 1999 Mar;33(3):634-39. PMID: 10080462.

Azar RR, Badaoui G, Sarkis A, et al. Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention. *Clin Cardiol* 2010 Jan;33(1):E14-E19. PMID: 19816871.

Banks DC, Mitchell JR. Leucocytes and thrombosis. 3. Effect on white cell behaviour of substances which induce or inhibit platelet aggregation. *Thromb Diath Haemorrh* 1973 Sep 15;30(1):62-71. PMID: 4788754.

Behr T, Kuch B, Behr W, et al. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. *Clin Res Cardiol* 2011 Oct;100(10):907-14. PMID: 21533581.

Berent R, Auer J, Franklin B, et al. Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. *Am J Cardiol* 2011 Sep 1;108(5):644-50. PMID: 21684508.

Bierend A, Rau T, Maas R, et al. P2Y₁₂ polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. *Br J Clin Pharmacol* 2008 Apr;65(4):540-47. PMID: 17995973.

Bizzi B, Leone G, Boni P. Basic considerations on treatment of increased platelet aggregation in diabetic vasculopathic patients. *Acta Diabetol Lat* 1974 Nov;11(6):437-45. PMID: 4469856.

Bologna E. Influence of some drugs on platelet aggregation: a study in hypertensive patients. *Acta Univ Carol Med Monogr* 1972;52:87-92. PMID: 4669830.

Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. *J Am Coll Cardiol* 2011 Jul 26;58(5):467-73. PMID: 21777742.

Borgermann J, Kanashnik A, Sossdorf M, et al. Individual variability of response and non-response to acetyl salicylic acid after cardiac surgery. *Platelets* 2010;21(8):610-15. PMID: 20807171.

Bray PF, Mathias RA, Faraday N, et al. Heritability of platelet function in families with premature coronary artery disease. *J Thromb Haemost* 2007 Aug;5(8):1617-23. PMID: 17663734.

Broome A, Davidsson T, Eklof B, et al. Effect of platelet aggregation inhibitors on the rate of thrombectomy following arterial reconstructions with Gore-Tex prostheses: a retrospective study. *Vasa* 1982;11(3):210-12. PMID: 7136240.

Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. *Circ Cardiovasc Interv* 2011 Apr 1;4(2):180-87. PMID: 21386092.

Cattano D, Altamirano AV, Kaynak HE, et al. Perioperative assessment of platelet function by Thromboelastograph Platelet Mapping in cardiovascular patients undergoing non-cardiac surgery. *J Thromb Thrombolysis* 2013 Jan;35(1):23-30. PMID: 22851059.

Chandler AB, Earhart AD, Speich HE, et al. Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. *Thromb Res* 2010 Jan;125(1):44-52. PMID: 19487018.

Chen WY, Lee FN, Hsieh BS, et al. Studies on platelet aggregation and antiplatelet therapy in blackfoot disease. *Taiwan Yi Xue Hui Za Zhi* 1981 Sep;80(9):873-83. PMID: 6948081.

Chitkara K, Hogrefe K, Vasa-Nicotera M, et al. Eptifibatide-eluting stent as an antiproliferative and antithrombotic agent: in vitro evaluation. *J Invasive Cardiol* 2006 Sep;18(9):417-22. PMID: 16954580.

Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. *Platelets* 2008 Mar;19(2):104-10. PMID: 17852773.

Coulter SA, Cannon CP, Ault KA, et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. *Circulation* 2000 Jun 13;101(23):2690-95. PMID: 10851205.

Cox D, Smith R, Quinn M, et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. *J Am Coll Cardiol* 2000 Nov 1;36(5):1514-19. PMID: 11079651.

Danta G. Second phase platelet aggregation induced by adenosine diphosphate in patients with cerebral vascular disease and in control subjects. *Thromb Diath Haemorrh* 1970 Feb 28;23(1):159-69. PMID: 5420427.

Danta G. Platelet aggregation in patients with cerebral vascular disease and in control subjects. *Thromb Diath Haemorrh* 1973 Jun 28;29(3):730-32. PMID: 4761838.

Danzi GB, Capuano C, Sesana M, et al. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. *Curr Med Res Opin* 2003;19(1):28-33. PMID: 12661777.

de GG, Donati MB, Garattini S. Drugs affecting platelet function tests: their effects on haemostasis and surgical bleeding. *Thromb Diath Haemorrh* 1975 Sep 30;34(1):285-303. PMID: 1081280.

de LM, Boissonnat P, Mamelle N, et al. Platelet aggregation and HDL cholesterol are predictive of acute coronary events in heart transplant recipients. *Circulation* 1994 Jun;89(6):2590-94. PMID: 8205669.

Duzenli MA, Ozdemir K, Aygul N, et al. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. *Am J Cardiol* 2008 Aug 15;102(4):396-400. PMID: 18678294.

Elwood PC, Renaud S, Beswick AD, et al. Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. *Heart* 1998 Dec;80(6):578-82. PMID: 10065026.

Elwood PC, Beswick A, Pickering J, et al. Platelet tests in the prediction of myocardial infarction and ischaemic stroke: evidence from the Caerphilly Prospective Study. *Br J Haematol* 2001 May;113(2):514-20. PMID: 11380425.

Eriksson S, Berg LM, Wadelius M, et al. Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology. *Assay Drug Dev Technol* 2002 Nov;1(1 Pt 1):49-59. PMID: 15090156.

Eto K, Takeshita S, Ochiai M, et al. Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser light scattering to assess platelet aggregability. *Cardiovasc Res* 1998 Oct;40(1):223-29. PMID: 9876335.

Fredrickson BJ, Turner NA, Kleiman NS, et al. Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. *Circulation* 2000 Mar 14;101(10):1122-29. PMID: 10715258.

Gawaz M, Neumann FJ, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty. *Circulation* 1996 Jan 15;93(2):229-37. PMID: 8548893.

Gawaz M, Ruf A, Neumann FJ, et al. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. *Thromb Haemost* 1998 Dec;80(6):994-1001. PMID: 9869173.

Gazzaniga PP, Ferroni P, Mina C, et al. A multiparametric index of platelet in vitro aggregation in cerebrovascular disease. *Ital J Neurol Sci* 1987 Dec;8(6):561-66. PMID: 3429215.

Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. *Circulation* 2001 May 29;103(21):2550-54. PMID: 11382722.

Gilchrist IC, O'Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. *Circulation* 2001 Jul 24;104(4):406-11. PMID: 11468201.

Gorog DA, Kovacs IB. Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood. *Thromb Haemost* 1995 Mar;73(3):514-20. PMID: 7667836.

Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. *J Am Coll Cardiol* 1998 Jun;31(7):1466-73. PMID: 9626821.

Gurbel PA, Kereiakes DJ, Atar D, et al. Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. *Scand Cardiovasc J* 2000;34(1):53-58. PMID: 10816061.

Haft JJ, Gershengorn K, Kranz PD, et al. Protection against epinephrine-induced myocardial necrosis by drugs that inhibit platelet aggregation. *Am J Cardiol* 1972 Dec;30(8):838-43. PMID: 4634281.

Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. *Am J Cardiol* 1995 Dec 15;76(17):1222-27. PMID: 7503000.

Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. *N Engl J Med* 2003 Mar 20;348(12):1104-11. PMID: 12646667.

Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain. *JAMA* 2004 Jan 28;291(4):435-41. PMID: 14747500.

Hezard N, Metz D, Nazeyrollas P, et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. *Thromb Haemost* 2000 Apr;83(4):540-44. PMID: 10780313.

Holmes MB, Schneider DJ. Optimizing antiplatelet therapy in patients with acute coronary syndromes: a role for monitoring platelet reactivity. *J Invasive Cardiol* 1999 Dec;11 Suppl C:21C-5C. PMID: 10745617.

Holmes MB, Sobel BE, Cannon CP, et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. *Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol* 2000 Feb 15;85(4):491-3, A10. PMID: 10728957.

Hughes A, Daunt S, Vass G, et al. In vivo platelet activation following myocardial infarction and acute coronary ischaemia. *Thromb Haemost* 1982 Oct 29;48(2):133-35. PMID: 6184842.

Inoue T, Uchida T, Sakuma M, et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. *J Am Coll Cardiol* 2004 Oct 6;44(7):1408-14. PMID: 15464320.

Inoue T, Hikichi Y, Morooka T, et al. Comparison of changes in circulating platelet-derived microparticles and platelet surface P-selectin expression after coronary stent implantation. *Platelets* 2006 Sep;17(6):416-20. PMID: 16973503.

Ivandic BT, Spanuth E, Haase D, et al. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. *Clin Chem* 2007 Jul;53(7):1231-34. PMID: 17495016.

Iwamoto T, Jingzi J, Sugiyama T, et al. Prognosis of the elderly with asymptomatic atherosclerotic plaques of the carotid arteries. *Intern Med* 2002 Jul;41(7):526-31. PMID: 12132519.

Jeong YH, Park Y, Muse WC, et al. Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study. *J Thromb Haemost* 2012 Aug;10(8):1685-88. PMID: 22612904.

Kammerer I, Bach J, Saggau W, et al. Functional evaluation of platelet aspirin resistance after on-pump coronary bypass grafting using multiple aggregation tests. *Thorac Cardiovasc Surg* 2011 Oct;59(7):425-29. PMID: 21437867.

Karlberg KE, Chen J, Hagerman I, et al. Streptokinase, but not tissue plasminogen activator, attenuates platelet aggregation in patients with acute myocardial infarction. *J Intern Med* 1993 Nov;234(5):513-19. PMID: 8228797.

Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. *Circulation* 1996 Sep 1;94(5):906-10. PMID: 8790024.

Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. *Circulation* 1997 Aug 19;96(4):1117-21. PMID: 9286938.

Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. *Am J Cardiol* 1999 Aug 15;84(4):391-95. PMID: 10468074.

Kereiakes DJ, Mueller M, Howard W, et al. Efficacy of abciximab induced platelet blockade using a rapid point of care assay. *J Thromb Thrombolysis* 1999 Jun;7(3):265-76. PMID: 10375388.

Kereiakes DJ, Broderick TM, Roth EM, et al. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. *J Thromb Thrombolysis* 2000 Feb;9(2):149-55. PMID: 10613996.

Keyl C, Kmitta E, Kueri S, et al. Effects of aspirin and desmopressin on platelet reactivity in patients undergoing cardiac surgery with extracorporeal circulation. *Thromb Haemost* 2011 Jan;105(1):113-21. PMID: 21057697.

Kinoshita Y, Ashida K, Hongo M. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. *Aliment Pharmacol Ther* 2011 Jan;33(2):213-24. PMID: 21083596.

Kitai T, Nishikawa M, Tanigawa T, et al. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease. *Am Heart J* 2001 Aug;142(2):E1. PMID: 11479480.

Kralisz P, Dobrzycki S, Nowak K, et al. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction. *Kardiol Pol* 2004 May;60(5):459-67. PMID: 15247961.

Lilienberg G, Venge P. Platelet adhesion in patients prone to arterial and venous thrombosis: the impact of gender, smoking and heredity. *Scand J Clin Lab Invest* 1998 Jul;58(4):279-86. PMID: 9741815.

Lynch DR, Jr., Khan FH, Vaidya D, et al. Persistent high on-treatment platelet reactivity in acute coronary syndrome. *J Thromb Thrombolysis* 2012 Apr;33(3):267-73. PMID: 22362558.

Madan M, Berkowitz SD, Christie DJ, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. *Am Heart J* 2001 Feb;141(2):226-33. PMID: 11174336.

Mascelli MA, Kleiman NS, Marciniak SJ, Jr., et al. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. *Am Heart J* 2000 Apr;139(4):696-703. PMID: 10740154.

Mascelli MA, Deliargyris EN, Damaraju LV, et al. Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. *J Thromb Thrombolysis* 2004 Dec;18(3):171-75. PMID: 15815878.

Mendolicchio GL, Zavalloni D, Bacci M, et al. Variable effect of P2Y₁₂ inhibition on platelet thrombus volume in flowing blood. *J Thromb Haemost* 2011 Feb;9(2):373-82. PMID: 21083646.

Milburn JA, Cassar K, Ford I, et al. Prothrombotic changes in platelet, endothelial and coagulation function following hemodialysis. *Int J Artif Organs* 2011 Mar;34(3):280-87. PMID: 21445833.

Mody M, Lazarus AH, Semple JW, et al. Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant. *Transfus Med* 1999 Jun;9(2):147-54. PMID: 10354385.

Mueller HS, Rao PS, Greenberg MA, et al. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin. *Circulation* 1985 Dec;72(6):1336-45. PMID: 2933181.

Muhlhauser I, Schernthaner G, Silberbauer K, et al. Platelet proteins (beta-TG and PF4) in atherosclerosis and related diseases. *Artery* 1980;8(1):73-79. PMID: 6158934.

Nagakawa Y, Orimo H, Harasawa M. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the anti-platelet effect. *Thromb Res* 1985 Nov 15;40(4):543-53. PMID: 4082125.

Nenci GG, Agnelli G, Parise P, et al. Sex difference in circulating platelet aggregates and response to antiplatelet treatment. *Thromb Haemost* 1982 Dec 27;48(3):341. PMID: 7164022.

Neumann FJ, Hochholzer W, Pogatsa-Murray G, et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. *J Am Coll Cardiol* 2001 Apr;37(5):1323-28. PMID: 11300442.

Nita I, Papilian M, Theodorini S, et al. [Spontaneous thrombocyte aggregation in patients with ischemic cardiopathy. Effect of anti-aggregant treatment on thrombocyte function and other coagulation factors]. *Med Interne* 1984 Apr;22(2):113-22. PMID: 6740182.

Ohmori T, Yano Y, Sakata A, et al. Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. *Thromb Res* 2012 Apr;129(4):e36-e40. PMID: 22115701.

Olsson JE. Comparison between induced platelet aggregation and circulating platelet aggregates as platelet function tests in patients with transient ischemic attacks. *Acta Neurol Scand* 1982 Feb;65(2):122-32. PMID: 7072482.

Onoda K, Ohashi K, Hashimoto A, et al. Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery. *Ann Thorac Cardiovasc Surg* 2008 Aug;14(4):230-37. PMID: 18818572.

Pamukcu B, Oflaz H, Acar RD, et al. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation. *J Thromb Thrombolysis* 2005 Aug;20(1):17-22. PMID: 16133890.

Peter K, Straub A, Kohler B, et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. *Am J Cardiol* 1999 Sep 1;84(5):519-24. PMID: 10482148.

Peter K, Kohler B, Straub A, et al. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. *Circulation* 2000 Sep 26;102(13):1490-96. PMID: 11004138.

Peters AJ, Borries M, Gradaus F, et al. In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. *J Thromb Thrombolysis* 2001 Dec;12(3):263-72. PMID: 11981109.

Pothula S, Sanchala VT, Nagappala B, et al. The effect of preoperative antiplatelet/anticoagulant prophylaxis on postoperative blood loss in cardiac surgery. *Anesth Analg* 2004 Jan;98(1):4-10, table. PMID: 14693573.

Robless PA, Okonko D, Lintott P, et al. Increased platelet aggregation and activation in peripheral arterial disease. *Eur J Vasc Endovasc Surg* 2003 Jan;25(1):16-22. PMID: 12525806.

Saad EM, Kaplan S, el-Massry S, et al. Platelet aggregometry can accurately predict failure of externally supported knitted Dacron femoropopliteal bypass grafts. *J Vasc Surg* 1993 Oct;18(4):587-94. PMID: 8411466.

Saltzman AJ, Mehran R, Hooper WC, et al. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. *J Invasive Cardiol* 2010 Jan;22(1):2-6. PMID: 20048389.

Salzman EW, Harris WH, DeSanctis RW. Reduction in venous thromboembolism by agents affecting platelet function. *N Engl J Med* 1971 Jun 10;284(23):1287-92. PMID: 5576438.

Sambu N, Dent H, Englyst N, et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. *Heart* 2011 Oct;97(20):1661-67. PMID: 21795297.

Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. *N Engl J Med* 2000 Aug 10;343(6):385-91. PMID: 10933737.

Serebruany V, McKenzie M, Meister A, et al. Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial). *Eur J Heart Fail* 2002 Aug;4(4):461-67. PMID: 12167384.

Serebruany VL, Lowry DR, Fuzailov SY, et al. Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction. *J Thromb Thrombolysis* 2000 Apr;9(3):229-34. PMID: 10728021.

Serebruany VL, Alford AB, Meister AF, et al. Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). *Thromb Res* 2001 Mar 15;101(6):427-33. PMID: 11322999.

Serebruany VL, McKenzie ME, Meister AF, et al. Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure. *Pathophysiol Haemost Thromb* 2002 Jan;32(1):8-15. PMID: 12214158.

Serebruany VL, Malinin AI, Oshrine BR, et al. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. *Thromb Res* 2004;113(3-4):197-204. PMID: 15140583.

Serebruany VL, Malinin AI, Lowry DR, et al. Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. *J Cardiovasc Pharmacol* 2004 May;43(5):677-84. PMID: 15071355.

Serebruany VL, Miller M, Pokov AN, et al. Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. *Cardiology* 2011;118(3):187-94. PMID: 21701167.

Serrano CV, Jr., Nicolau JC, Venturinelli M, et al. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. *Cardiovasc Drugs Ther* 2003 Mar;17(2):129-32. PMID: 12975594.

Sestito A, Sgueglia GA, Spinelli A, et al. Increased platelet reactivity in unstable angina patients is not related to C-reactive protein levels. *Platelets* 2006 Aug;17(5):336-39. PMID: 16928607.

Siriswangvat S, Sansanayudh N, Nathisuwan S, et al. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. *Circ J* 2010 Oct;74(10):2187-92. PMID: 20736505.

Small DS, Farid NA, Li YG, et al. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease. *J Clin Pharm Ther* 2009 Oct;34(5):575-83. PMID: 19744013.

Smout J, Dyker A, Cleanthis M, et al. Platelet function following acute cerebral ischemia. *Angiology* 2009 Jun;60(3):362-69. PMID: 19398427.

Steinhubl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. *Circulation* 1999 Nov 9;100(19):1977-82. PMID: 10556224.

Storey RF, Melissa TS, Lawrance R, et al. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. *Platelets* 2009 Aug;20(5):341-48. PMID: 19637098.

Sucker C, Zotz RB, Kurt M, et al. Platelet-function analyzer closure times indicate shear stress-induced hemostatic abnormalities in patients with aortic valve stenosis and correlate with perioperative transfusion requirements. *Perfusion* 2010 May;25(3):153-58. PMID: 20406747.

Sucker C, Litmathe J, Feindt P, et al. Platelet function analyzer (PFA-100) as a useful tool for the prediction of transfusion requirements during aortic valve replacement. *Thorac Cardiovasc Surg* 2011 Jun;59(4):233-36. PMID: 21412708.

Tanaka KA, Szlam F, Kelly AB, et al. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. *Platelets* 2004 Aug;15(5):325-32. PMID: 15370104.

Tanigawa T, Nishikawa M, Kitai T, et al. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. *Am J Cardiol* 2000 May 1;85(9):1054-59. PMID: 10781751.

Tello-Montoliu A, Tomasello SD, Ferreira JL, et al. Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study. *J Am Coll Cardiol* 2012 May 8;59(19):1681-87. PMID: 22554598.

Tobin WO, Kinsella JA, Collins DR, et al. Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. *Br J Haematol* 2011 Mar;152(5):640-47. PMID: 21223254.

Tsukahara K, Kimura K, Morita S, et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. *Circ J* 2010 Apr;74(4):679-85. PMID: 20173303.

Vaidya D, Yanek LR, Faraday N, et al. Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. *Metab Syndr Relat Disord* 2009 Aug;7(4):289-96. PMID: 19351291.

van den Dungen JJ, Karliczek GF, Brenken U, et al. The effect of prostaglandin E1 in patients undergoing clinical cardiopulmonary bypass. *Ann Thorac Surg* 1983 Apr;35(4):406-14. PMID: 6682305.

Vavalle JP, Stevens SR, Hassinger N, et al. The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. *Am Heart J* 2011 Dec;162(6):996-1002. PMID: 22137072.

Wada R, Rohatagi S, Small D, et al. Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes. *J Clin Pharmacol* 2010 Aug;50(8):904-13. PMID: 20147617.

Woinke M, Zeiger F, Ruehlmann C, et al. Changes in signal transduction in the platelets of patients with peripheral occlusive arterial disease. *Int Angiol* 2000 Dec;19(4):345-50. PMID: 11305734.

Wykrzykowska JJ, Warnholtz A, de JP, et al. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. *J Thromb Thrombolysis* 2009 Nov;28(4):410-17. PMID: 19504052.

Yano Y, Ohmori T, Hoshida S, et al. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. *Eur Heart J* 2008 Jul;29(14):1729-38. PMID: 18270211.

Zurbano MJ, Anguera I, Heras M, et al. Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIIa in early postmyocardial infarction stage. *Arterioscler Thromb Vasc Biol* 1999 Jul;19(7):1791-95. PMID: 10428581.

Not Outcome of Interest

Alexopoulos D, Plakomyti TE, Xanthopoulou I. Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity. *Int J Cardiol* 2012 Feb 9;154(3):333-34. PMID: 22075413.

Angiolillo DJ, Capranzano P, Desai B, et al. Impact of P2Y₁₂ inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. *Thromb Res* 2009 Jul;124(3):318-22. PMID: 19012950.

Bonello L, Harhour K, Sabatier F, et al. Level of adenosine diphosphate receptor P2Y₁₂ blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement. *J Am Coll Cardiol* 2010 Sep 21;56(13):1024-31. PMID: 20846600.

Boulenc X, Djebli N, Shi J, et al. Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite. *Drug Metab Dispos* 2012 Jan;40(1):187-97. PMID: 22004687.

Breet NJ, Sluman MA, van Berkel MA, et al. Effect of gender difference on platelet reactivity. *Neth Heart J* 2011 Nov;19(11):451-57. PMID: 21901505.

Chang MH, Lindegren ML, Butler MA, et al. Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. *Am J Epidemiol* 2009 Jan 1;169(1):54-66. PMID: 18936436.

Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 2004 Sep;128(3):425-31. PMID: 15354103.

Chirumamilla AP, Maehara A, Mintz GS, et al. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. *JACC Cardiovasc Imaging* 2012 May;5(5):540-49. PMID: 22595163.

Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. *J Am Coll Cardiol* 2008 Dec 9;52(24):1968-77. PMID: 19055987.

Gaglia MA, Jr., Torguson R, Pakala R, et al. Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity. *Am J Cardiol* 2011 Sep 15;108(6):766-71. PMID: 21752347.

Gremmel T, Kopp CW, Seidinger D, et al. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity. *Atherosclerosis* 2009 Dec;207(2):608-13. PMID: 19616779.

Gremmel T, Fruhwirth K, Kopp CW, et al. Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity. *Clin Res Cardiol* 2012 Jun;101(6):445-52. PMID: 22234620.

Hamilos M, Muller O, Ntalianis A, et al. Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. *J Thromb Thrombolysis* 2011 Jul;32(1):64-71. PMID: 21290254.

Kim BJ, Lee SW, Park SW, et al. Insufficient platelet inhibition is related to silent embolic cerebral infarctions after coronary angiography. *Stroke* 2012 Mar;43(3):727-32. PMID: 22207508.

Koerner H, Derveaux C, Alexandrou M, et al. Do Clopidogrel Nonresponders Have an Increased Risk of Adverse Events during Supra-Aortal Angioplasty and Stenting? *Stroke Res Treat* 2012;2012:904534. PMID: 22577603.

Kuliczkowski W, Gasior M, Pres D, et al. Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction. *Am J Cardiol* 2012 Aug 1;110(3):331-36. PMID: 22551736.

Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. *J Am Coll Cardiol* 2006 Jan 3;47(1):27-33. PMID: 16386660.

Lev EI, Ramchandani M, Garg R, et al. Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery. *J Thromb Thrombolysis* 2007 Aug;24(1):15-21. PMID: 17277998.

Malek LA, Grabowski M, Spiewak M, et al. Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. *J Thromb Thrombolysis* 2007 Dec;24(3):301-05. PMID: 17404690.

Mangiaccapra F, Peace AJ, Wijns W, et al. Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. *J Thromb Thrombolysis* 2011 Jul;32(1):54-58. PMID: 21221715.

Meen O, Brosstad F, Bjornsen S, et al. Variability in aggregometry response before and after initiation of clopidogrel therapy. *Scand J Clin Lab Invest* 2009;69(6):673-79. PMID: 19484660.

Minarik M, Kopeckova M, Gassman M, et al. Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis. *Electrophoresis* 2012 Apr;33(8):1306-10. PMID: 22589111.

Muller O, Hamilos M, Bartunek J, et al. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. *Am J Cardiol* 2010 Feb 1;105(3):333-38. PMID: 20102944.

Perez de PA, Fernandez-Vazquez F, Cuellas JC, et al. Association between level of platelet inhibition after early use of abciximab and myocardial reperfusion in ST-elevation acute myocardial Infarction treated by primary percutaneous coronary intervention. *Am J Cardiol* 2006 Mar 15;97(6):798-803. PMID: 16516579.

Serebruany V, Rao SV, Silva MA, et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. *Eur Heart J* 2010 Jan;31(2):227-35. PMID: 19854728.

Serebruany VL, Malinin AI, Pokov AN, et al. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. *Clin Ther* 2008 Feb;30(2):249-59. PMID: 18343263.

Stellos K, Bigalke B, Stakos D, et al. Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. *J Thromb Haemost* 2010 Jan;8(1):205-07. PMID: 19874461.

Taomoto K, Ohnishi H, Kuga Y, et al. Platelet function and spontaneous thrombolytic activity of patients with cerebral infarction assessed by the global thrombosis test. *Pathophysiol Haemost Thromb* 2010;37(1):43-48. PMID: 20516672.

Velik-Salchner C, Maier S, Innerhofer P, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. *Anesth Analg* 2008 Dec;107(6):1798-806. PMID: 19020120.

Zalewski J, Durak M, Lech P, et al. Platelet activation and microvascular injury in patients with ST-segment elevation myocardial infarction. *Kardiol Pol* 2012;70(7):677-84. PMID: 22825940.

Appendix C. U.S. Food and Drug Administration Documents Reviewed

The following documents from the U.S. Food and Drug administration were reviewed for this report. They were identified through a search of the database of the 510(k) Database† (1996–current) using the following stem or key words: aggreg*, PFA*, Ultegra*, Impact*, VerifyNow*, platelet*, plateletwork*, CY2C19, *2C19*, CYP2*, VASP*.

Appendix Table C1. U.S. Food and Drug Administration documents reviewed: type of testing, test name, and comments

Document	Test name	Comments
Genetic testing		
K101683	INFINITI CYP2C19 Assay	Population not described so document not included; however, indirect data given on limits of detection, sequencing concordance, and interlaboratory reproducibility.
K042259	Roche AmpliChip CYP450 Test	Gene not of interest (CYPCD6).
K043576	Amplichip CYP450 Test for CYP2C19	Population not described so document not included; however, indirect data given on limits of detection, sensitivity and specificity, sequencing concordance, interassay agreement, comparison with a reference standard, cross-contamination, and reproducibility.
K012966	COBAS TaqMan Analyzer	Population not described so document not included; however, indirect data given on the dynamic range, limits of detection, sensitivity, and specificity.
Phenotypic testing		
K992531	Accumetrics Ultegra System Rapid Platelet Function Assay-TRAP	Population is of interest (patients undergoing PCI [also treated with abciximab]) and reports interassay correlation. However, antiplatelet agents other than abciximab were not reported.
K011337	Accumetrics Ultegra System Rapid Platelet Function Assay-TRAP	Population is of interest (patients undergoing PCI [also treated with abciximab]) and reports interassay correlation. However, antiplatelet agents other than abciximab were not reported.
K012701	Accumetrics Ultegra System Rapid Platelet Function Assay-ASA	Test not of interest (measuring response to aspirin)
K013596	Accumetrics Ultegra System Rapid Platelet Function Assay	Population is of interest (patients undergoing PCI [also treated with abciximab or eptifibatide]) and reports interassay correlation. However, antiplatelet agents other than abciximab or eptifibatide were not reported..
K060489	Dade PFA-100 Platelet Function Analyzer Dade PFA-100 Reagents	Populations not of interest (data summarized from studies in children and in patients with bleeding disorders)
K970505	Dade PFA-100 Platelet Function Analyzer Dade PFA Collagen/Epinephrine Test Cartridge Dade PFA Collagen/ADP Test Cartridge Dade PFA Trigger Solution	Collagen/epinephrine test not of interest. For collagen/ADP test, populations not of interest (data summarized from a study of subjects with normal platelet function or patients with von Willebrand disease, aspirin-induced dysfunction, or Glanzmann's thromasthenia)

Document	Test name	Comments
K002885	Dade PFA-100 Platelet Function Analyzer Dade PFA Collagen/Epinephrine Test Cartridge Dade PFA Collagen/ADP Test Cartridge Dade PFA Trigger Solution	Collagen/epinephrine test not of interest. For collagen/ADP test, populations not of interest (data summarized from studies of healthy children, healthy adults, and children with von Willebrand disease))
K042423	Accumetrics VerifyNow-Aspirin Assay	Test not of interest (measuring response to aspirin)
K051231	Accumetrics VerifyNow P2Y12 Assay	Population is of interest (patients treated with clopidogrel with a history of vascular disease or risk factors) but n=10 only.
K093626	INNOVANCE D-Dimer Assay	Population not of interest (patients presenting to emergency department with suspected deep-vein thrombosis)
K990398	Plateletworks Platelet Aggregation Assay	Population not of interest (includes healthy volunteers)
K012723	Collagen for Plateletworks	No data available (only approval statement is in database)
K023761	Plateletworks	No data available (only approval statement is in database)
K061991	Plateletworks Arachidonic Acid	Test not of interest (measuring response to arachidonic acid)
K032951	Chrono-log Whole Blood Aggregometer, Model 591A/592A	Population not of interest ("normal, healthy, drug free subjects" or "normal donors and patients known to have von Willebrands Disease")
K050265	Model 700 Chrono-log Whole Blood Lumi-Aggregometer	Population not of interest ("normal, healthy, drug free subjects")
K830749	Chrono-log Model 560 Whole Blood Lumi-Aggregometer	No data available (no downloadable information in database)
K851025	AGGRO/LINK Interface	No data available (no downloadable information in database)
K962426	Chrono-log Whole Blood Aggregometer, Model 591/592	No data available (only one-page summary is in database)
K954997	Centocor Aggrestat, Collagen Reagent, Control Reagent	No data available (no downloadable information in database)

† Available at www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm; last accessed: April 25, 2012.

Abbreviations: ASA=acetylsalicylic acid (aspirin), RPFA=rapid platelet function assay, TRAP=thrombin receptor activating peptide.

Appendix D. Appendix Tables for Key Question 1

Appendix Table D1. Descriptive characteristics of studies reporting analytic validity information for CYP2C19 assays

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Study design for the assessment of analytic validity	Sample size	Results
Shuldiner 2009 USA 19706858	Patients undergoing nonemergent PCI; those with MI within 48 h were excluded.	TaqMan SNP assay (rs4244285, rs4986893, rs56337013, rs12248560, corresponding to *2, *3, *5, *17, respectively) [Applied Biosystems, Foster City, CA]	Not clear	Repeat genotyping of samples	Not reported (for the subset of duplicate samples)	Genotype concordance rate >98%
Sibbing 2009 Germany 19193675	Patients undergoing PCI in a single center; patients included in the study were selected among those participating in a set of randomized trials of abciximab	TaqMan assay (rs4244285, corresponding to *2) [ABI Prism Sequence Detector 7000, Applied Biosystems]	Blood was obtained after diagnostic angiography and before PCI; timing of genetic analysis was not clear	Repeat genotyping of samples (20% of all genotyped samples; selection NR)	20% of 2485 = 497	"All repeated experiments revealed identical results when compared with the initial genotype"
Sibbing 2011 Germany 21527445	Patients undergoing PCI in a single center; patients included in the study were selected among those participating in a prospective trial (blood for genotyping was available for 95% of the study participants)	TaqMan assay (rs4244285, corresponding to *2) [ABI Prism Sequence Detector 7000, Applied Biosystems]	Blood was obtained after diagnostic angiography and before PCI; timing of genetic analysis was not clear	Repeat genotyping of samples (20% of all genotyped samples; selection NR)	20% of 1524 = 305	"Repeat genotyping revealed identical results", the call rate was 100%

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Study design for the assessment of analytic validity	Sample size	Results
Trenk 2011 Germany 21685174	Patients undergoing elective coronary stent placement after pre-treatment with 600 mg of clopidogrel and aspirin (≥ 100 mg per day for at least 5 days) in a single center; patients were participants in the EXCELSIOR study	For CYP2C19 *2 (rs4244285): PCR using the Drug Metabolism Genotyping Assay (Applied Biosystems, Frankfurt, Germany)† For CYP2C19 *17 (rs12248560): TaqMan assay [Applied Biosystems, Foster City, CA]	Not clear	Repeat genotyping of samples	Not reported (for the subset of duplicate samples)	Concordance rate = 100%
Sibbing 2010 Germany 20083681	Patients with CAD undergoing PCI in a single center; patients included in the study were selected among those participating in a prospective study (blood for genotyping was available for 95% of the study participants)	TaqMan assay (rs12248560, corresponding to *7) [ABI Prism Sequence Detector 7000, Applied Biosystems, Foster City, CA]	Blood was obtained directly before PCI; timing of genetic analysis was not clear	Repeat genotyping of samples (20% of all genotyped samples; selection NR)	20% of 1524 = 305	"Repeat genotyping revealed identical results"

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Study design for the assessment of analytic validity	Sample size	Results
Siller-Matula 2012 Austria 22260716 PAGASUS- PCI	Consecutive patients with coronary artery disease undergoing PCI with stent placement at least 2h post- loading with clopidogrel 600 mg; 99% received DES	TaqMan Drug Metabolism Genotyping Assay (rs12248560, corresponding to *17) [ABI Prism Sequence Detector 7000, Applied Biosystems, Foster City, CA] Real-time allelic discrimination assay (rs4244285, corresponding to *2) [ABI Prism Sequence Detector 7000, Applied Biosystems, Foster City, CA] Sequencing (did not report if both variants were evaluated) [BigDye Terminator v. 3.1 sequencing kit and 3130xl Genetic Analyzer, Applied Biosystems, Foster City, CA]	Blood samples were obtained in the catheterization laboratory directly post-PCI	Sequencing of randomly selected samples among those analyzed using allelic discrimination techniques	Not reported (for the subset of samples genotyped with both methods)	"No discrepancies were observed"

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Study design for the assessment of analytic validity	Sample size	Results
Namazi 2012 Iran 22265638	Patients undergoing elective PCI with DES placement in a single center; all patients received a loading dose of clopidogrel (600 mg) at least 24h pre-PCI and all patients had received aspirin for ≥ 7 d pre-PCI	PCR-RFLP (rs4244285 and rs4986893, corresponding to *2 and *3, respectively) [additional information NR] Direct sequencing [additional information NR]	Samples were obtained at baseline, 2h post-loading, and 24h and 30d post-PCI	Sequencing of randomly selected samples among those analyzed with PCR RFLP	Not reported (for the subset of samples genotyped with both methods)	Sequencing analysis "confirmed" the results of PCR-RFLP analysis
Delaney 2012 USA 22190063	Patients started on clopidogrel post-MI and/or PCI; samples were obtained from participants in the BioVU DNA biobank linked to de-identified health records	TaqMan (rs4244285, rs4986893, rs28399504; rs12248560, corresponding to *2, *3, *4, *17, respectively) [Applied Biosystems, Foster City, CA]	Samples obtained "during routine clinical care and about to be discarded"	Repeat genotyping of samples	Not reported (for the subset of duplicate samples)	"Concordance >98% between duplicates"; call rates >95%; 1 sample excluded because of poor genotyping efficiency; *3 and *4 polymorphisms were excluded from subsequent analysis because they were very rare (*4 observed only in 5 subjects; *3 not polymorphic in the study population)
Bhatt 2012 Multinational 22450429 CHARISMA	Patients with manifest atherothrombotic disease (coronary, cerebrovascular, or peripheral arterial) or with multiple risk factors for atherothrombotic disease randomized to clopidogrel+aspirin or placebo + aspirin; patients were participants in the genetics substudy of the CHARISMA randomized trial	PCR-RFLP (rs4244285, corresponding to *2) [additional information NR] TaqMan allelic discrimination assay (rs4986893, corresponding to *3) [additional information NR]	Samples obtained from the available population [additional information NR]	Repeat genotyping of randomly selected samples	11% of 4862 patients with adequate DNA recovered = 535 samples (4924 patients provided blood)	"No errors were identified in the replicates"; "missingness was <2% for all SNPs"

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Study design for the assessment of analytic validity	Sample size	Results
Roberts 2012 Canada 22464343 RAPID GENE	Patients undergoing PCI for NSTEMI-ACS or stable angina; all patients were treated with 600 mg clopidogrel \geq 24h pre-PCI	Point-of-care genotyping (rs4244285, corresponding to *2) [Spartan RX CYP2C19 device, Spartan Biosciences, Ottawa, ON, Canada] Direct sequencing (rs4244285, corresponding to *2) [ABI PRISM dye terminator method; Applied Biosystems, Foster City, CA]	Screening for *2 variants was performed at the time of randomization; *2 status was also investigated with the Spartan device and sequencing 1w post-PCI	Genotyping of samples using both methods	187 patients with complete followup	1 sample had discrepant results (*2 carrier by Spartan RX but non-carrier by sequencing) Analytic sensitivity of Spartan RX using sequencing as the reference standard = 100% (95% CI 92.3%, 100%) Analytic specificity of Spartan RX using sequencing as the reference standard = 99.3% (95% CI 96.3%, 100%) Conclusive rate = 93.6%
Mega 2011 USA 22088980 ELEVATE-TIMI 56	Patients with known cardiovascular disease on clopidogrel maintenance therapy	Pyrosequencing (*2 allele) [additional information NR] Nucleic acid research-use only assay (*2 allele) [Nanosphere Verigene 2C19/CBS assay, additional information NR]	At the time of study enrollment	Genotyping of samples using both methods	333 patients successfully genotyped (of 335 enrolled)	"Results were confirmed for CYP2C19*2 status"

†Information on the genotyping assay was extracted from Trenk et al. 2008 (PMID = 18482659)

Abbreviations: h = hour; MI = myocardial infarction; PCI = percutaneous coronary intervention; PMID = PubMed identification number.

Appendix Table D2. Reporting characteristics and methodological quality of studies of analytic validity

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/ instruments/ reagent lots/ different days of the week/ different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Shuldiner 2009 USA 19706858	YES	NR	NA	NR	NR	NR	NO	NO	YES (concordance on repeat genotyping)	NO	NO
Sibbing 2009 Germany 19193675	YES	NR	NA	NR	NR	NR	NO	NO	YES (concordance on repeat genotyping)	NO	NO
Sibbing 2011 Germany 21527445	YES	NR	NA	NR	NR	NR	NO	NO	YES (concordance on repeat genotyping)	NO	NO
Trenk 2011 Germany 21685174	YES	NR	NA	NR	NR	NR	NO	NO	YES (concordance on repeat genotyping)	NO	NO
Sibbing 2010 Germany 20083681	YES	NR	NA	NR	NR	NR	NO	NO	YES (concordance on repeat genotyping)	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/ instruments/ reagent lots/ different days of the week/ different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Siller-Matula 2012 Austria 22260716 PAGASUS-PCI	YES	NR	NA	NR [the blinding procedures described were not applicable to control samples]	NR [the blinding procedures described were not applicable to control samples]	NR	NO	NO	NO (agreement between different genotyping methods)	YES (assessment of different genotyping methods)	NO
Namazi 2012 Iran 22265638	YES	NR	NA	NR	NR	NR	NO	NO	NO (agreement between different genotyping methods)	YES (assessment of different genotyping methods)	NO
Delaney 2012 USA 22190063	YES	NR	NA	NR	NR	NR	NO	NO	YES (concordance on repeat genotyping)	NO	NO
Bhatt 2012 Multinational 22450429 CHARISMA	NO	NR	NA	NR	NR	NR	NO	NO	YES (concordance on repeat genotyping)	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/ instruments/ reagent lots/ different days of the week/ different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Roberts 2012 Canada 22464343 RAPID GENE	YES	NR (for the assessment of patient samples)	NA	NR	NR	NR	NO	NO	YES (genotyping was repeated at one week)	YES (assessment of different genotyping methods)	NO
Mega 2011 USA 22088980 ELEVATE- TIMI 56	NO (pyrosequencing methods not described)	NR	NA	NR	NR	NR	NO	NO	NO	YES (assessment of different genotyping methods)	NO

Abbreviations: NA = not applicable; NR = not reported; PMID = PubMed identification number.

Appendix Table D3. Descriptive characteristics of included studies

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Collet, 2009 19108880 France AFIJI (Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention) registry	259 78% White European 16.6% North African 3.1% Black 2.3% Asian 92.3% 40.1 (± 5.1)	NR NR NR 73% PCI ; 8% CABG NR NR NR NR 78.8% STEMI; 21.2% NSTEMI	54% 56% NR 20.1% HTN 10.4%	3.1% Clopidogrel: 83.4% initiated at first event; 19.9% not on clopidogrel NR NR	86% 32% DES 54% BMS	Survivors of AMI enrolled in a multicenter registry; followup was on an outpatient basis	Clopidogrel MD = 75 mg for at least 1 mo	Low dose aspirin (dose NR)
Fontana, 2008 17681590 Switzerland NR	81 100% Caucasian 79% 65.9± 12.2	NR NR NR NR NR NR 50.6% ACS NR	71.6% Hyperlipidemia 30.9% 59.3% HTN 18.5%	NR NR 98.8% 13.6%	100% NR NR	PCI with stent placement	Clopidogrel LD=300 mg MD = 75 mg	99% Aspirin maintenance (dose NR)

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Giusti, 2007 18004210 Italy NR	1419 NR 73% Median= 69 (range: 27-94)	NR NR NR NR NR NR NR NR NR	56.1% Dyslipidemia 40.9% "Smoking habit" 65% HTN 21.1%	NR NR NR NR	NR NR NR	PCI for ACS	LD: clopidogrel 600 mg (orally) + 500 mg ASA (IV); MD: clopidogrel 75 mg and ASA 100 mg (both daily)	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	804 (of whom 772 consented to participation in the genetics substudy) NR 74.6% NR	NR LVEF = 47% ±12% NR 20.9% PCI 7.5% CABG 33.9% 40.2% NR 25.5% NR	59.7% Dyslipidemia; 89.4% on statins 34.4% 65.4% HTN 22.2%	NR NR 94.8%	100% 100% DES (sirolimus or paclitaxel) 439 (56.8%) had multi-vessel disease; NR if all received multiple stents	PCI	All patients received aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance). Loading dose was administered before the procedure	UFH was used during the procedure as the anticoagulant.

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Gladding, 2009 19926050 New Zealand NR	40 88% Caucasian 78% 67±11	18% 5% NR 88% NR NR NR NR	43% 10% NR 50% 20%	NR 100% NR 33%	NR NR NR	PCI>2 wk previously	All patients had a 600-mg clopidogrel loading dose, followed by clopidogrel 150 mg once daily for 7 days	NR
Jinnai, 2009 19531897 Japan Partly industry funded	30 100% East Asian 73.3% 70 ± 8.3	NR NR NR NR NR NR 12% NR	64% Hyperlipidemia; 72% on statin 16% Current smokers 68% HTN 16%	NR NR NR 20%	NR NR NR	Elective PCI, for symptoms or based on stress testing	Patients were on low-dose Aspirin (81-100 mg/day) at study enrollment; They received clopidogrel 300 mg loading dose on the first day and then 75 mg daily maintenance.	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Mega, 2009 19106084 Multinational Genetics substudy of TRITON-TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction]	1477 Caucasian, 1442 (97.6%); Hispanic, 18 (1.2%); African, 10 (0.7%); Asian, 5 (0.3%); Other, 2 (0.1%) 1044 (70.7%) 60.1 ± 11.1	NR NR 51 (3.5%) NR NR NR NR 240 (16.2%) NR	725 (49.1) 562 (38.1%) HTN=972 (65.8%) 322 (21.8%)	NR NR NR NR	1389 (1389 of the 1459 subjects with analyzable data = 95% of all included in analyses) NR NR	ACS with planned PCI	Clopidogrel 300 mg loading dose, followed by a 75 mg daily maintenance dose.	All decisions regarding concomitant medications were left to the treating physician. It was recommended that long-term aspirin therapy be 75 to 162 mg. Patients may receive unfractionated heparin, low-molecular-weight heparin, any approved direct thrombin inhibitor, and/or GPIIb/IIIa receptor antagonist. Because of a

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
								lack of information regarding the safety of thienopyridines in combination with warfarin, blinded study drug is discontinued in patients requiring anticoagulation with warfarin, and open-label thienopyridine use is left to the discretion of the treating physician. (source: Wiviott et al., American Heart Journal, Volume 152, Issue 4, Pages

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
								627-635, PMID = 16996826)
Shuldiner, 2009 19706858 USA Sinai Hospital of Baltimore Study	227 White=140 (61.7%); African-American=83 (36.6%); other=4 (1.8%) 139 (59.9%) 64.3 ± 11.5	100% (all undergoing non-emergent PCI) NR NR NR NR NR NR All patients underwent non-emergent PCI	183 (80.6%) 58 (25.6%) [current smoker] SBP = 140.7 ± 20.2; DBP = 72.3 ± 14.1; HTN=174 (76.7%) 83 (36.6%)	NR 90 (39.6%) at the time of study entry 227(100%) NR	NR NR NR	Non-emergent PCI	On the day of PCI patients received clopidogrel 600 mg (n=112) or 300 mg (n=25) loading dose; 90 subjects already on clopidogrel maintenance therapy with 75 mg daily at the time of PCI were not reloaded. All patients received 81-325 mg aspirin daily for ≥1 week prior to	Patients were also treated with bivalirudin or heparin, with (n=107) or without (n=120) eptifibatide. Anticoagulant therapy was discontinued at the completion of the procedure.

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
							PCI and 325 mg on the day of the procedure. Aspirin 325 mg per day and clopidogrel 75 mg per day was prescribed to all patients at discharge.	
Sibbing, 2009 19193675 Germany NR	2661 fulfilled the study inclusion criteria; of those 2485 had DNA available for genotyping NR 539 (78.3%) 66.5 ± 10.2	NR NR NR Previous CABG 325 (13%) NR UA = NR; Total ACS = 846 (34%) NR 801 (32%) NR	Hypercholesterolemia = 1204 (48%) 402 (16%) HTN = 1563 (63%) 881 (35%)	NR NR NR NR	100% DES = 623 (25%); BMS = 1862 (75%) 2006 (81%)	Patients undergoing planned PCI	Clopidogrel LD= 600 mg before stent placement.	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	1608 patients were included in a study of platelet function; 1524 (95%) of those had samples available for inclusion in the genetic study. NR 1180 (77.4%) 67.4 ± 10.5	All patients had known CAD NR [ejection fraction = 54.7± 11.1] NR CABG = 223 (14.6%) NR NR NR 483 (31.7%) NSTE MI = 169 (11.1%) of all included patients	Hypercholesterolemia = 1068 (70.1%) Active smokers = 207 (13.6%) Arterial HTN = 1392 (91.3%) 430 (28.2%)	164 (10.8%) On any thienopyridine = 644 (42.3%) 1155 (75.8%) 270 (18.1%)	100% DES = 100% (planned) 1292 (84.8%)	CAD and planned DES placement	All patients received a loading dose of clopidogrel 600 mg; After PCI patients received clopidogrel 75 mg (1/d) and aspirin 100 mg (2/d) maintenance	UFH was used as the anticoagulant ("in the majority of patients") and bivalirudin was used for "only some of the patients". <5% of patients received abciximab

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Varenhorst, 2009 19429918 Sweden Genetic sub-study	110 patients in parent study; 98 consented to inclusion in the genetics sub-study; of these 47 were on the clopidogrel group White = 47 (100%) 96% 65 ± 5.7	NR NR NR NR NR NR NR NR NR	NR "Yes" = 4 (9%); "No" = 43 (91%) NR Yes = 8 (17%)	NR NR All patients were aspirin treated 9 (19%)	NR NR NR	Stable CAD	Patients were aspirin treated. The group relevant to this KQ received clopidogrel LD= 600 mg, followed by MD= 75 mg	None
Frere, 2008 18394438 France NONE	603 NR 456 (75.7%) 64.7 ± 12.2	NR Excluded NYHA IV heart failure NR NR NR NR NR NR 100% NSTE-ACS	NR [56.4% on statin treatment] 266 (44.1%) Hypertensive = 339 (56.3%) 169 (28%)	NR NR NR NR	NR NR NR	NSTE-ACS undergoing angiography	clopidogrel LD= 600 mg Aspirin LD= 250 mg ≥12 hours before coronary angiography	None; patients receiving IIb/IIIa inhibitors before the procedure were excluded.

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Frere, 2009 19496924 France Part of larger observational study	598 NR 453 (76%) 64.7±12 (NR if SD or SE)	NR NR NR NR NR NR NR NR 100% NSTE-ACS	Dyslipidemic = 321 (54%); On statin = 336 (45%) Current smokers=263 (44%) HTN = 332 (56%) 169 (28%)	NR NR NR NR	NR NR NR	NSTE-ACS	clopidogrel LD= 600 mg; no additional details reported	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Bonello-Palot 2009 19932784 France NR	73 NR 59 (80.8%) 62.8 ± 12.4	ACS: 40% NR (Left ventricular ejection fraction in %: 54.6 ± 9.8) NR NR NR NR Previous MI: 40.1% NR	Hypercholesterolemia (total chol >250 mg/dL): 61.1% 38.4% HTN (>140/90 mm Hg at rest): 58.9% 31.5%	NR NR (Though all patients received clopidogrel during the study) NR Omeprazole: 5%	NR NR NR	PCI for ACS	Clopidogrel LD=600 mg; for pts with high on treatment platelet reactivity :up to 3 additional LDs of 600 mg were prescribed 24 hours after the previous dose till a VASP index <50% was obtained.	None
Harmsze 2010 19934793 Netherlands NR	428 NR 335 (78.2%) 62.9	65.2% NR NR NR NR NR 47.2%	82% 12% 79.4% 19%	NR 69.4% 100% 23%	NR NR NR	PCI for ACS	Chronic clopidogrel maintenance: 75 mg/day for more than 5 days before the coronary stent	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
		NR					<p>implantation</p> <p>Clopidogrel loading dose (LD): Loading dose of 300 mg clopidogrel 24 h to 5 days before the coronary stent implantation followed by 75mg/day.</p> <p>All patients received aspirin (80–100mg daily) for >5 days before the coronary stent implantation.</p>	
Trenk 2008	802	NR	NR	NR	36.4%	CAD, elective	Pretreatment:	During

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	NR 627 (78%) 66.4 ± 9.1	NR [LVEF<55%: 35.8% NR Previous balloon angioplasty:34.2%; previous CABG: 14% CANADIAN Cardiovascular Society angina class III or IV: 24.8% NR NR 22.9% NR	Active smokers: 10.8% arterial hypertension (definition NR): 82.3% 24.8%	NR 100% NR	100% DES multivessel PCI: 22.2%	PCI with stent implantation	with pre-treatment with 600 mg of clopidogrel & aspirin (100 mg per day for at least 5 days); After PCI: All patients received aspirin (≥100 mg per day) lifelong & clopidogrel (75 mg per day) for 30 days after placement of bare-metal stents or for 6 months after placement of at least 1 drug-eluting stent.	procedure: All patients received an intra-arterial dose of 100 to 140 U/kg heparin;

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Tantry 2010 21079055 Multicountry - North America and Europe Genetic substudy of ONSET/OFFSET and RESPOND	82 (clopidogrel group, from RESPOND and ONSET/OFFSET) White 74 (90%) Black 6 (7%) 62 (76%) 65± 8	NR NR NR CABG 32 (39%) NR NR NR 41 (50%) NR	Dyslipidemia including hypercholesterolemia 79 (96%) 8 (10%) HTN 60 (73%) 17 (21%)	NR NR 100% 17 (21%)	NR NA NA	Stable CAD receiving aspirin who consented to genotyping	All patients received 75 to 100 mg/d aspirin clopidogrel (600-mg load, 75 mg/d thereafter)	None
Wallentin, 2010 20801498 Multiple countries (43 countries in North America, South America, Europe, Asia, Australia) PLATO	5148 (clopidogrel group) White 5058 (98%) 3571 (69%) 62.5 ±11.04	NR NR NR NR NR NR NR NR	NR Non-smoker 2049 (40%) Ex-smoker 1270 (25%) Habitual smoker 829 (36%) NR 1189 (23%)	NR 2486 (48%) 4946 (96%) 2083 (40%)	NR NR NR	Hospitalization for ACS, with or without ST-segment elevation	75 mg once daily (300–600 mg loading dose)	None
Hochholzer, 2010 20510210	802 NR	NR NR NR	NR NR	NR NR	37% NR	Elective coronary stent placement	Pre-intervention: All patients	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Germany EXCELSIOR	72% 66	NR NR NR NR NR	NR NR NR	NR NR	NR		received a LD of 600 mg of clopidogrel. After PCI: All patients received clopidogrel (75 mg/day) for 30 days after placement of bare-metal stents or for 6 months after placement of at least 1 drug-eluting stent. After PCI: All patients received aspirin (≥100 mg/day), lifelong,	

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Jeong 2010 20650435 Korea NR	126 Whites: 0% 85 (67.5) 61.6±11	NR NR 6 (4.8) 1 (0.8) 28 (22.2) 34 (27) NR 70 (55.6) 36 (28.6)/ 28(22.2)	46 (36.5) 35 (27.8) 67(53.2) 31 (24.6)	NR 100 NR 1 (0.8)	122 (96.8) 4 (3.2) 35 (27.8)	treated with PCI for symptomatic coronary artery disease.	One-hundred and six patients were collected from a registry of the ACCEL (Adjunctive Cilostazol Versus High-MD Clopidogrel) studies , which were performed to compare the degree of platelet inhibition by adjunctive cilostazol versus high-MD clopidogrel in patients within a	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
							specific subset: HPPR, diabetes, drug-eluting stent implantation for complex lesions, and acute myocardial infarction. The high-MD group received a high-MD clopidogrel of 150 mg/day for 1 month. A minority (n = 20, 15.9%) of patients received high-MD clopidogrel for over 1 month after	

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
							PCI at the attending physician's discretion.	
Barker, 2010 20965456 USA NR	41 NR 35 (85.3) 66.6±10.6	NR NR NR (>80%) NR NR NR 13 (31.7) NR	36 (87.8) NR 36 (87.8) 16 (39)	NR NR NR 10 (24.3)	NR NR NR	CAD patients if they: 1) had received maintenance clopidogrel or a loading dose of clopidogrel ≥300 mg and 2) had high OTR, defined as Verifynow P2Y12 reaction units (PRU) ≥235.	Patients were administered clopidogrel 150 mg/day for 7 days, after which platelet reactivity was reassessed.	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Bonello, 2010 20708365 France NR	411 NR 321 (78.1) 62.9±12.2	NR NR NR NR NR NR NR NR NR	218 (53) 154 (37.5) 243 (59.1) 143 (34.8)	NR 100% 100% 65 (15.8)	NR NR NR	undergoing PCI for non-ST-segment elevation acute coronary syndrome	All patients received oral LDs of 250 mg aspirin and 600 mg clopidogrel at least 6 h before the first VASP index measurement. Dose adjustment was performed before PCI in all patients.	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Gurbel 2011 21392617 USA NR	118 94(63%) 52 (35%) 63± 11	NR NR NR 29 (21%) NR NR NR 37 (31%) NR	85(72%) History 23 (19%) Current 18 (15%) Systolic 135±18 Diastolic 72±15 HTN 93(79%) 46 (39%)	NR 100% 100% 22(29%)	NR NR NR	Established CAD	Maintenance clopidogrel for at least 2 weeks (Dose NR)	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Hwang 2011 21075428 South Korea NR	190 Asian 100% 71.6 62.6 ±11	NR NR 1.6 PCI 8.9, CABG 2.6; NR 40.5 NR 8.4 NR	22.6 41.1 HTN 57.9 30	NR NR NR 2.1	97.9 DES 24.7	Elective coronary stent implantation	All patients received a 300-mg loading dose (LD) of clopidogrel and aspirin at least 12 hours before PCI, followed by 200 mg/day maintenance dose of aspirin and 75 mg/day of clopidogrel thereafter.	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Kang, 2010 20724801 Korea NR	215 Asian 100% 136 (63.3) 63.5±10.8	NR NR 3(1.4) PCI:21(9.8)/CABG: 3(1.4) NR NR NR 14 (6.5) NR	33(15.4) 84 (39.1) 127 (59.1) 65 (30.2)	NR 100% 100% 4 (1.9)	NR NR 58 (27.5)	Scheduled coronary stenting	A 300-mg LD of clopidogrel and aspirin was administered 12-24 hours before scheduled PCI, followed by 200 mg/day MD of aspirin and 75 mg/day clopidogrel	None
Liu 2010 21163112 China NR	722 Whites: 0 568 (78.7) 67.4±8.9	NR NR NR PCI:139 (19.5)/ CABG: 37 (5.1) NR NR NR 144 (19.9) NR	281 (34.9) NR 453 (62.7) 187 (25.9)	NR 100% 100% NR	NR NR NR	Elective PCI for symptomatic stable CAD	A loading dose of 300 mg clopidogrel was given to all patients and a daily maintenance dose of 75 mg for a minimum of 12 months.	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Maeda, 2011 21178986 Japan NR	97 Asian 100% 67 (69) 67±10	NR NR NR NR NR NR NR NR NR	NR 12(12) NR 6(18)	NR NR NR NR	NR NR NR	with CAD after percutaneous coronary intervention	(i) aspirin (100 mg, q.d.), (ii) aspirin (100 mg, q.d.) plus clopidogrel (75 mg, q.d.; Plavix, Sanofi-Aventis, Tokyo, Japan), or (iii) aspirin (100 mg, q.d.) plus ticlopidine (100 mg, b.i.d.;	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Malek, 2010 20924183 Poland NR	261 NR 67.4 60.4±10.9	NR 6.5 1.5 10.0 NR NR 9.2 17.7 78.5/NR	72.7 39.8 HTN 83.5 31.6	NR 100 96.9 NR	NR NR NR	AMI with or without STE; PCI with stenting was attempted.	Pre-hospital 300 or 600 mg loading dose followed by 75 mg daily for at least 1 month	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Simon 2011 21262992 France FAST-MI	2353 NR 72.3 63.4±13.4	NR 2.9 3.2 PCI 8, CABG 3.3; NR NR NR 11.3 NR	44.4 34.6 52.3 31.7	NR 100 94.9 NR	NR NR NR	ACS patients undergoing PCI (<80%)	NR	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Yamamoto 2011 21168310 Japan NR	123 Asian 100% 81(66%) 68.6 ± 10	NR NR NR NR NR NR NR	61 16 HTN 78 49	NR 61 39 26	NR NR NR	Cardiac catheterization upon diagnosis of stable CAD	300mg loading dose and 75mg/day clopidogrel maintenance dose plus 100mg aspirin	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Park 2011 21345843 Korea CILON-T	474 NR 69.6 63.3±8.7	NR 0.2 NR PCI 10.5, CABG 3.6; 47.7 46.6 NR 5.6 NR	44.3 20.7 HTN 67.9 33.5	NR NR NR 0.8	NR NR NR	Angina pectoris or positive stress test, native coronary artery lesions for which DES implantation was feasible.	Clopidogrel loading dose 300-600 mg and 75mg daily for at least 6 months	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Tiroch, 2010 20826260 Germany NR	928 NR 75 64.8±12.9	NR NR NR CABG 6.1 NR NR NR 13.9 NR	51.9 36.5 HTN 74.5 24.1	NR NR NR NR	97.5 NR NR	ACS patients (M)I, >90% PCI with BMS	All patients received a loading dose of 600mg clopidogrel. Post procedural therapy consisted of aspirin (100mg twice daily, indefinitely) and clopidogrel (75mg once Daily for at least 6months).	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Sorich, 2010 20492467 707 sites in 30 countries Substudy of TRITON-TIMI 38	2943 Caucasian 91.9 Hispanic 4 African 3 Asian 0.9 Other 0.2 75 60.9±11.2	NR NR 2.7 NR NR NR 18 74/30.2	55.6 38.3 HTN 64.1 23.1	NR NR NR NR	NR NR NR	Acute coronary syndromes (representative of the entire spectrum of those syndromes) with scheduled PCI	clopidogrel (300-mg loading dose and 75-mg daily maintenance dose) for 6–15 months.	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Sibbing, 2010 20492469 Germany NR	986 NR 77.2 67.3±10.3	NR NR NR 17 NR NR 40.2 NR	77.6 10.9 68.1 25.9	NR 100 100 NR	NR NR NR	CAD patients in a stable condition and were on dual antiplatelet treatment with aspirin and clopidogrel	Aspirin (dose NR) and clopidogrel (75 mg/day)	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Sawada, 2010 21099121 Japan NR	100 NR 85 69.6±9.2	NR NR NR NR NR NR NR NR	69 41 HTN 81 42	NR 100 NR 50	NR NR NR	CAD, PCI with DES implantation	All patients with DES implantation received dual antiplatelet therapy consisting of aspirin and clopidogrel	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Pare, 2010 20979470 Multiple countries CURE	2549 Whites: 86.2 58.8 63.8±11	NR NR NR PCI=3.2% & CABG=9.8 NR/NR NR/NR NR/NR NR/NR NR/NR	NR 23.1 135.5±22.3&78.6±13.6 NR 20.7	NR NR NR NR	15.5 NR NR	ACS & Stroke	Clopidogrel (at a dose of 75 mg per day)	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Pare, 2010 20979470 Multiple countries ACTIVE-A	570 Whites: 100 54.4 70.8±10.1	NR NR NR NR NR NR NR NR NR	NR 8.4 136.6±19&80.9±11.5 NR 21.8	NR NR NR NR	NR NR NR	ACS & Stroke	Clopidogrel (at a dose of 75 mg per day)	None

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Mega, 2010 20801494 707 sites in 30 countries TRITON-TIMI 38	2932 Whites: 97.6 72% 60.2±10.9	NR NR NR NR NR NR 868 (30) 2064 (70)	NR NR NR NR	NR NR NR NR	NR NR NR	Patients with acute coronary syndromes undergoing planned percutaneous coronary interventions	clopidogrel (300-mg loading dose and 75-mg daily maintenance dose) for 6–15 months.	None
Bouman, 2011 21628721 Netherlands	1024 NR 75.1%	100 NR NR	NR 1.2 76.9	NR 41.1 NR	100 DES 63.2 BMS 36.8	CAD patients undergoing PCI with stenting	pretreated with clopidogrel (75 mg daily for >5 days, or a loading dose of 300 mg ≥24 h	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Genetic substudy of the Popular study	64±11	NR NR NR NR NR NR	18.5	15.1			or 600 mg ≥4 h before (PCI)) and aspirin (80-100 mg daily ≥10 days prior to PCI) unless on long-term anticoagulation with coumarin derivatives. All patients (after receiving drug-eluting or bare-metal stenting) were treated with clopidogrel for at least 1 year. Clopidogrel and aspirin maintenance doses were 75 mg and 80 to	

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
							100 mg daily, respectively.	

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Campo, 2011 21679849 Italy NR	300 NR 77 66 ± 13	NR NR NR PCI 16, CABG 11 NR NR NR 27 Non-STEMI ACS 61	51 24 HTN 72 24	NR 100 at 6month 97 100 at 6month 99 53	NR DES 71 Multivessel PCI 36	Patients with ischemic HD undergoing PCI with stenting	aspirin (300 mg as loading dose [LD] at hospital admission, followed by 100 mg daily, independently to previous or not chronic use). Clopidogrel 600 mg was given as LD at least 12 h before PCI. After intervention, clopidogrel 75 mg/day was continued for 12 months.	Anticoagulant and glycoprotein IIb/IIIa inhibitors treatment was administered at the interventionalist's discretion.
Fernando, 2011	31	NR	76	NR	See next row	ACS patients	open label	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
21696537 Australia NR	NR 93 62 ± 11	NR NR NR 24 NR See next row 41/34	3 HTN 83 3	0 100 NR	BMS 62 DES 38 NR	undergoing PCI	clopidogrel 75 mg daily and randomized to either esomeprazole 40 mg or placebo (sugar filled) capsule daily for a period of 6 weeks. All patients continued routine medications, including aspirin (100 mg). This was followed by a 2-week wash-out period after the first treatment	

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
							period where study medications were ceased. Patients then resumed clopidogrel 75 mg daily and the opposite therapy to which they were randomized in the first 6-week period (crossed-over to alternative therapy).	

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Geisler, 2008 18781853 Germany NR	237 Caucasian 100 76.4 69(11.3) median and IQR	NR NR NR NR NR NR 12.7/22.8	73.8 NR HTN 85.2 34.6	NR NR NR NR	NR NR NR	CAD patients undergoing PCI	Loading dose of 600 mg clopidogrel was given prior to PCI, followed by a daily dose of 75 mg; also 500 mg IV aspirin given PCI, followed by 100 mg orally per day after, unless contraindicated because of GI bleeding or allergy; 70 units per kg body weight of unfractionated heparin given before PCI	NR
Gladding, 2008	60	NR	NR	NR	Multi stent 15	CAD patients	All patients:	glycoprotein

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
19463375 New Zealand PRINC (Plavix Response in Coronary Intervention) Trial	Caucasian 95 83 68 (10)	CHF 3 NR PCI 20, CABG 10; NR NR NR 5/7	10 HTN 57 18	0 98 NR	DES 35 DES NR	undergoing elective PCI	600-mg clopidogrel at the start of the PCI procedure. At 2 hours after, 37 patients received 600 mg clopidogrel and 23 received placebo. Starting the next day, all patients were separately randomized to receive clopidogrel 75 or 150 mg once daily for 1 week, followed by 75 mg once	IIb/IIIa inhibitor and medications inhibiting CYP3A4. Patients on warfarin were eligible if the international normalized ratio was <1.5 at study entry and warfarin could be withheld for the 7-day study duration

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Gurbel , 2010 19817997 USA NR	36 Whites: 70% NR NR	NR NR NR NR NR NR NR	NR NR NR NR	NR NR NR NR	NR NR NR	CAD patients undergoing PCI with stenting now in stable condition	daily thereafter. chronic daily 75 mg clopidogrel and 81 mg aspirin therapy PLUS one 60-mg dose of elinogrel	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Harmsze, 2010 20833683 Netherlands NR	176 cases, 334 controls NR 77.8, 79.5 64.1(10.5), 62.1(9.4)	NR NR NR NR NR NR 23.9, 42.4; NR	52.3, 50.5; 22.2, 12.1; HTN 46.6, 49.5; 17.6, 16.4;	NR 100 100 29.0, 22.7;	100, 100 DES 31.3, 47.4; NR	CAD patients undergoing PCI with stenting	Cases: still on aspirin and clopidogrel at the time of stent thrombosis. All control subjects were on clopidogrel maintenance therapy and aspirin (80–100 mg) during the entire followup period.	NR
Kim. 2011 21511217 South korea ACCELAMI2C19	62 pts on 150 mg clopidogrel daily NR 69.4	NR NR 3.2	25.8 62.9 NR	NR 100 100	93.5, 96.9; DES 93.5, BMS 0; DES 95.3, BMS 1.6;	Patients with ACS (AMI undergoing PCI with stenting)	all patients received a 600-mg loading-dose (LD) of clopidogrel, followed by a	Use of low-molecular-weight heparin (enoxaparin) or unfractionated heparin was at

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
(High-dose clopidogrel group)	59.4±12.2	NR NR NR NR 6.5 56.5/43.5	45.2 24.2	0	Multivessel 25.8 20.3;		maintenance dose (MD) of 75 mg daily before randomization. All patients also took a 300-mg LD of aspirin, followed by aspirin 200 mg daily throughout the study period. After blood sampling pre-discharge, the patients were randomly assigned to high-MD clopidogrel of 150 mg daily	the physician's discretion, and only tirofiban with a short half-life was administered if needed.

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
							(high-dose group) or adjunctive cilostazol 100 mg twice daily to clopidogrel 75 mg daily (standard dose + cilostazol group).	

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Kim, 2011 21511217 South korea ACCELAMI2C19 (cilostazol group)	64 pts on 75 mg clopidogrel +cilostazol daily NR 76.6 63.9±11.9	NR NR 7.8 NR NR NR NR 4.7 48.4/51.6	29.7 56.3 NR 48.4 31.3;	NR 100 100 1.6				

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Lee, 2011 21786436 South korea NR	166 NR 69 64.4±11.6	NR NR NR NR NR NR NR	NR 49 HTN 68 30	NR NR NR NR	NR NR NR	Patients with cerebrovascular disease	75 mg clopidogrel daily for at least six days before platelet testing	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Malek, 2008 18577829 Poland NR	105 NR 70 60.0±11.6	NR NR 4 10 NR NR 8 16 82	34 47 HTN NR 17	NR 100 100 NR	NR NR NR	Patients with ACS undergoing PCI	loading dose of 300 mg of aspirin followed by a daily regimen of 75 mg and a loading dose of either 300 or 600 mg of clopidogrel followed by 75 mg daily	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Pettersen, 2011 21426546 Norway Aspirin and Clopidogrel non-responsiveness clinical Endpoint Trial (ASCET)	219 Caucasian 100 79 62 (8.5)	100 NR NR PCI 38, CABG 19; NR NR 37 NR	NR 16 Diastolic 82.1±9.2 /systolic 138.2±18.6 11	NR 100 100 14	NR NR NR	CAD patients undergoing PCI (<80% PCI)	75 mg/day clopidogrel; also possibly aspirin but details NR	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Sibbing, 2011 21527445 Germany NR (cohort)	1524 NR 77 67.4±10.6	NR NR NR CABG 14.6 NR NR NR 31.9 NR	NR 13.6 NR HTN 91.3 28.2	NR 100 100 18.1	100 NR NR	CAD pts undergoing PCI	Pretreatment with a loading dose of 600 mg of clopidogrel prior to the procedure. The recommended pr-treatment interval was ≥ 2 h.	Excluded patients on GP IIb/IIIa during the 10 days before the PCI

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Sibbing, 2011 21527445 Germany NR (case control)	1566 NR 78 67.6	NR NR NR 13 NR NR 32.3 NR	NR 14.6 NR 90 29.1	NR 100 100 NR	NR NR NR	CAD pts undergoing PCI	Pretreatment with a loading dose of 600 mg of clopidogrel prior to the procedure.	Excluded patients on GP IIb/IIIa during the 10 days before the PCI

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Simon, 2009 19106083 France FAST-MI	2208 NR 71 66.2/13.7	23 4 TIA 3, stroke 5; PCI 14, CABG 5; NR NR NR 9 STEMI 53	49 NR diastolic 81/17, systolic 141/28 32	NR 14 23 at screening and 98 in hospital 73	NR NR NR	ACS patients undergoing PCI (<80% PCI)	Mean loading dose, 300 mg/day; mean maintenance dose at time of hospital discharge, 75 mg/day	NR
Hwang, 2010 20823393 Korea	65 Whites:0 NR	NR NR 6.2	30.8 40 NR	NR 89.2 NR	96.9 DES 30.8	CAD patients undergoing PCI	All patients received a 300-mg loading dose of clopidogrel at least 12 hours	The high-MD group received clopidogrel 150 mg daily for 30 days.

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
ACCEL-RESISTANCE, DM, COMPLEX (High-dose clopidogrel group)	69.2±7.9	18.4 NR NR 9.2 NR	58.5 26.2	15			before PCI (n=98) or were receiving chronic clopidogrel therapy (75 mg daily for ≥7 days, n=36). All patients received a 300-mg loading dose of aspirin, followed by 200 mg daily for 1 month. They were randomly assigned to adjunctive cilostazol (triple group) or high-MD clopidogrel (high-MD group).	

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Hwang, 2010 20823393 Korea ACCEL-RESISTANCE, DM, COMPLEX (Triple antiplatelet therapy group)	69 Whites:0 NR 63.4±9.4	NR NR 4.3 29 NR NR 17.4 NR	18.8 36.2 NR 55.1 28.9	NR 99.5 NR 4.3	95.7 DES 30.4	CAD patients undergoing PCI	All patients received a 300-mg loading dose of clopidogrel at least 12 hours before PCI (n=98) or were receiving chronic clopidogrel therapy (75 mg daily for ≥7 days, n=36). All patients received a 300-mg loading dose of aspirin, followed by 200 mg daily for 1 month. They were randomly assigned to	The triple group (n=69) received adjunctive cilostazol 100 mg twice daily to clopidogrel 75 mg daily for 30 days

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
							adjunctive cilostazol (triple group) or high-MD clopidogrel (high-MD group).	
Price, 2012 22624833 US GIFT (Genotype Information and Functional Testing) Study—a prespecified genetic substudy of GRAVITAS [Price 2011, PMID 21406646]	1028 100% white 70.7 65.3 +/-10.5 years	CAD or ACS, 100 NR NR 100 NR NR NR NR	NR NR NR NR	NR 100 NR NR	100 DES, 100 NR	CAD or ACS patients undergoing PCI	Of the 578 patients with high on-treatment reactivity (OTR, PRU>=230), 285 randomized to high-dose clopidogrel and 293 randomized to standard-dose clopidogrel; of the remaining 450 patients with normal	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
							OTR (PRU<230), 163 given standard-dose clopidogrel and 287 were not followed in the study.	
Cuisset, 2011 21803320 France NR	346 NR 81.2 mean 62.7±12	30.9 NR NR NR NR NR NR NR	hyper 60.4 40.2 HTN 60.4 28.6	NR NR NR 87.3	NR NR NR	NSTE ACS patients undergone PCI	LD clopidogrel 600mg and aspirin 250mg, low responders received higher 150 mg MD clopidogrel	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Chen, 2012 22723959 Taiwan CAPTAIN	60 Asian 100 78 mean 59.4±8	NR NR NR NR NR NR NR NR NR	NR 46.7 51.7 35	NR NR NR NR	NR NR NR	CAD patients received PCI	clopidogrel	NR
Gajos, 2012 22623230 Poland OMEGA-PCI	63 NR 24 mean 63.8±9.4	60 NR stroke 30.2 PCI 23.3; CABG 3.3 NR NR 36.7 40 NR	hyper 96.7 active 20; previous 53.3 96.7 30	NR NR NR 26.7	100 BMS 76.7 DES 23.3 3.3	stable CAD patients undergoing PCI	LD clopidogrel 600mg and MD 75mg daily+75 mg aspirin daily	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Luo, 2011 22118006 China NR	1738 Asian 100 67 mean 71	NR NR NR CABG 2.4 NR NR NR 12.4 NR	hyper 39.1 25 62.1 35.8	NR NR NR 7.6	NR DES 75.5 BMS 24.2 NR	patients with CAD undergoing PCI	LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d	NR
Tello-Montoliu, 2012 22116003 Spain study one of the paper	40 Caucasian 100 90 mean 65.8	NR NR NR NR NR NR NR NR	hyper 59.5 18.9 HTN 75.7 45.9	NR NR NR NR	NR NR NR	stable ACS patients with stent	100mg AA and 75mg MD clopidogrel	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Tello-Montoliu, 2012 22116003 Spain study two of the paper	428 Caucasian 100 65 mean 67.3	NR NR NR NR NR NR NR NR NR	hyper 70 22 HTN 70 42.4	NR NR NR NR	NR NR NR	non-ST elevation acute coronary syndrome	100mg AA and 75mg MD clopidogrel	NR
Harmsze, 2011 21854540 Netherlands POPular	725 NR 76 63.2	NR NR NR NR NR NR NR NR	80.6 9.5 75.3 17	NR NR NR NR	NR NR NR	CAD for PCI	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Harmsze, 2012 22228204 Netherlands NR	820 NR 74.4 63.3+/-10.5	100 NR NR 7.0 CABG NR NR 42.1 NR	80.4 10.0 NR 76.0 18.2	NR 100 100 25.4	100 NR NR	CAD patients undergoing elective stenting	All patients used clopidogrel during the entire followup period at a daily dose of 75 mg Before PCI, all patients were pretreated with clopidogrel (75 mg/day for >5 days, loading dose of 300 mg >24 hr before PCI, or 600 mg >4 hr before PCI)	Aspirin maintenance dose, 80-100 mg daily Aspirin loading dose, 80-100 mg/day for >10 days before PCI 6.5% of patients received glycoprotein IIb/IIIa inhibitors after platelet function testing

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Kreutz, 2012 22427735 US NR	151 White 77 African-American 23 63 58.4±9.9 yr	100 NR NR PCI 36, CABG 17 NR NR 18 NR NR	96 44 NR 96 40	NR 100 100 34	NR NR NR	CAD patients receiving clopidogrel	Before study, 81-325 mg clopidogrel and aspirin daily; clopsidogrel 75 mg/day at least 14 days before enrollment or 600 mg loading dose for PCI	Glycoprotein IIb/IIIa users during PCI excluded All patients were on aspirin

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Dai, 2012 22704413 China NR	520 Chinese 100 59 63.5± 10.7	NR NR NR 100 (all PCI) NR NR NR 39 13§	NR 26 NR 85 27	NR 100 100 21	100 NR NR	Patients undergoing PCI with stenting (some PCI was emergency for AMI)‡	Pretreatment with loading dose of 300 mg clopidogrel and aspirin 12 hr before PCI; after, 300 mg/day of aspirin and clopidogrel for the first month and 75 mg/day for the next 11 months	For AMI patients undergoing emergency PCI, 0.4 ml Low-molecular-weight heparin calcium every 12 hr on the first day, followed by clopidogrel 75 mg/day and aspirin twice/day
Ono, 2011 21862109 Japan NR	202 Asian 75.2 mean 68.9	NR NR NR NR NR NR NR NR	hyper 75.7 21.8 HTN 80.7 40.1	NR NR NR 28.7	NR NR NR	CAD patients undergoing PCI	clopidogrel LD 300mg and 75mg MD aspirin 100mg/day	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Delaney, 2012 22190063 USA NR	693 European American 88.2 63.5 68.4	NR NR NR NR NR NR NR NR	hyper 92.8 current 16.2 HTN 80.8 34.8	NR NR NR NR	95.1 BMS 29.6; DES 62.9 NR	patients started clopidogrel after an MI and/or PCI with stent placement	clopidogrel	NR
Bhatt, 2012 22450429 USA CHARISMA	2266 100 71.9 64	NR 7.4 10.4 PCI 28.4 NR NR 20.8 41.1 NR	NR 20.1 HTN71.2 43.8	NR NR NR NR	NR NR NR	patient on clopidogrel for high atherothrombotic risk and ischemic stabilization	clopidogrel	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Fontana, 2011 21692977 Switzerland ADRIE	548 NR 82 61.9	73.4 NR ICD 9.1 NR NR NR 17.5 NR NR	hyper 66.2 20.6 HTN 56.2 21.1	NR 96.7 NR NR	80.3 NR NR	ischemic atherothrombotic disease (CAD, ICD, PAD)	aspirin and clopidogrel	NR
Aleil, 2009 19624462 France VASP-02 [genetic reanalysis thereof]	153 NR 82 64.9	NR NR NR 7 NR NR NR 11 NR	65 16 NR 63 24	NR 100 100 27	100 NR NR	Adults without ACS undergoing elective stenting	300-600 mg clopidogrel as loading dose day before stenting; subsequent randomization to 75 or 150 mg daily for 2 weeks; also 75 mg/day aspirin	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Chen, 2012 22071359 China NR	654 Chinese, 100% 81.5 65.17	100 NR NR 20.3 (PCI, 15.7; CABG, 4.6) NR NR NR NR NR	NR (but 28.7 on statins) NR 75.74/129.58 56.4 19.4	NR 95.7 97.7 22.8	65.9 NR NR (but triple vessel in 17.0)	Adults with CAD proven on angiography (ACS or stable angina)	Clopidogrel (details NR; in 95.7% of patients) Aspirin (details NR; in 97.7% of patients)	NR
Kreutz, 2012 22385219 USA NR	96 NR 53.1 56.3	100 NR NR CABG 16 NR NR 20 82 NR	100 NR NR 97 35	NR NR 100 30	NR NR NR	Adults with stable CAD receiving dual antiplatelet therapy	75 mg clopidogrel daily and aspirin 81-325 mg daily, for at least 14 days prior to enrollment	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Marcucci, 2012 22390861 Italy NR	1187 NR 75 69	NR NR NR NR NR NR 100 (ACS) 35	54 37 NR 65 24	NR 100 100 94	100 DES 18%/BMS NR NR	Adults undergoing PCI and stenting for ACS	600 mg clopidogrel loading dose followed by 75 mg daily dose ASA IV 500 mg followed by 100-325 mg daily dose	"Unfractionated" heparin 70 IU/kg during PCI
Mega, 2011 22088980 USA ELEVATE-TIMI 56	333 White 88.0, black 9.0, Asian 2.4, other 0.6 74.8 60.2	NR NR NR PCI 97.3, CABG 17.7 NR NR NR 57.1 NR	94.6 0 (exclusion criterion) 76.0/126.8 86.2 35.4	NR NR 100 0 (exclusion criterion)	NR NR NR	Adults with stable CV disease (MI or PCI >=4 weeks or <=6 mo before enrollment)	*2 noncarriers randomized to receive 75 mg clopidogrel daily for 14 days and then 150 mg daily for 14 days OR vice versa *2 carriers randomized to receive 225 mg clopidogrel daily for 14	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
							days and then 300 mg daily for 14 days OR vice versa Patients had been taking 81-325 mg aspirin daily and maintained a stable dose if medically indicated	

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Nishio, 2012 22785462 Japan NR	160 100 Japanese 76 69.7	NR NR NR NR NR NR NR NR	68 39 NR 83 47	NR NR NR 49	100 DES 100 NR	PCI with DES	Clopidogrel: 300 mg loading dose given at least 24 hr before PCI; maintenance dose, 75 mg Aspirin: 100 mg maintenance Maintenance doses given for at least 1 yr after	NR
Park, 2012 22507978 Korea ACCEL-STATIN	50 NR 68 61	NR NR NR 100 PCI 0 0 NR 68 NR	100 32 NR 48 18	NR 100 100 0	94 92 DES, 2 BMS NR	Adults with HPR having had a PCI with ≥6 mo of antiplatelet therapy	All patients had received clopidogrel (75 mg/day), atorvastatin (10 mg/day), and aspirin (100 mg/day) for at least 6 mo	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Teixeira, 2012 22377481 Portugal NR	95 NR 83.2 62.0 median	NR NR NR NR 27.4 NR 72.6 37.9/34.7	62.1 20.0 790/140.0 76.8 31.6	NR 16.8 40.0 NR	NR NR NR	Patients <75 yr admitted for ACS and survived	75 mg/day clopidogrel on discharge from hospital Aspirin 100 mg/day on discharge	NR
Parri, 2012 22727972 Italy NR	105 NR 78 60	NR NR NR 100 PCI NR NR 11 100/0	56 54 NR 54 17	NR 100 100 NR	NR NR NR	Patients with STEMI and undergoing PCI	Aspirin 100 mg/day; clopidogrel loading dose 300 mg, then 75 mg/day	Periprocedural gp IIb/IIIa antagonists used at the discretion of investigators

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Yamane, 2012 22472213 Japan NR	40 NR 82.5 67.8	NR NR NR NR NR NR 50 NR	NR 22.5 92.5 60	NR NR NR 62.5	100 NR NR	PCI, stent	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily	PPI (omeprazole or rabeprazole)
Hsu, 2011 21144850 Taiwan NR	165 NR 75.2 71.9	NR NR NR NR NR NR NR NR	NR 9.1 68.5 35.2	NR NR NR NR	NR NR NR	atherosclerosis	clopidogrel 75 mg or 35.5 mg/day for 2 weeks	esomeprazole

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Kim, 2012 22007612 Korea ACCEL-TRIPLE	127 NR 70.1 62.9	NR NR 3.1 3.1 25.2 31.5 NR 52.8 22.8/20.5	hyper 25.2 44.1 53.5 35.4	NR NR NR 3.1	100 DES 96.8 BMS 1.6 Ballooning only 1.6 multi 29.1	patients with PCI	cilostazol 100 mg twice a day clopidogrel 75 mg once a day aspirin 200mg once a day	none
Siller-matula, 2012 22260716 Austria PEGASUS-PCI	416 NR 76 64±12	NR NR NR PCI 47 NR NR 13 31 18/NR	hyper 76 55 htn 84 32	NR 100 100 76	100 DES 99 NR	CAD patients undergoing PCI	clopidogrel LD 600mg, MD 75mg	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Bonello, 2012 22285300 France NR	498 NR 80 Mean: 62±12	NR NR NR NR NR NR NR NR NR	53 42 NR 54 29	NR NR NR 12	NR NR NR	PCI for non-ST elevation Acute Coronary Syndrome (NSTEMI ACS)	oral LD: 600 mg clopidogrel and 250 mg aspirin	NR
Simon, 2011 21918510 France FAST-MI	2208 (1538 who underwent PCI) NR NR NR	NR NR NR NR NR NR NR NR	NR NR NR NR	NR NR NR NR	NR NR NR	Patients with Acute MI (subgroup of patients with Acute MI who undergoing PCI)	Clopidogrel LD: 300-900 mg; MD 75 mg/d	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Collet, 2011 21511218 France CLOVIS-2	106 White European: 81.1%; North African 12.3%; Black 0.9%; Asian 5.6% 100 Mean 40.1 ± 4.8	38 NR NR Bypass: 5.6%; PCI:88.8%; Both:5.6% NR NR NR 100 NR	68.9 56.9 NR HTN:28.3 15.1	NR 82.1 92.1 44.3	NR NR Triple vessel: 16.2	CAD patients with a history of AMI	LD: Clopidogrel 300 or 900 mg MD: Aspirin 75 mg/d and/or clopidogrel 75 mg and	NR
Jaitner, 2012 22298798 Germany NR	1474 Caucasian: 100% 78 Weighted mean (from cases and control groups reported separately): 67.4	NR NR NR CABG 14.1 NR NR NR 32.2 STEMI:3.1	17 14 NR HTN 90.9 29	NR 100 100 NR	100 DES:100% NR	CAD pts undergoing PCI (from a cohort and a registry)	Pretreatment with a loading dose of 600 mg of clopidogrel prior to the procedure. The recommended pr-treatment interval was ≥ 2 h.	Excluded patients on GP IIb/IIIa during the 10 days before the PCI

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Hochholzer, 2011 21884870 NR EXCELSIOR	765 Caucasian: 100% NR NR	NR NR NR NR NR NR NR NR NR	NR NR NR NR NR	NR NR 100 NR	NR NR NR	Patients undergoing PCI	Pretreatment with LD of 600 mg of clopidogrel prior to PCI. After PCI, MD of aspirin (≥100 mg/d) and clopidogrel (75 mg/d) for 30 days (bare-metal stents) or 6 months (at least 1 drug-eluting stent)	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Kassimis, 2012 21831410 Greece NR	146 NR 91.8 mean 62.02 ± 11.08	NR NR NR PCI: 10.3 NR NR NR 11 NR	63.7 52.7 NR HTN: 61 33.6	NR >7 days: 22.6 NR 95.9	NR NR NR	CAD patients undergoing PCI with stenting	No clopidogrel LD for those on 75 mg/d MD; LD 600 mg before PCI (if no and <7 days pretreatment) Post PCI: Clopidogrel MD 75 mg/d and aspirin 100 mg/d	NR
Namazi, 2012 22265638 Iran NR	112 NR 70 mean 58 ± 11	NR NR NR NR NR NR NR NR	68 42 NR HTN: 51 19	0 7 days before PCI: 0 7 days before PCI: 100 NR	100 DES: 100 NR Multivessel disease: 30%	CAD patients undergoing PCI with stenting	Clopidogrel LD: 600 mg Clopidogrel MD: 150 mg/day for two weeks and 75 mg/day for 12 months Aspirin 80 mg/d	Unfractionated heparin (50–70 IU/kg) immediately before stenting

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Rideg, 2011 21806387 Hungary DOSER	189 NR 61.4 weighted mean 61.8	NR NR 2.6 PCI-7.4/CABG-10.6 100 0 NR NR NR	51.9 35.4 NR 85.2 37.5	NR 17.5 NR 23.2	NR DES: 68.8 NR	Stable angina patients for coronary stent implantation	LD: 600 mg clopidogrel & 300 mg aspirin Randomized to 4 weeks of 75 or 150 mg clopidogrel MD: 75 mg clopidogrel/day	NR
Jeong, 2011 22045970 Korea NR	266 East Asian: 100 73.3 mean 63±11.9	NR NR 2.6 PCI: 7.5/CABG:0.8 NR NR NR 100 52.6/47.4	26.7 53 NR 47 26.3	NR NR NR 1.5	90.6 DES: 89.8/BMS:0.8 multivessel: 25.6	AMI patients who underwent PCI/angiography	LD: 600 mg clopidogrel & 300 mg aspirin MD: 75 mg/d clopidogrel & aspirin 200 mg/d for 1 month and 100-200 mg/day for 1 year	Anticoagulation with low-molecular weight heparin (enoxaparin) or unfractionated heparin before angiography

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Chan, 2012 22462746 Singapore NR	89 Chinese: 61.8/Malay & Indian: 38.2 75.3 weighted mean: 55.4	89.9 NR NR NR NR NR NR NR NR	NR 32.5 NR NR 40.4	NR 100 100 30.3	NR NR NR	CAD patients undergoing PCI/angiography	LD: 300 mg clopidogrel MD: 75 mg/d clopidogrel for 5-7 days	NR
Goodman, 2012 22261200 Multi-country PLATO	4,903 NR NR NR	NR NR NR NR NR NR NR NR	NR NR NR NR NR	NR NR NR NR	NR NR NR	ACS patients undergoing PCI	Clopidogrel 300-mg loading dose, 75-mg daily maintenance dose	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Park, 2012 22735685 Korea CROSS-VERIFY	1258 East Asian: 100 67.9 mean: 64±9	NR NR NR NR 58.1 35.6 NR 5.1 NR	45.9 49.1 NR 68 32.1	NR NR NR 2.5	100 DES: 100 NR	CAD and ACS patients undergoing PCI	LD: 300 -600 mg of clopidogrel Aspirin 100 mg per day.	NR
Kreutz, 2012 22459907 USA NR	55 African American: 13 80 mean 62±9	67 15 NR NR NR NR NR NR	91 33 NR 98 45	NR NR NR 42	NR NR NR	CAD patients undergoing PCI	LD: 600 mg of clopidogrel	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Yan, 2011 21778720 China NR	497 East Asian:100 82.7 65.2	NR NR NR PCI:10.7/CABG:3.8 NR NR NR 37.8 NR	NR 60.8 129.1±22.3/75.6±13.7 54.1 18.9	NR NR 40.4 NR	NR NR NR	Adult ACS patients for PCI	Clopidogrel + Aspirin (Regimen and Dose NR)	β-Blockers, CCB, ACEI/ARB, Statin, PPI

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Jeong, 2012 22837373 Korea ACCEL-DM	80 NR 68.8 63	NR NR 7.5 20/3.8 26.3 25 NR 13.8 48.8	hyper 33.8 42.5 70 NR	NR chronic use 58.8 300 mg loading dose 41.3 NR 7.5	NR DES 96.3 ballooning 3.8 28.8	type 2 diabetes undergoing PCI	elective patients LD clopidogrel 300mg. Acute MI clopidogrel LD 600 mg. after randomization, triple group receive cilostazol 100mg bid, clopidogrel 75mg MD, aspirin 200 mg/d, double group receive clopidogrel 150mg/d MD, and aspirin 200 mg/d.	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Cayla, 2011 22028352 France ONASSIST	369 Caucasian: 96.3/Black:0.4/Asian:3.3 80.5 62.7	NR NR NR 4.1 (CABG) NR NR 11.4 43.9 NR	58.1 30.9 50.4 21.5	2.4 100 100 53.3	NR DES: 51.5 3 vessel: 26.8	Cases: Patients with stent thrombosis from a registry Controls: Patients receiving dual antiplatelet therapy	clopidogrel or aspirin (Dose and frequency NR)	NR
Hulot, 2011 21972404 France AFIJI	371 European: 94.8/Black 2.2/Asian 3 84.6 40.3	NR NR NR PCI = 79.8; CABG = 8.1 NR NR NR 100 NR	56.1 51.5 23.2 10.5	NR NR NR NR	NR NR NR	CAD patients with history of MI	MD clopidogrel 75 mg/d	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year UID Country Study name	Total N Enrolled Race (% by group) Male (%) Age†	Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%) Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist (%) Clopidogrel (%) Aspirin (%) PPI (%)	Stent implantation (%) Type of stent (%) Multi-or single vessel (%)			
Hulot, 2011 21972404 France CLOVIS-2	106 NR (~95% in parent registry) 100 40.1	NR NR NR NR NR NR 100 NR	NR NR NR NR	NR NR NR	NR NR NR NR	CAD patients with history of MI	LD: 300 or 900 mg	NR
Roberts, 2012 22464343 Canada RAPID GENE	187 White: 94.7 78.1 60.2	NR NR NR NR NR NR 16 NR	81.3 31 63.6 22.5	0 NR 92 19.8		Adult patients undergoing PCI for non-ST-elevation acute coronary syndrome or stable coronary artery disease	CYP2C19*2 Carriers : 10 mg prasugrel daily Non-carriers: 75 mg clopidogrel daily	NR

† Mean (standard deviation), unless otherwise stated.

§This entry is intended to be for “STEMI/Non-STEMI” but the article reports “Non-STEMI/STEMI” given as a single percentage, so the meaning is unclear.

‡Patients were selected for “blood stasis syndrome” (a diagnosis in traditional Chinese medicine) but also for having undergone PCI with stent placement. Because patients were only eligible if they had undergone PCI and were enrolled after PCI, the study was included.

Data are means unless otherwise indicated; “estimated” is noted if reported as an estimate. ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal

stents; BP = blood pressure; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DES=Drug eluting stent; HTN = hypertension, IV=Intravenous; LD=Loading dose; MD=Maintenance dose; MI = myocardial infarction; NR=Not reported; NSTE = non-ST-elevation; NSTEMI = non-ST-elevation MI; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; pts = patients; STEMI = ST-elevation MI; TIA = transient ischemic attack; UFH=Unfractionated Heparin; ICD, ischemic cerebrovascular disease.

Appendix Table D4. Study design characteristics

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Collet, 2009 19108880 France AFIJI (Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention) registry	Prospective observational, registry based study	YES	Convenience sample of patients from a registry of AMI in patients <45 yr, on clopidogrel for ≥1 mo, with available genotyping information	Young patients with AMI (STE MI or NSTEMI)	The registry covers the period from April, 1996 to April, 2008; patients entered before 1999 (year when clopidogrel became available in the study population) were excluded	Median clopidogrel exposure = 1.07 yr (IQR = 0.28, 3.0) Maximum FU = 8 yr Mean followup = 2.7 yr for CYP2C19 *2 carriers; 2.9 yr for CYP2C19 non-carriers Mean followup = 2.84 yr	Patients were survivors of AMI enrolled in a multicenter registry; followup was on an outpatient basis	Not performed	Non-industry
Fontana, 2008 17681590 Switzerland	Prospective observational study	YES	Consecutive patients who received PCI with stenting in a single center	Patients undergoing PCI with stent placement	NR	Measurements after ≥15 d under clopidogrel (median FU = 19 d; IQR = 15- 47)	Inpatient for PCI; outpatient for followup after discharge	Power calculations performed; enrolled 81 patients out of a planned sample size of 100	Non-industry only
Giusti, 2007 18004210 Italy NR	Observational study, prospective (measurements 24 h after PCI)	NO	Consecutive patients	Patients with ACS, undergoing primary PCI	NR	24 h post PCI	Inpatient	no (posthoc only)	Non-industry only

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Prospective observational study of patients enrolled in the RECLOSE study in a single center	NO (single center recruitment for this study)	Consecutive patients consenting to genetic study identified from the RECLOSE study population	Patients with ACS or CAD undergoing PCI with stenting	July 2005 to August 2006 [recruitment period of the RECLOSE study; information from pmid = 17572245]	6 months (unclear what metric; from the KM curves implied maximum FU)	In hospital (PCI)	Not performed	Non-industry only
Gladding, 2009 19926050 New Zealand NR	Prospective “open label dose escalation study with molecular randomization”	No	NR	Patients who had undergone PCI >2 weeks previously and were on clopidogrel	NR	Total 7 days	Inpatient, with outpatient followup after the inpatient procedure	Yes (“~90%”)	NR (except “genotyping” was “supplied” by AutoGenomics, which is the affiliation of one of the authors)
Jinnai, 2009 19531897 Japan Partly industry funded	Prospective	Unclear	Convenience sample	Patients scheduled for PCI	NR	Maximum 28 days; results reported only up to 48 hours	In-patient; patients undergoing elective PCI	Not performed	Partly industry funded

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Mega, 2009 19106084 Multinational Genetics substudy of TRITON-TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction]	Prospective cohort study (genetics substudy of RCT, only one of the randomized arms included)	YES	Sub study of RCT	Patients with ACS (STE MI, NSTEMI, UA) planned for PCI	2004-2007	15 months	Inpatient	Not performed	Industry funding
Shuldiner, 2009 19706858 USA Sinai Hospital of Baltimore Study	Retrospective, based on medical records (based on followup procedures)	NO	Convenience	CAD patients undergoing non- emergent PCI	January 2004– May 2007	12 months post- PCI	In-patient in a single catheterization laboratory (non- emergent PCI)	Not performed	Non-industry only
Sibbing, 2009 19193675 Germany NR	Prospective observational study	NO	Convenience sample; patients participating in several randomized clinical trials of abciximab	CAD patients undergoing PCI	May 2000– December 2005	Complete followup to 30 days	Inpatient for PCI, outpatient followup for the duration of the study followup. Patients with cardiac symptoms were seen in the outpatient clinic for further investigation	Not performed [power analysis was performed post hoc, based on the observed effect size]	Non-industry only (several authors with COI)

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	Observational study, prospective	NO	Consecutive patients recruited from a study of the Multiplate analyzer	Patients with CAD with planned DES implantation; patients were eligible regardless of clinical presentation (stable angina, UA, STE MI, or NSTEMI).	February 2007– April 2008	30 d \pm 7 days (all outcomes adjudicated at that time-point by phone interview with outpatient clinic visits for those reporting cardiac symptoms)	Inpatient for elective PCI (patients were hospitalized for \geq 2 days); patients were the interviewed by phone (outpatient) and those reporting symptoms were examined in the outpatient clinic (for clinical, EKG, and laboratory checkup)	Not performed	Partly industry supported (material provided by manufacturer of the Multiplate analyzer, which was used here as a reference standard)
Varenhorst, 2009 19429918 Sweden NR	Prospective observational study (genetics sub study of RCT comparing antiplatelet regimens)	Yes (2 centers in Sweden)	Sub study of RCT	Patients with CAD (~98% had received PCI before inclusion in the parent trial)	April 2006 to December 2006 [for the parent study]	Maximum followup 29 d \pm 3 d (last measurements obtained)	Outpatients who had regular visits for reactivity measurements	Not performed (for the genetic sub- study)	Industry funded
Frere, 2008 18394438 France NR	Prospective	NO	Consecutive patients	NSTEMI ACS patients undergoing angiography	2004–2006	\geq 12 h after loading	Inpatient	NO	NR
Frere, 2009 19496924 France Part of larger observational study	Retrospective	NO	Convenience	NSTEMI ACS patients undergoing angiography	2004–2006	NR (measurements appear to have been obtained after the clopidogrel loading dose)	In-patient, single cardiology department	Not performed	NR (authors' stated that there was "no conflict of interest")

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Bonello-Palot, 2009 19932784 France NR	Prospective observational study	YES	Convenience sample	Patients undergoing percutaneous coronary intervention (PCI) for ACS; Patients with acute coronary syndromes (ACS)	Aug 2007–Mar 2008	NR (patients were followed up from admission till the PCI was performed)	Inpatient	Not performed	Partly Industry
Harmsze 2010 19934793 Netherlands NR	Prospective observational cohort	NO	Consecutive patients	Patients undergoing percutaneous coronary intervention (PCI) for ACS	NR	NR	Inpatient	Not performed	Partly Industry
Trenk 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	Prospective observational study	NO	Substudy of the EXCELSIOR prospective study	CAD patients undergoing elective PCI with stent implantation	NR	30 day follow up for all patients, and 12 month follow up for 795 patients (99.1%)	followup after intervention	no (power analysis for the parent study)	Non-industry only

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Tantry, 2010 21079055 Multicountry- North America and Europe Genetic substudy of ONSET/ OFFSET and RESPOND	RESPOND and ONSET/OFFSET were randomized, double-blind, double-dummy, multicenter studies. RESPOND was crossover; ONSET/OFFSET was parallel- group (prospective)	YES	Sub study of RCT	Adults with stable coronary artery disease receiving aspirin who consented to genotyping	RESPOND, May 19, 2008, to March 25, 2009 ONSET/OFFSET, October 2007 to March 2009	2-6 weeks	Outpatient	For both RESPOND and ONSET/OFFSET, YES [YES] Not done for genetic substudy (they took whoever consented)	All industry
Wallentin, 2010 20801498 Multinational (43 countries in North America, South America, Europe, Asia, Australia) PLATO	Prospective observational study	YES	Sub study of RCT	ACS patients with <80% undergoing PCI	October 2006 through July 2008	Median, 277 days	Inpatient	NO (not prospectively powered and had to be based on the maximum number of patients consenting to provide a blood sample for genetic analysis)	All Industry
Hochholzer, 2010 20510210 Germany EXCELSIOR	Prospective cohort	No	Unclear	Patients undergoing PCI with stenting	NR	30 days to 6 months	inpatient	Not performed	NR

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Jeong 2010 20650435 Korea ACCEL-DOUBLE	Cohort	No	Sub study of RCT	Patients with CAD undergoing PCI	Jan 2008-June 2009	≥1 mo	inpatient	it was estimated that a total of 95 patients (57 carriers and 38 noncarriers of the <i>CYP2C19</i> variant allele) would be required to provide a power of 90% to detect a statistically significant difference with a 2-sided alpha- level of 0.05.	NR
Barker, 2010 20965456 USA NR	Prospective cohort	No	Selected CAD patients; unclear methods	CAD patients had clopidogrel for >7 days or high OTR	NR	Mean 8 days	Unclear	Yes, 90%	Non-industry
Bonello, 2010 20708365 France NR	Prospective cohort	Yes	Selected sample of Patients with PCI	Patients with PCI	Jan 2009-Jan 2010	NR	Inpatient	Not performed	NR

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Gurbel 2011 21392617 USA NR	Cohort	No	Unclear	Patients had established coronary artery disease (CAD) and were on aspirin (81-325 mg/d) therapy for a minimum of 2 weeks were studied (N = 261).	NR	NR	Outpatient	Yes. Given the frequency of the *2 allele in the population, to determine a 20% absolute difference in the prevalence of HPR between these 2 groups, a sample size of 105 patients was required with an $\alpha = .05$ and power of 80%.	Non-industry
Hwang 2011 21075428 South Korea NR	Cohort	No	Consecutive patients	CAD patients undergoing elective PCI with stent implantation	Jan 2008-March 2009	NR	Inpatients from Department of Cardiology of the Gyeongsang National University Hospital	Not performed	Non-industry
Kang, 2010 20724801 Korea NR	Cohort	No	Consecutive	CAD patients with elective stent implantation	July 2008-June 2009	NR	Hospital	Not performed	Non-industry
Liu 2010 21163112 China NR	Cohort	No	Consecutive	Patients were admitted for elective coronary intervention with symptomatic stable CAD.	Oct 2006-Sep 2007	12 months minimum	Hospital	Not performed	NR
Maeda, 2010 21178986 Japan NR	Cohort	No	NR	CAD	NR	>4 weeks	Unclear	Not performed	NR

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Malek, 2010 20924183 Poland NR	Cohort	No	Consecutive	AMI with and without ST- elevation, PCI with stenting was attempted.	2005-2005	4 years	Hospital	Not performed	Non-industry
Simon 2011 21262992 France FAST-MI	Prospective observational study (registry- based)	Yes	Consecutive	AMI patients undergoing PCI (<80%)	2005-2006	1 year	Inpatient (from ICU)	Not performed	Partly industry
Simon 2011 19106083 France FAST-MI	Prospective observational study (registry- based)	Yes	Consecutive	AMI patients undergoing PCI (<80%)	2005-2006	1 year	Inpatient (from ICU)	Not performed	Partly industry
Yamamoto 2011 21168310 Japan NR	cohort	No	Consecutive	CAD undergoing angiography (and PCI when needed); PCI(for those assessed for clinical outcomes)	NR	340 days	Inpatient	Not performed	NR
Park 2011 21345843 Korea CILON-T	Randomized trial	yes	Sub study of RCT	CAD patients undergoing PCI with stenting	2006-2009	6 months	Inpatient	Yes 18 non- carriers and 11 carriers of CYP2C19-LOF would be needed to provide a power of 95% to detect a statistically significant difference between groups with a two-sided a-level of 0.05.	Non-industry

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Tiroch, 2010 20826260 Germany NR	Cohort	No	Consecutive	AMI patients with >90% of them undergoing PCI with BMS placement	2005-2008	1 year	Inpatients in a Hospital	yes 80%	NR
Sorich, 2010 20492467 707 sites in 30 countries Substudy of TRITON-TIMI 38	Substudy of RCT	Yes	Selected sample	PCI	November 2004 and January 2007.	6 to 15 months.	Hospital (inpatient)	Not performed	Industry
Sibbing, 2010 20492469 Germany NR	Cohort	No	Consecutive	Stable CAD patients undergoing angiography	Aug 2007 to Sep 2008	NR	Inpatients in a Hospital	Not performed	NR [Speaker fee from industry by first author]
Sawada, 2010 21099121 Japan NR	Cohort	No	NR	PCI	Jan 2008-Jan 2010	243.8±88.1 days Median 223.5 days, range 7– 546 days	In patients at Kobe University Hospital	Not performed	NR
Pare, 2010 20979470 Multinational CURE	Prospective cohort study	Yes	Sub-study of RCT	Patients with ACS-NSTE	1998–2000	3.6 years	Inpatient	NO	Industry
Pare, 2010 20979470 Multinational ACTIVE-A	Prospective cohort study	Yes	Sub-study of RCT	Patients with AFIB	2000–2006	3–12 months	Outpatient	NO	Industry
Mega, 2010 20801494 707 sites in 30 countries TRITON-TIMI 38	Prospective cohort study	Yes	Sub study of RCT	ACS	November 2004 and January 2007.	6–15 months.	Inpatient	Not performed	Industry

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Bouman 2011 21628721 Netherlands Genetic substudy of the Popular study	Prospective, observational, single-center cohort study	NO	Consecutive sampling (but then patients without DNA samples were excluded)	Patients with CAD taking clopidogrel undergoing elective coronary stent implantation and who were genotyped	December 2005 and December 2007	Total 1 year	Inpatient/outpatient followup after intervention	Not performed	NR but authors received speakers fee from industry. (NB Popular study received platelet-testing equipment from industry)
Campo 2011 21679849 Italy NR	Prospective cohort	No	Consecutive	Patients undergoing PCI for ischemic heart disease who had a baseline and 1 month PRU evaluation and a baseline blood sample for genotyping	December 2008 to May 2009	Max, 1 year	Inpatient followed by outpatient followup	Not performed	NR but authors have COIs with drug companies
Fernando 2011 21696537 Australia NR	Prospective (randomized crossover study design)	NO	Unclear	Patients with ACS and stents on aspirin but not clopidogrel	NR	Duration for all patients who completed study, 14 weeks (6 weeks in each study arm with 2-wk washout in between)	Outpatient	YES 80%	Non-industry only

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Geisler 2008 18781853 Germany NR	Prospective pharmacogenetic trial	NO	Consecutive	Caucasian patients undergoing PCI for CAD	July 2006-March 2007	NR	Inpatient	YES (86%)	NR except "The authors have no relevant financial involvement with any...entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes...grants...received or pending..."
Gladding 2008 19463375 New Zealand PRINC (Plavix Response in Coronary Intervention) Trial	2 by 2 factorial, randomized, placebo- controlled, double-blind study over the first 24 h, followed by a 1- week randomized, placebo- controlled, double-blind study	NR	Sub study of RCT	Patients undergoing elective PCI	NR	7 Days total	Inpatient, with outpatient followup after the inpatient procedure	YES [YES ("~80%")]	Non-industry (except VerifyNow analyzer was provided by Sanofi Aventis)
Gurbel 2010 19817997 USA NR	Prospective comparative?	NO	Unclear	Patients with stenting and stable condition who were screened for HPR	Feb. 1,-Sept. 15, 2008	NR (max. follow-up, 7 to 10 days)	Outpatient	Not performed	All industry

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Harmsze 2010 20833683 Netherlands NR	Retrospective case-control	YES	Consecutive enrollment	Patients undergoing PCI with stenting	Cases: January 2004 to February 2007 Controls: December 2005 and December 2006	Total, 1 yr from the time of PCI	Hospital/outpatient	Not performed	Partly industry
Kim 2011 21511217 South Korea ACCELAMI2C19 High-dose clopidogrel	Randomized prospective	NO	Sub study of RCT	62 AMI patients treated with emergent PCI receiving a high- MD of clopidogrel	2007-2009	30 days	Inpatient	YES [YES] 80%	Partly industry
Kim 2011 21511217 South Korea ACCELAMI2C19 Cilostazol group	Randomized prospective	NO	Sub study of RCT	64 AMI patients treated with emergent PCI receiving an adjunctive dose of cilostazol	2007-2009	30 days	Inpatient	YES [YES] 80%	Partly industry
Lee 2011 21786436 South Korea NR	Retrospective	NO	Selection of patients with testing for resistance and polymorphism	Patients with cerebrovascular disease who received clopidogrel and were tested for clopidogrel resistance and CYP2C19 polymorphism	January 2009 to June 2010	NR	Outpatient	Not performed	Non-industry only
Malek 2008 18577829 Poland NR	Prospective observational	Unclear	NR	Patients with any ACS undergoing PCI and receiving clopidogrel and aspirin	NR	12 months	Inpatient and then outpatient followup (by phone)	Not performed	Non-industry only

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Pettersen 2011 21426546 Norway Aspirin and Clopidogrel non- responsiveness clinical Endpoint Trial (ASCET)	Prospective observational study	NO	Consecutively included randomized clopidogrel group from ASCET (n=219)	CAD patients randomized to receive maintenance clopidogrel (<80% PCI)	October 2005 to June 2008	NR	Outpatient	Not performed	Non-industry only
Sibbing 2011 21527445 Germany NR	Prospective cohort	NO	For PCI cohort: volunteers for DNA sampling from prospective trial (1524/1608 [95%]) For early ST cohort, consecutive recruitment and DNA sample availability	CAD patients undergoing PCI with stenting (>95%) and receiving clopidogrel and aspirin and who had DNA samples	For PCI cohort (who were the control cohort also), Feb 2007– April 2008	NR	Inpatient	Not performed [Non-industry only [except “material for platelet function analysis on the Multiplate device was provided free of charge from Dynabyte”]
Sibbing 2011 21527445 Germany NR	Case-control	NO	Consecutive	CAD patients undergoing PCI with stenting	1999-2008	NR	Inpatient	Not performed	Non-industry only [except “material for platelet function analysis on the Multiplate device was provided free of charge from Dynabyte”]
Simon 2009 19106083 France FAST-MI	Prospective observational	YES	Consecutive	Patients with AMI in a French registry receiving clopidogrel	October 1– December 24, 2005	Total 1 year	Inpatient (for the subgroup undergoing PCI); outpatient followup	Not performed	Partly industry

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Hwang 2010 20823393 Korea ACCEL- RESISTANCE, DM, COMPLEX (High-dose clopidogrel group)	Prospective cohort Hwang	No	Sub study of RCT	High-risk CAD patients undergoing PCI	Jan 2008–June 2009	30 days	Inpatient	Not performed	Non industry
Hwang, 2010 20823393 Korea ACCEL- RESISTANCE, DM, COMPLEX (Triple antiplatelet therapy group)	Prospective cohort Hwang	No	Sub study of RCT	High-risk CAD patients undergoing PCI	Jan 2008–June 2009	30 days	Inpatient	Not performed	Non industry
Bouman, 2011 Multinational 21170047 NR	Case-cohort study	Yes	Random (for controls); incident cases (convenience because of refusals)	Patients with CAD undergoing PCI with stenting	2003–2007	18 mo	Inpatient	Yes (but not for CYP2C19 variants)	No funding information; reported that the authors had no financial conflicts of interest
Bouman 2011 Multinational 21170047 NR	Prospective cohort	Yes	Convenience sample	Patients undergoing PCI with stenting	2007–2009	12 months	Inpatient	Yes(80%)	No funding information; reported that the authors had no financial conflicts of interest

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Price, 2012 22624833 US GIFT (Genotype Information and Functional Testing) Study— a prespecified genetic substudy of GRAVITAS (Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety) trial	Genetic substudy of randomized, multicenter trial (GRAVITAS)	YES (all in North America)	Subsample of GRAVITAS patients— those with samples for genotyping and who were randomized to receive clopidogrel	Adults with CAD or ACS undergoing PCI with at least 1 DES, with or without high on- treatment platelet reactivity	July 2008–April 2010	Total 6 mo	48 Hospital centers	YES (YES: 80%)	All industry
Gremmel, 2012 22154242 Austria NR	Prospective observational	NO	NR	CAD patients undergoing stenting	Jan. 2008–Nov. 2010	~1 day (no followup time points)	Hospital (Medical University of Vienna, Division of Angiology)	NO (NA)	NR
Harmsze, 2012 22228204 Netherlands POPular substudy	Genetic substudy of prospective POPular study but otherwise NR	YES	Consecutive (part of POPular)	CAD patients undergoing elective stenting	NR	1 yr total	Hospital and then outpatient followup	NO (NA)	NR
Kreutz, 2012 22427735 US NR	Observational	NO	NR	CAD patients receiving clopidogrel	NR	1 day total	Hospital visit for measurements	NO (NA)	NR

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Dai, 2012 22704413 China NR	Prospective observational	NO	NR	Patients undergoing PCI and stenting†	July 2009-April 2011	1 month	Hospital for intervention, outpatient measurement of reactivity at 10 days, and telephone contact with outpatients at 1 month	NO (NA)	NR
Cuisset, 2011 21803320 France NR	Prospective cohort	no	consecutive	NSTE ACS patients undergone PCI	July 2008- Jan 2010	1 month	inpatient	no	NR
Chen. 2012 22723959 Taiwan CAPTAIN	cohort study	no	registry	CAD patients undergone PCI with stenting	Nov 1995-June 2011	NR	inpatient	NR	non-industry
Gajos, 2012 22623230 Poland OMEGA-PCI	RCT	no	consecutive	patients with stable CAD undergoing PCI	NR	1 month	inpatients	NR	NR
Luo, 2011 22118006 China NR	prospective cohort	no	consecutive	patients with stable CAD undergoing PCI	March 2006-May 2010	6 months	inpatients and then outpatients	NR	non-industry
Tello-Montoliu 2012 22116003 Spain study one of the paper	cohort for first objective	no	selective patients undergone PCI	stable ACS patients with stent	NR	NR	outpatient clinic	NR	non-industry

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Tello-Montoliu 2011 22116003 Spain Second objective	cohort for second objective	no	consecutive	non-ST elevation acute coronary syndrome	NR	6 months	inpatient	NR	non-industry
Harmsze, 2011 21854540 Netherlands NR	prospective	no	consecutive	CAD for PCI	NR	1 year	inpatient	NR	industry
Ono, 2011 21862109 Japan NR	NR	No	consecutive	CAD for PCI	Oct 2008-Nov 2010	12 months	inpatients then follow up	NR	non-industry
Delaney, 2012 22190063 USA NR	NR	NR	BioVU database	patients started clopidogrel after an MI and/or PCI with stent placement	NR-June 2011	2 years	Vanderbilt DNA biobank	NR	non-industry
Bhatt, 2012 22450429 USA CHARISMA	subset of RCT	yes	RCT	patient on clopidogrel for high atherothrombotic risk and ischemic stabilization	NR	800 days	NR	NR	industry
Fontana 2011 21692977 Switzerland ADRIE	prospective cohort	yes	consecutive	ischemic atherothrombotic disease (CAD, ICD, PAD)	June 2006-Dec 2008	3 years	inpatient	NR	non-industry
Aleil, 2009 19624462 France VASP-02 [genetic reanalysis thereof]	Genetic posthoc analysis of RCT (nonblinded)	YES	NR	Adults without ACS undergoing elective stenting	April 2005-Dec. 2007	Total 1 mo	Inpatient	NO (NA)	Partly industry

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Chen, 2012 22071359 China NR	Prospective observational	NO	Consecutive	Adults with CAD	July 2008-Sept. 2009	Mean 11.42 mo	Inpatient for angiography, outpatient thereafter	NO (NA)	Nonindustry
Kreutz, 2012 22385219 USA NR	Prospective observational	NO	NR	Adults with stable CAD	NR	15 days	Outpatient	NO (NA)	Nonindustry
Marcucci, 2012 22390861 Italy NR	Prospective observational	NO	NR	Adults undergoing PCI and stenting for ACS	NR	12 mo	Inpatient	NO (NA)	Nonindustry
Nishio, 2012 22785462 Japan NR	Prospective observational	NO	NR	Patients undergoing PCI with DES stenting	June 2008-June 2010	Mean 646.2 days, median 692.5 days	Inpatient	NO (NA)	NR
Park, 2012 22507978 Korea ACCEL-STATIN	RCT (patients enrolled already having received clopidogrel and already ascertained as having HPR; randomization was for pravastatin or rosuvastatin)	NO	"Prospective"	Adults with HPR having had a PCI with ≥ 6 mo of antiplatelet therapy	April 2009-Dec. 2011	15 day total	Inpatient	YES (YES)	Nonindustry (article says "partly funded" by nonindustry and does not mention industry)
Teixeira, 2012 22377481 Portugal NR	Prospective observational	NO	NR	Patients <75 yr admitted for ACS and survived	March [or April— one stated in one place and one another place]- Oct 2009	Median 136.0 days after discharge	Inpatient	NO (NA)	NR

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Parri, 2012 22727972 Italy NR	RCT (with randomization only to pantoprazole or ranitidine)	NO	NR	Patients with STEMI and undergoing PCI	July 2009-Feb 2010	30 days total	Inpatient	YES (YES)	NR
Yamane, 2012 22472213 Japan NR	cohort study	no	NR	patients with prior coronary stent implantation who had received dual anti-platelet therapy	Sep 2009 and May 2011	≥ 4 weeks	inpatient	yes (<80%)	non-industry
Hsu, 2011 21144850 Taiwan NR	open label RCT	no	consecutive	atherosclerotic disease such as ischemic heart disease or stroke	Aug 2008 to Jan 2010	6 months	inpatient	yes (90%)	non-industry
Kim, 2012 22007612 Korea ACCEL-TRIPLE	prospective cohort	no	NR	PCI treated patients	Jan 2008–June 2009	1 months	inpatients	yes (90%)	non-industry
Siller-Matula, 2012 22260716 Austria PEGASUS-PCI	prospective cohort	no	consecutive	patients undergoing PCI	March 2007–Nov 2009	12 months	inpatient and then followup	yes, 80%	Austrian National Bank
Bonello, 2012 22285300 France NR	prospective	yes	NR	PCI for non-ST elevation Acute Coronary Syndrome (NSTEMI ACS)	January 2010– September 2011	6-12 hours after clopidogrel loading dose	Inpatient	No	Non-industry (Research grant from the Assistance Publique - Hopitaux de Marseille)
Simon, 2011 21918510 France FAST-MI	Prospective observational study (registry- based)	Yes	Consecutive	All AMI patients (and a subset of AMI patients undergoing PCI)	November 2005	1 year	Inpatient (from ICU) and then outpatient followup	No	Partly industry

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Collet, 2011 21511218 France CLOVIS-2	RCT-Crossover trial	NR	Selected sample (from a registry)	Patients who had survived an MI before age 45	NR	6 hours (between baseline and measurement of platelet reactivity)	Inpatient	Yes; >80% of target	Non-industry only
Jaitner, 2012 22298798 Germany NR	Cases from a registry and controls from a prospective cohort	No	Cases from a registry with a DES thrombosis & event free patients from a cohort of subjects undergoing PCI for CAD	CAD patients undergoing PCI with stenting	For PCI cohort (who were the control cohort also), Feb 2007– April 2008 Cases: 1999– 2008	NR	Inpatient	No	Non-industry only
Mega, 2011 22088980 USA ELEVATE-TIMI 56	RCT	Yes	Consecutive	CAD patients on clopidogrel	October 2010– September 2011	2 weeks	Outpatient	Yes; >80% of target	Industry
Hochholzer, 2011 21884870 NR EXCELSIOR	Prospective cohort	NR	NR	CAD patients undergoing PCI with stenting	NR	24 hours	Inpatient	No	NR
Kassimis, 2012 21831410 Greece NR	Prospective	No	Consecutive	CAD patients undergoing PCI with stenting	NR	24 hours	Inpatient	No	NR
Namazi, 2012 22265638 Iran NR	Prospective	No	NR	CAD patients undergoing PCI with stenting	September 2007– October 2008	30 days	Inpatient and then outpatient	No	Non-industry only

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Rideg, 2011 21806387 Hungary DOSER	Substudy of RCT	No	consecutive	CAD stable angina patients undergoing PCI with stenting	February 2008– September 2009	1 year	Inpatient and then outpatient	No	Non-industry only
Jeong, 2011 22045970 Korea NR	Prospective	No	selected sample	AMI patients who underwent angiography	September 2007– August 2009	1 year	Inpatient and then outpatient	yes (accrual >80%)	Non-industry only
Chan, 2012 22462746 Singapore NR	Prospective	No	selected sample	CAD patients undergoing PCI or angiography	NR	7 days	Inpatient; followup after intervention	No	Industry and Non-industry
Goodman, 2012 22261200 Multi-country PLATO	Clopidogrel arm of an RCT	Yes	consecutive	ACS patients undergoing PCI	NR	1 year	Inpatient and then outpatient	No	Industry only
Park, 2012 22735685 Korea CROSS-VERIFY	Prospective	No	consecutive	CAD patients undergoing PCI	June 2006–June 2010	12 months	Inpatient and then outpatient	No	Non-industry only
Kreutz, 2012 22459907 USA NR	Prospective	No	Selected sample	CAD patients undergoing PCI	NR	16-24 hours	Inpatient	No	Non-industry only
Yan, 2011 21778720 China NR	Prospective	No	Consecutive	ACS patients undergoing PCI	NR	24 months (NR in text, seen in Fig 1)	Inpatient and then outpatient	No	Non-industry only
Jeong, 2012 22837373 Korea ACCEL-DM	prospective cohort	no	selected sample	type 2 diabetes undergoing PCI	NR	30 days	inpatient then followup	yes (90%)	NR

Author, Year PMID Country Study name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Cayla, 2011 22028352 France ONASSIST	case-control study	Yes	Consecutive	Patients undergoing PCI with stenting	January 2007– May 2010	NR	Inpatient	Yes	Industry and on-industry grants
Hulot, 2011 21972404 France AFIJI	prospective cohort	Yes	Convenience sample	AMI before age 45	NR	2.6 yr (median clopidogrel exposure time)	NR	no	Non-industry only
Hulot, 2011 21972404 France CLOVIS-2	prospective cohort	Unclear	Substudy of RCT	AMI before age 45	NR–April 2008	6 hours	inpatient	No	Non-industry only
Roberts, 2012 22464343 Canada RAPID GENE	RCT	no	NR	NSTE-ACS or chronic CAD undergoing PCI with stenting	August 2010–July 2011	30 days	inpatient	yes	Industry and on-industry grants

Abbreviations: ACS = acute coronary syndrome; AMI = acute MI; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DES=Drug eluting stent; HTN = hypertension, IV=Intravenous; LD=Loading dose; MD=Maintenance dose; MI = myocardial infarction; NR=Not reported; NSTE = non-ST-elevation;NSTEMI = non-ST-elevation MI; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; RCT=randomized controlled trials; STEMI = ST-elevation MI; TIA = transient ischemic attack; UFH=Unfractionated Heparin; ICD, ischemic cerebrovascular disease.

†Patients were selected for “blood stasis syndrome” (a diagnosis in traditional Chinese medicine) but also for having undergone PCI with stent placement. Because patients were only eligible if they had undergone PCI and were enrolled after PCI, the study was included.

Appendix Table D5. Genotypic test information

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Collet, 2009 19108880 France AFIJI (Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention) registry	TaqMan Validated SNP assays (Applied Biosystems, Foster City, CA, USA) with the 7900HT sequence detection system (Applied Biosystems)	Periph. blood NR NR NR	259 (only included patients with available genotyping information)	CYP2C19 *2 rs4244285 *3 *4 *5 *6 *2/*2 = 9 (3.5%) *2/*1 = 64 (24.7%) *1/*1 = 186 (71.8%) A *3 was detected in two patients; *4 in 3 patients; *5 and *6 were not detected in any patient.	Not explicitly provided	Carriers (*2/*2 or *2/*1) = 73 (28.2%) Non-carriers (*1/*1) = 186 (71.8%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Fontana, 2008 17681590 Switzerland NR	PCR-RFLP	Blood NR NR NR	81 (100%)	CYP2C19 *2 (rs4244285) *2/*2 = 2 (2.5%) *2/*1 = 25 (30.7%) *1/*1 = 54 (66.7%)	In analyses relevant to this Key Question, no grouping was used. For other analyses heterozygotes and homozygotes for the rare variant (*2) were combined. Small sample size of the *2/*2 group was given as the reason for this grouping.	For this key question no grouping was performed. However, for analyses relevant to KQ3 analyses were performed by contrasting carriers with non-carriers (a dominant model).
Giusti, 2007 18004210 Italy NR	PCR-RFLP	Whole blood Blood was collected "after PCI intervention" NR NR	1419 (not clear if genotyping failed on some patients)	CYP2C19 *2 (rs4244285) *2/*2 = 40 (2.8%) *2/*1 = 405 (28.6%) *1/*1 = 974 (68.6%)	Not explicitly reported.	Carriers (*2/*2 or *2/*1) [for some analyses] = 445 (31.4%) *1/*1 = 974 (68.6%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	PCR-RFLP	Whole Blood Venous blood samples were obtained 12-18 h from clopidogrel loading (assuming that blood for genetic and phenotypic testing was obtained at the same time); NR NR	772 (100%)	CYP2C19*2 (rs4244285) *2/*2 = 26 (3.4%) *2/*1 = 221 (28.6%) *1/*1 = 525 (68.0%)	Not explicitly reported (analyses were reported both with grouped and ungrouped genotypes).	“Carriers (*2/*2 or *2/*1) [for some analyses] = 247 (32%) Non-carriers (*1/*1) [for some analyses] = 525 (68%)”
Gladding, 2009 19926050 New Zealand NR	Autogenomics 2C19+ assay involving BioFilmChip microarray on the INFINITI analyzer	Whole blood “Genotyping was done after the second platelet function test [7 days after enrollment] and the results were retrospectively assessed” so patients had been receiving clopidogrel for a mean of over 10 weeks before genotyping. NR NR	39 (100%)	CYP2C19*2 (rs4244285) = 33% carriers CYP2C19*3 (rs1057910) = 0% carriers CYP2C19*17 (rs28399504) = 46% carriers	Not explicitly reported	CYP2C19*2 (and CYP2C9*3 though this is not of interest) carriers (poor metabolizers) = NR (but could try and count from Fig. 4) CYP2C19*2 (and CYP2C9*3 though this is not of interest) carriers (poor metabolizers) = NR (but could try and count from Fig. 4)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Jinnai, 2009 19531897 Japan Partly industry funded	Direct sequencing (ABI 3100 genetic analyzer; PE Applied Biosystems, Foster City, CA)	Peripheral whole blood NR NR NR	25 (100%) (Of the 30 patients included 2 patients were not evaluated at 48 hours; 1 died of cancer; 1 refused genomic analysis; 1 was lost to followup)	CYP2C19*2 and *3 [Additional genes, not relevant to the report, were also genotyped] *2/*2 = 3 (12%) *3/*3 = 0 (0%) *2/*3 = 3 (12%) **3/*1 = 2 (8%) *2/*1 = 6 (24%) *1/*1 = 11 (44%)	Not explicitly reported.	PM = *2/*2 or *2/*3 = 6 (24%) IM = *2/*1 or *3/*1 = 8 (32%) EM = *1/*1 = 11 (44%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Mega, 2009 19106084 Multinational Genetics substudy of TRITON-TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction]	98% of genotyping procedures were done with the Affymetrix Targeted Human DMET (drug metabolizing enzymes and transporters) 1.0 Assay (Affymetrix); for missing data from the DMET chip additional genotyping was performed with bi- directional sequencing or exon- specific PCR followed by RFLP analysis.	NR NR NR NR	1477 of which 1459 could be classified as CYP2C19 carriers or non- carriers (> 98.8%- this excludes patients that could not be assigned to a functional category based on genotype – exact count not provided)	CYP2C19 *1A;*2A;*3;*4;*5A;*6;*7;*8;*9;*10;*12;*13;*14 *1A/*1A = 1064 (73%) *1/*2A, *1A/*3, *1A/*4, *1A/*8 = 357 (24%) *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8 = 38 (3%) *1A/*9, *1A/*10, *2A/*17, *6/*17= NR	CYP alleles were classified a priori by their effects on enzymatic function based on the literature. For each CYP gene, subjects were dichotomized a priori into 2 groups on the basis of whether they possessed at least one allele with significantly reduced function.	Non-carrier (includes extensive and ultra- metabolizers) = 1064 Carriers (intermediate + poor metabolizers) = 395 Unknown corresponding phenotype (not included in main analyses)= Excluded & Frequency NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Shuldiner, 2009 19706858 USA Sinai Hospital of Baltimore Study	TaqMan SNP assay (Applied Biosystems, Foster City, California)	Blood 90 patients were already on clopidogrel when entering the study; all pther patients received clopidogrel loading followed by maintenance treatment NR NR	227 (99.1% - 225 patients included in analyses)	CYP2C19*2 (rs4244285) [Additional CYP2C19 variants were genotyped in healthy volunteers] CYP2C19 *2/*2 = 3 (1.6%) CYP2C19 *2/*1 = 54 (28.7%) CYP2C19 *1/*1 = 131 (69.7%)	Not explicitly reported	Carriers (*2/*2 or *2/*1) = 67 (29.8%) Non-carriers (*1/*1) = 158 (70.2%)
Sibbing, 2009 19193675 Germany NR	TaqMan (ABI Prism Sequence Detector 7000, Applied Biosystems)	Whole blood Median = 5.1 h (IQR = 3.0 to 14.0 h) NR NR	2485 (100%)	CYP2C19 rs4244285 CYP2C19 *2/*2 = 47 (2%) CYP2C19 *2/*1 = 633 (25%) CYP2C19 *1/*1 = 1805 (73%)	Carriers vs. non- carriers was used in the majority of analyses. A dominant model was chosen because the mutant *2 allele results in a complete loss of enzyme function. A citation was provided to a paper on the functional relevance of CYP alleles.	Carriers = 680 (27%) Non-carriers = 1805 (73%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	TaqMan assay (ABI Prism Sequence Detector 7000, Applied Biosystems, Foster City, CA)	Arterial blood All patients received a clopidogrel loading dose with a recommended pre-treatment interval of 2h; blood was sampled directly before PCI. NR NR	1524 which is 95% of all eligible patients (100%)	CYP2C19 *17, (rs12248560) *17/*17 = 76 (5%) *17/*1 = 546 (35.8%) *1/*1 = 902 (59.2%)	Some analyses were reported without grouping the genotypes. No rationale was presented for the choice of model.	Carriers (*17/*17 or *17/*1) = 622 (40.8%) Non-carriers (*1/*1) = 902 (59.2%)
Varenhorst, 2009 19429918 Sweden Genetic sub- study	Affymetrix Targeted Human Drug Metabolizing Enzyme and Transporter (DMET) 1.0 assay (Affymetrix, Santa Clara, CA, USA) for all alleles except *17; Conventional PCR-RFLP for *17 (no other information provided)	Peripheral Blood NR NR NR	51 in the clopidogrel group consented to testing (100%)	*1A; *2A; *3; *4; *5A; *6; *7; *8; *9; *10; *12; *13; *14; *17 Ungrouped (by locus) data were not reported		Extensive metabolizers (*17/*17, *1A/*17, *1A/*1A) = 37 (79%) Reduced metabolizers (*1A/*2A, *1A/*8, *2A/*2A) = 9 (19%) *2A/*17=1 (2%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Frere, 2008 18394438 France NONE	Allele-specific PCR	DNA extracted from peripheral blood leucocytes NR NR NR	603 (99.7% [601- based on genotypes reported])	CYP2C19*2 (rs4244285) CYP2C19 *2/*2 = 23 (3.8%) CYP2C19 *2/*1 = 143 (23.8%) CYP2C19 *1/*1 = 435 (72.4%)	Not explicitly reported (also presents analyses from a general linear model where polymorphism was treated as the independent variable)	Recessive and codominant models were analyzed (Frequency NR)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Frere, 2009 19496924 France Part of larger observational study	Allele-specific PCR	NR NR NR NR	598 (99.7% for CYP2C19 *4; 10% for CYP2C19 *5; 99.8% for CYP2C19 *6; 99.7% for CYP2C19 *17)	CYP2C19 *4; CYP2C19 *5; CYP2C19 *6; CYP2C19 *17 CYP2C19 *17/*4 = 25 (4.2) CYP2C19 *17/*1 = 189 (31.7) CYP2C19 *17/*1 = 382 (64.1) CYP2C19 *4/*4 = 0 (0%) CYP2C19 *4/*1 = 8 (1.3%) CYP2C19 *1/*1 = 589(98.7%) CYP2C19 *5/*5 = 0 (0) CYP2C19 *5/*1 = 0 (0) CYP2C19 *1/*1 = 598(100%) CYP2C19 *6/*6 = 0 (0) CYP2C19 *6/*1 = 1 (0.2) CYP2C19 *1/*1 = 596 (99.8)	Recessive, dominant (carriers vs. non-carriers), and co-dominant models were analyzed. No rationale was reported for these groupings.	*17/*17 + *17/*1 (carriers, also referred to as extensive metabolizers) = 214 (35.9%) *1/*1 (non-carriers) = 382 (64.1%) Frequency of grouping NR Frequency of grouping NR Frequency of grouping NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Bonello-Palot 2009 19932784 France NR	PCR amplification using primer oligonucleotides designed with Primer3 software tool.	Whole blood NR NR NR	73 (100%)	CYP2C19 2* (rs4244285) **2/*2 = 7 (9.6%) Wild-type/*2 = 15 (20.5%) Wild-type/wild-type = 51 (69.9%)	Not explicitly reported	≥ 1 CYP2C19*2 allele (*2/*2 or Wild-type/*2) = 22 (30.1%) Wild-type genotype (Wild- type/wild-type) = 51 (69.9%)
Harmsze 2010 19934793 Netherlands NR	Real-time PCR (manufacturer NR)	Whole blood NR NR NR	428 (100%)	CYP2C19 G681A (*1>*2) (rs4244285) CYP2C19 G636A (*1>*3) (rs4986893) CYP2C19 G681A (*1>*1) = 296 (69%) CYP2C19 G681A (*1>*2) = 120 (28%) CYP2C19 G681A (*2>*2) = 12 (3%) CYP2C19 G636A (*1>*1) = 426 (99.5%) CYP2C19 G636A (*1>*3) = 2 (0.5%) CYP2C19 G636A (*3>*3) = 0 (0%)	Not explicitly reported	Carriers of variant allele of CYP2C19 G681A = 132 (31%) Noncarriers of variant allele of CYP2C19 G681A = 296 (69%) Allele frequencies (not used for grouping) “CYP2C19 G681A *2 = 17% CYP2C19 G636A *3 = 3%

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Trenk 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	TaqMan PCR (Applied Biosystems; Germany; part no. C_25986767_70)	Whole blood NR; Blood was drawn before administration of clopidogrel, at time of PCI and after clopidogrel. It was NR which one was used for genomic analysis NR 1 hr	797 (100%)	CYP2C19*2 681G>A (rs4244285) CYP2C19 wildtype homozygotes (*1/*1) = 552 (69.3%) CYP2C19 (*1/*2) heterozygote = 228 (28.6%)	They reported allele frequencies of 83.6% for CYP2C19*1 (G) and 16.4% for CYP2C19*2 (A) but grouping was done by carriers of the CYP2C19*2 allele and wild-type homozygotes due to low numbers of *2/*2 homozygotes. Background talked about how the role of the CYP2C19*2 loss-of-function polymorphism is not clear.	Noncarriers (*1/*1) = 552 (69.3%) Carriers (*1/*2 or *2/*2) = 245 (30.7%)
Tantry 2010 21079055 Multicountry- North America and Europe Genetic substtudy of ONSET/OFFSET and RESPOND	TaqMan Assays (Life Technologies; Pleasanton, Calif)	NR NR NR NR	82 (100%)	CYP2C19 (*1, *2, *3, *4, *5, *6, *7, *8, *17 "CYP2C19*1/*1 Extensive metabolizer = 31 (38%) CYP2C19*1/*2 = 13 (16%) CYP2C19*1/*3 = 1 (1%)	Not explicitly reported	Group I: metabolizer status Ultrametabolizers (UM) (=ultrarapid+rapid heterozygous, i.e., *17/*17 or *1/*17) = 28 (34%) Extensive metabolizers (EM) = 31 (38%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
				CYP2C19*1/*2*8 Intermediate metabolizer [NB Seems like *2*8 throughout really means just *2 or *3. Not sure whether they tested for 4-8.] = NR CYP2C19*2/*2 = 3 (4%) CYP2C19*2*8/*2*8 Poor metabolizer = NR CYP2C19*1/*17 Rapd heterozygous = 28 (34%) CYP2C19*2/*17 = 6 (7%) CYP2C19*8/*17 = 0 (0%) CYP2C19*2-8/*17 Poor/rapd heterozygous = NR CYP2C19*17/*17 Ultrarapid metabolizer = 0 (0%)		Intermediate metabolizers (IM) (=intermediate+poor/rapid heterozygous; i.e., *1/*2- *8 or *2*8/*17) = 20 (24%) Poor metabolizers (PM) = 3 (4%) Group II: LOF-allele carrier status LOF carrier (=IM+PM) = 23 (28%) LOF noncarrier (=UM+EM) = 59 (72%) Group III: GOF-allele carrier status GOF carriers (=UM) = 28 (34%) EM = 31 (38%) LOF carriers (=IM+PM) = 23 (28%)
Wallentin, 2010 20801498 Multiple countries (43 countries in North America,	TaqMan assays (Applied Biosystems, Life Technologies, Pleasanton, CA,	Blood NR NR	5148 (98.8–99.5%)	CYP2C19 loss-of- function alleles *2, *3, *4, *5, *6, *7, and *8; CYP2C19 gain-of- function allele *17	Phenotype groupings were based on the presence or absence of loss-of-	Extensive (*1/*1) = 1862 (36%) intermediate (*1/*2–*8) = 935 (18%) poor (*2–*8/*2–*8) = 125

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
South America, Europe, Asia, Australia) PLATO	USA)	NR		*1/*1 = 1862 (36%) *1/*17 = 1386 (27%) *1/*2 = 898 (17%) *1/*3 = 6 (<1%) *1/*4 = 8 (<1%) *1/*6 = 2 (<1%) *1/*8 = 21 (<1%) *17/*17 = 268 (5%) *2/*17 = 318 (6%) *2/*2 = 115 (2%) *2/*4 = 3 (<1%) *2/*5 = 1 (<1%) *2/*8 = 6 (<1%) *3/*17 = 1 (<1%) *4/*17 = 1 (<1%) *8/*17 = 8 (<1%) Missing = 244 (5%)	function alleles (ie, extensive, ultra rapid, and rapid heterozygote vs intermediatee, poor, and poor or rapid heterozygote) to allow direct comparisons with previous reports. NB: Authors noted that "In outcomes within each treatment group in relation to the CYP2C19 genotype and predicted phenotype groupings, we did not identify any model explaining the variation in clinical outcomes so genotype groupings in the fi nal comparisons	(2%) poor or rapid heterozygote (*2-*8/*17) = 328 (6%) rapid heterozygote (*1/*17) = 1386 (27%) ultra rapid (*17/*17) = 268 (5%) Missing = 244 (5%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
					were based on the presence or absence of any loss-of-function allele." Hence results aren't based on the above phenotypic categories.	
Hochholzer, 2010 20510210 Germany EXCELSIOR	Drug Metabolism Genotyping Assay(Applied Biosystems, Frankfurt, Germany). [this is based on TaqMan]	Blood NR NR NR	760 (NR)	CYP2C19*2 Frequency NR	NR	Grouping NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Jeong 2010 20650435 Korea NR	ABI SNaPshot	Blood NR NR NR	126 (100%)	CYP2C19*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3 *1/*1 Normal = 46 (36.5) *1/*2 Decreased = 45 (35.7) *1/*3 Decreased = 15 (11.9) *2/*2 Decreased or absent = 13 (10.3) *2/*3 Decreased or absent = 7 (5.6) *3/*3 Decreased or absent = 0(0)	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Barker, 2010 20965456 USA NR	the Illumina CYP2C19 Panel and Fast Goldengate assay on the BeadXpress Platform (Illumina, San Diego, California).	Blood NR NR NR	41 (100%)	The CYP2C19 genotyping for the *2, *3, *4, *5, *6, *7, *8, and *17 single nucleotide polymorphisms CYP2C19 *1/*1 = 15(36.6) CYP2C19 *1/*2 = 14(14.1) CYP2C19 *1/*3 = 1(2.4) CYP2C19 *1/*4 = 1(2.4) CYP2C19 *1/*17 = 3(7.3) CYP2C19 *17/*17 = 3(7.3) CYP2C19 *2/*2 = 2(4.8) CYP2C19 *2/*3 = 1(2.4) CYP2C19 *2/*17 = 1(2.4)	Metabolize status	EM, CYP2C19 *17/*17, *1/*17,*1/*1 = 21(52.5) IM, CYP2C19 *1/*2, *1/*3, *1/*4 = 16(40) PM, CYP2C19 *2/*2, *2/*3 = 3 (7.5) CYP2C19 *1 = 0.6 CYP2C19 *2 = 0.24 CYP2C19 *3 = 0.024 CYP2C19 *4 = 0.012 CYP2C19 *17 = 0.122
Bonello, 2010 20708365 France NR	Home made with the primers from (Invitrogen, Carlsbad, California) [PCR]	Blood NR NR NR	411 (100%)	CYP2C19 *2 *2/*2 = 11 (2.7) Wt/*2 = 123 (29.9) Wt/wt = 277 (67.4)	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Gurbel 2011 21392617 USA NR	Taqman SNP genotyping assays (Applied Biosystems, Foster City, CA)	Blood NR NR NR	261 (NR)	CYP2C19 *1, *2, *3, *17 Frequency: White/African America/Asian American CYP2C19 *17/*17 = 7(5)/ 2 (2)/0(0) CYP2C19 *1/*17 = 43 (28)/ 27 (27)/ 3 (60) CYP2C19 *1/*1 = 55 (35)/ 42 (42)/0(0) CYP2C19 *2/*17 = 9 (6)/ 3 (3)/0(0) CYP2C19 *1/*2 = 38 (25)/ 24 (23)/2 (20) CYP2C19 *2/*2 = 3 (2)/ 3 (3)/0(0) Alleles: White/African America/Asian American CYP2C19*2 = 53 (17)/ 32 (15)/2(20) CYP2C19*1 = 257 (83)/170 (85)/ 8(80) CYP2C19*17 = 66 (21)/33(17)/ 2(20)	NR	Frequency: White/African America/Asian American EM = 50 (32)/29 (28)/ 2 (40) NM = 64 (41)/ 45 (45)/ 1 (25) IM = 38 (25)/24 (24)/2 (40) PM = 3 (2)/3 (3)/0(0)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Hwang 2011 21075428 South Korea NR	ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer (Applied Biosystems, Foster City, CA, USA).	Blood Immediately after insertion of the arterial sheath in the catheterization laboratory, blood samples were obtained. NR NR	190 (100%)	CYP2C19 *1, *2, *3 CYP2C19 *1 = 62.9 CYP2C19 *2 = 30.3 CYP2C19 *3 = 6.8	NR	*1/*1 extensive metabolizers = 75(39.5) *1/*2 intermediate metabolizers = 71 (37.3) *1/*3 intermediate metabolizers = 18 (9.5) *2/*2 poor metabolizers = 18 (9.5) *2/*3 poor metabolizers = 8 (4.2) *3/*3 poor metabolizers = 0(0)
Kang, 2010 20724801 Korea NR	ABI Snap- shot reaction and the ABI 3100 automated genetic analyzer (Applied Biosystems, Foster City, CA, USA)	Blood Immediately after insertion of the arterial sheath in the catheterization lab. NR NR	176 (82%)	CYP2C19*1/*2, *1/*3, *2/*2, *2/*3, *3/*3 *1/*2 = 61(34.7%) *1/*3 = 14 (8%) *2/*2 = 21(11.8%) *2/*3 = 7 (4%) *3/*3 = 1(0.6%)	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Liu 2010 21163112 China NR	PCR-RFLP	Blood Patient blood samples were collected before clopidogrel administration, and at least 24 hours after the first 300 mg clopidogrel dose to make sure maximum platelet inhibition has been achieved. NR NR	722 (100%)	SNP rs4244285 NR	NR	NR
Maeda, 2010 21178986 Japan NR	Applied Biosystems StepOnePlus real- time PCR system. Specific sets of primers and TaqMan probes (TaqMan SNP genotyping assays) were obtained from Applied Biosystems.	Blood NR NR NR	165 (100%)	Assay IDs were C_25986767_70 for CYP2C19*2 and C_27861809_10 for CYP2C19*3 CYP2C19*1/*1 = 0.33 CYP2C19*1/*2 = 0.36 CYP2C19*1/*3 = 0.14 CYP2C19*2/*2 = 0.08 CYP2C19*2/*3 = 0.08 CYP2C19*3/*3 = 0.006	NR	EM CYP2C19*1/*1 = 34(35) IM CYP2C19*1/*2 and *1/*3 = 46(47) PM CYP2C19*2/*2, *2/*3 and *3/*3 = 17(18)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Malek, 2010 20924183 Poland NR	PCR-RFLP	Blood NR NR NR	261 (94.6%)	CYP2C19*2 NR	NR	NR
Simon 2011 21262992 France NR	NR	NR NR NR NR	1579 (NR)	CYP2C19 loss of function alleles NR	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Yamamoto 2011 21168310 Japan NR	home made with AmpliTaq DNA polymerase (Hoffmann-La Roche, Ltd., Base& Switzerland)	Whole blood NR NR NR	201 (NR)	*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3 CYP2C19 *1/*1 = 37 CYP2C19 *1/*2 = 33 CYP2C19 *1/*3 = 11 CYP2C19 *2/*2 = 11 CYP2C19 *2/*3 = 7 CYP2C19 *3/*3 = 1 CYP2C19 *1 = 145 (58.9%) CYP2C19 *2 = 76 (30.9%) CYP2C19 *3 = 25 (10.2%)	NR	EM = 47 IM = 51 PM = 25
Park 2011 21345843 Korea CILON-T	TaqMan fluorogenic 59 nuclease assay (ABI, Foster City, California, USA).	Blood NR NR NR	478 (99%)	CYP2C19 *2, *3, *17 NR	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Tiroch, 2010 20826260 Germany NR	Home made or BigDye Terminator V1.1 Cycle Sequencing Kit (Applied Biosystems, patent no. 4336776)	Blood NR NR NR	928 (100%)	CYP2C19*17, *2 NR	NR	NR
Sorich, 2010 20492467 707 sites in 30 countries Substudy of TRITON-TIMI 38	Affymetrix Targeted Human DMET Assay	Blood NR NR NR	2943 (99%)	CYP2C19 alleles detected included *1A, *2A, *3, *4, *5A, *6, *7, *8, *9, *10, *12, *13 and *14, of which *2A, *3, *4, *5A, *6, *7 and *8 were considered to result in significantly reduced function NR	Carrier of allele status	EMs (no reduced function alleles). 72% RMs(with one or two reduced function alleles) 28%

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Sibbing, 2010 20492469 Germany	Genotypes were determined with a TaqMan assay, using an ABI Prism Sequence Detector 7000 (Applied Biosystems, Darmstadt, Germany),	Blood Peripheral venous blood samples were drawn Directly at hospital admission, after the daily dose of 75mg of Clopidogrel had been taken and before any in-hospital drug. NR NR	986 (100%)	CYP2C* 2, *17 CYP2C19 *2 (wt/wt) = 738 (74.8) CYP2C19 *2 (wt/*2) = 229 (23.2) CYP2C19 *2 (*2/*2) = 19 (1.9) CYP2C19 *17 (wt/wt) = 608 (61.7) CYP2C19 *17 (wt/*17) = 335 (34) CYP2C19 *17 (*17/*17) = 43 (4.4)	Carrier of allele status	Wild type allele = 86.5 Carrier for at least one*2 allele = 248 (25) *2 allele = 13.5 Wild type carrier = 78.7 Carrier for at least one*17 allele = 378 (38.4) *17 allele = 21.3

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Sawada, 2010 21099121 Japan NR	CYP2C19*2 polymorphisms were genotyped using TaqMan™ Drug Metabolism Genotyping Assays (Applied Biosystems, Foster City, CA, USA) with the Applied Biosystems 7500 Real-Time PCR System.	Blood NR NR NR	100 (NR)	CYP2C19*2 NR	NR	NR
Pare, 2010 20979470 Multiple countries CURE and ACTIVE	TaqMan	NR (ACTIVE-A) "stored-DNA" (CURE) NR NR NR	1156 (ACTIVE-A) + 5059 (CURE) (>98%)	CYP2C19 *2, *3, *17 NR	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Mega, 2010 20801494 707 sites in 30 countries TRITON-TIMI 38	Affymetrix Targeted Human DMET Assay	Blood NR NR NR	2932 (NR)	CYP2C19 alleles detected included *1A, *2A, *3, *4, *5A, *6, *7, *8, *9, *10, *12, *13 and *14, of which *2A, *3, *4, *5A, *6, *7 and *8 were considered to result in significantly reduced function NR	NR	NR
Bouman 2011 21628721 Netherlands Genetic substudy of the Popular study	Real-time PCR (company not given)	blood NR NR NR	Unclear NR	*1/*1 n=737 (72%) *1/*2 n=260 (25.4%) *2/*2 n=27 (2.6%)	Not explicitly provided	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Campo 2011 21679849 Italy NR	allelic discrimination assay (TaqMan Assays, Applied Biosystems, Foster City, California) on the Chromo4 Real- Time PCR System detection (Bio-Rad Laboratories, Hercules, California) using TaqMan Universal Master Mix. The data were analyzed by Opticon Monitor 3.1 software (Bio-Rad Laboratories).	Whole blood NR NR NR	300 NR	CYP2C19*2 heterozygote n=76(25%) CYP2C19*2 homozygote n=5(2%) CYP2C19*2 noncarrier n =219 (73%) CYP2C19*17 heterozygote n=85 (28%) CYP2C19*17 homozygote n=17 (6%) CYP2C19*17 noncarrier n =198 (66%)	Poor response threshold from Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug- eluting stent implantation. Eur Heart J 2008;29:992–1000.	*2 carrier (heterozygote or homozygote) n=81 (27%) *17 carrier (heterozygote or homozygote) n=102 (34%) Poor responders at baseline n=107 (36%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Fernando 2011 21696537 Australia NR	PCR with probe hybridization and single base extension	Whole blood NR NR NR	29 NR	*1/*17 Heterozygous ultrarapid extensive metabolizer n=10(34%) *1/*1 Extensive metabolizer n=13 (45%) *1/*2 Intermediate metabolizer n=5(17%) *2/*2 Poor metabolizer n=1(3%)	Gain and loss of function given for interest, not analysis, and based on known allele function. Groupings for analysis: No difference found between extensive and heterozygous ultrarapid extensive (data not shown) Poor and intermediate combined because of small n's in each group.	Gain of function n=10 (34%) Loss of function N= 6(20%) Extensive and heterozygous ultrarapid extensive (*1/*17 or *1/*1) n=23 (74%) Poor/intermediate metabolizers (*1/*2 or *2/*2) n=6(26%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Geisler 2008 18781853 Germany NR	Matrix-assisted laser desorption/ ionization time-of- flight mass spectrometry (MALDI-TOF MS) using the MassARRAY Compact system (Sequenom, CA)	Blood NR NR NR	273 100%	CYP2C19*1/*1 (*2 noncarriers) n=175 (74%) CYP2C19*1/*2 n=52 (22%) CYP2C19*2/*2 n=10 (4%) CYP2C19*2/*2 n=15.2% *3 frequency n=0% CYP2C19*1/*1 (*17 noncarriers) n=137 (58%) CYP2C19*1/*17 n=79 (33%) CYP2C19*17/*17 n=21 (9%) *17 frequency n= 25.5%	Not explicitly reported	*2 carriers (*1/*2 or *2/*2) n=62 (26%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Gladding 2008 19463375 New Zealand PRINC (Plavix Response in Coronary Intervention) Trial	PCR with TaqMan kits (Applied Biosystems, Foster City, California) and ABI PRISM 7000 Sequence Detection System (Applied Biosystems); genotyping using the Sequenom mass spectrometer	Whole blood Dose came first. Interval varied over study period. Platelet function was tested (blood was taken) at baseline, 2, 4, and 7 h from the first clopidogrel loading dose; and at 7 days. Clopidogrel given at baseline and on days 1-7 after PCI in all patients as well as at 2 hours after PCI in 37 patients. NR NR	60 NR	CYP2C19*1 (normal function) n=24/60 (40%) CYP2C19*2 (19154G>A, rs4244285) n=0/60 (0%) CYP2C19*3 n=0/60 (0%) CYP2C19*4 (1A>G, rs28399504) n=0/60 (0%) CYP2C19*17 (-806C>T, rs12248560) n=17 (28%)	Reference: Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacody- namic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-36.	[good?] response genotype (CYP2C19*1*1 or CYP2C9*1*/*2) =NR poor response genotype (CYP2C19*2 or *4 or *17 OR CYP2C9*3 [note is not only CYP2C19])=NR CYP2C19*2 or *4 carriers n=19/60 (32%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Gurbel 2010 19817997 USA NR	TaqMan SNP genotyping assay (Applied Biosystems, Foster City CA)	NR(Probably blood) NR NR NR	36 NR	CYP2C19*2 N=13/17 with HPR (77%) N=3/19 without HPR (16%) CYP2C19*3 n=0%in both groups CYP2C19*5 n=0% in both groups CYP2C19*17 N=75% of patients with HPR N=NR for those without HPR	Not explicitly reported	≥1 CYP2C19*2 allele N=44% of all genotyped patients (17 w/HPR, 19 without HPR)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Harmsze 2010 20833683 Netherlands NR	Real-time PCR (company NR)	Blood for all controls and 38 cases; saliva for remaining 138 cases NR NR NR	176 cases and 420 controls NR	*2 allele n=Cases 70/176 (39.8%) [allele frequency, 22.6%] N=Controls 123/420 (29.3%) [allele frequency, 17.0%] *1/*1 n= Cases 60.0% N=Controls 70.5% *1/*2 n= Cases 34.9% N=Controls 25.7% *2/*2 n= Cases 5.1% N=Controls 3.8% CYP2C19*3 SNP *3 allele n= Cases 0% N=Controls 0.2% *1/*1 n= Cases 100% N=Controls 99.8% *1/*3 n= Cases 0% N=Controls 0.2% *3/*3 n= Cases 0% N=Controls 0%	NA	NA (carriage of the CYP2C19*2 allele was only variable used)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Kim 2011 21511217 South korea CCELAMI2C19	PCR + ABI SNaPshot	Leukocytes in whole blood NR NR NR	126 (62+64) Unclear	High-dose clopidogrel n=62 *1/*1 Extensive metabolizer (noncarrier) = 24 (38.7%) 1/*2 Intermediate metabolizer = 22 (35.5%) *1/*3 Intermediate metabolizer = 6 (9.7%) *2/*2 Poor metabolizer = 6 (9.7%) *2/*3 Poor metabolizer = 4 (6.4%) *3/*3 Poor metabolizer = 0 (0%) Standard-dose clopidogrel plus cilostazol (n=64) *1/*1 Extensive metabolizer (noncarrier) = 25 (39.1%) 1/*2 Intermediate metabolizer = 24 (37.5%) *1/*3 Intermediate metabolizer = 6 (9.4%)	Not explicitly stated	High-dose clopidogrel (N=62) Noncarrier/extensive metabolizer (*1/*1) = 24 (38.7%) Carrier (of *2 or *3)/intermediate or poor metabolizer [=*1/*2, *1/*3, *2/*2, *2/*3, or *3/*3] = 38 (61.3%) Any intermediate metabolizer (1/*2 or *1/*3) = 28 (45.2%) Any poor metabolizer (*2/*2, *2/*3, or *3/*3) = 10 (16.1%) Standard-dose clopidogrel plus cilostazol (n=64) Noncarrier/extensive metabolizer (*1/*1) = 25 (39.1%) Carrier (of *2 or *3)/intermediate or poor metabolizer [=*1/*2, *1/*3, *2/*2, *2/*3, or *3/*3] = 39 (60.9%) Any intermediate

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
				*2/*2 Poor metabolizer = 5 (7.8%) *2/*3 Poor metabolizer = 4 (6.2%) *3/*3 Poor metabolizer = 0 (0%)		metabolizer (1/*2 or *1/*3) = 30 (46.9%) Any poor metabolizer (*2/*2, *2/*3, or *3/*3) = 9 (14.1%)
Lee 2011 21786436 South korea NR	Seeplex CYP2C19 ACE Genotyping system (Seegene, Seoul, Korea)	Blood NR NR NR	166 NR	CYP2C19 *1/*1 = 68 (40.9%) *1/*2 = 56 (33.7%) *1/*3 = 18 (10.8%) *2/*2 = 14 (8.4%) *2/*3 = 9 (5.4%) *3/*3 = 1 (0.6%)	Not explicitly reported	extensive metabolizer (*1/*1) = 68 (40.9%) Intermediate metabolizer (*1/*2, *1/*3) = 74 (44.6%) poor metabolizer (*2/*2, *2/*3, *3/*3) = 24 (14.5%)
Malek 2008 18577829 Poland NR	PCR-RFLP	Peripheral vein blood NR NR NR	105 100%	CYP2C19*1/*1 = 84 (80%) *1/*2 = 20 (19%) *2/*2 = 1 (1%)	Not explicitly reported	Group 1: mutant P2Y12 and *2 CYP2C19 = 7 Group 2: wild type P2Y12 and *2CYP2C19 = 14 Group 3: mutant P2Y12 and *1 CYP2C19 = 17 Controls: wild-type P2Y12 and *2 CYP2C19 = 67

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Pettersen 2011 21426546 Norway Aspirin and Clopidogrel non- responsiveness clinical Endpoint Trial (ASCET)	ABI Prism 7900 HT Sequence Detection System using allele- specific primers and probes included in the TaqMan Drug Metabolism Assay mix (Applied Biosystems, Foster City, CA)	Whole blood Blood drawn 1 month after first clopidogrel dose NR NR	219 (99%)	CYP2C19*2 homozygote = 3/218 (1%) CYP2C19*2 heterozygote = 61/218 (28%) CYP2C19*2 carrier = 64/218 (29%)	NA	NA
Sibbing 2011 21527445 Germany NR	TaqMan assay using an ABI Prism Sequence Detector 7000 (Applied Biosystems)	Blood NR NR NR	1525 (cohort) 1566 (case-control) (100%)	PCI cohort (n=1524) CYP2C19*1/*1 = 32 (2.1%) CYP2C19*1/*2 = 345 (22.6%) CYP2C19*2/*2 = 1147 (75.3%) St cohort (n=127) CYP2C19*1/*1 = 81 (64%) CYP2C19*1/*2 = 43 (34%) CYP2C19*2/*2 = 3 (2%)	NA	NA
Simon 2009 19106083 France FAST-MI	For *2 or *3, oligonucleotide ligation assay (SNPlex, Applied Biosystems) after	whole blood Drawn at time of admission NR	2208 *2: 2178 (99%) *3: 2187 (99%) *4: 2189 (99%)	CYP2C19*2 noncarrier = 1571/2178 (72%) CYP2C19*2 heterozygote = 564/2178 (26%)	Not explicitly reported	No CYP2C19 loss-of- function SNP (*2, *3, *4, or *5) = 1573/2208 (71%) Any CYP2C19 loss-of- function SNP (*2, *3, *4,

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
	initial amplification by PCR For *4,*5,*17: custom TaqMan	NR	*5: 2176 (99%) Any LOF (*2,3,4, or 5): 2208 (100%) *17: 2164 (98%)	CYP2C19*2 homozygote = 53/2178 (2%) CYP2C19*3 noncarrier = 2186/2187 (99.9%) CYP2C19*3 heterozygote = 1/2187 (<1%) CYP2C19*4 heterozygote = 2168/2189 (99%) CYP2C19*4 homozygote = 21/2189 (1%) CYP2C19*5 noncarrier = 2175/2176 (99.9%) CYP2C19*5 heterozygote = 1/2176 (<1%) CYP2C19*17 noncarrier = 1390/2164 (64%) CYP2C19*17 heterozygote = 674/2164 (31%) CYP2C19*17 homozygote = 100/2164 (5%)		or *5) = 577/2208 (26%) Any 2 CYP2C19 loss-of- function SNPs (*2, *3, *4, or *5) = 58/2208 (3%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Hwang 2010 20823393 Korea ACCEL	SNaPshot single base primer extension	Blood NR NR NR	65 (from the high- dose clopidogrel group) + 69 (from the triple antiplatelet therapy group) Unclear	*1/*1: 44 (32.8) *1/*2: 47 (35.1) *1/*3: 16 (11.9) *2/*2: 18 (13.4) *2/*3: 8(6.0) *3/*3: 1(0.7)	previous publication	*1: 56.3% *2: 34% *3: 9.7%
Cuisset, 2011 21803320 France NR	amplification refractory mutation system polymerase chain reaction	blood >12 h after the LD clopidogrel NR NR	346 (100%)	CYP2C19*2 *2/*2 (AA)=4% n=13 *2/WT heterozygotes(AG)=21% n=73 WT/WT homozygous (GG)=75% n=260	NR	NR
Price, 2012 22624833 US GIFT (Genotype Information and Functional Testing) Study— a prespecified genetic substudy of GRAVITAS (Gauging Responsiveness with A VerifyNow assay—Impact on	MassARRAY platform, iPLEX Gold assay, aQnd MassARRAY Typer version 4.0 (all Sequenom, San Diego, CA)	Blood NR NR NR	1170 (with 142 excluded for various reasons, for a total of 1028 patients in study) Mean call rate across 43 SNPs was 99.6% (range, 93.3% to 100%) [success data NA for CYP2C19 variants specifically]	CYP2C19 *2, rs4244285; frequency 0.15 CYP2C19 *17, rs12248560; frequency 0.23 CYP2C19 *8, rs4244285; frequency 0.002 CYP2C19 *4, rs28399504; frequency 0.002 CYP2C19 *3, rs4986893; frequency	Not explicitly provided	Carriers of any 1 reduced-function alleles represented in study population (*2, *3, *4, *6, *8) vs. noncarriers Carriers of any 2 reduced-function alleles vs. noncarriers

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Thrombosis And Safety) trial				0.008 CYP2C19 *6, rs72552267; frequency 0 [12-24 hr after PCI but there are data for later time points, for unclear reasons] CYP2C19 *5, rs56337013; frequency 0 CYP2C19 *7, rs72558186; frequency 0 Frequencies are in a cohort of 611 of the study patients (both with and without high OTR and randomized or not to receive clopidogrel)		

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Gremmel, 2012 22154242 Austria NR	Infiniti® CYP450 2C19+ assay (AutoGenomics, Carlsbad, CA, USA)	Blood 24 hr between PCI and sampling 1-3 hr NR	288 (NR)	CYP2C19*2 (915 4 G > A), *3 (17948 G > A), *4 (1A > G), *5 (9 0033 C > T) *6 (1274 8 G > A) *7 (1 9294 T > A), *8 (12711 T > C), *9 (12784 G > A), *10 (19153 C > T), *17 (– 806 C > T)	4 Metabolizer categories based on a previous study: Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: The ONSET/ OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010;3:556- 66	Genotype, Frequency, n (%,) [Phenotype Metabolizer Status]: *17/*17, 15 (5.2) Ultrarapid [UM] *17/wt 79 (27.4) Rapid heterozygous [UM] wt/wt 106 (36.8) Extensive [EM] *2/*17 29 (10.1) Poor/rapid heterozygous [IM] *8/wt 1 (0.3) Intermediate [IM] *2/wt 54 (18.8) Intermediate [IM] *2/*2 4 (1.4) Poor [PM]

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Harmsze, 2012 22228204 Netherlands POPular substudy	Real-time PCR	Blood NR NR NR	820 (NR)	CYP2C19 *2, rs4244285 CYP2C19 *17, rs12248560 *17/*17, n=33 *1/*17, n=207 *1/*1, n=351 *2/*17, n=47 *1/*2, n=157 *2/*2, n=25	Not explicitly provided	Ultrarapid metabolizers (*1 or *17/*17) Extensive metabolizers (*1 /*1) Intermediate/poor metabolizers (*2/*2, *1, or *17)
Kreutz, 2012 22427735 US NR	Bio-Rad Laboratories real- time iCycler thermal cycler (Bio-Rad Laboratories, Inc, Hercules, CA) And TaqMan® probes (Applied Biosystems, Foster City, CA)	Whole blood 4 hr and 16-24 hr since most recent dose NR NR	151 (NR)	CYP2C19*2 (681G>A; rs4244285): , CYP2C19*3 (636G>A; rs4986893) *3 was found in 0 patients 0*1/*1, n=107 *1/*2, n=39 *2/*2, n=5	Not explicitly provided	No additional grouping.

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Dai, 2012 22704413 China NR	PCR-RFLP (Multigene Gradient PCR amplifier, LABNET)	Blood NR NR NR	520 (NR)	CYP2C19*17 *17/*17: 6 (1%) *17/wild type: 71 (14%) Wild type/wild type: 443 (85%) Wild type allele carrier: 957 alleles (92%) *17 allele carrier: 83 alleles (8%)	NA (further grouping not done)	NA (further grouping not done)
Cuisset, 2011 21803320 France NR	Amplification refractory mutation system polymerase chain reaction	blood >12 h after the LD clopidogrel NR NR	346 (100%)	CYP2C19*2 *2/*2 (AA)=4% n=13 *2/WT heterozygotes(AG)=21% n=73 WT/WT homozygous (GG)=75% n=260	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Chen. 2012 22723959 Taiwan CAPTAIN	TaqMan assay by using an ABI Prism Sequence Detector 7000 (Applied Biosystems)	blood NR NR NR	60 (~99%)	CYP2C19*2 AA 13.3% GA 38.3% GG 48.4% CYP2C19*3 AA 0 GA 38.3% GG 86.7% CYP2C19*17 TT 0 GA 0 CC 100	NR	NR
Gajos, 2012 22623230 Poland OMEGA-PCI	validated Drug Metabolism Genotyping Assay (TaqMan MGB probes, FAM and VIC dye-labeled) and TaqMan Universal PCR Master Mix	Blood blood collection 12 h before PCI NR NR	30 (NR)	G681A CYP2C19 GG 70% GA 30% AA 0	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Luo, 2011 22118006 China NR	TaqMan® Single Nucleotide Polymorphism Genotyping Assay kit and TaqMan® Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA),	blood blood collected before angiography immediately NR	1738 (NR)	CYP2C19 *2/*2 136,7.8% CYP2C19 *1/*2 666,38.3% CYP2C19 *1/*1 936,53.9%	NR	NR
Tello-Montoliu 2012 22116003 Spain study one of the paper	TaqMan SNP Genotyping Assays (Applied Biosystems, Carlsbad, California, United States)	blood on clopidogrel NR NR	40 (100%)	CYP2C19 *2 G/G n=31 */A n=9 CYP2C19 *17 C/C n=27 */T n=13	NR	NR
Tello-Montoliu 2012 22116003 Spain study two of the paper	TaqMan SNP Genotyping Assays (Applied Biosystems, Carlsbad, CA USA)	blood before angiography NR NR	428 (100%)	CYP2C19 *2 G/G 71.96% G/A 24.77% A/A 3.27% CYP2C19 *17 C/C 66.12% C/T 30.14% T/T 3.74%	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Harmsze, 2011 21854540 Netherlands NR	CYP2C19 alleles CYP2C19*2 (rs4244285) and CYP2C19*17 (rs12248560) were identified by RT- PCR and DNA sequence analysis	blood blood collected before PCI NR NR	725 (NR)	NR	NR	NR
Ono, 2011 21862109 Japan NR	CYP2C19 PCR-RFLP	blood NR NR NR	202 (NR)	CYP2C19*1/*1 =35.1 CYP2C19*1/*2=34.2 CYP2C19*1/*3=14.9 CYP2C19*2/*2=9.9% CYP2C19*2/*3=5.4% CYP2C19*3/*3=0.5%	NR	extensive metabolizer (EM) =35% (CYP2C19*1/*1) intermediate metabolizer (IM)=49% (CYP2C19*1/*2, *1/*3) poor metabolizer (PM)=16% (*2/*2, *2/*3, *3/*3)
Delaney, 2012 22190063 USA NR	TaqMan (Applied Biosystems, Foster City, CA).	blood NR NR NR	693 (NR)	CYP2C19*2 CYP2C19*17	NR	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Bhatt, 2012 22450429 USA CHARISMA	Taqman	blood NR NR NR	2266 (NR)	CYP2C19*2 CYP2C19*3 CYP2C19*17	NR	poor (*2/*2 or *2/*3), intermediate (wt/*2 or wt/*3), extensive (wt/wt), ultra (wt/*17 or *17/*17), unknown (*2/*17 or *3/17)
Fontana 2011 21692977 Switzerland ADRIE	PCR-RFLP	blood NR NR NR	538 NR	CYP2C19*1 CYP2C19*2	NR	CYP2C19*2 non-carriers (n=366) one carriers (n=152) two carriers (n=17)
Aleil, 2009 19624462 France VASP-02 [genetic reanalysis thereof]	NR	NR NR NR NR	153 NR	CYP2C19*2 NR	NO except previous reports that genotype could have an effect on response to clopidogrel	Among the 37 poor responders: LOF carriers (*2/wild type or *2/*2), 16 (42%) LOF noncarriers (wild type/wild type), 21 (57%) Among 116 responders: LOF carriers (*2/wild type or *2/*2), 26 (22%) LOF noncarriers (wild type/wild type), 90 (78%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Chen, 2012 22071359 China NR	TaqMan validated SNP assay (Applied Biosystems, Foster City CA)	Blood NR NR NR	654 100	CYP2C19*2 (681G>A; rs4244285) *2/*1, 291/654 (44%) *2/*2, 57/654 (9%) *1/*1, 306/654 (47%)	NO	NONE (NA)
Kreutz, 2012 22385219 USA NR	Real-time PCR (Bio- Rad Laboratories)	Whole blood NR NR NR	96 NR	CYP2C19*2 (681G>A; rs4244285) CYP2C19*3 (636G>A; rs4986893) No patients were *3 carriers For *2: *1/*1, 68/96 (71%)16 *2/*1, 24/96 (25%) *2/*2, 4/96 (4%)	NO	*2 noncarrier (*1/*1), 68/96 (71%) *2 carrier (*2/*1 or *2/*2), 28/96 (29%)
Marcucci, 2012 22390861 Italy NR	Allelic discrimination assay (ABI Prism 7900 HT Sequence Detection System; Applied Biosystems)	Whole blood NR NR NR	1187 NR	CYP2C19*2 (rs4244285) *1/*1, 892/1187 (75%) *2/*1, 264/1187 (22%) *2/*2, 31/1187 (3%)	NO	*2 noncarrier (*1/*1), 892/1187 (75%) *2 carrier (*2/*1 or *2/*2), 295/1187 (25%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Mega, 2011 22088980 USA ELEVATE-TIMI 56	Pyrosequencing assay and Nanosphere Verigene 2C19/CBS nucleic acid research use only assay	Blood NR but genotyping came first NR NR	333 NR	CYP2C19*2 *1/*1, 247 (74%) *1/*2, 80 (24%) *2/*2, 6 (2%)	NO	*2 noncarrier (*1/*1), 247 (74%) *2 carrier (*2/*1 or *2/*2), 86 (26%)
Nishio, 2012 22785462 Japan NR	TaqMan Drug Metabolism Genotyping Assay with the Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City CA)	Blood NR NR NR	160 NR	CYP2C19*2 (681G>A; rs4244285) CYP2C19*3 (636G>A; rs4986893) *1/*1, 60 patients *2/*1: 49 patients *3/*1: 28 patients *2/*2: 9 patients *2/*3: 10 patients *3/*3: 4 patients	NO	Extensive metabolizer (*1/*1): 60 patients Intermediate metabolizer (*1/*2 or *3): 77 patients Poor metabolizer (*2/*2, *2/*3, or *3/*3): 23 patients

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Park, 2012 22507978 Korea ACCEL-STATIN	TaqMan with the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City CA)	Whole blood leukocytes At least 6 mo NR NR	45 Unclear [the article simply says 50 patients were enrolled and 45 were genotyped. Failure is not explicitly given as the reason for the 5 missing.]	CYP2C19*2 (681G>A; rs4244285) CYP2C19*3 (636G>A; rs4986893) *1/*1, 15 patients *2/*1: 14 patients *3/*1: 6 patients *2/*2: 4 patients *2/*3: 6 patients *3/*3: 0 patients	NO	NONE
Teixeira, 2012 22377481 Portugal NR	PCR (See gene, Seoul, S. Korea)	Peripheral blood leukocytes NR NR NR	95 Unclear	CYP2C19*2 (681G>A; rs4244285) *1/*1, 69 patients *1/*2, 25 patients *2/*2, 1 patient	NO	*2 noncarrier (*1/*1), 69 patients *2 carrier (*2/*1 or *2/*2), 26 patients
Parri, 2012 22727972 Italy NR	Allelic discrimination assay (ABI Prism 7900 HT Sequence Detection System; Applied Biosystems)	NR NR NR NR	105 Unclear	CYP2C19*2 (681G>A; rs4244285) *1/*1, 70 patients *1/*2, NR *2/*2, NR	YES (refs7-9 in article as evidence of expected difference in response with carriage of *2)	*2 noncarrier (*1/*1), 70 patients *2 carrier (*2/*1 or *2/*2), 35 patients

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Yamane, 2012 22472213 Japan NR	PCR and direct sequencing	blood 6 months NR NR	25 NR	CYP2C19 *1, *2, *3, EM (*1/*1) n=8 IM (*1/*2, n=12; *1/*3, n=2) PM (*2/*2, n=2, *2/*3, n=1)	no	EM (*1/*1) n=8 IM (*1/*2, n=12; *1/*3, n=2) PM (*2/*2, n=2, *2/*3, n=1)
Hsu, 2011 21144850 Taiwan NR	PCR and RFLP	blood >2 weeks NR NR	125 NR	CYP2C19*1/ CYP2C19*2/ CYP2C19*3	No	homEM, CYP2C19*1/ CYP2C19*1 hetEM, CYP2C19*1/ CYP2C19*2 and CYP2C19*1/ CYP2C10*3 PM, CYP2C19*2/ CYP2C19*2, CYP2C19*2/ CYP2C19*3, and CYP2C19*3/ CYP2C19*3
Kim, 2012 22007612 Korea ACCEL-TRIPLE	ABI SNaPshot (Applied Biosystems, Foster City, California)	blood NR NR NR	127 NR	CYP2C19*2 CYP2C19*3	No	*1 59.1% *2 31.5% *3 9.4% *1/*1 48 (37.8%) EM *1/*2 42 (33.1%) IM *1/*3 12 (9.4%) IM *2/*2 15 (11.8%) PM *2/*3 8 (6.3%) PM *3/*3 2 (1.6%) PM

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Siller-Matula, 2012 22260716 Austria PEGASUS-PCI	CYP2C19*17 (CYP2C19_- 806_C>T, rs12248560) and CYP2C19*2 (CYP2C19_681_ G>A; rs4244285) with ABI Prism Sequence Detector 7000 (Applied Biosystems)	blood 0.08 days (2 hours) after LD NR NR	416 (100%)	CYP2C19*1 allele = 279 (69.4%) CYP2C19*2 allele = 123 (30.6%)	NR	CYP2C19*2 LOF allele =poor metabolizers (CYP2C19*1/*2, heterozygote poor metabolizers; CYP2C19*2/*2, homozygote poor metabolizers), CYP2C19*17 GOF allele = ultra-metabolizers (CYP2C19*1/*17, heterozygote ultra- metabolizers; CYP2C19*17/*17, homozygote ultra- metabolizers) CYP2C19*1 allele = regular metabolizers CYP2C19*2/*17 allele = mixed metabolizers.
Bonello, 2012 22285300 France NR	CYP 2C19*2 (rs4244285) genotyping: done with ARMS-PCR (manufacturer NR)	Peripheral blood lymphocytes 0.025-0.5 days (6-12 hours) LD NR NR	367 (73.7% - Unclear if this reflect availability of samples or genotyping success)	wild-type (wt) / wild-type (wt): 261/367 (71%) wild-type (wt) /*2: 95/367 (26%) *2/*2: 11/367 (3%)	NR	Carriers of atleast one *2 allele (wt /*2 or *2/*2): 106/367 (29%) wild-type (wt) / wild-type (wt): 261/367 (71%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Simon, 2011 21918510 France FAST-MI	CYP2C19, TaqMan allelic discrimination assay (ABI 7900 Sequence Detector System software, version 2.3, Applied Biosystems, Courtaboeuf, France)	circulating blood leukocytes NR NR NR	2208 (100%)	Based on zero, one, or two LOF alleles	NR	NR
Collet, 2011 21511218 France CLOVIS-2	CYP2C19*2 and other loss-of- function CYP2C19 variants (*3, *4, *5, *6) variants TaqMan Validated SNP assays (C_25986767_70) with the 7900HT sequence Detection System (Applied Biosystems, Courtaboeuf, France).	Peripheral blood NR NR NR	106 (100%)	wild-type (wt) / wild-type (wt): 58/106 (55%) wild-type (wt) /*2: 41/106 (39%) *2/*2: 7/106 (6%)	Yes [To determine whether response to high or standard clopidogrel LDs differs according to the presence of 1 or 2 CYP2C19 reduced-function alleles]	wild-type (wt) / wild-type (wt): 58/106 (55%) wild-type (wt) /*2: 41/106 (39%) *2/*2: 7/106 (6%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Jaitner, 2012 22298798 Germany NR	NR	Blood NR NR NR	1408(cohort) 66 (cases) (100%)	NR	NA	Cases - St registry(n=66) CYP2C19*2 carrier= 25 (37.9%) CYP2C19*2 noncarrier= 41 (62.1%) Controls - PCI cohort (n=1408) CYP2C19*2 carrier= 353 (25.1%) CYP2C19*2 noncarrier= 1055 (74.9%)
Hochholzer, 2011 21884870 NR EXCELSIOR	NR	NR NR NR NR	765(100%)	NR NR	NR	Homozygous or heterozygous carrier of CYP2C19 *2 allele

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Kassimis, 2012 21831410 Greece NR	CYP2C19*2 (681 GNA), CYP2C19*17 (806 CNT); Real Time Polymerase Chain Reactions (PCR) analysis Light- Cycler2.0 apparatus (Roche, Mannheim, Germany)	Blood NR NR NR	146 (100%)	CYP2C19*2 = 13.4% CYP2C19*17 = 24.7%	NR	CYP2C19*2 Noncarriers= 108(74.0) CYP2C19*2 Heterozygous carriers=37(25.3) CYP2C19*2 Homozygous carriers= 1(0.7) CYP2C19*2 Carriers of at least one allele=38(26.0) CYP2C19*17 Noncarriers= 81(55.5) CYP2C19*17 Heterozygous carriers=58(39.7) CYP2C19*17 Homozygous carriers= 7(4.8) CYP2C19*17 Carriers of at least one allele=65(44.5)
Namazi, 2012 22265638 Iran NR	CYP2C19*2(rs4244 285), and CYP2C19*3(rs4986 893)	Blood NR NR NR	112 (100%)	CYP2C19*1: 88.99% CYP2C19*2: 10.09% CYP2C19*3:0.91%	NR	wild type 1*/1* 1 variant allele(CYP2C19 *2 and *3)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Rideg, 2011 21806387 Hungary DOSER	CYP2C19*2 (681 GtoA), CYP2C19*3 (636 CtoA); CYP2C19*17 (806 Ctot) Real Time Polymerase Chain Reactions (PCR) analysis Light- Cycler2.0 apparatus (Roche, Mannheim, Germany)	Blood NR NR NR	189 (100%)	*1/*1: 75(39.7) *1/*17: 41(21.7) *17/*17: 28(14.8) *1/*2: 27(14.3) *2/*17: 13(6.9) *2/*2: 4(2.1) *3/*17: 1(0.5)	NR	LOF (Atleast one CYP2C19*2 or *3):45 No LOF:144 GOF (Atleast one CYP2C19*17): 83 No GOF: 106
Jeong, 2011 22045970 Korea NR	CYP2C19*2, CYP2C19*3; CYP2C19*17 QIAamp DNA Blood Mini Kit, Qiagen, Hilden, Germany	Blood NR NR NR	266 (100%)	*1/*1: 104(39.1) *1/*2:98(36.8) *1/*3: 30(11.3) *2/*2: 20(7.5) *2/*3: 14(5.3)	Based on literature	extensive (no LOF carriers), intermediate (1 LOF carriers), and poor metabolizers (2 LOF carriers).
Chan,2012 22462746 Singapore NR	CYP2C19*2, CYP2C19*3; PCR and RFLP on ABI 9700 (ABI Biosystems) CYP2C19*17 Light Scanner 32 (Idaho Tech Int, USA)	Blood 5-7 days NR NR	89 (100%)	Poor (*2/non*17 or *3- non*17) Normal (*1-non*17) Rapid (*1-*17)	Based on literature	Poor metabolizer: P/P, N/P: 49 (55.1%) normal metabolizer: N/N, P/R: 37(41.6%) rapid metabolizer: N/R,R/R: 3 (3.3%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Goodman, 2012 22261200 Multi-country PLATO	CYP2C19 *2 through *8	NR NR NR NR	2852 (100%)	NR	NR	CYP2C19 loss-of-function alleles (*2 through *8) No CYP2C19 loss-of- function alleles (*2 through *8)
Park, 2012 22735685 Korea CROSS-VERIFY	CYP2C19*2 (P227P, rs4244285) and CYP2C19*3 (W212X, rs4986893) TaqMan fluorogenic 5- nuclease assay (ABI, Foster City, California, USA).	Blood NR NR NR	CYP3A5 expressers n=509 (100%)	NR	Based on literature	CYP 2C19 LOF allele carrier in whole population:128 (10.3%) Proportion in CYP3A5 expressers is NR
Kreutz, 2012 22459907 USA NR	CYP2C19*2 (681 G>A; rs4244285) and CYP2C19*3 (636 G>A; rs4986893) Bio-Rad Laboratories real- time PCR system (iCycler thermal cycler, Bio-Rad Laboratories, USA)	Blood NR NR NR	55 (100%)	*1/*1: 39(70.9) *1/*2:15(27.3) *2/*2: 1(1.8)	NR	CYP 2C19 *2 carrier: 16 non CYP 2C19 *2 carrier: 39

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Yan, 2011 21778720 China NR	CYP2C19 * 2 (681G 1 A; rs4244285) TaqMan Validated SNP assays, C_25986767_70; Applied Biosystems, Foster City, Calif., USA	Blood NR NR NR	497 (NR)	CYP2C19 * 2: 42.0% homozygous (A/A): 39 (7.8%) heterozygous (G/A): 216 (43.5%) noncarrier (G/G) : 242 (48.7%)	NR	NR
Jeong, 2012 22837373 Korea ACCEL-DM	ABI SNaPshot	blood immediately before PCI or 5 days after emergency PCI NR NR	80 (NR)	CYP2C19 *1 56.9% *2 32.5% *3 10.6%	NR	*1/*1 EM 26(32.5) *1/*2 IM 28 (35) *1/*3 IM 11 (13.8) *2/*2 PM 9(11.2) *2/*3 PM 6 (7.5) *3/*3 PM 0(0)
Cayla, 2011 22028352 France ONASSIST	TaqMan Validated SNP assays with the 7900HT Sequence Detection System (Applied Biosystems)	Blood NR NR NR	369 (99.7%)	681G>A, CYP2C19*2 (rs4244285) homozygous (A/A): 26 (7.1%) heterozygous (G/A): 101 (27.4%) noncarrier (G/G) : 241 (65.5%) 636G>A, CYP2C19*3 (rs4986893) noncarrier (G/G) : 368 (100%)	Based on literature	Poor metabolizer *2/*2: 26 Intermediate metabolizer *1/*2,*1/*4: 78 Extensive metabolizer *1/*1,*2/*17: 183 Rapid metabolizer *1/*17, *17/*17: 81 CYP2C19 loss-of-function alleles (*2 through *8): 127 (34.5%) No CYP2C19 loss-of- function alleles: 242

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
				1A>G, CYP2C19*4 (rs28399504) heterozygous (G/A): 1 (0.3%) noncarrier (G/G) : 367(99.7%) 1297C>T, CYP2C19*5 (rs56337013) noncarrier (C/C) : 368 (100%) 395G>A, CYP2C19*6 (rs72552267) noncarrier (G/G) : 368 (100%) -806C>T, CYP2C19*17 (rs12248560) homozygous (T/T): 12 (3.3%) heterozygous (T/C): 93 (25.3%) noncarrier (C/C):		(65.5%) CYP2C19 gain-of- function alleles (*17): 105 (28.5%) No CYP2C19 gain -of- function alleles: 263 (71.5%)

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
				263(71.5%)		
Hulot, 2011 21972404 France AFIJI	CYP2C19 * 2 - *6 TaqMan Validated SNP assays; Applied Biosystems, Foster City, Calif., USA	NR NR NR NR	371 (NR)	CYP2C19*2 wt/wt homozygotes, n=262; (71.0%). heterozygotes wt/*2, n=94, (25.5%) homozygous *2/*2, n=13 (3.5%) Carriers of *4 LOF allele = 4 (1.1%) Noncarriers of *4 LOF allele = 367(98.9%) Carriers of *3 LOF allele = 2 (0.5%) Noncarriers of *4 LOF allele = 367(99.5%)	Based on literature	CYP2C19 loss-of-function alleles (*2 through *6): 107(29%) No CYP2C19 loss-of- function alleles: 262 (71%)
Hulot, 2011 21972404 France CLOVIS-2	CYP2C19 * 2 - *6 TaqMan Validated SNP assays; Applied Biosystems, Foster City, Calif., USA	NR NR NR NR	106 (97.2)	CYP2C19*2 wt/wt homozygotes, n=55; (53.4%). heterozygotes wt/*2, n=41, (39.8%) homozygous *2/*2, n=7 (6.8%)	Based on literature	NR

Author, year UID Country Study name	Genotyping assay (manufacturer):	Type of sample from which DNA extracted Interval between clopidogrel doses and DNA sampling (in days) Interval between sampling and genotyping results (in days) Interval between collection and DNA extraction	N genotyped: Genotyping success (%)	Alleles tested Genotypes tested Frequency of genotype	Rational for the grouping of genotypes reported (Yes/No) [short description]	Grouping of genotypes: Frequency of group:
Roberts, 2012 22464343 Canada RAPID GENE	SPARTAN RX CYP2C19 and direct sequencing	Buccal swab	200 (93.5)	CYP2C19*2 *1/*1 homozygotes, n=141; (75.4%). heterozygotes *1/*2, n=39, (20.9%) homozygous *2/*2, n=7 (3.7%)	Based on literature	CYP2C19 loss-of-function alleles (*2 through *6): 46 (24.6%) No CYP2C19 loss-of- function alleles: 141 (75.4%)

*E.g., nonresponsive vs. responsive to clopidogrel, high vs. low platelet reactivity, or combination of metabolizer phenotypes: e.g., EM- extensive metabolizers; UM; ultrarapid metabolizers; IM- intermediate metabolizers; SM- slow metabolizers; PM-poor metabolizers; PCR=Polymerase Chain Reaction

Appendix Table D6. Methods for reactivity assessment (used for outcome ascertainment)

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Fontana, 2008 17681590 Switzerland	VASP assay (platelet reactivity index)	VASP phosphorylation after ADP stimulation measured by flow cytometry	Platelet VASP/ P2Y12 assay using FACStrack flow cytometer	Assay: Biocytex, Marseille, France; flow cytometer: Becton Dickinson, Meylan, France	Samples were obtained 15 days after discharge (hospitalization for PCI)	Citrated blood	ADP	15 days post discharge (i.e. post-PCI hospitalization)	NR
Giusti, 2007 18004210 Italy NR	Turbidimetric aggregometry to determine platelet aggregation	Light transmission aggregometry (turbidimetric method)	APACT 4	Labor Biomedical Technologies GmbH, Ahrensburg, Germany	Venous blood samples were collected 24 h after PCI intervention; for patients receiving both clopidogrel and IIb/IIIa inhibitors samples were obtained after 6 d	Citrated blood	ADP 2 µmol/L and ADP 10 µmol/L	Samples were obtained 24 h after PCI intervention; for patients receiving both clopidogrel and IIb/IIIa inhibitors samples were obtained after 6 d	NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Platelet aggregation	Turbidimetric aggregometry	APACT4 (4 channel aggregometer)	Helena Laboratories (Milan, Italy)	Venous blood was obtained	Citrated blood	ADP (10 µM)	Venous blood was obtained 12-18 h from clopidogrel loading; for patients administered IIb/IIIa inhibitors blood was obtained 6 d after catheterization	NR
Gladding, 2009 19926050 New Zealand NR	VerifyNow	Agglutination plus light transmittance	point-of-care rapid platelet function analyzer (RPFA) and its P2Y12 cartridge	Accumetrics Ltd., San Diego, California	Venous blood; collection tubes were inverted 4 times to mix the anticoagulant and left for 10 min at ambient temperature (24°C) before testing	3.2% citrate	ADP, 20 µmol/l	Platelet function was tested at baseline and at 7 days	10 min
Jinnai, 2009 19531897 Japan Partly industry funded	Inhibition of platelet aggregation (IPA)	Optical aggregometry	NR	NR	Platelet-rich plasma was obtained at different timepoints	NR	ADP 2 µmol/L	obtained at baseline, 4h, 24h, 48h and the 14 th and 28 th post- treatment days	NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Shuldiner, 2009 19706858 USA Sinai Hospital of Baltimore Study	ADP-stimulated reactivity	Light-transmission aggregometry (lumi- aggregometry)	Chronolog Lumi- Aggregometer (Model 490-4D)	Chronolog; Havertown, PA	Samples were obtained at baseline (for 143 patients not receiving clopidogrel) and post-clopidogrel (188 patients)	Citrated blood	ADP 20 μmol/L or arachidonic acid 2 mmol/L	Platelet function was measured on the day of discharge for patients not receiving eptifibatide and 5 d or more after discharge for patients receiving eptifibatide	NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	Multiplate analyzer	Whole-blood electrode platelet aggregometry	Multiplate analyzer (no model information)	Dynabyte, Munich, Germany	Arterial blood samples were collected "directly before PCI"	lepirudin	ADP (6.4 μmol/L)	All patients received a clopidogrel loading dose with a recommended pre-treatment interval of 2h; blood was sampled directly before PCI. The median clopidogrel loading interval was 3.5h for *1/*1; 3.5 h for *17/*1; and 5.3 h for *17/*17.	NR
Varenhorst, 2009 19429918 Sweden Genetic sub- study	VASP PRI assay with flow cytometry	VASP assay with flow cytometry	Platelet VASP kit	Biocytex, Marseille, France	NR	Citrated blood	ADP ± PGE1, concentration not reported	Samples were collected at baseline, 2 h and 24 h post- loading dose; also at day 14 ±3 and day 29 ±3, both before that day's maintenance dose	NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
	VerifyNow P2Y12 assay	Whole blood LTA, point-of-care test	VerifyNow VN- P2Y12 assay	Accumetrics, San Diego, CA	Whole-blood, point-of-care assay	NR	ADP (with fibrinogen- coated beads), concentration not reported	The assay was performed on day 1 at baseline (pre- dose), 2, and 24±4 h post- loading dose; also on day 14 ±3 and day 29 ±3, both before that day's maintenance dose	NR
Frere, 2008 18394438 France NONE	VASP phosphorylation assay	Flow cytometry with and without ADP stimulation (along with PGE1 for all measurements)	Platelet VASP assay with flow cytometry (EPICS XL- MCL flow cytometer)	For the VASP assay = Diagnostica Stago [Biocytex], Asnieres, France For the flow cytometer =	Blood was drawn in the catheterization laboratory, before coronary angiography	Citrated blood	ADP 10 µmol/L	Patients received 600 mg loading dose of clopidogrel and 250 mg aspirin ≥12 hours before coronary angiography	Samples were sent "immediately" to the hemostasis laboratory

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
	ADP-induced aggregation	Light-transmission aggregometry	PAP4 Aggregometer	Biodata Corporation, Wellcome, Paris, France	Blood was drawn in the catheterization laboratory, before coronary angiography	Citrated blood	ADP 10 μmol/L	Patients received 600 mg loading dose of clopidogrel and 250 mg aspirin ≥12 hours before coronary angiography	Samples were sent “immediately” to the hemostasis laboratory
	ADP-induced P- selectin expression	P-selectin expression using flow cytometry with or without ADP	EPICS XL-MCL flow cytometer	For the flow cytometer = Biodata Corporation, Wellcome, Paris, France	Blood was drawn in the catheterization laboratory, before coronary angiography	Citrated blood	ADP 10 μmol/L final concentration	Patients received 600 mg loading dose of clopidogrel and 250 mg aspirin ≥12 hours before coronary angiography	Samples were sent “immediately” to the hemostasis laboratory
Frere, 2009 19496924 France Part of larger observational study	VASP phosphorylation assay	VASP phosphorylation assay by flow cytometry	NR	NR	Samples for platelet aggregation testing were obtained after the administration of 600 mg clopidogrel loading dose.	NR	NR (presumably ADP as in other publications from the same group)	NR	NR
	ADP-induced platelet aggregation	NR	NR	NR	Samples for platelet aggregation testing were obtained after the administration of 600 mg clopidogrel loading dose.	NR	ADP 10 μM	NR	NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Bonello-Palot 2009 19932784 France NR	VASP phosphorylation	VASP phosphorylation	platelet VASP kits	Diagnostica Stago, Asnières, France	VASP analysis done within 24 hours of blood collection	3.8% trisodium citrate	prostaglandin E1, and ADP is adenosine diphosphate	>0.25 to <0.5 days (>6 to < 12 hours); Clopidogrel came first	<1 day
Harmsze 2010 19934793 Netherlands NR	LTA	light transmission aggregometry	APACT 4004 four-channel light transmission aggregometer	LABiTec, Ahrensburg, Germany	Before the coronary stent implantation procedure & heparinization	3.2% citrate	5 and 20 µmol/l ADP	1 day; clopidogrel came first	0.083 days (2 hours)
	VerifyNow	light transmission aggregometry	VerifyNow P2Y12 test cartridge system	Accumetrics, San Diego, CA, USA (company name obtained from Ref 21)	Before the coronary stent implantation procedure & heparinization	3.2% citrate	ADP and PGE1	1 day; clopidogrel came first	0.083 days (2 hours)
Trenk 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	4-channel Bio/ Data PAP4 aggregometer	light transmission aggregometry	4-channel Bio/ Data PAP4 aggregometer	Mölab, Langenfeld, Germany	At baseline beforeclopidogrel and at cardiac catheterization	3.8% sodium- citrate	ADP at final concentrations of 5 and 20 µmol/l.	1 day and clopidogrel came first	1 hour

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Tantry 2010 21079055 Multicountry - North America and Europe Genetic substudy of ONSET/OFFSET and RESPOND	NR	light transmittance aggregometry	Chronolog Optical Aggregometer (Model 490-4D)	NR	Blood was collected from the antecubital vein. After discarding the first 2 to 3 mL of free-flowing blood, the tubes were filled to capacity and gently inverted 3 to 5 times to ensure complete mixing of the anticoagulant.	3.2% trisodium citrate	5 and 20 umol/L ADP	platelet function measurements performed at predose, 8 hours after the loading dose on day 1, and 8 hours after the last maintenance dose	NR
	NR	VASP	VASP-FCM kit	Biocytex, Inc; Marseille, France		3.2% trisodium citrate	NR		NR
	VerifyNow	NR	NR	NR		3.2% sodium citrate	NR		NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Hochholzer, 2010 20510210 Germany EXCELSIOR	Platelet function assay	Light transmission aggregometry	4-channel Bio/Data PAP4 aggregometer	Mölab, Langenfeld, Germany	Blood samples for platelet function testing were drawn before discharge at day 1 after loading with clopidogrel, 2 to 4 h after intake of the first maintenance dose (in the vast majority of patients between 16 and 24 h after loading dose).	Samples were drawn into tubes containing 3.8% sodium- citrate (Sarstedt, Nuembrecht, Germany)	ADP	Blood samples for platelet function testing were drawn before discharge at day 1 after loading with clopidogrel, 2 to 4 h after intake of the first maintenance dose (in the vast majority of patients between 16 and 24 h after loading dose).	Within 1 hour

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Jeong 2010 20650435 Korea ACCEL- DOUBLE	Platelet function assays	Light transmittance aggregometry	an AggRAM aggregometer	Helena Laboratories Corporation, Beaumont, Texas	Within 2 to 4 h after the last intake of regimen, blood samples were collected using the double syringe technique, and the first 2 to 4 ml of blood was discarded to avoid the bias of spontaneous platelet activation. Platelet reactivity was simultaneously measured <1 h after venipuncture by light transmittance aggregometry and the VerifyNow P2Y12 assay	Containing 0.5 ml of 3.2% sodium citrate	ADP	With 2-4 hours	<60 mins
	Platelet function assays	VerifyNow P2Y12 assay	Ultegra rapid platelet function assay,	Accumetrics Inc., San Diego, California	Blood was drawn into a Greiner Bio-One Vacuette tube	3.2% citrate	ADP	With 2-4 hours	NR
Barker, 2010 20965456 USA NR	Platelet function measurement	VerifyNow P2Y12 assay	VerifyNow P2Y12 assay	Accumetrics, Inc., San Diego, California	NR	NR	NR	NR	NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Bonello, 2010 20708365 France NR	VASP index	Platelet VASP kits (Diagnostica Stago, Asnières, France)	Analyses were performed on an EPICS XL- MCL flow cytometer	Beckman Coultronics, Margency, France	Blood samples for VASP index analysis were drawn by atraumatic venipuncture of the antecubital vein between 6 and 12 h after each clopidogrel LD.	blood was collected into a Vacutainer containing 3.8% trisodium citrate and filled to capacity.	ADP 10 μ mol/l	Blood samples for VASP index analysis were drawn by atraumatic venipuncture of the antecubital vein between 6 and 12 h after each clopidogrel LD.	VASP index phosphorylation analysis was performed within 24 h of blood collection.
Gurbel 2011 21392617 USA NR	Platelet aggregation	Aggregation was assessed using a Chronolog Lumi- Aggregometer	Chronolog Lumi- Aggregometer (Model 490-4D) with the AGGRO/LINK control software	Chronolog, Havertown, PA	Blood samples were collected by venipuncture in vacutainer tubes (Becton- Dickinson, Franklin Lakes, NJ)	3.8% trisodium citrate.	ADP 5 and 20 μ M	NR	Within 2 hours

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Hwang 2011 21075428 South Korea NR	LTA	light transmittance aggregometry (LTA)	AggRAM aggregometer	Helena Laboratories Corp., Beaumont, Texas, USA	blood samples were drawn into Vacutainer tubes (Becton-Dickinson, San Jose, CA, USA)	containing 0.5 mL of sodium citrate 3.2%	ADP 5 and 20 um	All patients received a 300-mg loading dose (LD) of clopidogrel and aspirin at least 12 hours before PCI, followed by 200 mg/day maintenance dose of aspirin and 75 mg/day of clopidogrel thereafter. Immediately after insertion of the arterial sheath in the catheterization laboratory, blood samples were obtained.	Within 60 minutes
		VerifyNow P2Y12 assay	Ultegra rapid platelet function assay; Accumetrics Inc.	San Diego, CA, USA	whole-blood was drawn into vacutainer tube (Greiner Bio-One, Frickenhausen, Germany).	a Greiner Bio- One 3.2% citrate vacutainer tube	ADP 20uM		NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Kang, 2010 20724801 Korea NR	Light transmittance aggregometry (LTA)	Light transmittance aggregometry (LTA)	AggRAM aggregometer	(Helena Laboratories Corp., Beaumont, Texas, USA)	Blood samples were drawn into Vacutainer tubes. Blood samples were obtained Immediately after insertion of the arterial sheath in the catheterization lab.	with 0.5ml sodium citrate 3.2%	5 or 20 uM ADP	A 300-mg LD of clopidogrel and aspirin was administrated 12 to 24 hours before scheduled PCI, followed by 200 mg maintenance dose of aspirin and 75 mg/day clopidogrel thereafter. Blood samples were obtained Immediately after insertion of the arterial sheath in the catheterization lab.	Within 2 hours
	VerifyNow P2Y12 assay	NR	VerifyNow P2Y12 assay (Ultegrarapid platelet function assay, Accumetrics Inc., San Diego, CA, USA)	NR	NR	NR	20uM ADP	NR	NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Liu 2010 21163112 China NR	Light transmittance aggregometry	Chrono-Log Lume- Aggregometer (model 700) and the Aggro/Link software package	Chrono-Log Lume- Aggregometer (model 700)	Chrono-Log Corporation, Havertown, Pennsylvania, USA	Blood samples were collected in evacuated container tubes which were filled to capacity and then inverted 3 to 5 times for gentle mixing.	3.8% sodium citrate	5 umol/L ADP	Blood sample were collected before clopidogrel administration, and at least 24 hours after the first 300 mg clopidogrel dose to make sure maximum platelet inhibition has been achieved.	NR
Maeda, 2010 21178986 Japan NR	Residual platelet aggregation	a light-transmittance aggregometer	Multichannel platelet- aggregation analyzer model PAT-2M	Mebanix, Tokyo, Japan	Venous blood samples were collected from each participant between 12:00 and 15:00	3.13% sodium citrate	5 or 20 umol/l ADP	NR	NR
Yamamoto 2011 21168310 Japan NR	Platelet aggregation	Light transmission aggregometer	MCM HEMA TRACER 313; PAM12C	LMS inc., Japan	platelet aggregation test was done in 69 patients at <7 days and 54 patients at >7 days.	0.38% sodium citrate	20 uMol/LADP	Test was performed at least 24 h after clopidogrel loading.	NR
Park 2011 21345843 Korea CILON-T	VerifyNow assay	The VerifyNow assay	The VerifyNow assay	Accumetrics, Inc., San Diego, California, USA	NR	NR	ADP	NR	NR

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Sibbing, 2010 20492469 Germany NR	Multiple electrode platelet aggregometry (MEA)	Multiplate analyzer	NR	(Dynabyte)	For all patients, peripheral venous blood samples were drawn directly at hospital admission, after the daily dose of 75 mg of clopidogrel had been taken and before any in-hospital drug administration, with a loose tourniquet through a short venous catheter inserted into a forearm vein.	EDTA	ADP	peripheral venous blood samples were drawn directly at hospital admission, after the daily dose of 75 mg of clopidogrel had been taken and before any in- hospital drug administration.	NR
Bouman 2011 21628721 Netherlands Genetic substudy of the Popular study	NR	LTA	IMPACT-R	Matis Medical Inc, Beersel, Belgium	Whole blood samples were drawn from the femoral or radial artery sheath	3.2% citrate	5 and 20 umol/l ADP (n = 1005 and n=1006, respectively)	NR Clopidogrel given before and after stenting so most likely dosing came first.	2 hours after blood collection.
	NR	NR	PlateletWorks assay	Helena Laboratories, Beaumont, Texas		K3-EDTA or diphenylalanyl- L-prolyl-L- arginine chloromethyl ketone (PPACK [50 μmol/L])	N=511		
	NR	NR	VerifyNow P2Y12 assay	Accumetrics, San Diego, CA		Greiner tubes	N=1010		

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Campo 2011 21679849 Italy NR	VerifyNow P2Y12	NR	NR	Accumetrics, San Diego CA	NR	NR	NR	Blood samples were drawn at baseline (just before PCI and administration of interventional therapy) and at 1 and 6 months after PCI. Clopidogrel dosing came first (at least 12 hours before PCI)	NR
Fernando 2011 21696537 Australia NR	NR	Light transmittance aggregometry (LTA)	AggRAM light transmittance aggregometer	Helena I aboratories, Melbourne, A ustralia	Platelet-rich and platelet- poor plasma were obtained by centrifuging whole blood	3.8% citrate	20 uM ADP over 10 min	NR, except noted to be at baseline, after treatment (first or second period), and after washout	Within 30 min
	VerifyNow	Light transmittance	VerifyNow P2Y12 cartridge	Accumetrics , San Diego, CA	Whole blood	3.8% citrate	ADP	NR, except noted to be at baseline, after treatment (first or second period), and after washout	Between 10 and 30 m in after

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Geisler 2008 18781853 Germany NR	NR	Turbidometry	Chronolog Lumi aggregometer with Aggro-link software	NR	Blood samples were centrifuged at 1000 rpm for 10 min to obtain platelet- rich plasma and for another 10 minutes to recover platelet-poor plasma	3.8% citrate	20 umol/L ADP	Platelet aggregation measured after first 600-mg dose of clopidogrel (at least 6 hours after)	RPA was measured at 5 min after ADP added (median, 21 hours; IQR, 5.1-285.0)
Gladding 2008 19463375 New Zealand PRINC (Plavix Response in Coronary Intervention) Trial	VerifyNow	Agglutination plus light transmittance	point-of-care rapid platelet function analyzer (RPFA) and its P2Y12 cartridge	Accumetrics Ltd., San Diego, California	Arterial blood was sampled through a 6-F femoral sheath and transferred immediately; collection tubes were inverted 4 times to mix the anticoagulant and left at ambient temperature (24°C)	3.2% citrate	ADP, 20 umol/l	Platelet function was tested at baseline, 2, 4, and 7 h from the first clopidogrel loading dose; and at 7 days.	10 min
Gurbel 2010 19817997 USA NR	NR	LTA	Chronolog Optical Aggregometer (Model 490-4D) with Aggrolink software	Chronolog, Havertown, PA	Blood was collected from the antecubital vein with an 18-gauge needle.	3.2% trisodium citrate	5 and 20 uM ADP, propriet ary anticoag ulant CT 921- 78 (f actor Xa Inhibitor), or 10 uM ADP and 4 mg/ml collagen	At screening (before dosing) and at 12– 6 h after the previous day's clopidogrel dose; then at 4 h, 6 h, 24 h, and 7–10 days after dosing with elinogrel	NR
	NR	VASP	Platelet VASP; Diagnostics Stago	Biocytex, Asnieres, France		NR	NR		

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
	TEG PlateletMapping	Thrombelastography	TEG Hemostasis Analyzer with PlateletMapping assay	Haemoscope Corporation, Niles, IL		Lithium heparin	ADP		
	VerifyNow	Turbidimetric-based optical detection	NR	NR		.2% sodi um citr ate	NR		

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Kim 2011 21511217 South Korea CCELAMI2C19	NR	Light transmittance aggregometry	AggRAM Aggregometer	Helena Laboratories Corp., Beaumont, Texas	Blood samples were collected using the double- syringe technique, in which the first 2 to 4 ml of blood were discarded to avoid spontaneous platelet activation.	0.5 ml of 3.2% sodium citrate	5 and 20 umol/l ADP	Platelet reactivity measured pre- discharge (either at least 3 days after PCI in patients not treated with tirofiban or at least 5 days after procedure in patients treated with tirofiban) and at 30 day followup (At 30-day follow- up, peripheral venous blood was drawn from an antecubital vein within 2 to 4 h after the last intake of clopidogrel dose.)	within 2 h
	VerifyNow P2Y12 assay	NR	NR	Accumetrics Inc, San Diego, CA	SAME AS ABOVE	3.2% citrate	20 umol/l ADP	SAME AS ABOVE	SAME AS ABOVE

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Lee 2011 21786436 South Korea NR	VerifyNow	LTA	P2Y12 assay	Accumetrics, San Diego, CA	Venous whole blood	NR	NR		within 10 to 15 min
Malek 2008 18577829 Poland NR	NR	Closure time (CADP- CT)	PFA-100	Dade Behring, German	blood from the peripheral vein. Results are reported as the closure time (CADP- CT) in seconds. The test stops automatically after 300 s, which is considered a maximal response to the agonist	3.2% buffered citrate	Collagen, ADP	after a median of 6 days of antiplatelet treatment (interquartile range (IQR) 5– 7)	analyzed within 2 h of sampling
Pettersen 2011 21426546 Norway Aspirin and Clopidogrel non- responsiveness clinical Endpoint Trial (ASCET)	NR	VASP	PLT VASP/P2Y12 assay	Biocytex, France	Blood samples drawn between 8 and 10:30 am in a fasting condition	Citrated blood (0.129 mM in dilution 1:10)	NR	1 month after randomization, 24 hours after the last intake of medication	within 48 hours
	VerifyNow	LTA	NR	Accumetrics, San Diego, CA		Vacurette tubes (Grüner Bio- One, Austria, 0.109 mM in dilution 1: 10)	ADP		

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Sibbing 2011 21527445 Germany NR	NR	Multiple electrode aggregometry (MEA)	Multiplate analyzer	NR	Blood for genomic DNA extraction and genotyping was taken from the arterial sheath of all patients directly prior to PCI. Whole blood was obtained from the arterial sheath of all patients directly before PCI and prior to the administration of any anticoagulant/antithrombotic treatment in the cath lab.	lepirudin (25 mg/mL, Refludan, Dynabyte, Munich, Germany)	ADP (6.4 uM)	NR	NR
Cuisset, 2011 21803320 France NR	VASP	VASP	Platelet VASP	Diagnostica Stago (Biocytex), Asnières, France	Blood samples for testing clopidogrel response were drawn ≥ 12 hours after the loading dose of clopidogrel and at 1-month follow-up.	ADP or PGE1	NR	≥ 12 hours after clopidogrel loading dose. clopidogrel first	immediately
Gajos, 2012 22623230 Poland OMEGA-PCI	LTA- ADP	light transmittance aggregometry	chrono-log Model 700,	Chrono-log corp, Haverton, USA	blood was collected before initiation of clopidogrel, 12- 14 h after clopidogrel, 3-5 days after PCI, 30 days	5 and 20 uM ADP	citrate	0.5 or 3-5, or 30 days blood sample first	NR
Tello-Montoliu 2012 22116003 Spain study one of the paper	LTA-ADP	light transmittance aggregometry	Aggrecoorder II,	Menarini Diagnostics, Florence, Italy	blood samples were collected when patients were taking daily dural antiplatelet therapy	3.2% trisodium- citrate	ADP, TRAP	NR clopidogrel first	within 3 h

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Tello-Montoliu 2012 22116003 Spain study two of the paper	VASP	vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12	Platelet VASP, Diagnostica Stago,	Biocytex Inc, Marseille, France	blood samples were collected when patients were taking daily dural antiplatelet therapy	3.2% trisodium- citrate	ADP, PGE1	NR clopidogrel first	NR
Price, 2012 22624833 US GIFT (Genotype Information and Functional Testing) Study— a prespecified genetic substudy of GRAVITAS (Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety) trial	VerifyNow P2Y12	NR	NR	Accumetrics, San Diego CA	NR	NR	NR	NR but clopidogrel came first— sampling done 12-24 hr after PCI	NR
Gremmel, 2012 22154242 Austria NR	LTA	LTA	APACT 4S Plus aggregomete)	LABiTec, Ahrensburg, Germany	Blood sampled from antecubital vein 24 hr after PCI, after overnight fast and no smoking for 12 hr	EDTA and 3.8% sodium citrate	ADP (10 µM)	24 hr between PCI and sampling	1-3 hr
	VASP phosphorylantion	NR	NR	NR		EDTA and 3.8% sodium citrate	ADP		1-3 hr
	VerifyNow P2Y12	NR	NR	Accumetrics, San Diego CA		3.8% sodium citrate	ADP		1-3 hr

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
	MEA	Impedence aggregometry	NR	Dynabyte, Munich, Germany		18 IU/ml lithium heparin	ADP (6.4 μ M)		1-2 hr
	Impact-R	NR	Impact-R ADP response test	DiaMed, Cressier, Switzerland		18 IU/ml lithium heparin	NR		1-3 hr
Harmsze, 2012 22228204 Netherlands POPular substudy	LTA	NR	NR	NR	Whole blood	3.2% citrate	ADP 20 μ mol/L	NR but dose came first	Within 2 hr
	VerifyNow P2Y12	NR	NR	Accumetrics, San Diego CA	Whole blood	Heparin	NR	NR but dose came first	Within 2 hr
Kreutz, 2012 22427735 US NR	LTA	NR	Optical Lumi- Aggregometer (Model 700 with AGGRO/LINK 8 software)	Chrono-Log Corporation, Havertown, PA)	Whole blood	3.2% sodium citrate	ADP 5, 10, and 20 μ mol/L	4 and 16-24 hr after previous dose	Within 2 hr
	VerifyNow P2Y12	NR	NR	Accumetrics, San Diego CA	Whole blood	NR	NR	4 and 16-24 hr after previous dose	Within 2 hr
Dai, 2012 22704413 China NR	LTA	Turbidoaggregometry	LBY-NJ4- channel platelet aggregation analyzer	Beijing Precil Instrument Co. Ltd.	Blood was collected after 10 days of clopidogrel	3.8% sodium citrate	ADP 5 μ mol/L	10 days (dose came first)	NR
Ono, 2011 21862109 Japan NR	LTA	NR	MCM HEMA TRACER 313 M,	MC Medical, Inc., Tokyo, Japan	blood was collected 24 h after clopidogrel loading dose	3.2% sodium citrate	ADP	24 h clopidogrel first	1 h

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Ono, 2011 21862109 Japan NR	Verifynow	NR	Ultegra rapid platelet function assay;	Accumetrics Inc., San Diego, CA	blood was collected 24 h after clopidogrel loading dose	3.2% sodium citrate	ADP	24 h clopidogrel first	1 h
Fontana 2011 21692977 Switzerland ADRIE	VASP	vasodilator-stimulated phosphoprotein	Platelet VASP/P2Y12	Biocytex, Marseille, France	blood	NR	NR	NR	NR
Fontana 2011 21692977 Switzerland ADRIE	LTA ADP	light transmission aggregometer	TA-8V; SD Medical,	Heillecourt, France	blood	NR	ADP	NR	3 h
Aleil, 2009 19624462 France VASP-02 [genetic reanalysis thereof]	VASP assay (platelet reactivity index)	VASP phosphorylation after ADP stimulation measured by flow cytometry	FACS Calibur spectrometer	Becton Dickinson (location NR)	Whole blood samples were obtained and shipped by truck to central lab, at room temperature	Sodium citrate, 0.129 mol/liter	PGE1 alone or with ADP	Before dosing, 10-12 hr after loading dose, and 2-4 weeks after start of maintenance dose	Within 36 hr
Kreutz, 2012 22385219 USA NR	VerifyNow P2Y12 assay	NR	NR	NR	Blood obtained on day 15	3.2% sodium citrate	ADP	1 day (dose came first; blood sampling done 1 day after the last dose)	10-30 min after sampling for VerifyNow
	LTA	LTA	Optical Lumi- Aggregometer, model 700 with AggroLink 8 software	Chrono-Log Corp., Havertown PA			20 uM ADP, with or without 22 or 88 nM PGE1		within 2 hr after for LTA

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Marcucci, 2012 22390861 Italy NR	LTA	LTA	APACT 4 aggregometer	Helena Laboratories, Milan, Italy	Venous blood samples	0.109 M sodium citrate	10 uM ADP	1 day (dose came first)	Within 24 hr after loading dose or 6 days after (in patients receiving IIb/IIIa inhibitor; thus, during maintenance dosing)
Mega, 2011 22088980 USA ELEVATE-TIMI 56	VASP	NR	NR	NR	"Ambient" blood samples sent to central lab	NR	NR	NR	NR
	VerifyNow	NR	NR	Accumetrics (NR)	NR	NR	ADP	NR	NR
Park, 2012 22507978 Korea ACCEL-STATIN	LTA	LTA	AggRAM aggregometer	Helena Laboratories Corp., Beaumont TX	Blood	0.5 ml sodium citrate 3.2%	5 or 20 uM ADP	Sampling done at baseline and 2-6 hr after last dose of 15-day study period	NR
	VerifyNow	Turbidoaggregometry	NR	Accumetrics, San Diego, CA	Blood	3.2% citrate	20 uM ADP		
Yamane, 2012 22472213 Japan NR	LTA	12-channel light transmission aggregometer	MCM HEMA TRACER 313;	MC Medical, Tokyo, Japan	blood	0.313% sodium citrate	20umol/L ADP	blood sample done at >2 weeks follow up. Clopidogrel first	within 2 hours after blood sampling

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
	Verifynow	the VerifyNow P2Y12 assay	Accumetrics,	San Diego, CA, USA	blood	0.313% sodium citrate	ADP	blood sample done at >2 weeks follow up. Clopidogrel first	NR
Hsu, 2011 21144850 Taiwan NR	ADP-induced platelet aggregation	ADP-induced platelet aggregation	ADP; Bio/Data Corp	Horsham, PA	blood	NR	ADP	blood sample was collected on day 1 and 28. blood first	NR
Kim, 2012 22007612 Korea ACCEL-TRIPLE	LTA	LTA-ADP	AggRAM aggregometer	Helena Laboratories Corporation, Beaumont, Texas	blood	3.2% sodium citrate	5uM ADP	blood samples were obtained 2-4 h after the last intake of triple antiplatelet therapy clopidogrel first	2h
	VerifyNow P2Y12	VerifyNow P2Y12	NR	NR	blood	3.2% citrate Vacurette	20uM ADP	blood samples were obtained 2-4 h after the last intake of triple antiplatelet therapy clopidogrel first	NR
Siller-Matula, 2012 22260716 Austria PEGASUS-PCI	multiple electrode aggregometry (MEA)	Impedence aggregometry	Multiplate Analyzer	Verum Diagnostica GmbH, Munich, Germany	Blood collected after PCI	NR	ADP (6.4µM) and PGE1 (9.4 nM)	NR [clopidogrel first]	Immediately after sampling

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Bonello, 2012 22285300 France NR	VASP	vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12	Platelet VASP kits	Diagnostica Stago, Asnières, France	6-12 hrs after clopidogrel LD & before PCI	3.8% trisodium- citrate	NR	0.25-0.5 days (6-12 hrs) clopidogrel first	<1 (<24 hours)
Collet, 2011 21511218 France CLOVIS-2	LTA	LTA	Model 490-4D	Chrono-Log Corporation, Kordia, the Netherlands	Whole blood	3.2% sodium citrate	20 µmol/L ADP	6 hr after LD of clopidogrel	NR
	VerifyNow	Turbidoaggregometry	VerifyNow P2Y12 assay	Accumetrics Inc., San Diego, California, USA	Whole blood	3.2% sodium citrate	ADP	6 hr after LD of clopidogrel	NR
Hochholzer, 2011 21884870 NR EXCELSIOR	LTA	LTA	Bio/Data PAP4 aggregometer	Bio/Data, Mölab, Germany	Whole blood	3.2% sodium citrate	5 and 20 µmol/L ADP	24 hr after procedure [clopidogrel first]	NR
Kassimis, 2012 21831410 Greece NR	VerifyNow	Turbidoaggregometry	VerifyNow P2Y12 assay	Accumetrics Inc., San Diego, California, USA	Whole blood	3.2% sodium citrate	ADP	24 hr after procedure [clopidogrel first]	NR
Namazi, 2012 22265638 Iran NR	LTA	LTA	PACKS-4	Helena laboratories, Helena BioSciences Europe, Sunderland	Samples obtained before procedure, 2 h after taking LD 600 mg clopidogrel, 24 h and later 30 days after stenting	3.8% sodium citrate	ADP 5 or 20 µmol	30 days [clopidogrel first]	2-3 hrs

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Rideg, 2011 21806387 Hungary DOSER	LTA	LTA	CARAT TX-4 4- channel aggregometer	Carat Diagnostics, Budapest, Hungary	Blood sample before procedure	3.8% sodium citrate	ADP 5 µmol	12-24 hrs [clopidogrel first]	2 hrs
	VASP	vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12	Platelet VASP, Diagnostica Stago,	Biocytex Inc, Marseille, France	Blood sample before procedure	3.8% sodium citrate	ADP, PGE1	12-24 hrs [clopidogrel first]	2 hrs
Jeong, 2011 22045970 Korea NR	LTA	LTA	AggRAM aggregometer.	Helena Laboratories Corp, Beaumont, TX	Whole blood	3.2% sodium citrate	ADP	2-6 hr after clopidogrel	NR
	VerifyNow	Turbidoaggregometry	VerifyNow P2Y12 assay	Accumetrics Inc., San Diego, California, USA	Whole blood	3.2% sodium citrate	ADP	2-6 hr after clopidogrel	NR
Chan, 2012 22462746 Singapore NR	VASP	vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12	Platelet VASP, Diagnostica Stago,	Biocytex Inc, Marseille, France	Blood sample before procedure	sodium-citrate	ADP 10 µmol, PGE1	5-7 days [clopidogrel first]	48 hrs
Park, 2012 22735685 Korea CROSS-VERIFY	VerifyNow	Turbidoaggregometry	VerifyNow P2Y12 assay	Accumetrics Inc., San Diego, California, USA	Whole blood	sodium citrate	ADP	16-24 hr after clopidogrel	NR
Kreutz, 2012 22459907 USA NR	LTA	LTA	Optical Lumi- Aggregometer (Model 700 with AGGRO/LINK 8 software)	Chrono-Log Corporation, Havertown, PA	Whole blood	3.2% sodium citrate	ADP 20 µmol/L and TRAP at 15 and 25 µmol conc	16-24 hr after clopidogrel	Within 2 hr

Author Year PMID Country Study name	Test name	Device category (e.g., light transmission aggregometry, turbidoaggregometry)	Device name and model information	Manufacturer, location	Sample collection and procurement	Anticoagulant used	Agonist used*	Interval between clopidogrel dose and blood sampling [in days] and which came first	Interval between sampling and testing [in days]
Jeong, 2012 22837373 Korea ACCEL-DM	LTA- ADP	LTA	AggRAM aggregometer	Helena Laboratories Corp., Beaumont, Texas	blood	NR	5uM or 20uM ADP	blood collected immediately before elective PCI or at least 5 days after emergency PCI, and 2-6 hours after last dose at the 30- day follow-up	NR
Hulot, 2011 21972404 France CLOVIS-2	LTA-ADP	LTA	Model 490–4D	Chrono-Log Corporation, Kordia, The Netherlands	blood	NR	20 µM ADP	6 hrs	NR
	VerifyNow	Turbidoaggregometry	VerifyNow P2Y12 assay	NR	Whole blood	NR	ADP	6 hrs	NR
Roberts, 2012 22464343 Canada RAPID GENE	VerifyNow	Turbidoaggregometry	VerifyNow P2Y12 assay	Accumetrics, San Diego, CA, USA	Whole blood	NR	ADP	NR	NR

Appendix Table D7. Clinical outcome information—mortality

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Collet, 2009 19108880 France AFIJI	Clopidogrel (75 mg maintenance dose for at least 1 mo)	CYP2C19 *2	CV death	Death with a demonstrable cardiovascular cause or any death not clearly attributable to non- cardiovascular cause.	Mean FU = 2.8 yr	Carriers (*2/*2 or *2/*1) N = 73	2 1.45 events per 100 person- years	HR = 5.74 Adjusted HR = NON EVALUABLE (small number of events)	0.52, 63.48 NA	0.10 NA	Unadjusted NA	NO	None.
						Non-carriers (*1/*1) N = 186	1 0.26 events per 100 person- years						
Giusti, 2009 19268736 Italy RECLOSE	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	CYP2C19*2	Cardiac mortality	NR	Maximum FU of 6 mo	*2/*2 or *2/*1 N = 247	10 (4%)	NR	NR	0.037 (chi square test)	NO	NO	Component of composite secondary outcome
						*1/*1 N = 525	8 (1.5%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Mega, 2009 19106084 Multinational Genetics substudy of TRITON- TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction]	Clopidogrel 300 mg loading dose, 75 mg maintenance	CYP2C19	Death from cardiovascular causes	NR; all outcomes were adjudicated by a committee unaware of group assignments	Up to 15 mo (maximum duration of treatment on trial)	IM or PM (1/*2A, *1A/*3, *1A/*4, *1A/*8, *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8) N = 395	NR Rate = 2.0% (Kaplan- Meier)	HR = 4.79	1.40, 16.37	NR	ACS subtype (STE or NSTE was used as a stratification factor)	NO	Secondary outcome
						EM (*1A/*1A) N = 1064	NR Rate = 0.4% (Kaplan- Meier rate)						
Sibbing, 2009 19193675 Germany NR	Clopidogrel 600 mg loading dose before stent placement	CYP2C19 *2	Death	NR	30 days	CYP2C19 *2 carriers (*2/*2 and *2/*1) N = 680	5 (<1%)	HR = 0.83	0.30, 2.26	0.71 [Cox proportional hazards regression; carriers vs. non-carriers]	NO	NO	None
						CYP2C19 non-carriers (*1/*1) N = 1805	16 (1%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	Clopidogrel 600 mg loading dose; clopidogrel 75 mg (1/d) and aspirin 100 mg (2/d) maintenance.	CYP2C19 *17	Mortality	Death within 30 days	30 d	*17/*17 N = 76	1 (1.3%)	OR = 0.87	0.23, 3.31	(carriers vs. non-carriers) [logistic regression] P = 0.84 (across 3 groups) [chi- square test for trend]	NO	NO	Secondary efficacy endpoint
						*17/*1 N = 546	2 (0.4%)						
						*1/*1 N = 902	5 (0.6%)						
Bonello 2010 20708365 France NR	All patients received oral LDs of 250 mg aspirin and 600 mg clopidogrel at least 6 h before the first VASP index measurement	CYP2C19	Death	Death	In hospital	Wild-type N = 277	0 (0%)	NR	NR	NS	NR	NR	None
						Heterozygotes 2C19*2 N = 123	0 (0%)						
						Homozygotes 2C19*2 N = 11	0 (0%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Malek 2010 20924183 Poland NR	Aspirin + clopidogrel	CYP2C19*2	All cause mortality	All cause mortality	4 years	*2/*2 or *2/*1 N = 56	10 (17.9%); count calculated based on proportion	HR = 1.9	0.9, 4.0	0.09 [noncarrier Vs. carrier of *2; Kaplan- Meier]	NR	NR	curve in figure 1b
						*2 noncarriers N = 205	20 (9.8%); count calculated based on proportion						
Yamamoto 2011 21168310 Japan NR	clopidogrel	CYP2C19*2 or *3	Cardiovascular death	Cardiovascular death	74 days	Carriers N = 61	1 ()	NR	NR	NR	NR	NR	
		CYP2C19*2/*2	Cardiovascular death	Cardiovascular death	NR	CYP2C19*2/*2	NR	NR	NR	NR	NR	NR	
Tiroch, 2010 20826260 Germany NR	aspirin (100mg twice daily) and clopidogrel (75mg once Daily)	CYP2C19*2 GG	Death	Death	1 year	CYP2C19*2 GG N = 680	54 (7.9)	NR	NR	0.08, CYP2C19*2 GG vs *2 A allele	NR	NR	
		CYP2C19*2 A allele	Death	Death	1 year	CYP2C19*2 A allele N = 248	11 (4.4)	NR	NR		NR	NR	
		CYP2C19*17 CC	Death	Death	1 year	CYP2C19*17 CC N = 565	34 (6)	NR	NR	0.203 CYP2C19*17 CC vs T allele	NR	NR	
		CYP2C19*17 T allele	Death	Death	1 year	CYP2C19*17 T allele N = 363	30 (8.3)	NR	NR		NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Sorich, 2010 20492467 707 sites in 30 countries Substudy of TRITON- TIMI 38	300-mg loading dose and 75-mg daily maintenance dose	CYP2C19	CV death	CV death	15 months	RM(with one or two reduced function alleles) vs EM (no reduced function allele) N = 802	4.2%	OR=4.79	1.4-16.37	NR	NR	No	
			CV death,	CV death,	15 months	EM	0.9%		0.3-1.7	NR	NR	No	
			CV death,	CV death,	15 months	RM	NR		2.2-6.1	NR	NR	No	
Sawada, 2010 21099121 Japan NR	loading dose of clopidogrel (300 mg) and maintenance dose of clopidogrel (75 mg/day) and aspirin (100 mg/day)	CYP2C19	Death	Death	Mean 243.8 days	Non-carrier	58	0 (0%)	NR	0.87, Non- carrier vs *2 carrier	No	No	
			Death	Death	Mean 243.8 days	*2 carrier	42	1 (2.4%)	NR	NO	NO	NO	
Campo 2011 21679849 Italy NR	Clopidogrel + aspirin	TaqMan	Death	All cause death	1 mo to 1 yr after PCI	*2 noncarriers	4 (1.8%)	NR	NR	NR	NR	NO	
						*2 carriers	2 (2.5%)	NR	NR				
						*17 noncarriers	5 (2.5%)	NR	NR				
						*17 carriers	1 (1.0%)	NR	NR				

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Luo, 2011 22118006 China NR	LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d	CYP2C19 *1/*1	cardiac death	cardiac death	6 months	CYP2C19 *1/*1	6/936	HR 0.95	0.45-2.36	>0.05 comparing with the next row chi-square test	NR	NR	
		CYP2C19 *1/*2 or *2/*2				CYP2C19 *1/*2 or *2/*2	5/802						
Delaney, 2011 22190063 USA NR	clopidogrel	CYP2C19*2	death	death	2 years	CYP2C19*2 SNP rs4244285	NR	HR=1.76	0.57-5.37	0.323 comparing with non carrier of *2	No	NR	NR
	clopidogrel	CYP2C19*17	death	death	2 years	CYP2C19*17 SNP rs4244285	NR	HR=1.62	0.69-3.81	0.267 comparing with non carrier of *17	No	NR	NR
Chen, 2012 22071359 China NR	Clopidogrel and aspirin	TaqMan	CV death	Within the 1-yr followup period	NR	*2/*2 (n=57)	6	Vs. *1/*1: Unadjusted HR 5.733 Adjusted HR 6.321	For unadjusted, 1.502- 21.884 For adjusted, 2.081- 19.205	For unadjusted, 0.011 (K-M) For adjusted, 0.001 (logistic regression)	For adjusted: adjusted for age, sex, DM, smoking, drug use, stenting, and ACS vs. stable angina	NR	NONE

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*1/*2 (n=291)	9	Vs. *1/*1: Unadjusted HR 1.258 Adjusted HR 1.303	For unadjusted, 0.386- 4.102 For adjusted, 0.478- 3.548	For unadjusted, 0.704 (K-M) For adjusted, 0.605 (logistic regression)	For adjusted: adjusted for age, sex, DM, smoking, drug use, stenting, and ACS vs. stable angina		
						*1/*1 (n=306)	7	NA	NA	NA	NA		
			Death from any cause	Within the 1-yr followup period	NR	*2/*2 (n=57)	6	Vs. *1/*1: Unadjusted HR 4.086 Adjusted HR 4.794	For unadjusted, 1.115- 14.461 For adjusted, 1.683- 13.659	For unadjusted, 0.029 (K-M) For adjusted, 0.003 (logistic regression)	For adjusted: adjusted for age, sex, DM, smoking, drug use, stenting, and ACS vs. stable angina	NR	NONE
						*1/*2 (n=291)	10	Vs. *1/*1: Unadjusted HR 1.053 Adjusted HR 1.089	For unadjusted, 0.368- 3.016 For adjusted, 0.437- 2.713	For unadjusted, 0.923 (K-M) For adjusted, 0.855 (logistic regression)	For adjusted: adjusted for age, sex, DM, smoking, drug use, stenting, and ACS vs. stable angina		
						*1/*1 (n=306)	9	NA	NA	NA	NA		

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Nishio, 2012 22785462 Japan NR	Clopidogrel and aspirin	TaqMan	Death	NR	Any time during study	Extensive metabolizer (n=60)	1	NR	NR	Across this and next two rows, 0.24 (chi-square test)	NR	NR	NONE
						Intermediate metabolizer (n=77)	2	NR	NR		NR	NR	NONE
						Poor metabolizer (n=23)	2	NR	NR		NR	NR	NONE
			Cardiac death	NR		Extensive metabolizer (n=60)	0	NR	NR	Across this and next two rows, 0.34 (chi-square test)	NR	NR	NONE
						Intermediate metabolizer (n=77)	2 (the same 2 as classified just above in this group)	NR	NR		NR	NR	NONE
						Poor metabolizer (n=23)	0	NR	NR		NR	NR	NONE
Goodman, 2012 22261200 Multi-country PLATO	Clopidogrel 300-mg loading dose, 75-mg daily maintenance dose	CYP2C19 *2	All cause mortality	death	12 months	CYP2C19 loss-of- function carriers (*2 through *8) on a PPI n=434	11 (2.5%)	HR= 1.67	1.03–2.71	NR	no	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						non carriers of CYP2C19 loss-of- function allele or not taking a PPI n=2418	24 (1%)						

Appendix Table D8. Clinical outcome information—myocardial infarction

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Collet 2009 19108880 France AFIJI	Clopidogrel (75 mg maintenance dose for at least 1 mo)	CYP2C19 *2	MI	Recent ischemic symptom with EKG abnormalities in the ST segmen (depression or elevation of at least 0.1 mV)t and a positive troponin measurement as defined locally.	Mean FU = 2.8 yr	Carriers (*2/*2 or *2/*1) N = 73	N = 10 7.27 events per 100 person-years	HR = 4.57 Adjusted HR = 5.57	1.64, 12.53 1.94, 16.01	0.001 0.001	Unadjusted Adjusted [baseline BMI, smoking status, diabetes status, stent implantation, initial STE MI, use of PPI]	NO	None.
						Non-carriers (*1/*1) N = 186	N = 6 1.58 events per 100 person-years						
Mega 2009 19106084 Multinational TRITON-TIMI 38	Clopidogrel 300 mg loading dose, 75 mg maintenance	CYP2C19	Non-fatal MI	NR; all outcomes were adjudicated by a committee unaware of group assignments	Up to 15 mo (maximum duration of treatment on trial)	IM or PM (1/*2A, *1A/*3, *1A/*4, *1A/*8, *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8) N = 395	NR Rate = 10.1% (Kaplan-Meier)	HR = 1.38	0.94, 2.02	NR	ACS subtype (STE or NSTEMI was used as a stratification factor)	NO	Secondary outcome

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						EM (*1A/*1A) N = 1064	NR Rate = 7.5% (Kaplan- Meier rate)						
Sibbing 2009 19193675 Germany NR	Clopidogrel 600 mg loading dose before stent placement	CYP2C19 *2	MI	Thrombolysis in Myocardial Infarction Criteria (TIMI), based on new abnormal Q- wave appearance in the EKG or increase in CK-MB value to three or more times the upper limit of normal; appears to have included NSTE-ACS	30 days	CYP2C19 *2 carriers (*2/*2 and *2/*1) N = 680	48 (7%)	HR = 1.15	0.82, 1.61	P = 0.42 [Cox proportional hazards regression; carriers vs. non-carriers]	NO	NO	None
						CYP2C19 non-carriers (*1/*1) N = 1805	111 (6%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
			STEMI	NR	30 days	CYP2C19 *2 carriers (*2/*2 and *2/*1) N = 680	10 (1%)	HR = 2.96	1.20, 7.28	0.02 [Cox proportional hazards regression; carriers vs. non-carriers]	NO	NO	None
						CYP2C19 non-carriers (*1/*1) N = 1805	9 (<1%)						
			NSTE-ACS	NSTE-ACS	30 days	CYP2C19 *2 carriers (*2/*2 and *2/*1) N = 680	38 (6%)	HR = 0.99	0.68, 1.44	0.96 [Cox proportional hazards regression; carriers vs. non-carriers]	NO	NO	None
						CYP2C19 non-carriers (*1/*1) N = 1805	102 (6%)						
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	Clopidogrel 600 mg loading dose; clopidogrel 75 mg (1/d) and aspirin 100 mg (2/d) maintenance.	CYP2C19 *17	MI	Based on TIMI criteria (new abnormal Q-wave appearance in EKG or increase in CK-MB $\geq 3 \times$ normal)	30 d	*17/*17 N = 76	4 (5.3%)	OR = 1.05	0.59, 1.85	(carriers vs. non-carriers) [logistic regression] P = 0.61 (across 3 groups) [chi-square test for trend]	NO	NO	Secondary efficacy endpoint

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*17/*1 N = 546	17 (3.1%)						
						*1/*1 N = 902	29 (3.2%)						
Bonello, 2010 20708365 France NR	All patients received oral LDs of 250 mg aspirin and 600 mg clopidogrel at least 6 h before the first VASP index measurement	CYP2C19	ACS	Non-ST- segment elevation acs= clinical symptoms of acute myocardial ischemia within 12 h before admission + at least 1 of the following: a new finding of ST- segment depression >0.05 mV, T- wave inversion >0.3 mV in at least 2 leads, or elevated levels of cardiac markers.	In hospital	Wild-type N = 277	0 (0%)	NR	NR	NS	NR	NR	None

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Heterozygotes 2C19*2 N = 123	0 (0%)						
						Homozygotes 2C19*2 N = 11	0 (0%)						
Yamamoto 2011 21168310 Japan NR	clopidogrel	CYP2C19*2 or *3	Nonfatal myocardial infarction	Nonfatal myocardial infarction	NR	carriers	2/62	NR	NR	NR	NR	NR	
		CYP2C19*1/*2	Myocardial infarction	Myocardial infarction	21 days	CYP2C19*1/*2	NR	NR	NR	NR	NR	NR	
		CYP2C19*1/*3	Myocardial infarction	Myocardial infarction	340 days	CYP2C19*1/*3	NR	NR	NR	NR	NR	NR	
Tiroch, 2010 20826260 Germany NR	aspirin (100mg twice daily) and clopidogrel (75mg once Daily)	CYP2C19*2 GG	Repeat MI	Repeat MI	1 year	CYP2C19*2 GG	680	N(%) 17 (2.5)	NR	0.666, CYP2C19*2 GG vs *2 A allele	NR	NR	
		CYP2C19*2 A allele	Repeat MI	Repeat MI	1 year	CYP2C19*2 A allele	248	N(%) 5(2)	NR		NR	NR	
		CYP2C19*2 GG	Repeat MI	Repeat MI	1 year	CYP2C19*2 GG	565	N(%) 15 (2.7)	NR	0.48 CYP2C19*17 CC vs T allele	NR	NR	
		CYP2C19*2 A allele	Repeat MI	Repeat MI	1 year	CYP2C19*2 A allele	363	N(%) 7 (1.9)	NR		NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Sorich, 2010 20492467 707 sites in 30 countries Substudy of TRITON-TIMI 38	300-mg loading dose and 75-mg daily maintenance dose	CYP2C19	Non-fatal MI	Non-fatal MI	15 months	RM vs EM	802	OR=1.38	0.94-2.02	NR	NR	No	
			Non-fatal MI	Non-fatal MI	15 months	EM	NR	8.3%	7.0-9.6	NR	NR	No	
			Non-fatal MI	Non-fatal MI	15 months	RM	NR	11.6%	8.7-14.8	NR	NR	No	
Sawada, 2010 21099121 Japan NR	loading dose of clopidogrel (300 mg) and maintenance dose of clopidogrel (75 mg/day) and aspirin (100 mg/day)	CYP2C19	MI	MI	Mean 243.8 days	Non-carrier	58	2(3.4)	NR	0.76, Non-carrier vs *2 carrier	No	No	
			MI	MI	Mean 243.8 days	*2 carrier	42	1 (2.4)	NR		No	No	
Malek 2008 18577829 Poland NR	Clopidogrel and aspirin	CYP2C19	CV Death or MI	NR	Within 12 months after PCI	Group 1	0	NR	NR	NR	NR	NR	NR
						Group 2	1	NR	NR	NR	NR	NR	NR
						Group 3	0	NR	NR	NR	NR	NR	NR
						Controls	5	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Luo, 2011 22118006 China NR	LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d	CYP2C19 *1/*1	MI	MI	6 months	CYP2C19 *1/*1	67/936	HR 2.88	1.56- 8.74	>0.05 comparing with the next row chi-square test	NR	NR	
		CYP2C19 *1/*2 or *2/*2				CYP2C19 *1/*2 or *2/*2	115/802						
Luo, 2011 22118006 China NR	LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d	CYP2C19 *1/*1	STEMI	STEMI	6 months	CYP2C19 *1/*1	8/936	HR 3.85	1.33- 10.05	>0.05 <omparing with the next row chi-square test	NR	NR	
		CYP2C19 *1/*2 or *2/*2				CYP2C19 *1/*2 or *2/*2	17/802						
Luo, 2011 22118006 China NR	LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d	CYP2C19 *1/*1	NSTEMI	NSTEMI	6 months	CYP2C19 *1/*1	59/936	HR 2.44	1.16- 7.13	<0.05 comparing with the next row chi-square test	NR	NR	
		CYP2C19 *1/*2 or *2/*2				CYP2C19 *1/*2 or *2/*2	98/802						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Delaney, 2012 22190063 USA NR	clopidogrel	CYP2C19*2	MI	MI,	2 years	CYP2C19*2 SNP rs4244285	NR	HR=2.02	0.99-4.12	0.054 comparing with non carrier of *2	No	NR	NR
	clopidogrel	CYP2C19*17	MI	MI,	2 years	CYP2C19*17 SNP rs4244285	NR	HR=0.63	0.31-1.29	0.207 comparing with non carrier of *17	No	NR	NR
Nishio, 2012 22785462 Japan NR	Clopidogrel and aspirin	TaqMan	MI	NR	Any time during study	Extensive metabolizer (n=60)	1	NR	NR	Across this and next two rows, 0.69 (chi-square test)	NR	NR	NONE
						Intermediate metabolizer (n=77)	1	NR	NR	NR	NR	NR	NONE
						Poor metabolizer (n=23)	1	NR	NR	NR	NR	NR	NONE

AFIJI = Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention registry; TRITON-TIMI 38 = Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction.

Appendix Table D9. Clinical outcome information—stent thrombosis													
Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Collet, 2009 19108880 France AFIJI (Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention) registry	Clopidogrel (75 mg maintenance dose for at least 1 mo)	CYP2C19 *2	Definite stent thrombosis	Based on definitions from the Academic Research Consortium. Definite = total occlusion originating or within 5 mm of the stent; or visible thrombus within the stent or within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 h	Mean FU = 2.8 yr	Carriers (*2/*2 or *2/*1) N = 61 (patients with stent implantation)	N = 8 6.79 events per 100 person- years	HR = 6.02 Adjusted HR = 6.04	1.81, 20.04 1.75, 20.80	0.0009 0.004	Unadjusted Adjusted [baseline BMI, smoking status, diabetes status, stent implantation, initial STE MI, use of PPI]	NO	NO
						Non-carriers (*1/*1) N = 162 (patients with stent implantation)	N = 4 1.14 events per 100 person- years						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	CYP2C19*2	Stent thrombosis	Definite or probable stent thrombosis. Definite = ACS + angiographic or pathologic confirmation of thrombosis; probable = unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	Maximum FU of 6 mo	*2/*2 N = 26	2 (7.7%)	NR	NR	0.046 across groups (chi square test)	NO	NO	Primary outcome
						*2/*1 N = 221	11 (5.0%)						
						*1/*1 N = 525	11 (2.1%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	CYP2C19*2 + ADP residual platelet reactivity (see also KQ2b extraction form)	Stent thrombosis	Definite or probable stent thrombosis. Definite = ACS + angiographic or pathologic confirmation of thrombosis; probable = unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	Maximum FU of 6 mo	*2/*2 + RPR N = 40	6 (15%)	NR OR=5.79	NR (1.04, 39.01)	<0.0001 across groups (chi square test) 0.033 (logistic regression)	NO Adjusted (“for traditional cardiovascular risk factors and clinical and procedural risk factors for stent thrombosis”)	NO	Primary outcome
						*1/*1 or low RPR N = 732	18 (2.5%)						
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	CYP2C19*2	Stent thrombosis	Definite or probable stent thrombosis. Definite = ACS + angiographic or pathologic confirmation of thrombosis; probable = unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	Maximum FU of 6 mo	*2/*2 or *2/*1 N = 247	13 (5.3%)	NR OR=2.59 OR=3.43	NR (1.15, 5.88) (1.01, 12.78)	0.025 (chi square test) 0.022 (logistic regression) 0.047 (logistic regression)	NO NO (univariate) YES (ADP-RPR, traditional cardiovascular risk factors, clinical and procedural risk factors for ST)	NO	Primary outcome

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*1/*1 N = 525	11 (2.1%)						
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	CYP2C19*2	Stent thrombosis	Definite or probable stent thrombosis. Definite = ACS + angiographic or pathologic confirmation of thrombosis; probable = unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	Maximum FU of 6 mo	*2/*2 or *2/*1 N = 247	13 (crude proportion 5.3%)	NR	NR	<0.01 (log rank)	NO	NO	Primary outcome
						*1/*1 N = 525	11 (crude proportion 2.1%)						
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	CYP2C19*2	Definite stent thrombosis	ACS + angiographic or pathologic confirmation of thrombosis	Maximum FU of 6 mo	*2/*2 or *2/*1 N = 247	6 (2.4%)	NR	NR	0.100 (chi square test)	NO	NO	Component of composite secondary outcome
						*1/*1 N = 525	5 (1%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	CYP2C19*2	Probable stent thrombosis	Unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	Maximum FU of 6 mo	*2/*2 or *2/*1 N = 247	7 (2.8%)	NR	NR	0.083 (chi square test)	NO	NO	Component of composite secondary outcome
						*1/*1 N = 525	6 (1%)						
Mega 2009 19106084 TRITON-TIMI 38	Clopidogrel 300 mg loading dose, 75 mg maintenance	CYP2C19 (multiple alleles)	Stent thrombosis	Definite or probable, as defined by the Academic Research Consortium	Up to 15 mo (maximum duration of treatment on trial)	IM or PM (1/*2A, *1A/*3, *1A/*4, *1A/*8, *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8) N = 375 (patients who had stent placement)	N = NR Rate = 2.6% (Kaplan-Meier)	HR = 3.09	1.19, 8.00	0.02 [Kaplan-Meier]	ACS subtype (STE or NSTEMI was used as a stratification factor)	NO	Secondary outcome
						EM (*1A/*1A) N = 1014 (patients who had stent placement)	N = NR Rate = 0.8% (Kaplan-Meier rate)						
		CYP2C19*2	Stent thrombosis	Definite or probable, as defined by the Academic Research Consortium	Up to 15 mo (maximum duration of treatment on trial)	*2 carriers (*2/*2 or *2/*1) 95% of all carriers = 375	N = NR Rate = 2.7% (Kaplan-Meier)	HR = 3.33	1.28, 8.62	0.004 [Kaplan-Meier]	ACS subtype (STE or NSTEMI was used as a stratification factor)	NO	Secondary outcome
						Non-*2 carriers (*1/*1) N = 1084 (= 1459 - 375)	N = NR Rate = 0.8% (Kaplan-Meier rate)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Sibbing, 2009 19193675 Germany NR	Clopidogrel 600 mg loading dose before stent placement	CYP2C19 *2	Stent thrombosis (definite)	Definite stent thrombosis according to the Academic Research Consortium criteria (ACS with angiographic or pathologic confirmation of thrombosis)	30 days	CYP2C19 *2/*2 N = 47	NR	NR	NR	P = 0.002 [chi-square test for trend]	NO	NO	Additional data on the cumulative incidence is presented in Figure 2
						CYP2C19 *2/*1 N = 633	NR	NR	NR				Additional data on the cumulative incidence is presented in Figure 2
						CYP2C19 *1/*1 N = 1805	NR	NR	NR				Additional data on the cumulative incidence is presented in Figure 2

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Sibbing, 2009 19193675 Germany NR	Clopidogrel 600 mg loading dose before stent placement	CYP2C19 *2	Stent thrombosis (definite)	Definite stent thrombosis according to the Academic Research Consortium criteria (ACS with angiographic or pathologic confirmation of thrombosis)	30 days	CYP2C19 *2 carriers (*2/*2 and *2/*1) N = 680	10	HR = 3.81 HR = 3.86	1.45, 10.02 1.47, 10.14	P = 0.007 [Cox proportional hazards regression; carriers vs. non-carriers] P = 0.006 [Cox proportional hazards regression; carriers vs. non-carriers]	Unadjusted Adjusted [age, diabetes, ACS, type of stent, substudy from which patient was selected, use of abciximab]	NO	None
						CYP2C19 non- carriers (*1/*1) N = 1805	7						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	Clopidogrel 600 mg loading dose; clopidogrel 75 mg (1/d) and aspirin 100 mg (2/d) maintenance.	CYP2C19 *17	Definite or probable stent thrombosis	Definite stent thrombosis according to Academic Research Consortium Criteria = ACS with either angiographic or pathological confirmation of thrombosis; probable = any unexplained death or target vessel MI, without angiographic confirmation of thrombosis or other identified culprit lesion	30 d	*17/*17 N = 76	1 (1.3%)	OR = 1.09	0.39, 3.02	(carriers vs. non-carriers) [logistic regression] P = 0.79 (across 3 groups) [chi- square test for trend]	NO	NO	Primary efficacy endpoint
						*17/*1 N = 546	5 (0.9%)						
						*1/*1 N = 902	8 (0.9%)						
Wallentin, 2010 20801498 Multiple countries (43 countries in North America, South America, Europe, Asia, Australia) PLATO	75 mg clopidogrel once daily (300–600 mg loading dose)	CYP2C19 genotyping	Definite stent thrombosis	Definite stent thrombosis	30 days	Any LOF allele (*2-*8)	934 (2.3%)	NR	NR	NR	NR	NR	NR
						No LOF allele	2300 (1.5%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Bonello, 2010 20708365 France NR	All patients received oral LDs of 250 mg aspirin and 600 mg clopidogrel at least 6 h before the first VASP index measurement	CYP2C19	Stent thrombosis	Stent thrombosis	In hospital	Wild-type N = 277	0 (0%)	NR	NR	NS	NR	NR	None
						Heterozygotes 2C19*2 N = 123	1 (1%)						
						Homozygotes 2C19*2 N = 11	0 (0%)						
Tiroch, 2010 20826260 Germany NR	aspirin (100mg twice daily) and clopidogrel (75mg once Daily)	CYP2C19*2 GG	Stent thrombosis	Stent thrombosis	1 year	CYP2C19*2 GG	680	N(%) 7 (1.0)	NR	0.822 CYP2C19*2 GG vs *2 A allele	NR	NR	no
		CYP2C19*2 A allele	Stent thrombosis	Stent thrombosis	1 year	CYP2C19*2 A allele	248	N(%) 3(1.2)	NR				
Tiroch, 2010 20826260 Germany NR	aspirin (100mg twice daily) and clopidogrel (75mg once Daily)	CYP2C19*2 GG	Stent thrombosis	Stent thrombosis	1 year	CYP2C19*2 GG	565	N(%) 6 (1.1)	NR	0.964 CYP2C19*17 CC vs T allele	NR	NR	no
		CYP2C19*2 A allele	Stent thrombosis	Stent thrombosis	1 year	CYP2C19*2 A allele	363	N(%) 4 (1.1)	NR		NR	NR	
Sawada, 2010 21099121 Japan NR	loading dose of clopidogrel (300 mg) and maintenance dose of clopidogrel (75 mg/day) and aspirin (100 mg/day)	CYP2C19	Intra-stent thrombus	Intra-stent thrombus	Mean 243.8 days	Non-carrier	58	9(15.5)		0.0002 Non-carrier vs *2 carrier	No	No	no
			Intra-stent thrombus	Intra-stent thrombus	Mean 243.8 days	*2 carrier	42	22 (52.3)			No	No	
			Intra-stent thrombus	Intra-stent thrombus	Mean 243.8 days	Non-carrier	100		2.475-16.812	0.0001 *2 carrier vs non-carrier	No	No	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
			Intra-stent thrombus	Intra-stent thrombus	Mean 243.8 days	Non-carrier	100		3.401-36.018	0.00006 *2 carrier vs non-carrier	Yes, age, sex, factors with p<0.2	No	
Campo 2011 21679849 Italy NR	aspirin (300 mg [LD + 100 mg daily, Clopidogrel 600 mg LD+ 75 mg/day for 12 months.	TaqMan	Definite or probable stent thrombosis (Academic Research Consortium classification)	Definite or probable stent thrombosis (Academic Research Consortium classification)	1 mo to 1 yr after PCI	*2 noncarriers N = 219	3 (1.4%)	NR	NR	NR	NO	NO	NO
						*2 carriers N = 81	1 (1.2%)						
						*17 noncarriers N = 198	4 (2.0%)	NR	NR	NR	NO	NO	NO
						*17 carriers N = 102	0 (0.0%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Harmsze 2010 20833683 Netherlands NR	Clopidogrel+aspirin	Real-time PCR	Stent thrombosis	NR	Any time within 1 yr after PCI	CYP2C19*2 carriers	fNR	Crude OR 1.6 Adjusted OR 1.7	Crude CI 1.1- 2.3 Adjusted CI 1.0-2.6	Crude P 0.013 Adjusted P 0.018 [Logistic regression]	YES for potential confounders (i.e., a ge, gender, body mass index (BMI), smoking, diabetes mellitus, prior MI, the use of PPIs, the use of CCBs, acute coronary syndrome (ACS) as the indication for PCI, peri- procedural variables being stent length, stent diameter, and stent type (bare metal or drug eluting), and the use of glycoprotein IIb/IIIa antagonists during the procedure)	YES (by performing the false discovery rate test (q- value threshold 0.20))	NO
						CYP2C19*2 noncarriers							
						CYP2C19*2 carriers		OR 1.7	1.0 –3.1	0.040 [Multivariate analysis]			
						CYP2C19*2 noncarriers							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
			Acute stent thrombosis	Occurrence within the first 24 h after PCI	first 24 h after PCI	CYP2C19*2 carriers		Crude OR 1.3 Adjusted OR 1.7	Crude CI 0.8– 2.3 Adjusted CI 0.8–3.5	Crude P 0.34 Adjusted P 0.11 [Logistic regression]			NO
						CYP2C19*2 noncarriers							
			Subacute stent thrombosis	from 24 h to 30 days after PCI	24 h to 30 days after PCI	CYP2C19*2 carriers		Crude OR 2.0 Adjusted OR 2.5	Crude CI 1.3– 3.3 Adjusted CI 1.1–5.5	Crude P 0.003 Adjusted P 0.026 [Logistic regression]			NO
						CYP2C19*2 noncarriers							
			Late stent thrombosis	from 30 days to 1 year after PCI	30 days to 1 year after PCI	CYP2C19*2 carriers		Crude OR 1.0 Adjusted OR 1.4	Crude CI 0.4 –2.6 Adjusted CI 0.6–9.5	Crude P 0.92 Adjusted P 0.54 [Logistic regression]			NO
						CYP2C19*2 noncarriers							
Sibbing 2012 21527445 Germany NR	Clopidogrel	TaqMan assay	Early ST	Stent thrombosis ≤30 days after stenting	≤30 days after stenting	*2/*1	Had event 33.9% of patients	Adjusted OR 2.27 vs *1/*1 Unadjusted OR 2.25	Adjusted 1.08 – 4.74 Undadjusted 1.17 – 4.32	Adjusted 0.03 (multivariable logistic regression model that assumed a codominant allele effect) Undadjusted 0.015	YES for adjusted [all baseline variables] NO for unadjusted	NR	NONE
						*2/*2	Had event 2.4%						
						*2 noncarrier (*1/*1)	Had event 63.7%						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*2/*2	Did not have event 22.9%						
						*2/*1	Did not have event 2.2%		OR 1.51 *2 vs. non carrier	1.04 – 2.18			
						*2 noncarrier (*1/*1)	Did not have event 74.9%			P=0.019 for comparison of frequencies in this row and all above rows (chi-square)			
Chen. 2012 22723959 Taiwan CAPTAIN	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis	9 months	CYP2C19*2	15	OR=4.2	1.263-9.544	0.031	NO	NR	no
						CYP2C19*3	2	OR=0.83	0.315-4.451	0.577	NO	NR	
						CYP2C19*17	0	-	-	-	No	NR	
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis	9 months	CYP2C19*2	75% in ST	NR	NR	NR	NR	NR	no
							40 in Non- ST						
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis	9 months	CYP2C19*3	1015in ST	NR	NR	NR	NR	NR	no
							40 in Non- ST						
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis	9 months	CYP2C19*17	0% in ST	NR	NR	NR	NR	NR	no
							0 in Non-ST						
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis acute	9 months	CYP2C19*2 AA	n=2 (40%)	NR	NR	NR	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis acute	9 months	CYP2C19*2 GA	n=2 (40%)	NR	NR	NR	NR	NR	no
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis acute	9 months	CYP2C19*2 GG	n=2 (20%)	NR	NR	NR	NR	NR	no
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis subacute	9 months	CYP2C19*2 AA	n=0 (0)	NR	NR	NR	NR	NR	no
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis subacute	9 months	CYP2C19*2 GA	n=4 (57.1)	NR	NR	NR	NR	NR	no
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis subacute	9 months	CYP2C19*2 GG	n=3 (42.9)	NR	NR	NR	NR	NR	no
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis late	9 months	CYP2C19*2 AA	n=2 (28.6%)	NR	NR	NR	NR	NR	no
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis late	9 months	CYP2C19*2 GA	n=4 (57.1)	NR	NR	NR	NR	NR	no
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis late	9 months	CYP2C19*2 GG	n=1 (42.9)	NR	NR	NR	NR	NR	no
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis very late	9 months	CYP2C19*2 AA	n=0	NR	NR	NR	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis very late	9 months	CYP2C19*2 GA	n=1 (100%)	NR	NR	NR	NR	NR	no
	clopidogrel	CAD patients undergone PCI with stenting	stent thrombosis	stent thrombosis very late	9 months	CYP2C19*2 GG	n=0	NR	NR	NR	NR	NR	no
Luo, 2011 22118006 China NR	LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d	CYP2C19 *1/*1	stent thrombosis	stent thrombosis (definite)	6 months	CYP2C19 *1/*1	7/936	HR 4.26	1.28-9.22	<0.05 comparing with the next row chi-square test	NR	NR	no
		CYP2C19 *1/*2 or *2/*2				CYP2C19 *1/*2 or *2/*2	19/802						
Luo, 2011 22118006 China NR	LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d	CYP2C19 *2	stent thrombosis	stent thrombosis	6 months	CYP2C19 *2	NR	HR3.38	1.25-9.34	<0.01 comparing with non *2 carrier cox proportional model	yes, age, tobacco use, DM, hypertension, calcium antagonist, tirofiban, omeprazole.	NR	no
Delaney, 2012 22190063 USA N	clopidogrel	CYP2C19*2	ST	Stent Thrombosis,	2 years	CYP2C19*2 SNP rs4244285	NR	HR=2.79	0.7-11.16	0.147 comparing with non carrier of *2	No	NR	no
	clopidogrel	CYP2C19*17	ST	Stent thrombosis	2 years	CYP2C19*17 SNP rs4244285	NR	HR=0.27	0.04-2.09	0.210 comparing with non carrier of *17	No	NR	no
Nishio, 2012 22785462 Japan NR	Clopidogrel and aspirin	TaqMan	ST	NR	Any time during study	Extensive metabolizer (n=60)	1	NR	NR	Across this and next two rows, 0.79 (chi- square test)	NR	NR	NONE
						Intermediate metabolizer (n=77)	2	NR	NR	NR	NR	NR	NONE

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Poor metabolizer (n=23)	1	NR	NR	NR	NR	NR	NONE
Goodman, 2012 22261200 Multi-country PLATO	Clopidogrel 300-mg loading dose, 75-mg daily maintenance dose	CYP2C19 *2	definite or probable stent thrombosis	stent thrombosis	12 months	CYP2C19 loss-of- function carriers (*2 through *8) on a PPI n=434	11 (2.6%)	HR= 2.73	1.37–5.43	NR	no	NR	
						non carriers of CYP2C19 loss-of- function allele or not taking a PPI n=2418	15 (0.6%)						
Siller-matula, 2012 22260716 Austria PEGASUS-PCI	clopidogrel LD 600mg, MD 75mg	CYP2C19 *2	Stent thrombosis	ST	12 months	*2/*2 or *1/*2 N=84	3 (2.7%)			0.926 (carrier vs noncarrier) [log rank test]	No	NR	
						*1/*1 n-=167	4 (2.5%)						
		CYP2C19 *2	Stent thrombosis	ST	12 months	*2/*2 or *1/*2	NR	AUC: 0.56 Sensitivity: 30% Specificity: 71%	AUC: 0.32– 0.69)	0.95 (carrier vs noncarrier)	No	NR	
						*1/*1	NR						
		CYP2C19 *2	Stent thrombosis	ST	12 months	regular metabolizers (CYP2C19*1/*1) n=167	4 (2.1%)	NR	NR	P = 0.837 (ANOVA) (between regular and heterozygote and homozygote poor metabolizers))			
						Heterozygote poor metabolizers (CYP2C19*1/*2) N=nr	3.2%						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Homozygote poor metabolizers (CYP2C19*2/*2) n=NR	0						
Jaitner, 2012 22298798 Germany NR	Pretreatment with a loading dose of 600 mg of clopidogrel prior to the procedure. The recommended pr- treatment interval was ≥ 2 h.	CYP2C19 *2	Stent Thrombosis	Definite stent thrombosis due to drug eluting stents	NA	CYP2C19*2 carrier N=378	NR	OR=1.86	1.05-3.31	P=0.03; (CYP2C19*2 carriers versus the remaining patients) [logistic regression]	no	NR	
						CYP2C19*2 noncarrier N=1096	NR						
Cayla, 2011 22028352 France ONASSIST	clopidogrel or aspirin (Dose and frequency NR)	CYP2C19 *2	Stent Thrombosis	Stent Thrombosis	NA	CYP2C19*2 carrier N=127	60	OR(calculated)=2.53	1.61-3.97	P=NR; (CYP2C19*2 carriers versus noncarriers) [logistic regression]	no	NR	
						CYP2C19*2 noncarrier N=241	63						
		CYP2C19 *4	Stent Thrombosis	Stent Thrombosis	NA	CYP2C19*4 carrier N=1	0	NR	NR	NR	NR	NR	
						CYP2C19*4 noncarrier N=367	123						
		CYP2C19 *17	Stent Thrombosis	Stent Thrombosis	NA	CYP2C19*17 carrier N=105	25	OR (calculated)=0.53	0.31-0.88	NR	NR	NR	
						CYP2C19*4 noncarrier N=263	98						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Hulot, 2011 21972404 France AFIJI	MD clopidogrel 75 mg/d	CYP2C19 *2- *6	Stent Thrombosis	Stent Thrombosis	6 months	CYP2C19 loss-of- function alleles (*2 through *6): 107	NR	HR=2.79	1.09-7.16	P=0.03 (LOF vs no LOF) [log rank test]	No	NR	
						No CYP2C19 loss-of-function alleles: 262	NR						

TRITON-TIMI 38 = Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction

Appendix Table D10. Clinical outcome information—major adverse cardiovascular events													
Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Collet 2009 19108880 France AFIJI	Clopidogrel (75 mg maintenance dose for at least 1 mo)	CYP2C19 *2	First MACE	First death, non- fatal MI, or urgent revascularization during FU. See below for definitions of components.	Mean FU = 2.8 yr	*2/*2 N = 9	2 (22%)	NR	NR	NR	NA	NO	Only counts provided
						*2/*1 N = 64	13 (20%)						
						*1/*1 N = 186	11 (5.9%)						
			First MACE	First death, non- fatal MI, or urgent revascularization during FU. See below for definitions of components.	Mean FU = 2.8 yr	Carriers (*2/*2 or *2/*1) N = 73	15 (21%) 10.9 events per 100 person-years	HR = 3.69 Adjusted HR = 5.38	1.69, 8.05 2.32, 12.47	0.0005 <0.0001	Unadjusted Adjusted [baseline BMI, smoking status, diabetes status, stent implantation, initial STE MI, use of PPI]	NO	Primary endpoint; survival curve in Figure 3A
						Non-carriers (*1/*1) N = 186	11 (6%) 2.89 events per 100 person-years						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
			First MACE, landmark analysis (from 6 mo after clopidogrel initiation)	First death, non- fatal MI, urgent revascularization, for patients on clopidogrel for at least 6 mo	Mean FU = 2.8 yr [for the whole cohort; does not account for patient with FU shorter than 6 mo, or for person time during the first 6 mo]	Carriers (*2/*2 or *2/*1) N = 61 (landmark analysis)	10 (16%)	HR = 3.00	1.27, 7.10	0.009	Unadjusted (based on the other HR reported in the same graph)	NO	Landmark analysis; survival curve in Figure 3b.
						Non-carriers (*1/*1) N = 122 (landmark analysis)	9 (7%)						
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	CYP2C19*2	MACE	Composite of cardiac mortality and stent thrombosis (definite or probable)	Maximum FU of 6 mo	*2/*2 N = 26	2 (7.7%)	NR	NR	0.061 across groups (chi square test)	NO	NO	Secondary outcome
						*2/*1 N = 221	13 (5.9%)						
						*1/*1 N = 525	14 (2.7%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
		CYP2C19*2 + ADP residual platelet reactivity (see also KQ2b extraction form)	MACE	Composite of cardiac mortality and stent thrombosis (definite or probable)	Maximum FU of 6 mo	*2/*2 + RPR N = 40	7 (17.5%)	NR OR=11.45	NR (1.84, 71.27)	<0.0001 (chi square test) 0.009 (logistic regression)	NO Adjusted ("for traditional cardiovascular risk factors and clinical and procedural risk factors for stent thrombosis")	NO	Secondary outcome
						*1/*1 or low RPR N = 732	22 (3%)						
		CYP2C19*2	MACE	Composite of cardiac mortality and stent thrombosis (definite or probable)	Maximum FU of 6 mo	*2/*2 or *2/*1 N = 247	15 (6.1%)	NR OR=2.36 OR=2.70	NR (1.12, 4.97) (1.00, 8.42)	0.020 (chi square test) 0.024 (logistic regression) 0.049 (logistic regression)	NO NO (univariate) YES (ADP-RPR, traditional cardiovascular risk factors, clinical and procedural risk factors for ST)	NO	Secondary outcome
						*1/*1 N = 525	14 (2.7%)						
		CYP2C19*2	MACE	Composite of cardiac mortality and stent thrombosis (definite or probable)	Maximum FU of 6 mo	*2/*2 or *2/*1 N = 247	15 (crude proportion 6.1%)	NR	NR	<0.01 (log rank)	NO	NO	Secondary outcome
						*1/*1 N = 525	14 (crude proportion 2.7%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Mega 2009 19106084 Multinational TRITON-TIMI 38	Clopidogrel 300 mg loading dose, 75 mg maintenance	CYP2C19	MACE	Death from cardiovascular causes, myocardial infarction, or stroke	Up to 15 mo (maximum duration of treatment on trial)	IM or PM (1/*2A, *1A/*3, *1A/*4, *1A/*8, *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8) N = 395	N = 46 Rate = 12.1% (Kaplan- Meier)	HR = 1.53	1.07, 2.19	0.01 carriers vs. non-carriers [Gehan- Wilcoxon test]	ACS subtype (STE or NSTE was used as a stratification factor)	NO	Primary outcome
						EM (*1A/*1A) N = 1064	N = 83 Rate = 8.0% (Kaplan- Meier rate)						
		CYP2C19	MACE	Death from cardiovascular causes, myocardial infarction, or stroke	Up to 15 mo (maximum duration of treatment on trial)	*2 carriers (*2/*2 or *2/*1) 95% of all carriers = 375	N = NR Rate = 11.7% (Kaplan- Meier)	HR = 1.42	0.98, 2.05	0.04 [Kaplan- Meier]	ACS subtype (STE or NSTE was used as a stratification factor)	NO	Primary outcome
						Non-*2 carriers (*1/*1) N = 1084 (= 1459 - 375)	N = NR Rate = 8.3% (Kaplan- Meier rate)						
Shuldiner 2009 19706858 USA Sinai Hospital of Baltimore Study	Clopidogrel LD 600 mg (n=112) or 300 mg (n=25) or maintenance therapy with 75 mg daily (n=90) + 81-325 mg aspirin daily before PCI and LD 325 mg. Aspirin 325 mg/d & clopidogrel 75 mg/d at discharge	CYP2C19 *2	Post-discharge ischemic events	MI, ischemic stroke, stent thrombosis (definite), unplanned TVR, unplanned non-TVR, hospitalization for coronary ischemia without revascularization, and death due to CV cause	At one and 12 mo (results reported from time to event analyses covering the whole time period)	*2/*2 or *2/*1 N = 67	14 (20.9%)	HR = 2.42 HR = 1.58	1.18, 4.99 0.68, 3.66	P = 0.02 (carriers vs. non-carriers) P = 0.29 (carriers vs. non-carriers) Based on proportional hazards model (time-to-event)	Adjusted (age, sex, race) Adjusted (age, sex, race, and ADP-stimulated platelet reactivity as a covariate)	NO	KM plots in figure 4, with number at risk. Also reports analyses stratified by clopidogrel treatment status at the time of the outcome event

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*1/*1 N = 158	16 (10%)						
Sibbing 2009 19193675 Germany NR	Clopidogrel 600 mg loading dose before stent placement	CYP2C19 *2	MACE	Death or MI	30 d	CYP2C19 *2 carriers (*2/*2 and *2/*1) N = 680	52 (8%)	HR = 1.14	0.83, 1.58	0.42 [Cox proportional hazards regression; carriers vs. non-carriers]	NO	NO	None
						CYP2C19 non- carriers (*1/*1) N = 1805	121 (7%)						
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	Clopidogrel 600 mg loading dose; clopidogrel 75 mg (1/d) and aspirin 100 mg (2/d) maintenance.	CYP2C19 *17	MACE	Death, MI, or urgent TVR	30 d	*17/*17 N = 76	4 (5.3%)	OR = 0.94	0.5, 1.61	(carriers vs. non-carriers) [logistic regression] P = 0.94 (across 3 groups) [chi- square test for trend]	NO	NO	Secondary efficacy endpoint
						*17/*1 N = 546	18 (3.3%)						
						*1/*1 N = 902	34 (3.8%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Trenk 2008 18482659 Germany EXCELSIOR	600 mg clopidogrel loading dose + 75 mg/day clopidogrel (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug- eluting stent	CYP2C19 *2	Composite of death and MI	MI = new rise in troponin T ≥0.03 mg/l associated with typical symptoms and/or typical electrocardiogram changes and/or typical angiographic finding; death = as reported in phone interview	1 year	Carriers (*1/*2 or *2/*2) N = 245	5 (2%) (3/90 when limited to patients with at least 1 drug eluting stent implanted)	NR	NR	P=0.371 (between carriers and noncarriers) P=0.684 (same contrast; limited to patients with at least one drug eluting stent implanted)	NO	NR	NO
						Noncarriers (*1/*1) N = 552	19 (3.4%) (4/190 when limited to patients with at least 1 drug eluting stent implanted)						
Wallentin 2010 20801498 Multiple countries (43 countries in North America, South America, Europe, Asia, Australia) PLATO	75 mg clopidogrel once daily (300–600 mg loading dose)	CYP2C19 genotyping	Cardiovascular death, MI, and stroke	NR	From baseline through end of followup (≤360 days)	Any LOF allele (*2-*8) N = 1388	149 (10.7% crude, 11.2% actuarial)	NR	NR	NR	NO	NO	Primary efficacy end point
						No LOF allele N = 3516	332 (9.4% crude, 10.0% actuarial)						
			Cardiovascular death, MI, and stroke	NR	At 30 days	Any LOF allele (*2-*8) N = 1388	5.7% crude	NR	NR	NR	NO	NO	Additional data (daily) in Fig. 1 (K-M)

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						No LOF allele N = 3516	3.8% crude						
			Cardiovascular death, MI, and stroke	NR	From 31 days through end of followup (≤360 days)	Any LOF allele (*2-*8) N = 1302	5.8% actuarial	NR	NR	NR	NO	NO	Additional data (daily) in Fig. 2 (K-M)
						No LOF allele N = 3370	6.4% actuarial						
			Cardiovascular death or MI	NR	From baseline through end of followup (≤360 days)	Any LOF allele (*2-*8) N = 1388	138 (9.9% crude, 10.4% actuarial)	NR	NR	NR	NO	NO	None
						No LOF allele N = 3516	306 (8.7% crude , 9.2% actuarial)						
Bonello, 2010 20708365 France NR	All patients received oral LDs of 250 mg aspirin and 600 mg clopidogrel at least 6 h before the first VASP index measurement	CYP2C19	All MACE	All MACE	In hospital	Wild-type N = 277	1 (<1%)	Count	NR	NS	NR	NR	None
						Heterozygotes 2C19*2 N = 123	1 (1%)						
						Homozygotes 2C19*2 N = 11	0 (0%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Simon 2011 21262992 France NR	Clopidogrel no specific regimen reported	CYP2C19	Death , MI or stroke	Death , MI or stroke	1 year	No PPI, No variant allele	41/485 (8.5)	HR= 1.13	0.74-1.74	NR	Yes. GRACE score, sex, current smoking, hyperlipidemia, hypertension, diabetes mellitus	NR	Supplement data for whole population, N=3670
			Death , MI or stroke	Death , MI or stroke	1 year	PPI, No variant allele	50/545 (9)			NR		NR	
			Death , MI or stroke	Death , MI or stroke	1 year	No PPI, 1variant allele	11/171 (6)	HR= 1.02	0.44-2.4	NR	Yes	NR	
			Death , MI or stroke	Death , MI or stroke	1 year	PPI, 1variant allele	11/190 (6)			NR		NR	
			Death , MI or stroke	Death , MI or stroke	1 year	No PPI, 2 variant allele	3/19 (16)	HR= 0.25	0.02-3.58	NR	NR		
			Death , MI or stroke	Death , MI or stroke	1 year	PPI, 2 variant allele	1/15 (7)						
Tiroch, 2010 20826260 Germany NR	aspirin (100mg twice daily) and clopidogrel (75mg once Daily)	CYP2C19*2 GG	Death or MI	Death or MI	1 year	CYP2C19*2 GG N = 680	680	63 (9.2%)	NR	0.086 CYP2C19*2 GG vs *2 A allele	NR	NR	
		CYP2C19*2 A allele	Death or MI	Death or MI	1 year	CYP2C19*2 A allele N = 248	248	14 (5.7%)	NR		NR	NR	
		CYP2C19*2 GG	MACE	MACE	1 year	CYP2C19*2 GG N = 680	680	N(%) 179 (26.3)	NR	0.525 CYP2C19*2 GG vs *2 A allele	NR	NR	
		CYP2C19*2 A allele	MACE	MACE	1 year	CYP2C19*2 A allele	248	N(%) 60 (24.2)	NR		NR	NR	
		CYP2C19*2 GG	MACE or stroke	MACE or stroke	1 year	CYP2C19*2 GG	680	N(%) 184 (27.1)	NR	0.378 CYP2C19*2 GG vs *2 A allele	NR	NR	
		CYP2C19*2 A allele	MACE or stroke	MACE or stroke	1 year	CYP2C19*2 A allele	248	N(%) 60 (24.2)	NR		NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
		CYP2C19*2 GG	Death or MI	Death or MI	1 year	CYP2C19*2 GG	565	N(%) 42 (7.4)	NR	0.255 CYP2C19*17 CC vs T allele	NR	NR	
		CYP2C19*2 A allele	Death or MI	Death or MI	1 year	CYP2C19*2 A allele	363	N(%) 35 (936)	NR		NR	NR	
		CYP2C19*2 GG	MACE	MACE	1 year	CYP2C19*2 GG	565	N(%) 159 (28.1)	NR	0.04 CYP2C19*17 CC vs T allele	NR	NR	
		CYP2C19*2 A allele	MACE	MACE	1 year	CYP2C19*2 A allele	363	N(%) 80 (22)	NR		NR	NR	
Sorich, 2010 20492467 707 sites in 30 countries Substudy of TRITON-TIMI 38	300-mg loading dose and 75-mg daily maintenance dose	CYP2C19	CV death, non- fatal MI or non- fatal stroke	CV death, non-fatal MI or non-fatal stroke	15 months	RM(with one or two reduced function alleles) vs EM(no reduced function allele)	802	OR=1.53	1.07-2.19	NR	NR	No	
			CV death, non- fatal MI or non- fatal stroke	CV death, non-fatal MI or non-fatal stroke	15 months	EM	NR	9.8%	8.3-11.3	NR	NR	No	
			CV death, non- fatal MI or non- fatal stroke	CV death, non-fatal MI or non-fatal stroke	15 months	RM	NR	15%	11.6-18.8	NR	NR	No	
Sawada, 2010 21099121 Japan NR	loading dose of clopidogrel (300 mg) and maintenance dose of clopidogrel (75 mg/day) and aspirin (100 mg/day)	CYP2C19	Total MACE	Total MACE	Mean 243.8 days	Non-carrier	58	11(19)	NR	0.25, Non- carrier vs *2 carrier	No	No	
			Total MACE	Total MACE	Mean 243.8 days	*2 carrier	42	13(31)	NR				

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Pare, 2010 20979470 Multinational ACTIVE	clopidogrel dose of 75 mg per day in combination with aspirin	CYP2C19	MACE (first definition)	Composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke	12 months	Poor metabolizers N = 61	4 (7%)	NR	NR	NR	NR	NR	NR
						Intermediate metabolizers N = 437	37 (9%)						
						Extensive metabolizers N = 1033	112 (11%)						
						Ultra metabolizers N = 847	66 (8%)						
						Unknown status N = 152	11 (7%)						
			MACE (second definition)	Composite of death from cardiovascular causes, nonfatal myocardial infarction, stroke, recurrent ischemia, or hospitalization for unstable angina	12 months	Poor metabolizers N = 61	13 (21%)	NR	NR	NR	NR	NR	NR
						Intermediate metabolizers N = 437	70 (16%)						
						Extensive metabolizers N = 1033	193 (19%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Ultra metabolizers N = 847	123 (15%)						
						Unknown status N = 152	19 (13%)						
Pare, 2010 20979470 Multiple countries ACTIVE-A	clopidogrel dose of 75 mg per day in combination with aspirin	CYP2C19	composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke - ACTIVE trial	composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke	Median 3.6 y	Poor metabolizers N = 9	1 (11%)	NR	NR	NR	NR	NR	NR
						Intermediate metabolizers N = 93	21 (23%)						
						Extensive metabolizers N = 199	34 (17%)						
						Ultra metabolizers N = 222	49 (22%)						
						Unknown status N = 37	7 (19%)						
Mega, 2010 20801494 707 sites in 30 countries TRITON-TIMI 38	clopidogrel (300- mg loading dose and 75-mg daily maintenance dose)	CYP2C19	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	15 months	Reduced- function allele carrier vs non- carrier		HR=1.77	1.11-2.80	0.0155, Reduced- function allele carrier vs non- carrier	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
		CYP2C19 and ABCB1 3435 C- T	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	15 months	No risk gene of either CYP2C19 and ABCB1 3435 C- T	KM rate 6.3% 48/773		NR	NR	NR	NR	
		CYP2C19	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	15 months	CYP2C19 reduced- function allele only	KM rate 11.5%, 29/268		NR	NR	NR	NR	
		ABCB1 3435 TT homozygotes only	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	15 months	ABCB1 3435 TT homozygotes only	KM rate 12.6%, 35/288		NR	NR	NR	NR	
		CYP2C19 and ABCB1 3435 C- T	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	15 months	risk gene of both CYP2C19 and ABCB1 3435 C-T	KM rate 13.6%, 17/125		NR	NR	NR	NR	
		CYP2C19	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	30 days	No risk gene of either CYP2C19 and ABCB1 3435 C- T	KM rate 4%, 31/773		NR	NR	NR	NR	
		CYP2C19	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	30 days	ABCB1 3435 TT homozygotes	KM rate 7%, 20/288		NR	NR	NR	NR	
		CYP2C19	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	30 days	carriers of CYP2C19 reduced function allele		KM rate 6%, 16/268	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
		CYP2C19	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	30 days	Carriers of either Reduced-function allele vs carriers of neither		HR=1.64	1.01-2.65	0.0441, Carriers either of Reduced-function allele vs carriers of neither	NR	NR	
		CYP2C19	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	30 days	carriers of both CYP2C19 reduced function allele and ABCB1 3435 TT homozygotes		KM rate 12% 15/125	NR				
		CYP2C19	Cardiovascular death, myocardial infarction, or stroke	Cardiovascular death, myocardial infarction, or stroke	30 days	Carriers of either Reduced-function allele vs carriers of neither		HR=3.16	1.71-5.85	0.0003, Carriers of both Reduced-function allele vs carriers of neither	NR	NR	
Campo 2011 21679849 Italy NR	aspirin (300 mg [LD + 100 mg daily, . Clopidogrel 600 mg LD+ 75 mg/day for 12 months.	TaqMan	Death, MI (Recurrence of ischemic symptoms and elevation of creatine kinase-myocardial band $\geq 3 \times$ ULN), or stroke	Death, MI (Recurrence of ischemic symptoms and elevation of creatine kinase-myocardial band $\geq 3 \times$ ULN), or stroke	1 mo to 1 yr after PCI	*2 noncarriers	219	11 (5.0%)	NR	0.02 vs, next row [Fisher exact test]	NO	NO	NO
						*2 carriers	81	10 (12.3%)					
						*17 noncarriers	198	16 (8.1%)	NR	0.1 vs, next row [Fisher exact test]	NO	NO	NO
						*17 carriers	102	5 (4.9%)					
Malek 2008 18577829 Poland NR	Clopidogrel and aspirin	CYP2C19 *2	CV Death or MI	NR	Within 12 months after PCI	Group 1	0	NR	NR	NR	NR	NR	NR
						Group 2	1	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Group 3	0	NR	NR	NR	NR	NR	NR
						Controls	5	NR	NR	NR	NR	NR	NR
Simon 2009 19106083 France FAST-MI	Clopidogrel	CYP2C19*2	Death from any cause, nonfatal stroke, or MI	Primary outcome	Within 1 yr	CYP2C19*2 noncarrier N = 1561	214 (14%)	NR	NR	0.17 (univariate Cox across genotype groups)	NO	NO	Check Table 2—should ensure P values are for these comparisons exactly Also %s here dif't from those reporter but not sure it's the best data to present
						CYP2C19*2 heterozygote N = 564	64 (11%)						
						CYP2C19*2 homozygote N = 53	10 (19%)						
		CYP2C19*3	Death from any cause, nonfatal stroke, or MI	Primary outcome	Within 1 yr	CYP2C19*3 noncarrier N = 2186	291 (13%)	NR	NR	0.97 (univariate Cox across genotype groups)	NO	NO	NO
						CYP2C19*3 heterozygote N = 1	0 (0%)						
						CYP2C19*2 homozygote N = 0	NA						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
		CYP2C19*4	Death from any cause, nonfatal stroke, or MI	Primary outcome	Within 1 yr	CYP2C19*4 noncarrier N = 2168	286 (13%)	NR	NR	0.31 (univariate Cox across genotype groups)	NO	NO	NO
						CYP2C19*4 heterozygote N = 21	4 (19%)						
						CYP2C19*4 homozygote N = 0	NA						
		CYP2C19*5	Death from any cause, nonfatal stroke, or MI	Primary outcome	Within 1 yr	CYP2C19*5 noncarrier N = 2175	289 (13%)	NR	NR	0.97 (univariate Cox across genotype groups)	NO	NO	NO
						CYP2C19*5 heterozygote N = 1	0 (0%)						
						CYP2C19*5 homozygote N = 0	NA						
		CYP2C19*17	Death from any cause, nonfatal stroke, or MI	Primary outcome	Within 1 yr	CYP2C19*17 noncarrier N = 1390	199 (14%)	NR	NR	0.18 (univariate Cox across genotype groups)	NO	NO	NO
						CYP2C19*17 heterozygote N = 674	77 (11%)						
						CYP2C19*17 homozygote N = 100	11 (11%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
		Any CYP2C19 loss-of-function SNP (*2, *3, *4, or *5)	Death from any cause, nonfatal stroke, or MI	Primary outcome	Within 1 yr	None of *2, *3, *4, or *5 N = 1573	218 (14%)	NR	NR		NO	NO	NO
						One of *2, *3, *4, or *5 N = 577	64 (11%)						
						Two of *2, *3, *4, or *5 N = 58	12 (21%)						
		Any CYP2C19 loss-of-function SNP (*2, *3, *4, or *5)	Death from any cause, nonfatal stroke, or MI	In the 1535/2208 patients undergoing PCI		None of *2, *3, *4, or *5 N = 1573	NR	Adjusted HR 3.58, vs. next two rows	1.71-7.51	0.005	NO	NO	From Table 3 (which is subgroup analysis—is this OK?)
						One of *2, *3, *4, or *5 N = 577	NR	Adjusted HR 0.78, vs. previous and next row	0.50-1.21				
						Two of *2, *3, *4, or *5 N = 58	NR						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Price, 2012 22624833 US GIFT (Genotype Information and Functional Testing) Study—a prespecified genetic substudy of GRAVITAS (Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety) trial	Clopidogrel	MassARRAY and iPLEX Gold	Primary clinical endpoint of death due to cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis	NR	6 mo after PCI	Carriers of any 2 reduced- function CYP2C19 alleles (*2, *3, *3, *6, *8) [N=24]	1	HR 1.58	1.04-2.41	0.03, vs. noncarriers (next row)	NR	NR	NONE
						Noncarriers of a reduced- function CYP2C19 allele (*2, *3, *3, *6, *8) [N=466]	11	NR	NR	NR			
						Carriers of any 1 reduced- function CYP2C19 alleles (*2, *3, *3, *6, *8) [N=244]	2	HR 1.07	0.91-1.25	0.42, vs. noncarriers (previous row)			
Tello-Montoliu 2012 22116003 Spain study one of the paper	100mg AA and 75mg MD clopidogrel	CYP2C19 *2 and *17	cardiovascular death or recurrent acute coronary syndrome require hospital admission	adverse event	6 month	CYP2C19 *2	NR	HR=1	0.94-1.55	0.984 */A vs G/G	No	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Tello-Montoliu 2012 22116003 Spain study two of the paper	100mg AA and 75mg MD clopidogrel	CYP2C19 *2 and *17	cardiovascular death or recurrent acute coronary syndrome require hospital admission	adverse event	6 month	CYP2C19 *17	NR	HR=0.93	0.61-1.43	0.753 */T vs C/C	No	NR	NR
Harmsze, 2011 21854540 Netherlands NR	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	endpoint	all-cause death, non-fatal myocardial infarction (MI), stent thrombosis and ischemic stroke	12 months	CYP2C19 *2	NR	HR=1.4	0.82-2.3	0.23	NR	NR	
Harmsze, 2011 21854540 Netherlands NR	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	endpoint	all-cause death, non-fatal myocardial infarction (MI), stent thrombosis and ischemic stroke	12 months	CYP2C19 *17	NR	HR=0.74	0.43-1.3	0.26	NR	NR	
Harmsze, 2011 21854540 Netherlands NR	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	endpoint	all-cause death, non-fatal myocardial infarction (MI), stent thrombosis and ischemic stroke	12 months	CYP2C19 *2 carriers in CCB+PPI	NR	HR=2.6	0.70-9.3	0.15	NR	NR	
Harmsze, 2011 21854540 Netherlands NR	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	endpoint	all-cause death, non-fatal myocardial infarction (MI), stent thrombosis and ischemic stroke	12 months	CYP2C19 *2 non carriers in CCB+PPI	NR	HR=1.9	0.88-4.6	0.078	NR	NR	
Ono, 2011 21862109 Japan NR	clopidogrel LD 300mgand 75mg MD aspirin 100mg/day	CYP2C19	end-point	major cardiac and cerebrovascular event, such as cardia death, nonfatal myocardial infarction, unstable angina pectoris, and ischemic stroke	12 months	carrier of reduced function allele	2	NR	NR	NR	NR	NR	
						non- carrier of reduced function allele	0						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Delaney, 2012 22190063 USA NR	clopidogrel	CYP2C19*2	primary end point	composite of MI, revascularization, stroke, and/or all- cause mortality	2 years	CYP2C19*2 SNP rs4244285	NR	HR=1.54	1.16-2.06	0.003 comparing with non carriers cox-model	yes, age, smoking status, BMI	NR	NR
	clopidogrel	CYP2C19*17	primary end point	composite of MI, revascularization, stroke, and/or all- cause mortality	2 years	CYP2C19*17 SNP rs4244285	NR	HR=0.91	0.71-1.18	0.481 comparing with non carriers cox-model	yes, age, smoking status, BMI	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19*2or*3 (carrier of loss of function allele)	primary end point	first occurrence of non-fatal or fatal myocardial infarction, non-fatal or fatal stroke, or cardiovascular death	800 days	CYP2C19*2 or *3	carriers 48/665	NR	NR	0.17 comparing with non-carriers log-rank test	NR	NR	NR
							non-carriers 92/1601						
	clopidogrel	CYP2C19*2or*3 (carrier of loss of function allele)	secondary end point	hospitalization for unstable angina, transient ischaemic attack, or revascularization procedure	800 days	CYP2C19*2 or *3	carriers 117/665	NR	NR	0.593 comparing with non-carriers log-rank test	NR	NR	NR
							non-carriers 269/1601						
	clopidogrel	CYP2C19*17 (carrier of gain of function allele)	primary end point	first occurrence of non-fatal or fatal myocardial infarction, non-fatal or fatal stroke, or cardiovascular death	800 days	CYP2C19*17	carriers 52/872	NR	NR	0.71 comparing with non-carriers log-rank test	NR	NR	NR
							non-carriers 88/1394						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
	clopidogrel	CYP2C19*17 (carrier of gain of function allele)	secondary end point	hospitalization for unstable angina, transient ischemic attack, or revascularization procedure	800 days	CYP2C19*17	carriers 147/872	NR	NR	0.813 comparing with non-carriers log-rank test	NR	NR	NR
							non-carriers 239/1394						
	clopidogrel	CYP2C19*2/*2 or *2/*3	primary end point	first occurrence of non-fatal or fatal myocardial infarction, non-fatal or fatal stroke, or cardiovascular death	800 days	CYP2C19*2/*2	n=7 (13.5)	NR	NR	NR	NR	NR	NR
	clopidogrel	CYP2C19 wt/*2 or wt/*3	primary end point	first occurrence of non-fatal or fatal myocardial infarction, non-fatal or fatal stroke, or cardiovascular death	800 days	CYP2C19 wt/*2 or wt/*3	n=29 (6.3%)	NR	NR	NR	NR	NR	NR
	clopidogrel	CYP2C19 wt/wt	primary end point	first occurrence of non-fatal or fatal myocardial infarction, non-fatal or fatal stroke, or cardiovascular death	800 days	CYP2C19 wt/wt	n=52 (5.9%)	NR	NR	NR	NR	NR	NR
	clopidogrel	CYP2C19 Wt/*17 or *17/*17	primary end point	first occurrence of non-fatal or fatal myocardial infarction, non-fatal or fatal stroke, or cardiovascular death	800 days	CYP2C19 Wt/*17 or *17/*17	40 (5.6%)	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
	clopidogrel	CYP2C19 *2/*17 or *3/*17	primary end point	first occurrence of non-fatal or fatal myocardial infarction, non-fatal or fatal stroke, or cardiovascular death	800 days	CYP2C19 *2/*17 or *3/*17	n=12 (7.7%)	NR	NR	NR	NR	NR	NR
	clopidogrel	total	primary end point	first occurrence of non-fatal or fatal myocardial infarction, non-fatal or fatal stroke, or cardiovascular death	800 days	total	n=140 (6.2%)	NR	NR	NR	NR	NR	NR
	clopidogrel	CYP2C19*2/*2 or *2/*3	secondary end point	hospitalization for unstable angina, transient ischemic attack, or revascularization procedure	800 days	CYP2C19*2/*2	n=12 (23.1%)	NR	NR	NR	NR	NR	NR
	clopidogrel	CYP2C19 wt/*2 or wt/*3	secondary end point	hospitalization for unstable angina, transient ischemic attack, or revascularization procedure	800 days	CYP2C19 wt/*2 or wt/*3	n=82 (17.9%)	NR	NR	NR	NR	NR	NR
	clopidogrel	CYP2C19 wt/wt	secondary end point	hospitalization for unstable angina, transient ischemic attack, or revascularization procedure	800 days	CYP2C19 wt/wt	n=145 (16.4%)	NR	NR	NR	NR	NR	NR
	clopidogrel	CYP2C19 Wt/*17 or *17/*17	secondary end point	hospitalization for unstable angina, transient ischemic attack, or revascularization procedure	800 days	CYP2C19 Wt/*17 or *17/*17	n=124 (17.3%)	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
	clopidogrel	CYP2C19 *2/*17 or *3/*17	secondary end point	hospitalization for unstable angina, transient ischemic attack, or revascularization procedure	800 days	CYP2C19 *2/*17 or *3/*17	n=23 (14.7%)	NR	NR	NR	NR	NR	NR
	clopidogrel	total	secondary end point	hospitalization for unstable angina, transient ischemic attack, or revascularization procedure	800 days	total	n=386(17%)	NR	NR	NR	NR	NR	NR
Chen, 2012 22071359 China NR	Clopidogrel and aspirin	TaqMan	Composite of CV death, nonfatal MI, and nonfatal stroke (primary)	Within the 1-yr followup period	NR	*2/*2 (n=57)	7	Vs. *1/*1: Unadjusted HR 4.951 Adjusted HR 5.191	For unadjusted, 1.543- 15.884 For adjusted, 1.936- 13.917	For unadjusted, 0.007 (K-M) For adjusted, 0.001 (logistic regression)	For adjusted: adjusted for age, sex, DM, smoking, drug use, stenting, and ACS vs. stable angina	NR	NONE
						*1/*2 (n=291)	12	Vs. *1/*1: Unadjusted HR 1.041 Adjusted HR 1.208	For unadjusted, 0.369- 2.945 For adjusted, 0.517- 2.822	For unadjusted, 0.939 (K-M) For adjusted, 0.662 (logistic regression)	For adjusted: adjusted for age, sex, DM, smoking, drug use, stenting, and ACS vs. stable angina	NR	NONE
						*1/*1 (n=306)	10	NA	NA	NA	NA	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Marcucci, 2012 22390861 Italy NR	Clopidogrel and aspirin	Allelic discrimination assay	MACE	CV death or nonfatal MI	Within 12 mo	*2 noncarrier (*1/*1), 892/1187 (75%)	76	NR	NR	Vs. next row, <0.001 (log rank) both at 12 mo and also at 6 mo (Ns not reported for 6 mo)	NS	NR	Figs 2 and 3
						*2 carrier (*2/*1 or *2/*2), 295/1187 (25%)	39	NR	NR	NA	NR	NR	Figs 2 and 3
					0-6 mo	*2 carrier (*2/*1 or *2/*2), 295/1187 (25%)	NR	HR vs. noncarrier, 2.3	1.3-3.9	0.003	CV risk factors, renal failure, reduced EF, multivessel disease, total stent length, bifurcation lesions, no. of lesions treated, type of stent, and use of glycoprotein IIb/IIIa inhibitors	NR	NONE
					7-12 mo	*2 carrier (*2/*1 or *2/*2), 295/1187 (25%)	NR	HR 0.8	0.2-1.1	NS	CV risk factors, renal failure, reduced EF, multivessel disease, total stent length, bifurcation lesions, no. of lesions treated, type of stent, and use of glycoprotein IIb/IIIa inhibitors	NR	NONE
Nishio, 2012 22785462 Japan NR	Clopidogrel and aspirin	TaqMan	MACE	NR	Any time during study	Extensive metabolizer (n=60)	3	NR	NR	Across this and next two rows, 0.005 (chi- square test)	NR	NR	MACE-free survival data given in Fig. 2

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Intermediate metabolizer (n=77)	17	NR	NR	Vs. previous row, 0.03 (Scheffe's post hoc teset)	NR	NR	NONE
						Poor metabolizer (n=23)	7	NR	NR	Vs. 2 rows above, 0.02 (Scheffe's post hoc teset)	NR	NR	NONE
Teixeira, 2012 22377481 Portugal NR	Clopidogrel and aspirin	PCR	Combined outcome of CV death, nonfatal MI, or readmission for UA	NR	6 mo	*2 noncarrier (*1/*1) (N=67)	4	NR	NR	NA	NR	NR	NONE
						*2 carrier (*2/*1 or *2/*2) (N=24)	6	NR	NR	0.010 vs. previous row (log-rank test)	NR	NR	NONE
			Freedom from CV death or nonfatal MI			*2 noncarrier (*1/*1) (N=67)	98.5%	NR	NR	NA	NR	NR	NONE
						*2 carrier (*2/*1 or *2/*2) (N=24)	87.5%	Univariate OR vs. previous row, 5.25 Multivariate HR vs. previous row, 4.65	For OR, 1.36-20.65 For HR, 1.28-16.8	For counts, 0.026 vs. previous row (log-rank test) For OR, 0.011 [univariate model] For HR, 0.019 [multivariate model]	NR	NR	NONE
Parri, 2012 22727972 Italy NR	Clopidogrel and aspirin	Allelic discrimination assay	MACE	Death, MI or reinfarction, ST, stroke, major bleeding, and hospitalization for cardiovascular reasons	Within 30 days	*2 noncarrier (*1/*1), 70 patients	0	NR	NR	NR	NR	NR	NONE

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*2 carrier (*2/*1 or *2/*2), 26 patients	0	NR	NR	NR	NR	NR	NONE
Hsu, 2011 21144850 Taiwan NR	esomeprazole and 75 mg or 35.5 mg/day for 2 weeks	CYP2C19*1/ CYP2C19*2/ CYP2C19*3	cardiocerebral events	cardiocerebral events	6 months	esomeprazole- plus-clopidogrel group hetEMs	1/27 =3.7%	NR	NR	NR	NR	NR	NONE
						esomeprazole- plus-clopidogrel group PMs	1/7=14.3%						
						esomeprazole- plus-clopidogrel group homEM	0/27=0						
	75 mg or 35.5 mg/day for 2 weeks	CYP2C19*1/ CYP2C19*2/ CYP2C19*3	cardiocerebral events	cardiocerebral events	6 months	clopidogrel group hetEMs	2/25=8%	NR	NR	NR	NR	NR	NONE
						clopidogrel group PMs	1/7=14.3						
						clopidogrel group homEM	0/32=0						
	75 mg or 35.5 mg/day for 2 weeks	CYP2C19*1/ CYP2C19*2/ CYP2C19*3	cardiocerebral events	cardiocerebral events	6 months	hetEMs	3/53=5.7%	NR	NR	NR	NR	NR	NONE
						PMs	2/14=14.3%						
						homEM	0/60=0						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
	75 mg or 35.5 mg/day for 2 weeks	CYP2C19*1/ CYP2C19*2/ CYP2C19*3	cardiocerebral events	cardiocerebral events	6 months	hetEMs and PMs	7.5%	difference 7.5%	5.9%-9.1%	0.032 comparing with the lower row chi square test or Fisher's exact test	NR	NR	none
Goodman, 2012 22261200 Multi-country PLATO	Clopidogrel 300- mg loading dose, 75-mg daily maintenance dose	CYP2C19 *2	MACE	cardiovascular death/MI/stroke	12 months	CYP2C19 loss- of-function carriers (*2 through *8) on a PPI n=434	34 (7.8%)	HR= 1.55	1.15–2.09	NR	no	NR	
						non carriers of CYP2C19 loss- of-function allele or not taking a PPI n=2418	80 (3.3%)						
				cardiovascular death/MI	12 months	CYP2C19 loss- of-function carriers (*2 through *8) on a PPI n=434	33 (7.6%)	HR= 1.63	1.19–2.22	NR	no	NR	
						non carriers of CYP2C19 loss- of-function allele or not taking a PPI n=2418	70 (2.9%)						
Goodman, 2012 22261200 Multi-country PLATO	Clopidogrel 300- mg loading dose, 75-mg daily maintenance dose	CYP2C19 *2	MACE	cardiovascular death/MI/stroke	12 months	CYP2C19 loss- of-function carriers (*2 through *8) not on a PPI n=954	45 (7.8%)	NR	NR	NR	no	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						non carriers of CYP2C19 loss- of-function allele on a PPI n=1097	54 (3.3%)						
Park, 2012 22735685 Korea CROSS-VERIFY	LD: 300 -600 mg of clopidogrel Aspirin 100 mg per day.	CYP2C19 *2	MACE	cardiac death, non- fatal myocardial infarction, ischaemic stroke and stent thrombosis	12 months	CYP2C19 LOF allele carriage n=NR	NR	HR= 10.822	2.863 - 63.571	P<0.001 (carrier vs noncarrier) [Cox regression]	Yes	NR	
						Non carriers of the CYP2C19 LOF allele n=NR	NR						
Siller-matula, 2012 22260716 Austria PEGASUS-PCI	clopidogrel LD 600mg, MD 75mg	CYP2C19 *2	MACE	ST, ACS, cardiac death	12 months	*2/*2 or *1/*2 N=84	11 (13.5%)			0.556 (carrier vs noncarrier) [log rank test]	No	NR	
						*1/*1 n=167	20 (12.1%)						
Siller-matula, 2012 22260716 Austria PEGASUS-PCI	clopidogrel LD 600mg, MD 75mg	CYP2C19 *2	Stent thrombosis	ST	12 months	*2/*2 or *1/*2	NR	AUC: 0.48 Sensitivity: 33% Specificity: 71%	AUC: 0.39– 0.57)	0.63 (carrier vs noncarrier)	No	NR	
						*1/*1	NR						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Rideg, 2011 21806387 Hungary DOSER	LD: 600 mg clopidogrel & 300 mg aspirin Randomized to 4 weeks of 75 or 150 mg clopidogrel MD: 75 mg clopidogrel/day	CYP2C19 *1, *2, *3 and *17	MACE	CV death ST, MI, stroke, TVR	1 year	Any LOF carrier (*1*2 or *2*2 or *1*3 or *3*3) N=45	6 (13.8)	HR=1.24	0.44-3.47	P=0.69 (LOF carrier vs noncarrier) [Cox proportional hazard model]	yes	nr	
						Non LOF carrier N=144	16 (11.1)						
			MACE	CV death ST, MI, stroke, TVR	1 year	One LOF carrier (*1*2 or *1*3) N=nr	NR	HR=0.8	0.23-2.79	P=0.72 (one LOF allele carrier vs noncarrier) [Cox proportional hazard model]	yes	nr	
						Non LOF carrier N=nr	NR						
			MACE	CV death ST, MI, stroke, TVR	1 year	Two LOF carrier (*2*2 or *3*3) N=nr	NR	HR=7.22	1.61-32.65	P=0.01 (two LOF allele carrier vs noncarrier) [Cox proportional hazard model]	yes	nr	
						Non LOF carrier N=nr	NR						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
			MACE	CV death ST, MI, stroke, TVR	1 year	Two LOF carrier (*2*2 or *3*3) AND GOF allele N=nr	NR	HR=9.44	1.96-45.38	P=0.01 (two LOF allele carrier vs noncarrier) [Cox proportional hazard model]	yes	nr	
						Non LOF carrier N=nr	NR						
Jeong, 2011 22045970 Korea NR	LD: 600 mg clopidogrel & 300 mg aspirin MD: 75 mg/d clopidogrel & aspirin 200 mg/d for 1 month and 100-200 mg/day for 1 year	CYP2C19 *1, *2, and *3	MACE	cardiovascular death, nonfatal myocardial infarction, and ischemic stroke	1 year	1/*1 N=104	2 (1.9)			P=0.013 (0,1 and 2 CYP2C19 LOF allele) [Cox regression] P=0.057 (across all groups) [Cox regression]			
						*1/*2 N=98	4 (4.1)						
						*1/*3 N=30	2 (6.7)						
						*2/*2 N=20	3 (15.0)						
						*2/*3 N=14	2 (14.3)						
			MACE	cardiovascular death, nonfatal myocardial infarction, and ischemic stroke	1 year	Carriers of 1 LOF N=162	2 (1.9)	HR=3.1	0.8-11.6	P=0.089 (carrier vs noncarrier) [Cox regression]			
						Non Carriers of 1 LOF N=104	6 (5.7)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
			MACE	cardiovascular death, nonfatal myocardial infarction, and ischemic stroke	1 year	Carriers of 2LOF N=34	5 (1.9)	HR=10.1	1.8-58.8	P=0.008 (carrier vs noncarrier) [Cox regression]			
						Non Carriers of 2 LOF N=232	8 (5.7)						
Simon, 2011 21918510 France FAST-MI	Clopidogrel LD: 300-900 mg; MD 75 mg/d	CYP2C19 LOF alleles	MACE	In-hospital death, MI, stroke in all AMI patients (n=2208)	In hospital	2 CYP2C19 LOF alleles	NR	OR=2.27	0.85–6.08	NS (2 CYP2C19 LOF alleles vs. no variant) [logistic regression]			
						No LOF variant	NR						
				death, MI, stroke in all AMI patients (n=2208)	1 year	2 CYP2C19 LOF alleles	NR	OR=1.96	1.08–3.54	P<0.05 (2 CYP2C19 LOF alleles vs. no variant) [logistic regression]			
						No LOF variant	NR						
				In-hospital death, MI, stroke in AMI pts with PCI (n=1538)	In hospital	2 CYP2C19 LOF alleles	NR	OR=6.87	2.52–18.72	P<0.05 (2 CYP2C19 LOF alleles vs. no variant) [logistic regression]			
						No LOF variant	NR						
				death, MI, stroke in AMI pts with PCI (n=1538)	1 year	2 CYP2C19 LOF alleles	NR	OR=3.29	1.52–7.15	P<0.05 (2 CYP2C19 LOF alleles vs. no variant) [logistic regression]			
						No LOF variant	NR						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Yan, 2011 21778720 China NR	Clopidogrel + Aspirin (Regimen and Dose NR)	CYP2C19 *2	MACE	cardiovascular death, nonfatal myocardial infarction and nonfatal stroke	2 year	homozygous variant (A/A): n=39	NR	HR=4.86	1.62–14.56	P= 0.005 (homozygous variant vs noncarrier) [Cox regression]	No	NR	
						heterozygous variant (G/A) n=216	NR	NR	NR	P= 0.89 (heterozygous variant vs noncarrier) [Cox regression]			
						Noncarrier (G/G) N=242	NR						
			MACE	cardiovascular death, nonfatal myocardial infarction and nonfatal stroke	2 year	homozygous variant (A/A): n=39	NR	OR=5.96	1.77–20.03	P= 0.0039 (homozygous variant vs noncarrier) [logistic regression]	Yes (age, gender,BMI, diabetes, hypertension, smoke, prior re- vascularized history, prior pharmacological treatment, subtype of ACS, exposure to drugs, stent implantation, Killip class, creatinine clearance rate and GRACE Score)	NR	
						heterozygous variant (G/A) n=216	NR	OR=1.054	0.4-2.81	P= 0.92 (heterozygous variant vs noncarrier) [logistic regression]			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Noncarrier (G/G) N=242	NR						
			MACE	cardiovascular death, nonfatal myocardial infarction and nonfatal stroke	2 year	Genotype (details NR)	NR	AUC=0.61	0.49-0.73	P=0.059 (NR) [ROC analysis]	No	NR	
Hulot, 2011 21972404 France AFIJI	MD clopidogrel 75 mg/d	CYP2C19 *2-*6	MACE	cardiovascular death, nonfatal MI, and urgent revascularization	6 months	CYP2C19 loss- of-function alleles (*2 through *6): 107	NR	HR=2.26	1.15-4.41	P=0.02 (LOF vs no LOF) [log rank test]	No	NR	
						No CYP2C19 loss-of-function alleles: 262	NR						
Roberts, 2012 22464343 Canada RAPID GENE	CYP2C19*2 Carriers : 10 mg prasugrel daily Non-carriers: 75 mg clopidogrel daily	CYP2C19*2	<ACE	cardiovascular death, non-fatal myocardial infarction, readmission to hospital, and stent thrombosis	30 days	*1/*2 or *2/*2 N=46	0	NR	NR	NR	NR	NR	
						*1/*1 N=141	0						

Abbreviations: AFIJI = Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention registry; EXCELSIOR = Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation study; NR = not reported; NS = non-significant; TRITON-TIMI 38 = Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction.

Appendix Table D11. Clinical outcome information—bleeding													
Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Mega, 2009 19106084 Multinational Genetics substudy of TRITON-TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction]	Clopidogrel 300 mg loading dose, 75 mg maintenance	CYP2C19	Minor or major bleeding	TIMI major or minor bleeding not related to CABG; all outcomes were adjudicated by a committee unaware of group assignments	Up to 15 mo (maximum duration of treatment on trial)	IM or PM (1/*2A, *1A/*3, *1A/*4, *1A/*8, *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8)	N = 11 Rate = 12.1% (Kaplan-Meier)	HR = 1.01	0.51, 2.01	0.98 [Kaplan- Meier]	YES [ACS subtype (STE or NSTE was used as a stratification factor)]	NO	Secondary outcome
						EM (*1A/*1A) N = 1061 (patients who received clopidogrel treatment)	N = 30 Rate = 8.0% (Kaplan-Meier rate)						
Gladding, 2009 19926050 New Zealand NR	Clopidogrel 150 mg daily	Autogenomics 2C19+ assay	Bleeding	NR	7 d	CYP2C19*2 (and CYP2C9*3) carriers N=NR	0	NR	NR	NR	NR	NR	NR
						CYP2C19*2/*17 N=NR	0						
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	Clopidogrel 600 mg loading dose; clopidogrel 75 mg (1/d) and aspirin 100 mg (2/d) maintenance.	CYP2C19 *17	TIMI major and minor bleeding	Combined major or minor bleeding according to TIMI criteria	30 d	*17/*17 N = 76	6 (7.9%)	OR = 3.27	1.33, 8.10	(*17/*17 vs. *1/*1) [logistic regression] P = 0.1 (across 3 groups) [chi- square test for trend]	NO	NO	Primary safety endpoint
						*17/*1 N = 546	22 (4%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*1/*1 N = 902	23 (2.5%)						
			TIMI major and minor bleeding	Combined major or minor bleeding according to TIMI criteria	30 d	*17/*17 or *17/*1 N = 622	28 (4.5%)	OR = 1.80	1.03, 3.14	NR	NO	NO	Primary safety endpoint
						*1/*1 N = 902	23 (2.5%)						
			TIMI major and minor bleeding	Combined major or minor bleeding according to TIMI criteria	30 d	*17/*17 or *17/*1 N = 622	28 (4.5%)	OR = 1.85 OR = 3.41	1.19, 2.86 1.42, 8.17	P = 0.006 (carriers vs. non- carriers) [multivariable logistic regression] P = NR (*17/*17 vs. *1/*1) [multivariable logistic regression]	YES (age, sex, BMI, serum Creatinine, PPIs, abciximab, clopidogrel loading interval)	NO	Primary safety endpoint
						*1/*1 N = 902	23 (2.5%)						
			TIMI major bleeding	Major bleeding according to TIMI criteria	30 d	*17/*17 N = 76	1 (1.3%)	OR = 2.04 OR = 2.39	0.68, 6.12 0.95, 2.10	(carriers vs. non- carriers)[logistic regression] (*17/*17 vs. *1/*1) [logistic regression] P = 0.22 (across 3 groups) [chi- square test for trend]	NO	NO	Secondary safety endpoint

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*17/*1 N = 546	6 (1.1%)						
						*1/*1 N = 902	5 (0.6%)						
			TIMI minor bleeding	Minor bleeding according to TIMI criteria	30 d	*17/*17 N = 76	5 (6.6%)	OR = 1.72 OR = 3.46	0.92, 3.22 1.30, 9.27	(carriers vs. non- carriers)[logistic regression] (*17/*17 vs. *1/*1) [logistic regression] P = 0.025 (across 3 groups) [chi- square test for trend]	NO	NO	Secondary safety endpoint
						*17/*1 N = 546	16 (2.9%)						
						*1/*1 N = 902	18 (2%)						
			Fatal intracranial bleeding	Fatal intracranial bleeding	30 d	*17/*17 N = 76	1 (1.3%)	NR	NR	NR	NO	NO	Not mentioned as an explicit predefined endpoint
						*17/*1 N = 546	1 (0.2%)						
						*1/*1 N = 902	0 (0%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Wallentin, 2010 20801498 Multiple countries (43 countries in North America, South America, Europe, Asia, Australia) PLATO	75 mg clopidogrel once daily (300–600 mg loading dose)	CYP2C19 genotyping	Major bleeding	Major bleeding	Median treatment duration = 277 d	Any LOF allele (*2- *8) N = 1380	143 (10%)	NR	NR	NR	NO	NO	None
						No LOF allele N = 3506	340 (10%)						
			Major bleeding	Major bleeding	Median treatment duration = 277 d	No LOF or GOF allele N = 1856	161 (9%)	NR	NR	0.022 GOF allele vs. all others [Cox regression]	NO	NO	None
						Any LOF but no GOF allele N = 1053	108 (10%)						
						Any GOF allele N = 1977	214 (11%)						
			Major bleeding related to non- CABG	Major bleeding related to non- CABG	Median treatment duration = 277 d	Any LOF allele (*2- *8) N = 1380	41 (3%)	NR	NR	NR	NO	NO	None
						No LOF allele N = 3506	110 (3%)						
			Major bleeding related to CABG	Major bleeding related to CABG	Median treatment duration = 277 d	Any LOF allele (*2- *8) N = 1380	107 (8%)	NR	NR	NR	NO	NO	None
						No LOF allele N = 3506	246 (7%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Bonello 2010 20708365 France NR	Oral LDs of 250 mg aspirin and 600 mg clopidogrel	CYP2C19*2	TIMI major bleeding	TIMI major bleeding	In hospital	Wild-type N = 277	0 (%)	NR	NR	NS	NR	NR	None
						Heterozygotes 2C19*2 N = 123	0 (0%)						
						Homozygotes 2C19*2 N = 11	0 (0%)						
			TIMI minor bleeding	TIMI minor bleeding	In hospital	Wild-type N = 277	4 (1%)	NR	NR	NS	NR	NR	None
						Heterozygotes 2C19*2 N = 123	0 (0%)						
						Homozygotes 2C19*2 N = 11	0 (0%)						
			TIMI major or minorbleeding	TIMI minor bleeding	In hospital	Wild-type N = 277	4 (1%)	NR	NR	NS	NR	NR	None
						Heterozygotes 2C19*2 N = 123	0 (0%)						
						Homozygotes 2C19*2 N = 11	0 (0%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Sorich, 2010 20492467 707 sites in 30 countries Substudy of TRITON-TIMI 38	clopidogrel (300-mg loading dose and 75- mg daily maintenance dose) for 6–15 months.	CYP2C19	Major or minor bleeding	Major or minor bleeding	15 months	extensive metabolizers	NR	3.4%	2.6- 4.2	NR	NR	No	
			Major or minor bleeding	Major or minor bleeding	15 months	RM	NR	3.5%	2.0- 5.5	NR	NR	No	
Pare 2010 20979470 Multinational CURE	clopidogrel (at a dose of 75 mg per day) in combination with aspirin	CYP2C19	Major Bleeding - CURE trial	Major bleeding	12 months	Poor metabolizers N = 61	0 (0%)	NR	NR	NR	NR	NR	None
						Intermediate metabolizers N = 437	19 (4%)						
						Extensive metabolizers N = 1033	42 (4%)						
						Ultra metabolizers N = 847	39 (5%)						
						Unknown status N = 152	2 (1%)						
Pare 2010 20979470 Multinational ACTIVE-A	clopidogrel (at a dose of 75 mg per day) in combination with aspirin	CYP2C19	Major Bleeding – ACTIVE trial	Major bleeding	Median 3.6 y	Poor N = 9	0 (0%)	NR	NR	NR	NR	NR	None
						Intermediate metabolizers N = 93	10 (11%)						
						Extensive metabolizers N = 199	10 (5%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Ultra metabolizers N = 222	8 (4%)						
						Unknown status N = 37	4 (11%)						
Campo 2011 21679849 Italy NR	Clopidogrel + aspirin	TaqMan	Bleeding event	Major + minor (TIMI classification)	1 mo to 1 yr after PCI	*2 noncarriers N = 219	219	16 (7.3%)	NR	0.4 vs, next row [Fisher exact test]	NO	NO	no
						*2 carriers N = 81	81	3 (3.7%)					
						*17 noncarriers N = 198	198	6 (3%)	NR	0.01 vs, next row [Fisher exact test]		NO	NO
						*17 carriers N = 102	102	13 (1.7%)					
				Superficial (BleedScore classification)	1 mo to 1 yr after PCI	*2 noncarriers N = 219	219	22 (10.1%)	NR	NR	NO	NO	NO
						*2 carriers N = 81	81	8 (9.8%)					
						*17 noncarriers N = 198	198	4 (2.0%)	NR	NR	NO	NO	NO
						*17 carriers N = 102	102	18 (9.1%)					
				Internal (melena, hematuria, hematemesis, epistaxis)+ alarming (intracranial or needing transfusion)	1 mo to 1 yr after PCI	*2 noncarriers N = 219	219	20 (9.1%)	NR	0.4 vs, next row [Fisher exact test]	NO	NO	NO

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*2 carriers N = 81	81	6 (7.4%)					
						*17 noncarriers N = 198	198	10 (5%)	NR	0.01 vs, next row [Fisher exact test]	NO	NO	NO
						*17 carriers N = 102	102	16 (16%)					
				“Composite bleeding endpoints”	1 mo to 1 yr after PCI	*17 carriers N = 102	NR	HR = 2.3	1.03- 5.3	0.03 [Cox proportional hazards model]	YES [age, on- clopidogrel platelet reactivity at 30 d, additional clinical, angiographic, and genetic characteristics]	NO	NO
						*17 noncarriers N = 198	NR						
Harmsze, 2012 22228204 Netherlands NR	Clopidogrel	Real-time PCR	TIMI major bleeding	NR	1 yr after PCI	Ultrarapid metabolizer (*1 or *17/*17) [n=240]	5.0%	HR 2.7 vs. extensive metabolizer	1.1- 7.0	For HR, 0.039 Also 0.048 among this and next 2 rows [Cox proportional hazards]	YES (sex, age, BMI, current smoking, eGFR <60ml/min, clopidogrel loading dose, coumarin use)	NR	NONE
								HR adj. for LTA, 2.8 HR adj. for VerifyNow, 2.4	1.1- 7.7 1.0- 6.3	0.038 0.046 [Cox proportional hazards]	YES (same as above + ptatelet function data)		
						Extensive metabolizer (*1/*1) [n=351]	2.0%	NR	NR	NR			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Intermediate/poor metabolizer (*2/*1, *2, or *17) [n=229]	2.3%	HR 1.3 vs. extensive metabolizer	0.45- 4.0	0.60 [Cox proportional hazards]	YES (sex, age, BMI, current smoking, eGFR <60ml/min, clopidogrel loading dose, coumarin use)		
Luo, 2011 22118006 China NR	LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d	CYP2C19 *1/*1	bleeding	bleeding	6 months	CYP2C19 *1/*1	33/936	HR 0.72	0.38- 2.58	>0.05 comparing with the next row chi-square test	NR	NR	
		CYP2C19 *1/*2 or *2/*2				CYP2C19 *1/*2 or *2/*2	30/802						
Dai, 2012 22704413 China NR	Clopidogrel and aspirin	PCR-FRLP	TIMI total bleeding	Major or minor, including GI bleed, purpura, hematuria, retinal bleeding, and intracranial hemorrhage	1 month	*17/*17 (n=6)	1	NR	NR	NS vs. wild type/wild type [chi-square test for trend]	NR	NR	NONE
						*17/wild type (n=71)	10			<0.01 vs. wild type/wild type [chi-square test for trend]	NR		
						Wild type/wild type (n=443)	20				NR		
						*17 carriers (n=77)	11	OR 1.95	1.31- 3.16	<0.01 vs. noncarriers [mutiple logistic regression model]	YES age, sex, BMI, serum creatinine		
						*17 noncarriers (n=443)	20				NR		
			TIMI major bleeding			*17/*17 (n=6)	1			NS vs. wild type/wild type [chi-square test for trend]	NR		

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						*17/wild type (n=71)	5			<0.05 vs. wild type/wild type [chi-square test for trend]	NR		
						Wild type/wild type (n=443)	9				NR		
			TIMI minor bleeding			*17/*17 (n=6)	0			<0.01 vs. wild type/wild type [chi-square test for trend]	NR		
						*17/wild type (n=71)	5			<0.01 vs. wild type/wild type [chi-square test for trend]	NR		
						Wild type/wild type (n=443)	11				NR		
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19*2or*3 (carrier of loss of function allele)	major bleeding	major bleeding	800 days	CYP2C19*2 or *3	carriers 28/665	NR	NR	0.59 comparing with non-carriers log-rank test	NR	NR	NR
							non-carriers 60/1601						
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19*2or*3 (carrier of loss of function allele)	all bleedings	all bleedings	800 days	CYP2C19*2 or *3	carriers 240/665	NR	NR	0.005 comparing with non-carriers log-rank test	NR	NR	NR
							non-carriers 681/1601						
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19*2or*3 (carrier of gain of function allele)	major bleeding	major bleeding	800 days	CYP2C19*17	carriers 32/872	NR	NR	0.677 comparing with non-carriers log-rank test	NR	NR	NR
							non-carriers 56/1394						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19*2or*3 (carrier of gain of function allele)	all bleedings	all bleedings	800 days	CYP2C19*17	carriers 367/872	NR	NR	0.203 comparing with non-carriers log-rank test	NR	NR	NR
							non-carriers 554/1394						
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19*2/*2 or *2/*3	major bleeding	major bleeding	800 days	CYP2C19*2/*2	n=0 (0)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19 wt/*2 or wt/*3	major bleeding	major bleeding	800 days	CYP2C19 wt/*2 or wt/*3	n=22(4.8%)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19 wt/wt	major bleeding	major bleeding	800 days	CYP2C19 wt/wt	n=34 (3.8%)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19 Wt/*17 or *17/*17	major bleeding	major bleeding	800 days	CYP2C19 Wt/*17 or *17/*17	26 (3.6%)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19 *2/*17 or *3/*17	major bleeding	major bleeding	800 days	CYP2C19 *2/*17 or *3/*17	n=6 (3.8%)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	total	major bleeding	major bleeding	800 days	total	n=88 (3.9%)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19*2/*2 or *2/*3	all bleeding	all bleeding	800 days	CYP2C19*2/*2	n=11 (21.2%)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19 wt/*2 or wt/*3	all bleeding	all bleeding	800 days	CYP2C19 wt/*2 or wt/*3	n=174(38.1%)	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19 wt/wt	all bleeding	all bleeding	800 days	CYP2C19 wt/wt	n=369 (41.7%)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19 Wt/*17 or *17/*17	all bleeding	all bleeding	800 days	CYP2C19 Wt/*17 or *17/*17	312(43.6%)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	CYP2C19 *2/*17 or *3/*17	all bleeding	all bleeding	800 days	CYP2C19 *2/*17 or *3/*17	n=55 (35.3%)	NR	NR	NR	NR	NR	NR
Bhatt, 2012 22450429 USA CHARISMA	clopidogrel	total	all bleeding	all bleeding	800 days	total	n=921 (40.6%)	NR	NR	NR	NR	NR	NR
Kim, 2012 22007612 Korea ACCEL-TRIPLE	cilostazol 100 mg twice a day clopidogrel 75 mg once a day aspirin 200mg once a day	CYP2C19	bleeding	bleeding	30 days	EM	48	0/48=0	NR	NR	NR	NR	none
						IM	54	0/54=0					
						PM	25	0/25=0					
Goodman, 2012 22261200 Multi-country PLATO	Clopidogrel 300-mg loading dose, 75-mg daily maintenance dose	CYP2C19 *2	major bleeding	TIMI major bleeding	12 months	CYP2C19 loss-of- function carriers (*2 through *8) on a PPI n=434	35 (8%)	HR= 1.46	1.08– 1.96	NR	no	NR	
						non carriers of CYP2C19 loss-of- function allele or not taking a PPI n=2418	126 (5.2%)						
Siller-matula, 2012 22260716 Austria PEGASUS-PCI	clopidogrel LD 600mg, MD 75mg	CYP2C19 *2	Major bleeding	TIMI major bleeding	12 months	regular metabolizers (CYP2C19*1/*1) n=167	4 (2.2%)			0.487 (carrier vs noncarrier) [log rank test]	No	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						ultra-metabolizers (CYP2C19*1/*17 or *17/*17) N=141	6 (4.1%)						
		CYP2C19 *2	Major bleeding	TIMI major bleeding	12 months	regular metabolizers (CYP2C19*1/*1) n=167	5 (2.9%)	NR	NR	P = 0.053 (ANOVA) (between regular and heterozygote and homozygote poor metabolizers)			
						heterozygote ultra- metabolizers (CYP2C19*1/*17 N=nr	2%						
						homozygote ultra- metabolizers (CYP2C19*17/*17 n=NR	9.5%						
Jeong, 2011 22045970 Korea NR	LD: 600 mg clopidogrel & 300 mg aspirin MD: 75 mg/d clopidogrel & aspirin 200 mg/d for 1 month and 100-200 mg/day for 1 year	CYP2C19 *1, *2, and *3	Bleeding	All bleeding	1 year	1/*1 N=104	3 (2.9)	NR	NR	P=0.810 (0,1 and 2 CYP2C19 LOF allele) [Cox regression] P=0.057 (across all groups) [Cox regression]			
						*1/*2 N=98	1 (1.0)						
						*1/*3 N=30	4 (13.3)						
						*2/*2 N=20	0						
						*2/*3 N=14	0						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Jeong, 2012 22837373 Korea ACCEL-DM	elective patients LD clopidogrel 300mg. Acute MI clopidogrel LD 600 mg. after randomization, triple group receive cilostazol 100mg bid, clopidogrel 75mg MD, aspirin 200 mg/d, double group receive clopidogrel 150mg/d MD, and aspirin 200 mg/d.	CYP2C19	bleeding events	bleeding events	30-day	CYP2C19*1	46	0/46	NR	NR	NR	NR	comparing with the lower row 0.097 t-test
						CYP2C19*2	26	0/26					
						CYP2C19*3	8	0/8					

Abbreviations: NR = not reported; NS = non-significant.

Appendix Table D12. Clinical outcome information—stroke													
Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Mega 2009 19106084 Multinational Genetics substudy of TRITON-TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction]	Clopidogrel 300 mg loading dose, 75 mg maintenance	CYP2C19	Non-fatal stroke	NR; all outcomes were adjudicated by a committee unaware of group assignments	Up to 15 mo (maximum duration of treatment on trial)	IM or PM (1/*2A, *1A/*3, *1A/*4, *1A/*8, *2A/*2A, *2A/*3, *2A/*4, *2A/*5A, *2A/*8) N = 395	N = NR Rate = 0.88% (Kaplan- Meier)	HR = 3.93	0.66, 23.51	NR	ACS subtype (STE or NSTE was used as a stratification factor)	NO	Secondary outcome
						EM (*1A/*1A) N = 1064	N = NR Rate = 0.24% (Kaplan-Meier rate)						
Sibbing, 2009 19193675 Germany NR	Clopidogrel 600 mg loading dose before stent placement	CYP2C19 *2	Ischemic stroke	Confirmed by brain CT or MRI	30 days	CYP2C19 *2 carriers (*2/*2 and *2/*1) N = 680	4	NR	NR	0.001	NO	NO	None
						CYP2C19 non- carriers (*1/*1) N = 1805	0						
Bonello, 2010 20708365 France NR	All patients received oral LDs of 250 mg aspirin and 600 mg clopidogrel at least 6 h before the first VASP index measurement	CYP2C19	stroke	stroke	In hospital	Wild-type N = 277	1 (<1%)	NR	NR	NS	NR	NR	None
						Heterozygotes 2C19*2 N = 123	0 (0%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
						Homozygotes 2C19*2 N = 11	0 (0%)						
Yamamoto 2011 21168310 Japan NR	clopidogrel	CYP2C19*2 or *3	Ischemic stroke	Ischemic stroke	NR	carriers	2/62	NR	NR	NR	NR	NR	
		CYP2C19*1/*2	Stroke	Stroke	1 days	CYP2C19*1/*2	NR	NR	NR	NR	NR	NR	
			Stroke	Stroke	10 days	CYP2C19*1/*2	NR	NR	NR	NR	NR	NR	
		CYP2C19*2/*2	Cardiovascular death	Cardiovascular death	74 days	CYP2C19*2/*2	NR	NR	NR	NR	NR	NR	
Tiroch, 2010 20826260 Germany NR	aspirin (100mg twice daily) and clopidogrel (75mg once Daily)	CYP2C19*2 GG	Stroke	Stroke	1 year	CYP2C19*2 GG	680	N(%) 8(1.2)	NR	0.085 CYP2C19*2 GG vs *2 A allele	NR	NR	
		CYP2C19*2 A allele	Stroke	Stroke	1 year	CYP2C19*2 A allele	248	N(%) 0(0)	NR		NR	NR	
		CYP2C19*2 GG	Stroke	Stroke	1 year	CYP2C19*2 GG	565	N(%) 5 (0.9)	NR	0.93 CYP2C19*17 CC vs T allele	NR	NR	
		CYP2C19*2 A allele	Stroke	Stroke	1 year	CYP2C19*2 A allele	363	N(%) 3 (0.8)	NR		NR	NR	
Luo, 2011 22118006 China NR	LD clopidogrel 300mg and MD 75mg/d and aspirin 300mg LD and MD 100mg/d	CYP2C19 *1/*1	stroke	ischaemic stroke	6 months	CYP2C19 *1/*1	21/936	HR 2.23	1.18- 9.27	<0.05 comparing with the next row chi-square test	NR	NR	
		CYP2C19 *1/*2 or *2/*2				CYP2C19 *1/*2 or *2/*2	39/802						

Appendix Table D13. Clinical outcome information—other clinical events													
Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Collet 2009 19108880 France AFIJI	Clopidogrel (75 mg maintenance dose for at least 1 mo)	CYP2C19 *2	Urgent revascularization	Coronary (any vessel) revascularization (any type of PCI or CABG) decided within 24 h of a recurrent episode of myocardial ischemia	Mean FU = 2.8 yr	Carriers (*2/*2 or *2/*1) N = 73	3 (4%) 2.18 events per 100 person-years	HR = 1.94 Adjusted HR = 3.24	0.43, 8.73 0.69, 15.09	0.38 0.13	Unadjusted Adjusted [baseline BMI, smoking status, diabetes status, stent implantation, initial STE MI, use of PPI]	NO	NO
						Non-carriers (*1/*1) N = 186	4 (2%) 1.05 events per 100 person-years						
						Carriers (*2/*2 or *2/*1) N = 73	6 (8%) 5.09 events per 100 person-years	HR = 2.38 Adjusted HR = 3.31	0.79, 7.13 1.05, 10.47	0.11 0.04	Unadjusted Adjusted [baseline BMI, smoking status, diabetes status, stent implantation, initial STE MI, use of PPI]		
			Ischemic endpoint not related to stent thrombosis	Acute coronary events occurring either in patients who did not receive a stent or in those with recurrent events affecting a non- stented artery	Mean FU = 2.8 yr		7 (4%) 1.99 events per 100 person-years						The authors stated that “when we took into account the other CYP2C19 variants (*3 to *6) that were present in 3 patients without the CYP2C19*2 variant, the overall results did not change”

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
			First cardiovascular event				NR	HR = 4.04	1.81, 9.02	0.0006	Adjusted (multivariable step- wise Cox regression, after elimination CYP2C19*2 was the only factor independently associated with the outcome) Stated that “we noted no significant effect of use of PPIs”	NO	Selection of covariates based on p-value criteria; additional information in Table 1 of the manuscript
							NR						
			First cardiovascular event; limited to stent implantation	Survival free of a cardiovascular event	Mean FU = 2.8 yr	Carriers (*2/*2 or *2/*1) N = 61 (patients with stent implantation)	n=61	HR = 4.09	1.81, 9.25	0.0008	Adjusted (multivariable step- wise Cox regression, after elimination CYP2C19*2 was the only factor independently associated with the outcome) Stated that “we noted no significant effect of use of PPIs”	NO	Selection of covariates based on p-value criteria; additional information in Table 1 of the manuscript
						Non-carriers (*1/*1) N = 162 (patients with stent implantation)	n=162						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Wallentin, 2010 20801498 Multiple countries (43 countries in North America, South America, Europe, Asia, Australia) PLATO	75 mg clopidogrel once daily (300–600 mg loading dose)	CYP2C19 genotyping	Net clinical benefit	net clinical benefit	from 31 days through end of followup (≤360 days)	Any LOF allele (*2-*8) N = 1388	n=1388	231/1388(16.6%) 17.1% actuarial	NR	NR	NR	NR	no
						No LOF allele N = 3516	n=3516	533/3516 (15.2%) 15.8% actuarial	NR	NR			
Bonello, 2010 20708365 France NR	All patients received oral LDs of 250 mg aspirin and 600 mg clopidogrel at least 6 h before the first VASP index measurement	CYP2C19	Urgent revascularization	Urgent revascularization	In hospital	Wild-type N = 277	0 (0%)	NR	NR	NS	NR	NR	None
						Heterozygotes 2C19*2 N = 123	0 (0%)						
						Homozygotes 2C19*2 N = 11	0 (0%)						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Sawada, 2010 21099121 Japan NR	loading dose of clopidogrel (300 mg) and maintenance dose of clopidogrel (75 mg/day) and aspirin (100 mg/day)	CYP2C19	Target vessel revascularization	Target vessel revascularization	Mean 243.8 days	Non-carrier N = 58	9 /58(15.5)	NR	NR	0.11, Non- carrier vs *2 carrier	NO	NO	NO
			Target vessel revascularization	Target vessel revascularization	Mean 243.8 days	*2 carrier N = 42	13/42 (31%)	NR	NR				
			Target lesion revascularization	Target lesion revascularization	Mean 243.8 days	Non-carrier N = 58	6/58 (10.3)	NR	NR	0.06, Non- carrier vs *2 carrier	NO	NO	NO
			Target lesion revascularization	Target lesion revascularization	Mean 243.8 days	*2 carrier N = 41	11/41 (26.1)	NR	NR				
Delaney, 2012 22190063 USA NR	clopidogrel	CYP2C19*2	revascularization	revascularization	2 years	CYP2C19*2 SNP rs4244285	NR	HR=1.54	1.14- 2.07	0.004 comparing with non carrier of *2	No	NR	NR
	clopidogrel	CYP2C19*17	revascularization	revascularization	2 years	CYP2C19*17 SNP rs4244285	NR	HR=0.86	0.66- 1.11	0.247 comparing with non carrier of *17	No	NR	NR
Chen, 2012 22071359 China NR	Clopidogrel	TaqMan	Death from any cause	Within the 1-yr followup period	NR	*2/*2 (n=57)	3	Vs. *1/*1: Unadjusted HR 2.287	0.587- 8.908	0.233 (K-M)	NO	NR	HRs not adjusted for this endpoint
						*1/*2 (n=291)	18	Vs. *1/*1: Unadjusted HR 2.159	0.877- 5.315	0.094)			
						*1/*1 (n=306)	12	NA	NA	NA			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Genotype groups	No. with outcome status within phenotype group	Comparative metric	95% CI	P (between which groups?) [statistical test]	Statistical Adjustment [If YES, for what factors?]	Procedures for multiple comparisons	Comments
Nishio, 2012 22785462 Japan NR	Clopidogrel and aspirin	TaqMan	Target-vessel revascularization	NR	Any time during study	Extensive metabolizer (n=60)	2	NR	NR	Across this and next two rows, 0.008 (chi-square test)	NR	NR	TLR-free survival data given in Fig. 2
						Intermediate metabolizer (n=77)	14	NR	NR	Vs. previous row, 0.04 (Scheffe's post hoc test)	NR	NR	NONE
						Poor metabolizer (n=23)	6	NR	NR	Vs. 2 rows above, 0.02 (Scheffe's post hoc teset)	NR	NR	NONE
Kim, 2012 22007612 Korea ACCEL- TRIPLE	cilostazol 100 mg twice a day clopidogrel 75 mg once a day aspirin 200mg once a day	CYP2C19	major cardiovascular event	major cardiovascular event	30 days	EM	48	0/48=0	NR	NR	NR	NR	none
						IM	54	0/54=0					
						PM	25	0/25=0					

Abbreviations: AFIJI = Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention registry; NR = not reported; NS = non-significant (used only when the exact p-value was not reported)

Appendix Table D14. Platelet reactivity during followup (discrete outcome)															
Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Giusti, 2007 18004210 Italy NR	LD: Clopidogrel 600 mg (orally) + 500 mg ASA (IV); MD: clopidogrel 75 mg and ASA 100 mg (both daily)	CYP2C19 *2	Aggregation with ADP 10 µmol/L	% maximal aggregation (discrete); cut- off based on previous literature	24 h after PCI (6 d for patients receiving IIb/IIIa inhibitors)	*2/*2 N = 40	High RPR	14 (35.0%)	≥70%	NR	NR	P=0.002 (across 3 groups) [chi- square test]	NO	NO	Additional data in combin- ation with AA as the agonist were not extracted (not agonist of interest to the report)
						*2/*1 N = 406 [unclear why the sample size changed]		85 (20.9%)							
						*1/*1 N = 973 [unclear why the sample size changed]		156 (16.0%)							
Jinnai, 2009 19531897 Japan Partly industry funded	low-dose aspirin (81- 100 mg/day) at enrollment; Clopidogrel LD= 300 mg on the first day + 75 mg/day MD.	CYP2C19 *2, *3 and *1	IPA	Change in platelet reactivity compared to baseline	48h	PM = *2/*2 or *2/*3 N = 6	Responders	1	IPA ≥ 30%	NR	NR	NR	NR	NO	None

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						IM = *2/*1 or *3/*1 N = 8	Responders	1	IPA ≥ 30%						
						EM = *1/*1 N = 11	Responders	7	IPA ≥ 30%						
						PM = *2/*2 or *2/*3 N = 6	Hypo- responders	3	10% ≤ IPA <30%						
						IM = *2/*1 or *3/*1 N = 8	Hypo- responders	6	10% ≤ IPA <30%						
						EM = *1/*1 N = 11	Hypo- responders	3	10% ≤ IPA <30%						
						PM = *2/*2 or *2/*3 N = 6	Non- responders	2	IPA < 10%						
						IM = *2/*1 or *3/*1 N = 8	Non- responders	1	IPA < 10%						
						EM = *1/*1 N = 11	Non- responders	1	IPA < 10%						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Cuisset, 2011 21803320 France NR	LD clopidogrel 600 mg and aspirin 250 mg, low responders received higher 150 mg MD clopidogrel	CYP2C19 *2 (rs4244285)	PRI VASP	PRI VASP>50% as clopidogrel low response	after LD clopidogrel	CYP2C19 *2 carrier	low response	46/86	PRI VASP >50%	46/86=53%	NR	0.04 chi-square test	NR	NR	NR
						CYP2C19*2 non carrier		105/260		105/260=41%					
Cuisset, 2011 21803320 France NR	LD clopidogrel 600 mg and aspirin 250 mg, low responders received higher 150 mg MD clopidogrel	CYP2C19 *2 (rs4244285)	PRI VASP	PRI VASP>50% as clopidogrel low response	1 month	CYP2C19*2 carrier	low response	NR	PRI VASP >50%	9.5%	NR	<0.01 chi-square test	NR	NR	NR
						CYP2C19*2 non carrier		NR		15.7%					

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Frere, 2008 18394438 France NONE	600 mg loading dose of clopidogrel + 250 mg aspirin	CYP2C19 *2 genotyping	ADP-induced reactivity by LTA	Measurement of ADP- stimulated aggregation	At the catheteri- zation laboratory (≥12h after the loading dose)	*2/*2	HPR +	10	>70% of baseline	NR	NR	0.03 [using a recessive model for the prevalence of HPR+ among *2/*2 patients] 0.03 [comparing the prevalence of HPR+ among *2/*1 patients; unclear genetic model]	NR	NO	Unclear reporting of statistical analyses but 2x3 data are adequate to recon- struct the analysis
						*2/*2	HPR -	13	<70% of baseline	NR	NR				
						*2/*1	HPR +	28	>70% of baseline	NR	NR				
						*2/*1	HPR -	115	<70% of baseline	NR	NR				
						*1/*1	HPR +	110	>70% of baseline	NR	NR				
						*1/*1	HPR -	325	<70% of baseline	NR	NR				
Frere, 2009 19496924 France Part of larger observational study	600 mg clopidogrel loading dose	CYP2C19 *17	VASP phosphorylation assay	Proportion of patients with PRI VASP >50%	After clopidogrel loading dose (exact timing NR)	*17/*17 and *17/*1 (carriers vs. non-carriers) N = 214	HPR+ = 50% HPR- = 50%	HPR+ = 107 HPR- = 107	>50% vs. ≤50%	NR	NR	P=0.007 (carriers vs. non- carriers) [analysis method NR]	NO	NO	None
						*1/*1 N = 382	HPR+ = 63% HPR- = 37%	HPR+ = 241 HPR- = 141							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Bonello-Palot 2009 19932784 France NR	600 mg clopidogrel LD	CYP2C19 *2	high on treatment platelet reactivity (HTPR)	Patients with a VASP index >50%	>6 to <12 hours after 600 mg clopidogrel LD	≥ 1 CYP2C19*2 allele (*2/*2 or Wild- type/*2)	HTPR+	17/43 (39.5%)	VASP index >50%	Calculated DOR: 3.27	1.04, 10.2	P=0.04 (≥ 1 CYP2C19*2 allele vs wild- type)	NO	NR	None
						Wild-type genotype (Wild- type/wild- type)	HTPR+	26/43 (60.5%)	VASP index >50%						
			Good responders	Patients with a VASP index <50%	>6 to <12 hours after 600 mg clopidogrel LD	≥ 1 CYP2C19*2 allele (*2/*2 or Wild- type/*2)	HTPR-	5/30 (16.7%)	VASP index <50%						
						Wild-type genotype (Wild- type/wild- type)	HTPR-	25/30 (83.3%)	VASP index <50%						
	600 mg loading dose (LD) of clopidogrel in good responders & 4 subsequent doses LD of of 600-mg clopidogrel	CYP2C19 *2	Failed Dose adjustment	VASP reactivity <50% after 4 LD of 600 mg clopidogrel	>6 to <12 hours after 4th 600 mg clopidogrel LD	≥ 1 CYP2C19 *2 allele (*2/*2 or Wild- type/*2)	Failed dose+	3/10 (30%)	VASP index >50%	Calculated DOR: 0.99	0.23, 4.25	P=0.01 (≥ 1 CYP2C19*2 allele vs wild- type)	NO	NR	The data reported in the table and text is discrepant with the calculate values; for example the percent- ages reported in the text varies

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Wild-type genotype (Wild- type/wild- type)	Failed dose+	7/10 (70%)	VASP index >50%						
			Successful Dose adjustment			≥ 1 CYP2C19*2 allele (*2/*2 or Wild- type/*2)	Failed dose-	19/63 (30.1%)	VASP index <50%						
						Wild-type genotype (Wild- type/wild- type)	Failed dose-	44/63 (69.9%)	VASP index <50%						
Harmsze 2010 19934793 Netherlands NR	clopidogrel mainten- ance: 75 mg/day	CYP2C19*2	Poor responder	>70% aggregation using 20 mmol/l ADP (LTA)	NR (Before stenting)	Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	Poor responder +	20% (N calculated as 59)	>70% aggregation	OR: 3.7	2.0,6.9	P<0.001 (Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1))	NO	YES; false discovery rate test (q value threshold 0.20)	
										OR: 3.8	2.0,7.2	P<0.001 (Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1))	YES; adjusted for gender, age, BMI, DM, previous MI, days of clopidogrel administration before intervention, CYP3A4-metabolized statins, Ca ⁺ channel blockers, PPI, SSRIs, and NSAIDs.	YES; false discovery rate test (q value threshold 0.20)	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	clopidogrel mainten- ance: 75 mg/day	CYP2C19*2	Poor responder	PRU value greater than 235 (VerifyNow P2Y12 assay).	NR (Before stenting)	Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	Poor responder +	NR	>235 PRU	OR: 2.8	1.6,5.0	P<0.001 (Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1))	NO	YES; false discovery rate test (q value threshold 0.20)	
										OR: 3.4	1.8,6.4	P<0.001 (Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1))	YES; adjusted for gender, age, BMI, DM, previous MI, days of clopidogrel administration before intervention, CYP3A4-metabolized statins, Ca ⁺ channel blockers, PPI, SSRIs, and NSAIDs.	YES; false discovery rate test (q value threshold 0.20)	
	300 mg clopidogrel loading dose	CYP2C19*2	Poor responder	>70% aggregation using 20 mmol/l ADP (LTA)	NR (Before stenting)	Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	Poor responder +	40% according to LTA (N calculated as 52)	>70% aggregation	OR: 3.7	2.0,6.9	P<0.001 (Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1))	NO	YES; false discovery rate test (q value threshold 0.20)	Responder status as per PRU was not reported (unlike for the chronic clopidogrel group)
										OR: 4.1	1.6,10.4	P=0.003 (Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1))	YES; adjusted for gender, age, BMI, DM, previous MI, days of clopidogrel administration before intervention, CYP3A4-metabolized statins, Ca ⁺ channel blockers, PPI, SSRIs, and NSAIDs.	YES; false discovery rate test (q value threshold 0.20)	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Trenk 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	600 mg clopidogrel loading dose + 75 mg/day clopidogrel (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	CYP2C19 *2	High on- clopidogrel platelet reactivity	proportion of patients achieving an residual platelet aggregation >14% after stimulation with 5 µmol/l ADP	At PCI	Carriers (*1/*2 or *2/*2)	High on- clopidogrel platelet reactivity	153/245 (62.4%)	14%	OR=2.18	1.6,2.97	P<0.001 (between carriers and noncarriers)	NO	NR	
						Noncarriers (*1/*1)	High on- clopidogrel platelet reactivity	239/552 (43.3%)	14%						
					Pre- discharge	Carriers (*1/*2 or *2/*2)	High on- clopidogrel platelet reactivity	97/235 (41.3%)	14%	OR=2.43	1.74,3.38	P<0.001 (between carriers and noncarriers)	NO	NR	
						Noncarriers (*1/*1)	High on- clopidogrel platelet reactivity	118/525 (22.5%)	14%						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
					At PCI	Carriers (*1/*2 or *2/*2)	High on- clopidogrel platelet reactivity	153/245 (62.4%)	14%	NR	NR	NR	YES; clinical characteristics (active smoker, BMI, hypertension, previous PCI), drug therapy (angiotensin- 1 blockers, diuretics, oral antidiabetics), or Angiographic parameters (American Heart Association/ American College of Cardiology coronary lesion type B2 or C, stenting in circumflex artery, vessel size, balloon size, minimal lumen diameter after PCI, stented length)	NR	OR was not reported; it can be estimate from digitizing Fig 1 & P value can be back calculated
						Noncarriers (*1/*1)	High on- clopidogrel platelet reactivity	239/552 (43.3%)	14%	NR	NR	NR			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
					Pre- discharge	Carriers (*1/*2 or *2/*2)	High on- clopidogrel platelet reactivity	97/235 (41.3%)	14%	NR	NR	NR	YES; clinical characteristics (active smoker, BMI, hypertension, previous PCI), drug therapy (angiotensin- 1 blockers, diuretics, oral antidiabetics), or Angiographic parameters (American Heart Association/ American College of Cardiology coronary lesion type B2 or C, stenting in circumflex artery, vessel size, balloon size, minimal lumen diameter after PCI, stented length)	NR	OR was not reported; it can be estimate from digitizing Fig 1 & P value can be back calculated
						Noncarriers (*1/*1)	High on- clopidogrel platelet reactivity	118/525(22.5 %)	14%	NR	NR	NR			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Hochholzer, 2010 20510210 Germany EXCELSIOR	clopidogrel	CYP2C19* polymorphism	Low response to clopidogrel	Residual platelet aggregation >14%	2-4 hours after mainten- ance dose	CYP2C19* polymorphism	Low response to clopidogrel	760	Residual platelet aggregation>1 4%	OR=2.738	1.925-3.895	<0.001	Yes, age, arterial hypertension, diabetes mellitus, body mass index, platelets, ACE inhibition, nitrates, verapamil/diltiazem, previous balloon angioplasty, previous balloon angioplasty, previous CABG, impaired LV function, CCS angina class III or IV	NR	Figure 1 box and whisker plot
	clopidogrel	CYP2C19* polymorphism	Low response to clopidogrel	Residual platelet aggregation after stimulation with 5 uM ADP	2-4 hours after mainten- ance dose	CYP2C19* polymorphism	Residual platelet aggregation	760	Residual platelet aggregation	Partial n2=0.052	NR	<0.001	Yes, age, arterial hypertension, diabetes mellitus, body mass index, platelets, ACE inhibition, nitrates, verapamil/diltiazem, previous balloon angioplasty, previous balloon angioplasty, previous CABG, impaired LV function, CCS angina class III or IV	NR	
Jeong 2010 20650435 Korea NR	Clopidogrel	CYP2C19	HPPR	See below	2-4 hours	*1/*1	HPPR+ 4(8.7)	46	5uM ADP induced maximal platelet reactivity >50%	%	NR	0.012 comparing the following row	NR	Yes	Figure 3-6 bar graph of LTA and genotype
						Rms	23(28.8)	80							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+) — ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	clopidogrel	CYP2C19	HPPR	See below	2-4 hours	CYP2C19 variant	HPPR+	126	5uM ADP induced maximal platelet reactivity >50%	OR=4.237	1.362-13.158	0.013	NO	NO	
	clopidogrel	CYP2C19	HPPR	See below	2-4 hours	CYP2C19 variant	HPPR+	126	5uM ADP induced maximal platelet reactivity >50%	OR=5.525	1.333-23.256	0.018	Yes, CYP3A5*3/*3 carriers, carriage of ABCB1 variant, female sex, age(per 10 yr increment), BMI, ACS, current cmoking, hypertension, diabetes mellitus, chronic kidney disease, LV ejection fraction<45%, CYP3A4-metabolized statin, beta-blocker, calcium-channel blocker, nitrate,	NO	
Bonello, 2010 20708365 France NR	Clopidogrel	CYP2C19	HTPR	High on treatment platelet reactivity	12h	*2 hetero- zygotes	HTRP+	97/123 (77%)	VASP index ≥50%	Proportion	NR	<0.001 compared with row 2 and 3	NR	NR	
	Clopidogrel	CYP2C19	HTPR	High on treatment platelet reactivity	12h	*2 homozygotes	HTRP+	6/11(54%)	VASP index ≥50%	Proportion	NR		NR	NR	
	Clopidogrel	CYP2C19	HTPR	High on treatment platelet reactivity	12h	Wild-type genotype	HTRP+	154/277 (55.6)	VASP index ≥50%	proportion	NR		NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	Clopidogrel	CYP2C19	HTPR	High on treatment platelet reactivity	12h	2C19*2 allele carriage	HTPR+	NR	VASP index ≥50%	OR=2.69	1.66-4.36	<0.0001	Yes, age, BMI	NR	
	Clopidogrel	CYP2C19	HTPR	High on treatment platelet reactivity	12h	No loss-of function allele	HTPR+	154/277 (55.6%)	VASP index ≥50%	NR	NR	NR	NR	NR	
	Clopidogrel	CYP2C19	HTPR	High on treatment platelet reactivity	3 additional 600-mg LDs	No loss-of function allele	HTPR+	137/154 (89%)	VASP index ≥50%	NR	NR	NR	NR	NR	
Gurbel 2011 21392617 USA NR	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 5uM ADP	*2	HRP +	46%	5 µM ADP 46%	Frequency	NR	0.015 carriers vs noncarries	NR	NR	
						*2 non carrier	HRP -	25%			NR		NR	NR	
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 20uM ADP	*2	HRP+	41%	20 µM ADP 59%	Frequency	NR	0.013 carriers vs noncarries	NR	NR	
						*2 non carrier	HRP-	18%			NR		NR	NR	
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 5uM ADP	*17	HRP +	27%	5 µM ADP 46%	Frequency	NR	0.32 carriers vs noncarries	NR	NR	
						*17 non carrier	HRP -	36%			NR		NR	NR	
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 20uM ADP	*17	HRP+	14%	20 µM ADP 59%	Frequency	NR	0.016 carriers vs noncarries	NR	NR	
						*17 non carrier	HRP-	35%			NR		NR	NR	
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 5uM ADP	*2 N=41	HRP +	15/27	5 µM ADP 46%	Count	NR	NR	NR	NR	
							HRP-	26/91							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+) — ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 5uM ADP	*2 noncarrier N=77	HRP +	12/27	5 µM ADP 46%	Count	NR	NR	NR	NR	
							HRP-	65/91							
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 5uM ADP	*17 N=45	HRP +	8/27	5 µM ADP 46%	Count	NR	NR	NR	NR	
							HRP-	37/91							
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 5uM ADP	*17 N=73	HRP +	19/27	5 µM ADP 46%	Count	NR	NR	NR	NR	
								54/91							
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 20uM ADP	*2 N=41	HRP +	20/40	20 µM ADP 59%	Count	NR	NR	NR	NR	
							HRP-	21/78							
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 20uM ADP	*2 noncarrier N=77	HRP +	20/40	20 µM ADP 59%	Count	NR	NR	NR	NR	
							HRP-	57/78							
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 20uM ADP	*17 N=45	HRP +	9/40	20 µM ADP 59%	Count	NR	NR	NR	NR	
							HRP-	36/78							
	Clopidogrel	CYP2C19	High platelet reactivity (HPR)	defined by specific cutoff values by ROC	HPR 20uM ADP	*17 N=73	HRP +	31/40	20 µM ADP 59%	Count	NR	NR	NR	NR	
							HRP-	42/78							
Hwang 2011 21075428 South Korea NR	Clopidogrel	CYP2C19 *2	HRP	5 umol/L ADP- MPA>50%	12h	Codominant	HRP+ 34	GG 93	5 umol/L ADP- MPA>50%	Count	NR	0.003 comparing the following 2 groups	NR	Yes	
							HRP- 59								

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+) — ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	Clopidogrel	CYP2C19 *2	HRP	5 umol/L ADP- MPA>50%	12h	Codominant	HPR+ 44	GA 79	5 umol/L ADP- MPA>50%	Count	NR		NR	Yes	
							HPR- 35								
	Clopidogrel	CYP2C19 *2	HRP	5 umol/L ADP- MPA>50%	12h	Codominant	HPR+ 13	AA 18	5 umol/L ADP- MPA>50%	Count	NR		NR	Yes	
							HPR 5								
	Clopidogrel	CYP2C19 *2	HRP	5 umol/L ADP- MPA>50%	12h	dominant	HPR+ 34	GG 93	5 umol/L ADP- MPA>50%	Count	NR	0.001 comparing the following group	NR	Yes	
							HPR 59								
	Clopidogrel	CYP2C19 *2	HRP	5 umol/L ADP- MPA>50%	12h	dominant	HPR+ 57	GA/AA 97	5 umol/L ADP- MPA>50%	Count	NR		NR	Yes	
							HPR- 40								
	Clopidogrel	CYP2C19 *2	HRP	5 umol/L ADP- MPA>50%	12h	recessive	HPR+ 78	GG/GA 172	5 umol/L ADP- MPA>50%	Count	NR	0.107 comparing the following group	NR	Yes	
							HPR- 94								
	Clopidogrel	CYP2C19 *2	HRP	5 umol/L ADP- MPA>50%	12h	recessive	HPR+ 13	AA 18	5 umol/L ADP- MPA>50%	Count	NR		NR	Yes	
							HPR- 5								
	Clopidogrel	CYP2C19 *3	HRP	5 umol/L ADP- MPA>50%	12h	Codominant	HPR+ 76	GG 165	5 umol/L ADP- MPA>50%	Count	NR	0.008 comparing the following 2 groups	NR	Yes	
							HPR- 88								
	Clopidogrel	CYP2C19 *3	HRP	5 umol/L ADP- MPA>50%	12h	Codominant	HPR+ 15	GA 25	5 umol/L ADP- MPA>50%	Count	NR		NR	Yes	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
							HRP- 11								
	Clopidogrel	CYP2C19 *3	HRP	5 umol/L ADP- MPA>50%	12h	Codominant	HRP+ -	AA 0	5 umol/L ADP- MPA>50%	Count	NR		NR	Yes	
							HRP- -								
	Clopidogrel	CYP2C19*3	HRP	5 umol/L ADP- MPA>50%	12h	dominant	HRP+ 76	GG 165	5 umol/L ADP- MPA>50%	Count	NR	0.008 comparing the following group	NR	Yes	
							HRP- 88								
	Clopidogrel	CYP2C19*3	HRP	5 umol/L ADP- MPA>50%	12h	dominant	HRP+ 15	GA/AA 25	5 umol/L ADP- MPA>50%	Count	NR		NR	Yes	
							HRP- 11								
	Clopidogrel	CYP2C19*3	HRP	5 umol/L ADP- MPA>50%	12h	recessive	HRP+ 91	GG/GA 190	5 umol/L ADP- MPA>50%	Count	NR		NR	Yes	
							HRP- 99								
	Clopidogrel	CYP2C19*3	HRP	5 umol/L ADP- MPA>50%	12h	recessive	HRP+ -	AA 0	5 umol/L ADP- MPA>50%	Count	NR		NR	Yes	
							HRP- -								

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Kang, 2010 20724801 Korea NR	clopidogrel	CYP2C19	HPPR	high post- treatment platelet reactivity	NR	Carrier of CYP2C19 varian	HPPR	112/215	5 umol/L ADP- induced PRmax>50%	OR 4.202	1.996-8.850	<0.001	Yes, sex, age, BMI, previous MI, previous stroke, current smoking, hypertension, diabetes mellitus, chronic kidney disease, LV ejection fraction<45%, CYP3A4-metabolized statin, beta blocker, angiotension blocker, calcium channel blocker, proton pump inhibitor	No	
Park 2011 21345843 Korea CILON-T	DAT	CYP2C19	on-treatment platelet reactivity (High OPR)	on-treatment platelet reactivity (High OPR)	NR	Non-carrier	on-treatment platelet reactivity (High OPR)	104	NR	Odds ratio 1	-	-	Yes. Age, gender, cigarette smoking, chronic kidney disease, antiplatelet treatment regimen according to CYP2C19 genotype	Yes	Figure E multiple compar- ison
	DAT	CYP2C19	High OPR	High OPR	NR	Carrier	(High OPR	132	NR	Odds ratio 2.93	1.64-5.21	<0.001	NR	NR	
	TAT	CYP2C19	High OPR	High OPR	NR	Non-carrier	(High OPR	87	NR	Odds ratio 0.75	0.39-1.44	0.388	NR	NR	
	TAT	CYP2C19	High OPR	High OPR	NR	Carrier	(High OPR	151	NR	Odds ratio 1.19	0.68-2.05	0.545	NR	NR	
	Dual Clopidogrel	CYP2C19	OPR	on-treatment platelet reactivity	NR	Non-carrier vs Carrier of	on-treatment platelet reactivity	CYP2C19 LOF allele 236	NR	N=104 for non carrier N=132 for carrier		Non-carrier vs Carrier of <0.001	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	Triple Clopidogrel	CYP2C19	OPR	on-treatment platelet reactivity	NR	Non-carrier vs Carrier of	on-treatment platelet reactivity	CYP2C19 LOF allele 238	NR	N=87 for non carrier N=151 for carrier		Non-carrier vs Carrier of 0.139	NR	NR	
	Dual Clopidogrel	CYP2C19	High OPR proportion	OPR >240 PRU	NR	Non-carrier vs Carrier of	OPR >240 PRU	CYP2C19 LOF allele 236	OPR >240 PRU	37% for non carrier 61% for carrier		Non-carrier vs Carrier <0.001	NR	NR	
	Triple Clopidogrel	CYP2C19	High OPR proportion	OPR >240 PRU	NR	Non-carrier vs Carrier of	OPR >240 PRU	CYP2C19 LOF allele 238	OPR >240 PRU	33% for non carrier 44% for carrier		Non-carrier vs Carrier 0.115	NR	NR	
	Dual and triple Clopidogrel	CYP2C19	OPR	on-treatment platelet reactivity	NR	Dual versus triple	on-treatment platelet reactivity	CYP2C19 LOF allele non carrier 191	NR	N=104 for dual N=87 for triple		Dual versus triple 0.242	NR	NR	
	Dual and triple Clopidogrel	CYP2C19	OPR	on-treatment platelet reactivity	NR	Dual versus triple	on-treatment platelet reactivity	CYP2C19 LOF allele carrier 283	NR	N=132 for dual N=151 for triple		Dual versus triple <0.001	NR	NR	
	Dual and triple Clopidogrel	CYP2C19	High OPR proportion	OPR >240 PRU	NR	Dual versus triple	OPR >240 PRU	CYP2C19 LOF allele non carrier	OPR >240 PRU	37% for dual 33% for triple		Dual versus triple 0.241	NR	NR	
	Dual and triple Clopidogrel	CYP2C19	High OPR proportion	OPR >240 PRU	NR	Dual versus triple	OPR >240 PRU	CYP2C19 LOF allele carrier	OPR >240 PRU	61% for dual 44% for triple		Dual versus triple <0.001	NR	NR	
Sibbing, 2010 20492469 Germany NR	Clopidogrel	CYP2C19	Platelet aggregation	Platelet aggregation	NR	CYP2C19 *17	Platelet aggregation	396	>188 Au*min	1.3	1.1-1.6	*17 vs no *17	no	no	
	Clopidogrel	CYP2C19	Platelet aggregation	Platelet aggregation	NR	CYP2C19 *17/*17	Platelet aggregation		>188 Au*min	1.7	1.1-2.7	*17/*17 vs no *17	no	no	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	Clopidogrel	CYP2C19	Platelet aggregation	Platelet aggregation	NR	CYP2C19 *17	Platelet aggregation	396	>188 Au*min	1.4	1.1-1.7	*17 vs no *17	Yes, age, gender, smoking, diabetes mellitus, arterial hypertension, hyper- cholesterolemia, omeprazole/ pantoprazole or ca2+ channel inhibition or phenprocouon, renal insufficiency, BMI,, fibrinogen levels.	no	
	Clopidogrel	CYP2C19	Platelet aggregation	Platelet aggregation	NR	CYP2C19 *17/*17	Platelet aggregation	396	>188 Au*min	1.9	1.2-3.0	*17/*17 vs no *17	Yes, age, gender, smoking, diabetes mellitus, arterial hypertension, hyper- cholesterolemia, omeprazole/ pantoprazole or ca2+ channel inhibition or phenprocoumon, renal insufficiency, BMI,fibrinogen levels.	no	
Bouman 2011 21628721 Netherlands Genetic substudy of the Popular study	Clopidogrel	CYP2C19 genetic test (real-time PCR)	High on- treatment platelet reactivity	5 umol/l ADP- induced LTA cutoff from ROC	Within 2 hr after blood sampling	*1/*1	HPR+	38% of 737 patients	>42.9% aggregation	NR	NR	<0.001 vs. each of next two rows [chi-square test]	YES (age, sex, BMI, current smoking, systolic BP >140 mm Hg or diastolic BP >90 mm Hg, diabetes mellitus, LVEF <45%, renal failure (creatinine level >1.36 mg/dl), platelet count, mean platelet volute, clopidogrel regimen, PPI use, and amlodipine use)	NR	NONE

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						*1/*2		53% of 260 patients	>42.9% aggregation	NR	NR	0.006 vs. next row			
						*2/*2		70% of 27 patients	>42.9% aggregation	NR	NR				
				20 umol/l ADP-induced LTA cutoff from ROC		*1/*1	HPR+	31% of 737 patients	>64.5% aggregation	NR	NR	<0.001 vs. each of next two rows	NR	NR	NR
						*1/*2		52% of 260 patients	>64.5% aggregation	NR	NR	0.013 vs. next row			
						*2/*2		78% of 27 patients	>64.5% aggregation	NR	NR				
				PlateletWorks assay cutoff from ROC		*1/*1	HPR+	33% of 737 patients	> 80.5% aggregation	NR	NR	<0.001 vs. next row	NR	NR	NR
						*1/*2		51% of 260 patients	> 80.5% aggregation	NR	NR	0.045 vs. next row			
						*2/*2		91% of 27 patients	> 80.5% aggregation	NR	NR	0.001 vs. first row			
				VerifyNow cutoff from ROC		*1/*1	HPR+	34% of 737 patients	>236 PRU (P2Y12 reaction units)	NR	NR	<0.001 vs. each of next two rows	NR	NR	NR
						*1/*2		49% of 260 patients	>236 PRU (P2Y12 reaction units)	NR	NR	0.08 vs. next row			
						*2/*2		67% of 27 patients	>236 PRU (P2Y12 reaction units)	NR	NR				
			Risk of HPR	5 umol/l ADP-induced LTA		*1/*2 vs.*1/*1			>42.9% aggregation	Adjusted OR 1.80	1.28-2.54	0.001 [multivariate binary logistic regression]	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
				20 umol/l ADP- induced LTA					>64.5% aggregation	Adjusted OR 2.53	1.78-3.60	<0.001 [multivariate binary logistic regression]			
				Plateletworks assay					> 80.5% aggregation	Adjusted OR 1.96	1.24-3.09	0.004 [multivariate binary logistic regression]			
				VerifyNow P2Y12					>236 PRU (P2Y12 reaction units)	Adjusted OR 2.14	1.50-3.07	<0.001 [multivariate binary logistic regression]			
				5 umol/l ADP- induced LTA		*2/*2 vs.*1/*1			>42.9% aggregation	Adjusted OR 2.33	0.88-6.19	0.091 [multivariate binary logistic regression]			
				20 umol/l ADP- induced LTA					>64.5% aggregation	Adjusted OR 4.54	1.61-12.80	0.004 [multivariate binary logistic regression]			
				Plateletworks assay					> 80.5% aggregation	Adjusted OR 12.92	1.52-109.98	0.019 [multivariate binary logistic regression]			
				VerifyNow P2Y12					>236 PRU	Adjusted OR 2.63	0.97-7.14	0.059 [multivariate binary logistic regression]			
Campo 2011 21679849 Italy NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Fernando 2011 21696537 Australia NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Geisler 2008 18781853 Germany NR	Clopidogrel	MassARRAY for *2	Residual platelet aggregation (RPA)	From turbidometry	Post- clopidogrel loading dose	*1/*1	Low RPA	144/175 patients with low RPA (82.3%)	RPA = or <47% at at least 6 hr after loading dose of clopidogrel	OR vs. *1/*2 + *2/*2, 4.6	2.5-8.7	<0.0001 high RPA vs low RPA logistic regression	NR	NR	ORs and chi-square values are for having high RPA vs. low RPA among the three genotype subgroups
							High RPA	31//62 patients with high RPA (50%)	RPA >47% at at least 6 hr after loading dose of clopidogrel						
	Clopidogrel	MassARRAY for *2	Residual platelet aggregation (RPA)	From turbidometry	Post- clopidogrel loading dose	*1/*2	Low RPA	28/175 (16%)	RPA = or <47% at at least 6 hr after loading dose of clopidogrel	Chi-square statistic vs. *1/*2 vs. *2/*2, 27.17	NR	<0.001 high RPA vs low RPA chi-square test	NR	NR	NR
							High RPA	24/62 (38.7%)	RPA >47% at at least 6 hr after loading dose of clopidogrel						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	Clopidogrel	MassARRAY for *2	Residual platelet aggregation (RPA)	From turbidometry	Post- clopidogrel loading dose	*2/*2	Low RPA	3/175 (1.7%)	RPA = or <47% at at least 6 hr after loading dose of clopidogrel						
							High RPA	7/62 (11.3%)	RPA >47% at at least 6 hr after loading dose of clopidogrel						
	Clopidogrel	MassARRAY for *17	Residual platelet aggregation (RPA)	From turbidometry	Post- clopidogrel loading dose	*1/*1	Low RPA	96/175 (54.9%)	RPA = or <47% at at least 6 hr after loading dose of clopidogrel	OR vs. *1/*17 + *17/*17, 0.62	0.34-1.14	0.14 high RPA vs low RPA logistic regression	NR	NR	NR
							High RPA	41/62 (66.1%)	RPA >47% at at least 6 hr after loading dose of clopidogrel						
	Clopidogrel	MassARRAY for *17	Residual platelet aggregation (RPA)	From turbidometry	Post- clopidogrel loading dose	*1/*17	Low RPA	65/175 (37.1%)	RPA = or <47% at at least 6 hr after loading dose of clopidogrel	Chi-square statistic vs. *1/*17 vs. *17/*17, 4.48	NR	0.11 high RPA vs low RPA chi square test	NR	NR	NR
							High RPA	14/62 (22.6%)	RPA >47% at at least 6 hr after loading dose of clopidogrel						
						*17/*17	Low RPA	14/175 (8.0%)	RPA = or <47% at at least 6 hr after loading dose of clopidogrel						

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
							High RPA	7/62 (11.3%)	RPA >47% at at least 6 hr after loading dose of clopidogrel						
	Clopidogrel	MassARRAY for *17	Residual platelet aggregation (RPA)	From turbidometry	Post- clopidogrel loading dose	*2 carriers	High RPA		RPA >47% at at least 6 hr after loading dose of clopidogrel	Chi-square statistic 21.31 OR, 4.38	2.3-8.33	<0.0001 high RPA vs low RPA logistic regression	yes [Multivariable logistic regression including age, diabetes status, LVEF, renal failure, ACS)	NR	NS for all other SNPs
						One *2 allele				OR 3.71	1.87-7.35				
						Two *2 alleles				OR 10.72	2.56-44.88				
Gurbel 2010 19817997 USA NR	75 mg clopidogrel daily	TaqMan	HPR	Upper tertile of 5 uM ADP- induced platelet aggregation	NR	CYP2C19*2 carrier	HPR+	13/17	<43%	NR	NR	NR	NR	NO	
						CYP2C19*2 noncarrier		4/19							
						CYP2C19*17 carrier	13/15 (NB the 13 is from text note that 75% of the 17 pts with HPR carried *17)	13/15							
						CYP2C19*17 noncarrier	4/21	4/21							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
			HPR	Upper tertile of 5 mM ADP- induced platelet aggregation	NR	CYP2C19*17 noncarrier	13/15 (NB the 13 is from text note that 75% of the 17 pts with HPR carried *17)	13/15	<43%	NR	NR	NR	NR	NO	No
						CYP2C19*17 noncarrier	4/21	4/21							
Kim 2011 21511217 South Korea CCELAMI- 2C19	High-dose clopidogrel	PCR and SNaPshot assay kit	HPR	20 mmol ADP- induced maximal platelet aggregation >59%	Predischarge	*2 or *3 noncarrier	Yes HPR	11/24 (45.8%)	20 mmol ADP- induced maximal platelet aggregation >59%	NR	NR	0.666 vs. corresponiding cilostazol row below [chi- square statistics or Fisher exact test]	NR	NR	NONE
						*2 or *3 carrier		20/38 (52.6%)				0.430 vs. corresponiding cilostazol row below [chi- square statistics or Fisher exact test]			
					At 30 days	*2 or *3 noncarrier		2/24 (8.3%)				0.235 vs. corresponiding cilostazol row below [chi- square statistics or Fisher exact test] Also P=0.002 vs next row [NR]			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						*2 or *3 carrier		17/38 (44.7%)				0.005 vs. corresponding cilostazol row below [chi- square statistics or Fisher exact test]			
	High-dose clopidogrel	PCR and SNaPshot assay kit	HPR	high platelet reactivity	Absolute change between baseline and 30 days	*2 or *3 noncarrier	HPR	24	NR	Mean 37.5% (SD NR)	NR	NR	NR	NR	Data also in Fig. 4
						*2 or *3 carrier		38	NR	Mean 7.9% (SD NR)	NR				
	Standar- dose clopidogrel + cilostazol				Pre- discharge	*2 or *3 noncarrier		21/25 (52%)	NR	NR	NR	NR	NR	NR	NO
						*2 or *3 carrier		24/39 (61.5%)							
					At 30 days	*2 or *3 noncarrier		0/25 (0%)	NR	NR	NR	P=0.174 vs. next row [NR]	NR	NR	no
						*2 or *3 carrier		6/39 (15.4%)							
				Absolute change between baseline and 30 days		*2 or *3 noncarrier		25	NR	Mean 54.2% (SD NR)					Data also in Fig. 4
						*2 or *3 carrier		39	NR	Mean 46.1% (SD NR)					

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Pettersen 2011 21426546 Norway Aspirin and Clopidogrel non- responsive- ness clinical Endpoint Trial (ASCET)	Clopidogrel	TaqMan Drug Metabolism Assay	Clopidogrel resistance	per VASPPRI	NR	*2 carrier	Resistant	46%	≥ 55% PRI	NR	NR	< 0.001 vs. row below (either Student 's unpaired t-test or Mann-Whitney U-test)	NR	NR	NONE
						*2 noncarrier	Resistant	22%							
				Per VerifyNow PRU		*2 carrier	Resistant	64 (54%)	≥ 170 PRU			0.003 vs. row below (either Student 's unpaired t-test or Mann-Whitney U-test)			
						*2 noncarrier	Resistant	104 (22%)							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Price, 2012 22624833 US GIFT (Genotype Information and Functional Testing) Study—a prespecified genetic substudy of GRAVITAS (Gauging Responsive- ness with A VerifyNow assay—Impact on Thrombosis And Safety) trial	Clopidogrel	MassARRAY and iPLEX	On-treatment platelet reactivity (OTR)	Per VerifyNow PRU	12–24 hr after PCI (N=898 with data across clopidogrel doses, but total n=1008 apparently)	*2 carrier	High OTR	NR	≥ 230 PRU	R ² = 0.07	NR	2.2 x 10 ⁻¹⁵	YES clinical covariates significantly associated with OTR according to univariate analysis (age,sex, body mass index, current smoking, creatinine clearance<60 ml/min, diabetes mellitus, history of congestive heart failure, hypertension, or hyperlipidemia)	NR	NONE
						*17 carrier	High OTR [apparently not low OTR here]	NR	≥ 230 PRU	R ² = 0.005	NR	0.08	YES, as above		
						Any 1 reduced- function CYP2C19 allele present in population (*2, *3, *4, *6, or *8) [N=288]	High OTR	200	≥ 230 PRU	OR 2.52	1.86-3.43	NR Vs. noncarriers (3 rows below)	YES, as above	NR	From Fig. 1a

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Any 1 or 2 reduced- function CYP2C19 alleles present in population (*2, *3, *4, *6, or *8) [N=317, overlapping with previous row]	High OTR	223	≥ 230 PRU	2.66	1.97-3.58	NR Vs. noncarriers (2 rows below)	YES, as above	NR	From Fig. 1a
						Any 2 reduced- function CYP2C19 alleles present in population (*2, *3, *4, *6, or *8) [N=29, overlapping with previous row]	High OTR	23	≥ 230 PRU	4.71	1.83-12.14	NR Vs. noncarriers (1 row below)	YES, as above		From Fig. 1a
						Noncarriers of a reduced- function CYP2C19 allele [N=691]	High OTR	346	≥ 230 PRU	NR	NR	NR	YES, as above		From Fig. 1a

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
					30 d after PCI (N=702 with data across all clopidogrel doses, although only 701 accounted for in this section)	*2 carrier	High OTR	NR	≥ 230 PRU	R ² = 0.10	NR	1.3 x 10 ⁻¹⁷	YES, as above		NONE
						*17 carrier	"Reduced levels of OTR"	NR	< 230 PRU?	R ² = 0.022	NR	0.0004	YES, as above		
						Any 1 reduced- function CYP2C19 allele present in population (*2, *3, *4, *6, or *8) [N=235]	High OTR	128	≥ 230 PRU	OR 2.29	1.59-3.30	NR Vs. noncarriers (3 rows below)	YES, as above		From Fig. 1b
						Any 1 or 2 reduced- function CYP2C19 alleles present in population (*2, *3, *4, *6, or *8) [N=256, overlapping with previous row]	High OTR	145	≥ 230 PRU	2.51	1.76-3.59	NR Vs. noncarriers (2 rows below)	YES, as above		From Fig. 1b

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Any 2 reduced- function CYP2C19 alleles present in population (*2, *3, *4, *6, or *8) [N=21, overlapping with previous row]	High OTR	17	≥ 230 PRU	9.51	2.86-31.63	NR Vs. noncarriers (1 row below)	YES, as above		From Fig. 1b
						Noncarriers of a reduced- function CYP2C19 allele [N=445]	High OTR	158	≥ 230 PRU	NR	NR	NR	YES, as above		From Fig. 1b
					6 mo after PCI (N=672 with data across all clopidogrel doses, although 676 noted in this section)	*2 carrier	High OTR	NR	≥ 230 PRU	R ² = 0.07	NR	1.9 x 10 ⁻¹¹	YES, as above	NR	
						*17 carrier	“Reduced levels of OTR”	NR	< 230 PRU?	R ² = 0.015	NR	0.01	YES, as above		

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Any 1 reduced- function CYP2C19 allele present in population (*2, *3, *4, *6, or *8) [N=220]	High OTR	111	≥ 230 PRU	OR 2.56	1.75-3.74	NR Vs. noncarriers (3 rows below)	YES, as above		From Fig. 1c
						Any 1 or 2 reduced- function CYP2C19 alleles present in population (*2, *3, *4, *6, or *8) [N=256, overlapping with previous row]	High OTR	128	≥ 230 PRU	2.80	1.93-4.07	NR Vs. noncarriers (2 rows below)	YES, as above		From Fig. 1a
						Any 2 reduced- function CYP2C19 alleles present in population (*2, *3, *4, *6, or *8) [N=21, overlapping with previous row]	High OTR	16	≥ 230 PRU	9.49	3.01-29.93	NR Vs. noncarriers (1 row below)	YES, as above		From Fig. 1b

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Noncarriers of a reduced- function CYP2C19 allele [N=420]	High OTR	130	≥ 230 PRU	NR	NR	NR	YES, as above		From Fig. 1a
Gremmel, 2012 22154242 Austria NR	Clopidogrel	Infiniti® CYP450 2C19+ assay	High on- treatment residual ADP- inducible platelet reactivity (HRPR) by LTA (n=286)	NR	24 hr after PCI	Ultrarapid metabolizer (*17/*17 or wild type) [N=94]	HRPR (n=38)	9	> 67% for LTA	NR	NR	<0.05 for trend (this and next 3 rows) [Cochran- Armitage trend test]			NB: Absolute platelet reactivity data reported for metabolize r groups for each test in Fig. 1—could be digitized and reported as continuous platelet outcome in other table
						Extensive metabolizer wild type/wild type) [N=105]		12							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Intermediate metabolizer (*2/*17 or wild type or *8/wild type) [N=84]		16							
						Poormetaboli- zer (*2/*2) [N=4]		1							
						Carrier of LOF allele (*2 or *8)		17		OR 2.3	1.1-4.77	NR (vs. next row)	Adjusted odds ratio for CYP2C19 *2 carrier status as a predictor in multiple logistic regression with HRPR as dependen t variable		
						Noncarrier of LOF allele		21							
			HRPR by VerifyNow (n=287)			Ultrarapid metabolizer (*17/*17 or wild type) [N=94]	HRPR (n=102)	26	PRU > 235 for VerifyNow			0.02 for trend (this and next 3 rows) [Cochran- Armitage trend test]			
						Extensive metabolizer wild type/wild type) [N=106]		39							
						Intermediate metabolizer (*2/*17 or wild type or *8/wild type) [N=83]		34							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Poor metabolizer (*2/*2) [N=4]		3							
						Carrier of LOF allele (*2 or *8)		37		OR 1.6	0.9-2.8	NR (vs. next row)	Adjusted odds ratio for CYP2C19 *2 carrier status as a predictor in multiple logistic regression with HRPR as dependen t variable		
						Noncarrier of LOF allele		65							
			HRPR by VASP (n=284)			Ultrarapid metabolizer (*17/*17 or wild type) [N=94]	HRPR (n=139)	38	PRI > 50% for VASP			<0.01for trend (this and next 3 rows) [Cochran- Armitage trend test]			
						Extensive metabolizer wild type/wild type) [N=103]		48							
						Intermediate metabolizer (*2/*17 or wild type or *8/wild type) [N=83]		49							
						Poor metabolizer (*2/*2) [N=4]		4							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Carrier of LOF allele (*2 or *8)		53		OR 2.0	1.2-3.5	NR (vs. next row)	Adjusted odds ratio for CYP2C19 *2 carrier status as a predictor in multiple logistic regression with HRPR as dependent variable		
						Noncarrier of LOF allele		86							
			HRPR by MEA (n=280)			Ultrarapid metabolizer (*17/*17 or wild type) [N=93]	HRPR (n=105)	30	AU ≥ 47 for MEA			0.17 for trend (this and next 3 rows) [Cochran- Armitage trend test]			
						Extensive metabolizer wild type/wild type) [N=101]	ndgdh jfg	39							
						Intermediate metabolizer (*2/*17 or wild type or *8/wild type) [N=82]		34							
						Poormetaboli- zer (*2/*2) [N=4]		2							
						Carrier of LOF allele (*2 or *8)		36		OR 1.4	0.8-2.4	NR (vs. next row)	Adjusted odds ratio for CYP2C19 *2 carrier status as a predictor in multiple logistic regression with HRPR as dependen t variable		

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Noncarrier of LOF allele		69							
			HRPR by Impact-R (n=280)			Ultrarapid metabolizer (*17/*17 or wild type) [N=93]	HRPR (n=121)	38	SC<3% for Impact-R			<0.1 for trend (this and next 3 rows) [Cochran- Armitage trend test]			
						Extensive metabolizer wild type/wild type) [N=101]		39							
						Intermediate metabolizer (*2/*17 or wild type or *8/wild type) [N=82]		40							
						Poor metabolizer (*2/*2) [N=4]		4							
						Carrier of LOF allele (*2 or *8)		44		OR 1.6	0.9-2.7	NR (vs. next row)	Adjusted odds ratio for CYP2C19 *2 carrier status as a predictor in multiple logistic regression with HRPR as dependen t variable		
						Noncarrier of LOF allele		77							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+) — ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Tello-Montoliu 2012 22116003 Spain study one of the paper	100mg AA and 75mg MD clopidogrel	CYP2C19 *2	LTA ADP platelet aggregation High on- clopidogrel platelet reactivity(HOPR)	LTA ADP 5uM	in hospital	G/G 31	HOPR+	18 (58.1)	>=46%	chi-square test	NR	NR	0.091 comparing with the next row	NR	NR
						*A 9		8(88.9)							
	100mg AA and 75mg MD clopidogrel	CYP2C19 *2	VASP ADP High on- clopidogrel platelet reactivity(HOPR)	VASP ADP	in hospital	G/G31	HOPR+	20 (64.5)	>=50%	chi-square test	NR	NR	0.036 comparing with the next row	NR	NR
						*A 9		9 (100)							
Tello-Montoliu 2012 22116003 Spain study one of the paper	100mg AA and 75mg MD clopidogrel	CYP2C19 *17	LTA ADP platelet aggregation High on- clopidogrel platelet reactivity(HOPR)	LTA ADP 5uM	in hospital	C/C 27	HOPR+	20 (74.1)	>=46%	chi-square test	NR	NR	0.084 comparing with the next row	NR	NR
						*T 13		6 (46.2)							
	100mg AA and 75mg MD clopidogrel	CYP2C19 *17	VASP ADP High on- clopidogrel platelet reactivity(HOPR)	VASP ADP	in hospital	C/C 27	HOPR+	22 (81.5)	>=50%	chi-square test	NR	NR	0.074 comparing with the next row	NR	NR
						*T 13		7 (53.9)							
Tello-Montoliu 2012 22116003 Spain study one of the paper	100mg AA and 75mg MD clopidogrel	CYP2C19 *2 and *17	LTA ADP platelet aggregation High on- clopidogrel platelet reactivity(HOPR)	LTA ADP 5uM	in hospital	*2 G/G *17 C/C n=19	HOPR+	13 (68.4)	>=46%	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						*2 */A *17 C/C n=8		7(87.5)	>=46%						
						*2 G/G *17 */T n=12		5 (41.7)	>=46%						
						*2 */A *17 */T n=1		1(100)	>=46%						
	100mg AA and 75mg MD clopidogrel	CYP2C19 *2	VASP ADP High on- clopidogrel platelet reactivity(HOPR)	VASP ADP	in hospital	*2 G/G *17 C/C n=19	HOPR+	14 (73.7)	>=50%	NR	NR	NR	NR	NR	NR
						*2 */A *17 C/C n=8		8 (100)							
						*2 G/G *17 */T n=12		6 (50)							
						*2 */A *17 */T n=1		1(100)							
Harmsze, 2011 21854540 Netherlands POPular	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB+, PPI- *2 -	HOPR+	NR	NR	OR=1.7	1.0-2.7	0.03 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB+, PPI- *2 -	HOPR+	NR	NR	OR=1.6	0.97-2.6	NR	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB-, PPI+, *2 -	HOPR+	NR	NR	OR=1.6	1.0-2.8	0.045compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB-, PPI+, *2 -	HOPR+	NR	NR	OR=1.5	1.0-2.6	0.035 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB+, PPI+, *2 -	HOPR+	NR	NR	OR=4.1	2.0-8.4	<0.0001 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB+, PPI+, *2 -	HOPR+	NR	NR	OR=3.2	1.5-6.9	0.002 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB-, PPI-, *2+	HOPR+	NR	NR	OR=2.8	1.8-4.4	<0.0001 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB-, PPI-, *2 +	HOPR+	NR	NR	OR=3.1	1.9-4.9	<0.0001 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB-, PPI+, *2+	HOPR+	NR	NR	OR=3.3	1.4-7.9	0.006 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB-, PPI+, *2 +	HOPR+	NR	NR	OR=3.0	1.3-7.4	0.014 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB+, PPI-, *2+	HOPR+	NR	NR	OR=4.5	2.4-8.6	<0.0001 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB+, PPI-, *2 +	HOPR+	NR	NR	OR=4.4	2.3-8.7	<0.0001 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+) — ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB+, PPI+, *2+-	HOPR+	NR	NR	OR=2.6	0.76-8.6	0.13 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on- treatment reactivity	in hospital	CCB+, PPI+, *2 +	HOPR+	NR	NR	OR=2.4	0.68-8.2	0.18 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
Harmsze, 2011 21854540 Netherlands POPular	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB+, PPI- ,*2 -	HOPR+	NR	NR	OR=1.8	1.1-2.8	0.016 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB+, PPI- ,*2 -	HOPR+	NR	NR	OR=1.6	1.0-2.6	0.019 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB-, PPI+ ,*2 -	HOPR+	NR	NR	OR=2.1	1.2-3.6	0.006 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB-, PPI+, *2 -	HOPR+	NR	NR	OR=1.8	1.0-3.1	0.05 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB+, PPI+, *2 -	HOPR+	NR	NR	OR=3.3	1.6-6.7	0.001 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB+, PPI+, *2 -	HOPR+	NR	NR	OR=2.4	1.2-5.2	0.021 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB-, PPI-, *2+	HOPR+	NR	NR	OR=2.2	1.4-3.4	0.001 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB-, PPI-, *2 +	HOPR+	NR	NR	OR=2.3	1.4-3.6	0.001 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB-, PPI+, *2+	HOPR+	NR	NR	OR=4.3	1.8-10.4	0.001 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB-, PPI+, *2 +	HOPR+	NR	NR	OR=3.1	1.3-7.8	0.014 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB+, PPI-, *2+	HOPR+	NR	NR	OR=3.4	1.8-6.4	<0.0001 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB+, PPI-, *2 +	HOPR+	NR	NR	OR=3.2	1.7-6.2	<0.0001 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB+, PPI+, *2+-	HOPR+	NR	NR	OR=7.4	1.9-28.6	0.004 compared with non-drug and non CYP2C19 *2 carriers	NR	NR	NR

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+) — ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80- 100 mg day	CYP2C19 *2	verify now P2Y12	verify now P2Y12 high on- treatment reactivity	in hospital	CCB+, PPI+, *2 +	HOPR+	NR	NR	OR=6.7	1.7-27.4	0.008 compared with non-drug and non CYP2C19 *2 carriers	yes, gender, age, BMI, renal function, clopidogrel loading dose, smoking, DM, LVEF<45%	NR	NR
Aleil, 2009 19624462 France VASP-02 [genetic reanalysis thereof]	75 (n=95) or 150 (n=58) mg/day clopidogrel	VASP	High platelet reactivity (>69% PRI) at baseline	NR	Baseline (before clopidogrel receipt)	*2 carrier (*2/wild type or *2/*2) (n=37)	High PRI (poor response)	16 (42%) overall (10 receiving 150 mg and 6 receiving 75 mg)	>69%	3.393	1.062-10.841	P=0.039 [multivariate logistic regression]	NR	NR	Table 2 shows continuous PRI data but it's by dose level and N's are not given, so not extracted
						*2 noncarrier (wild type/wild type) (n=116)	High PRI (poor response)	26 (22%) overall (NR by dose level)							
Mega, 2011 22088980 USA ELEVATE- TIMI 56	75 mg clopidogrel daily	Pyrosequencing and Nanosphere Verigene	Response to clopidogrel	On-treatment platelet reactivity by VerifyNow	Any time within 2- week treatment period for this dose	*1/*1 (N=234)	Nonresponse	53 (23%)	>=230 PRU	NR	NR	NR	NR	NR	NONE
						*2/*1 (N=76)		40 (52%)				<0.001 vs. corresponding count for 150 mg dose (2 rows below) [GLM]			
	150 mg clopidogrel daily					*1/*1 (N=227)		28 (12%)							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						*2 carrier (*2/*2 or *2/*1) (N=73)		27				0.002 vs. next row [GLM]			This datum estimated visually by extractor from Fig 3 (above and below data were given in text; only this datum was not)
	225 mg clopidogrel daily					*2/*1 (N=75)		8 (10%)				0.90 vs. next row [GLM]			
	300 mg clopidogrel daily					*2/*1 (N=73)		7 (10%)							
Kim, 2011 Korea ACCEL- TRIPLE	cilostazol 100 mg twice a day clopidogrel 75 mg once a day aspirin 200 mg once a day	CYP2C19	HPR 5uM ADP agg MAX(>)>46%	HPR 5uM ADP agg MAX(>)(%)	30 days	EM	48	3(6.3)	>46%	NR	NR	0.099 chi square test	NR	NR	NR
						IM	54	4(7.4)							
						PM	25	5 (20)							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Bonello, 2012 22285300 France NR	oral LD: 600 mg clopidogrel and 250 mg aspirin	CYP2C19 *2	VASP	high on- treatment platelet reactivity (HTPR) by VASP>50%	<24 hrs after clopidogrel LD	Carriers of at least one *2 allele (wt /*2 or *2/*2) N=106	HPR+	75	VASP PRI >50%	OR (calculated)=1. 762	1.056- 2.95[calculate d]	p=0.015 (reported); p=0.024 (calculated) (carriers of *2 vs wild-type allele) [Chi-square]	No	NR	
						Carriers of at least one *2 allele (wt /*2 or *2/*2) N=106	HPR-	31							
						wild-type (wt) / wild-type (wt) N=261	HPR+	151							
						wild-type (wt) / wild-type (wt) N=261	HPR-	110							
						Carriers of at least one *2 allele (wt /*2 or *2/*2) N=106	HPR+	75	VASP PRI >50%	OR=1.81	1.09-3.01	p=0.02 (carriers of *2 vs wild-type allele) [logistic regression]	Yes; age. BMI	NR	
						Carriers of at least one *2 allele (wt /*2 or *2/*2) N=106	HPR-	31							
						wild-type (wt) / wild-type (wt) N=261	HPR+	151							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						wild-type (wt)/ wild-type (wt) N=261	HPR-	110							
Hochholzer, 2011 21884870 NR EXCELSIOR	LD of 600 mg of clopidogrel prior to PCI. After PCI, MD of aspirin (≥100 mg/d) and clopidogrel (75 mg/d) for 30 days (bare-metal stents) or 6 months (at least 1 drug- eluting stent)	CYP2C19 *2	LTA	Residual platelet aggregation ≥14%	24 hrs	CYP2C19 *2 carrier	High on-tx platelet reactivity	NR	14%	OR= 2.90	NR	<0.001 (carrier vs non carrier) [logistic regression]	Yes	NR	
						Non CYP2C19 *2 carrier	High on-tx platelet reactivity	NR	14%						
Siller-matula, 2012 Austria PEGASUS- PCI	clopidogrel LD 600mg, MD 75mg	CYP2C19 *2	MEA	<48U	12 months	LOF allele (CYP2C19*2) N=123	MEA<48U	90	48	OR= 0.57	0.3418 to 0.93 97	P=0.027 (carrier vs non carrier) [chi square test]	Yes	NR	
							MEA>48U	33							
						No LOF allele (CYP2C19*1) N=278	MEA<48U	231							
							MEA>48U	48							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Kassimis, 2012 21831410 Greece NR	No clopidogrel LD for those on 75 mg/d MD; LD 600 mg before PCI (if no and <7 days pre- treatment) Post PCI: Clopidogrel MD 75 mg/d and aspirin 100 mg/d	CYP2C19*2	Aggregation by VerifyNow	Aggregation by VerifyNow	24-48 hours after procedure	CYP2C19*2 Carriers N=38	High on- treatmen platelet reactivity PRU>235	NR	235	OR=3.02	1.16-7.86	P=0.023 (carrier vs non carrier) [linear mixed maximum likelihood model]	no	nr	
						CYP2C19*2 noncarriers N=108		NR							
		CYP2C19*17	Aggregation by VerifyNow	Aggregation by VerifyNow	24-48 hours after procedure	CYP2C19*17 Carriers N=nr	High on- treatmen platelet reactivity PRU>235	NR	235	OR=1.95	0.85-4.44	P=0.1 (carrier vs non carrier) [linear mixed maximum likelihood model]	no	nr	
						CYP2C19*17 noncarriers N=nr		NR							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+) — ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Namazi, 2012 22265638 Iran NR	Clopidogrel LD: 600 mg Clopidogrel MD: 150 mg/day for two weeks and 75 mg/day for 12 months Aspirin 80 mg/d	CYP2C19 *2 and *3	Clopidogrel Nonresponsiven ess by LTA	Platelet inhibition <10%	24-48 hours after procedure	Carriers of CYP2C19 *2 and *3 allele N=12	Clopidogrel Non- responsivene ss by LTA	NR	IPA<10%	NR	NR	P>0.05 (carrier *2/*3 vs carrier *1) [Fisher's test]	no	nr	
						Carriers of CYP2C19 *1 allele N=100		NR							
Rideg, 2011 21806387 Hungary DOSER	LD: 600 mg clopidogrel & 300 mg aspirin Randomized to 4 weeks of 75 or 150 mg clopidogrel MD: 75 mg clopidogrel/ day	CYP2C19 *1, *2, *3 and *17	LTA - High on treatment platelet reactivity	>46%	24 hours	GOF/GOF	HTPR	28	46	NR (Prevalence of HTPR from Fig1b)	NR	P=0.05 Between all groups [Kruskal-wallis test]			
						Wt/GOF		41		NR (Fig 1b)					
						Wt/wt		75		NR (Fig 1b)					
						Wt/LOF GOF/LOF		41		NR (Fig 1b)					
						LOF/LOF		4		NR (Fig 1b)					

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Rideg, 2011 21806387 Hungary DOSER	LD: 600 mg clopidogrel & 300 mg aspirin Randomized to 4 weeks of 75 or 150 mg clopidogrel MD: 75 mg clopidogrel/ day	CYP2C19 *1, *2, *3 and *17	LTA - High on treatment platelet reactivity	>46%	24 hours	LOF carrier (*1*2 or *2*2)	HTPR	31	46%	OR=3.35	1.27-8.86	P=0.02 (LOF carrier vs noncarrier) [logistic regression]	no	nr	
						Non LOF carrier		158							
Rideg, 2011 21806387 Hungary DOSER	LD: 600 mg clopidogrel & 300 mg aspirin Randomized to 4 weeks of 75 or 150 mg clopidogrel MD: 75 mg clopidogrel/ day	CYP2C19 *1, *2, *3 and *17	LTA - High on treatment platelet reactivity	>46%	24 hours	LOF carrier (*1*2 or *2*2)	HTPR	31	46%	OR=3.67	1.34-9.99	P=0.01 (LOF carrier vs noncarrier) [logistic regression]	yes	nr	
						Non LOF carrier		158							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Rideg, 2011 21806387 Hungary DOSER	LD: 600 mg clopidogrel & 300 mg aspirin Randomized to 4 weeks of 75 or 150 mg clopidogrel MD: 75 mg clopidogrel/ day	CYP2C19 *1, *2, *3 and *17	LTA - High on treatment platelet reactivity	>46%	24 hours	GOF carrier (*1*17 or *17*17)	HTPR	4	46%	OR=9.82	1.3-74.23	P=0.03 (LOF carrier vs noncarrier) [logistic regression]	no	nr	
						Non homozygote LOF carrier		185							
Rideg, 2011 21806387 Hungary DOSER	LD: 600 mg clopidogrel & 300 mg aspirin Randomized to 4 weeks of 75 or 150 mg clopidogrel MD: 75 mg clopidogrel/ day	CYP2C19 *1, *2, *3 and *17	LTA - High on treatment platelet reactivity	>46%	24 hours	GOF carrier (*1*17 or *17*17)	HTPR	83	46%	OR=0.56	0.2-1.54	P=0.26 (LOF carrier vs noncarrier) [logistic regression]	no	nr	
						Non GOF carrier		106							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Rideg, 2011 21806387 Hungary DOSER	LD: 600 mg clopidogrel & 300 mg aspirin Randomized to 4 weeks of 75 or 150 mg clopidogrel MD: 75 mg clopidogrel/ day	LOF+GOF+ABC B1	LTA - High on treatment platelet reactivity	>46%	24 hours	LOF+ GOF+ ABCB1	HTPR	NR	46%	AUC=0.697	0.558-0.837	P=0.006 (LOF+GOF+AB CB1 vs non LOF+GOF+ABC B1) [ROC curve]	no	nr	
		LOF+GOF	LTA - High on treatment platelet reactivity	>46%	24 hours	LOF+GOF	HTPR	128	46%	AUC=0.677	0.538-0.802	P=0.018 (LOF+GOF vs non LOF+GOF) [ROC curve]	no	nr	
		LOF	LTA - High on treatment platelet reactivity	>46%	24 hours	LOF	HTPR	45	46%	AUC=0.639	0.495-0.783	P=0.053 (LOF+GOF vs non LOF+GOF) [ROC curve]	no	nr	
Jeong, 2011 22045970 Korea NR	LD: 600 mg clopidogrel & 300 mg aspirin MD: 75 mg/d clopidogrel & aspirin 200 mg/d for 1 month and 100-200 mg/day for 1 year	CYP2C19 *1, *2, and *3	LTA - High on treatment platelet reactivity	>59%	3 days	1/*1 N=104	HPR	45 (43.3%)	59%	OR=1.96	0.88–4.37	P=0.091 (One LOF allele carriage vs no carriage) [regression]	no	yes	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						*1/*2 N=98		50 (51.0%)		OR=1.83	0.80–4.17	P=0.152 (One LOF allele carriage vs no carriage) [regression]	Yes	yes	
						*1/*3 N=30		16 (53.3%)		OR=2.74	1.21–6.21	P=0.015 (two LOF allele carriage vs no carriage) [regression]	No	yes	
						*2/*2 N=20		13 (65.0%)		OR=2.81	1.21–6.54	P=0.016 (two LOF allele carriage vs no carriage) [regression]	Yes	yes	
						*2/*3 N=14		10 (71.4%)							
Collet, 2011 21511218 France CLOVIS-2	LD: Clopidogrel 300 or 900 mg MD: Aspirin 75 mg/d and/or clopidogrel 75 mg and	CYP2C19*2	LTA	High On- Treatment Platelet Reactivity (MPA >64.5%)	baseline	wt/wt	HPR	7/52 (13.46%)	NR	NR	NR	P=0.34 [between CYP2C19 *2 genotypes] [kruskal wallis test]			
						wt/*2		7/31 (22.6%)							
						*2/*2		1/3 (33.3%)							
					300 mg post loading	wt/wt	HPR	3/58 (5.17%)	NR	NR	NR	P=0.0017 [between CYP2C19 *2 genotypes] [kruskal wallis test]			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						wt/*2		6/41 (14.63%)							
						*2/*2		4/7 (57.14%)							
					900 mg post loading	wt/wt	HPR	2/58 (3.45%)	NR	NR	NR	P=0.005 [between CYP2C19 *2 genotypes] [kruskall wallis test]			
						wt/*2		2/41 (4.88%)							
						*2/*2		4/7 (51.14%)							
			VerifyNow	High On- Treatment Platelet Reactivity (PRU >235)	baseline	wt/wt	HPR	3/52 (5.77%)	NR	NR	NR	P=0.081 [between CYP2C19 *2 genotypes] [kruskall wallis test]			
						wt/*2		5/31 (16.13%)							
						*2/*2		1/3 (33.3%)							
					300 mg post loading	wt/wt	HPR	2/58 (3.45%)	NR	NR	NR	P=0.348 [between CYP2C19 *2 genotypes] [kruskall wallis test]			
						wt/*2		1/41 (2.44%)							
						*2/*2		1/7 (14.29%)							
					900 mg post loading	wt/wt	HPR	1/58 (1.72%)	NR	NR	NR	P=0.242 [between CYP2C19 *2 genotypes] [kruskall wallis test]			
						wt/*2		1/41 (2.44%)							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						*2/*2		1/7 (14.29%)							
Hulot, 2011 21972404 France CLOVIS-2	LD 300 or 900 mg clopidogrel	CYP2C19 *2	high on- treatment platelet reactivity	Maximal platelet aggregation >59%	6 hrs	*1/*1	HPR+	55	59%	NR	NR	NR	NR	NR	“Multi- variate analyses using maximal platelet aggrega- tion or high ontreat- ment platelet reactivity as dependent variables lead to same result (CYP2C19 *2 carriage remained the only significant predictor of platelet function response to clopidogrel LD irrespec- tive of the platelet function

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measure- ment	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Pro- cedures for multiple compar- isons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
															assay (P<0.001 for both loading doses))”
						*1/*2		41							
						*2/*2		7							

Appendix Table D15. Platelet reactivity during followup (continuous outcome)

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Fontana, 2008 17681590 Switzerland NR	600 mg clopidogrel loading dose; 75 mg maintenance dose; all patient except one were on aspirin at baseline; data NR for aspirin maintenance	CYP2C19 *2	PRI VASP continuous outcome	Measurement of PRI	After a minimum 15 d of clopidogrel treatment	*2/*2	2	Mean = 66.1	SD = 5.6	Non-parametric tests for comparison of medians	NR	NR	0.65 (across all 3 groups) [Kruskall-Wallis test]	NO	NO	NO
						*2/*1	25	Mean = 50.6	SD = 17.1							
						*1/*1	54	Mean = 50.9	SD = 13.7							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Giusti, 2007 18004210 Italy NR	Loading dose: clopidogrel 600 mg (orally) + 500 mg ASA (IV); maintenance dose: clopidogrel 75 mg and ASA 100 mg (both daily)	CYP2C19 *2	Aggregation with ADP 2 μmol/L	% maximal aggregation (continuous)	24 h after PCI (6 d for patients receiving IIb/IIIa inhibitors)	*2/*2	40	41 [median]	5, 84 [range]	Non-parametric comparison of medians	NR	NR	P < 0.0001 (across 3 groups) [Kruskall-Wallis] P < 0.0001 (*2/*1 vs. *1/*1) [Mann-Whitney] P < 0.0001 (*2/*2 vs. *1/*1) [Mann-Whitney] P = 0.028 (*2/*2 vs. *2/*1) [Mann-Whitney]	NO	NO	None.
						*2/*1	405	32 [median]	1, 94 [range]							
						*1/*1	974	26 [median]	1, 100 [range]							
						*2/2 or *2/*1 (carriers)	445	33 [median]	1, 94 [range]	Non-parametric comparison of medians	NR	NR	P < 0.0001 (carriers vs. non-carriers) [Mann-Whitney]	NO	NO	None.
						*1/*1 (non-carriers)	974	26 [median]	1, 100 [range]							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2/*2	40	62 [median]	26, 100 [range]	Non-parametric comparison of medians	NR	NR	P < 0.0001 (across 3 groups) [Kruskall-Wallis] P < 0.0001 (*2/*1 vs. *1/*1) [Mann-Whitney] P < 0.0001 (*2/*2 vs. *1/*1) [Mann-Whitney] P = 0.015 (*2/*2 vs. *2/*1) [Mann-Whitney]	NO	NO	None.
						*2/*1	405	54 [median]	2, 100 [range]							
						*1/*1	974	49 [median]	1, 100 [range]							
						*2/2 or *2/*1 (carriers)	445	56 [median]	2, 100 [range]	Non-parametric comparison of medians	NR	NR	P < 0.0001 (carriers vs. non-carriers) [Mann-Whitney]	NO	NO	None.
						*1/*1 (non-carriers)	974	49 [median]	1, 100 [range]							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2/2 or *2/*1 (carriers)	445	NR	NR	Linear regression	Coefficient = 5.3 Coefficient = 4.9	SE = 1.0 SE = 1.3	P < 0.0001 (carriers vs. non-carriers) [univariable linear regression] P = 0.0001 (carriers vs. non-carriers) [linear regression]	NO YES (age, sex, HTN, diabetes mellitus, dyslipidemia, smoking habits)	NO	None.
						*1/*1 (non-carriers)	974	NR	NR							
						*2/2 or *2/*1 (carriers)	445	NR	NR	Linear regression	Coefficient = 5.8 Coefficient = 5.5	SE = 1.2 SE = 1.3	P < 0.0001 (carriers vs. non-carriers) [univariable linear regression] P = 0.0001 (carriers vs. non-carriers) [linear regression]	NO YES (age, sex, HTN, diabetes mellitus, dyslipidemia, smoking habits)	NO	None.
						*1/*1 (non-carriers)	974	NR	NR							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Giusti, 2009 19268736 Italy RECLOSE study (Low Respon-siveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Throm-bosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	CYP2C19*2	ADP-RPR	Continuous measurement	12-18 h from clopidogrel loading	*2/*2 or *2/*1	N = 247	51% [median]	2%-100% [range]	Mann-Whitney U test	NR	NR	0.001	NO	NO	None
						*1/*1	N = 525	45% [median]	1%-100% [range]							
Gladding, 2009 19926050 New Zealand NR	Clopidogrel 150 mg daily	Auto-genomics 2C19+ assay	Platelet inhibition (%)	Per VerifyNow	Baseline	CYP2C19*2 carrier	NR	Median (range) 18% (0% to 72%)	NR	NR	NR	NR	0.01 (vs. next row) [Wilcoxon]	NO	NO	NONE
						CYP2C19*1/*1	NR	Median (range) 59% (11% to 95%)	NR							
					7 days	CYP2C19*2 carrier	NR	NR	NR	NR	NR	NR	0.03 (vs. next row) [Wilcoxon]	NR	NR	NONE
						CYP2C19*1/*1	NR	NR	NR							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Change in platelet inhibition (%) from baseline		7 days	CYP2C19*2 carrier	NR	Mean (SD) 9% (11%)	NR	NR	NR	NR	0.03 for this row's result (7 days vs. baseline) [Student's t]	NR	NR	Fig. 3 shows all raw data for this row and a P of 0.05 (?)
						CYP2C19*2 and CYP2C9*3) carriers: poor or intermediate metabolizers	NR	Mean -10% 95% CI -20 to -0.1%	NR	NR	NR	NR	0.05 (vs. wild type) [Student's t]	NO	NO	Raw data (separate for poor and intermediate, though result here is combined?) in Fig 4
Jinnai, 2009 19531897 Japan Partly industry funded	Patients were on low-dose aspirin (81-100 mg/day) at study enrollment. They received clopidogrel 300 mg loading dose on the first day and 75 mg daily maintenance thereafter.	CYP2C19 *2, *3 and *1	IPA	Change in platelet reactivity compared to baseline	48h	PM = *2/*2 or *2/*3	N = 6	16.0 [Mean % IPA]	SD = 13.0	T-test	NR	NR	0.04 (IM vs. EM)	NO	NO	Patient level data in figure 2b; data for other time-points in Figure 3 (individual patient data)
						IM = *2/*1 or *3/*1	N = 8	18.4 [Mean % IPA]	SD = 10.0	T-test	NR	NR	0.02 (PM vs. EM)	NO	NO	
						EM = *1/*1	N = 11	31.6 [Mean % IPA]	SD = 14.3	T-test	NR	NR	0.73 (PM vs. IM)	NO	NO	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Shuldiner, 2009 19706858 USA Sinai Hospital of Baltimore Study	Clopidogrel LD= 600 mg (n=112) or 300 mg (n=25); No LD for subjects on clopidogrel maintenance therapy (n=90). Aspirin: 81-325 mg aspirin daily for ≥1 week prior to PCI and 325 mg on the day of PCI. Post-PCI: Aspirin 325 mg/day and clopidogrel 75mg/day	CYP2C19 *2	Mean ADP-induced reactivity	Measurements of platelet reactivity before and after clopidogrel administration	Pre-clopidogrel vs. post clopidogrel	*2/*2 *2/*1 *1/*1	Pre clopidogrel N per group was *2/*2 = 4; *2/*1 = 37; *1/*1 = 102 (total=143) Post-clopidogrel N per group was *2/*2 = 3; *2/*1 = 54; *1/*1 = 131 (total=188)	Means can only be extracted from Figure 3.	NR	Additive genetic model within each treatment period (pre-clopidogrel and post-clopidogrel) no comparisons of the genetic effect across treatment periods	NR	NR	P=0.92 for the difference between the 3 genotypes (additive model) pre-clopidogrel. P=0.02 for the difference between the 3 genotypes (additive model) post-clopidogrel.	NO	NO	Measures were paired for some participants but data are not adequate to reconstruct before-after measurements. Patients receiving clopidogrel at baseline were excluded from baseline means.

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	Clopidogrel 600 mg loading dose; clopidogrel 75 mg (1/d) and aspirin 100 mg (2/d) maintenance.	CYP2C19 *17	Platelet aggregation	Continuous outcome, Multiplate analyzer	All patients received a clopidogrel loading dose with a recommended pre-treatment interval of 2h; blood was sampled directly before PCI. The median clopidogrel loading interval was 3.5h for *1/*1; 3.5 h for *17/*1; and 5.3 h for *17/*17.	*17/*17	N = 76	189 [median, in arbitrary units * minutes]	IQR = 119, 301	Comparison of medians using non-parametric tests	NR	NR	P = 0.007 (across all groups) P = 0.039 (*17/*1 vs *1/*1) P = 0.008 (*17/*17 vs. *1/*1)	NO	NO	Additional data in Figure (medians and bootstrap-based 95% CIs)
						*17/*1	N = 546	215 [median, in arbitrary units * minutes]	IQR = 140, 342							
						*1/*1	N = 902	238 [median, in arbitrary units * minutes]	IQR = 146, 388							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*17/*17 or *17/*1	N = 622	213 [median, in arbitrary units * minutes]	IQR = 136, 329	Linear regression	Coefficient values (adjusted mean difference) = -32.3	SE = 9.5	P = 0.0006 (carriers vs. non-carriers) [multivariable linear regression] P = 0.009 (non-parametric test, Wilcoxon)	YES (age, sex, BMI, serum creatinine, use of PPIs, clopidogrel loading interval)	NO	None
						*1/*1	N = 902	238 [median, in arbitrary units * minutes]	IQR = 146, 388							
Varenhorst, 2009 19429918 Sweden Genetic sub-study	Clopidogrel 600 mg loading dose; 75 mg maintenance	CYP2C19 genotyping	VASP phosphorylation measurements at multiple timepoints (continuous)	VASP PRI assay with flow cytometry	Samples were collected at baseline, 2 h and 24 h post-loading dose; also at day 14 ±3 and day 29 ±3, both before that day's maintenance dose	Extensive metabolizers = *17/*17, *1A/*17, *1A/*1A	N = 37	Only reported in graph [VASP PRI, means from a linear model]	Only reported in graph	Linear model with covariate for EM vs. RM	Only reported in graph	Only reported in graph	P<0.05 comparing EM vs. RM in the clopidogrel arm at 24 h, 14 d and 29 d	Yes [the linear model include body weight as a covariate]	NO (some attempt was made to limit multiple testing)	Figures 2 and 3
						Reduced metabolizers = *1A/*2A, *1A/*8, *2A/*2A	N = 9	Only reported in graph [VASP PRI, means from a linear model]	Only reported in graph		Only reported in graph	Only reported in graph				Figures 2 and 3

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Frere, 2008 18394438 France NONE	600 mg loading dose of clopidogrel + 250 mg aspirin	CYP2C19 *2 genotyping	VASP phosphorylation assay	Measurement of VASP phosphorylation	At the catheterization laboratory (≥12h after the loading dose)	CYP2C19 *2/*2 (rs4244285)	NR for this assay (455 patients received this assay)	69.1 [mean of %PRI VASP]	SEM = 5.7	General linear model with genotype as the explanatory variable	NR	NR	0.0001 [across 3 groups] 0.0001 [across 3 groups] <0.007 [recessive general linear model] <0.0001 [codo-minant general linear model across groups]	Unadjusted Adjusted [age, sex] Unadjusted Unadjusted	NO	Additional data in Figure 1 (however reported statistics are adequate)
						CYP2C19 *2/*1 (rs4244285)	NR for this assay (455 patients received this assay)	59.1 [mean of %PRI VASP]	SEM = 2.1							
						CYP2C19 *1/*1 (rs4244285)	NR for this assay (455 patients received this assay)	50.9 [mean of %PRI VASP]	SEM = 1.3							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600 mg loading dose of clopidogrel + 250 mg aspirin	CYP2C19 *2 genotyping	ADP-induced aggregation by LTA	Measurement of ADP-stimulated aggregation	At the catheterization laboratory (≥12h after the loading dose)	CYP2C19 *2/*2 (rs4244285)	23	66.1 [% change in light transmittance from baseline]	SEM = 4	General linear model with genotype as the explanatory variable	NR	NR	0.039 [across 3 groups] 0.05 [across 3 groups] <0.01 [recessive general linear model] <0.08 [codo- minant general linear model across groups]	Unadjusted Adjusted [age, sex] Unadjusted Unadjusted	NO	Additional data in Figure 1 (however reported statistics are adequate)
						CYP2C19 *2/*1 (rs4244285)	143	56.1 [% change in light transmittance from baseline]	SEM = 1.6							
						CYP2C19 *1/*1 (rs4244285)	435	55.7 [% change in light transmittance from baseline]	SEM = 0.9							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600 mg loading dose of clopidogrel + 250 mg aspirin	CYP2C19 *2 genotyping	ADP-induced P-selectin expression	Measurement of P-selecting expression	At the catheterization laboratory (≥12h after the loading dose)	CYP2C19 *2/*2 (rs4244285)	NR for this assay (455 patients received this assay)	0.43 [arbitrary units of fluorescence]	SEM = 0.04	General linear model with genotype as the explanatory variable	NR	NR	0.035 [across 3 groups] 0.030 [across 3 groups] <0.06 [recessive general linear model] <0.009 [codo-minant general linear model across groups]	Unadjusted Adjusted [age, sex] Unadjusted Unadjusted	NO	Additional data in Figure 1 (however reported statistics are adequate)
						CYP2C19 *2/*1 (rs4244285)	NR for this assay (455 patients received this assay)	0.39 [arbitrary units of fluorescence]	SEM = 0.01							
						CYP2C19 *1/*1 (rs4244285)	NR for this assay (455 patients received this assay)	0.35 [arbitrary units of fluorescence]	SEM = 0.01							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Frere, 2009 19496924 France Part of larger observational study	600 mg clopidogrel loading dose	CYP2C19 *4	Both VASP and ADP-induced aggregation	Measurement of PRI-VASP and ADP-induced aggregation	After clopidogrel loading dose (exact timing NR)	NR	*4/*4=0 *4/*1=8 *1/*1=589	NR	NR	Recessive and co-dominant models; analysis method NR	NR	NR	Non-significant	NR	NO	Only a text comment saying that these polymorphisms did not impact the reactivity measures
		CYP2C19 *5	Both VASP and ADP-induced aggregation	Measurement of PRI-VASP and ADP-induced aggregation	After clopidogrel loading dose (exact timing NR)	NR	*5/*5=0 *5/*1=8 *1/*1=589	NR	NR	Recessive and co-dominant models; analysis method NR	NR	NR	Non-significant	NR	NO	Only a text comment saying that these polymorphisms did not impact the reactivity measures
		CYP2C19 *6	Both VASP and ADP-induced aggregation	Measurement of PRI-VASP and ADP-induced aggregation	After clopidogrel loading dose (exact timing NR)	NR	*6/*6=0 *6/*1=8 *1/*1=589	NR	NR	Recessive and co-dominant models; analysis method NR	NR	NR	Non-significant	NR	NO	Only a text comment saying that these polymorphisms did not impact the reactivity measures
		CYP2C19 *17	VASP phosphorylation assay	Measurement of PRI-VASP	After clopidogrel loading dose (exact timing NR)	*17/*17	25	45.79 [mean of % PRI VASP]	SD=17.71	NR	NR	NR	0.0206 ["chi square"]	NO	NO	P=0.19 for the interaction with CYP2C19 *2 [analysis method NR]
						*17/*1	189	50.11 [mean of % PRI VASP]	SD=24.3						NO	
						*1/*1	382	55.9 [mean of % PRI VASP]	SD=22.80						NO	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		CYP2C19 *17	VASP phosphorylation assay	Measurement of PRI-VASP	After clopidogrel loading dose (exact timing NR)	*17/*17 and *17/*1 (carriers vs. non-carriers)	214	49.72 [mean of % PRI VASP]	SD=23.80	NR		NR	0.0073 ["chi-square"] 0.0005 ["chi square"]	NO	NO	P=0.08 for the interaction with CYP2C19 *2 [analysis method NR]
						*1/*1	382	55.9 [mean of % PRI VASP]	SD=22.80						NO	
		CYP2C19 *17	ADP-induced aggregation (assay NR)	Measurement of ADP-induced aggregation	After clopidogrel loading dose (exact timing NR)	*17/*17	25	50.8 [Mean of % aggregation]	SD=27.30	NR	NR	NR	0.2813 ["chi square"]	NO	NO	None
						*17/*1	189	55.5 [Mean of % aggregation]	SD=19.00						NO	
						*1/*1	382	57.03 [Mean of % aggregation]	SD=18.50						NO	
		CYP2C19 *17	ADP-induced aggregation (assay NR)	Measurement of ADP-induced aggregation	After clopidogrel loading dose (exact timing NR)	*17/*17 and *17/*1 (carriers vs. non-carriers)	214	54.96 [Mean of % aggregation]	SD=20.10	NR	NR	NR	0.2062 ["chi square"]	NO	NO	None
						*1/*1	382	57.03 [Mean of % aggregation]	SD=18.50						NO	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Harmsze 2010 19934793 Netherlands NR	clopidogrel maintenance 75 mg/day	CYP2C19*2	On-clopidogrel platelet reactivity	Maximal platelet aggregation achieved in any time during the run of 10 min with ADP 5 µmol/L	NR (Before stenting)	Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	NR	NR	NR	Linear regression	6.7	3.6,9.8	P<0.001 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	NO	NR	
						Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	NR	NR	NR	Linear regression	6.9	3.7,10	P<0.001 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	YES; adjusted for gender, age, BMI, DM, previous MI, days of clopidogrel administration before intervention, CYP3A4-metabolized statins, Ca ⁺ channel blockers, PPI, SSRIs, and NSAIDs.		
			On-clopidogrel platelet reactivity	Maximal platelet aggregation achieved in any time during the run of 10 min with ADP 20 µmol/L	NR (Before stenting)	Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	NR	NR	NR	Linear regression	6.3	3.4,9.3	P<0.001 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	NO	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
										Linear regression	7	4,10	P<0.001 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	YES; adjusted for gender, age, BMI, DM, previous MI, days of clopidogrel administration before intervention, CYP3A4-metabolized statins, Ca ⁺ channel blockers, PPI, SSRIs, and NSAIDs.		
			On-clopidogrel platelet reactivity	on-clopidogrel platelet reactivity expressed as P2Y12 reaction units (PRU)	NR (Before stenting)	Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	NR	NR	NR	Linear regression	35.1	17.2,53	P<0.001 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	NO	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
										Linear regression	34.8	16.8,52.8	P<0.001 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	YES; adjusted for gender, age, BMI, DM, previous MI, days of clopidogrel administration before intervention, CYP3A4-metabolized statins, Ca ⁺ channel blockers, PPI, SSRIs, and NSAIDs.		
Harmsze 2010 19934793 Netherlands	300 mg clopidogrel loading dose	CYP2C19*2	On-clopidogrel platelet reactivity	Maximal platelet aggregation achieved in any time during the run of 10 min with ADP 5 µmol/L	NR (Before stenting)	Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	NR	NR	NR	Linear regression	7.8	3.9,12.6	P=0.002 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	NO	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	NR	NR	NR	Linear regression	5.7	0.6,10.8	P=0.028 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	YES; adjusted for gender, age, BMI, DM, previous MI, days of clopidogrel administration before intervention, CYP3A4-metabolized statins, Ca ⁺ channel blockers, PPI, SSRIs, and NSAIDs.		
			On-clopidogrel platelet reactivity	Maximal platelet aggregation achieved in any time during the run of 10 min with ADP 20 μmol/L	NR (Before stenting)	Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	NR	NR	NR	Linear regression	7.4	3.3,11.6	P=0.001 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	NO	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
										Linear regression	7	2.6,11.5	P=0.002 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	YES; adjusted for gender, age, BMI, DM, previous MI, days of clopidogrel administration before intervention, CYP3A4-metabolized statins, Ca ⁺ channel blockers, PPI, SSRIs, and NSAIDs.		
			On-clopidogrel platelet reactivity	on-clopidogrel platelet reactivity expressed as P2Y12 reaction units (PRU)	NR (Before stenting)	Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)	NR	NR	NR	Linear regression	37.5	16.5,58.5	P=0.001 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	NO	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
										Linear regression	28.5	7.1,549.6	P=0.009 [Carriers (*1/*2 or *2/*2) vs Noncarriers (*1/*1)]	YES; adjusted for gender, age, BMI, DM, previous MI, days of clopidogrel administration before intervention, CYP3A4-metabolized statins, Ca ⁺ channel blockers, PPI, SSRIs, and NSAIDs.		
Tantry 2010 21079055 Multi-country-North America and Europe Genetic substudy of ONSET/OFFSET and RESPOND	All patients received 75 to 100 mg/d aspirin clopidogrel (600-mg load, 75 mg/d thereafter)	TaqMan	5 uM ADP-induced platelet aggregation (%)	NR	8 hr after loading dose	UM	28	see fig 3A	see fig 3A	Kruskal-Wallis (K-W) test	NR	NR	0.289 for this and next 3 rows [K-W]	NO	NO	Get data from Fig. 3A
						EM	31	see fig 3A	see fig 3A							Get data from Fig. 3A

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						IM	20	see fig 3A	see fig 3A							Get data from Fig. 3A
						PM	3	see fig 3A	see fig 3A							Get data from Fig. 3A
					8 hr after last maintenance dose	UM	28	see fig 3B	see fig 3B				0.33 for this and next 3 rows [K-W]			Get data from Fig. 3B
						EM	31	see fig 3B	see fig 3B							Get data from Fig. 3B
						IM	20	see fig 3B	see fig 3B							Get data from Fig. 3B
						PM	3	see fig 3B	see fig 3B							Get data from Fig. 3B
			20 uM ADP-induced platelet aggregation (%)		8 hr after loading dose	UM	28	see fig 4A	see fig 4A				0.307 for this and next 3 rows [K-W]			Get data from Fig. 4A
						EM	31	see fig 4A	see fig 4A							Get data from Fig. 4A
						IM	20	see fig 4A	see fig 4A							Get data from Fig. 4A
						PM	3	see fig 4A	see fig 4A							Get data from Fig. 4A
					8 hr after last maintenance dose	UM	28	see fig 4B	see fig 4B				0.056 for this and next 3 rows [K-W]			Get data from Fig. 4B
						EM	31	see fig 4B	see fig 4B							Get data from Fig. 4B
						IM	20	see fig 4B	see fig 4B							Get data from Fig. 4B
						PM	3	see fig 4B	see fig 4B							Get data from Fig. 4B

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			VerifyNow P2Y12 reaction units		8 hr after loading dose	UM	28	see fig 5A	see fig 5A				0.019 for this and next 3 rows [K-W]			Get data from Fig. 5A
						EM	31	see fig 5A	see fig 5A							Get data from Fig. 5A
						IM	20	see fig 5A	see fig 5A							Get data from Fig. 5A
						PM	3	see fig 5A	see fig 5A							Get data from Fig. 5A
					8 hr after last maintenance dose	UM	28	see fig 5B	see fig 5B				0.006 for this and next 3 rows [K-W]			Get data from Fig. 5B
						EM	31	see fig 5B	see fig 5B							Get data from Fig. 5B
						IM	20	see fig 5B	see fig 5B							Get data from Fig. 5B
						PM	3	see fig 5B	see fig 5B							Get data from Fig. 5B
			VASP platelet reactivity index (%)		8 hr after loading dose	UM	28	see fig 6A	see fig 6A				0.153 for this and next 3 rows [K-W]			Get data from Fig. 6A
						EM	31	see fig 6A	see fig 6A							Get data from Fig. 6A
						IM	20	see fig 6A	see fig 6A							Get data from Fig. 6A
						PM	3	see fig 6A	see fig 6A							Get data from Fig. 6A
					8 hr after last maintenance dose	UM	28	see fig 6B	see fig 6B				0.069 for this and next 3 rows [K-W]			Get data from Fig. 6B
						EM	31	see fig 6B	see fig 6B							Get data from Fig. 6B

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						IM	20	see fig 6B	see fig 6B							Get data from Fig. 6B
						PM	3	see fig 6B	see fig 6B							Get data from Fig. 6B
			5 mM ADP-induced platelet aggregation (%)		8 hr after loading dose	LOF allele carrier	23	see fig 3A	see fig 3A				0.078 vs. next row [K-W]			Get data from Fig. 3A
						LOF allele noncarrier	59	see fig 3A	see fig 3A							Get data from Fig. 3A
					8 hr after last maintenance dose	LOF allele carrier	23	see fig 3B	see fig 3B				0.097vs. next row [K-W]			Get data from Fig. 3B
						LOF allele noncarrier	59	see fig 3B	see fig 3B							Get data from Fig. 3B
			20 mM ADP-induced platelet aggregation (%)		8 hr after loading dose	LOF allele carrier	23	see fig 4A	see fig 4A				0.080 vs. next row [K-W]			Get data from Fig. 4A
						LOF allele noncarrier	59	see fig 4A	see fig 4A							Get data from Fig. 4A
					8 hr after last maintenance dose	LOF allele carrier	23	see fig 4B	see fig 4B				0.049vs. next row [K-W]			Get data from Fig. 4B
						LOF allele noncarrier	59	see fig 4B	see fig 4B							Get data from Fig. 4B
			VerifyNow P2Y12 reaction units		8 hr after loading dose	LOF allele carrier	23	see fig 5A	see fig 5A				0.010 vs. next row [K-W]			Get data from Fig. 5A
						LOF allele noncarrier	59	see fig 5A	see fig 5A							Get data from Fig. 5A

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					8 hr after last maintenance dose	LOF allele carrier	23	see fig 5B	see fig 5B				0.002 vs. next row [K-W]			Get data from Fig. 5B
						LOF allele noncarrier	59	see fig 5B	see fig 5B							Get data from Fig. 5B
			VASP platelet reactivity index (%)		8 hr after loading dose	LOF allele carrier	23	see fig 6A	see fig 6A				0.036 vs. next row [K-W]			Get data from Fig. 6A
						LOF allele noncarrier	59	see fig 6A	see fig 6A							Get data from Fig. 6A
					8 hr after last maintenance dose	LOF allele carrier	23	see fig 6B	see fig 6B				0.010 vs. next row [K-W]			Get data from Fig. 6B
						LOF allele noncarrier	59	see fig 6B	see fig 6B							Get data from Fig. 6B
			5 uM ADP-induced platelet aggregation (%)		8 hr after loading dose	GOF allele carrier	28	see fig 3A	see fig 3A				0.0168 for this row and corresponding LOF carrier and EM above [K-W]			Get data from Fig. 3A
					8 hr after last maintenance dose	GOF allele carrier	28	see fig 3B	see fig 3B				0.231 for this row and corresponding LOF carrier and EM above [K-W]			Get data from Fig. 3B

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			20 uM ADP-induced platelet aggregation (%)		8 hr after loading dose	GOF allele carrier	28	see fig 4A	see fig 4A				0.165 for this row and corresponding LOF carrier and EM above [K-W]			Get data from Fig. 4A
					8 hr after last maintenance dose	GOF allele carrier	28	see fig 4B	see fig 4B				0.080 for this row and corresponding LOF carrier and EM above [K-W]			Get data from Fig. 4B
			VerifyNow P2Y12 reaction units		8 hr after loading dose	GOF allele carrier	28	see fig 5A	see fig 5A				0.028 for this row and corresponding LOF carrier and EM above [K-W]			Get data from Fig. 5A
					8 hr after last maintenance dose	GOF allele carrier	28	see fig 5B	see fig 5B				0.007 for this row and corresponding LOF carrier and EM above [K-W]			Get data from Fig. 5B

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			VASP platelet reactivity index (%)		8 hr after loading dose	GOF allele carrier	28	see fig 6A	see fig 6A				0.109 for this row and corresponding LOF carrier and EM above [K-W]			Get data from Fig. 6A
					8 hr after last maintenance dose	GOF allele carrier	28	see fig 6B	see fig 6B				0.034 for this row and corresponding LOF carrier and EM above [K-W]			Get data from Fig. 6B
			5 uM ADP-induced platelet aggregation (%)		8 hr after last maintenance dose	*1/*1	31	see fig 7A	see fig 7A				NR			Get data from Fig. 7A
						*1/*2	13	see fig 7A	see fig 7A							Get data from Fig. 7A
						*1/*3	1	see fig 7A	see fig 7A							Get data from Fig. 7A
						*1/*17	28	see fig 7A	see fig 7A							Get data from Fig. 7A
						*2/*2	3	see fig 7A	see fig 7A							Get data from Fig. 7A
						*2/*17	6	see fig 7A	see fig 7A							Get data from Fig. 7A
			20 uM ADP-induced platelet aggregation (%)		8 hr after last maintenance dose	*1/*1	31	see fig 7B	see fig 7B							Get data from Fig. 7B

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*1/*2	13	see fig 7B	see fig 7B							Get data from Fig. 7B
						*1/*3	1	see fig 7B	see fig 7B							Get data from Fig. 7B
						*1/*17	28	see fig 7B	see fig 7B							Get data from Fig. 7B
						*2/*2	3	see fig 7B	see fig 7B							Get data from Fig. 7B
						*2/*17	6	see fig 7B	see fig 7B				0.0995 for this and 5 previous rows [K-W]			Get data from Fig. 7B
			VerifyNow P2Y12 reaction units		8 hr after last maintenance dose	*1/*1	31	see fig 7C	see fig 7C							Get data from Fig. 7C
						*1/*2	13	see fig 7C	see fig 7C							Get data from Fig. 7C
						*1/*3	1	see fig 7C	see fig 7C							Get data from Fig. 7C
						*1/*17	28	see fig 7C	see fig 7C							Get data from Fig. 7C
						*2/*2	3	see fig 7C	see fig 7C							Get data from Fig. 7C
						*2/*17	6	see fig 7C	see fig 7C				≤0.006 for this and 5 previous rows [K-W]			Get data from Fig. 7C
			VASP platelet reactivity index (%)		8 hr after last maintenance dose	*1/*1	31	see fig 7D	see fig 7D							Get data from Fig. 7D
						*1/*2	13	see fig 7D	see fig 7D							Get data from Fig. 7D
						*1/*3	1	see fig 7D	see fig 7D							Get data from Fig. 7D

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*1/*17	28	see fig 7D	see fig 7D							Get data from Fig. 7D
						*2/*2	3	see fig 7D	see fig 7D							Get data from Fig. 7D
						*2/*17	6	see fig 7D	see fig 7D				0.0996 for this and 5 previous rows [K-W]			Get data from Fig. 7D
Jeong 2010 20650435 Korea NR	high-MD clopidogrel of 150 mg/day	CYP2C19	Platelet reactivity (max)	LTA, 5uM ADP	2-4 hours	*1/*1	46	30.3	12.6	t-test	NR	NR	<0.001 comparing the following row	NR	NR	
						RMs		40.7	16.8							
			Platelet reactivity (late)	LTA, 5uM ADP	2-4 hours	*1/*1	46	17.5	12.6	t-test	NR	NR	0.001 comparing the following row	NR	NR	
						RMs		28.8	19.6							
			Platelet reactivity (max)	LTA, 20uM ADP	2-4 hours	*1/*1	46	40.5	15.8	t-test	NR	NR	<0.001 comparing the following row	NR	NR	
						RMs		54.2	16.2							
			Platelet reactivity (late)	LTA, 20uM ADP	2-4 hours	*1/*1	46	24.3	17.7	t-test	NR	NR	0.001 comparing the following row	NR	NR	
						RMs		42	21.7							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			VerifyNow P2Y12 assay(PRU)	ADP	2-4 hours	*1/*1	46	149.3	74.5	t-test	NR	NR	0.001 comparing the following row	NR	NR	
						RMs		197.7	78.1							
			VerifyNow P2Y12 assay(PRU), % inhibition	ADP	2-4 hours	*1/*1	46	55.7	20.4	t-test	NR	NR	0.001 comparing the following row	NR	NR	
						RMs		37.6	22.4							
Barker, 2010 20965456 USA NR	clopidogrel 150 mg/day for 7 days	CYP2C19	OTR	P2Y12 reaction units (PRU)	after 7 days	Lof allele		292	40	t-test	NR	NR	0.5	no	no	
						Vs Non-carriers		281	54							
	clopidogrel 150 mg/day for 7 days	CYP2C19	OTR	P2Y12 reaction units (PRU)	after 7 days	Lof allele		52	66	t-test	NR	NR	0.25	no	no	
						Vs Non-carriers		77	72		NR	NR				
			OTR	P2Y12 reaction units (PRU)	after 7 days	CYP2C19		61	75	ANOVA	NR	NR	0.5	no	no	
			OTR	P2Y12 reaction units (PRU)	after 7 days	CYP2C19		84	72		NR	NR				
			OTR	P2Y12 reaction units (PRU)	after 7 days	CYP2C19		56	71		NR	NR				
			OTR	P2Y12 reaction units (PRU)	after 7 days	CYP2C19		28	31		NR	NR				

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Bonello, 2010 20708365 France NR	All patients received oral LDs of 250 mg aspirin and 600 mg clopidogrel at least 6 h before the first VASP index measurement	CYP2C19	VASP index	Median fluorescence intensity (MFI)	12 h	Carrier of 1 mutant allele	411	61.7	18.4%	t-test	NR	NR	<0.001 compared with the second row	NR	NR	
			VASP index	Median fluorescence intensity (MFI)	12h	Wild-type allele homozygotes	411	49.2	24.2%	t-test	NR	NR		NR	NR	
			VASP index	Median fluorescence intensity (MFI)	First dose	Carrier of at least one CYP2C19*2 allele	103	69.7	10.1%	t-test	NR	NR	<0.0001 compare with the lower row	NR	NR	
			VASP index	Median fluorescence intensity (MFI)	Second dose	Carrier of at least one CYP2C19*2 allele	103	50.6	17.6%	t-test	NR	NR		NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Hwang 2011 21075428 South Korea NR	300-mg loading dose (LD) of clopidogrel and aspirin 200 mg/day maintenance dose of aspirin and 75 mg/day of clopidogrel thereafter.	CYP2C19*2	Platelet measures	5 umol/L ADP-MPA,%	12h	Codominant	GG 93	43.6	15.2	ANOVA	NR	NR	0.003 comparing with the following 2 groups	NR	Yes	
				5 umol/L ADP-MPA,%	12h	Codominant	GA 79	50.6	15.1		NR	NR		NR	Yes	
				5 umol/L ADP-MPA,%	12h	Codominant	AA 18	53.0	14.7		NR	NR		NR	Yes	
				5 umol/L ADP-MPA,%	12h	dominant	GG 93	43.6	15.2	t- test	NR	NR	0.001 comparing with the following group	NR	Yes	
				5 umol/L ADP-MPA,%	12h	dominant	GA/AA 97	51.1	14.9		NR	NR		NR	Yes	
				5 umol/L ADP-MPA,%	12h	recessive	GG/GA 172	46.8	15.5	t- test	NR	NR	0.107 comparing with the following group	NR	Yes	
				5 umol/L ADP-MPA,%	12h	recessive	AA 18	53	14.7		NR	NR		NR	Yes	
		CYP2C19*3	Platelet measures	5 umol/L ADP-MPA,%	12h	Codominant	GG 165	46.3	15.5	ANOVA	NR	NR	0.008 comparing with the following 2 groups	NR	Yes	
				5 umol/L ADP-MPA,%	12h	Codominant	GA 25	55.1	13.7		NR	NR		NR	Yes	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
				5 umol/L ADP-MPA,%	12h	Codominant	AA 0	-	-		NR	NR		NR	Yes	
				5 umol/L ADP-MPA,%	12h	dominant	GG 165	46.3	15.5	t- test	NR	NR	0.008 comparing with the following group	NR	Yes	
				5 umol/L ADP-MPA,%	12h	dominant	GA/AA 25	55.1	13.7		NR	NR		NR	Yes	
				5 umol/L ADP-MPA,%	12h	recessive	GG/GA 190	47.4	15.5		NR	NR		NR	Yes	
				5 umol/L ADP-MPA,%	12h	recessive	AA 0	-	-		NR	NR		NR	Yes	
		CYP2C19*2	Platelet measures	20 umol/L ADP-MPA,%	12h	Codominant	GG 93	56.7	15.4	ANOVA	NR	NR	<0.001 comparing with the following 2 group	NR	Yes	
				20 umol/L ADP-MPA,%	12h	Codominant	GA 79	63.8	12		NR	NR		NR	Yes	
				20 umol/L ADP-MPA,%	12h	Codominant	AA 18	67.5	10.5		NR	NR		NR	Yes	
				20 umol/L ADP-MPA,%	12h	dominant	GG 93	56.7	15.4	t- test	NR	NR	<0.001 comparing with the following group	NR	Yes	
				20 umol/L ADP-MPA,%	12h	dominant	GA/AA 97	64.5	11.8		NR	NR		NR	Yes	
				20 umol/L ADP-MPA,%	12h	recessive	GG/GA 172	59.9	14.3	t- test	NR	NR	0.03 comparing with the following group	NR	Yes	
				20 umol/L ADP-MPA,%	12h	recessive	AA 18	67.5	10.5		NR	NR		NR	Yes	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		CYP2C19*3	Platelet measures	20 umol/L ADP-MPA,%	12h	Codominant	GG 165	59.7	14.4	ANOVA	NR	NR	0.008 comparing with the following 2 groups	NR	Yes	
				20 umol/L ADP-MPA,%	12h	Codominant	GA 25	67.2	10.3		NR	NR		NR	Yes	
				20 umol/L ADP-MPA,%	12h	Codominant	AA 0	-	-		NR	NR		NR	Yes	
				20 umol/L ADP-MPA,%	12h	dominant	GG 165	59.7	14.4	t- test	NR	NR	0.008 comparing with the following group	NR	Yes	
				20 umol/L ADP-MPA,%	12h	dominant	GA/AA 25	67.2	10.3		NR	NR		NR	Yes	
				20 umol/L ADP-MPA,%	12h	recessive	GG/GA 190	60.7	14.2		NR	NR		NR	Yes	
				20 umol/L ADP-MPA,%	12h	recessive	AA 0	-	-		NR	NR		NR	Yes	
	Clopidogrel	CYP2C19*2	Platelet measures	P2Y12 reaction unit	12h	Codominant	GG 93	256.5	77.7	ANOVA	NR	NR	0.081 Comparing with the following 2 groups	NR	Yes	
				P2Y12 reaction unit	12h	Codominant	GA 79	270.9	71.9		NR	NR		NR	Yes	
				P2Y12 reaction unit	12h	Codominant	AA 18	297.6	68.3		NR	NR		NR	Yes	
				P2Y12 reaction unit	12h	dominant	GG 93	256.5	77.7	t- test	NR	NR	0.075 Comparing with the following group	NR	Yes	
				P2Y12 reaction unit	12h	dominant	GA/AA 97	275.9	71.7		NR	NR		NR	Yes	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
				P2Y12 reaction unit	12h	recessive	GG/GA 172	263.1	75.2	t- test	NR	NR	0.064 Comparing with the following group	NR	Yes	
				P2Y12 reaction unit	12h	recessive	AA 18	297.6	68.3		NR	NR		NR	Yes	
		CYP2C19*3	Platelet measures	P2Y12 reaction unit	12h	Codominant	GG 165	264	76.9	ANOVA	NR	NR	0.258 Comparing with the following 2 groups	NR	Yes	
				P2Y12 reaction unit	12h	Codominant	GA 25	282.2	60.5		NR	NR		NR	Yes	
				P2Y12 reaction unit	12h	Codominant	AA 0	-	-		NR	NR		NR	Yes	
				P2Y12 reaction unit	12h	dominant	GG 165	264	76.9	t- test	NR	NR	0.258 Comparing with the following group	NR	Yes	
				P2Y12 reaction unit	12h	dominant	GA/AA 25	282.2	60.5		NR	NR		NR	Yes	
				P2Y12 reaction unit	12h	recessive	GG/GA 190	266.4	75.1		NR	NR	-	NR	Yes	
				P2Y12 reaction unit	12h	recessive	AA 0	-	-		NR	NR		NR	Yes	
Kang, 2010 20724801 Korea NR	300-mg LD of clopidogrel and aspirin followed by 200 mg/day MD of aspirin and 75 mg/day clopidogrel	CYP2C19	5 umol/L ADP PRmax	Maximal platelet reactivity	NR	mutant allele	104	51.6	16.4	t-test	NR	NR	0.008 (mutant allele Vs no carrier)	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						No mutant carrier	72	44.7	17.4							
		CYP2C19	20 umol/L ADP PRmax	Maximal platelet reactivity	NR	mutant allele	104	64.6	13.9	t-test	NR	NR	0.007	NR	NR	
						No mutant carrier	72	58.2	17.4							
Liu 2010 21163112 China NR	300 mg clopidogrel and a daily maintenance dose of 75 mg	SNP rs4244285	Platelet aggregation	maximal percent change in LTA from the baseline value	At baseline	G/G,	426	62.8	6.6	t-test	NR	NR	P=0.756	NR	NR	
				maximal percent change in LTA from the baseline value	At baseline	G/A or A/A	296	62.7	7.1		NR	NR		NR	NR	
				maximal percent change in LTA from the baseline value	After loading	G/G,	426	36.3	11.5	t-test	NR	NR	P=0.039	NR	NR	
				maximal percent change in LTA from the baseline value	After loading	G/A or A/A	296	38.1	11.6		NR	NR		NR	NR	
				maximal percent change in LTA from the baseline value	Reduction	G/G,	426	26.9	12.3	t-test	NR	NR	P=0.038	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
				maximal percent change in LTA from the baseline value	Reduction	G/A or A/A	296	24.5	12.8		NR	NR		NR	NR	
		Smoking	Platelet aggregation	maximal percent change in LTA from the baseline value	At baseline	smoking	312	63.8±6.8	63.8±6.8	t-test	NR	NR	P<0.001	NR	NR	
		Non-smoking	Platelet aggregation	maximal percent change in LTA from the baseline value	At baseline	Non-smoking	410	62.0±6.8	62.0±6.8		NR	NR		NR	NR	
		Smoking	Platelet aggregation	maximal percent change in LTA from the baseline value	After loading	smoking	312	36.0±12.3	36.0±12.3	t-test	NR	NR	P=0.041	NR	NR	
		Non-smoking	Platelet aggregation	maximal percent change in LTA from the baseline value	After loading	Non-smoking	410	37.8±10.9	37.8±10.9		NR	NR		NR	NR	
		Smoking	Platelet aggregation	maximal percent change in LTA from the baseline value	Reduction	smoking	312	27.8±13.2	27.8±13.2	t-test	NR	NR	P<0.001	NR	NR	
		Non-smoking	Platelet aggregation	maximal percent change in LTA from the baseline value	Reduction	Non-smoking	410	24.2±11.8	24.2±11.8		NR	NR		NR	NR	dhhh jf

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Maeda, 2010 21178986 Japan NR	(i) aspirin (100 mg, q.d.), (ii) aspirin (100 mg, q.d.) plus clopidogrel (75 mg, q.d. or (iii) aspirin (100 mg, q.d.) plus ticlopidine (100 mg, b.i.d.;															Figure 2 a, box plot based on genotype, figure 3 a, box plot based on genotype
Yamamoto 2011 21168310 Japan NR	300mg loading dose and 75mg/day clopidogrel maintenance dose plus 100mg aspirin	CYP2C19*1/*1	Platelet reactivity	Aggregation units (AU) Min	NR	*1/*1	EM 47	3194	1570 Au min	Mann-Whitney U test	NR	NR	EM vs IM P<0.05	NR	NR	
		CYP2C19*1/*2, *1/*3	Platelet reactivity	Aggregation units (AU) Min	NR	*1/*2, *1/*3	IM 51	4184	1400 Au min		NR	NR		NR	NR	
		CYP2C19*2/*2, *2/*3, *3/*3	Platelet reactivity	Aggregation units (AU) Min	NR	*2/*2, *2/*3, *3/*3	PM 25	5088	1080 Au min	Mann-Whitney U test	NR	NR	IM vs P M P<0.05	NR	NR	
		CYP2C19*1/*1	Platelet reactivity	Aggregation units (AU) Min	<7 days	*1/*1	EM 25	3186	1595 Au min	Mann-Whitney U test	NR	NR	EM vs IM P<0.05	NR	NR	
		CYP2C19*1/*2, *1/*3	Platelet reactivity	Aggregation units (AU) Min	<7 days	*1/*2, *1/*3	IM 32	3007	1541 Au min	Mann-Whitney U test	NR	NR		NR	NR	
		CYP2C19*2/*2, *2/*3, *3/*3	Platelet reactivity	Aggregation units (AU) Min	<7 days	*2/*2, *2/*3, *3/*3	PM 12	4655	1380 Au min	Mann-Whitney U test	NR	NR	IM vs PM P<0.05	NR	NR	
		CYP2C19*1/*1	Platelet reactivity	Aggregation units (AU) Min	≥7 days	*1/*1	EM 22	3186	1595 Au min	Mann-Whitney U test	NR	NR	EM vs IM NS	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		CYP2C19*1/*2, *1/*3	Platelet reactivity	Aggregation units (AU) Min	≥7 days	*1/*2, *1/*3	IM 19	3007	1541 Au min	Mann-Whitney U test	NR	NR		NR	NR	
		CYP2C19*2/*2, *2/*3, *3/*3	Platelet reactivity	Aggregation units (AU) Min	≥7 days	*2/*2, *2/*3, *3/*3	PM 13	4655	1380 Au min	Mann-Whitney U test	NR	NR	IM vs PM P<0.05	NR	NR	
Sibbing, 2010 20492469 Germany	Aspirin and clopidogrel (75 mg/day)	CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *2 (wt/wt)	738	212	NR	Kruskal-Wallis test	NR	141-351	P=0.0001 for *2/*2 vs wt/wt	No	NR	Figure 2a and b, bootstrap results
		CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *2 (wt/*2)	229	305				162-482	P=0.01 for *2/*2 vs wt/*2 patients			
		CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *2 (*2/*2)	19	475				387-575				

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *17 (wt/wt)	608	243		Kruskal-Wallis test		151-416	P=0.007 for *17/*17 vs wt/wt	No	NR	
		CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *17 (wt/*17)	335	217				141-375	P=0.06 for *17/*17 vs wt/*17 patients			
		CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *17 (*17/*17)	43	164				120-273				

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *17+/*2-	319	207	NR	Kruskal-Wallis test	NR	132-332	P<0.001 for CYP2C19 *17+/*2- Vs CYP2C19 *17-/*2+	NR	NR	
		CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *17+/*2-	419	NR	NR	Kruskal-Wallis test	NR		No	NR	NR	
		CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *17+/*2+	59	NR	NR	Kruskal-Wallis test	NR		No	NR		

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		CYP2C19	Platelet aggregation	Aggregation measured with MEA is quantified as aggregation units(AU) and area under the curve(AUC) of aggregation units (AU*min).	NR	CYP2C19 *17-/*2+	189	309	NR	Kruskal-Wallis test	NR	172-490	No	NR		
Bouman 2011 21628721 Netherlands Genetic substudy of the Popular study	pretreated with clopidogrel (75 mg daily for >5 days, or a loading dose of 300 mg ≥24 h or 600 mg ≥4 h before (PCI)) and aspirin (80-100 mg daily ≥10 days prior to PCI) Clopidogrel and aspirin maintenance doses were 75 mg and 80 to 100 mg daily, respectively.	CYP2C19 genetic test (real-time PCR)	On-treatment platelet reactivity	5 umol/l ADP-induced LTA	Within 2 hr after blood sampling	CYP2C19*2 heterozygotes	260	44% aggregation	SD 14%	ANOVA) followed by the least significant difference post-hoc test	NR	NR	NR	YES (age, sex, BMI, current smoking, systolic BP >140 mm Hg or diastolic BP >90 mm Hg, diabetes mellitus, LVEF <45%, renal failure (creatinine level >1.36 mg/dl), platelet count, mean platelet volume, clopidogrel regimen, PPI use, and amlodipine use)	NR	
				20 umol/l ADP-induced LTA				63% aggregation	SD 13%							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
				Plateletworks assay				72% aggregation	SD 27%							
				VerifyNow P2Y12				230 platelet reactivity units (PRU)	SD 27 PRU							
				5 umol/l ADP-induced LTA		CYP2C19*2 homozygotes	27	52% aggregation	SD 14%							
				20 umol/l ADP-induced LTA				70% aggregation	SD 9%							
				Plateletworks assay				90% aggregation	SD 21%							
				VerifyNow P2Y12				257 platelet reactivity units (PRU)	SD 60 PRU							
				5 umol/l ADP-induced LTA		CYP2C19*2 noncarrier	737	38% aggregation	SD 14%							
				20 umol/l ADP-induced LTA				56% aggregation	SD 15%							
				Plateletworks assay				61% aggregation	SD 30%							
				VerifyNow P2Y12				202 platelet reactivity units (PRU)	SD 76 PRU							
Campo 2011 21679849 Italy NR	aspirin (300 mg as loading dose [LD and MD 100 mg daily, Clopidogrel 600 mg LD , clopidogrel 75 mg/day was continued for 12 months.	TaqMan	Platelet reactivity	VerifyNow values	Baseline (before PCI)	*2 noncarriers	219	Mean 181 PRU	SD 97 PRU	t test and 1-way analysis of variance	NR	NR	see table 2	linear mixed model	baseline, genetic, and procedural characteristics	Data are from Table 2. Some P values there are not yet reported here because I can't tell what comparison they're for
						*2 heterozygote	76	Mean 216 PRU	SD 92 PRU				<0.05 vs noncarrier			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 homozygote	5	Mean 236 PRU	SD 112 PRU				<0.05 vs noncarrier			
						*2 carrier	81	Mean 216 PRU	SD 91 PRU							
					1 mo after PCI	*2 noncarriers	219	Mean 133 PRU	SD 81 PRU							
						*2 heterozygote	76	Mean 182 PRU	SD 88 PRU				<0.05 vs noncarrier			
						*2 homozygote	5	Mean 221 PRU	SD 105 PRU				<0.05 vs noncarrier			
						*2 carrier	81	Mean 185 PRU	SD 90 PRU							
					6 mo after PCI	*2 noncarriers	204	Mean 132 PRU	SD 81 PRU							Ns are less at 6 mo because data for this time point only available for 281 pts
						*2 heterozygote	73	Mean 180 PRU	SD 85 PRU				<0.05 vs noncarrier			
						*2 homozygote	4	Mean 218 PRU	SD 95 PRU				<0.05 vs noncarrier			
						*2 carrier	77	Mean 183 PRU	SD 87 PRU							
					Baseline (before PCI)	*17 noncarriers	198	Mean 203 PRU	SD 92 PRU	t test and 1-way analysis of variance	NR	NR	see table 2			Data are from Table 2. Some P values there are not yet reported here because I can't tell what comparison they're for
						*17 heterozygote	85	Mean 171 PRU	SD 100 PRU				<0.05 vs noncarrier			
						*17 homozygote	17	Mean 139 PRU	SD 100 PRU				<0.05 vs noncarrier			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*17 carrier	102	Mean 165 PRU	SD 101 PRU							
					1 mo after PCI	*17 noncarriers	198	Mean 163 PRU	SD 83 PRU							
						*17 heterozygote	85	Mean 122 PRU	SD 79 PRU				<0.05 vs noncarrier			
						*17 homozygote	17	Mean 88 PRU	SD 88 PRU				<0.05 vs noncarrier			
						*17 carrier	102	Mean 117 PRU	SD 81 PRU							
					6 mo after PCI	*17 noncarriers	185	Mean 163 PRU	SD 81 PRU							Ns are less at 6 mo because data for this time point only available for 281 pts
						*17 heterozygote	79	Mean 119 PRU	SD 83 PRU				<0.05 vs noncarrier			
						*17 homozygote	17	Mean 88 PRU	SD 93 PRU				<0.05 vs noncarrier			
						*17 carrier	96	Mean 113 PRU	SD 85 PRU							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Fernando 2011 21696537 Australia NR	clopidogrel 75 mg daily and randomized to either esomeprazole 40 mg or placebo (sugar filled) capsule daily for a period of 6 weeks and routine aspirin (100 mg). followed by a 2-week wash-out. Patients then resumed clopidogrel 75 mg daily and the opposite therapy .	GenesFx (PCR)	Mean change in platelet reactivity from baseline	VASP data (PRI units)	After treatment (first or second) or washout, but otherwise NR	Poor/intermediate metabolizers	6	Mean	SEM	Two-way ANOVA	NR	NR	<0.01 vs. row below [Two-way ANOVA]	NR	NR	Get data from Fig 4—either report data for esomeprazole and placebo treatment separately or average?
						Extensive metabolizers	23									
				Aggregometry data (AUC units)		Poor/intermediate metabolizers	6						<0.01 vs. row below [Two-way ANOVA]			
						Extensive metabolizers	23									
				VerifyNow (PRU) data		Poor/intermediate metabolizers	6						<0.01 vs. row below [Two-way ANOVA]			
						Extensive metabolizers	23									

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Geisler 2008 18781853 Germany NR		MassARRAY for *2	Residual platelet aggregation (RPA)	From turbidometry	Post-clopidogrel loading dose	*2/*2	10	Median RPA 54%	NR	NR	NR	NR	NR	NR	NR	NO
						*1/*2	52	Median RPA, 46%								
						*1/*1	175	Median RPA, 30%								
						*17/*17	21	Median RPA 37%					NS for this and next two rows			
						*1/*17	79	Median RPA, 30%								
						*1/*1	137	Median RPA, 36%								

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gladding 2008 19463375 New Zealand PRINC (Plavix Response in Coronary Intervention) Trial	All patients: 600-mg clopidogrel at the start of the PCI procedure. At 2 hours after, 37 patients received 600 mg clopidogrel and 23 received placebo. Starting the next day, all patients were separately randomized to receive clopidogrel 75 or 150 mg once daily for 1 week, followed by 75 mg once daily thereafter.	TaqMan PCR	Platelet inhibition (% of baseline)	VerifyNow data	At 2 hr	CYP2C19*1*1 homozygotes	24	Median (range) 23 (0% to 66%)	NR	NR	NR	NR	0.0295 (vs. row below) [Mann-Whitney U test]	NO	NO	Raw data in Fig 3
						CYP2C19*2 or *4 carriers	19	Median (range) 10% (0% to 56%)								
						CYP2C19*17 carriers	17	Median (range) 9% (0% to 98%)					0.0262 (vs. 2 rows above) [Mann-Whitney U test]			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					At 4 hr	CYP2C19*1*1 homozygotes receiving 1200 mg total	15	Median (range) 43% (13% to 97%)	NR	NR	NR	NR	0.3 (vs. row below) [Mann-Whitney U test]	NO	NO	Raw data in Fig 4
						CYP2C19*1*1 homozygotes receiving 600 mg total	9	Median (range) 35% (0% to 65%)								
					At 7 hr	CYP2C19*1*1 homozygotes receiving 1200 mg total	15	Median (range) 63% (15% to 98%)	NR	NR	NR	NR	0.05(vs. row below) [Mann-Whitney U test]	NO	NO	Raw data in Fig 4
						CYP2C19*1*1 homozygotes receiving 600 mg total	9	Median (range) 29% (0% to 75%)								
					At 7 days	CYP2C19*1*1 homozygotes receiving 150 mg daily	12	Median (range) 46% (18% to 97%)	NR	NR	NR	NR	0.2 (vs. row below) [Mann-Whitney U test]	NO	NO	Raw data in Fig 4
						CYP2C19*1*1 homozygotes receiving 75 mg daily	6	Median (range) 32% (24% to 64%)								
					At 4 hours	CYP2C19*2 or *4 carriers receiving 1200 mg total	11	Median (range) 37% (8% to 87%)					0.002 (vs. row below) [Mann-Whitney U test]			Raw data in Fig 5
						CYP2C19*2 or *4 carriers receiving 600 mg total	8	Median (range) 14% (0% to 22%)								

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					At 7 hours	CYP2C19*2 or *4 carriers receiving 1200 mg total	11	Median (range) 42% (7% to 94%)					0.09 (vs. row below) [Mann-Whitney U test]			Raw data in Fig 5
						CYP2C19*2 or *4 carriers receiving 600 mg total	8	Median (range) 22% (0% to 51%)								
					At 7 days	CYP2C19*2 or *4 carriers receiving 150 mg daily	5	Median (range) 51% (15% to 86%)					0.042 (vs. row below) [Mann-Whitney U test]			Raw data in Fig 5
						CYP2C19*2 or *4 carriers receiving 75 mg daily	9	Median (range) 14% (0% to 67%)								
					At 7 hours	CYP2C9*1/*3 heterozygotes receiving 600 mg total	NR but something's wrong— "None of the patients carried the CYP2C19*3 allele."	Median (range) 9% (8% to 11%)					0.045 (vs. row below) [Mann-Whitney U test]			
						CYP2C9*1/*1 homozygotes receiving 600 mg total	9	Median (range) 31% (0% to 96%)								
Gurbel 2010 19817997 USA NR	75 mg clopidogrel daily	TaqMan	5uM ADP-induced platelet aggregation (%)	NR	Pre-elinogrel	CYP2C19*2 carrier	17	52 ± 13% Mean±SD	NR	NR	NR	NR	0.001 vs. row below [one-way ANOVA]	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						CYP2C19*2 noncarrier	19	36 ± 14% Mean±SD								
			20 uM ADP-induced platelet aggregation (%)		Pre-elinogrel	CYP2C19*2 carrier	17	61 ± 12% Mean±SD	NR	NR	NR	NR	0.03 vs. row below [one-way ANOVA]	NR	NR	
						CYP2C19*2 noncarrier	19	50 ± 13% Mean±SD								
			VASP assay platelet reactivity index		Pre-elinogrel	CYP2C19*2 carrier	17	72 ± 12 PRI Mean±SD	NR	NR	NR	NR	0.05 vs. row below [one-way ANOVA]	NR	NR	
						CYP2C19*2 noncarrier	19	58 ± 20 PRI Mean±SD								
			VerifyNow P2Y12 assay-platelet reactivity units		Pre-elinogrel	CYP2C19*2 carrier	17	259 ± 68 PRU Mean±SD	NR	NR	NR	NR	0.14 vs. row below [one-way ANOVA]	NR	NR	
						CYP2C19*2 noncarrier	19	214 ± 82 PRU Mean±SD								
			VerifyNow P2Y12 assay-percent inhibition		Pre-elinogrel	CYP2C19*2 carrier	17	19 ± 19% Mean±SD	NR	NR	NR	NR	0.07 vs. row below [one-way ANOVA]	NR	NR	
						CYP2C19*2 noncarrier	19	35 ± 24% Mean±SD								
			TEG-ADP-induced platelet-fibrin clot strength (mm)		Pre-elinogrel	CYP2C19*2 carrier	17	57 ± 8 mm Mean±SD	NR	NR	NR	NR	0.18 vs. row below [one-way ANOVA]	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						CYP2C19*2 noncarrier	19	49 ± 12 mm Mean±SD								
			TEG-percent inhibition		Pre-elinogrel	CYP2C19*2 carrier	17	23 ± 9% Mean±SD	NR	NR	NR	NR	0.07 vs. row below [one-way ANOVA]	NR	NR	
						CYP2C19*2 noncarrier	19	36 ± 20% Mean±SD								
			Change in 5 mM ADP-induced platelet aggregation (%)	Change in % aggregation between baseline and 4 hours in the 17 patients with HPR at baseline	Pre vs post-elinogrel	CYP2C19*2 carrier	14	see fig 12	NR	NR	NR	NR	0.0001 vs. row below[one-way ANOVA]	NR	NR	
						CYP2C19*2 noncarrier	3	see fig 12								
			5 mM ADP-induced platelet aggregation (%)		Pre-elinogrel	CYP2C19*17 noncarrier	15	41 ± 19% Mean±SD								
						CYP2C19*17 noncarrier	21	45 ± 14% Mean±SD	NR	NR	NR	NR	0.30 vs. row above [one-way ANOVA]	NR	NR	
			20 mM ADP-induced platelet aggregation (%)	20 mM ADP-induced platelet aggregation (%)	Pre-elinogrel	CYP2C19*17 noncarrier	15	51 ± 14% Mean±SD								
						CYP2C19*17 noncarrier	21	58 ± 13% Mean±SD								

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			VASP assay-platelet reactivity index	VASP assay-platelet reactivity index	Pre-elinogrel	CYP2C19*17 noncarrier	15	60 ± 23 PRI Mean±SD								
						CYP2C19*17 noncarrier	21	67 ± 15 PRI Mean±SD	NR	NR	NR	NR	0.35 vs. row above [one-way ANOVA]	NR	NR	
			VerifyNow P2Y12 assay-platelet reactivity units	VerifyNow P2Y12 assay-platelet reactivity units	Pre-elinogrel	CYP2C19*17 noncarrier	15	206 ± 91 PRU Mean±SD								
						CYP2C19*17 noncarrier	21	251 ± 65 PRU Mean±SD	NR	NR	NR	NR	0.13 vs. row above [one-way ANOVA]	NR	NR	
			VerifyNow P2Y12 assay-per cent inhibition	VerifyNow P2Y12 assay-per cent inhibition	Pre-elinogrel	CYP2C19*17 noncarrier	15	35 ± 28% Mean±SD								
						CYP2C19*17 noncarrier	21	24 ± 18% Mean±SD	NR	NR	NR	NR	0.24 vs. row above [one-way ANOVA]	NR	NR	
			TEG-ADP-induced platelet-fibrin clot strength (mm)	TEG-ADP-induced platelet-fibrin clot strength (mm)	Pre-elinogrel	CYP2C19*17 noncarrier	15	51 ± 12 mm Mean±SD								

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						CYP2C19*17 noncarrier	21	53 ± 11 mm Mean±SD	NR	NR	NR	NR	0.83 vs. row above [one-way ANOVA]	NR	NR	
			TEG-percent inhibition	TEG-percent inhibition	Pre-elinogrel	CYP2C19*17 noncarrier	15	35 ± 28% Mean±SD								
						CYP2C19*17 noncarrier	21	24 ± 18% Mean±SD	NR	NR	NR	NR	0.17 vs. row above [one-way ANOVA]	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Kim 2011 21511217 South Korea CCELAMI2 C19	600-mg (LD) of clopidogrel, followed (MD) of 75 mg daily before randomization. All patients also took a 300-mg LD of aspirin, followed by aspirin 200 mg daily throughout the study period. After blood sampling pre-discharge, the patients were randomly assigned to high-MD clopidogrel of 150 mg daily (high-dose group) or adjunctive cilostazol 100 mg twice daily to clopidogrel 75 mg daily (standard dose + cilostazol group).	PCR and SNaPshot assay kit	LTA maximal platelet aggregation	20 mmol/l ADP	Pre-discharge	*2 or *3 noncarrier	24	Mean 54.1%	SD 16.1%	Student unpaired t or Mann-Whitney U test	NR	NR	0.293 vs. corresponding cilostazol row below	NO	NO	NONE

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 or *3 carrier	38	Mean 60.0%	SD 15.2%				0.802 vs. corresponding cilostazol row below			
					At 30 days	*2 or *3 noncarrier	24	Mean 38.6%	SD 12.0%				0.752 vs. corresponding cilostazol row below			
						*2 or *3 carrier	38	Mean 52.3%	SD 17.5%				<0.001 vs. corresponding cilostazol row below			
					Absolute change between baseline and 30 days	*2 or *3 noncarrier	24	Mean 15.5%	SD 15.1%				0.197 vs. corresponding cilostazol row below			Data are also in Fig. 2
						*2 or *3 carrier	38	Mean 7.7%	SD 15.5%				<0.001 vs. corresponding cilostazol row below			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600-mg (LD) of clopidogrel, followed (MD) of 75 mg daily before randomization. All patients also took a 300-mg LD of aspirin, followed by aspirin 200 mg daily throughout the study period. After blood sampling pre-discharge, the patients were randomly assigned to high-MD clopidogrel of 150 mg daily (high-dose group) or adjunctive cilostazol 100 mg twice daily to clopidogrel 75 mg daily (standard dose + cilostazol group).	PCR and SNaPshot assay kit	LTA maximal platelet aggregation	20 mmol/l ADP	Pre-discharge	*2 or *3 noncarrier	25	Mean 58.4%	SD 11.9%							
						*2 or *3 carrier	39	Mean 59.2%	SD 14.4%							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					At 30 days	*2 or *3 noncarrier	25	Mean 37.5%	SD 13.2%							
						*2 or *3 carrier	39	Mean 35.0%	SD 19.3%							
				Absolute change between baseline and 30 days		*2 or *3 noncarrier	25	Mean 20.9%	SD 13.9%							Data are also in Fig. 2
						*2 or *3 carrier	39	Mean 24.2%	SD 17.2%							
	High-dose clopidogrel	PCR and SNaPshot assay kit	LTA maximal platelet aggregation	5 umol/l ADP	Pre-discharge	*2 or *3 noncarrier	24	Mean 42.4%	SD 15.7%				0.256 vs. corresponding cilostazol row below			
						*2 or *3 carrier	38	Mean 46.6%	SD 16.7%				0.995 vs. corresponding cilostazol row below			
					At 30 days	*2 or *3 noncarrier	24	Mean 30.1%	SD 10.1%				0.547 vs. corresponding cilostazol row below			
						*2 or *3 carrier	38	Mean 37.6%	SD 16.0%				<0.001 vs. corresponding cilostazol row below			
				Absolute change between baseline and 30 days		*2 or *3 noncarrier	24	Mean 12.3%	SD 13.8%				0.094 vs. corresponding cilostazol row below			Data are also in Fig. 2

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 or *3 carrier	38	Mean 9.0%	SD 13.3%				<0.001 vs. corresponding cilostazol row below			
	Standard-dose clopidogrel + cilostazol	PCR and SNaPshot assay kit	LTA maximal platelet aggregation	5 umol/l ADP	Pre-discharge	*2 or *3 noncarrier	25	Mean 46.9%	SD 11.8%							
						*2 or *3 carrier	39	Mean 46.6%	SD 15.6%							
					At 30 days	*2 or *3 noncarrier	25	Mean 28.2%	SD 11.5%							
						*2 or *3 carrier	39	Mean 24.9%	SD 14.3%							
				Absolute change between baseline and 30 days		*2 or *3 noncarrier	25	Mean 18.8%	SD 12.5%							
						*2 or *3 carrier	39									
	High-dose clopidogrel	PCR and SNaPshot assay kit	LTA late platelet aggregation	20 umol/l ADP	Pre-discharge	*2 or *3 noncarrier	24	Mean 44.4%	SD 22.7%				0.379 vs. corresponding cilostazol row below			
						*2 or *3 carrier	38	Mean 50.9%	SD 21.7%				0.878 vs. corresponding cilostazol row below			
					At 30 days	*2 or *3 noncarrier	24	Mean 21.8%	SD 40.6%				0.649 vs. corresponding cilostazol row below			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 or *3 carrier	38	Mean 40.6%	SD 22.2%				0.001 vs. corresponding cilostazol row below			
				Absolute change between baseline and 30 days		*2 or *3 noncarrier	24	Mean 22.6%	SD 19.6%				0.211 vs. corresponding cilostazol row below			Data are also in Fig. 3
						*2 or *3 carrier	38	Mean 10.3%	SD 20.9%				<0.001 vs. corresponding cilostazol row below			
	Standard-dose clopidogrel + cilostazol	PCR and SNaPshot assay kit	LTA late platelet aggregation	20 mmol/l ADP	Pre-discharge	*2 or *3 noncarrier	25	Mean 49.4%	SD 15.7%							
						*2 or *3 carrier	39	Mean 51,.6%	SD 17.7%							
					At 30 days	*2 or *3 noncarrier	25	Mean 19.7%	SD 16.8%							
						*2 or *3 carrier	39	Mean 23.5%	SD 19.2%							
					Absolute change between baseline and 30 days	*2 or *3 noncarrier	25	Mean 29.6%	SD 19.3%							
						*2 or *3 carrier	39	Mean 28.1%	SD 19.4%							
	High-dose clopidogrel	PCR and SNaPshot assay kit	LTA late platelet aggregation	5 mmol/l ADP	Pre-discharge	*2 or *3 noncarrier	24	Mean 32.5%	SD 18.2%				0.397 vs. corresponding cilostazol row below			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 or *3 carrier	38	Mean 38.4%	SD 20.7%				0.749 vs. corresponding cilostazol row below			
					At 30 days	*2 or *3 noncarrier	24	Mean 16.4%	SD 9.2%				0.347 vs. corresponding cilostazol row below			
						*2 or *3 carrier	38	Mean 26.7%	SD 16.5%				<0.001 vs. corresponding cilostazol row below			
					Absolute change between baseline and 30 days	*2 or *3 noncarrier	24	Mean 16.0%	SD 16.2%				0.144 vs. corresponding cilostazol row below			
						*2 or *3 carrier	38	Mean 11.7%	SD 15.2%				<0.001 vs. corresponding cilostazol row below			
	Standard-dose clopidogrel + cilostazol	PCR and SNaPshot assay kit	LTA late platelet aggregation	5 mmol/l ADP LTA	Pre-discharge	*2 or *3 noncarrier	25	Mean 36.4%	SD 13.5%							
						*2 or *3 carrier	39	Mean 39.8%	SD 17.4%							
					At 30 days	*2 or *3 noncarrier	25	Mean 13.6%	SD 11.7%							
						*2 or *3 carrier	39	Mean 15.2%	SD 12.4%							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					Absolute change between baseline and 30 days	*2 or *3 noncarrier	25	Mean 22.8%	SD 15.6%							
						*2 or *3 carrier	39	Mean 24.6%	SD 15.4%							
	High-dose clopidogrel	PCR and SNaPshot assay kit	VerifyNow platelet reactivity	VerifyNow platelet reactivity	Pre-discharge	*2 or *3 noncarrier	24	Mean 245.0 PRU	SD 91.6 PRU				0.959 vs. corresponding cilostazol row below			
						*2 or *3 carrier	38	Mean 241.6 PRU	SD 79.3 PRU				0.220 vs. corresponding cilostazol row below			
					At 30 days	*2 or *3 noncarrier	24	Mean 152.2 PRU	SD 70.4 PRU				0.441 vs. corresponding cilostazol row below			
						*2 or *3 carrier	38	Mean 184.2 PRU	SD 80.6 PRU				0.518 vs. corresponding cilostazol row below			
				Absolute change between baseline and 30 days	Change between pre-discharge and 30 days after discharge	*2 or *3 noncarrier	24	Mean 92.8 PRU	SD 60.7 PRU				0.347 vs. corresponding cilostazol row below			Data are also in Fig. 5

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 or *3 carrier	38	Mean 57.3 PRU	SD 69.4 PRU				0.060 vs. corresponding cilostazol row below			
	Standar-dose clopidogrel + cilostazol	PCR and SNaPshot assay kit	VerifyNow platelet reactivity	VerifyNow platelet reactivity	Pre-discharge	*2 or *3 noncarrier	25	Mean 246.2 PRU	SD 76.3 PRU							
						*2 or *3 carrier	39	Mean 263.0 PRU	SD 72.5 PRU							
					At 30 days	*2 or *3 noncarrier	25	Mean 136.6 PRU	SD 70.0 PRU							
						*2 or *3 carrier	39	Mean 171.9 PRU	SD 86.3 PRU							
				Absolute change between baseline and 30 days		*2 or *3 noncarrier	25	Mean 109.6 PRU	SD 63.1 PRU							
						*2 or *3 carrier	39	Mean 91.1 PRU	SD 85.0 PRU							
	High-dose clopidogrel	PCR and SNaPshot assay kit	VerifyNow % inhiibition		Pre-discharge	*2 or *3 noncarrier	24	Mean 26.2%	SD 25.0%				0.672 vs. corresponding cilostazol row below			
						*2 or *3 carrier	38	Mean 22.0%	SD 19.2%				0.825 vs. corresponding cilostazol row below			
					At 30 days	*2 or *3 noncarrier	24	Mean 54.7%	SD 22.3%				0.783 vs. corresponding cilostazol row below			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 or *3 carrier	38	Mean 40.3%	SD 23.5%				0.157 vs. corresponding cilostazol row below			
	Standar-dose clopidogrel + cilostazol	PCR and SNaPshot assay kit	VerifyNow % inhibition		Pre-discharge	*2 or *3 noncarrier	25	Mean 23.5%	SD 18.9%							
						*2 or *3 carrier	39	Mean 21.1%	SD 16.8%							
					At 30 days	*2 or *3 noncarrier	25	Mean 56.4%	SD 20.7%							
						*2 or *3 carrier	39	Mean 48.0%	SD 24.0%							
Lee 2011 21786436 South Korea NR	75 mg clopidogrel daily for at least six days before platelet testing	Seeplex CYP2C19 ACE Genotyping system	VerifyNow P2Y12 reactivity units (clopidogrel resistance)	VerifyNow P2Y12 reactivity units (clopidogrel resistance)	NR	Extensive CYP2C19 metabolizers	68	195.0 PRU mean	84.9 PRU SD	analysis of variance (ANOVA) test and post hoc analysis	NR	NR	$p < 0.001$ among this and next two rows [ANOVA]	NR	NR	Post hoc analysis using the Bonferroni test showed significant differences between all subgroups
						Intermediate metabolizers	74	237.9 PRU mean	88.0 PRU SD							
						Poor metabolizers	24	302.2 PRU mean	58.9 PRU SD							
			percent inhibition	percent inhibition	NR	Extensive CYP2C19 metabolizers	68	44.6% mean	21.8% SD				$p < 0.001$ among this and next two rows [ANOVA]			Post hoc analysis using the Bonferroni test showed significant differences between all subgroups
						Intermediate metabolizers	74	30.5%mean	21.5% SD							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Poor metabolizers	24	14.0 mean	13.4% SD							
Malek 2008 18577829 Poland NR	LD 300 mg of aspirin and MD 75 mg and LD 300 or 600 mg of clopidogrel and MD 75 mg daily	PFA-100	Median CADP-CT value	NR	Median 6 days after starting clopidogrel	Group 1	7	95 s (IQR 59–124 s)	NR	NR	NR	NR	0.002 vs. controls (Wilcoxon rank-sum test)	NR	NR	NR
						Group 2	14	210 s (IQR 115–300 s)					0.01 vs. Group 1 (Wilcoxon rank-sum test), NS vs. controls and group 3			
						Group 3	17	286 s (IQR 108–300 s)					0.01 vs. Group 1 (Wilcoxon rank-sum test), NS vs. controls and group 2			
						Controls	67	289 s (IQR 182–300 s)					NA			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Pettersen 2011 21426546 Norway Aspirin and Clopidogrel non-responsive-ness clinical Endpoint Trial (ASCET)	75 mg/day clopidogrel; also possibly aspirin but details NR	TaqMan Drug Metabolism Assay	Platelet reactivity	VASP	one month	CYP2C19*2 carrier	64	51% Mean platelet reactivity index value	NR	NR	NR	NR	< 0.001 vs. row below (either Student's unpaired t-test or Mann-Whitney U-test)	NO	NO	NONE
						*2 noncarrier	104	38% Mean platelet reactivity index value								
				VerifyNow	one month	*2 carrier	64	162 Mean platelet reactivity units					< 0.001 vs. row below (either Student's unpaired t-test or Mann-Whitney U-test)			
						*2 noncarrier	104	121 Mean platelet reactivity units								
Sibbing 2011 21527445 Germany NR	loading dose of 600 mg of clopidogrel	TaqMan assay	Platelet aggregation value	ADP-induced	NR	*2 carrier (*1/*2 or *2/*2)	377	Median (range) 286 (186 – 460) AU × min	NR	NR	NR	NR	0.0001 vs. row below [Kruskal – Wallis test]	NR	NR	Data in this table are for PCI cohort (n=5124)

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 noncarrier	1147	Median (range) 208 (134 – 329) AU x min								
						*1/*1	32	Median (range) 208 (134–329) AU x min					0.001 for this and next three rows [multivariable linear regression]	YES [all baseline variables]		10th, 25th, 75th, and 90th percentiles are in Fig 2
						*1/*2	345	Median (range) 267 (175 – 428) AU x min								
						*2/*2	1147	Median (range) 494 (341 – 732) AU x min								
Hwang 2010 20823393 Korea ACCEL	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	maximal platelet aggregation	5 umol/L ADP LTA	procedural	wild type homozygote	22	mean 47.7	16.4	t-test	NR	NR	0.600 comparing the following group	NR	NR	figure 2-5 are bar graphs.
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 50.2	15.8		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	maximal platelet aggregation	5 umol/L ADP LTA	30 days	wild type homozygote	22	mean 31.1	12.9	t-test	NR	NR	0.304 comparing the following group	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 26.7	15.2		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	maximal platelet aggregation	5 umol/L ADP LTA	procedural	mutant- type homozygote	43	mean 54	15.1	t-test	NR	NR	0.949 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 42.9	18.1		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	maximal platelet aggregation	5 umol/L ADP LTA	30 days	mutant type homozygote	43	mean 42.9	18.1	t-test	NR	NR	<0.001 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 28.4	13.9		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	maximal platelet aggregation	20 umol/L ADP LTA	procedural	wild type homozygote	22	mean 60.5	15.1	t-test	NR	NR	0.661 comparing the following group	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 62.4	13.8		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	maximal platelet aggregation	20umol/L ADP LTA	30 days	wild type homozygote	22	mean 41.9	16.4	t-test	NR	NR	0.276 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 36.0	19.2		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	maximal platelet aggregation	5 umol/L ADP LTA	procedural	mutant- type homozygote	43	mean 66.8	11.3	t-test	NR	NR	0.99 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 66.8	12.2		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	maximal platelet aggregation	5 umol/L ADP LTA	30 days	mutant type homozygote	43	mean 55.4	15.9	t-test	NR	NR	<0.001 comparing the following group	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 40.5	16.7		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	late platelet aggregation	5 umol/L ADP LTA	procedural	wild type homozygote	22	mean 40.3	20.3	t-test	NR	NR	0.913 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 41.0	17.9		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	late platelet aggregation	5 umol/L ADP LTA	30 days	wild type homozygote	22	mean 19.0	13.4	t-test	NR	NR	0.318 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 14.9	13.4		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	late platelet aggregation	5 umol/L ADP LTA	procedural	mutant- type homozygote	43	mean 47.1	20.1	t-test	NR	NR	0.742 comparing the following group	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 45.8	16.8		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	late platelet aggregation	5 umol/L ADP LTA	30 days	mutant type homozygote	43	mean 30.7	22.2	t-test	NR	NR	<0.001 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 16.7	11.5		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	late platelet aggregation	20 umol/L ADP LTA	procedural	wild type homozygote	22	mean 52.2	21.1	t-test	NR	NR	0.734 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 54.2	18.4		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	late platelet aggregation	20umol/L ADP LTA	30 days	wild type homozygote	22	mean 26.9	18.8	t-test	NR	NR	0.321 comparing the following group	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 21.2	19.0		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	late platelet aggregation	5 umol/L ADP LTA	procedural	mutant- type homozygote	43	mean 61.0	16.8	t-test	NR	NR	0.986 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 60.9	16.0		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	late platelet aggregation	5 umol/L ADP LTA	30 days	mutant type homozygote	43	mean 43.2	22.0	t-test	NR	NR	<0.001 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 26.4	17.4		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	VerifyNow PRU	P2Y12 reaction unit	procedural	wild type homozygote	22	mean 272.5	75.5	t-test	NR	NR	0.42 comparing the following group	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 253.8	76.7		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	VerifyNow PRU	P2Y12 reaction unit	30 days	wild type homozygote	22	mean 149.7	65.4	t-test	NR	NR	0.348 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 129.4	76.4		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	VerifyNow PRU	P2Y12 reaction unit	procedural	mutant- type homozygote	43	mean 278.3	69.7	t-test	NR	NR	0.167 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 296.5	53.2		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	VerifyNow PRU	P2Y12 reaction unit	30 days	mutant type homozygote	43	mean 214.1	68.5	t-test	NR	NR	0.153 comparing the following group	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 191.6	78.4		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	VerifyNow PRU	P2Y12 reaction unit	procedural	wild type homozygote	22	mean 20.2	18.7	t-test	NR	NR	0.733 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 22.4	22.9		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	VerifyNow PRU	P2Y12 reaction unit	30 days	wild type homozygote	22	mean 65.2	12.8	t-test	NR	NR	0.317 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						22	mean 70.5	7.6		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	VerifyNow PRU	P2Y12 reaction unit	procedural	mutant- type homozygote	43	mean 14.0	16.2	t-test	NR	NR	0.319 comparing the following group	NR	NR	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 11.1	10.8		NR	NR				
	clopidogrel therapy (75 mg +aspirin, 200 mg daily	CYP2C19*2 (rs4244285, c.681G>A) CYP2C19*3 (rs4986893, c.636G>A)	VerifyNow PRU	P2Y12 reaction unit	30 days	mutant type homozygote	43	mean 33.5	19.2	t-test	NR	NR	0.005 comparing the following group	NR	NR	no
	clopidogrel therapy (75 mg +aspirin, 200 mg daily +cilostazol						47	mean 45.8	21.2		NR	NR				
Cuisset, 2011 21803320 France NR	LD clopidogrel 600mgand aspirin 250mg, low responders received higher 150 mg MD clopidogrel	CYP2C19*2 (rs4244285)	PRI VASP mean response	PRI VASP mean response	after LD clopidogrel	CYP2C19*2 carrier	46/86	mean response 66	10	t-test	NR	NR	0.58 comparing with non-carriers	NR	NR	
						CYP2C19*2 non carrier	105/260	mean response 67	11							
Cuisset, 2011 21803320 France NR	LD clopidogrel 600mgand aspirin 250mg, low responders received higher 150 mg MD clopidogrel	CYP2C19*2 (rs4244285)	PRI VASP mean response	PRI VASP mean response	1 month	CYP2C19*2 carrier	46/86	mean response 57	14	t-test	NR	NR	0.01 comparing with non-carriers	NR	NR	
						CYP2C19*2 non carrier	105/260	mean response 50	16							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Harmsze, 2012 22228204 Netherlands NR	Clopidogrel	Real-time PCR	% Reactivity on LTA		After PCI	*17/*17	33	Mean % 32.2	SD 23.1	NR	-6.3 (vs. *1/*1)	-8.7 to -0.3	Vs. *1/*1 row: 0.043 for mean difference; 0.048 for mean reactivity; <0.0001 across this and next 5 rows for mean reactivity [ANOVA, with least-significant-difference test]	YES (sex, age, BMI, current smoking, eGFR <60ml/min, clopidogrel loading dose, coumarin use)	NR	
						*1/*17	207	Mean % 33.9	SD 23..9		-5.7 (vs. *1/*1)	-9.6 to -1.8	Vs. *1/*1 row: 0.004 for mean difference; 0.011 for mean reactivity [ANOVA, with least-significant-difference test]			
						*1/*1	351	Mean % 39.2	SD 23.6		NA	NA	NA			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2/*17	47	Mean % 49.5	SD 24.0		9.7 (vs. *1/*1)	2.8-16.6	Vs. *1/*1 row: 0.006 for mean difference; <0.0001 for mean reactivity [ANOVA, with least-significant-difference test]			
						*1/*2	157	Mean % 48.8	SD 22.8	ANOVA	9.8 (vs. *1/*1)	5.5-14.0	Vs. *1/*1 row: <0.0001 for mean difference; 0.005 for mean reactivity [ANOVA, with least-significant-difference test]			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2/*2	25	Mean % 64.3	SD 12.5	ANOVA	21.9 (vs. *1/*1)	12.6-31.2	Vs. *1/*1 row: 0.004 for mean difference; <0.0001 for mean reactivity [ANOVA, with least-significant-difference test]			
						Ultrarapid metabolizer (*1 or *17/*17)	240	NR	NR	ANOVA	-5.6 (vs. extensive)	-9.6 to -2.1	0.002 [ANOVA, with least-significant-difference test]	YES (see above)		
						Extensive metabolizer (*1/*1)	351	NR	NR		NA	NA	NA			
						Intermediate/poor metabolizer (*2/*1, *2, or *17)	229	NR	NR	ANOVA	11.1 (vs. extensive)	7.3-14.9	<0.0001 [ANOVA, with least-significant-difference test]	YES (see above)		

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Harmsze, 2012 22228204 Netherlands NR	Clopidogrel	Real-time PCR	PRU on VerifyNow	NR	After PCI	*17/*17	33	Mean PRU 189	SD 79	ANOVA	-17 (vs. *1/*1)	-42 to 7.7	Vs. *1/*1 row: 0.17 for mean difference and 0.08 for mean reactivity Also <0.0001 across this and next 5 rows for mean reactivity [ANOVA, with least-significant-difference test]	YES (sex, age, BMI, current smoking, eGFR <60ml/min, clopidogrel loading dose, coumarin use)	NR	
						*1/*17	207	Mean PRU 196	SD 79	ANOVA	-14 (vs. *1/*1)	-26 to -1.3	Vs. *1/*1 row: 0.031for mean difference and 0.047 for mean reactivity [ANOVA, with least-significant-difference test]			
						*1/*1	351	Mean PRU 208	SD 74		NA	NA	NA			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2/*17	47	Mean PRU 234	SD 74	ANOVA	24 (vs. *1/*1)	2.4-46	Vs. *1/*1 row: 0.030 for mean difference and <0.0001 for mean reactivity [ANOVA, with least-significant-difference test]			
						*1/*2	157	Mean PRU 233	SD 72	ANOVA	24 (vs. *1/*1)	11-38	Vs. *1/*1 row: <0.0001 for mean difference and <0.0001 for mean reactivity [ANOVA, with least-significant-difference test]			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2/*2	25	Mean PRU 254	SD 62	ANOVA	38 (vs. *1/*1)	8.8-66	Vs. *1/*1 row: 0.011 for mean difference and 0.003 for mean reactivity [ANOVA, with least-significant-difference test]			
						Ultrarapid metabolizer (*1 or *17/*17)	240	NR	NR	ANOVA	-14 (vs. extensive)	-26 to -2.4	0.018 [ANOVA, with least-significant-difference test]	YES (see above)		
						Extensive metabolizer (*1/*1)	351				NA	NA	NA			
						Intermediate/poor metabolizer (*2/*1, *2, or *17)	229			ANOVA	26 (vs. extensive)	14-38	<0.0001 [ANOVA, with least-significant-difference test]	YES (see above)		
Gajos, 2012 22623230 Poland OMEGA-PCI	LD clopidogrel 600mg and MD 75mg daily+75 mg aspirin daily	CYP2C19*1/*1	LTA ADP 5uM platelet aggregation	LTA ADP 5uM platelet aggregation	3-5 days	placebo	30	mean 46.8	SD 14.1	NR	NR	NR	NR	NR	NR	
					30 days			mean 48.1	SD10.6							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	LD clopidogrel 600mg and MD 75mg daily+75 mg aspirin daily	CYP2C19 *1/*1	LTA ADP 20uM platelet aggregation	LTA ADP 20uM platelet aggregation	3-5 days	placebo	30	mean 54.3	SD 17.9	NR	NR	NR	NR	NR	NR	
					30 days			mean 54.7	SD 10.6							
Gajos, 2012 22623230 Poland OMEGA-PCI	LD clopidogrel 600mg and MD 75mg daily+75 mg aspirin daily	CYP2C19 *1/*2 and *2/*2	LTA ADP 5uM platelet aggregation	LTA ADP 5uM platelet aggregation	3-5 days	placebo	30	mean 49.9	SD 9.7	NR	NR	NR	NR	NR	NR	
					30 days			mean 55.2	SD 11.6							
	LD clopidogrel 600mg and MD 75mg daily+75 mg aspirin daily	CYP2C19 *1/*2 and *2/*2	LTA ADP 5uM platelet aggregation	LTA ADP 20uM platelet aggregation	3-5 days	placebo	30	mean 61.4	SD 10.7	NR	NR	NR	NR	NR	NR	
					30 days			mean 60.2	SD 9.7							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Kreutz, 2012 22427735 US NR	Clopidogrel	PCR	Maximal platelet aggregation	By LTA, 5 µmol/L ADP	Within 24 hr	*2 carrier	44	Mean 37.9	SD 12	NR	NR	NR	Univariate linear regression, 0.037 Multi-variate, 0.04 Vs. next row	YES for multivariate regression, “clinical variables that are known to affect platelet reactivity and response to clopidogrel and variables with P < 0.1 in univariate analysis” [not otherwise specified]	NR	Similar results per genotype, not just carrier status (i.e., for *1/*1, *1/*2, and *2/*2) given in Fig. 1; could be digitized
						*2 noncarrier	107	Mean 29.9	SD 11.2							
					4 hr	*2 carrier in PCI subgroup	14	NR	NR	NR	NR	NR	0.25 vs. next row [Kruskal-Wallis] Also P=0.1 for mean change from baseline	NR	NR	Means and SEMs given in Fig. 4; could be digitized
						*2 noncarrier in PCI subgroup	28	NR	NR	NR	NR	NR				

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					16-24 hr	*2 carrier in PCI subgroup	14	NR	NR	NR	NR	NR	0.35 vs. next row [Kruskal-Wallis] Also P=0.13 for mean change from baseline			Means and SEMs given in Fig. 4; could be digitized
						*2 noncarrier in PCI subgroup	28	NR	NR	NR	NR	NR				
				By LTA, 10 µmol/L ADP		*2 carrier	44	Mean 45.0	SD 13.1				Univariate linear regression, 0.034 Multi-variate, 0.036 Vs. next row			
						*2 noncarrier	107	Mean 36.2	SD 14.3							
					4 hr	*2 carrier in PCI subgroup	14	NR	NR	NR	NR	NR	0.23 vs. next row [Kruskal-Wallis] Also P=0.03 for mean change from baseline	NR	NR	Means and SEMs given in Fig. 4; could be digitized
						*2 noncarrier in PCI subgroup	28	NR	NR	NR	NR	NR				

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					16-24 hr	*2 carrier in PCI subgroup	14	NR	NR	NR	NR	NR	0.23 vs. next row [Kruskal-Wallis] Also P=0.04 for mean change from baseline			Means and SEMs given in Fig. 4; could be digitized
						*2 noncarrier in PCI subgroup	28	NR	NR	NR	NR	NR				
				By LTA, 20 μmol/L ADP		*2 carrier	44	Mean 51.3	SD 11				Univariate linear regression, 0.034 Multi-variate, 0.034 Vs. next row			
						*2 noncarrier	107	Mean 43.6	SD 12							
					4 hr	*2 carrier in PCI subgroup	14	NR	NR	NR	NR	NR	0.49 vs. next row [Kruskal-Wallis] Also P=0.14for mean change from baseline	NR	NR	Means and SEMs given in Fig. 4; could be digitized
						*2 noncarrier in PCI subgroup	28	NR	NR	NR	NR	NR				dhdhd

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					16-24 hr	*2 carrier in PCI subgroup	14	NR	NR	NR	NR	NR	0.27 vs. next row [Kruskal-Wallis] Also P=0.09 for mean change from baseline			Means and SEMs given in Fig. 4; could be digitized
						*2 noncarrier in PCI subgroup	28	NR	NR	NR	NR	NR				
				VerifyNow PRU		*2 carrier	44	Mean 234.6	SD 67				Univariate linear regression, 0.027 Multi-variate, 0.014 Vs. next row			
						*2 noncarrier	107	Mean 195.0	SD 78							
				VerifyNow % inhibition		*2 carrier	44	Mean 12.9	SD 14				Univariate linear regression, 0.013 Multi-variate, 0.012 Vs. next row			
						*2 noncarrier	107	Mean 27.7	SD 25							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Tello-Montoliu 2012 22116003 Spain study one of the paper	100mg AA and 75mg MD clopidogrel	CYP2C19 *2	LTA ADP platelet aggregation	LTA ADP 5uM	in hospital	G/G	31	mean 47.1	SD 14.3	t-test	NR	NR	0.19 comparing with the next row	NR	NR	
						*/A	9	mean 54.2	SD 12.5							
	100mg AA and 75mg MD clopidogrel	CYP2C19 *2	LTA ADP platelet aggregation	LTA ADP 10uM	in hospital	G/G	31	mean 54.2	SD 15.5	t-test	NR	NR	0.17 comparing with the next row	NR	NR	
						*/A	9	mean 62.6	SD 17.4							
	100mg AA and 75mg MD clopidogrel	CYP2C19 *17	LTA ADP platelet aggregation	LTA ADP 5uM	in hospital	C/C	27	mean 50.3	SD 14.6	t-test	NR	NR	0.319 comparing with the next row	NR	NR	
						*/T	13	mean 45.5	SD 12.8							
	100mg AA and 75mg MD clopidogrel	CYP2C19 *17	LTA ADP platelet aggregation	LTA ADP 10uM	in hospital	C/C	27	mean 58.1	SD 16.4	t-test	NR	NR	0.265 comparing with the next row	NR	NR	
						*/T	13	mean 51.9	SD 15.4							
Dai, 2012 22704413 China NR	Clopidogrel and aspirin	PCR-RFLP	Mean late inhibition (%)	Inhibition 5 min after addition of agonist, thought to reflect clopidogrel action better than max. inhibition	Baseline	*17/*17 (n=6)	6	Mean 46.32	SD 8.79	NR	NR	NR	<0.01 vs wild type/wild type [ANOVA and SNK-q (?) test]	NR	NR	Table 3 also reports max. aggregation, max. inhibition, and disaggregation.

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*17/wild type (n=71)	71	Mean 39.68	SD 8.26				<0.01 vs wild type/wild type [ANOVA and SNK-q (?) test]			
						Wild type/wild type (n=443)	443	Mean 26.77	SD 9.18							
			Mean late aggregation (%)	Aggregation 5 min after addition of agonist, thought to reflect clopidogrel action better than max. inhibition	Baseline	*17/*17 (n=6)	6	Mean 47.55	SD 9.54				NS vs wild type/wild type [ANOVA and SNK-q (?) test]			
						*17/wild type (n=71)	71	Mean 47.45	SD 11.98				NS vs wild type/wild type [ANOVA and SNK-q (?) test]			
						Wild type/wild type (n=443)	443	Mean 48.92	SD 35.87							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Mean late aggregation (%)	Aggregation 5 min after addition of agonist, thought to reflect clopidogrel action better than max. inhibition	10 days	*17/*17 (n=6)	6	Mean 24.87	SD 8.20				<0.05 vs wild type/wild type [ANOVA and SNK-q (?) test]			
						*17/wild type (n=71)	71	Mean 29.12	SD 9.75				<0.01 vs wild type/wild type [ANOVA and SNK-q (?) test]			
						Wild type/wild type (n=443)	443	Mean 35.87	SD 11.50							
Harmsze, 2011 21854540 Netherlands POPular	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on-treatment reactivity	in hospital	CCB+, PPI-, *2 -	HOPR+	NR	NR	NR	-1.4	-4.7,-0.68	0.039	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on-treatment reactivity	in hospital	CCB-, PPI+, *2 -	HOPR+	NR	NR	NR	-3.6	-7.1,0.003	0.05	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on-treatment reactivity	in hospital	CCB+, PPI+, *2 -	HOPR+	NR	NR	NR	-2.6	-6.8,-1.5	0.034	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on-treatment reactivity	in hospital	CCB-, PPI-, *2+	HOPR+	NR	NR	NR	-7.0	-10.2,-3.8	<0.0001	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on-treatment reactivity	in hospital	CCB+, PPI-, *2+	HOPR+	NR	NR	NR	-7.6	-13.1,-2.1	0.007	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on-treatment reactivity	in hospital	CCB-, PPI+, *2+	HOPR+	NR	NR	NR	-7.8	-12.6,-3.0	0.002	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 5uM	LTA ADP high on-treatment reactivity	in hospital	CCB+, PPI+, *2 +	HOPR+	NR	NR	NR	-10	-16.1,-3.9	0.001	NR	NR	
Harmsze, 2011 21854540 Nether-lands POPular	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 20uM	LTA ADP high on-treatment reactivity	in hospital	CCB+, PPI-, *2 -	HOPR+	NR	NR	NR	-3.6	-6.7,-0.56	0.02	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 20uM	LTA ADP high on-treatment reactivity	in hospital	CCB-, PPI+, *2 -	HOPR+	NR	NR	NR	-3.8	-7.4,-0.31	0.033	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 20uM	LTA ADP high on-treatment reactivity	in hospital	CCB+, PPI+, *2 -	HOPR+	NR	NR	NR	-7.7	-12.5,-2.9	0.002	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 20uM	LTA ADP high on-treatment reactivity	in hospital	CCB-, PPI-, *2+	HOPR+	NR	NR	NR	-8.0	-10.9,-5.1	<0.0001	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 20uM	LTA ADP high on-treatment reactivity	in hospital	CCB+, PPI-, *2+	HOPR+	NR	NR	NR	-11	-16.9,-5.2	<0.0001	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 20uM	LTA ADP high on-treatment reactivity	in hospital	CCB-, PPI+, *2+	HOPR+	NR	NR	NR	-11.3	-15.6,-7.1	<0.0001	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	LTA-ADP 20uM	LTA ADP high on-treatment reactivity	in hospital	CCB+, PPI+, *2 +	HOPR+	NR	NR	NR	-11.6	-19.5, -2.9	0.008	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Harmsze, 2011 21854540 Netherlands POPular	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	verifynow	verifynow P2Y12	in hospital	CCB+, PPI-, *2 -	HOPR+	NR	NR	NR	-8.0	-16,-0.06	0.013	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	verifynow	verifynow P2Y12	in hospital	CCB-, PPI+, *2 -	HOPR+	NR	NR	NR	-18	-34,-2.2	0.026	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	verifynow	verifynow P2Y12	in hospital	CCB+, PPI+, *2 -	HOPR+	NR	NR	NR	-42	-67,-17	0.001	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	verifynow	verifynow P2Y12	in hospital	CCB-, PPI-, *2+	HOPR+	NR	NR	NR	-30	-45,-15	<0.0001	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	verifynow	verifynow P2Y12	in hospital	CCB+, PPI-, *2+	HOPR+	NR	NR	NR	-50	-71,-28	<0.0001	NR	NR	
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	verifynow	verifynow P2Y12	in hospital	CCB-, PPI+, *2+	HOPR+	NR	NR	NR	-53	-83,-23	0.001	NR	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel LD 600 mg and 75mg/d >5 days+ aspirin 80-100 mg day	CYP2C19 *2	verifynow	verifynow P2Y12	in hospital	CCB+, PPI+, *2 +	HOPR+	NR	NR	NR	-70	-113,-27	0.001	NR	NR	
Ono, 2011 21862109 Japan NR	clopidogrel LD 300mgand 75mg MD aspirin 100mg/day	CYP2C19	LTA	LTA	in hospital	carrier of reduced function allele	20uM ADP-PR max	mean 57	10.4	t-test	NR	NR	<0.001 comparing with the next row t-test	NR	NR	NR
						non- carrier of reduced function allele		mean 48.5	12							
	clopidogrel LD 300mgand 75mg MD aspirin 100mg/day	CYP2C19	LTA	LTA	in hospital	carrier of reduced function allele	20uM ADP-PR area	mean 4306	1389	t-test	NR	NR	<0.001 comparing with the next row t-test	NR	NR	NR
						non- carrier of reduced function allele		mean 2960	1740							
	clopidogrel LD 300mgand 75mg MD aspirin 100mg/day	CYP2C19	Verifynow	Verifynow	in hospital	carrier of reduced function allele	P2Y12 reaction Unit	mean 290	81.2	t-test	NR	NR	<0.001 comparing with the next row t-test	NR	NR	NR
						non- carrier of reduced function allele		mean 217.6	82.4							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel LD 300mgand 75mg MD aspirin 100mg/day	CYP2C19	Verifynow	Verifynow	in hospital	carrier of reduced function allele	inhibition	mean 17.9	17.8	t-test	NR	NR	<0.001 comparing with the next row t-test	NR	NR	NR
						non- carrier of reduced function allele		mean 35.5	22.8							
Fontana 2011 21692977 Switzerland ADRIE	aspirin and 75 mg clopidogrel	CYP2C19*1 and *2	VASP	vasodilator-stimulated phosphor-protein	1 month	non-carrier of *2	368	mean 46% PRI	NR	NR	NR	IQR 33-57	0.0001 NR	NR	NR	NR
						carrier of one*2	151	mean 58%PRI				IQR 48-69				
						carrier of two *2	17	mean 78% PRI				IQR 68-75				
	aspirin and 75 mg clopidogrel	CYP2C19*1 and *2	LTA ADP	light transmission aggregometer	1 month	non-carrier of *2	366	mean 55%	NR	NR	NR	IQR 45-63	0.011 NR	NR	NR	NR
						carrier of one*2	152	mean 62%				IQR 56-70				
						carrier of two *2	17	mean 66%				IQR 54-72				

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)— ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Kreutz, 2012 22385219 USA NR	Clopidogrel and aspirin	Real-time PCR	Mean maximal platelet aggregation, ADP 20 micromol as agonist	By LTA	15 days	*1/*1	68	43.6%	12%	Unpaired 2-sided test (Student's t if normally distributed and Wilcoxon rank sum if not, but article doesn't say)	NR	NR	0.005 vs. next row	NR	NR	NONE
			Mean maximal platelet aggregation, ADP 20 micromol as agonist			*2 carrier (*2/*2 or *2/*1)	28	51%	11%		NR	NR	NA	NR	NR	NONE
			Mean maximal platelet aggregation, ADP 20 micromol + PGE1 22 nM as agonists			*1/*1	68	17.7%	13%		NR	NR	0.002 vs. next row	NR	NR	NONE
			Mean maximal platelet aggregation, ADP 20 micromol + PGE1 22 nM as agonists			*2 carrier (*2/*2 or *2/*1)	28	27.9%	14%		NR	NR	NA	NR	NR	NONE

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Mean maximal platelet aggregation, ADP 20 micromol + PGE1 88 nM as agonists			*1/*1	68	6.7%	13%		NR	NR	0.01 vs. next row	NR	NR	NONE
			Mean maximal platelet aggregation, ADP 20 micromol + PGE1 88 nM as agonists			*2 carrier (*2/*2 or *2/*1)	28	13.9%	14%		NR	NR	NA	NR	NR	NONE
			Mean PRU	By VerifyNow		*1/*1	68	195 PRU	78 PRU		NR	NR	0.017 vs. next row	NR	NR	NONE
			Mean PRU			*2 carrier (*2/*2 or *2/*1)	28	234.6 PRU	67 PRU		NR	NR	NA	NR	NR	NONE
Marcucci, 2012 22390861 Italy NR	Clopidogrel and aspirin	Allelic discrimination assay	Mean maximal platelet aggregation, ADP 10 micromol	By LTA	12 mo	*1/*1	892	46.8%	21.7%	NR	NR	NR	<0.0001 vs. next row (Student's t or Mann-Whitney U)	NR	NR	NONE
					12 mo	*2 carrier (*2/*2 or *2/*1)	295	52.5%	19.9%	NR	NR	NR	NA	NR	NR	NONE
					12 mo	*1/*1	892	AUC 0.66	95% CI 0.57-0.75	NR	NR	NR	<0.001	NR	NR	Fig. 2 reports data for this row identical to next row, but text reports the data recorded here
					12 mo	*2 carrier (*2/*2 or *2/*1)	295	AUC 0.64	95% CI 0.57-0.71	NR	NR	NR	<0.001	NR	NR	NONE

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Mega, 2011 22088980 USA ELEVATE-TIMI 56	75 mg clopidogrel daily	Pyrosequencing and Nanosphere Verigene	Mean VASP PRI	NR	Any time within 2-week treatment period for this dose	*1/*1	237	57.5%	55.1-59.9%	NR	NR	NR	<0.001 for trend, across this and all *1/*1 data in subsequent rows (different doses) [mixed model]	Time from sample collection to analysis	Tukey-Kramer correction	From Fig 2 and Table 2
						*2/*1	75	70.0%	66.0-74.0%				<0.001 for trend, across this and all *2/*1 data in subsequent rows (different doses) [mixed model]			
						*2/*2 (n=6)	5	86.6%	80.7-92.5%				0.003 for trend, across this and all *2/*2 data in subsequent rows (different doses) [mixed model]			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 carrier (*2/*2 or *2/*1) (n=86)	80	71.0	67.1-74.9				<0.001 for trend, across this and all *2 carriers data in subsequent rows (different doses) [mixed model]			
	150 mg daily					*1/*1	232	46.9%	44.3-49.1%							
						*2/*1	75	61.4%	57.0-65.9%							
						*2*2 (n=6)	5	77.8%	67.4-88.1%							
						*2 carrier (*2/*2 or *2/*1) (n=86)	80	62.4%	58.1-66.7%							
	225 mg clopidogrel daily					*2/*1	76	52.7%	48.0-57.4%							
						*2*2 (n=6)	5	73.0%	50.6-95.5%							
						*2 carrier (*2/*2 or *2/*1) (n=86)	81	54.0%	49.4-58.5%							
	300 mg clopidogrel daily					*2/*1	75	48.9%	44.6-53.2%							
						*2*2 (n=6)	5	68.3%	44.9-91.6%							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2 carrier (*2/*2 or *2/*1) (n=86)	81	50.1%	45.9-54.3%							
	75 mg clopidogrel daily		Mean VerifyNow PRU	NR	Any time within 2-week treatment period for this dose	*1/*1	236	163.6	154.4-173.9	NR	NR	NR	<0.001 for trend, across this and all *1/*1 data in subsequent rows (different doses) [mixed model]	Time from sample collection to analysis	Tukey-Kramer correction	From Fig 2 and Table 2
						*2/*1	76	225.6	207.7-243.4				<0.001 for trend, across this and all *2/*1 data in subsequent rows (different doses) [mixed model]			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2/*2 (n=6)	5	328.8	247.9-409.7				0.32 for trend, across this and all *2/*2 data in subsequent rows (different doses) [mixed model]			
						*2 carrier (*2/*2 or *2/*1) (n=86)	81	231.9	214.0-249.8				<0.001 for trend, across this and all *2 carriers data in subsequent rows (different doses) [mixed model]			
	150 mg daily					*1/*1	230	126.7	117.7-137.5							
						*2/*1	73	188.1	170.8-205.4							
						*2/*2 (n=6)	5	310.2	247.5-372.9							
						*2 carrier (*2/*2 or *2/*1) (n=86)	78	195.9	178.2-213.7							
	225 mg clopidogrel daily					*2/*1	75	152.9	135.2-170.6							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2/*2 (n=6)	5	286.0	177.9-394.1							
						*2 carrier (*2/*2 or *2/*1) (n=86)	80	161.2	142.6-179.8							
	300 mg clopidogrel daily					*2/*1	73	127.5	109.9-145.2							
						*2/*2 (n=6)	5	287.0	170.2-403.8							
						*2 carrier (*2/*2 or *2/*1) (n=86)	78	137.7	118.4-157.1							
Park, 2012 22507978 Korea ACCEL-STATIN	At least 6 mo daily maintenance clopidogrel and aspirin	TaqMan	Mean maximal platelet aggregation	By LTA with 20 micromol ADP	Baseline	*2 or *3 carriage	30	68.2%	SD 8.7%	NR	Beta coefficient 5.3	SE 2.6	0.057 for %, vs. next row [Student's unpaired t or Mann-Whitney U and ANOVA] 0.055 for beta	NR	NR	NONE
						*1*1	15	63.2%	SD 7.0%							
				By LTA with 5 micromol ADP		*2 or *3 carriage	30	54.5%	SD 11.0%				0.075 vs. next row [Student's unpaired t or Mann-Whitney U and ANOVA]			
						*1*1	15	48.6%	SD 8.4%							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Mean final platelet aggregation	By LTA with 20 micromol ADP		*2 or *3 carriage	30	61.6%	SD 12.8%				0.027vs. next row [Student's unpaired t or Mann-Whitney U and ANOVA]			
						*1*1	15	52.1%	SD 13.7%							
				By LTA with 5 micromol ADP		*2 or *3 carriage	30	44.8%	SD 15.2%				0.044 vs. next row [Student's unpaired t or Mann-Whitney U and ANOVA]			
						*1*1	15	35.6%	SD 11.3%							
			PRU	By VerifyNow with 20 micromol ADP		*2 or *3 carriage	30	296	SD 68				0.561 vs. next row [Student's unpaired t or Mann-Whitney U and ANOVA]			
						*1*1	15	284	SD 58							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Percent inhibition	By VerifyNow with 20 micromol ADP		*2 or *3 carriage	30	17.9%	SD 16.6%				0.725 vs. next row [Student's unpaired t or Mann-Whitney U and ANOVA]			
						*1*1	15	19.6%	SD 11.2%							
Yamane, 2012 22472213 Japan NR	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and rabeprazole	CYP2C19	LTA ADP	maximal aggregation rates (MARs)	2 weeks	CYP2C19	EM N=8	23.9	SD 13.8%	wilxocon matched-pairs signed-ranks test	NR	NR	0.0547 comparing with omeprazole treated group wilxocon matched-pairs signed-ranks test	No	no	no
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and omeprazole	CYP2C19	LTA ADP	maximal aggregation rates (MARs)	2 weeks	CYP2C19	EM N=8	35.6	SD 15.2%							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and rabeprazole	CYP2C19	LTA ADP	maximal aggregation rates (MARs)	2 weeks	CYP2C19	IM N=14	27.6	SD 16.2%	wilcocon matched-pairs signed-ranks test	NR	NR	0.0156 comparing with omeprazole treated group wilxocon matched-pairs signed-ranks test	No	no	no
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and omeprazole	CYP2C19	LTA ADP	maximal aggregation rates (MARs)	2 weeks	CYP2C19	IM N=14	36.9	16.5							
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and rabeprazole	CYP2C19	LTA ADP	maximal aggregation rates (MARs)	2 weeks	CYP2C19	PM N=3	33.7	SD 14.7	wilxocon matched-pairs signed-ranks test	NR	NR	NR	No	no	no
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and omeprazole	CYP2C19	LTA ADP	maximal aggregation rates (MARs)	2 weeks	CYP2C19	PM N=3	29.8	SD 19.3%							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Yamane, 2012 22472213 Japan NR	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and rabeprazole	CYP2C19	VeryfyNow P2y12	P2Y12 reaction units (PRU)	2-4 weeks	CYP2C19	EM N=8	197.1	SD 69.1	wilxocon matched-pairs signed-ranks test	NR	NR	0.0142 comparing with omeprazole treated group wilxocon matched-pairs signed-ranks test	No	no	no
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and omeprazole	CYP2C19	VeryfyNow P2y12	P2Y12 reaction units (PRU)	2-4 weeks	CYP2C19	EM N=8	251.5	SD 59.5							
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and rabeprazole	CYP2C19	VeryfyNow P2y12	P2Y12 reaction units (PRU)	2-4 weeks	CYP2C19	IM N=14	232.9	78.1	wilxocon matched-pairs signed-ranks test	NR	NR	0.0516 comparing with omeprazole treated group wilxocon matched-pairs signed-ranks test	No	no	no

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and omeprazole	CYP2C19	VerifyNow P2y12	P2Y12 reaction units (PRU)	2-4 weeks	CYP2C19	IM N=14	269.5	SD 62							
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and rabeprazole	CYP2C19	VerifyNow P2y12	P2Y12 reaction units (PRU)	2-4 weeks	CYP2C19	PM N=3	192.0	SD 25	wilcoxon matched-pairs signed-ranks test	NR	NR	NR	No	no	no
	aspirin 82-162 mg/day and 75 mg/day clopidogrel daily and omeprazole	CYP2C19	VerifyNow P2y12	P2Y12 reaction units (PRU)	2-4 weeks	CYP2C19	PM N=3	173.3	SD 19.4							
Hsu, 2011 21144850 Taiwan NR	esomeprazole and 75 mg or 35.5 mg/day for 2 weeks	CYP2C19*1/ CYP2C19*2/ CYP2C19*3	ADP induced platlet aggregation	PPA (percent of platelet aggregation)	day 1	esomeprazole-plus-clopidogrel group hetEMs	n=7	34.6%	14.6%	chi square test or Fisher's exact test	NR	NR	0.965 comparing with day 28 homEM	NR	NR	no
						esomeprazole-plus-clopidogrel group PMs	n=3	38%	26.1	chi square test or Fisher's exact test			0.817 comparing with day 28 homEM 7			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						esomeprazole-plus-clopidogrel group homEM	n=8	22%	16%	chi square test or Fisher's exact test			0.229 comparing with day 28 homEM			
	esomeprazole and 75 mg or 35.5 mg/day for 2 weeks	CYP2C19*1/CYP2C19*2/CYP2C19*3	ADP induced platlet aggregation		day 28	esomeprazole-plus-clopidogrel group hetEMs	n=7	40.3%	10.7%	chi square test or Fisher's exact test	NR	NR	see above	NR	NR	no
						esomeprazole-plus-clopidogrel group PMs	n=3	38%	26.1%	chi square test or Fisher's exact test						
						esomeprazole-plus-clopidogrel group homEM	n=8	27.5%	14%	chi square test or Fisher's exact test						
	clopidogrel 75 mg or 35.5 mg/day for 2 weeks	CYP2C19*1/CYP2C19*2/CYP2C19*3	ADP induced platlet aggregation	PPA (percent of platelet aggregation)	day 1	hetEMs	n=6	31.5%	23.9%	chi square test or Fisher's exact test	NR	NR	0.512 comparing with day 28 homEM	NR	NR	no
						PMs	n=2	63%	1.4%	chi square test or Fisher's exact test			0.838 comparing with day 28 homEM 7			
						homEM	n=12	24.9%	19.7%	chi square test or Fisher's exact test			0.871 comparing with day 28 homEM			

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 75 mg or 35.5 mg/day for 2 weeks	CYP2C19*1/CYP2C19*2/CYP2C19*3	ADP induced platlet aggregation		day 28	hetEMs	n=6	40.2%	25.3%	chi square test or Fisher's exact test	NR	NR	see above	NR	NR	no
						PMs	n=2	57%	13.1%	chi square test or Fisher's exact test						
						homEM	n=12	26%	19.3%	chi square test or Fisher's exact test						
Kim, 2011 Korea ACCEL-TRIPLE	cilostazol 100 mg twice a day clopidogrel 75 mg once a day aspirin 200mg once a day	CYP2C19	5uM ADP agg MAX(%)	5uM ADP agg MAX(%)	30 days	EM	48	24.6	13.3	ANOVA of the three groups Jonckheere-Terpstra	NR	20.8-28.5	0.062 ANOVA of the three groups 0.016 Jonckheere-Terpstra	NR	NR	no
						IM	54	28.7	12.2			25.4-32				
						PM	25	32.3	15.7			25.8-38.7				
	cilostazol 100 mg twice a day clopidogrel 75 mg once a day aspirin 200mg once a day	CYP2C19	5uM ADP agg Late (%)	5uM ADP agg Late(%)	30 days	EM	48	12.1	12.2	ANOVA of the three groups Jonckheere-Terpstra	NR	8.6-15.7	0.021 ANOVA of the three groups 0.002 Jonckheere-Terpstra	NR	NR	no
						IM	54	16.4	11.1			13.3-19.4				
						PM	25	21	14			15.2-26.7				

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	cilostazol 100 mg twice a day clopidogrel 75 mg once a day aspirin 200mg once a day	CYP2C19	20uM ADP agg MAX(%)	5uM ADP agg MAX(%)	30 days	EM	48	34.2	16.7	ANOVA of the three groups Jonckheere-Terpstra	NR	29.3-39	0.007 ANOVA of the three groups 0.003 Jonckheere-Terpstra	NR	NR	no
						IM	54	41.7	14.2			37.8-45.6				
						PM	25	44.9	17			37.9-51.0				
	cilostazol 100 mg twice a day clopidogrel 75 mg once a day aspirin 200mg once a day	CYP2C19	20uM ADP agg Late (%)	5uM ADP agg Late(%)	30 days	EM	48	18.5	17.4	ANOVA of the three groups Jonckheere-Terpstra	NR	13.4-23.5	0.002 ANOVA of the three groups <0.001 Jonckheere-Terpstra	NR	NR	no
						IM	54	27.1	16.8			22.5-31.6				
						PM	25	32.9	18.1			25.4-40.4				
	cilostazol 100 mg twice a day clopidogrel 75 mg once a day aspirin 200mg once a day	CYP2C19	VerifyNow p2Y12 assay	VerifyNow P2Y12 assay	30 days	EM	48	125	76	ANOVA of the three groups Jonckheere-Terpstra	NR	103-147	<0.001 ANOVA of the three groups <0.001 Jonckheere-Terpstra	NR	NR	no
						IM	54	188	75			168-209				
						PM	25	226	88			190-262				
Bonello, 2012 22285300 France NR	oral LD: 600 mg clopidogrel and 250 mg aspirin	CYP2C19 *2	Platelet aggregation	Platelet aggregation after clopidogrel LD measured by VASP	<24 hrs after clopidogrel LD	Carriers of atleast one *2 allele (wt /*2 or *2/*2)	106	Mean=59%	Sd=19%	NR	NR	NR	p=0.001 (wt/wt vs *2/*2) [Student t-test]	No	NR	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						wild-type (wt) / wild-type (wt)	261	Mean=50%	Sd=24%	NR	NR	NR	NR			
Hoch-holzer, 2011 21884870 NR EXCEL-SIOR	LD of 600 mg of clopidogrel prior to PCI. After PCI, MD of aspirin (≥100 mg/d) and clopidogrel (75 mg/d) for 30 days (bare-metal stents) or 6 months (at least 1 drug-eluting stent)	CYP2C19 *2	LTA	Aggregation with 5 µmol/L ADP	24 hrs	CYP2C19 *2 carrier	NR	NR	NR	linear regression	NR	NR	<0.001 (carrier vs noncarrier)	Yes	NR	r2 for the regression =0.029
						Non CYP2C19 *2 carrier	NR	NR	NR							
Kreutz, 2012 22459907 USA NR	LD: 600 mg of clopidogrel	CYP2C19 *2	LTA	Aggregation with 5 µmol/L ADP	24 hrs	CYP2C19 *2 carrier	16	Mean=41.8	Sd=18%	t-test	2.7%	-7.5% to 12.8%	0.87 Carrier vs noncarrier [t-test]	no	no	
						Non CYP2C19 *2 carrier	39	Mean=39.1	Sd=17%							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Kassimis, 2012 21831410 Greece NR	No clopidogrel LD for those on 75 mg/d MD; LD 600 mg before PCI (if no and <7 days pretreatment) Post PCI: Clopidogrel MD 75 mg/d and aspirin 100 mg/d	CYP2C19*2	Aggregation by VerifyNow	Aggregation by VerifyNow	24-48 hours after procedure	CYP2C19*2 noncarriers N=108	108	Ls mean= 205.4	95% ci=180.9-229.9	T test	-45.3	-75.9 to -14.7	0.003 (noncarrier vs carrier) [t test]	no	Nr	
						CYP2C19*2 Carriers N=38	38	LS mean 250.7	95%ci=215.9-285.5							
						CYP2C19*2 noncarriers N=108	108	Ls mean= 180.1	95%ci=125.1-235.1	T test	-44.5	-73.3 to -15.8	0.003 (noncarrier vs carrier) [t test]	Yes (gender, age, BMI, DM, prior MI, statin, CCBs, PPIs, IIb/IIIa inhibitors, smoking and ACS indication for PC)	nr	
						CYP2C19*2 Carriers N=38	38	LS mean 224.6	95%ci=163-286.3							
		CYP2C19*17	Aggregation by VerifyNow	Aggregation by VerifyNow	24-48 hours after procedure	CYP2C19*17 noncarriers N=nr	NR	LS mean 188.8	95%ci=156.4-221.3	T test	-14.0	-46.1 to 18.0	0.4 (noncarrier vs carrier) [t test]	no	Nr	

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						CYP2C19*17 Carriers N=nr	NR	Ls mean= 202.9	95% ci= 172.9-232.8							
						CYP2C19*17 noncarriers N=nr	NR	Ls mean= 153.9	95% ci= 92.6-215.2	T test	-2.9	-33.4 to 27.6	0.9 (noncarrier vs carrier) [t test]	Yes (gender, age, BMI, DM, prior MI, statin, CCBs, PPIs, IIb/IIIa inhibitors, smoking and ACS indication for PC)	nr	
						CYP2C19*17 Carriers N=nr	NR	LS mean 156.8	95%ci=91.7-221.9							
Chan,2012 22462746 Singapore NR	LD: 300 mg clopidogrel MD: 75 mg/d clopidogrel for 5-7 days	CYP2C19*2 and CYP2C19*3	VASP PRI	PRI as measured by VASP phosphorylation	7 days	No LOF allele (CYP2C19*1/*1)	NR	Median 65.4	IQR=50.3-77.1	Kruskal-wallis	NR	NR	P=0.003 [between no LOF, 1 LOF and 2 LOF] [Kruskal-wallis]	no	nr	
						One LOF allele (heterozygous CYP2C19*2 or *3)	NR	Median 74	IQR=66.9-82.7							
						Two LOF allele (homoozygous CYP2C19*2 and/or *3)	NR	Median 80.3	IQR=73.5-83.7							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		CYP2C19 *17	VASP PRI	PRI as measured by VASP phosphorylation	7 days	Homogygous wild type(CYP2C19 *1/*1)	NR	Median 73.9	IQR=63.8-80.3	Kruskal-wallis	NR	NR	P=0.001 [wild type vs variant] [Kruskal-wallis]	no	nr	
						heterozygous CYP2C19*17	NR	Median 58	IQR=44.7-77.4							
		CYP2C19 diplotypes based on *2, *3 and *17 and P, N and R status – see below (P=*2/non*17 or *3-non*17; N=*1-non*17; R=*1-*17)				Poor metabolizer: P/P, N/P	49	Median 74.7	IQR=68.8-83.1	Kruskal-wallis	NR	NR	P=0.001 [wild type vs variant] [Kruskal-wallis]	no	nr	
						normal metabolizer: N/N, P/R	35	Median 66.7	IQR=51.8-77.3							
						rapid metabolizer: N/R,R/R	3	Median 50.7	IQR=42.7-65.4							
Rideg, 2011 21806387 Hungary DOSER	LD: 600 mg clopidogrel & 300 mg aspirin Randomized to 4 weeks of 75 or 150 mg clopidogrel MD: 75 mg clopidogrel/day	CYP2C19 *1, *2, *3 and *17	Aggregation max	LTA	24 hrs	GOF/GOF	28	Mean 20.1	Sd 5.2	Kruskal-wallis	NR	NR	P=0.02 [across all groups] [Kruskal-wallis]	no	nr	
						Wt/GOF	41	Mean 26.1	Sd 13.4							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Wt/wt	75	Mean 27.9	Sd 14.8							
						Wt/LOF	41	Mean 31.7	Sd 13.4							
						GOF/LOF	4	Mean 45.2	Sd 11.8							
		CYP2C19 *1, *2, *3 and *17	VASP PRI	VASP	24 hrs	GOF/GOF	28	Mean 44	Sd 22.5	Kruskal-wallis	NR	NR	P=0.11 [across all groups] [Kruskal-wallis]	no	nr	
						Wt/GOF	41	Mean 51.6	Sd 23.2							
						Wt/wt	75	Mean 46.7	Sd 20.4							
						Wt/LOF	41	Mean 57.1	Sd 22							
						GOF/LOF	4	Mean 61.8	Sd 5.9							
Jeong, 2011 22045970 Korea NR	LD: 600 mg clopidogrel & 300 mg aspirin MD: 75 mg/d clopidogrel & aspirin 200 mg/d for 1 month and 100-200 mg/day for 1 year	CYP2C19 *1, *2, and *3	LTA Aggregation maximum	Max aggregation with 5 µmol/L ADP-Aggmax	3 days	1/*1	104	Mean 41.9	Sd 15.7	ANOVA	NR	NR	P=0.031 [across all groups] [ANOVA]			
						*1/*2	98	Mean 45.4	Sd 16.1							
						*1/*3	30	Mean 45.9	Sd 15.8							
						*2/*2	20	Mean 50.4	Sd 15.1							
						*2/*3	14	Mean 53.9	Sd 15.1							
				Max aggregation with 20 µmol/L ADP-Aggmax	3 days	1/*1	104	Mean 53.8	Sd 15.7	ANOVA	NR	NR	P=0.003 [across all groups] [ANOVA]			
						*1/*2	98	Mean 58.1	Sd 14.7							
						*1/*3	30	Mean 59.0	Sd 15.1							

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						*2/*2	20	Mean 64.1	Sd 12.1							
						*2/*3	14	Mean 67.2	Sd 11.3							
		VerifyNow	P2Y12 reaction units (PRU)	3 days	1/*1	104	Mean 231	Sd 88	ANOVA	NR	NR	P=0.02 [across all groups] [ANOVA]				
					*1/*2	98	Mean 245	Sd 80								
					*1/*3	30	Mean261	Sd 76								
					*2/*2	20	Mean 276	Sd71								
					*2/*3	14	Mean 291	Sd 46								
Jeong, 2012 22837373 Korea ACCEL-DM	elective patients LD clopidogrel 300mg. Acute MI clopidogrel LD 600 mg. after randomization, triple group receive cilostazol 100mg bid, clopidogrel 75mg MD, aspirin 200 mg/d, double group receive clopidogrel 150mg/d MD, and aspirin 200 mg/d.	CYP2C19 in triple treatment group	LTA ADP 20uM maximal PA	LTA ADP 20uM maximal PA	30-day	*1/*1	12	NR	NR	ANOVA	NR	NR	comparing with the lower row 0.647 t-test	NR	NR	NR
						*1/LOF	21									
						LOF/LOF	8									

Author, year UID Country Study name	Treatment	Genetic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+)—ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Hulot, 2011 21972404 France CLOVIS-2	LD 300 or 900 mg clopidogrel	CYP2C19*2	Relative change in platelet aggregation	NR	6 hrs	*1/*1	55	NR	NR	NR	NR	NR	NR	NR	NR	CYP2C19*2 carriage remained the only significant predictor of platelet function response to clopidogrel LD irrespective of the platelet function assay (P<0.001 for both loading doses)
						*1/*2	41									
						*2/*2	7									
Roberts, 2012 22464343 Canada RAPID GENE	CYP2C19*2 Carriers : 10 mg prasugrel daily Non-carriers: 75 mg clopidogrel daily	CYP2C19*2	Aggregation by VerifyNow	PRU	7 days	*1/*2 or *2/*2	46	198.8	Sd 85.6	T –test	NR	NR	P=0.0011 (carriers vs non carriers)	No	NR	
						*1/*1	141	143.8	Sd 100.5							

Appendix Table D16. Quality assessment

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Collet, 2009 19108880 France AFIJI (Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention) registry	YES (explicitly states consecutive patients were enrolled)	YES	NO [the study included person time during which patients were not exposed to clopidogrel– and the drug was started a subsequent hospitalization; 16%]	LOW	LOW (all patients younger than 45 yrs)	NR	NO (no rationale for the grouping of genotypes)	HIGH	LOW	YES	YES (events adjudicate by 2 cardiologists blind to the genetic analysis)	LOW	LOW	YES (mean FU= 2.84 yr)	YES	YES	YES	LOW
Fontana, 2008 17681590 Switzerland NR	YES	YES	YES	LOW	LOW	YES (genotype technician was blind to phenotypic status)	NO (based on observed sample size)	HIGH	HIGH (PCR-RFLP assay home- brew)	NO (laboratory measurements only)	NO	HIGH	YES	NO (median = 19 d)	YES	YES	YES	LOW
Giusti, 2007 18004210 Italy NR	YES	YES	YES	LOW	LOW	NR	NO (multiple genetic models tested)	HIGH	HIGH	NO (lab measurements only)	NR	HIGH	HIGH	NO (24 h; 6 d for patients receiving IIb/IIIa inhibitors)	YES	YES	YES	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	YES	YES	YES	LOW	LOW	NR	NO	HIGH	HIGH	YES	YES (states that event adjudication was blind to laboratory results)	LOW	LOW	NO (6 mo)	YES	YES	YES	LOW
Gladding, 2009 19926050 New Zealand NR	NR	YES	YES	LOW	LOW	NO	NO	HIGH	LOW	NO	NR	UNCLEAR	HIGH	NO	YES	YES	YES	LOW
Jinnai, 2009 19531897 Japan Partly industry funded	NO	YES	NO	HIGH	LOW	NR	NO	HIGH	LOW	YES (for stent thrombosis)	NR	UNCLEAR	UNCLEAR (because the ascertainment method for stent thromboses was not reported)	NO	YES	YES	YES (2/25 = 8%)	LOW
Mega, 2009 19106084 Multinational Genetics substudy of TRITON-TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction]	NO (sample selected from those participating in a trial)	YES	YES	LOW	LOW	NR	YES (literature based)	UNCLEAR	LOW	YES	NR (blinding was to treatment assignment, not genotype status)	UNCLEAR	LOW	YES (upto 15 mo)	YES	YES	YES	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Shuldiner, 2009 19706858 USA Sinai Hospital of Baltimore Study	NR	YES	YES	LOW	LOW	NR	No	HIGH	LOW	YES	YES	LOW	LOW (composite outcome only)	YES (12 month for time-to- event analyses)	YES	YES	YES	LOW
Sibbing, 2009 19193675 Germany NR	NO	YES	NO [convenience sample of 46% of the patients in 4 ISAR trials + genotyping material not available from all]	HIGH	LOW	NR	YES	UNCLEAR	LOW	YES	YES (explicitly states blinding of outcome assessor to genotype data)	LOW	LOW	NO (30d)	YES	YES	YES	LOW
Sibbing, 2010 20083681 Germany Part of a prospective study of the Multiplate analyzer	YES	YES	YES	LOW	LOW	YES (blind genotyping)	NO (analyses performed with multiple genetic models)	HIGH	LOW	YES (several clinical endpoints)	YES (blind outcome adjudication)	LOW	LOW	NO (all outcome ascertained at 30 d)	YES	YES	YES	LOW
Varenhorst, 2009 19429918 Sweden Genetic sub- study	NO	YES	NO (11% of eligible patients refused to provide Conseco)	HIGH	LOW	NR (unclear when genetic testing was performed)	YES (grouping was based on literature)	UNCLEAR	LOW	NO	NR (unclear if blinding was used for the test results)	HIGH	HIGH	NO [max followup was 29 d]	YES	YES	YES [1 patients was classified as “uncertain functional status”]	LOW
Frere, 2008 18394438 France NONE	YES	YES	YES	LOW	LOW	NR	NO	HIGH	HIGH	NO	NR	YES	HIGH	NO	NO [not for all assays; i.e. there was incomplete verification]	YES [there was no differential verification]	NO [at least for some of the assays]	HIGH

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Frere, 2009 19496924 France Part of larger observational study	NO	YES	NR (appears that patients were selected from a previous study but criteria NR)	UNCLEAR	UNCLEAR	NR	NO	HIGH	UNCLEAR (genotyping assay not reported)	NO (only lab measurements)	NR	HIGH	HIGH	NO (details about timing poorly reported)	YES	YES	YES	LOW
Bonello-Palot 2009 19932784 France NR	NO	YES	YES	LOW	LOW	NR	YES	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NO	YES	YES	YES	LOW
Harmsze 2010 19934793 Netherlands NR	YES	YES	YES	LOW	LOW	NR	YES	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NO	YES	YES	YES	LOW
Trenk 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	NO (included all patients in the prospective EXCELSIOR cohort that had genotypic information)	YES	NO	HIGH	LOW	YES	YES	LOW	LOW	YES	YES	LOW	LOW	YES; 12 months	YES	YES	YES	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Tantry 2010 21079055 Multicountry- North America and Europe Genetic substudy of ONSET/OFFSET and RESPOND	NO [but patients are volunteers from 2 RCTs]	YES	YES	LOW	LOW	NR	NO [not explicitly based on independent information]	HIGH	LOW	NO [lab measurements]	NR	HIGH	HIGH	NO [2-6 weeks]	YES	YES	YES	LOW
Wallentin, 2010 20801498 Multiple countries (43 countries in North America, South America, Europe, Asia, Australia) PLATO	NO [substudy, voluntary provision of samples]	YES	YES	LOW	LOW	NR [study was “double- blind, double- dummy” but genetic testing done only in substudy and NR there]	NO	HIGH	LOW	YES	NR [study was “double- blind, double- dummy” but genetic testing done only in substudy and NR there]	UNCLEAR	LOW	YES [12months]	YES	YES	YES	LOW
Hochholzer, 2010 20510210 Germany EXCELSIOR	NO	YES	YES	LOW	LOW	NR	YES	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NO [6months]	YES	YES	YES	LOW
Jeong 2010 20650435 Korea NR	NO	YES	YES	LOW	LOW	NR	NO	HIGH	HIGH	NO	NR	HIGH	HIGH	NO [1 month]	YES	YES	YES	LOW
Barker, 2010 20965456 USA NR	NO	YES	NO	UNCLEAR	LOW	NR	YES	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NO	YES	YES	YES	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Bonello, 2010 20708365 France NR	NR	YES	YES	LOW	LOW	NR	NO	UNCLEAR	HIGH	YES	NR	UNCLEAR	LOW	NO	YES	YES	YES	LOW
Gurbel 2011 21392617 USA NR	YES	YES	No [1 patient with CYP2C19*3 excluded]	LOW	LOW	NR	YES	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NR	YES	YES	YES	LOW
Hwang 2011 21075428 Souh Korea NR	YES	YES	NR	LOW	LOW	NR	YES	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NO	YES	YES	YES	HIGH
Kang, 2010 20724801 Korea NR	YES	YES	No[19.1% excluded]	LOW	LOW	NR	YES	UNCLEAR	LOW	NO	NR	HIGH	HIGH	No [1 month]	YES	YES	NO [176 of 215 included;19.1% excluded]	HIGH
Liu 2010 21163112 China NR	YES	YES	NR	LOW	LOW	NR	NR	NR	HIGH	NO	NR	HIGH	HIGH	YES [12 months]	YES	YES	YES	LOW
Maeda, 2010 21178986 Japan NR	NR	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NO	YES	YES	YES	LOW
Malek, 2010 20924183 Poland NR	YES	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	YES	NR	UNCLEAR	LOW	YES [4 years]	YES	YES	YES	LOW
Simon 2011 21262992 France NR	NO	YES	YES	LOW	LOW	NR	NR	unclear	NR	YES	NR	NR	LOW	NR	YES	YES	NO	low
Yamamoto 2011 21168310 Japan NR	YES	YES	YES	LOW	LOW	NR	YES	UNCLEAR	HIGH	YES	NR	UNCLEAR	LOW	YES [1 year]	YES	YES	NO [20%]	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Park 2011 21345843 Korea CILON-T	YES	YES	YES	LOW	LOW	NR	YES	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NO [6 months]	YES	YES	YES	LOW
Tiroch, 2010 20826260 Germany NR	YES	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	YES	NR	UNCLEAR	LOW	YES [1 year]	YES	YES	YES	LOW
Sorich, 2010 20492467 707 sites in 30 countries Substudy of TRITON-TIMI 38	YES	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	YES	NR	UNCLEAR	LOW	YES [15 months]	YES	YES	YES	LOW
Sibbing, 2010 20492469 Germany	YES	YES	YES	LOW	LOW	YES	NO	HIGH	LOW	NO	YES	HIGH	HIGH	NO	YES	YES	YES	LOW
Sawada, 2010 21099121 Japan NR	NR	YES	NR [367 patients at start, end up 100]	UNCLEAR	LOW	NR	NR	UNCLEAR	LOW	YES	NR	UNCLEAR	LOW	NO	YES	YES	YES	LOW
Pare, 2010 20979470 Multiple countries CURE and ACTIVE	YES	YES	YES	LOW	LOW	NR	NR	UNCLEAR	UNCLEAR	YES	NR	UNCLEAR	LOW	Yes/no [3- 12 months for CURE; 3.6 years for ACTIVE]	YES	YES	YES	LOW
Mega, 2010 20801494 707 sites in 30 countries TRITON-TIMI 38	YES	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	YES	NR	UNCLEAR	LOW	YES [15 months]	YES	YES	YES	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Bouman 2011 21628721 Netherlands Genetic substudy of the Popular study	yes	Yes	NO [but 45 (4%) of patients without DNA samples were excluded	Low	Low	NR	NA (no grouping used)	Unclear	UNCLEAR [manufacturer not reported]	NO [lab measurements]	NR	High	High	NR	Yes	Yes	NO	UNCLEAR
Campo 2011 21679849 Italy NR	Yes	Yes	Yes	Low	Low	NR	Yes	Low	Low	Yes	NR	Unclear	Low	Yes 12 mo	Yes	Yes	Yes	LOW
Fernando 2011 21696537 Australia NR	NO [but study is a randomized crossover trial]	Yes	Yes	Low	Low	NR	NO	High	Low	No	NR	High	High	No	Yes	Yes	Yes 2/31<10%	Low
Geisler 2008 18781853 Germany NR	Yes	Yes	Yes	Low	Low	Yes	No	High	Low	No	NR	High	High	No max 285 hours	Yes	Yes	Yes	LOW
Gladding 2008 19463375 New Zealand PRINC (Plavix Response in Coronary Intervention) Trial	Yes	Yes	Yes	Low	Low	NR	Yes	Unclear	Low	No	NR	High	Low	No 7 days	Yes	Yes	Yes	LOW
Gurbel 2010 19817997 USA NR	No	Yes	Yes (20 pts were excluded on basis of HPR threshold but this was part of study?)	Low	Low	NR	Yes	Unclear	Low	No	NR	High	High	No 97-10 days)	Yes	Yes	Yes	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Harmsze 2010 20833683 Netherlands NR	Yes	No	no [176/210, N was reduced on basis of available DNA samples]	high	LOW	NR	NA	Unclear	UNCLEAR [manufacturer not named]	Yes	NR	Unclean	Low	Yes	Yes	Yes	no	LOW
Kim 2011 21511217 South korea CCELAMI2C19	Yes	Yes	no	LOW	LOW	NR	NO	High	Low	No	NR	High	High	No (30 days)	Yes	Yes	NO [14 patients (11.4%) excluded for lack of DNA sample or poor compliance]	HIGH
Lee 2011 21786436 South Korea NR	No	Yes	Yes	LOW	LOW	NR	No	High	Low	No	NR	High	High	No	YES	YES	YES	LOW
Malek 2008 18577829 Poland NR	NR	Yes	Yes	LOW	LOW	NR	No	High	Low	Yes	NR	Unclean	Low	Yes (12 mo)	YES	YES	YES	LOW
Pettersen 2011 21426546 Norway Aspirin and Clopidogrel non- responsiveness clinical Endpoint Trial (ASCET)	Yes	Yes	Yes	LOW	LOW	NR	Yes	Unclear	Low	No	NR	High	High	NR	Yes	Yes	Yes	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Sibbing 2011 21527445 Germany NR	NO [but from larger consecutive samples]	NO [it was in one group—the main, PCI cohort, but not in the second part of the study]	Yes	High	LOW	NR	NA	UNCLEAR	Low	YES	NR	Low	Low	NR	YES	YES	YES	LOW
Simon 2009 19106083 France FAST-MI	yes	yes	YES [66% of FAST-MI patients had genetic data]	low	LOW	NR	No	high	low	YES	YES	low	low	YES	YES	YES	YES	LOW
Hwang 2010 20823393 Korea ACCEL	no	yes	no	high	low	yes	yes	low	low	no	NR	high	high	no	yes	yes	no	unclear
Chen. 2012 22723959 Taiwan CAPTAIN	NR	no	yes	unclear	low	NR	NR	unclear	high	yes	NR	unclear	low	no	yes	yes	yes	low
Cuisset, 2011 21803320 France NR	yes	yes	yes	low	low	NR	yes	unclear	high	no	NR	high	high	no	yes	yes	yes	low
Gajos, 2012 22623230 Poland OMEGA-PCI	yes	yes	yes	low	low	yes	NA	unclear	low	no	NR	unclear	high	no	yes	yes	yes	low

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Luo, 2011 22118006 China NR	yes	yes	yes	low	low	NR	NA	unclear	low	yes	yes	low	low	no	yes	yes	yes	low
Tello-Montoliu 2012 22116003 Spain study one of the paper	no	yes	yes	low	low	yes	NA	unclear	low	no	NR	unclear	high	no	yes	yes	yes	low
Tello-Montoliu 2012 Spain study two of the paper	yes	yes	no	low	low	yes	NA	unclear	low	yes	NR	unclear	low	no	yes	yes	no	high
Price, 2012 22624833 US GIFT (Genotype Information and Functional Testing) Study— a prespecified genetic substudy of GRAVITAS [Price 2011, PMID 21406646]	YES (substudy of RCT)	YES	YES	LOW	LOW	UNCLEAR	NO	UNCLEAR	LOW	YES	YES	LOW	LOW	NO	YES	YES	YES	LOW
Gremmel, 2012 22154242 Austria NR	UNCLEAR	YES	YES	LOW	LOW	YES	YES	LOW	LOW	NO	YES	HIGH	HIGH	NO	YES	YES	YES	LOW
Harmsze, 2012 22228204 Netherlands NR	YES	YES	YES	LOW	LOW	UNCLEAR	NO	UNCLEAR	LOW	YES	YES	LOW	LOW	YES	YES	YES	YES	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Kreutz, 2012 22427735 US NR	UNCLEAR	YES	YES	LOW	LOW	UNCLEAR	UNCLEAR	UNCLEAR	LOW	NO	UNCLEAR	UNCLEAR	HIGH	NO	YES	YES	YES	LOW
Dai, 2012 22704413 China NR	UNCLEAR	YES	YES	LOW	LOW	UNCLEAR	YES	UNCLEAR	LOW	YES	UNCLEAR	UNCLEAR	LOW	NO	YES	YES	YES	LOW
Harmsze, 2011 21854540 Netherlands POPular	yes	yes	no	low	low	NR	NR	unclear	high	yes	yes	low	low	yes	yes	yes	no	low
Ono, 2011 21862109 Japan NR	yes	yes	yes	low	low	NR	NR	unclear	HIGH	yes	NR	unclear	low	yes	yes	yes	yes	low
Delaney, 2012 22190063 USA NR	no	no	no	high	low	NR	NR	unclear	low	yes	NR	low	low	yes	yes	yes	no	low
Bhatt, 2012 22450429 USA CHARISMA	NR	yes	yes	low	low	NR	NR	UNCLEAR	low	yes	NR	unclear	low	yes	yes	yes	yes	low
Fontana 2011 21692977 Switzerland ADRIE	yes	yes	yes	low	low	NR	NR	UNCLEAR	high	no	NR	high	high	no	yes	yes	yes	low
Aleil, 2009 19624462 France VASP-02 [genetic reanalysis thereof]	YES	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NO	YES	YES	YES	LOW

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Chen, 2012 22071359 China NR	YES	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	YES	NR	UNCLEAR	LOW	YES	YES	YES	YES	LOW
Kreutz, 2012 22385219 USA NR	NR	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	NO	NR	HIGH	HIGH	NO	YES	YES	YES	LOW
Marcucci, 2012 22390861 Italy NR	NR	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	NR	NR	UNCLEAR	LOW	YES	YES	YES	YES	LOW
Mega, 2011 22088980 USA ELEVATE-TIMI 56	NR	YES	YES	LOW	LOW	YES	NR	UNCLEAR	LOW	NO	YES	HIGH	LOW	YES	YES	YES	YES	LOW
Nishio, 2012 22785462 Japan NR	NR	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	NR	NR	UNCLEAR	LOW	YES	YES	YES	YES	LOW
Park, 2012 22507978 Korea ACCEL-STATIN	NR	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	NO	NR	UNCLEAR	HIGH	NO	YES	YES	YES	LOW
Teixeira, 2012 22377481 Portugal NR	NR	YES	YES	LOW	LOW	NR	NR	UNCLEAR	LOW	YES	NR	UNCLEAR	LOW	NO	YES	YES	YES	LOW
Parri, 2012 22727972 Italy NR	NR	YES	YES	LOW	LOW	NR	YES	LOW	LOW	YES	NR	UNCLEAR	LOW	NO	YES	YES	YES	LOW
Yamane, 2012 22472213 Japan NR	NR	yes	yes	low	low	NR	NR	unclear	high	no	NR	unclear	high	no	yes	yes	yes	low

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Hsu, 2011 21144850 Taiwan NR	yes	yes	no	low	low	NR	NR	unclear	low	yes	NR	unclear	low	no	yes	yes	no	unclear
Kim, 2012 22007612 Korea ACCEL-TRIPLE	NR	yes	yes	low	low	NR	NR	unclear	low	yes	NR	unclear	low	no	yes	yes	yes	low
Siller-Matula, 2012 22260716 Austria PEGASUS-PCI	Yes	yes	yes	low	low	yes	yes	low	low	yes	yes	low	low	Yes [12 months]	yes	yes	yes	low
Bonello, 2012 22285300 France NR	NR	Yes	Yes	Low	Low	NR	No	High	Low	No	NR	High	High	No (1 day)	Yes	Yes	No	High
Simon, 2011 21918510 France FAST-MI	NR	yes	Yes	Low	Low	NR	Yes	Unclear	Low	Yes	Yes	Low	Low	Yes [1 year]	Yes	Yes	Yes	Low
Collet, 2011 21511218 France CLOVIS-2	NR	Yes	Yes	Low	Low	NR	Yes	Unclear	Low	No	Yes	High	high	No; 0.25 days	Yes	yes	Yes	Low
Jaitner, 2012 22298798 Germany NR	No	No	No	High	LOW	NR	NR	Unclear	Low	YES	NR	High	Low	No (<30 days)	Yes	Yes	Yes	Low
Hochholzer, 2011 21884870 NR EXCELSIOR	NR	Yes	Yes	Low	Low	NR	NR	Unclear	Low	No	NR	High	High	No [1 day]	Yes	Yes	Yes	Low

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Kassimis, 2012 21831410 Greece NR	Yes	Yes	Yes	Low	Low	Yes	Yes	Low	Low	No	NR	High	High	No [1 day]	Yes	Yes	Yes	Low
Namazi, 2012 22265638 Iran NR	No	Yes	Yes	Low	Low	Yes	Yes	Low	Low	No	NR	High	High	No [30 days]	Yes	Yes	Yes	Low
Rideg, 2011 21806387 Hungary DOSER	No	Yes	Yes	Low	Low	Yes	Yes	Low	Low	YES	Yes	Low	Low	Yes [1 year]	Yes	Yes	Yes	Low
Jeong, 2011 22045970 Korea NR	No	Yes	Yes	Low	Low	Yes	Yes	Low	Low	YES	Yes	Low	Low	Yes [1 year]	Yes	Yes	Yes	Low
Chan,2012 22462746 Singapore NR	Yes	Yes	Yes	Low	Low	Yes	Yes	Low	Low	No	NR	High	High	No [7 days]	Yes	Yes	Yes	Low
Goodman, 2012 22261200 Multi-country PLATO	Yes	Yes	Yes	Low	Low	Yes	Yes	Low	Low	YES	Yes	Low	Low	Yes [1 year]	Yes	Yes	Yes	Low
Park, 2012 22735685 Korea CROSS-VERIFY	Yes	Yes	No (CYP2C19 results were only reporter for CYP3A5 expressers)	Low	Low	Yes	Yes	Low	Low	YES	Yes	Low	Low	Yes [1 year]	Yes	Yes	Yes	Low
Kreutz, 2012 22459907 USA NR	NR	Yes	Yes	Low	Low	Yes	Yes	Low	Low	No	NR	High	High	No [1 day]	Yes	Yes	Yes	Low

Author, year UID Country Study name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Yan, 2011 21778720 China NR	Yes	Yes	Yes	Low	Low	NR	Yes	Unclear	Low	Yes	Yes	Low	Low	Yes [2 years]	Yes	Yes	Yes	Low
Cayla, 2011 22028352 France ONASSIST	No	No	Yes	High	Low	NR	Yes	Unclear	Low	Yes	NR	Unclear	Low	NA [case- control study]	Yes	yes	Yes	Low
Hulot, 2011 21972404 France AFIJI	No	Yes	Yes	Low	Low	Yes	Yes	Low	Low	Yes	Yes	Low	Low	No [6 months]	Yes	Yes	Yes	Low
Hulot, 2011 21972404 France CLOVIS-2	No	Yes	Yes	Low	Low	Yes	Yes	Low	Low	No	Yes	High	High	No [6 hours]	Yes	Yes	Yes	Low
Roberts, 2012 22464343	Yes	Yes	Yes	Low	Low	yes	NR	Unclear	Low	No	NR	High	High	No [7 days]	Yes	Yes	Yes	Low
Jeong, 2012 22837373 Korea ACCEL-DM	no	yes	yes	low	low	NR	NR	unclear	low	yes	NR	unclear	low	no	yes	yes	yes	low

Appendix E. Appendix Tables for Key Question 2

Appendix Table E1. Descriptive characteristics of studies reporting analytic validity information

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Michelson 2009 USA 19435740	Patients with ACS scheduled for PCI in the TRITON-TIMI 38 trial. Patients who had received abciximab within 30 d, or tirofiban or eptifibatide within 7 d of testing, were excluded from the LTA component of the study.	VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [BioCytex, Marseilles, France]; using flow cytometry [FACSCalibur, Becton Dickinson, San Jose, California] LTA (ADP 5 µmol/L and 20 µmol/L) [not reported]	Samples were collected at 3 timepoints: at baseline (pre-PCI, pre-study drug); 1-2 h post PCI (at least 1 h after dosing); and at 30 d post-PCI.	A loading dose of the study medication (1:1 randomization; prasugrel 60 mg or clopidogrel 300 mg) was administered between randomization and 1 h after leaving the catheterization laboratory. Pretreatment with the study drug was permitted for up to 24 h pre-PCI. Adjunctive medication was left at the discretion of the treating physician. After PCI patients received maintenance doses of prasugrel (10 mg) or clopidogrel (75 mg). Aspirin use was required (recommended 325-500 mg loading dose; 75-162 mg maintenance dose).	All 13 participating sites sent samples for the VASP phosphorylation assay; 3 pre-selected sites performed LTA on site.	125 using the VASP assay; of these 31 were also evaluated with LTA (both ADP concentrations). Measurements at baseline, 1-2 h post PCI, and 30 days (clopidogrel and prasugrel treated subjects) were analyzed together and observations were treated as independent.	Relative risk for identifying responders between VASP assay and MPA (20 µmol/L) = 5.25 (95% CI 2.34, 11.75)

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Paniccia 2009 Italy 19461090	Patients admitted to the coronary care of a single center unit for ACS; all patients underwent coronary angiography and PCI	<p>Impedance aggregometry (ADP, 10 μmol/L) [Multiplate analyzer, Dynabyte, Munich, Germany]</p> <p>LTA (ADP, 10 μmol/L) [APACT-4004 aggregometer, LABiTec, Ahrensburg, Germany]</p> <p>High shear platelet function (collagen/ADP) [PFA-100, Dade-Behring, Marburg, Germany]</p>	Samples were collected 24-48 h after PCI.	A loading dose of aspirin (500 mg IV) and oral clopidogrel (600 mg), followed by daily aspirin (325 mg) and clopidogrel (75 mg). During the procedure patients received UFH.	Measurements of samples with 3 techniques and different agonists; ROC analysis to identify optimal cut-offs for the Multiplate analyzer and PFA-100, using LTA as the reference method; 50 datapoints (10 measurements in each of 5 patient samples) for LTA	<p>Multiplate analyzer and LTA (ADP as agonist): 297</p> <p>Multiplate analyzer and PFA-100 (ADP as agonist): 111</p>	<p>Agreement for residual platelet reactivity between the Multiplate analyzer and LTA (ADP as agonist): kappa = 0.74 (95% CI 0.64, 0.84); P<0.001</p> <p>Agreement for residual platelet reactivity between the Multiplate analyzer and PFA-100 (ADP as agonist): kappa = 0.19; P = NS</p> <p>Multiplate analyzer analytic test performance (using LTA as the reference test, ADP as the agonist): sensitivity = 0.78 (95% CI 0.68, 0.89); specificity = 0.95 (95% CI 0.92, 0.98); accuracy = 0.92 (95% CI NR); PPV = 0.80 (95% CI 0.69, 0.90); NPV = 0.95 (95% CI 0.92, 0.97)</p> <p>ROC analysis for the Multiplate analyzer for detecting residual platelet reactivity on LTA (ADP as agonist): AUC = 0.93 (95% CI 0.89, 0.96); P<0.001</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Oestreich 2009 USA 19318928	Patients with CAD from a single center outpatient cardiology clinic on dual antiplatelet therapy	LTA (ADP, 5 and 20 μ M) [570VS aggregometer, Chrono- Log, Havertown, Pennsylvania] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, additional details NR]	At baseline; days 30 and 60 after enrollment	At baseline patients were receiving daily clopidogrel (75 mg) and aspirin (81-325 mg); clopidogrel was then increased to 150 mg for 30 d; after that, clopidogrel dosing at 75 mg was resumed for another 30 d (total duration of the study = 60 d)	Agreement between assays and different agonists, using predefined cut-offs for poor response	20 subjects measured 3 times (different timepoints)	Agreement between PRU and MPA (LTA, ADP 5 μ M): kappa = 0.85 Agreement between PRU and MPA (LTA, ADP 20 μ M): kappa = 0.46 Agreement between PRU and RPA (LTA, ADP 5 μ M): kappa = 1.00 Agreement between PRU and RPA (LTA, ADP 20 μ M): kappa = 0.30 Agreement between MPA (LTA, ADP 5 μ M) and MPA (LTA, 20 μ M): kappa = 0.62 Agreement between MPA (LTA, ADP 5 μ M) and RPA (LTA, 5 μ M): kappa = 0.85 Agreement between MPA (LTA, ADP 5 μ M) and RPA (LTA, 20 μ M): kappa = 0.43 Agreement between MPA (LTA, ADP 20 μ M) and RPA (LTA, 5 μ M): kappa = 0.46 Agreement between MPA (LTA, ADP 20 μ M) and RPA (LTA, 20 μ M): kappa = 0.33 Agreement between RPA (LTA, ADP 5 μ M) and RPA (LTA, 20 μ M): kappa = 0.30

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Marcucci 2007 Italy 17938810	Consecutive patients with STE MI admitted to a single center coronary care unit	LTA (ADP, 2 and 10 μ M) [APACT 4 aggregometer, Helena Laboratories Italia s.p.a., Milan, Italy]	12-15 h after PCI for patients receiving aspirin + clopidogrel; 24 h after the infusion of abciximab for patients receiving aspirin + clopidogrel + IIb/IIIa inhibitor	All patients underwent angiography and primary PCI; 200 patients received aspirin (500 mg loading dose; 100 mg maintenance) + clopidogrel (300 mg loading dose; 75 mg maintenance) and 167 received aspirin (500 mg loading dose; 100 mg maintenance) + clopidogrel (300 mg loading dose; 75 mg maintenance) + IIb/IIIa inhibitor (abciximab bolus 0.25 mg/kg of body weight, followed by continuous infusion 0.125 μ g/kg/minute for 12 hours). All patients received UFH.	Agreement between LTA using alternative ADP concentrations	367 subjects measured with two agonist concentrations	Agreement between LTA with ADP 2 μ M and ADP 10 μ M: out of 367 measurements, 17 were positive by both tests; 279 were negative by both tests; 71 were positive with ADP 10 μ M but not ADP 2 μ M; none were positive with ADP 2 μ M but not ADP 10 μ M.
Frere 2007 France 17938809	Consecutive patients with NSTEMI ACS admitted to the department of cardiology in a single center, following successful coronary stenting.	LTA (ADP 10 μ mol/L) [PAP4, Biodata Corporation, Wellcome, Paris, France] VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP, Diagnostica Stago (BioCytex), Asnieres, France]; using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France]	Before the PCI, at least 12 h after the loading dose of clopidogrel and aspirin; before the administration of tirofiban (if needed)	Clopidogrel (600 mg loading; 75 mg maintenance) + aspirin (250 mg loading; 75 mg maintenance); LMWH or UFH was used for anticoagulation	Agreement between LTA and VASP for determining low clopidogrel response	195 patients measured with both tests	Weighted kappa for agreement between methods = 0.32
Paniccia 2007 Italy 17723123	Consecutive adult patients admitted to the coronary care units of a single center for ACS (STEMI, NSTEMI, UA), who underwent coronary angiography and PCI	LTA (ADP, 2 μ mol/L and 10 μ mol/L) [APACT-4 aggregometer, LABiTec, Ahrensburg, Germany] High shear platelet function (collagen/ADP) [PFA-100, Dade-Behring,	24-48 h after PCI; assays performed within 2 h of blood sampling	Acetylsalicylic acid (500 mg loading; 100-325 mg maintenance) + clopidogrel orally (300 mg loading; 75 mg maintenance). UFH was used as the anticoagulant. Patients receiving IIb/IIIa inhibitors were excluded.	Measurements of samples from the same patient with multiple methods to assess agreement	For analyses of agreement, 626 to 1267 samples measured with the tests of interest (specific sample sizes reported by specific comparisons)	USING CUT-OFFS DERIVED FROM STUDY DATA Agreement between LTA (ADP 2 μ mol/L) and PFA-100 (collagen/ADP cartridge) for residual platelet reactivity: out of 626 measurements, 22 were

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
		<p>Marburg, Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>					<p>positive by both tests; 393 were negative by both tests; 80 were positive with LTA (ADP 2µmL/L) but not PFA-100 (collagen/ADP cartridge); 131 were positive with PFA-100 (collagen/ADP cartridge) but not LTA (ADP 2µmL/L). NOTE: discrepant numbers are reported in the text of the paper for the same comparison: out of 626 measurements, 41 were positive by both tests; 335 were negative by both tests; 138 were positive with LTA (ADP 2µmL/L) but not PFA-100 (collagen/ADP cartridge); 112 were positive with PFA-100 (collagen/ADP cartridge) but not LTA (ADP 2µmL/L). Agreement between LTA (ADP 2µmol/L) with PFA-100 (collagen/ADP cartridge) for residual platelet reactivity: kappa = -0.02; P = NS.</p> <p>Agreement between LTA (ADP 10µmL/L) and PFA-100 (collagen/ADP cartridge) for residual platelet reactivity: out of 626 measurements, 35 were positive by both tests; 345 were negative by both tests; 128 were positive with LTA (ADP 10µmL/L) but not PFA-100 (collagen/ADP cartridge); 118 were positive with PFA-100 (collagen/ADP cartridge) but not LTA (ADP 10µmL/L). Agreement between LTA (ADP 10µmol/L) with PFA-100</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>(collagen/ADP cartridge) for residual platelet reactivity: kappa = -0.04; P = NS</p> <p>Agreement between LTA (ADP 2µmL/L) and VerifyNow (P2Y12 assay) for residual platelet reactivity: out of 1267 measurements, 159 were positive by both tests; 795 were negative by both tests; 159 were positive with LTA (ADP 2µmL/L) but not VerifyNow (P2Y12 assay); 154 were positive with VerifyNow (P2Y12 assay) but not LTA (ADP 2µmL/L). Agreement between LTA (ADP 2µmol/L) with VerifyNow (ADP assay) for residual platelet reactivity: kappa = 0.34; 95% CI 0.29, 0.35; P<0.001.</p> <p>Agreement between LTA (ADP 10µmL/L) and VerifyNow (P2Y12 assay) for residual platelet reactivity: out of 1267 measurements, 171 were positive by both tests; 831 were negative by both tests; 123 were positive with LTA (ADP 10µmL/L) but not VerifyNow (P2Y12 assay); 142 were positive with VerifyNow (P2Y12 assay) but not LTA (ADP 10µmL/L). Agreement between LTA (ADP 10µmol/L) with VerifyNow (ADP assay) for residual platelet reactivity: kappa = 0.43; 95% CI 0.36, 0.42; P<0.001.</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>Agreement between VerifyNow (P2Y12 assay) and PFA-100 (collagen/ADP cartridge) for residual platelet reactivity: out of 626 measurements, 53 were positive by both tests; 315 were negative by both tests; 158 were positive with VerifyNow (P2Y12 assay) but not PFA-100 (collagen/ADP cartridge); 100 were positive with PFA-100 (collagen/ADP cartridge) but not VerifyNow (P2Y12 assay). Agreement between PFA-100 (collagen/ADP cartridge) with VerifyNow (ADP assay) for residual platelet reactivity: kappa = -0.01; P=NS.</p> <p>Analytic performance of VerifyNow, using LTA (ADP 2 µmL/L) as the reference standard (cut-off based on study data): sensitivity = 50.0%; specificity = 83.8%; PPV = 50.8%; NPV = 83.3%.</p> <p>Analytic performance of VerifyNow, using LTA (ADP 10 µmL/L) as the reference standard (cut-off based on study data): sensitivity = 58.2%; specificity = 85.4%; PPV = 54.6%; NPV = 87.1%.</p> <p>USING CUT-OFFS DERIVED FROM PRIOR LITERATURE</p> <p>Agreement between LTA (ADP</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>10 µml/L) and VerifyNow (P2Y12 assay) for residual platelet reactivity: out of 1267 measurements, 142 were positive by both tests; 858 were negative by both tests; 96 were positive with LTA (ADP 10µml/L) but not VerifyNow (P2Y12 assay); 171 were positive with VerifyNow (P2Y12 assay) but not LTA (ADP 10µml/L). Agreement between LTA (ADP 10µmol/L) with VerifyNow (ADP assay) for residual platelet reactivity: kappa = 0.38; 95% CI 0.33, 0.39; P<0.001.</p> <p>Analytic performance of VerifyNow, using LTA (ADP 10 µml/L) as the reference standard (70% cut-off, based on prior literature): sensitivity = 59.7%; specificity = 83.4%; PPV = 45.5%; NPV = 89.9%.</p>
Van Werkum 2006 Netherlands 16938130	Consecutive patients undergoing elective PCI with stenting referred to a single center	<p>LTA (ADP, 20 µmol/L) [NR]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>	Variable (based on patient referral patterns)	Clopidogrel pre-treatment varied by center (maintenance therapy of 75mg for >5 d, n = 116; loading dose 300mg at least 24 h before PCI, n = 75; loading dose 600 mg at least 4 h before PCI, n = 20). All patients were on aspirin ≥80mg of aspirin for at least 7 days.	Assessment of agreement between measurements using both assays	211 patients	<p>Bland-Altman analysis “did not show proportional or systematic bias, with minimal clustering of values” for the following pairs of measurements:</p> <p>“Peak aggregation” with LTA versus VerifyNow PRU units, and</p> <p>“Late aggregation” with LTA versus VerifyNow PRU units</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Mobley 2004 USA 14969622	Patients scheduled for cardiac catheterization at a single center	Optical platelet aggregometry (ADP, 1 μ M) [Dual Channel Aggregometer; Chrono-Log Corp., Havertown, PA] TEG (ADP, 1 μ M) [Thromboelastograph assay, Hemoscope, additional details NR] PlateletWorks (ADP, 1 μ M) [PlateletWorks assay, Ichor, additional details NR]	"After a variable number of days on therapy"	300 mg loading doses administered at the clinicians discretion; orally 75 mg maintenance; samples drawn to monitor platelet inhibition were obtained before treatment with additional anticoagulants or antiplatelet agents	Assessment of agreement between measurements with different assays	50 patients	Agreement between was 89% for optical platelet aggregation; 91% for TEG; 76% for PlateletWorks; agreement was judged against an average of % change from baseline across all analyzers.
Ren 2011 China 21518592	Patients with high-risk ACS undergoing elective PCI	TEG (ADP, 2 μ mol/L) [Thromboelastograph mapping assay in TEG5000, Hemoscope Corp., USA]	Blood samples were obtained after 5 days of using omeprazole.	Clopidogrel (600 mg loading dose; 75 mg daily maintenance) + aspirin (300 mg loading dose; 100 mg daily maintenance); no patients received IIb/IIIa inhibitors. At the beginning of elective PCI patients were randomized to omeprazole (20 mg) or placebo for 30 days.	Not reported (for analytic validity assessment)	Not reported (for analytic validity assessment)	Analytic sensitivity for the ADP pathway = 80% Analytic specificity for the ADP pathway = 86%
Godino 2009 Italy 19419580	Consecutive patients with evidence of stable coronary artery disease undergoing elective PCI	ADP-stimulated IIb/IIIa receptor AND P-selectin expression (considered jointly as the reference standard) (ADP, 20 μ M and collagen, 5 μ g/mL) Using flow cytometry [FC500; Beckman Coulter, S.p.A., Cassina De' Pecchi, Milan, Italy] Platelet agglutination assay (ADP cartridges)	Patients had to have been under treatment for 7 or d prior to testing; 2 samples were obtained within 1 hour; analyzed at least 10 min and within 2 h of sampling	Clopidogrel (75 mg) and aspirin (100 mg), daily, for at least 7 days prior to testing. Patients who had received heparin, abciximab, tirofiban, or eptifibatide in the previous week were excluded from the study.	Samples from patients measured with 2 assays; flow cytometry used as the reference standard to determine analytic sensitivity and specificity for identifying non-responders using cut-offs determined by measurements in control individuals	52 patients measured with both tests	Using % inhibition and a cut-off of $\leq 15\%$ inhibition, derived from ROC analysis (AUC = 0.94; 95% CI 0.84, 0.98; P<0.0001): Analytic sensitivity of VerifyNow, using ADP-stimulated IIb/IIIa receptor and P-selectin expression as the reference standard = 100% Analytic specificity, using ADP-stimulated IIb/IIIa receptor and

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
		[VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]					<p>P-selectin expression as the reference standard = 89.1%</p> <p>Using absolute PRU values and a cut-off of >213 units of inhibition, derived from ROC analysis (AUC = 0.85; 95% CI 0.72, 0.93; P<0.005):</p> <p>Analytic sensitivity of VerifyNow, using ADP-stimulated IIb/IIIa receptor and P-selectin expression as the reference standard = 83.3%</p> <p>Analytic specificity, using ADP-stimulated IIb/IIIa receptor and P-selectin expression as the reference standard = 84.4%</p> <p>Agreement between ADP-stimulated IIb/IIIa receptor and P-selectin expression: out of 52 measurements, 6 were positive by both tests; 23 were negative by both tests; 2 were positive based on P-selectin expression but not IIb/IIIa receptor expression; 21 were positive based on IIb/IIIa receptor expression but not P-selectin expression.</p>
Paniccia 2011 Italy 21192314	Patients with CAD admitted to a single center's coronary care unit for ACS. All patients underwent coronary angiography and PCI.	<p>LTA (ADP, 2 µmol/L, 5 µmol/L, 10 µmol/L, and 20 µmol/L) [APACT-4004 aggregometer, LABiTec, Ahrensburg, Germany]</p> <p>Platelet agglutination assay (ADP cartridges)</p>	Samples were collected 24 or 48 h after the end of PCI; all assays were performed within 2 h of blood sampling.	Acetylsalicylic acid (500 mg IV) followed by aspirin (maintenance dose 100-325 mg) + clopidogrel (300 mg loading dose; followed by maintenance dosing at 75 mg daily). Patients receiving IIb/IIIa receptor inhibitors	Measurements of samples with 2 assays (and different agonist concentrations for LTA) for the assessment of agreement and the derivation of limits of agreement; for the assessment of reliability,	Samples from 466 patients for assessment of agreement	<p>Agreement between LTA (ADP 2 µmol/L) and LTA (ADP 5 µmol/L): kappa = 0.69 (95% CI 0.59, 0.79); P < 0.0001; percentage agreement = 93.1%</p> <p>Agreement between LTA (ADP</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
		[VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]		were excluded.	repeat measurements on samples from smaller groups of patients were performed (only for LTA)		<p>2 µmol/L) and LTA (ADP 10 µmol/L): kappa = 0.63 (95% CI 0.53, 0.73); P < 0.0001; percentage agreement = 90.3%</p> <p>Agreement between LTA (ADP 2 µmol/L) and LTA (ADP 20 µmol/L): kappa = 0.61 (95% CI 0.51, 0.71); P < 0.0001; percentage agreement = 89.2%</p> <p>Agreement between LTA (ADP 5 µmol/L) and LTA (ADP 10 µmol/L): kappa = 0.68 (95% CI 0.59, 0.77); P < 0.0001; percentage agreement = 91.6%</p> <p>Agreement between LTA (ADP 5 µmol/L) and LTA (ADP 20 µmol/L): kappa = 0.65 (95% CI 0.56, 0.74); P < 0.0001; percentage agreement = 90.6%</p> <p>Agreement between LTA (ADP 10 µmol/L) and LTA (ADP 20 µmol/L): kappa = 0.86 (95% CI 0.80, 0.92); P < 0.0001; percentage agreement = 95.9%</p> <p>Agreement between VerifyNow and LTA (ADP 10 µmol/L): kappa = 0.51 (95% CI 0.43, 0.60); P < 0.0001; percentage agreement = 82.4%</p> <p>Agreement between VerifyNow</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							and LTA (ADP 20 µmol/L): kappa = 0.44 (95% CI 0.35, 0.53); P < 0.0001; percentage agreement = 79.6%
							Bland-Altman limits of agreement comparing LTA with ADP 10 µmol/L and 20 µmol/L: mean difference = -0.70% ±4.6% (CI, -9.7%, 8.3%). The difference in platelet reactivity between assays using these ADP concentrations was >20% in 3 samples (out of 466)
Koessler 2011 Germany 20873965	Patients with stable coronary artery disease under dual antiplatelet therapy who underwent PCI	High shear platelet function (collagen/ADP) [INNOVANCE PFA-100 P2Y*, Dade Behring (now Siemens), Marburg, Germany] VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP/P2Y12, BioCytex, Marseille, France]; using flow cytometry [FACScan, Becton Dickinson, Heidelberg, Germany]	The intended timing of measurements was not reported for the patient group; in the total population (n=50) samples were obtained on average 1.4 days post PCI	Patients were on dual antiplatelet treatment (aspirin + clopidogrel).	Agreement between the PFA-100 assay (at different thresholds) and VASP phosphorylation assay; analytic sensitivity and specificity of PFA-100 against VASP phosphorylation assay	50 patients measured with both tests; alternative cut- offs applied to the PFA- 100 measurements	Analytic sensitivity of INNOVANCE PFA-100 (cut-off 106 sec) against VASP (cut-off of PRI 50%) = 100% (among 31 responders) Analytic specificity of INNOVANCE PFA-100 (cut-off 106 sec) against VASP (cut-off of PRI 50%) = 42% (among 19 non-responders) Highest agreement between INNOVANCE PFA-100 and VASP assay was achieved using a cut-off of 200 sec for the former and 55% for the latter (Cohen's kappa = 0.66). Using these cut-offs the analytic sensitivity of PFA-100 is 97% and specificity = 65%. Results at additional thresholds (where agreement was lower) are presented in Figure 5 of the paper.

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Paniccia 2010 Italy 20458439	Adult patients referred to a single vascular disease center enrolled in a registry of ACS; patients underwent PCI with stent implantation	LTA (ADP, 10 μ M) [APACT-4004 aggregometer, LABiTec, Ahrensburg, Germany] Impedance aggregometry (ADP, 10 μ M final concentration) [Multiplate analyzer, Dynabyte, Munich, Germany] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Samples were collected 24 or 48 h after the end of PCI; PCI was performed 3-6 h after the ACS. All assays were performed within 2 h of blood sampling.	Acetylsalicylic acid (500 mg IV) followed by aspirin (maintenance 100-325 mg) + clopidogrel (300-600 mg loading dose) followed by maintenance dosing (75 mg daily). None of the investigated patients received other platelet function inhibitors (including IIb/IIIa receptor inhibitors).	Measurement of samples with 3 assays for assessment of agreement; cut-offs for residual platelet reactivity were based on prior literature. For the assessment of reliability, repeat measurements on samples from smaller groups of patients were performed (adequate information for the assessment of reliability was provided for LTA only)	801 samples for the assessment of agreement; 5 samples from each of 10 patients of the assessment of reliability	<p>Agreement between Multiplate analyzer and LTA: out of a total of 801 samples, 102 samples were positive with both tests; 609 samples were negative with both tests; 27 samples were positive by LTA but not the Multiplate analyzer; 63 samples were positive by the Multiplate analyzer but not LTA. Agreement kappa = 0.63 (95% CI 0.56, 0.70); P < 0.0001.</p> <p>Agreement between Multiplate analyzer and VerifyNow: out of a total of 801 samples, 132 samples were positive by both tests; 521 samples were negative by both tests; 33 samples were positive by Multiplate analyzer but negative by VerifyNow; 115 samples were positive by VerifyNow but not Multiplate analyzer. Agreement kappa = 0.52 (95% CI 0.46, 0.58); P < 0.0001.</p> <p>Agreement between VerifyNow and LTA: out of a total of 801 samples, 105 samples were positive by both tests; 635 samples were negative by both tests; 24 samples were positive by LTA but not VerifyNow; 142 samples were positive by VerifyNow but not LTA. Agreement kappa = 0.44 (95% CI 0.38, 0.50); P < 0.0001</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Ko 2011 Korea 21315223	Consecutive CAD patients undergoing PCI in two university hospitals; all patients received drug eluting stents	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, additional details not reported] Impedance aggregometry (ADP, concentration not reported) [Multiplate analyzer, Dynabyte, additional details not reported]	Samples were obtained in the catheterization room through the femoral catheter, before the administration of heparin	Patients were pre-treated with aspirin (100 mg/d) and clopidogrel (75 mg/d) \geq 5 d before the procedure, or received oral loading doses of aspirin (250 mg) and clopidogrel (300 mg) 12-24 h before the procedure.	Measurement of samples using both tests to calculate limits of agreement	Data from both tests were available from 222 patients	Bland-Altman* limits of agreement between VerifyNow PRU and Multiplate analyzer = -17.1 (SD = 232.1) with 95% limits of agreement from -472.0 to 437.8
Aradi 2010 Hungary 20642320	Prospectively recruited clopidogrel-naïve stable angina patients with planned PCI	LTA (ADP, 5 μ M and epinephrine, 10 μ M) [CARAT TX4 aggregometer, Carat Diagnostics, Budapest, Hungary] VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP/P2Y12 kit, BioCytex, Marseille, France]; using flow cytometry [Beckman Coulter flow cytometer, no additional details reported]	Samples were obtained 12-18 h post-clopidogrel loading and at 25 ± 2 d after PCI	All patients received clopidogrel (600 mg) and aspirin (300 mg) loading doses after angiography and immediately before PCI.	Measurement of samples with both assays (and different reactivity indexes from the same assay) to obtain limits of agreement; repeat measurements were obtained after clopidogrel loading and 25 ± 2 d after PCI but were treated as independent	242 samples from 121 patients, all assessed with both assays	<p>Bland-Altman analysis comparing maximal aggregation by LTA and PRI VASP measurements = +1.3</p> <p>Bland-Altman analysis comparing late aggregation by LTA and PRI VASP measurements; bias = -10.6</p> <p>Bland-Altman analysis comparing disaggregation by LTA and PRI VASP measurements; bias = -19.9</p> <p>Bland-Altman analysis comparing LTA AUC of the light transmission curve and PRI VASP; bias measurements = -15.1</p> <p>The authors noted the presence of substantial heteroscedasticity in the Bland-Altman plots for the last three of the four analyses listed above.†</p> <p>Analytic accuracy using PRI</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>VASP (50% cut-off) as the reference standard:</p> <p>- Maximal aggregation by LTA (34.5% cut-off, based on ROC analysis): Specificity = 79.4% Sensitivity = 61.3% Concordant pairs = 71.1% Discordant pairs = 28.9% Kappa = 0.4 (P<0.001) AUC (95% CI) = 0.75 (0.68, 0.81); P<0.0001</p> <p>- Late aggregation by LTA (12% cut-off, based on ROC analysis): Specificity = 83.2% Sensitivity = 62.2% Concordant pairs = 73.1% Discordant pairs = 26.9% Kappa = 0.45; P<0.001 AUC (95% CI) = 0.73 (0.67, 0.80)</p> <p>- Disaggregation by LTA (63.5% cut-off, based on ROC analysis): Specificity = 80.2% Sensitivity = 63.1% Concordant pairs = 72.7% Discordant pairs = 27.3% Kappa = 0.44; P<0.001 AUC (95% CI) = 0.71 (0.64, 0.78); P<0.0001</p> <p>- AUC of LTA light transmission curve (82xmin cut-off, based on ROC analysis): Specificity = 86.7% Sensitivity = 60.8% Concordant pairs = 72.3% Discordant pairs = 27.7% Kappa = 0.44; P<0.001</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							AUC (95% CI) = 0.76 (0.69-0.82); P<0.0001
Woo 2010 Korea 20890076	Patients with CAD scheduled to undergo PCI with DES placement in a single center.	<p>LTA (ADP, 10 µM) [Chronolog impedance aggregometer Series 590, Probe and Co., Endingen Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p> <p>Impedance aggregometry (ADP, 20 µM) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p> <p>VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP/P2Y12 kit, BioCytex, Marseille, France]; using flow cytometry [no additional details reported]</p>	Samples were collected “just before” PCI	All patients were administered loading doses of aspirin (300 mg), clopidogrel (300 mg), and cilostazol (200 mg) ≥ 12 h before stenting.	Measurements with 4 assays to assess agreement	66 patients	<p>Agreement between LTA and VerifyNow, kappa = 0.25</p> <p>Agreement between LTA and Multiplate analyzer, kappa = 0.21</p> <p>Agreement between LTA and PRI VASP assay, kappa = 0.14</p>
Madsen 2010 Canada 20224050	Patients undergoing PCI at a single center	<p>LTA (ADP, 5 µM) [Chrono-Log Lumi Aggregometer, model 810; Chrono-Log Corporation, no additional details provided]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, no additional details provided]</p> <p>TEG</p>	Before PCI and on 1 d, 1 mo, 6 mo, and 12 mo, post-treatment	“Just before” PCI patients received 600 mg of clopidogrel; during the procedure use of tirofiban or eptifibatide was permitted but their administration was to be stopped ≥ 10 h before blood was drawn; abciximab was not permitted. Aspirin (325 mg/d) and clopidogrel (75 mg/day) were administered for a year post-PCI.	Measurement of samples with all three techniques and comparison of measurements for agreement	33 patients, 26 of whom completed all study visits. Patients contributed samples at multiple timepoints and measurements were considered independent. The total number of measurements for each comparison was not reported; as such data are incomplete for the assessment of agreement.	<p>Agreement between absolute maximal ADP aggregation (50% cut-off) and change in aggregation (cut-off 10%) by LTA: “low response” by both tests, 1; “normal response” by change in aggregation but not absolute aggregation, 6; “normal response” by absolute aggregation but not change in aggregation, 14.</p> <p>Agreement between VerifyNow and change in aggregation</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
		(ADP, 2 µmol/L) [TEG Hemostasis Analyzer, Haemonetics Corporation, no additional details provided]					<p>(cut-off 10%) by LTA: “low response” by both tests, 1; “normal response” by change in aggregation but not VerifyNow, 3; “normal response” by VerifyNow but not change in aggregation, 8.</p> <p>Agreement between TEG and change in aggregation (cut-off 10%) by LTA: “low response” by both tests, 1; “normal response” by change in aggregation but not TEG, 12; “normal response” by TEG but not change in aggregation, 8.</p> <p>Agreement between VerifyNow and absolute maximal aggregation (cut-off 50%) by LTA: “low response” by both tests, 3; “normal response” by absolute aggregation but not VerifyNow, 1; “normal response” by VerifyNow but not change in aggregation, 5.</p> <p>Agreement between TEG and absolute aggregation (cut-off 50%) by LTA: “low response” by both tests, 2; “normal response” by absolute aggregation but not TEG, 15; “normal response” by TEG but not change in aggregation, 4.</p> <p>Agreement between VerifyNow and TEG: “low response” by both tests, 1; “normal response” by TEG but not VerifyNow, 1; “normal</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							response” by VerifyNow but not TEG, 14.
Siller-Matula 2010 Austria 19943879	Single center prospective observational study of patients undergoing PCI with stent implantation ≥ 2 hours after clopidogrel loading. The majority of patients were undergoing elective PCI.	VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP/P2Y12 kit, BioCytex, Marseille, France]; using flow cytometry [FACSCalibur System, BD Biosciences, Vienna, Austria] Impedance aggregometry (ADP, concentration not reported) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]	Blood samples were obtained in the catheterization laboratory “directly after” PCI and at least 5 min after the IV administration of aspirin	326 patients were on chronic clopidogrel treatment; 90 patients received a clopidogrel loading dose (600mg) within 2 d before PCI, followed by a maintenance dose of 75 mg. All patients received 250 mg of IV acetylsalicylic acid directly after stent placement, followed by a daily dose of 100 mg. Patients receiving IIb/IIIa inhibitors were excluded from analyses with the Multiplate analyzer.	Measurement of samples with both assays	402 patients with results available from both assays	<p>Agreement between Multiplate analyzer and VASP assay: “non-responders” by both tests, 54 (13%); “responders” by both tests, 138 (34%); “non-responders” by Multiplate analyzer but “responders” by VASP, 7 (2%); “responders” by Multiplate analyzer but “non-responders” by VASP assay, 203 (51%)</p> <p>Bland-Altman analysis for agreement between VASP assay and Multiplate analyzer*: average difference (bias) = 21; 95% limits of agreement, -34 to 78</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Cuisset 2010 France 20142119	Consecutive patients admitted to a single institution for NSTEMI ACS	<p>LTA (ADP 10 µmol/L) [PAP4, Biodata Corporation, Wellcome, Paris, France]</p> <p>VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP-FCM kit, Diagnostic Stago (BioCytex), Asnieres, France]; using flow cytometry [no additional details reported]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>	Samples were drawn 1 mo after discharge	Patients received oral loading doses of aspirin (250 mg) and clopidogrel (600 mg) at least 12 h before stenting	Measurement of patient samples with all three assays to determine limits of agreement and kappa statistics	70 patients, assessed with all 3 assays	<p>Bland-Altman analysis comparing aggregation by LTA versus PRI VASP*: bias = 10.6; 95% limits of agreement, -23.3, 44.4</p> <p>Bland-Altman analysis comparing aggregation by LTA versus VerifyNow PRU*: bias = -146.4; 95% limits of agreement, -331.6, 39.0</p> <p>Bland-Altman analysis comparing PRI VASP versus VerifyNow PRU*: bias = -156.9; 95% limits of agreement, - 342.1, 28.3</p> <p>Agreement between LTA (cut- off 70%) and VASP PRI: kappa = 0.35</p> <p>Agreement between VerifyNow PRU and LTA (cut-off 70%): kappa = 0.36</p> <p>Agreement between VASP PRI and VerifyNow PRU: kappa = 0.46</p> <p>Additional analysis using a different threshold:</p> <p>Agreement between LTA (cut- off 50%) and VASP PRI: kappa = 0.42</p> <p>Agreement between VerifyNow PRU and LTA (cut-off 50%): kappa = 0.52</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Smit 2009 Netherlands 19200163	Patients participating in a multicenter trial of tirofiban vs. placebo (On-TIME 2 study) for STEMI requiring PCI	Fe-induced platelet aggregation [samples were added to tubes containing 100 mg of steel wool (Haemoscan, Groningen, Netherlands)] and a platelet counter was use to assess platelet aggregation (against a control tube no containing iron). Plateletworks (ADP, 20 µM/L) [PlateletWorks, Helena Laboratories, Beaumont, TX]	Samples were obtained before PCI, but after the patients received the study medication (tirofiban or placebo) and antiplatelets	Before testing, patients received clopidogrel (600 mg orally) and acetylsalicylic acid (500 mg IV); blood was drawn at the “start of catheterization”	Measurement of samples with three assays to assess limits of agreement	111 patients (53 randomized to tirofiban and 58 randomized to placebo)	Bland-Altman comparison between duplicate measurements using the iron-based assay: the mean was close to 0 (exact result not reported) and in ~6/111 samples were outside “limits of agreement of ±20%” (see also Figure 2 of the paper). Bland-Altman comparison of the iron-based assay versus Plateletworks (ADP as the agonist): ~4/111 samples were outside limits of agreement of ±40% (see also Figure 4 of the paper).
Gremmel 2009 Austria 19190818	Patients with peripheral, coronary, or carotid artery disease after elective percutaneous intervention with endovascular stent implantation	LTA (ADP 10 µM) [APACT 4S Plus aggregometer, LABiTec, Ahrensburg, Germany] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA] VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP kit, Diagnostica Stago, BioCytex, Marseille, France]; using flow cytometry [FACSCalibur system, Becton Dickinson, BD Biosciences, Vienna, Austria] Impedance aggregometry (ADP, 6.4 µM) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]	Samples were obtained 24 h after the percutaneous intervention	Patients had received acetylsalicylic acid (100 mg/d) at least 2 w prior to the percutaneous intervention. All patients received a loading dose of clopidogrel (300 mg) 24 h prior to the intervention, followed by a maintenance dose of 75 mg/day	Measurement of samples with 5 methods; assessment of correlations between methods, agreement between methods, and analytic sensitivity and specificity using LTA as the reference standard test (treated as a gold standard)	80 patients assessed with 5 assays	Analytic performance, using LTA as the reference standard (20 positive samples): Analytic sensitivity -VerifyNow, 55% - VASP assay, 45% -Multiplate analyzer, 35% - Impact-R, 40% Analytic specificity -VerifyNow, 85% - VASP assay, 81.7% -Multiplate analyzer, 78.3% - Impact-R, 78.3% Analytic positive predictive value -VerifyNow, 55% - VASP assay, 45% -Multiplate analyzer, 35% - Impact-R, 38.1% Analytic negative predictive value -VerifyNow, 85% - VASP assay, 81.7%

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
		Cone and plate analyzer (ADP 1.36 μ M) [Impact-R test, DiaMed, Cressier, Switzerland]					<p>-Multiplate analyzer, 78.3% - Impact-R, 79.7%</p> <p>Agreement between LTA and VerifyNow: concordant positive samples = 11; concordant negative samples = 51; positive with LTA but not VerifyNow = 9; positive with VerifyNow but not LTA = 9</p> <p>Agreement between LTA and VASP assay: concordant positive samples = 9; concordant negative samples = 49; positive with LTA but not VASP assay = 11; positive with VASP assay but not LTA = 11</p> <p>Agreement between LTA and Multiplate analyzer: concordant positive samples = 7; concordant negative samples = 47; positive with LTA but not Multiplate analyzer = 13; positive with Multiplate analyzer but not LTA = 13</p> <p>Agreement between LTA and Impact-R: concordant positive samples = 8; concordant negative samples = 47; positive with LTA but not Impact-R = 12; positive with Impact-R but not LTA = 13</p> <p>Cut-offs for all assays were based on quartiles of the observed measurement distribution (most extreme reactivity quartile vs. all others).</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Schafer 2008 Germany 18841284	Consecutive patients with CAD admitted to a single center	LTA (ADP 20 μ M) [PAP-8, BioData, Horsham, PA] VASP phosphorylation assay (PGE1 \pm ADP, 20 μ M) [Platelet VASP Test kit, American Diagnostica, Pfungstadt, Germany]; using flow cytometry [FACSCalibur, Becton Dickinson, Heidelberg, Germany]	Samples were obtained 2-4 h after drug intake	Patients had been on maintenance dose clopidogrel (75 mg/d) for \geq 5 d after a loading dose of 300-600 mg (on the first day); patients not on clopidogrel were used as controls (no data extracted)	Measurement of samples using 3 assays for assessment of agreement	100 patients on clopidogrel	Agreement between VASP assay (cut-off 50%) and LTA (cut-off 50%): concordant positive results, 44%; concordant negative results, 28%; positive by VASP but not LTA, 25%; positive by LTA but not VASP assay, 3%.
							Subgroup analysis by diabetic status: Diabetic patients (n=30): agreement between VASP assay (cut-off 50%) and LTA (cut-off 50%): concordant positive results, 41%; concordant negative results, 24%; positive by VASP but not LTA, 34%; positive by LTA but not VASP assay, 0%. Non-diabetic patients (n=70): agreement between VASP assay (cut-off 50%) and LTA (cut-off 50%): concordant positive results, 44%; concordant negative results, 28%; positive by VASP but not LTA, 23%; positive by LTA but not VASP assay, 5%.

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Shenkman 2008 Israel 18155752	Consecutive ACS patients who underwent PCI with stent implantation	LTA (ADP, 5.5 µM) [PACKS-4 aggregometer, Helena Laboratories, Beaumont, TX] Impact-R (ADP 1.38 µM) [DiaMed, Cressier, Switzerland]	In one group of patients (n=114) blood samples were obtained before and 4 d after clopidogrel administration. In a second group (n=290) samples were obtained only 4 d after clopidogrel treatment.	All patients received aspirin 300 mg on admission and 200 mg/d thereafter. Eptifibatide was administered before PCI and for at least 12 h after the procedure. Clopidogrel was administered at a loading dose of 300 mg on completion of PCI, followed by a maintenance dose of 75 mg/d.	Measurement of samples with both assays to determine agreement and analytic sensitivity and specificity. For the later analyses LTA results were treated as a “gold standard”	114 patients contributed measurements before and after clopidogrel administration; 290 patients only contributed measurements after clopidogrel administration. Only results from the second groups of patients were used for ROC and agreement analyses.	Analytic performance using LTA as the reference standard (cut-off 70%) Optimal cut-off value for Impact_r = 2.8 Analytic sensitivity = 71% Analytic specificity = 83% Analytic positive predictive value = 72% Analytic negative predictive = 83% AUC = 0.867
							Agreement between LTA and Impact-R for non-response using the cut-offs identified through ROC analysis: concordant positive results, 78; concordant negative results, 151; non-responders by LTS but responders by Impact-R, 32; non-responders by Impact- R but responders by LTA, 29.

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Lordkipanidze 2008 Canada 18520610	Patients with CAD requiring elective diagnostic coronary angiography with or without PCI from a single center. Patients were participants in a prospective, randomized, double-blind, placebo controlled trial	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA] Comparisons were performed between a before-after assessment of the clopidogrel effect (based on two measurements using VerifyNow, pre- and post-clopidogrel administration) and a single on-clopidogrel measurement with VerifyNow where the TRAP channel of the assay is used to “approximate” the pre-clopidogrel reactivity level.	Blood was drawn “before clopidogrel initiation” (pre-clopidogrel measurement) and “just before” elective angiography	Patients were allocated randomly to 4 groups: 300 or 600 mg on the day before angiography, or 300 mg loading followed by 75 or 150 mg maintenance daily dose, started 1 w before angiography. All patients received aspirin (80 mg). Patients receiving IIb/IIIa inhibitors were excluded.	Two measurements with VerifyNow (before and after clopidogrel) to compare the before-after contrast versus as “estimated” contrast using the post-clopidogrel measurement and the TRAP channel of the same device	68 patients contributing data for both timepoints	Bland-Altman analysis: bias = 8%; limits of agreement from -49% to 65%
Lordkipanidze 2009 Canada 19840560	Consecutive patients with stable CAD treated with aspirin and clopidogrel selected from the outpatient cardiology clinic of a single center	LTA (ADP 5, 10, and 20 μ M) [Chrono-Log aggregometer 540 model, Chrono-Log, Havertown, PA] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Samples were obtained 2-12 h after the last aspirin and clopidogrel dose.	All patients were on aspirin (≥ 80 mg/d) and clopidogrel (≥ 75 mg/d) for ≥ 3 mo.	Measurements were obtained with both assays (and using different concentrations of ADP for LTA) to compare agreement	85 patients contributed measurements with LTA, using ADP 5 and 20 μ M concentrations, and VerifyNow; 77 patients were also assessed with LTA using an ADP concentration of 10 μ M	Agreement between VerifyNow and LTA ADP 5 μ M: kappa = 0.487; P<0.0001 Agreement between VerifyNow and LTA ADP 10 μ M: kappa = 0.309; P=0.004 Agreement between VerifyNow and LTA ADP 20 μ M: kappa = 0.661; P<0.0001

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Lordkipanidze 2009 Canada 19419755	Patients presenting at a single center outpatient cardiology department with symptomatic CAD requiring diagnostic coronary angiography. Patients were participants in a prospective, randomized, double-blind, placebo controlled trial.	LTA (ADP 5 and 20 μ M) [ChronoLog aggregometer 540 model, Havertown, PA]	Samples were obtained before clopidogrel initiation and “just before” elective angiography.	Patients were allocated randomly to 4 groups: 300 or 600 mg on the day before angiography, or 300 mg loading followed by 75 or 150 mg maintenance daily dose, started 1 w before angiography. All patients received aspirin (80 mg). Patients receiving IIb/IIIa inhibitors were excluded	Measurements obtained with both ADP concentrations to assess agreement	120 patients contributed measurements	<p>Bland-Altman analysis of peak versus late aggregation using LTA ADP 5 μM: bias = 10.8%; limits of agreement from -5.8% to 27.3%</p> <p>Bland-Altman analysis of peak versus late aggregation using LTA ADP 20 μM: bias = 10.3%; limits of agreement from -8.5% to 29.2%</p> <p>Analyses of inhibition of platelet reactivity (i.e., change from baseline)</p> <p>Bland-Altman analysis of peak versus late absolute inhibition using LTA ADP 5 μM: bias = 3.4%; limits of agreement from -18% to 25%</p> <p>Bland-Altman analysis of peak versus late absolute inhibition using LTA ADP 20 μM: bias = 5.9%; limits of agreement from -18% to 30%</p> <p>Bland-Altman analysis of peak versus late relative inhibition using LTA ADP 5 μM: bias = -16.3%; limits of agreement from -59% to 26%</p> <p>Bland-Altman analysis of peak versus late relative inhibition using LTA ADP 20 μM: bias = -12.3%; limits of agreement from -49% to 23%</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Collet 2008 France 18765393	Adult patients on maintenance clopidogrel for > 7 d scheduled to undergo cardiac catheterization because of unstable CAD or stable angina. Patients were participants in a prospective trial of alternative clopidogrel loading doses.†	LTA (ADP 5, 10, 20, and 50 µmol/L) [Chronolog Aggregometer model 490-4D, Chrono-Log Corp., Kordia, Netherlands] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Samples were obtained before the first and second loading doses and 24 h after the first loading dose (see adjacent cell for details). Agreement was assessed using the baseline measurements only (i.e., reflective of patients' reactivity on maintenance clopidogrel)	All patients were on clopidogrel maintenance (75 mg/d) for > 7 d. They were alternately allocated to clopidogrel loading doses of 300, 600, or 900 mg (first loading dose). Depending on the initial assignment, patients then received a second loading dose, such that the total clopidogrel amount received would be 900 mg. Thereafter, all patients received maintenance clopidogrel (75 mg/d) and aspirin (≤100 mg/d). Only baseline measurements were used for the assessment of agreement.	Agreement regarding baseline on-clopidogrel non-responsiveness between assays	166 patients measured at baseline	Agreement for poor response between LTA (cut-off 50% for residual platelet reactivity) and VerifyNow (cut-off 15%): kappa = 0.20; 95% CI 0.06, 0.40

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Von Beckerath 2010 Germany 19823079	Consecutive patients without clopidogrel treatment within the last 4 week, scheduled for coronary angiography	LTA (ADP 5 µmol/L) [PAP 8 aggregometer, Molab, Berlin, Germany] Impedance aggregometry (ADP 6.4 µmol/L ± PGE1 9.4 µmol/L) [Multiplate analyzer, Dynabyte Medical, Munich, Germany] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA] VASP phosphorylation assay (PGE1 ± ADP, 20 µM) [Platelet VASP, Biocytex, Marseille, France]; using flow cytometry [no additional details provided]	Samples were obtained before the administration of clopidogrel and immediately after stent placement (post- clopidogrel loading)	All patients received a single clopidogrel loading dose (600 mg), which was recommended to be given ≥ 2 h before catheterization. Patients treated with IIb/IIIa inhibitors within 28 d were excluded.	Assessment of samples with all 3 assessment and assessment of agreement for identifying “lack of response”. Lack of response was defined as values in the top quintile of measurements obtained from each assay.	Samples from 60 patients measured with 4 assays (2 different agonist types were used for the Multiplate analyzer)	12 patients were in the upper quintile of the Multiplate analyzer using ADP as the agonist; of those 7 were in the upper quintile of VerifyNow (P<0.001), 6 in the upper quintile if Multiplate analyzer using ADP+ PGE1 as the agonist (P=0.004), and 3 were in the upper quintile of VASP PRI (P=0.63). P-values were from a “chi-square test”; it was unclear whether the paired nature of the measurements was accounted for in the analysis. The authors stated that “comparisons of categorical classifications (upper quintiles) yielded a poor agreement of post-clopidogrel values” [no additional statistics were reported]
Varenhorst 2009 Sweden 19249429	Patients with stable CAD participating in a parallel- group randomized trial of prasugrel versus clopidogrel, both in combination with aspirin	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA] VASP phosphorylation assay (PGE1 ± ADP, concentrations NR) [Platelet VASP kit, BioCytex, Marseille, France]; using flow cytometry [samples were analyzed on different flow- cytometers in 2 participating centers: Epics XL, Beckman Coulter, Fullerton, CA; and FACScan, Becton Dickinson, Franklin Lakes, NJ]. The authors	Samples were obtained before the loading dose, 2h and 24h post- loading, and the 14th and 29th day of clopidogrel maintenance treatment	Patients received aspirin 75mg/d for 5-21 d before randomization and were then assigned to clopidogrel (600 mg loading, 75 mg maintenance dose) or prasugrel (60 mg loading; 10 mg maintenance) groups, while continuing the same aspirin regimen	Two measurements with VerifyNow (before and after antiplatelet treatment) to compare the before-after contrast versus an “estimated” contrast using the post-clopidogrel measurement and the TRAP channel of the same device	110 patients (1:1 randomized to clopidogrel or prasugrel) measured at 5 timepoints (not clear if all measurements were available for all patients and timepoints)	Lin's concordance correlation coefficient between observed and estimated % inhibition = 0.97; P<0.0001 (the authors indicated that there is “modest underestimation by the device- reported %inhibition”) Agreement for high platelet inhibition (quartile 1 vs. quartiles 2-4 for each assay), 95% CI Agreement between VASP PRI and PRU, during loading phase = 0.35 (0.20, 0.49)

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
		<p>reported that “synchronization between the flow cytometers was performed”.</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>					<p>Agreement between VASP PRI and PRU, during maintenance phase = 0.55 (0.42, 0.68)</p> <p>Agreement between late reactivity by LTA and PRU, during loading phase = 0.54 (0.41, 0.67)</p> <p>Agreement between late reactivity by LTA and PRU, during maintenance phase = 0.52 (0.39, 0.66)</p> <p>Agreement for low platelet inhibition (quartile 4 vs. quartiles 1-3 for each assay), 95% CI</p> <p>Agreement between VASP PRI and PRU, during loading phase = 0.79 (0.69, 0.89)</p> <p>Agreement between VASP PRI and PRU, during maintenance phase = 0.66 (0.54, 0.78)</p> <p>Agreement between late reactivity by LTA and PRU, during loading phase = 0.75 (0.64, 0.85)</p> <p>Agreement between late reactivity by LTA and PRU, during maintenance phase = 0.66 (0.54, 0.77)</p>
Lordkipanidze 2008 Canada	Patients with suspected CAD requiring elective diagnostic coronary	LTA (ADP 5 and 20 µM) [ChronoLog 540 model,	Blood was drawn at two time points: before clopidogrel initiation	Patients were allocated randomly to 4 groups: 300 or 600 mg on the day before	Measurement of samples with all assays to assess agreement	116 patients contributed samples to the analyses; only 72 patients had	Data were extracted only for on-clopidogrel measurements.

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
18826988	angiography, recruited from the pre-angiography outpatient clinic of a single center. The current study was a pre-specified analysis nested within a prospective randomized trial of alternative clopidogrel dosing regimens	Havertown, PA] Impedance aggregometry (ADP 5 and 20 μ M) [ChronoLog 560 model, Havertown, PA] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	and “just before” coronary angiography	angiography, or 300 mg loading followed by 75 or 150 mg maintenance daily dose, started 1 w before angiography. All patients received aspirin (80 mg). Patients receiving IIb/IIIa inhibitors were excluded		measurements with VerifyNow	<p>Bland-Altman analyses</p> <p>Agreement between LTA ADP 5 μM and 20 μM: bias = 4.5% (95% CI, 1.3%, 7.7%); P=0.006 by paired t-test; limits of agreement: -26% to 38%.</p> <p>Agreement between LTA ADP 20 μM and impedance aggregometry ADP 5 μM: bias = 13% (95% CI, 2.6%, 24.0%; overestimation by impedance aggregometry); P=0.01 by paired t-test; limits of agreement: -97% to 124%.</p> <p>Agreement between LTA ADP 20 μM and impedance aggregometry ADP 20 μM: bias = -11% (95% CI, -20.7%, -1.8%; underestimation by impedance aggregometry); P=0.02 by paired t-test; limits of agreement: -110% to 87%.</p> <p>Agreement between LTA ADP 20 μM and VerifyNow: bias = 6.3% (95% CI, -1.6%, 14.2%; non-significant overestimation by VerifyNow); P=0.117 by paired t-test; limits of agreement: -54.4% to 67.0%.</p> <p>Agreement using a cut-off of 50%</p> <p>Agreement between LTA ADP 5 μM and LTA ADP 20 μM: kappa = 0.679; P<0.05</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>Agreement between LTA ADP 5 μM and impedance aggregometry ADP 5 μM: kappa = -0.117; P=NS</p> <p>Agreement between LTA ADP 5 μM and impedance aggregometry ADP 20 μM: kappa = 0.057; P=NS</p> <p>Agreement between LTA ADP 5 μM and VerifyNow: kappa = 0.295; P<0.05</p> <p>Agreement between LTA ADP 20 μM and impedance aggregometry ADP 5 μM: kappa = -0.187; P<0.05</p> <p>Agreement between LTA ADP 20 μM and impedance aggregometry ADP 20 μM: kappa = 0.101; P=NS</p> <p>Agreement between LTA ADP 20 μM and VerifyNow: kappa = 0.364; P<0.05</p> <p>Agreement between impedance aggregometry ADP 5μM and impedance aggregometry ADP 20 μM: kappa = 0.308; P<0.05</p> <p>Agreement between impedance aggregometry ADP 5μM and VerifyNow: kappa = -0.047; P=NS</p> <p>Agreement between impedance aggregometry ADP</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							20 µM and VerifyNow: kappa = 0.132; P=NS (exact p-values were not reported)
Jeong 2008 S. Korea 18617479	Consecutive patients undergoing PCI with DES implantation at a single center	LTA (ADP 5 µM) [ChronoLog 540 model, Havertown, PA] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	“from the arterial sheath”	Unclear (on-clopidogrel)	Measurements with both assays to assess analytic performance using LTA as the reference standard	300 patients provided measurements with both assays	Optimal VerifyNow cut-off for HPR using LTA (with 50% cut-off) as the reference standard = 239 PRU; AUC = 0.794; 95% CI 0.736, 0.851; P<0.001 At this cut-off analytic sensitivity = 83.6%; analytic specificity = 68.3% The authors also reported the analytic sensitivity and specificity of LTA % inhibition as 76.2% and 83.6% respectively, presumably against LTA on-treatment reactivity. For this analysis the optimal LTA cut-off was determined to be 20% (AUC = 0.841; 95% CI 0.790, 0.891).
Kim 2010 S. Korea 20449634	Unselected patients treated with coronary stenting for symptomatic coronary artery disease, including AMI	LTA (ADP 5 and 20 µM) [AggRam aggregometer, Helena Laboratories Corp., Beaumont, TX] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	“Pre-discharge” measurement, either ≥3 d after coronary stenting in patients not treated with tirofiban or at ≥5 d post-procedure in patients treated with tirofiban	In cases of scheduled coronary stenting, clopidogrel-naïve patients received clopidogrel 300-mg (loading) at least 12 h pre-PCI. In patients already on chronic clopidogrel therapy, no loading dose was used. All AMI patients received clopidogrel 600 mg loading, followed by 75 mg/d maintenance. Tirofiban was the only IIb/IIIa inhibitor allowed.	Measurements with both assays to assess agreement and analytic performance	1058 patients contributed measurements	Agreement between maximal reactivity by LTA ADP 5 µmol/L (50% cut-off) and VerifyNow (PRU 240 cut-off): kappa = 0.438; P<0.001; 29.1% concordant positives; 42.5% concordant negatives; 5.9% positive by LTA but not VerifyNow; 22.5% positive by VerifyNow but not LTA; overall concordance = 71.6% Agreement between maximal reactivity by LTA ADP 20 µmol/L (50% cut-off) and

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							VerifyNow (PRU 240 cut-off): kappa = 0.505; P<0.001; 35.0% concordant positives; 40.2% concordant negatives; 8.2% positive by LTA but not VerifyNow; 16.6% positive by VerifyNow but not LTA; overall concordance = 75.1%
							Analytic performance using LTA as the reference standard test (however, with different thresholds for each analysis)
							Analytic performance of VerifyNow against maximal reactivity by LTA ADP 5 µmol/L (cut-off 50%): optimal cut-off for VerifyNow = 241; AUC = 0.822 (95% CI 0.797, 0.847); analytic sensitivity = 0.830; analytic specificity = 0.660
							Analytic performance of VerifyNow against maximal reactivity by LTA ADP 20 µmol/L (cut-off 62%): optimal cut-off for VerifyNow = 241; AUC = 0.840 (95% CI 0.816, 0.863); analytic sensitivity = 0.807; analytic specificity = 0.714
							Analytic performance of VerifyNow against maximal reactivity by LTA ADP 20 µmol/L (cut-off 50%): optimal cut-off for VerifyNow = 195; AUC = 0.851 (95% CI 0.827, 0.875); analytic sensitivity =

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>0.889; analytic specificity = 0.635</p> <p>Analytic performance of VerifyNow against late reactivity by LTA ADP 5 µmol/L (cut-off 14%): optimal cut-off for VerifyNow = 194; AUC = 0.826 (95% CI 0.796, 0.856); analytic sensitivity = 0.829; analytic specificity = 0.683</p> <p>The paper also includes a table (see Table 2 in the manuscript for additional details) reporting comparisons between LTA (both maximal and late reactivity and 5 and 20 µmol/L ADP concentration) and VerifyNow using different thresholds for each test. Kappa statistics for all combinations assessed ranged between 0.260 and 0.734; concordance rates ranged between 56.7% and 87.2%; analytic sensitivities ranged between 68.8% and 100%; analytic specificities ranged between 34.4% and 83.9%.</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Lordkipanidze 2009 Canada 19250657	Patients with CAD receiving aspirin and clopidogrel§ were recruited from a single center's pre-angiography clinic	LTA (ADP 5 and 20 µM) [ChronoLog Aggregometer, 540 model, Havertown, PA] "Platelet count drop method" using impedance platelet counting before and after exposure to the agonist (ADP 5 and 20 µM) Using a Coulter ACT Series Analyzer, Beckman Coulter Inc., Fullerton, CA]	NR	Patients were on aspirin (80 mg/d) and clopidogrel (varying dosing schemes)	Measurements with both methods to assess agreement	91 patients on clopidogrel + aspirin	<p>Bland-Altman analysis comparing LTA (ADP 5 µM) and platelet count drop method (ADP 5 µM): bias = 13% (overestimation by platelet count drop); limits of agreement -27% to 52%.</p> <p>Bland-Altman analysis comparing LTA (ADP 20 µM) and platelet count drop method (ADP 20 µM): bias = 18% (overestimation by platelet count drop); limits of agreement -30% to 65%.</p> <p>Agreement between LTA (ADP 5 µM) and platelet count drop method (ADP 5 µM) using a cut-off of 50% for both: kappa = 0.192; P = 0.02</p> <p>Agreement between LTA (ADP 20 µM) and platelet count drop method (ADP 20 µM) using a cut-off of 50% for both: kappa = 0.281; P = 0.002</p> <p>Agreement between LTA (ADP 5 µM) and platelet count drop method (ADP 5 µM) using a cut-off of 70% for both: kappa = 0.207; P = 0.001</p> <p>Agreement between LTA (ADP 20 µM) and platelet count drop method (ADP 20 µM) using a cut-off of 70% for both: kappa = 0.089; P = 0.191</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Pettersen 2011 Norway 21426546	Patients with symptomatic CAD randomized to the aspirin + clopidogrel arm of a randomized trial	VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [PLT VASP/P2Y12 assay, Biocytex, France]; using flow cytometry [FACS Calibur System, Becton Dickinson, Plymouth, UK] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	One month post-randomization to the clopidogrel arm	Aspirin (160 mg/d) + clopidogrel (75 mg/day) treatment for ≥ 1 mo; patients on aspirin only were used to derive the cut-off for “clopidogrel resistance”	Measurements with both assays to determine agreement	219 patients were on aspirin + clopidogrel; 155 were analyzed successfully with the VASP assay and 212 with the VerifyNow assay	Agreement between VASP assay and VerifyNow: kappa = 0.379; P<0.001; concordance rate = 74.5%
Sibbing 2008 Germany 18217143	Consecutive patients scheduled for coronary angiography; patients were required to not have received clopidogrel within 4 w of enrollment	LTA (ADP 5 or 20 µM) [PAPA 8 aggregometer, Bio/Data, no additional information reported] Impedance aggregometry (ADP, 6.4 µM) [Multiplate analyzer, Dynabyte, Munich, Germany]	Samples were obtained from a subset of 60 patients at baseline (pre-clopidogrel loading) and from all participating patients (n=149) during catheterization (post-loading dose)	Patients received a loading dose of clopidogrel of 600 mg, recommended to be given ≥ 2 h before catheterization	Measurements with both methods to assess agreement	149 patients contributed on-clopidogrel measurements; 60 patients also had baseline (pre-clopidogrel) measurements available	Agreement between LTA and Multiplate analyzer for lowest quartile of inhibition (n = 60): concordant positives = 7 (12%); concordant negatives = 35 (58%); positives by LTA but not Multiplate analyzer = 8 (13%); positives by Multiplate analyzer but not LTA = 10 (17%) Agreement between LTA and Multiplate analyzer for lowest quartile of inhibition (n=149): concordant positives = 21 (14%); concordant negatives = 94 (63%); positives by LTA but not Multiplate analyzer = 17 (11%); positives by Multiplate analyzer but not LTA = 17 (11%)

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Gaglia 2011 USA 21919956	Patients undergoing urgent or elective PCI in a single center	LTA (ADP 5 or 20 μ M) [ChronoLog, Havertown, PA] VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [PLT VASP/P2Y12 assay, BioCytex, Marseille, France]; using flow cytometry [FACSCalibur flow cytometer, BD Biosciences, San Jose, CA] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Measurements of on- treatment platelet reactivity were obtained between 6 and 24 h following PCI and \geq 6 hours following clopidogrel loading	Patients received clopidogrel loading (600 mg) \geq 2 h prior to platelet testing or where on clopidogrel maintenance (75 mg) \geq 5 d prior	Measurements with 3 assays to assess agreement	200 patients	“All kappa statistics had P values <0.001” and “ranged from 0.33-0.53” Agreement between LTA ADP 5 μ M and LTA ADP 20 μ M: kappa = 0.53 (95% CI 0.37, 0.68) Agreement between VASP and LTA ADP 5 μ M: kappa = 0.33 (95% CI 0.19, 0.47) [agreement results were not reported for other pairs of assays] “Overall, the level of agreement between assays was in the moderate to poor range”
McGlasson 2011 USA 21799401	Patients scheduled to receive clopidogrel for cardiovascular or cerebrovascular disease, or with \geq 2 risk factors for vascular disease (AHA criteria)	High shear platelet function (ADP/PGE1 cartridges and collagen/ADP) [INNOVANCE PFA P2Y and PFA-100 collagen/ADP cartridges, Siemens Healthcare Inc., Deerfield, IL]; the INNOVANCE assay was used on samples anticoagulated with 3.2% and 3.8% citrate Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA] LTA (ADP 20 μ mol/L) [ChronoLog 700 aggregometer, Chrono-Log, Havertown, PA]	Blood was collected 6- 24 h post-clopidogrel loading or \geq 7 d of maintenance therapy	Patients scheduled to receive clopidogrel; patients receiving non-clopidogrel platelet function inhibitors were excluded. 96 patients were receiving clopidogrel maintenance treatment (75 mg/day for \geq 7 d); 5 received clopidogrel loading with 300- 600 mg.	Measurements with multiple assays and using different anti-coagulants to assess agreement	101 patients	concordance between PFA P2Y (3.2% citrate) and %inhibition = 71% concordance between PFA P2Y (3.2% citrate) and P2Y12 PRU = 74% concordance between PFA P2Y (3.2% citrate) and whole- blood aggregometry (5 μ mol/L) = 64% concordance between PFA P2Y (3.2% citrate) and whole- blood aggregometry (10 μ mol/L) = 65% concordance between PFA P2Y (3.2% citrate) and LTA = 69%

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
		Whole blood aggregometry (ADP 5 and 10 $\mu\text{mol/L}$) [ChronoLog 700 aggregometer, Chrono-Log, Havertown, PA]					concordance between PFA P2Y (3.8% citrate) and VerifyNow P2Y12 %inhibition = 72% concordance between PFA P2Y (3.8% citrate) and P2Y12 PRU = 62% concordance between PFA P2Y (3.8% citrate) and whole- blood aggregometry (5 $\mu\text{mol/L}$) = 90% concordance between PFA P2Y (3.8% citrate) and whole- blood aggregometry (10 $\mu\text{mol/L}$) = 90% concordance between PFA P2Y (3.8% citrate) and LTA = 76% concordance between VerifyNow P2Y12 %inhibition and whole-blood aggregometry (5 $\mu\text{mol/L}$) = 68% concordance between VerifyNow P2Y12 %inhibition and whole-blood aggregometry (10 $\mu\text{mol/L}$) = 67% concordance between VerifyNow P2Y12 %inhibition and LTA = 72% concordance between VerifyNow P2Y12 PRU and whole-blood aggregometry (5

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>μmol/L) = 60%</p> <p>concordance between VerifyNow P2Y12 PRU and whole-blood aggregometry (10 μmol/L) = 59%</p> <p>concordance between VerifyNow P2Y12 PRU and LTA = 69%</p>
Park 2012 Korea 21942752	Consecutive patients admitted to a single academic cardiology department to undergo non-emergent PCI	<p>LTA (ADP 5 and 20 μM and ADP 5 μM + 5 nM PGE1) [AggRAM aggregometer, Helena Laboratories Corp., Beaumont, TX]</p> <p>Impedance aggregometry (ADPtest 6.4 μM ADP and high- sensitivity ADPtest 6.4 μM ADP + 9.4 nM PGE1) [Multiplate analyzer, Dynabyte, Munich, Germany]</p>	Blood samples were obtained from the arterial sheath at the catheterization laboratory (pre-PCI)	Patients were pre-treated with aspirin (100 mg/d) and clopidogrel (75 mg/d) for ≥ 5 d pre-PCI or received loading doses of aspirin (300 mg) and clopidogrel (600 mg); patients receiving IIb/IIIa inhibitors were excluded	Testing of samples with two assays, and different agonists/ agonist concentrations, to assess agreement	246 patients	<p>Cut-offs for the assessment of agreement and analytic performance (summarized below) were obtained using ROC analysis with the ADPtest treated as the reference standard; cut-offs were chosen to maximize the sum of analytic sensitivity and specificity.</p> <p><i>Analytic performance for high on-clopidogrel reactivity</i></p> <p>Analytic performance of LTA maximal platelet reactivity (5 μM ADP) AUC = 0.836, 95% CI: 0.777, 0.896; P<0.001. At the cut-off of ≥46%, analytic sensitivity = 70.6% and analytic specificity = 89.3%</p> <p>Analytic performance of LTA maximal platelet reactivity (20 μM ADP) AUC = 0.846, 95% CI: 0.785, 0.908; P<0.001. At the cut-off of ≥59%, analytic sensitivity = 75.0% and analytic specificity = 88.2%</p> <p><i>Agreement for high on-</i></p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p><i>clopidogrel reactivity</i></p> <p>Agreement between ADPtest (≥ 47 U), and LTA maximal platelet aggregation (5 μM ADP) $\geq 46\%$: kappa = 0.537; $P < 0.001$ and concordance = 80.5%</p> <p>Agreement between ADPtest (≥ 47 U) and LTA maximal platelet aggregation (20 mM ADP) $\geq 59\%$: kappa = 0.564; $P < 0.001$ and concordance = 81.7%</p> <p><i>Analytic performance for low on-clopidogrel reactivity</i></p> <p>Analytic performance of LTA maximal platelet reactivity (5 μM ADP) AUC = 0.714, 95% CI: 0.618, 0.809; $P < 0.001$. At the cut-off of $\leq 26.6\%$, analytic sensitivity = 64.0% and analytic specificity = 76.2%</p> <p>Analytic performance of LTA maximal platelet reactivity (20 μM ADP) AUC = 0.796, 95% CI: 0.714, 0.879; $P < 0.001$. At the cut-off of $\leq 35.3\%$, analytic sensitivity = 64.0% and analytic specificity = 88.9%</p> <p><i>Agreement for low on-clopidogrel reactivity</i></p> <p>Agreement between ADPtest (≤ 19 U), and LTA maximal</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>platelet aggregation (5 μM ADP) \leq26.6%: kappa = 0.152; P<0.001 and concordance = 65.0%</p> <p>Agreement between ADPtest (\leq19 U) and LTA maximal platelet aggregation (20 μM ADP) \leq35.3: kappa = 0.152; P<0.001 and concordance = 65.0%</p>
							<p>Bland-Altman analysis</p> <p>Agreement between LTA maximal platelet aggregation (ADP 5 μM) and ADPtest: difference = -3.0; SD of difference = 17.6; 95% limits of agreement = -37.4 to 31.4</p> <p>Agreement between LTA final platelet aggregation (ADP 5 μM) and ADPtest: difference = -14.9; SD of difference = 19.2; 95% limits of agreement = -52.5 to 22.6</p> <p>Agreement between LTA maximal platelet aggregation (ADP 5 μM + PGE1) and ADPtest: difference = -9.4; SD of difference = 16.0; 95% limits of agreement = -40.8 to 21.9</p> <p>Agreement between LTA final platelet aggregation (ADP 5 μM + PGE1) and ADPtest: difference = -18.5; SD of difference = 17.4; 95% limits of</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>agreement = -52.7 to 15.6</p> <p>Agreement between LTA maximal platelet reactivity (20 μM) and ADPtest: difference = 5.4; SD of difference = 18.8; 95% limits of agreement = -31.5 to 42.3</p> <p>Agreement between LTA final platelet reactivity (20 μM) and ADPtest: difference = -7.3; SD of difference = 22.4; 95% limits of agreement = -51.2 to 36.6</p> <p>Agreement between ADPtest HS and ADPtest: difference = -15.3; SD of difference = 11.4; 95% limits of agreement = -37.6 to 7.0</p> <p>Agreement between LTA maximal platelet reactivity (5 μM) and ADPtest HS: difference = 12.3; SD of difference = 18.4; 95% limits of agreement = -23.8 to 48.3</p> <p>Agreement between LTA final platelet reactivity (5 μM) and ADPtest HS: difference = 0.3; SD of difference = 20.1; 95% limits of agreement = -39.1 to 39.8</p> <p>Agreement between LTA maximal platelet reactivity (5 μM + PGE1) and ADPtest HS: difference = 5.9; SD of difference = 16.5; 95% limits of agreement = -26.4 to 38.1</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>Agreement between LTA final platelet reactivity (5 μM + PGE1) and ADPtest HS: difference = -3.2; SD of difference = 17.4; 95% limits of agreement = -37.3 to 30.8</p> <p>Agreement between LTA maximal platelet reactivity (20 μM) and ADPtest HS: difference = 20.7; SD of difference = 20.1; 95% limits of agreement = -18.8 to 60.2</p> <p>Agreement between LTA final platelet reactivity (20 μM) and ADPtest HS: difference = 8.0; SD of difference = 24.5; 95% limits of agreement = -40.1 to 56.1</p>
Zhang 2012 Korea 22774770	Patients with CAD undergoing PCI in a single center	<p>LTA (ADP 10 μM) [additional information NR]</p> <p>Impedance aggregometry (ADP, 6.4 μM, sample anticoagulated with hirudin or citrate) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>	Blood samples were obtained from the arterial sheath at the catheterization laboratory (pre-PCI) and then 24-36 h post PCI	Patients were on clopidogrel maintenance treatment (75 mg/d for \geq 5 d) or received clopidogrel loading (300 or 600 mg) \geq 4 h pre-PCI; all patients were on aspirin maintenance treatment (100mg/d) or receive aspirin loading (300 mg) \geq 4 h pre-PCI; patients receiving IIb/IIIa inhibitors were excluded	Measurement of samples with three assays to assess analytic performance at 2 timepoints (at PCI and post-PCI); assessments performed with samples treated with different anti-coagulants (pre-analytically)	119 patients	<p><i>Using LTA as the reference standard and citrate anticoagulated samples at PCI</i></p> <p>Analytic sensitivity = 68.6% Analytic specificity = 56.1% AUC = 0.71 (95% CI 0.62, 0.79)</p> <p><i>Using LTA as the reference standard and hirudin anticoagulated samples at PCI</i></p> <p>Analytic sensitivity = 86.5% Analytic specificity = 71.8% AUC = 0.72 (95% CI 0.63, 0.80)</p> <p><i>Using LTA as the reference</i></p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<i>standard and citrate anticoagulated samples post-PCI</i> Analytic sensitivity = 64.0% Analytic specificity = 80.7% AUC = 0.75 (95% CI 0.66, 0.83)
							<i>Using LTA as the reference standard and hirudin anticoagulated samples post-PCI</i> Analytic sensitivity = 64.0% Analytic specificity = 80.7% AUC = 0.77 (95% CI 0.68, 0.85)
							<i>Using VerifyNow as the reference standard and citrate anticoagulated samples at PCI</i> Analytic sensitivity = 56.8% Analytic specificity = 87.5% AUC = 0.74 (0.65–0.82)
							<i>Using VerifyNow as the reference standard and hirudin anticoagulated samples at PCI</i> Analytic sensitivity = 72.6% Analytic specificity = 66.7% AUC = 0.69 (95% CI 0.60, 0.78)
							<i>Using VerifyNow as the reference standard and citrate anticoagulated samples post-PCI</i>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p>Analytic sensitivity = 60.0% Analytic specificity = 92.7% AUC = 0.79 (95% CI 0.71, 0.87)</p> <p><i>Using VerifyNow as the reference standard and hirudin anticoagulated samples post-PCI</i></p> <p>Analytic sensitivity = 58.0% Analytic specificity = 80.5% AUC = 0.74 (95% CI 0.65, 0.82)</p>
Tsantes 2012 Greece 22646492	Consecutive patients with coronary angiography-documented CAD, hospitalized after ACS, undergoing elective coronary angiography at a single cardiology department	<p>LTA (ADP 10 μM) [Biodata-PAP-4 aggregometer, Bio/Data Corporation, Horsham, PA]</p> <p>High shear platelet function (PFA-100 ADP/PGE1 cartridges) [INNOVANCE PFA P2Y, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany]</p> <p>Impedance aggregometry (ADP 6.5 μM) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p>	Blood samples were obtained 1-24 h after the last dose of antithrombotic medication	Patients were on clopidogrel maintenance therapy (75 mg/d for >5 d) in combination with aspirin (100 mg/d)	Measurement of samples with two assays to assess agreement	90 patients [Note: data were also presented from analyses using the VASP assay; however this information did not meet the sample size requirement for our review; N<50]	<p><i>Based on cut-offs suggested by manufacturers</i></p> <p>Agreement between LTA and INNOVANCE PFA-100 P2Y: kappa = 0.31; SE = 0.08; P<0.05 [exact p-value not reported]; concordance = 74.4%</p> <p>Agreement between Multiplate analyzer and INNOVANCE PFA-100 P2Y: kappa = 0.37; SE = 0.09; P<0.05 [exact p-value not reported] concordance = 75.6%</p> <p>Agreement between Multiplate analyzer and LTA: kappa = 0.30; SE = 0.10; P<0.05 [exact p-value not reported] concordance = 85.6%</p> <p><i>Based on cut-offs associated with thrombotic risk (from</i></p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
							<p><i>previous publications)</i></p> <p>Agreement between LTA and INNOVANCE PFA-100 P2Y: kappa = 0.24; SE = 0.07; P<0.05 [exact p-value not reported] concordance = 72.2%</p> <p>Agreement between Multiplate analyzer and INNOVANCE PFA-100 P2Y: kappa = 0.20; SE = 0.06; P<0.05 [exact p-value not reported] concordance = 71.1%</p> <p>Agreement between Multiplate analyzer and LTA: kappa = 0.13; SE = 0.10; P=NS [p-value not reported] concordance = 90.0%</p>

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Liang 2012 Canada 22797934	Stable patients with established CAD on dual antiplatelet treatment; patients were participants in a factorial RCT designed to explore the possibility of an interaction between clopidogrel and aspirin treatment	LTA (ADP 5 μ mol/L) [Chrono-log aggregometer, Model 560-Ca] Impedance aggregometry (ADP 6.5 μ M) [Multiplate analyzer, Dynabyte Medical, Munich, Germany] VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [PLT VASP/P2Y12 assay, BioCytex, Marseille, France]; using flow cytometry [FACSCaliber Flow Cytometer, Becton-Dickinson, San Jose, CA]	Blood samples were collected 6 h post-loading on d 1 and 1 h post-treatment on d 7 and 14	Participants where on “regular” dual antiplatelet treatment; they were randomized to clopidogrel 600 mg loading followed by 150 mg/d for 1 wk and 75 mg/d thereafter, or to clopidogrel 300 mg loading followed by 75 mg/d, and were also randomized to aspirin 325 mg/d or 81 mg/d (2x2 factorial design); all treatments were continued for 2 wk	Measurements with 3 assays to assess concordance (ICC)	82 patients measured at measured at 6 h post-loading on d 1 and 1 h post-treatment on d 7 and 14	6 h post-loading on day 1 ICC between VASP-PRI and LTA = 0.6446 ICC between VASP-PRI and Multiplate = 0.4720 ICC between LTA and MEA = 0.4693
							1 h post-treatment, d 7 ICC between VASP-PRI and LTA = 0.5570 ICC between VASP-PRI and Multiplate = 0.4212 ICC between LTA and MEA = 0.5041
							1 h post-treatment, d 14 ICC between VASP-PRI and LTA = 0.4724 ICC between VASP-PRI and Multiplate = 0.3965 ICC between LTA and MEA = 0.5022 No significant difference between each pair of ICCs on any day
Jang 2012 Korea 22811359	Patients undergoing PCI at a single cardiology center	High shear platelet function (PFA-100 ADP/PGE1 cartridges) [INNOVANCE PFA P2Y, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Blood samples were collected at 48 h post clopidogrel loading	Patients were preliminarily treated with aspirin (100 mg/d), followed by co-administration of clopidogrel (loading dose, 600 mg; maintenance dose, 75 mg/d)	Measurement of samples with two assays to assess agreement	255 patients	Agreement between INNOVANCE PFA P2Y and VerifyNow %inhibition: kappa = 0.52; % concordance = 85% Agreement between INNOVANCE PFA P2Y and VerifyNow PRU: kappa = 0.44; % concordance = 79%

Author Year Country PMID	Patient population	Assays evaluated (agonist) [brand name, manufacturer]	Test timing	Treatment preceding testing	Study design for the assessment of analytic validity	Sample size (measurements performed and included in analyses)	Results
Park 2011 S. Korea 21880289	Patients undergoing PCI with stent implantation for native coronary artery stenosis	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	"After clopidogrel therapy"	Patients taking clopidogrel for >7 days underwent PCI without loading doses. Loading doses of clopidogrel (300 mg) were administered in patients who had been taking clopidogrel for <7 days. Patients who were expected to undergo PCI in <6 hours were given loading doses of 600 mg. Dual-antiplatelet therapy (aspirin 100 mg/day and clopidogrel 75 mg/day) was continued for ≥6 months post-PCI.	Measurement of samples with one assay and assessment of agreement between different measures of reactivity	809 patients	Agreement between P2Y12 %inhibition (cut-off 5%) and P2Y12 PRU (cut-off 275 PRU): concordant positive, 126; concordant negative, 493; positive by PRU but not %inhibition, 121; positive by %inhibition but not PRU, 69. Kappa= 0.412 (95% CI 0.343, 0.481) [calculated value]

*The two tests report results in different units; thus Bland-Altman analysis is not strictly valid.

†The interpretation of “bias” (or limits of agreement) from the Bland-Altman test is not straightforward in the presence of heteroscedasticity.

‡The trial was described as “randomized,” however it appears to have been a alternate allocation design (often called, “pseudo-randomized” or “quasi-randomized” design).

§The paper also reported on a cohort of patients receiving aspirin alone. We only extracted data from patients on clopidogrel.

Abbreviations: ACS = acute coronary syndrome; ADP = adenosine diphosphate; CI = confidence interval; d = days; h = hour; ICC = intra-class correlation coefficient; LMWH = low molecular weight heparin; LTA = light transmittance aggregometry; MI = myocardial infarction; mo = month; MPA = maximal platelet aggregation; NPV = negative predictive value; NS = non-significant; NSTE = non-ST elevation; PCI = percutaneous coronary intervention; PGE1 = prostaglandin E1; PMID = PubMed identification number; PPV = positive predictive value; PRI = platelet reactivity index; PRU = platelet reactivity units; RPA = residual platelet aggregation; UA = unstable angina; UFH = unfractionated heparin; VASP = vasodilator-stimulated phosphoprotein. Percentages may not sum to 100% because of rounding.

Appendix Table E2. Studies reporting correlation results between alternative platelet reactivity assays

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Cuisset 2009 France 19761935	LTA (ADP 10 µmol/L) [PAP4, Biodata Corporation, Wellcome, Paris, France] VASP phosphorylation assay (PGE1 ± ADP 10 µmol/L) [Platelet VASP, Diagnostica Stago [Biocytex], Asnieres, France]; using flow cytometry [Beckman Coultronics, Margency, France]	104 patients measured with both assays	Correlation of maximal intensity of aggregation (PAP4) with VASP PRI (flow cytometry) = 0.55; P < 0.01
Michelson 2009 USA 19435740	VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [BioCytex, Marseilles, France]; using flow cytometry [FACSCalibur, Becton Dickinson, San Jose, California] LTA (ADP 5 µmol/L and 20 µmol/L) [not reported]	125 using the VASP assay; of these 31 were also evaluated with LTA (both ADP concentrations). Measurements at baseline, 1-2 h post PCI, and 30 days (clopidogrel and prasugrel treated subjects) were analyzed together and observations were treated as independent.	Spearman rho between VASP assay and MPA (ADP 20 µmol/L)= 0.724; P<0.001 Spearman rho between VASP assay and MPA (ADP 5 µmol/L)= 0.655; P<0.001
Antonino 2009 USA 19463513	LTA (ADP 5 µmol/L and 20 µmol/L) [Chronolog Lumi-Aggregometer 490-4D, CHRONO-LOG Corporation, Havertown, Pennsylvania] Surface expression of P-selectin (ADP, 5µmol/L) Using flow cytometry [Immunocytometry Systems, Becton Dickinson and Company, Franklin Lakes, New Jersey] Surface expression of activated IIb/IIIa receptors (ADP, concentration NR) Using flow cytometry [Immunocytometry Systems, Becton Dickinson and Company, Franklin Lakes, New Jersey]	110 patients measured for aggregation with both ADP concentrations and for platelet marker expression in response to ADP using flow cytometry	Spearman rho between platelet aggregation using 5 and 20 µmol/L ADP= 0.866; P<0.001 Spearman rho between platelet aggregation using 20 µmol/L ADP and ADP-induced P-selectin expression = 0.296; P=0.04 Spearman rho between platelet aggregation using 20 µmol/L ADP and ADP-induced activated IIb/IIIa receptor expression = 0.428; P<0.001

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Paniccia 2009 Italy 19461090	<p>Impedance aggregometry (ADP, 10 μmol/L) [Multiplate analyzer, Dynabyte, Munich, Germany]</p> <p>LTA (ADP, 10 μmol/L) [APACT-4004 aggregometer, LABiTec, Ahrensburg, Germany]</p> <p>High shear platelet function (collagen/ADP) [PFA-100, Dade-Behring, Marburg, Germany]</p>	<p>Multiplate analyzer and LTA (ADP as agonist): 297</p> <p>Multiplate analyzer and PFA-100 (ADP as agonist): 111</p> <p>PFA-100 and LTA (ADP as agonist): 111</p>	<p>Spearman rho between the Multiplate analyzer and LTA (ADP as agonist) = 0.73; $P < 0.001$</p> <p>Spearman rho between the Multiplate analyzer and PFA-100 (ADP as agonist) = -0.40; $P < 0.001$</p> <p>Spearman rho between the PFA-100 and LTA (ADP as agonist) = -0.51; $P < 0.001$</p>
Frere 2008 France 18394438	<p>LTA (ADP 10 μmol/L) [PAP4, Biodata Corporation, Wellcome, Paris, France]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, 10μg/L) [Biocytex, Asnieres, France]; using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France]</p> <p>Surface expression of P-selectin (ADP 10μM/L) Using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France]</p>	603 patients for PAP4; 455 measurements for PRI-VASP, and 600 for ADP-stimulated P-selectin expression	<p>Pearson correlation between LTA (PAP4) and VASP assay (PRI) = 0.62; $P < 0.001$</p> <p>Pearson correlation between VASP assay (PRI) and ADP-induced P-selectin expression = 0.52; $P < 0.001$</p> <p>Pearson correlation between LTA (PAP4) and ADP-induced P-selectin expression = 0.36; $P < 0.001$</p>
Marcucci 2007 Italy 17938810	<p>LTA (ADP, 2 and 10 μM) [APACT 4 aggregometer, Helena Laboratories Italia s.p.a., Milan, Italy]</p>	367 subjects measured with two agonist concentrations	<p>Correlation between maximal and late aggregation with ADP 2 μM = 0.96; $P < 0.001$</p> <p>Correlation between maximal and late aggregation with ADP 10 μM = 0.95; $P < 0.001$</p>
Frere 2007 France 17938809	<p>LTA (ADP 10 μM) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP, Diagnostica Stago (BioCytex), Asnieres, France]; using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France]</p>	195 patients measured with both assays	Pearson correlation between LTA and VASP phosphorylation assay = 0.61; $P < 0.001$

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Cuisset 2007 France 17337040	<p>LTA (ADP 10 µmol/L) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France]</p> <p>VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP, Diagnostica Stago (BioCytex), Asnieres, France]; using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France]</p> <p>Surface expression of P-selectin (ADP 10 µmol/mL final concentration) Using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France]</p>	597 patients measured with LTA and flow cytometry for P-selectin expression; 454 of those patients were also measured the VASP phosphorylation assay	<p>Correlation between LTA and VASP phosphorylation assay = 0.64; P<0.001</p> <p>Correlation between P-selectin expression and LTA = 0.50; P<0.001</p> <p>Correlation between P-selectin expression and VASP phosphorylation assay = 0.58; P<0.001</p>
Paniccia 2007 Italy 17723123	<p>LTA (ADP, 2 µmol/L and 10 µmol/L) [APACT-4 aggregometer, LABiTec, Ahrensburg, Germany]</p> <p>High shear platelet function (collagen/ADP) [PFA-100, Dade-Behring, Marburg, Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p> <p>VASP phosphorylation assay (PGE1 ± ADP; for ADP, the final concentration was 10 µmol/L) [Platelet VASP, Diagnostica Stago (BioCytex), Marseille, France]; using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France]</p>	1267 patients measured with LTA (ADP 2 µmol/L and 10 µmol/L) and VerifyNow (P2Y12 assay); 626 patients measured with PFA-100 (collagen/ADP cartridge); 115 patients measured with VASP phosphorylation assay	<p>Spearman correlation between LTA (ADP 2 µmol/L) and PFA-100 collagen/ADP cartridge) = -0.07; P = NS</p> <p>Spearman correlation between LTA (ADP 10 µmol/L) and PFA-100 collagen/ADP cartridge) = -0.11; P < 0.01</p> <p>Spearman correlation between LTA (ADP 2 µmol/L) and VerifyNow (P2Y12 assay) = 0.62; P < 0.0001</p> <p>Spearman correlation between LTA (ADP 10 µmol/L) and VerifyNow (P2Y12 assay) = 0.64; P < 0.0001</p> <p>Spearman correlation between VerifyNow (P2Y12 assay) and PFA-100 (collagen/ADP cartridge) = -0.09; P < 0.05</p> <p>Spearman correlation between LTA (ADP 2 µmol/L) and VASP phosphorylation assay = 0.47; P < 0.001</p> <p>Spearman correlation between LTA (ADP 10 µmol/L) and VASP phosphorylation assay = 0.50; P < 0.0001</p> <p>Spearman correlation between VerifyNow (P2Y12 assay; PRU units) and VASP phosphorylation assay = 0.52; P < 0.001</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Bliden 2007 USA 17291930	LTA (ADP 10 µmol/L) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France] TEG (ADP 2µmol) [Thromboelastograph Hemostasis Analyzer with Platelet Mapping, Haemoscope Corp., Niles, Illinois]	100 patients measured with both tests	Pearson correlation between LTA and TEG = 0.82; P<0.0001
Cuisset 2007 France 17264949	LTA (ADP 10 µM) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France] VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP, Diagnostica Stago (BioCytex), Asnieres, France]; using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France] Surface expression of P-selectin (ADP 10 µM final concentration) Using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France]	LTA results were available for 601 patients; VASP phosphorylation assay results were available for 454 patients; P-selectin expression results were available from 599 patients	Correlation between LTA and VASP phosphorylation = 0.64; P<0.001 Correlation between ADP-induced P-selectin expression and LTA = 0.50; P<0.001 Correlation between ADP-induced P-selectin expression and VASP phosphorylation = 0.58; P<0.001
Van Werkum 2006 Netherlands 16938130	LTA (ADP, 20 µmol/L) [NR] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	211 patients	Linear regression of LTA “peak aggregation” versus VerifyNow PRU: Y = 0.1289*X + 37.551 R = 0.73; P<0.01 Linear regression of LTA “late aggregation” versus VerifyNow PRU: Y = 0.2386*X – 8.5151 R = 0.75; P<0.01

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Gurbel 2005 USA 16286166	LTA (ADP 5 µmol/L and 20 µmol/L) [Chronolog Aggregometer model 490, Havertown, Pennsylvania] Surface expression of activated IIb/IIIa receptors (ADP, 5 µmol/L) Using flow cytometry [FACScan flow cytometer, Becton Dickinson] VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP-FCM kit, Biocytex Inc., Marseille, France]; using flow cytometry [additional details NR]	120 patients	Pearson correlation between LTA assays (ADP 5 µmol/L and 20 µmol/L) = 0.93; P = NR Pearson correlation between VASP phosphorylation assay and LTA (ADP 20 µmol/L) = 0.57; P=0.019 Pearson correlation between ADP-stimulated IIb/IIIa receptor expression and LTA (ADP 20 µmol/L) = 0.29; P=0.23
Mobley 2004 USA 14969622	Optical platelet aggregometry (ADP, 1 µM) [Dual Channel Aggregometer; Chrono-Log Corp., Havertown, PA] TEG (ADP, 1 µM) [Thromboelastograph assay, Hemoscope, additional details NR] PlateletWorks (ADP, 1 µM) [PlateletWorks assay, Ichor, additional details NR]	50 patients measured with all 3 assays	Correlation between optical platelet aggregometry and TEG; P<0.0003 Correlation between optical platelet aggregometry and PlateletWorks; P=0.05
Muller 2003 Germany 12719773	Optical aggregometry (ADP 5 and 20 µmol/L) [additional details NR]	105 patients	Correlation between optical aggregometry using 5 and 20 µmol/L ADP = 0.820; P<0.001
Bliden 2011 International (USA and UK) 21742103	LTA (ADP 20 µM) [Chronolog Aggregometer model 490-4D, Havertown, PA] Platelet agglutination assay (ADP cartridges) [NR] VASP phosphorylation assay (PGE1 ± ADP, concentration NR) [Platelet VASP-FCM kit, Biocytex Inc., Marseille, France]; using flow cytometry [additional details NR]	103 patients on clopidogrel and 106 on ticagrelor; platelet function was evaluable in 201 patients measured with the 3 assays	Pearson correlation between LTA and VerifyNow, for patients on clopidogrel = 0.6644; P<0.001 Pearson correlation between LTA and VASP phosphorylation, for patients on clopidogrel = 0.4304; P<0.001 Pearson correlation between LTA and VerifyNow, for patients on ticagrelor = 0.7753; P<0.001 Pearson correlation between LTA and VASP phosphorylation, for patients on ticagrelor = 0.6356; P<0.001

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Godino 2009 Italy 19419580	ADP-stimulated IIb/IIIa receptor AND P-selectin expression (considered jointly as the reference standard) (ADP, 20 µM) Using flow cytometry [FC500; Beckman Coulter, S.p.A., Cassina De' Pecchi, Milan, Italy] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	52 patients measured both for ADP-stimulated IIb/IIIa receptor and P-selectin expression and using the VerifyNow assay	Spearman correlation between ADP-stimulated P-selectin expression and VerifyNow (% inhibition) = -0.67 (95% CI - 0.82, -0.41); P<0.0001 Spearman correlation between ADP-stimulated IIb/IIIa receptor expression and VerifyNow (% inhibition) = -0.49 (95% CI -0.67, -0.24); P<0.002
Collet 2008 France 18765393	LTA (ADP 5, 10, 20 and 50 µmol/L) [Chronolog Aggregometer model 490-4D, Chrono-Log Corp., Kordia, Netherlands] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	166 patients measured at different timepoints (some patients did not have measurements available at all time points)	Spearman correlation between LTA and VerifyNow at 4 h post clopidogrel = 0.73; P<0.0001 Spearman correlation between LTA and VerifyNow at 24 h post clopidogrel = 0.83; P<0.0001
Lau 2002 USA 17890800	LTA (ADP 5, 10, 20 and 50 µmol/L) [Chronolog platelet aggregometer model 490-4D, Chronolog Corporation, Haverton, PA] Plateletworks (ADP, 1 µM) [PlateletWorks assay, ICHOR hematology analyzer, Array Medical, Somerville, NJ]	225 measurements using ADP as the agonist [the measurements used in these analyses were performed across different patients populations; it was not clear if all patients received clopidogrel; a minority of measurements (<20%) were performed on populations that did not meet our eligibility criteria]	Pearson correlation between Plateletworks and LTA (ADP) = 0.82; P<0.01 (225 samples) Spearman correlation between Plateletworks and LTA (ADP) = 0.80; P<0.01 (225 samples)
Campo 2010 International (Italy and Spain) 20951320	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	840 patients represented the “final patient population”; 468 were screened for clopidogrel response	Correlation between % platelet inhibition and PRU measurements from the VerifyNow assay = -0.86 [note: the correlation in the paper is reported as -86, which is an impossible value; based on Figure 2 of the paper -0.86 appears to be the correct value]

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Gurbel 2010 USA 19817997	<p>LTA (ADP 5 µmol/L, 10 µmol/L and 20 µmol/L) [Chronolog Aggregometer model 490-4D, Havertown, PA]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p> <p>TEG (ADP, concentration not reported) [Thromboelastograph assay, Haemoscope Corporation, Niles, IL]</p> <p>VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP-FCM kit, Diagnostic Stago (Biocytex), Asnieres, France]; using flow cytometry [additional details NR]</p>	20 patients on clopidogrel therapy who received a single dose of elinogrel (and were then continued on clopidogrel therapy) underwent multiple measurements over time (6 time points), with multiple assays. In correlation analyses repeat measurements were considered as independent observations.	<p>Correlation between LTA (ADP 5 µM, maximum platelet aggregation) with LTA (ADP 5 µM, final platelet aggregation) = 0.863; P<0.0001</p> <p>Correlation between LTA (ADP 5 µM, maximum platelet aggregation) with LTA (ADP 10 µM, maximum platelet aggregation) = 0.736; P<0.0001</p> <p>Correlation between LTA (ADP 5 µM, maximum platelet aggregation) with LTA (ADP 20 µM, maximum platelet aggregation) = 0.892; P<0.0001</p> <p>Correlation between LTA (ADP 5 µM, maximum platelet aggregation) with VerifyNow = 0.720; P<0.0001</p> <p>Correlation between LTA (ADP 5 µM, maximum platelet aggregation) with VASP assay = 0.601; P<0.0001</p> <p>Correlation between LTA (ADP 5 µM, maximum platelet aggregation) with TEG assay = 0.470; P<0.0001</p>
Gori 2008 Italy 19132241	<p>LTA (ADP, 10 µmol/L) [APACT-4, Helena Laboratories, Italy]</p> <p>High shear platelet function (collagen/ADP) [PFA-100, Dade-Behring, Marburg, Germany]</p>	746 patients were assessed with LTA using ADP as the agonist; 398 were assessed with PFA-100 using collagen/ADP as the agonist	Correlation between PFA-100 (collagen/ADP) and LTA (ADP) = -0.28; P<0.001 [results on 398 patients with measurements available on both assays]

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Paniccia 2011 Italy 21192314	LTA (ADP, 2 µmol/L, 5 µmol/L, 10 µmol/L, and 20 µmol/L) [APACT-4004 aggregometer, LABiTec, Ahrensburg, Germany] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	5 samples from each of 10 patients of the assessment of reliability; samples from 466 patients for the assessment of agreement [data from 46 healthy individuals (~9% of the total population) were also included in the assessment of agreement]	Spearman correlation between LTA using ADP 2 µmol and 5 µmol = 0.89; P < 0.0001 Spearman correlation between LTA using ADP 2 µmol and 10 µmol = 0.90; P < 0.0001 Spearman correlation between LTA using ADP 2 µmol and 20 µmol = 0.90; P < 0.0001 Spearman correlation between LTA using ADP 5 µmol and 10 µmol = 0.88; P < 0.0001 Spearman correlation between LTA using ADP 5 µmol and 20 µmol = 0.88; P < 0.0001 Spearman correlation between LTA using ADP 10 µmol and 20 µmol = 0.98; P < 0.0001
Wenaweser 2010 Switzerland 20664903	LTA (ADP, 5 µmol and 20 µmol) [APACT, Endotell AG, Allschwil, Switzerland] Impedance aggregometry (multiple electrode) (ADP, 2 µM) [Multiplate analyzer, Dynabyte, Munich, Germany]	77 patients measured with both assays and different concentrations of agonists at 2 timepoints (both under clopidogrel therapy)	Pearson correlation between LTA using ADP 5µmol and 20 µmol = 0.892 at the first timepoint Pearson correlation between LTA using ADP 5µmol and 20 µmol = 0.933 at the second timepoint Pearson correlation between LTA (ADP 20 µmol) and Multiplate analyzer (AUC) = 0.563 at the first timepoint Pearson correlation between LTA (ADP 20 µmol) and Multiplate analyzer (AUC) = 0.0.456 at the second timepoint
Paniccia 2010 Italy 20458439	LTA (ADP, 10 µM) [APACT-4004 aggregometer, LABiTec, Ahrensburg, Germany] Impedance aggregometry (ADP, 10 µM final concentration) [Multiplate analyzer, Dynabyte, Munich, Germany] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Samples from 801 patients measured by 3 assays	Spearman correlation between Multiplate analyzer and LTA = 0.71, P < 0.0001 Spearman correlation between Multiplate analyzer and VerifyNow = 0.62; P< 0.0001 Spearman correlation between VerifyNow and LTA = 0.70; P < 0.0001

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Ko 2011 Korea 21315223	<p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, additional details not reported]</p> <p>Impedance aggregometry (ADP, concentration not reported) [Multiplate analyzer, Dynabyte, additional details not reported]</p>	Samples from 222 patients measured with both assays	Spearman correlation between VerifyNow PRU and Multiplate analyzer units = 0.390 (P < 0.001)
Gremmel 2010 Austria 20729752	<p>LTA (ADP 10 µM) [LABiTec, Ahrensburg, Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p> <p>VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP, Diagnostic Stago (Biocytex), Marseille, France]; using flow cytometry [FACSCalibur system, Becton Dickinson Biosciences, Vienna, Austria]</p> <p>Impedance aggregometry (multiple electrode) (ADP, 6.4 µM) [Multiplate analyzer, Dynabyte, Munich, Germany]</p> <p>Impact-R (ADP 1.36 M) [DiaMed, Cressier, Switzerland]</p>	Samples from 230 patients measured with 5 assays	<p>Spearman correlation between LTA and VerifyNow = 0.67</p> <p>Spearman correlation between LTA and VASP assay = 0.38</p> <p>Spearman correlation between LTA and Multiplate analyzer = 0.45</p> <p>Spearman correlation between LTA and Impact-R = -0.34</p> <p>Spearman correlation between VerifyNow and VASP assay = 0.38</p> <p>Spearman correlation between VerifyNow and Multiplate analyzer = 0.33</p> <p>Spearman correlation between VerifyNow and Impact-R = -0.5</p> <p>Spearman correlation between VASP assay and Multiplate analyzer = 0.32</p> <p>Spearman correlation between VASP assay and Impact-R = -0.23</p> <p>Spearman correlation between Multiplate analyzer and Impact-R = -0.26 [P-values NR]</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Aradi 2010 Hungary 20642320	<p>LTA (ADP 5 μM) [CARAT TX4 aggregometer, Carat Diagnostics, Budapest, Hungary]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP/P2Y12 kit, BioCytex, Marseille, France]; using flow cytometry [Beckman Coulter flow cytometer, no additional details reported]</p>	242 samples from 121 patients, all assessed with both assays	<p>Spearman correlation between maximal and late aggregation LTA measurements = 0.91 (P<0.001)</p> <p>Spearman correlation between maximal aggregation by LTA and PRI VASP measurements = 0.47 (P<0.001)</p> <p>Spearman correlation between late aggregation by LTA and PRI VASP measurements = 0.45 (P<0.001)</p> <p>Spearman correlation between disaggregation by LTA and PRI VASP measurements = -0.44 (P<0.001)</p> <p>Spearman correlation between LTA AUC of the light transmission curve and PRI VASP measurements = 0.50 (P<0.001)</p>
Woo 2010 Korea 20890076	<p>LTA (ADP, 10 μM) [Chronolog impedance aggregometer Series 590, Probe and Co., Endingen Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p> <p>Impedance aggregometry (ADP, 20 μM) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP/P2Y12 kit, BioCytex, Marseille, France]; using flow cytometry [no additional details reported]</p>	66 patients measured with 4 assays	<p>Spearman correlation coefficient between LTA and VerifyNow PRU = -0.5640; P<0.0001</p> <p>Spearman correlation coefficient between LTA and VerifyNow %inhibition = -0.5765; P<0.0001</p> <p>Spearman correlation coefficient between LTA and Multiplate analyzer = -0.3449; P=0.0046</p> <p>Spearman correlation coefficient between LTA and VASP PRI assay = -0.3650; P=0.0026</p>
Madsen 2010 Canada 20224050	<p>LTA (ADP, 5 μM) [Chrono-Log Lumi Aggregometer, model 810; Chrono-Log Corporation, no additional details provided]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, no additional details provided]</p>	33 patients, 26 of whom completed all study visits. Patients contributed samples at multiple timepoints and measurements were considered independent. The total number of measurements for each comparison was not reported; as such data are incomplete for the assessment of agreement. Number of measurements available for each comparison	<p>Authors reported that baseline values only reflected the effect of aspirin. Data were extracted for measurements on clopidogrel (1d to 12 mo). The number of measurements available for each comparison is reported in brackets.</p> <p>Spearman correlation coefficient between TEG ADP inhibition and TEG maximal amplitude = -0.92; P<0.001 [n=78]</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
	TEG (ADP, 2 µmol/L) [TEG Hemostasis Analyzer, Haemonetics Corporation, no additional details provided]	was variable (given in the next column)	<p>Spearman correlation coefficient between maximal aggregation by LTA and late aggregation by LTA = 0.88; P<0.001 [n=112]</p> <p>Spearman correlation coefficient between VerifyNow PRU and VerifyNow ADP inhibition = -0.83; P<0.001 [n=87]</p> <p>Spearman correlation coefficient between maximal aggregation by LTA and VerifyNow PRU = 0.66; P<0.001 [n=87]</p> <p>Spearman correlation coefficient between late aggregation by LTA and VerifyNow PRU = 0.64; P<0.001 [n=87]</p> <p>Spearman correlation coefficient between maximal aggregation by LTA and VerifyNow ADP inhibition = -0.53; P<0.001 [n=97]</p> <p>Spearman correlation coefficient between late aggregation by LTA and VerifyNow ADP inhibition = -0.51; P<0.001 [n=97]</p> <p>Spearman correlation coefficient between maximal aggregation by LTA and TEG ADP inhibition = -0.32; P=0.005 [n=79]</p> <p>Spearman correlation coefficient between late aggregation by LTA and TEG ADP inhibition = -0.30; P=0.01 [n=79]</p> <p>Spearman correlation coefficient between TEG ADP inhibition and VerifyNow PRU = -0.11; P=0.39 [n=68]</p> <p>Spearman correlation coefficient between TEG ADP inhibition and VerifyNow ADP inhibition = -0.01; P=0.95 [n=68]</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Siller-Matula 2010 Austria 19943879	VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP/P2Y12 kit, BioCytex, Marseille, France]; using flow cytometry [FACSCalibur System, BD Biosciences, Vienna, Austria] Impedance aggregometry (ADP, concentration not reported) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]	402 samples measured with both assays	Correlation between Multiplate analyzer and VASP assay = 0.34; P<0.001

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Bidet 2010 France 20148735	<p>LTA (ADP 10 μM) [PAP4 aggregometer, Bio/Data Corp., Welcome Laboratories, Paris, France]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP-FCM kit, Diagnostic Stago, Asnieres, France]; using flow cytometry [FC500, Beckman Coulter, Villepinte, France]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>	Samples from 100 patients measured with 3 methods	<p>Pearson correlation between results expressed as PRU and %inhibition using the VerifyNow assay = 0.63; P<0.001</p> <p>Pearson correlation between maximum platelet aggregation by LTA and VASP assay = 0.53</p> <p>Pearson correlation between maximum platelet aggregation by LTA and VerifyNow (% inhibition) = -0.63</p> <p>Pearson correlation between VASP assay and VerifyNow (% inhibition) = -0.77</p> <p>Pearson correlation between residual platelet aggregation by LTA and VASP assay = 0.59</p> <p>Pearson correlation between degree of disaggregation by LTA and VASP assay = -0.63</p> <p>Pearson correlation between residual platelet aggregation by LTA and VerifyNow (% inhibition) = -0.75</p> <p>Pearson correlation between degree of disaggregation by LTA and VerifyNow (% inhibition) = 0.77</p> <hr/> <p>Patients studied during the chronic period (after one month of treatment):</p> <p>Pearson correlation between maximum platelet aggregation by LTA and VASP assay = 0.72</p> <p>Pearson correlation between maximum platelet aggregation by LTA and VerifyNow (% inhibition) = -0.77</p> <p>Pearson correlation between VASP assay and VerifyNow (% inhibition) = -0.83</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Cuisset 2010 France 20142119	<p>LTA (ADP 10 µmol/L) [PAP4, Biodata Corporation, Wellcome, Paris, France]</p> <p>VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP-FCM kit, Diagnostic Stago (BioCytex), Asnieres, France]; using flow cytometry [no additional details reported]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>	70 patients with NSTEMI ACS measured with all assays	<p>Pearson correlation coefficient between platelet aggregation by LTA and PRI VASP = 0.55; P<0.0001</p> <p>Pearson correlation coefficient between platelet aggregation by LTA and VerifyNow PRU = 0.64; P<0.0001</p> <p>Pearson correlation coefficient between PRI VASP and VerifyNow PRU = 0.59; P< 0.0001</p>
Smit 2009 Netherlands 19200163	<p>Fe-induced platelet aggregation [samples were added to tubes containing 100 mg of steel wool (Haemoscan, Groningen, Netherlands)] and a platelet counter was used to assess platelet aggregation (against a control tube not containing iron).</p> <p>Plateletworks (ADP, 20 µM/L) [PlateletWorks, Helena Laboratories, Beaumont, TX]</p>	111 patients contributed samples for 3 assays; measurements with the Fe-based assay were performed in duplicate to assess reliability	<p>Duplicate measurements with the iron-based assay to assess reliability: correlation between measurements = 0.94; P<0.001.</p> <p>Correlation coefficient between the iron-based assay and Plateletworks = 0.834; P<0.001</p> <p>The authors stated that they calculated “a Spearman Rho correlation coefficient [...] using the Pearson product-moment correlation”. It is unclear which statistical procedure was used.</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Gremmel 2009 Austria 19190818	<p>LTA (ADP 10 μM) [APACT 4S Plus aggregometer, LABiTec, Ahrensburg, Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP kit, Diagnostica Stago, BioCytex, Marseille, France]; using flow cytometry [FACSCalibur system, Becton Dickinson, BD Biosciences, Vienna, Austria]</p> <p>Impedance aggregometry (ADP, 6.4 μM) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p> <p>Cone and plate analyzer (ADP 1.36 μM) [Impact-R test, DiaMed, Cressier, Switzerland]</p>	80 patients assessed with 5 assays	<p>Spearman correlation coefficient between LTA and VerifyNow = 0.61; P<0.001</p> <p>Spearman correlation coefficient between LTA and VASP PRI = 0.52; P<0.001</p> <p>Spearman correlation coefficient between LTA and Multiplate analyzer = 0.35; P=0.001</p> <p>Spearman correlation coefficient between LTA and Impact-R = 0.33; P=0.002</p>
Cuisset 2009 France 18499233	<p>LTA (ADP 10 μmol/L) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP, Diagnostica Stago (BioCytex), Asnieres, France]; using flow cytometry [EPICS XL-MCL, Beckman Coultronics, Margency, France]</p>	Samples from 635 patients were measured with LTA and 442 with VASP phosphorylation assay (i.e. 442 pairs of measurements were available for the correlation analysis).	Spearman correlation between LTA and VASP assay = 0.61; P<0.001
Thomson 2008 India 19276493	<p>LTA (ADP 2.5 and 10 μmol/L) [Chronolog aggregometer, Model 810 Aggro/Link, additional information NR]</p>	69 patients measured with two ADP concentrations: 63 samples were measured at 2.5 μ mol/L and 65 at 10 μ mol/L. Measurements were performed at 3 timepoints; at all timepoints patients had been exposed to clopidogrel	<p>Correlation between platelet aggregation measured with 2.5 and 10 μmol/L = 0.67 at baseline</p> <p>Correlation between platelet aggregation measured with 2.5 and 10 μmol/L = 0.55 at 2 h</p> <p>Correlation between platelet aggregation measured with 2.5 and 10 μmol/L = 0.74 at 24 h</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Gurbel 2008 USA 19012177	LTA (ADP 5 µM and 20 µM) [Chronolog Lumi-Aggregometer, Model 490-4D, Havertown, PA]	Samples from 297 patients were measured with both agonist concentrations	Pearson correlation between measurements using the two agonist concentrations = 0.87; P<0.0001
Schafer 2008 Germany 18841284	LTA (ADP 20 µM) [PAP-8, BioData, Horsham, PA] VASP phosphorylation assay (PGE1 ± ADP, 20 µM) [Platelet VASP Test kit, American Diagnostica, Pfungstadt, Germany]; using flow cytometry [FACSCalibur, Becton Dickinson, Heidelberg, Germany] Surface expression of P-selectin (ADP, 20 µM) Using flow cytometry [FACSCalibur, Becton Dickinson, Heidelberg, Germany]	Samples from 100 patients measured with 3 assays	Correlation* between VASP PRI and LTA = 0.44; P<0.0001 Correlation between P-selecting expression and PRI VASP = 0.31; P<0.0001 <hr/> Subgroup analysis by diabetes status Diabetic patients (n=30): correlation between VASP PRI and LTA = 0.52; P<0.0001 Non-diabetic patients (n=70): correlation between VASP PRI and LTA = 0.40; P<0.0001
Shenkman 2008 Israel 18155752	LTA (ADP, 5.5 µM) [PACKS-4 aggregometer, Helena Laboratories, Beaumont, TX] Impact-R (ADP 1.38 µM) [DiaMed, Cressier, Switzerland]	Samples from 114 patients were measured at baseline and post-treatment; correlation analyses were used to compare % maximal aggregation with change in maximal aggregation from baseline	Bivariate regression of maximal aggregation vs. change in maximal aggregation: $r^2 = 0.867$; P<0.0001. This value corresponds to a correlation of 0.931.

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Von Beckerath 2010 Germany 19823079	<p>LTA (ADP 5 μmol/L) [PAP 8 aggregometer, Molab, Berlin, Germany]</p> <p>Impedance aggregometry (ADP 6.4 μmol/L \pm PGE1 9.4 μmol/L) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, 20 μM) [Platelet VASP, Biocytex, Marseille, France]; using flow cytometry [no additional details provided]</p>	Samples from 60 patients measured with 4 assays (2 different agonist types were used for the Multiplate analyzer)	<p>Spearman correlation between LTA and Multiplate analyzer (ADP) = 0.47; P=NR</p> <p>Spearman correlation between LTA and Multiplate analyzer (ADP + PGE1) = 0.29; P=NR</p> <p>Spearman correlation between LTA and VerifyNow = 0.63; P<0.0001</p> <p>Spearman correlation between LTA and VASP assay = 0.49; P=0.0002</p> <p>Spearman correlation between Multiplate analyzer (ADP) and multiplate analyzer (ADP + PGE1) = 0.83; P<0.0001</p> <p>Spearman correlation between Multiplate analyzer (ADP) and VerifyNow = 0.47; P=0.0004</p> <p>Spearman correlation between Multiplate analyzer (ADP) and VASP assay = 0.35; P=0.0007</p> <p>Spearman correlation between Multiplate analyzer (ADP + PGE1) and VerifyNow = 0.81; P=NR</p> <p>Spearman correlation between Multiplate analyzer (ADP + PGE1) and VASP assay = 0.22; P=NR</p> <p>Spearman correlation between VerifyNow and VASP assay = 0.59; P<0.0001</p> <p>[Results were only extracted for measurements while patients were on clopidogrel]</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Gurbel 2009 International (USA and UK) 19923168	<p>LTA (ADP 5 μmol/L and 20 μmol/L) [Chronolog Optical Aggregometer model 490-4D, Chrono-log Corporation, Havertown, PA]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Biocytex Inc, Marseille, France]; using flow cytometry [additional details NR]</p> <p>ADP-stimulated surface expression of activated IIb/IIIa receptors (ADP, 5 μmol/L final concentration) Using flow cytometry [FACScan flow cytometer, Becton Dickinson]</p> <p>ADP-stimulated P-selectin expression (ADP, 5 μmol/L final concentration) Using flow cytometry [FACScan flow cytometer, Becton Dickinson]</p>	50 patients on clopidogrel	<p>Pearson correlation between inhibition of platelet aggregation with LTA ADP 20 μM (final extent) and LTA ADP 5 μM ADP (maximum) = 0.8805; P < 0.0001</p> <p>Pearson correlation between inhibition of platelet aggregation with LTA ADP 20 μM (final extent) and LTA ADP 5 μM ADP (final) = 0.9067; P < 0.0001</p> <p>Pearson correlation between inhibition of platelet aggregation with LTA ADP 20 μM (final extent) and LTA ADP 20 μM ADP (maximum) = 0.9396; P < 0.0001</p> <p>Pearson correlation between inhibition of platelet aggregation with LTA ADP 20 μM (final extent) and VASP PRI (%) = 0.3973; P < 0.0001</p> <p>Pearson correlation between inhibition of platelet aggregation with LTA ADP 20 μM (final extent) and Inhibition of stimulated P-selectin expression = 0.3586; P < 0.0001</p> <p>Pearson correlation between inhibition of platelet aggregation with LTA ADP 20 μM (final extent) and inhibition of stimulated IIb/IIIa receptor expression = 0.2934; P < 0.0001</p> <p>Pearson correlation between inhibition of platelet aggregation with LTA ADP 20 μM (final extent) and VerifyNow (% inhibition) = 0.7408; P < 0.0001</p> <p>Pearson correlation between inhibition of platelet aggregation with LTA ADP 20 μM (final extent) and VerifyNow (PRU units) = -0.5921; P < 0.0001</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Lordkipanidze 2009 Canada 19419755	LTA (ADP 5 and 20 μ M) [ChronoLog aggregometer 540 model, Havertown, PA]	120 patients contributed measurements	<p>Spearman correlation coefficient between late and peak aggregation by LTA ADP 5 μM = 0.853; P<0.0001</p> <p>Spearman correlation coefficient between late and peak aggregation by LTA ADP 20 μM = 0.912; P<0.0001</p> <p>Spearman correlation coefficient between absolute inhibition using late vs. peak aggregation by LTA ADP 5 μM = 0.848; P<0.0001</p> <p>Spearman correlation coefficient between absolute inhibition using late vs. peak aggregation by LTA ADP 20 μM = 0.799; P<0.0001</p> <p>Spearman correlation coefficient between relative inhibition using late vs. peak aggregation by LTA ADP 5 μM = 0.824; P<0.0001</p> <p>Spearman correlation coefficient between relative inhibition using late vs. peak aggregation by LTA ADP 20 μM = 0.857; P<0.0001</p>
Voisin 2011 France 21544318	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	93 patients tested at two timepoints (24-48h and 5-7 w post-PCI) to assess the correlation between different measurements produced by the same assay	<p>Spearman correlation between PRU and %inhibition at 24-48 h post-PCI = -0.93; P < 0.0001</p> <p>Spearman correlation between PRU and %inhibition at 5-7 w post-PCI = -0.86; P < 0.0001</p> <hr/> <p>Linear regression results (PRU ~ %inhibition) were also reported by Hb quartile:</p> <p>Q1: PRU = 393 – 4.16*(%inh); r^2=0.88</p> <p>Q2: PRU = 352 – 3.56*(%inh); r^2=0.90</p> <p>Q3: PRU = 332 – 3.41*(%inh); r^2=0.85</p> <p>Q4: PRU = 314 – 3.28*(%inh); r^2=0.87</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Von Beckerath 2006 Germany 16676093	LTA (ADP 5 and 20 μ M) [Chrono-log lumi-aggregometer; Probe & go Labordiagnostica; Endingen, Germany] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Measurements were obtained in 30 patients, before and after clopidogrel administration (results were not analyzed separately) with all 3 assays; results from VerifyNow were correlated with LTA (using two different ADP concentrations)	“Correlations assessed by linear regression” between VerifyNow PRU units and LTA (ADP 5 μ M) = 0.86; P < 0.0001 “Correlations assessed by linear regression” between VerifyNow PRU units and LTA (ADP 20 μ M) = 0.86; P < 0.0001 “Correlations assessed by linear regression” between VerifyNow %inhibition units and LTA (ADP 5 μ M) = -0.85 “Correlations assessed by linear regression” between VerifyNow %inhibition units and LTA (ADP 5 μ M) = -0.84
Sambu 2011 UK 21231856	TEG (ADP channel, concentrations NR) [TEG Haemostasis system; Haemonetics Corp., MA, USA] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Analyses were based on “296 timepoints”. In the methods section the patients included in this analyses are reported as follows: 30 on clopidogrel 600 mg \times 5 timepoints = 150 measurements; 29 on clopidogrel 900 mg \times 5 timepoints = 145 measurements; 20 on dual treatment (presumably at a single time point) = 20 measurements, for a total of 315 measurements. The discrepancy is not clarified in the paper. It is also unclear if a small number of healthy volunteers were included (at most they would represent 17% of the total sample size).	Pearson correlation between TEG ADP channel (AUC for the response curve at 15 minutes) and VerifyNow = 0.609; P<0.001 (R^2 =0.371 from linear regression)
Freynhofer 2011 Austria 21614416	VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Biocytex Inc, Marseille, France]; using flow cytometry [additional details NR] Impedance aggregometry (ADP 6.5 μ M \pm PGE1 9.4 μ M) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]	196 patients with valid measurements on both assays	Spearman correlation coefficient between Multiplate analyzer and PRI VASP = 0.587; P<0.001
Ang 2008 USA 18848137	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	157 patients provided measurements to compare two metrics reported by the same assay	Pearson correlation coefficient between % inhibition and final PRU values = -0.879; P<0.001

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Varenhorst 2009 Sweden 19249429	<p>LTA (ADP 20 µmol/L) [PAP-4 optical aggregometer, BioData, no additional information reported]</p> <p>VASP phosphorylation assay (PGE1 ± ADP, concentrations NR) [Platelet VASP kit, BioCytex, Marseille, France]; using flow cytometry [samples were analyzed on different flow-cytometers in 2 participating centers: Epics XL, Beckman Coulter, Fullerton, CA; and FACScan, Becton Dickinson, Franklin Lakes, NJ]. The authors reported that “synchronization between the flow cytometers was performed”.</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>	110 patients (1:1 randomized to clopidogrel or prasugrel) measured at 5 timepoints (not clear if all measurements were available for all patients and timepoints)	<p>Pearson correlation coefficient between PRI VASP and VerifyNow PRU = 0.86; P<0.0001 during the loading dose phase</p> <p>Pearson correlation coefficient between PRI VASP and VerifyNow PRU = 0.81; P<0.0001 during the maintenance dose phase</p> <p>Pearson correlation coefficient between late reactivity (6 min) by LTA and VerifyNow PRU = 0.88; P<0.0001 during the loading dose phase</p> <p>Pearson correlation coefficient between late reactivity (6 min) by LTA and VerifyNow PRU = 0.79; P<0.0001 during the maintenance dose phase</p> <p>Pearson correlation coefficient between maximal reactivity by LTA and VerifyNow PRU = 0.76; P<0.0001 during the loading dose phase</p> <hr/> <p>Linear regression of PRI VASP over VerifyNow PRU: (PRI VASP) = 8.418 + 0.284*(VerifyNow PRU), during the loading dose phase</p> <p>Linear regression of PRI VASP over VerifyNow PRU: (PRI VASP) = 16.335 + 0.192*(VerifyNow PRU), during the maintenance dose phase</p> <p>Linear regression of late reactivity (6 min) by LTA over VerifyNow PRU: (LTA reactivity) = 3.096 + 0.233*(VerifyNow PRU), during the loading dose phase</p> <p>Linear regression of late reactivity (6 min) by LTA over VerifyNow PRU: (LTA reactivity) = 9.839 + 0.177*(VerifyNow PRU), during the maintenance dose phase</p>
Lordkipanidze 2008 Canada 18826988	<p>LTA (ADP 5 and 20 µM) [ChronoLog 540 model, Havertown, PA]</p> <p>Impedance aggregometry</p>	116 patients contributed samples to the analyses; only 72 patients had measurements with VerifyNow	<p>Partial correlations (accounting for randomization group)</p> <p>Correlation between LTA ADP 5 µM and LTA ADP 20 µM = 0.902 (95% CI, 0.862, 0.931); P<0.05</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
	<p>(ADP 5 and 20 μM) [ChronoLog 560 model, Havertown, PA]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p> <p>High shear platelet function (collagen/ADP cartridges) [PFA-100, Dade Behring, Deerfield, IL]</p>		<p>Correlation between LTA ADP 5 μM and impedance aggregometry ADP 5 μM = 0.255 (95% CI, 0.077, 0.417); P<0.05</p> <p>Correlation between LTA ADP 5 μM and impedance aggregometry ADP 20 μM = 0.307 (95% CI, 0.133, 0.463); P<0.05</p> <p>Correlation between LTA ADP 5 μM and PFA-100 = -0.270 (95% CI, -0.438, -0.102); P<0.05</p> <p>Correlation between LTA ADP 5 μM and VerifyNow = 0.370 (95% CI, 0.152, 0.554); P<0.05</p> <p>Correlation between LTA ADP 20 μM and impedance aggregometry ADP 5 μM = 0.291 (95% CI, 0.112, 0.449); P<0.05</p> <p>Correlation between LTA ADP 20 μM and impedance aggregometry ADP 20 μM = 0.382 (95% CI, 0.215, 0.527); P<0.05</p> <p>Correlation between LTA ADP 20 μM and PFA-100 = -0.274 (95% CI, -0.434, -0.097); P<0.05</p> <p>Correlation between LTA ADP 20 μM and VerifyNow = 0.496 (95% CI, 0.299, 0.652); P<0.05</p> <p>Correlation between impedance aggregometry ADP 5μM and impedance aggregometry ADP 20 μM = 0.881 (95% CI, 0.833, 0.916); P<0.05</p> <p>Correlation between impedance aggregometry ADP 5μM and PFA-100 = -0.139 (95% CI, -0.313, 0.044); P=NS</p> <p>Correlation between impedance aggregometry ADP 5μM and VerifyNow = 0.187 (95% CI, -0.046, 0.401); P=NS</p> <p>Correlation between impedance aggregometry ADP 20 μM and PFA-100 = -0.150 (95% CI,- 0.322, 0.033); P=NS</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
			Correlation between impedance aggregometry ADP 20 µM and VerifyNow = 0.293 (95% CI, 0.066, 0.491); P<0.05 Correlation between PFA-100 and VerifyNow = -0.334 (95% CI, -0.525, -0.111); P<0.05
Jeong 2008 S. Korea 18617479	LTA (ADP 5 µM) [ChronoLog 540 model, Havertown, PA] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	300 patients measured with both assays	Correlation between LTA PRU and VerifyNow = 0.641; P<0.001 Correlation between LTA % inhibition and VerifyNow = 0.679; P<0.001
Kim 2010 S. Korea 20449634	LTA (ADP 5 and 20 µM) [AggRam aggregometer, Helena Laboratories Corp., Beaumont, TX] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	1058 patients contributed measurements	Pearson correlation between maximal reactivity by LTA ADP 5 µmol/L and VerifyNow PRU = 0.653 P<0.001 Pearson correlation between late reactivity by LTA ADP 5 µmol/L and VerifyNow PRU = 0.669 P<0.001 Pearson correlation between maximal reactivity by LTA ADP 20 µmol/L and VerifyNow PRU = 0.683 P<0.001 Pearson correlation between late reactivity by LTA ADP 20 µmol/L and VerifyNow PRU = 0.718 P<0.001
Malinin 2006 USA 16845449	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	131 patients with CAD contributed two measurements with VerifyNow (before and after clopidogrel) to compare the before-after contrast (using the measured values) versus an “estimated” contrast using the post-clopidogrel measurement and the TRAP channel of the same device	Pearson correlation between estimated and observed contrast = 0.971 Base on linear regression of the %inhibition using the TRAP channel versus inhibition using the observed baseline value: (estimated %inhibition) = 0.9989*(observed % inhibition) – 0.0129

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Hochholzer 2007 Germany 16603231	<p>LTA (ADP 20 µmol/L) [PAP4, Molab, Hilden, Germany]</p> <p>Impedance aggregometry (ADP 20 µmol/L) [Chronolog Series 590; Probe and Co, Endingen, Germany]</p> <p>ADP-stimulated P-selectin and activated IIb/IIIa expression (ADP 20 µmol/L final concentration) Using flow cytometry [FACSCalibur flow cytometer, Becton Dickinson, Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [ULTEGRA rapid platelet function assay, Accumetrics, San Diego, CA]</p>	27 patients presumably at two timepoints; on-clopidogrel samples were obtained before PCI (after loading) and 24 h post-PCI; measurements in analyses of correlations appear to have been treated as independent observations	<p>Spearman correlation coefficient between LTA and P-selectin expression = 0.515; P<0.001</p> <p>Spearman correlation coefficient between LTA and activated IIb/IIIa expression = 0.568; P<0.001</p> <p>Spearman correlation coefficient between LTA and impedance aggregometry = 0.257; P=0.196</p> <p>Spearman correlation coefficient between LTA and ULTEGRA assay = 0.135; P=0.504</p> <p>Spearman correlation coefficient between P-selectin expression and activated IIb/IIIa expression = 0.815; P<0.001</p> <p>Spearman correlation coefficient between P-selectin expression and impedance aggregometry = 0.292; P=0.139</p> <p>Spearman correlation coefficient between P-selectin expression and ULTEGRA assay = 0.453; P=0.059</p> <p>Spearman correlation coefficient between activated IIb/IIIa expression and impedance aggregometry = 0.471; P=0.013</p> <p>Spearman correlation coefficient between activated IIb/IIIa expression and ULTEGRA assay = 0.523; P=0.026</p>
Lordkipanidze 2009 Canada 19250657	<p>LTA (ADP 5 and 20 µM) [ChronoLog Aggregometer, 540 model, Havertown, PA]</p> <p>“Platelet count drop method” using impedance platelet counting before and after exposure to the agonist (ADP 5 and 20 µM) Using a Coulter ACT Series Analyzer, Beckman Coulter Inc., Fullerton, CA]</p>	91 patients receiving aspirin + clopidogrel	<p>Spearman correlation coefficient between LTA (ADP 5 µM) and platelet count drop method (ADP 5 µM) = 0.374; P<0.001</p> <p>Spearman correlation coefficient between LTA (ADP 20 µM) and platelet count drop method (ADP 20 µM) = 0.402; P<0.001</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Pettersen 2011 Norway 21426546	VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [PLT VASP/P2Y12 assay, Biocytex, France]; using flow cytometry [FACS Calibur System, Becton Dickinson, Plymouth, UK] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	219 patients were on aspirin + clopidogrel; 155 were analyzed successfully with the VASP assay and 212 with the VerifyNow assay	Spearman correlation coefficient between PRI VASP and VerifyNow PRU = 0.682; P<0.001
Sibbing 2008 Germany 18217143	LTA (ADP 5 or 20 µM) [PAPA 8 aggregometer, Bio/Data, no additional information reported] Impedance aggregometry (ADP, 6.4 µM) [Multiplate analyzer, Dynabyte, Munich, Germany]	149 patients were included in the study and contributed on-clopidogrel measurements to the analysis; baseline (pre-clopidogrel) measurements were available from 60 patients (data not reported separately); pre- and post-clopidogrel measurements were treated as independent observations	Correlation between LTA (ADP 5 µM) and Multiplate analyzer = 0.71; P<0.0001 Correlation between LTA (ADP 20 µM) and Multiplate analyzer = 0.71; P<0.0001
Lakkis 2002 USA 12124955	Platelet agglutination assay (4 µM iso-TRAP) [ULTEGRA rapid platelet function assay, Accumetrics, San Diego, CA] blood for this device was treated with 2 different anticoagulants: D-phenylalanine-L-propyl-L-arginine chloromethyl ketone (PPACK) or citrate PlateletWorks (ADP, 20 µM) [PlateletWorks assay, additional details NR] LTA (ADP 20 µM) [PACKS-4, Helena Laboratories, Beaumont, TX]	25 patients on aspirin + clopidogrel participating in a comparative study of tirofiban dosing; measurements were obtained before tirofiban and at 5, 15, 30, 45, 60, and 120 minutes following administration, for a total of 175 measurements, which were treated as independent observations	Pearson correlation between Ultegra RPFA-PPACK and RPFA-citrate = 0.79 Pearson correlation between Ultegra RPFA-PPACK and PlateletWorks = 0.72 Pearson correlation between Ultegra RPFA-PPACK and LTA = 0.76
Kreutz 2012 USA 22385219	LTA (ADP 20 µM; for some measurements samples were pre-treated with PGE1 22 nM and 88 nM, before ADP) [Optical Lumi-Aggregometer, Model 700, Chrono-Log Corporation, Havertown, PA] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	94 patients on aspirin + clopidogrel provided samples that were measured with all assays	Pearson correlation between VerifyNow P2Y12 and LTA (ADP) = 0.72; P<0.001 Spearman correlation between VerifyNow and LTA (ADP + PGE1 22 nM) = 0.62; P<0.001 Spearman correlation between VerifyNow and LTA (ADP + PGE1 88 nM) = 0.59; P<0.001 Spearman correlation between LTA (ADP) and LTA (ADP + PGE1 88 nM) = 0.74; P<0.001

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Gaborit 2009 France 20015321	aggregometry (ADP 10 μ mol/L) [additional details NR] VASP phosphorylation assay [additional details NR]	124 diabetic patients treated with clopidogrel for ≥ 1 mo, without aspirin measured with both assays	Correlation between maximal ADP aggregation and PRI VASP = 0.517; P<0.001
Toma 2012 USA 22277895	LTA (ADP 5 μ M) [PAP4, Bio/Data Corp., Horsham, PA] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	255 patients undergoing PCI with clopidogrel loading provided samples measured with both assays (50 patients who were clopidogrel naïve at study enrollment were also measured before the loading dose)	Spearman correlation between LTA and VerifyNow = 0.64; P<0.001
Gremmel 2011 Austria 21621250	LTA (ADP 10 μ M) [additional information NR] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA] VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP, Diagnostic Stago, Biocytex, Marseille, France]; using flow cytometry [FACSCalibur system, BD Biosciences, Vienna, Austria] Impedance aggregometry (multiple electrode) (ADP, 6.4 μ M) [Multiplate analyzer, Dynabyte, Munich, Germany] Impact-R (ADP 1.36 M) [Matis Medical Inc., Beersel, Belgium; and DiaMed, Cressier, Switzerland]	288 patients receiving aspirin + clopidogrel post PCI with stent placement provided samples measured with all assays	Spearman correlation between LTA and VerifyNow P2Y12 = 0.65 Spearman correlation between LTA and VASP = 0.37 Spearman correlation between LTA and Multiplate = 0.45 Spearman correlation between LTA and Impact-R = -0.32 Spearman correlation between VerifyNow P2Y12 and VASP = 0.44 Spearman correlation between VerifyNow P2Y12 and Multiplate = 0.32 Spearman correlation between VerifyNow P2Y12 and Impact-R = -0.52 Spearman correlation between VASP and Multiplate = 0.33 Spearman correlation between VASP and Impact-R = -0.26 Spearman correlation between Multiplate and Impact-R = -0.20 All results were statistically significant (p-values NR)

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Saad 2012 Egypt 22146578	LTA (ADP 5 μ M) [Chrono-Log 450 Model, Chrono-Log, Havertown, PA] Surface expression of activated IIb/IIIa receptors (ADP 5 μ M) Using flow cytometry [EPICS-XL PROFILE II Coulter, Beckman Coulter]	90 patients undergoing PCI with clopidogrel loading provided samples measured with both assays	Spearman correlation between LTA and IIb/IIIa receptor expression = 0.927; P<0.001 (in the overall population)
Stellbaum 2012 Germany 22503564	Impedance aggregometry (multiple electrode) (ADP and ADP + prostaglandin; agonist concentrations NR) [Multiplate analyzer, Dynabyte, Munich, Germany]	100 patients receiving clopidogrel loading before cardiac catheterization	Correlation between aggregation with ADP and ADP + prostaglandin = 0.764 (95% CI 0.656, 0.841); P<0.001
Bliden 2011 USA + UK 21742103 ONSET/OFFSET and RESPOND studies	LTA (ADP 20 μ M) [Chronolog Model 490-4D, Chronolog, Havertown, PA] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA] VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Platelet VASP-FCM kit, Biocytex Inc., Marseille, France]; using flow cytometry [additional information NR]	103 patients receiving clopidogrel provided samples measured by all assays; patients were participants in the ONSET/OFFSET and RESPOND trials	Correlation between maximum platelet aggregation by LTA and VerifyNow P2Y12 PRU = 0.6644; P<0.001 Correlation between maximum platelet aggregation by LTA and PRI VASP = 0.4304; P<0.001
Ono 2011 Japan 21862109	LTA (ADP 20 μ mol/L) [MCM HEMA TRACER 313 M, MC Medical, Inc., Tokyo, Japan] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	202 patients with coronary artery disease undergoing elective PCI contributed samples measured with both assays	Pearson correlation between LTA maximal reactivity and VerifyNow PRU = 0.705; P<0.001 Pearson correlation between LTA area under the curve and VerifyNow PRU = 0.793; P<0.001 Pearson correlation between LTA maximal reactivity and VerifyNow %inhibition = -0.728; P<0.001 Pearson correlation between LTA area under the curve and VerifyNow %inhibition = -0.805; P<0.001

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Gaglia 2011 USA 21919956	<p>LTA (ADP 5 or 20 μM) [ChronoLog, Havertown, PA]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [PLT VASP/P2Y12 assay, BioCytex, Marseille, France]; using flow cytometry [FACSCalibur flow cytometer, BD Biosciences, San Jose, CA]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>	200 patients contributed samples to be measured with 3 assays	<p>Spearman correlation between VASP and VerifyNow P2Y12 = 0.71 (0.63, 0.77); P<0.0001</p> <p>Spearman correlation between VASP and LTA ADP 5 μM = 0.60 (0.50, 0.69); P<0.0001</p> <p>Spearman correlation between VASP and LTA ADP 20 μM = 0.69 (0.60, 0.76); P<0.0001</p> <p>Spearman correlation between VerifyNow P2Y12 and LTA ADP 5 μM = 0.67 (0.57, 0.74); P<0.0001</p> <p>Spearman correlation between VerifyNow P2Y12 and LTA ADP 20 μM = 0.77 (0.70, 0.83); P<0.0001</p> <p>Spearman correlation between LTA ADP 5 μM and LTA ADP 20 μM = 0.86 (0.81, 0.89); P<0.0001</p>
Park 2012 Korea 21942752	<p>LTA (ADP 5 and 20 μM and ADP 5 μM + 5 nM PGE1) [AggRAM aggregometer, Helena Laboratories Corp., Beaumont, TX]</p> <p>Impedance aggregometry (ADPtest 6.4 μM ADP and high-sensitivity ADPtest (ADPtest HS) 6.4 μM ADP + 9.4 nM PGE1) [Multiplate analyzer, Dynabyte, Munich, Germany]</p>	246 patients	<p>Pearson correlation between LTA maximal platelet aggregation (ADP 5μM) and LTA final platelet aggregation (ADP 5 μM) = 0.956; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5μM) and LTA maximal platelet aggregation (ADP 5 μM + PGE1) = 0.964; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5 μM) and LTA final platelet aggregation (ADP 5μM + PGE1) = 0.923; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5μM) and LTA maximal platelet aggregation (ADP 20 μM) = 0.945; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5μM) and LTA final platelet aggregation (ADP 20 μM) = 0.920; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5μM) and ADPtest = 0.678; P<0.01</p> <p>Pearson correlation between LTA maximal platelet</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
			<p>aggregation (ADP 5µM) and ADPtest HS = 0.632; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 5 µM) and LTA maximal platelet aggregation (ADP 5 µM + PGE1) = 0.946; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 5 µM) and LTA final platelet aggregation (ADP 5 µM + PGE1) = 0.968; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5 µM) and LTA maximal platelet aggregation (ADP 20 µM) = 0.894; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 5 µM) and LTA maximal platelet aggregation (ADP 20 µM) = 0.939; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 5 µM) and ADPtest = 0.710; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 5 µM) and ADPtest HS = 0.691; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5 µM + PGE1) and LTA final platelet aggregation (ADP 5 µM + PGE1) = 0.961; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5 µM + PGE1) and LTA maximal platelet aggregation (ADP 20 µM) = 0.923; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5µM + PGE1) and LTA final platelet aggregation (ADP 20 µM) = 0.921; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 5µM + PGE1) and ADPtest = 0.697; P<0.01</p> <p>Pearson correlation between LTA maximal platelet</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
			<p>aggregation (ADP 5 μM + PGE1) and ADPtest HS = 0.662; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 5 μM + PGE1) and LTA maximal platelet aggregation (ADP 20 μM) = 0.865; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 5 μM + PGE1) and LTA final platelet aggregation (ADP 20 μM) = 0.913; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 5 μM + PGE1) and ADPtest = 0.688; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 5 μM + PGE1) and ADPtest HS = 0.693; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 20 μM) and LTA final platelet aggregation (ADP 20 μM) = 0.958; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 20 μM) and ADPtest = 0.663; P<0.01</p> <p>Pearson correlation between LTA maximal platelet aggregation (ADP 20 μM) and ADPtest HS = 0.596; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 20 μM) and ADPtest = 0.698; P<0.01</p> <p>Pearson correlation between LTA final platelet aggregation (ADP 20 μM) and ADPtest HS = 0.630; P<0.01</p> <p>Pearson correlation between ADPtest and ADPtest HS = 0.776; P<0.01</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Zhang 2012 Korea 22774770	<p>LTA (ADP 10 μM) [additional information NR]</p> <p>Impedance aggregometry (ADP, 6.4 μM, sample anticoagulated with hirudin or citrate) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p> <p>Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]</p>	119 patients; measurement of samples with three assays to assess analytic performance at 2 timepoints (at PCI and post-PCI); assessments performed with samples treated with different anti-coagulants (pre-analytically)	<p>Pearson correlation between Multiplate analyses (at PCI) using samples anticoagulated with citrate and samples anticoagulated with hirudin = 0.60; P<0.001</p> <p>Pearson correlation between Multiplate analyses (post-PCI) using samples anticoagulated with citrate and samples anticoagulated with hirudin = 0.65; P<0.001</p> <p>Pearson correlation between LTA and Multiplate using samples antcoagulated with citrate at PCI = 0.4</p> <p>Pearson correlation between LTA and Multiplate using samples antcoagulated with hirudin at PCI = 0.38</p> <p>Pearson correlation between LTA and Multiplate using samples antcoagulated with citrate post-PCI = 0.42</p> <p>Pearson correlation between LTA and Multiplate using samples antcoagulated with hirudin post- PCI = 0.51</p> <p>Pearson correlation between VerifyNow and Multiplate using samples antcoagulated with citrate at PCI = 0.47</p> <p>Pearson correlation between VerifyNow and Multiplate using samples antcoagulated with hirudin at PCI = 0.37</p> <p>Pearson correlation between VerifyNow and Multiplate using samples antcoagulated with citrate post-PCI = 0.5</p> <p>Pearson correlation between VerifyNow and Multiplate using samples antcoagulated with hirudin post-PCI = 0.42</p>

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Tsantes 2012 Greece 22646492	<p>LTA (ADP 10 μM) [Biodata-PAP-4 aggregometer, Bio/ Data Corporation, Horsham, PA]</p> <p>High shear platelet function (PFA-100 ADP/PGE1 cartridges) [INNOVANCE PFA P2Y, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany]</p> <p>Impedance aggregometry (ADP 6.5 μM) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [PLT VASP/P2Y12 assay, Biocytex, Marseille, France]; using flow cytometry [Partec CyFlow ML, Partec GmbH, Munster, Germany]</p>	90 patients contributed samples measured with 4 different methods	<p>Spearman correlation between INNOVANCE PFA-100 P2Y and LTA peak aggregation = -0.51; P<0.001</p> <p>Spearman correlation between INNOVANCE PFA-100 P2Y and LTA late aggregation (6 min) = -0.55; P<0.001</p> <p>Spearman correlation between INNOVANCE PFA-100 P2Y and LTA disaggregation = 0.39; P<0.001</p> <p>Spearman correlation between INNOVANCE PFA-100 P2Y and Multiplate analyzer AUC = -0.47; P<0.001</p> <p>Spearman correlation between INNOVANCE PFA-100 P2Y and VASP PRI = -0.41; P = 0.003</p>
Liang 2012 Canada 22797934	<p>LTA (ADP 5 μmol/L) [Chrono-log aggregometer, Model 560-Ca]</p> <p>Impedance aggregometry (ADP 6.5 μM) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p> <p>VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [PLT VASP/P2Y12 assay, BioCytex, Marseille, France]; using flow cytometry [FACSCaliber Flow Cytometer, Becton-Dickinson, San Jose, CA]</p>	82 patients measured at measured at 6 h post- loading on d 1 and 1 h post-treatment on d 7 and 14	<p><i>6 h post-loading on day 1</i> Pearson correlation between VASP-PRI and LTA = 0.6410 Pearson correlation between VASP-PRI and Multiplate = 0.4672 Pearson correlation between LTA and MEA = 0.4645</p> <hr/> <p><i>1 h post-treatment, d 7</i> Pearson correlation between VASP-PRI and LTA = 0.5527 Pearson correlation between VASP-PRI and Multiplate = 0.4161 Pearson correlation between LTA and MEA = 0.4995</p> <hr/> <p><i>1 h post-treatment, d 14</i> Pearson correlation between VASP-PRI and LTA = 0.4676 Pearson correlation between VASP-PRI and Multiplate = 0.3913 Pearson correlation between LTA and MEA = 0.4976</p>
Namazi 2012 Iran 22232732	<p>LTA (ADP 5 and 20 μM) [PACKS-4, Helena BioSciences Europe, Sunderland, UK]</p>	112 patients with measurements obtained at 3 times points; repeat measurements were treated as independent observations	Pearson correlation between maximal aggregation with LTA 5 and 20 μ M = 0.88; P <0.001

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Sample size	Results
Jang 2012 Korea 22811359	High shear platelet function (PFA-100 ADP/PGE1 cartridges) [INNOVANCE PFA P2Y, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	255 patients	Spearman correlation between INNOVANCE PFA P2Y and VerifyNow %inhibition = 0.412; P<0.0001 Spearman correlation between INNOVANCE PFA P2Y and VerifyNow PRU = - 0.402; P<0.0001

*The study reported “r2” values as correlations and used fitted regression lines to summarize bivariate linear relationship

Abbreviations: NA = not applicable; NR = not reported; PMID = PubMed identification number; TEG = Thromboelastography.

Appendix Table E3. Studies reporting results on the reliability of platelet reactivity assays with unclear study designs

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Results
Cuisset 2009 France 19761935	LTA (ADP 10 µmol/L) [PAP4, Biodata Corporation, Wellcome, Paris, France]	COV of maximal intensity of aggregation (PAP4) = 6.5%
Cecchi 2009 Italy 19733708	LTA (ADP 10 µmol/L) [APACT 4, Helena Laboratories, Milan, Italy]	Mean COV for ADP-induced aggregation = 6.8%
Paniccia 2009 Italy 19461090	LTA (ADP, 10 µmol/L) [APACT-4004 aggregometer, LABiTec, Ahrensburg, Germany] Impedance aggregometry (ADP, 10 µmol/L) [Multiplate analyzer, Dynabyte, Munich, Germany]	Mean COV for LTA (50 measurements) = 6.8% (ADP as agonist) Mean COV (5 repeat measurements in an unspecified number of patients) = 6.2% (ADP as agonist)
Cuisset 2009 France 18990434	LTA (ADP 10 µmol/L) [PAP4, Biodata Corporation, Wellcome, Paris, France]	COV of maximal intensity of platelet aggregation = 6.5%
Frere 2008 France 18394438	LTA (ADP 10 µmol/L) [PAP4, Biodata Corporation, Wellcome, Paris, France]	COV of maximal intensity of platelet aggregation = 6.5%
Bonello 2008 France 18387444	VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP kit, Diagnostica Stago, Asnieres, France]; using flow cytometry [EPICS XL cytometer, Beckman Coulter Inc., Fullerton, California]	Intra-assay COV was <5%; interassay coefficient of variation was <8%
Mani 2008 Germany 18223467	LTA (ADP 2µmol/L) [Behring Coagulation Timer, BCT, Dade Behring, Dudingon, Switzerland]	Within-subject variation was 3.3%
Frere 2007 France 17938809	LTA (ADP 10 µM) [PAP4 aggregometer, Biodata Corporation, Wellcome, Paris, France]	COV of maximal intensity of platelet aggregation = 6.5%
Cuisset 2007 France 17337040	LTA (ADP 10 µmol/L) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France]	COV of maximal intensity of platelet aggregation = 6.5%

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Results
Bonello 2007 France 17488353	VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP kit, Biocytex, Marseille, France]; using flow cytometry [Coulter EpicsXL cytometer, no additional information reported]	Intra-assay COV <5%.
Cuisset 2007 France 17264949	LTA (ADP 10 µM) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France]	COV of maximal intensity of platelet aggregation = 6.5%
Cuisset 2006 France 16371119	LTA (ADP 10 µmol/L) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France]	COV of maximal intensity of platelet aggregation = 6.5%
Wang 2011 China 21538380	VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP kit, Becton Dickinson, Franklin Lakes, NJ]; using flow cytometry [Coulter Epics XL cytometer, FACSCalibur, Becton Dickinson, Franklin Lakes, NJ]	Intra-assay COV < 5% Inter-assay COV < 8%
Gori 2008 Italy 19132241	LTA (ADP, 10 µmol/L) [APACT-4, Helena Laboratories, Italy] High shear platelet function (collagen/ADP) [PFA-100, Dade-Behring, Marburg, Germany]	COV for LTA (ADP) = 6.8% COV for PFA-100 (collagen/ADP) = 9.3%
Neubauer 2011 Germany 21226927	Impedance aggregometry (ADP 5µM) [Whole Blood Aggregometry, Model 590, Chrono-log Corporation, Havertown, PA]	“Results were reproducible with a variability <10%”
Armero 2010 France 20670107	VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [Platelet VASP kit, Diagnostica Stago, Asnieres, France]; using flow cytometry [Coulter Epics XL cytometer, Beckman Coulter, Inc., Fullerton, CA]	Intra-assay COV <5%.
Neubauer 2010 Germany 20410834	Impedance aggregometry (ADP 5µmol/L) [Model 590, Chrono-log Corporation, Havertown, PA]	Results were “reproducible with a variability <10%”

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Results
Madsen 2010 Canada 20224050	LTA (ADP, 5 µM) [Chrono-Log Lumi Aggregometer, model 810; Chrono-Log Corporation, no additional details provided]	Duplicate measurements were performed only for LTA (other tests were assessed in the study) While patients were on clopidogrel (measurements within 1 d to 12 mo of drug initiation) the standard deviations between duplicate measurements of maximal aggregation and late aggregation were 3.0% and 3.3%, respectively.
Cuisset 2010 France 20142119	LTA (ADP 10 µmol/L) [PAP4, Biodata Corporation, Wellcome, Paris, France]	COV of maximal platelet aggregation = 6.5%
Cuisset 2009 France 18499233	LTA (ADP 10 µmol/L) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France]	COV of maximal platelet aggregation = 6.5%
Lordkipanidze 2009 Canada 19419755	LTA (ADP 5 and 20 µM) [ChronoLog aggregometer 540 model, Havertown, PA]	Intra-assay variability for peak platelet aggregation ranged from 8.5% to 11.3% at baseline, and 12.1% to 12.9% post-clopidogrel Intra-assay variability for late platelet aggregation ranged from 10.5% to 17.1% at baseline, and 16.6% to 17.5% post-clopidogrel
Paniccia 2010 Italy 20458439	LTA (ADP, 10 µM) [APACT-4004 aggregometer, LABiTec, Ahrensburg, Germany] Impedance aggregometry (ADP, 10 µM final concentration) [Multiplate analyzer, Dynabyte, Munich, Germany]	Mean COV for LTA = 4.8% (5 samples × 10 patients = 50 datapoints) Mean COV of Multiplate analyzer based on 5 samples obtained from each of several subjects (exact number not reported) = 5.8%
Migliorini 2009 Italy 19917884	LTA (ADP, 10 µmol/L) [APACT4 aggregometer, Helena Laboratories, Milan, Italy]	COV of maximal percentage platelet aggregation = 6.8%
Gori 2008 Italy 18718420	LTA (ADP, 10 µM) [APACT4 aggregometer, Helena Laboratories, Milan, Italy]	COV of platelet aggregation (ADP) = 6.8%
Wilson 2009 UK 19786240	Percentage of platelets binding fibrinogen (ADP, 10 ⁻⁵ mol/L) [using flow cytometry, Coulter Epics XL-MCL Flow Cytometer; Beckman Coulter Inc., Brea, CA]	Inter-assay COV = 5.7%

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Results
Cuisset 2006 France 17010792	LTA (ADP 10 μ mol/L) [PAP4 Aggregometer, Biodata Corporation, Wellcome, Paris, France]	COV of maximal intensity of platelet aggregation = 6.5%
Huczek 2008 Poland 18301358	High shear platelet function (collagen/ADP) [PFA-100, Dade-Behring, Marburg, Germany]	In “duplicate analyses”: COV using the collagen/ADP cartridge = 9.5%
Patti 2011 Italy 21256470	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Repeat analyses in 25 patients (number of replicate samples NR) Intra-assay variability = 2.0% \pm 1.1% Intra-assay COV = 6%
Lee 2011 S. Korea 21791883	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Variability of the P2Y12 assay = 7.5% at “the authors institution”
Freynhofer 2011 Austria 21614416	VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [Biocytex Inc, Marseille, France]; using flow cytometry [additional details NR]	Repeatability coefficient for PRI VASP = 6.6%
Marcucci 2007 Italy 17555759	LTA (ADP 2 and 10 μ M) [APACT4 aggregometer, Helena Laboratories Italia s.p.a., Milan, Italy]	COV of LTA (ADP) = 6.8%
Pettersen 2011 Norway 21426546	VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [PLT VASP/P2Y12 assay, Biocytex, France]; using flow cytometry [FACS Calibur System, Becton Dickinson, Plymouth, UK] Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	Intra-assay COV for VASP assay = 2.3% Intra-assay COV for VerifyNow assay = 7%
Paniccia 2007 Italy 17723123	LTA (ADP, 2 μ mol/L and 10 μ mol/L) [APACT-4 aggregometer, LABiTec, Ahrensburg, Germany]	Mean COV of LTA = 6.8% (5 measurements \times 10 CAD patients (50 data-points)

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Results
Paniccia 2011 Italy 21192314	LTA (ADP, 2 μ mol/L, 5 μ mol/L, 10 μ mol/L, and 20 μ mol/L) [APACT-4004 aggregometer, LABiTec, Ahrensburg, Germany]	5 samples from each of 10 patients of the assessment of reliability: Mean COV for LTA (ADP 2 μ mol/L) = 6.8% Mean COV for LTA (ADP 5 μ mol/L) = 5.2% Mean COV for LTA (ADP 10 μ mol/L) = 2.7% Mean COV for LTA (ADP 20 μ mol/L) = 3.1%
Kalantzi 2012 Greece 21806493	VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [BioCytex, Marseille, France]; using flow cytometry [FACS Calibur, Becton-Dickinson, San Jose, CA]	Intra-assay COV <5%; inter-assay COV <8%
Siller-Matula 2012 Austria 22260716	VASP phosphorylation assay (PGE1 \pm ADP, concentration not reported) [BioCytex, Marseille, France]; using flow cytometry [FACS Calibur, BD biosciences, San Jose, CA]	COV for duplicate analysis = 5%
Park 2011 Korea 21880289 CROSS VERIFY	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	COV = 7.5% “at the authors’ institution”
Lee 2011 Korea 21857144 CILON-T	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	COV = 7.5% “at the authors’ institution”
Park 2011 Korea 21129165 CROSS VERIFY	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	COV = 7.5% “at the authors’ institution”
Meen 2012 Norway 22724626	LTA (ADP, 10 μ M) [ChronoLog 500 VS, Havertown, PA] Impedance aggregometry (ADP, 10 μ M) [Multiplate analyzer, Dynabyte, Munich, Germany]	LTA COV = 8.2% “at the authors’ laboratory” Multiplate COV = 5.7% “at the authors’ laboratory”

Author Year Country PMID	Assays evaluated (agonist) [brand name, manufacturer]	Results
Chiu 2011 Taiwan 21925055	High shear platelet function (collagen/ADP cartridges) [PFA-100, Dade-Behring, Marburg, Germany]	COV = 7.7% “at the authors’ laboratory”
Tsantes 2012 Greece 22646492	<p>LTA (ADP 10 µM) [Biodata-PAP-4 aggregometer, Bio/ Data Corporation, Horsham, PA]</p> <p>High shear platelet function (PFA-100 ADP/PGE1 cartridges) [INNOVANCE PFA P2Y, Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany]</p> <p>Impedance aggregometry (ADP 6.5 µM) [Multiplate analyzer, Dynabyte Medical, Munich, Germany]</p> <p>VASP phosphorylation assay (PGE1 ± ADP, concentration not reported) [PLT VASP/P2Y12 assay, Biocytex, Marseille, France]; using flow cytometry [Partec CyFlow ML, Partec GmbH, Munster, Germany]</p>	<p><i>ICCs for repeat measurement</i></p> <p>ICC for VASP assay = 0.84 (95% CI 0.15, 0.97)</p> <p>ICC for Multiplate analyzer = 0.94 (95% CI 0.68, 0.99)</p> <p>ICC for INNOVANCE PFA-100 P2Y = 0.89 (95% CI 0.46, 0.98)</p> <p>ICC for LTA = 0.90 (95% CI 0.47, 0.98)</p> <hr/> <p>COV for VASP assay = 2%</p> <p>COV for Multiplate analyzer = 7.4%</p> <p>COV for INNOVANCE PFA-100 P2Y = 11.9%</p> <p>COV for LTA = 3.3%</p>
Park 2011 S. Korea 21880289	Platelet agglutination assay (ADP cartridges) [VerifyNow P2Y12 assay, Accumetrics, San Diego, CA]	COV = 7.5% “at the authors’ institution”

Abbreviations: COV = coefficient of variation; NA = not applicable; NR = not reported; PMID = PubMed identification number.

Appendix Table E4. Reporting characteristics and methodological quality of studies of analytic validity

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples being blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/instruments/reagent lots/different days of the week/different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Michelson 2009 USA 19435740	YES	NR	NA	NR	NR	YES (thresholds based on prior literature; criteria for non-evaluable samples)	NO	NO	NO	NO	YES (data read locally at each of the 13 participating centers; centralized testing was done for all samples; agreement between central and local readings NR)
Paniccia 2009 Italy 19461090	YES	NR	NA	NR	NR	YES (thresholds based on prior literature; alternative thresholds for analytic performance derived from ROC analysis)	NO	NO	YES	NO	NO
Oestreich 2009 USA 19318928	YES	NR	NA	NR	NR	NO (thresholds for poor response were defined based on the study data: values 2 or more standard errors higher than the mean value for each assay)	NO	NO	NO	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples being blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/instruments/reagent lots/different days of the week/different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Marcucci 2007 Italy 17938810	YES	NR	NA	NR	NR	NO (thresholds for poor response were defined based on study data on control individuals: values beyond the 90th percentile of controls were considered positive)	NO	NO	NO	NO	NO
Frere 2007 France 17938809	YES	NR	NA	NR	NR	NO (thresholds for poor response were defined based on study data on subsequent vascular events, using ROC analysis)	NO	NO	UNCLEAR (COV reported for one of the assays but methods for calculation not reported)	NO	NO
Paniccia 2007 Italy 17723123	YES	NR	NA	NR	NR	YES (for <i>some</i> of the assays cut-offs were derived from the prior literature)	NO	NO	YES (for one of the assays)	NO	NO
Van Werkum 2006 Netherlands 16938130	YES	NR	NA	NR	NR	NA (no thresholds were employed)	NO	NO	NO	NO	NO
Mobley 2004 USA 14969622	YES	NR	NA	NR	NR	NO	NO	NO	NO	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples being blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/instruments/reagent lots/different days of the week/different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Ren 2011 China 21518592	YES	NR	NA	NR	NR	NO	NO	NO	NO	NO	NO
Godino 2009 Italy 19419580	YES	NR	NA	NR	NR	NO (thresholds were determined based on the observed distribution of measurements)	NO	NO	NO	NO	NO
Paniccia 2011 Italy 21192314	YES	NR	NA	NR	NR	YES (cut-offs were derived based on prior literature)	NO	NO	YES	NO	NO
Koessler 2011 Germany 20873965	YES	NR	NA	NR	NR	YES (cut-offs in some analyses were those suggested by the manufacturer; other cut-offs were used as part of the study design)	NO	NO	NO (however, experiments were run at least in duplicate and results were averaged)	NO	NO
Paniccia 2010 Italy 20458439	YES	NR	NA	NR	NR	YES (based on prior literature)	NO	NO	YES	NO	NO
Ko 2011 Korea 21315223	YES	NR	NA	NR	NR	NA (no thresholds were used)	NO	NO	NO	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples being blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/instruments/reagent lots/different days of the week/different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Aradi 2010 Hungary 20642320	YES	NR	YES	NR	NR	YES (based on literature for PRI VASP; ROC analyses for LAT)	NO	NO	NO	NO	NO
Woo 2010 Korea 20890076	YES	NR	NA	NR	NR	YES (based on prior literature for all assays)	NO	NO	NO	NO	NO
Madsen 2010 Canada 20224050	YES	NR	NA	NR	NR	YES (cut-offs based on prior literature)	NO	NO	YES (for LTA duplicate measurements were obtained and the mean used in analyses; the variance in repeat testing was also reported)	NO (repeat measurements only for one of the tests of interest; details about reproducibility assessment not reported)	NO
Siller-Matula 2010 Austria 19943879	YES	NR	NA	NR	NR	NO (cut-offs were determined based on observed data, using ROC analysis)	NO	NO	NO (however references were provided to previous investigations, some from the same investigators)	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples being blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/instruments/reagent lots/different days of the week/different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Cuisset 2010 France 20142119	YES	NR	NA	NR	NR	YES (main analyses used cut-offs obtained from prior literature; analyses with alternative thresholds were also presented)	NO	NO	NO (references to previous investigations on reproducibility are provided)	NO	NO
Smit 2009 Netherlands 19200163	YES	NR	NA	NR	NR	NO (no explicit thresholds were used)	NO (however, the authors commented that the iron-based assay could obtain measurement beyond the detection limit of other assays used in the study)	NO	YES (duplicate measurements were performed in 111 samples for one of the assays)	NO	NO
Gremmel 2009 Austria 19190818	YES	NR	NA	NR	NR	NO (thresholds were determined based on the empirical distribution of the results in the study)	NO	NO	NO	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples being blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/instruments/reagent lots/different days of the week/different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Schafer 2008 Germany 18841284	YES	NR	NA	NR	NR	YES (thresholds were based on prior literature)	NO	NO	NO (measures of variability were obtained from a population not on clopidogrel treatment)	NO	NO
Shenkman 2008 Israel 18155752	YES	NR	NA	NR	NR	YES (cut-offs for the reference standard test were)	NO	NO	NO	NO	NO
Lordkipanidze 2008 Canada 18520610	YES	NR	NA	NR	NR	NA (no explicit thresholds were used)	NO	NO	NO	NO	NO
Lordkipanidze 2009 Canada 19840560	YES	NR	NA	NR	NR	NO (thresholds were determined based on the observed distribution of measurements; positive tests were defined as those > mean + 2*SD)	NO	NO	NO	NO	NO
Lordkipanidze 2009 Canada 19419755	YES	NR	NA	NR	NR	NO (no thresholds were used in analyses relevant to analytic validity)	NO	NO	YES (analyses of intra-assay variability were reported)	NO	NO
Collet 2008 France 18765393	YES	NR	NA	NR	NR	YES (based on prior literature)	NO	NO	NO	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples being blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/instruments/reagent lots/different days of the week/different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Von Beckerath 2010 Germany 19823079	YES	NR	NA	NR	NR	NO (thresholds were determined based on the observed distribution of measurements)	NO	NO	NO	NO	NO
Varenhorst 2009 Sweden 19249429	YES	NR	NA	NR	NR	NO (thresholds were determined based on the observed distribution of measurements)	NO	NO	NO	NO	NO (however, two laboratories participated in the study and the authors reported that flow cytometers were “synchronized”)
Lordkipanidze 2008 Canada 18826988	YES	NR	NA	NR	NR	YES (based on published guidelines)	NO	NO	NO	NO	NO
Jeong 2008 S. Korea 18617479	NO	NR	NA	NR	NR	NO (thresholds were determined based on the observed distribution of measurements)	NO	NO	NO	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples being blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/instruments/reagent lots/different days of the week/different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
Kim 2010 S. Korea 20449634	YES	NR	NA	NR	NR	YES (for some analyses thresholds were determined based on prior literature; analyses with alternative thresholds were also presented)	NO	NO	NO	NO	NO
Lordkipanidze 2009 Canada 19250657	YES	NR	NA	NR	NR	YES (based on prior literature)	NO	NO	NO	NO	NO
Pettersen 2011 Norway 21426546	YES	NR	NA	NR	NR	YES (determined based on an independent group of patients receiving aspirin only)	NO	NO	NO	NO	NO
Sibbing 2008 Germany 18217143	YES	YES (mentions the use of control samples for quality control)	NR	NR	NR	NO (thresholds were determined based on the observed distribution of measurements)	NO	NO	YES (assessed assay variability)	NO	NO
Gaglia 2011 USA 21919956	YWA	NR	NA	NR	NR	YES (based on prior literature)	NO	NO	NO	NO	NO

Author Year Country PMID	Was the execution of the assay described in sufficient detail to permit replication?	Were both positive and negative control samples tested?	Were negative control materials from the same type of tissue, and collected, stored, and processed in the same way that sample materials used clinically for testing will be?	Were the tests performed with positive or negative control samples being blinded to the testers?	Were the testing results interpreted with positive or negative control samples being blinded to the interpreters?	Were criteria for determining a testing result as positive, negative, indeterminate, or uninterpretable set <i>a priori</i> ?	Was the limit of detection of the test reported?	Was the assay linearity range reported?	Was the reproducibility of the test when performed multiple times on a single specimen established?	Was the reproducibility of the test adequately established (across operators/instruments/reagent lots/different days of the week/different laboratories)?	Were the study data from a multisite collaborative, proficiency testing, or interlaboratory exchange programs?
McGlasson 2011 USA 21799401	YES	NR	NA	NR	NR	UNCLEAR (criteria were developed locally by “in house method validations”)	NO	NO	NO	NO	NO
Park 2012 Korea 21942752	YES	NR	NA	NR	NR	YES (based on prior literature)	NO	NO	NO	NO	NO
Zhang 2012 Korea 22774770	YES	NR	NA	NR	NR	YES (based on prior literature)	NO	NO	NO	NO	NO
Tsantes 2012 Greece 22646492	YES	NR	NA	NR	NR	YES (based on prior literature and manufacturer information)	NO	NO	YES	NO	NO
Liang 2012 Canada 22797934	YES	NR	NA	NR	NR	NA (no cut-offs were used)	NO	NO	NO	NO	NO
Jang 2012 Korea 22811359	YES	NR	NA	NR	NR	YES (based on prior literature or manufacturer information)	NO	NO	NO	NO	NO

Abbreviations: NA = not applicable; NR = not reported; PMID = PubMed identification number; ROC = receiver operating characteristic.

Appendix Table E5. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of LTA

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Geisler, 2010 20526607 Germany NR	1703 NR 74.8 67.5±10.9	NR NR NR NR NR NR NR	hyper 62.4 40.6 HTN 81.5 32	NR 100 100 NR	26 DES 25; BMS 1 NR	PCI	Patients who were naïve to clopidogrel received a 600 mg loading dose and patients already receiving chronic clopidogrel therapy were treated by a 300 mg LD prior to stent implantation. A standard maintenance dose of 75 mg/day Clopidogrel and ASA 100 mg/day was prescribed for all patients.	NR
Cuisset, 2009 19801028 France NR	599 NR 465 (77.8) Median: 65	NR NR NR NR NR NR NR	331 (55.4) 232 (38.8) 334 (55.9) 210 (35.1)	NR NR NR NR	NR 182 (30.4) NR	Treatment of NSTEMI ACS	Patients received oral loading doses of 250 mg aspirin and 600 mg clopidogrel ≥12 hours before stenting.	NR
Frere, 2007 17938809 France NR	195 NR 158 (81) 63.4±11.1	NR NR NR NR NR NR NR	107 (54.9) 96 (49.2) 111(56.9) 68 (34.9)	NR 100 100 NR	NR NR NR	Patients had undergone successful coronary stenting	All patients received a 600 mg loading dose of clopidogrel and a 250 mg loading dose of aspirin administered at least 12 h before stenting. After PCI, patients received clopidogrel and aspirin 75 mg daily during one-month follow-up.	Anticoagulation was performed with low-molecular-weight heparin (enoxaparin), or unfractionated heparin if age over 75 years or in case of renal insufficiency (creatinin clearance < 60 ml/min).

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Hoshino, 2009 19106460 Japan NR	30 ? Asian: 30 (100%) 22 (73%) 70 ± 7	1 NR Prior cerebrovascular disease: 3% PCI: 13% NR NR 7% 3% NR	hyperlipidemia: 73% Current: 33% HTN (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg): 60% 2HbA1c >6.5 %: 23%	0 NR NR 23%	NR NR NR	Patients undergoing percutaneous coronary intervention (PCI) for ischemic heart disease	Clopidogrel 300 mg LD 24 hrs before PCI + 75 mg/d MD Aspirin 81-100 mg/day	NR
Breet, 2010 20179285 Netherlands POPULAR	1069 NR 75 64±10.6	NR NR NR NR NR NR 54.5 NR	80.3 11.1 HTN 76.9 18.6	NR 100 89.4 27.8	100 DES 63.5 NR	coronary artery disease scheduled for elective PCI with stent	clopidogrel treatment (a maintenance of 75 mg/d therapy for>5 days or a loading dose of 300 mg ≥24 hours before PCI or 600 mg ≥4 hours before PCI) and aspirin (80-100 mg/d ≥10 days).	unless they were receiving long-term anticoagulation with warfarins

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Gurbel, 2010 20194878 10 study sites in North America and Europe RESPOND	98 White 87 (89); Black 8 (8); Other 3 (3) 76 (78%) 65±8	1 NR NR PCI:48%; CABG:37% NR NR NR NR NR	Hyperlipidemia: 94% Current: 17% HTN: 81% 26%	NR NR 100% 22%	NR NR NR	Patients with CAD on aspirin therapy	Nonresponders and responders were randomly treated with either a 600-mg clopidogrel load followed by 14±2 days of 75-mg daily maintenance therapy or a 180-mg ticagrelor load followed by 14±2 days of 90-mg twice daily maintenance therapy (period 1). In period 2, all nonresponders switched treatment, whereas half of the responders continued the same treatment, and the other half of the responders switched to the other treatment.	
Kim, 2010 20449634 Korea NR	1058 NR 70.1 62.2±11.2	62.2±11.2 NR 3.6% PCI 30.4% NR NR NR 20.9% NR	19% 39.8% 52% 29%	NR 25.3% NR NR	NR NR 27.6%	Patients treated with coronary stenting for symptomatic coronary artery disease, including acute myocardial infarction (AMI) and on chronic clopidogrel therapy	scheduled coronary stenting procedures, 300-mg loading-dose (LD) of clopidogrel at least 12 h before procedure. In AMI patients, all received a 600-mg LD of clopidogrel immediately after emergency room arrival, followed by a maintenance dose of 75 mg daily.	If use of glycoprotein IIb/IIIa inhibitor (GPI) was deemed necessary, only tirofiban, which has a short half-life, was administered.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Angiolillo, 2008 18312754 USA OPTIMUS	34 NR 22 (64.7) 64.5±9	NR NR NR CABG 6(17.6) NR NR NR 14 (41.2) NR	31 (91.2) 10 (29.4) 31 (91.2) 100	NR 100 100 NR	NR NR 27(79.4)	Patients underwent PCI and were treated with standard clopidogrel	Clopidogrel 75 mg/day, and 1 month after clopidogrel 150 mg/ day. Thereafter, all patients resumed the standard 75 mg/day maintenance dose.	None
Blindt, 2007 18064332 Germany NR	99 NR 74 (74.7) 63.7±11.2	NR NR NR PCI 47 (47.5) 35 (35.4) NR NR 47 (47.5) 22(22.2)/29 (29.3)	58 (58.6) 42 (42.4) 70 (70.1) 16 (16.2)	NR 100 100 NR	NR DES 65 (65.7); BMS 34 (34.3) NR	Patients with an elevated risk to develop ST acute MI within 48 hours undergoing emergency or elective PCI	All patients were given 75 mg clopidogrel and 100 mg aspirin once a day at least five days prior to PCI. Only in case of emergency PCI, patients received a loading dose of 600 mg before the intervention. Dual antiplatelets for 6 months.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Bliden, 2007 17291930 USA NR	100 Caucasian male 60 African-American male 12 66±11	NR NR NR CABG 31 NR 13 NR 40 NR	83 56 HTN 74; systolic 145±22; diastolic 76±16 44	NR 100 100 NR	100 DES 75 BMS 24 NR	Non-emergent coronary stenting	Clopidogrel therapy (75 mg qd) for ≥1 month before undergoing non-emergent coronary stenting were enrolled after giving informed consent. A clopidogrel loading dose was not administered. All patients had received at least 81 mg aspirin for 7 days before the procedure.	Eptifibatide was administered at the discretion of the treating physician with the ESPRIT study protocol as a double bolus (180 ug/kg) followed by an infusion (2 ug/kg/min) for 18 to 24 h after procedure. Unfractionated heparin was administered according to the ESPRIT dosing regimen (60 U/kg) as a bolus to all patients in the catheterization laboratory immediately before stenting.
Gori, 2008 19132241 Italy RECLOSE	746 NR 75 68±12	NR NR NR PCI 23; coronary artery surgery 6 33 40 NR 25 26	hyper 49 23 HTN 61 20	NR NR NR NR	100 DES 93 multi 57	not used	All patients received aspirin (325 mg) and a loading dose of 600 mg of clopidogrel followed by a maintenance dose of 75 mg daily.	Patients on a maintenance dose of ticlopidine or clopidogrel at the time of admission received a loading dose of clopidogrel (600 mg).

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Gurbel, 2010 20691842 USA PREPARE POST-STENTING	225 White male: 54 African American male: 13 66±12	NR NR CVA 12 PTCA 35;CABG 24 NR NR 8 33 NR	hyper 80 55 Systolic BP, mm Hg: 144 ± 25 Diastolic BP, mm Hg 75 ± 17;HTN: 74 41	NR NR NR 34	NR NR NR	not used	Clopidogrel: 300 (n=73) to 600 mg (n=75) LD + 75 mg/d MD; no LD for pts on clopidogrel (n=77) Aspirin: 325 mg LD + 81-325 mg MD	Eptifibatide (n=123) Unfractionated heparin to achieve a clotting time of 200 to 250 seconds (for those given GPIIb/IIIa inhibitor) and >300 seconds (all other patients)
Matetzky, 2004 15184279 Israel No	60 NR 80 58±13	55 NR NR NR NR NR 13 100	28 47 18 27	NR NR NR NR	NR NR NR	NR	All received 300 mg of chewable aspirin on admission and 200 mg/d thereafter throughout the study period. Clopidogrel was administered as a loading dose of 300 mg on completion of the PCI, followed by doses of 75 mg/d for 3 months.	Heparin was administered during the procedure but was discouraged after the procedure. Eptifibatide was administered for a mean of 14±2 hours.
Angiolollo, 2007 17936152 Spain NR	173 173 (100) 113 (65) 67±9	127 (73) NR 7(4) 7(4) NR NR 21 (12) 92 (53) NR	118 (68) 23(13) 112 (65) 100	NR 100 100 NR	108 (62) Drug-eluting stent 127 (73)	Patients with coronary artery disease (CAD)	Treatment with clopidogrel (75 mg/day) had been prescribed for 12 months. Aspirin (100 mg/day) was used indefinitely.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Aradi, 2008 18388039 Hungary NR	134 NR 79 (58.96%) 61.07 ± 0.86 mean ± SD	NR NR NR NR NR NR 25 (18.66%) previous MI NR	15 (11.19%) Hypecholesterinaemia Ever 57 (42.54%)/Current 28 (20.90%) HTN 104 (77.61%) (>140/90 or receiving antiHTN treatment) 32 (23.88%)	NR NR NR NR	100% Bare metal NR	Patients referred for PCI with stenting	Antiplatelet agents were given at the time of the procedure, 300 mg ASA with 300 mg clopidogrel or 500 mg ticlopidine, orally at the discretion of the operator. After PCI, 100 mg ASA supplemented by 75 mg clopidogrel or 2 x ticlopidine were given daily to patients until 12 months.	PCI done after administration of 60 to 90 IU/body weight kilograms of unfractionated heparin. No platelet glycoprotein IIb/IIIa receptor blocker was used.
Bellemain-Appaix, 2010 20170822 France ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis)	96 NR 76 (79%) mean: 61.7	NR NR NR NR NR NR 100% n-STEMI: 100%	hyperlipidemia: 51% Tobacco use: 30% High BP: 57% 21.9%	NR NR 39.5% NR	NR NR NR	Patients with ACS	In the RCT, patients were allocated to receive a clopidogrel LD of 300, 600, or 900 mg orally on the morning of day 1 of the study. All patients received an LD of 250 to 500 mg of aspirin twice daily.	All patients received low molecular weight heparin twice daily.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Breet, 2011 21478385 The Netherlands POPular	951 NR 717 (75.4) 64±10.6	NR NR NR NR NR NR 519 (54.6) NR	Hyper 769 (80.9) 107 (11.3) 737 (77.5) 175 (18.4)	NR 489 (51.4) NR 270 (28.4)	Total length 28.3±17.1 DES 604 (63.8) NR	Patients scheduled for PCI with stent implantation	All patients on aspirin 80-100 mg daily for >0 days unless they were on long-term anticoagulation with coumarin derivatives; clopidogrel - chronic maintenance therapy of 75 mg for >5 days or a clopidogrel loading dose of 300 mg at least 24 h before PCI or 600 mg at least 4 h before PCI. Aspirin 80-100 mg daily for ≥10 days unless they were on long-term anticoagulation with coumarin derivatives.	
Breet, 2010 20695984 Netherlands Substudy of a larger cohort (Breet 2010 PMID: 20179285)	692 NR NR NR	NR NR NR NR NR NR NR NR	NR NR NR NR	NR NR NR NR	NR NR NR NR	Patients with PCI and stent implantation	Clopidogrel and aspirin maintenance doses were 75 mg and 80 to 100 mg daily, respectively. [These details are obtained from original study]	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Buonamici, 2007 17572245 Italy NR	804 NR 602 (75) NR	NR NR NR 186 (23) 275 (34) 312 (39) NR 206 (26) NR	405 (50) 179 (22) 501 (62) 169 (21)	NR 100 100 NR	100 Drug-eluting 457 (57)	Patients received successful drug eluting stent implantation	All patients received aspirin (325 mg) and a loading dose of 600 mg of clopidogrel followed by a maintenance dose of 75 mg daily. Patients on a maintenance dose of ticlopidine or clopidogrel at the time of admission received a loading dose of clopidogrel (600 mg).	
Campo, 2007 17868803 Italy NR	143 NR 99 (69) 67±10	NR NR NR PCI 25 (17)/ CABG 7 (5) NR NR NR 26 (18) NR	NR 31 (22) 104 (73) 32 (27)	NR 100 NR NR	NR NR NR NR	Patients undergoing PCI	clopidogrel 300-mg loading dose, followed by 75 mg/day+ aspirin (250 mg intravenously) for patients with STEMI. Patients with stable angina (SA) received aspirin (100 mg once a day) at least 7 days and clopidogrel at least 6 h before procedure. Aspirin (100 mg once a day) was given to all patients indefinitely, whereas thienopyridines were given for 1 or 6 months according to implanted stent.	All pts received , heparin (50 to 70 U/kg), and glycoprotein IIb/IIIa inhibitors

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Cuisset, 2009 19736156 France NR	597 NR 456 (76.4%) Mean: 64.2	NR NR NR NR NR NR NR NR	54.1% Current: 44.2% HTN: 59.8% 28.5%	NR NR NR NR	NR NR NR	Patients admitted with a NSTEMI ACS for coronary angiography/PCI	Clopidogrel 600 mg LD + Aspirin 250 mg LD at least 12 hours before coronary angiography and PCI as indicated	
Cuisset, 2006 16371119 France NR	106 NR 82 (77%) 64 ± 10 mean ± SD	NR NR NR NR NR NR NR NR	59 (56%) 40 (38%) HTN 62 (58%) 26 (25%)	NR NR NR NR	NR NR NR	Patients with clinical symptoms compatible with acute myocardial ischemia admitted for PCI and stenting	Patients on chronic therapy with a daily dose of 75 mg clopidogrel for >5 days did not receive a loading dose of clopidogrel. Other patients received 300 mg of clopidogrel at least 12 h before stenting. All patients received aspirin 160 mg daily administered at least 12 h before stenting.	
Cuisset, 2006 17010792 France NR	292 NR 222 (76%) 64.7	Previous ACS: 44.5% NR NR NR NR NR NR NSTEMI: 100%	55.5% Current: 46% HTN: 57% 31%	NR NR NR NR	NR NR NR	Patients undergoing percutaneous coronary intervention (PCI) for NSTEMI ACS	Patients were randomly assigned to receive a 300-mg or 600-mg loading dose of clopidogrel at least 12 h before stenting. All patients received aspirin 160 mg daily after a loading dose of 250 mg administered at least 12 h before stenting.	For all patients, anticoagulation was begun before PCI in the intensive care unit and performed with low-molecular-weight heparin (enoxaparin), or unfractionated heparin in patients over 75 years old or with renal insufficiency.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Cuisset, 2007 17264958 France NR	190 NR 146 (76.8) NO PMI 66±11/PMI 4±13	NR NR NR NR NR NR NR	190 (100) 91 (47.9) 110 (57.9) 64 (33.7)	NR 42 (22.1) 89 (46.8) NR	NR NR NR	NSTE ACS patients	After collecting baseline blood samples for troponin I (TnI), patients received oral loading doses of 250 mg aspirin and 600 mg of clopidogrel at least 12 h before stenting	Anticoagulation was performed with low-weight-molecular heparin (LWMH) (enoxaparin) when possible, or unfractionated heparin (UFH) in patients over 75 years or with renal failure. Use of a GPIIb/IIIa antagonist was allowed at the operator's discretion.
Geisler, 2008 17949474 Germany NR	1092 NR 806 (73.8%) 67.5 ±10.8 yr	100% NR NR NR 529 (48%) NR NR 222 (27.4%) 193 (17.7%)/225 (20.6%)	Hyperlipidemia 641 (58.7%) 425 (38.9%) HTN 876 (80.2%) 363 (33.2%)	NR 155 (14.2%) around 90% NR	100% DES 206 (18.9%)/BMS 793 (72.6%)/Both 93 (8.5%) NR	Adults undergoing coronary stenting for symptomatic CAD	300 or 600 mg clopidogrel given as loading dose before PCI and stenting. After, daily dose was 75 mg for 3 mo. 500 mg ASA given as loading dose, followed by 100 mg/day.	Unfractionated heparin given periprocedurally (70 U per kg of body weight).
Geisler, 2006 17005534 Germany NR	363 NR 277 (73.1) 67.5±10	NR NR NR NR NR NR NR NR	220 (60.6) 151 (41.6) 289 (79.6) 126 (34.7)	NR 100 100 NR	NR NR NR	CAD patients	A loading dose of 600 mg clopidogrel was given to all patients prior to PCI followed by a daily dose of 75 mg for at least 3 months. All patients received a standard dose of aspirin 100 mg daily before enrollment in the study.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Geisler, 2010 19812059 Germany NR	1019 NR 756 (74.2%) mean: 67.8	NR NR NR NR NR NR NR	Hyperlipidemia: 59.6% 37.9% HTN: 80.4% 33.1%	NR NR NR NR	100% BMS: 72.7%/DES: 27.3% Multivessel: 76.1%	Patients with CAD & ACS for PCI	Clopidogrel: 600 mg LD (300 mg for those on clopidogrel therapy) + 75 mg/d MD x 6-12 months Aspirin: 500 mg LD + 100 mg/d MD	Unfractionated heparin was peri-procedurally administered to all patients at a dosage of 70 U/kg body weight
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	804 (of whom 772 consented to participation in the genetics substudy) NR 576 (74.6%) NR	NR LVEF = 47% ±12% NR PCI = 161 (20.9%)/CABG = 58 (7.5%) 262 (33.9%) 310 (40.2%) NR 197 (25.5%) NR	Dyslipidemia = 461 (59.7%)/ Statin = 690 (89.4%) 266 (34.4%) HTN = 505 (65.4%) 171 (22.2%)	NR NR (100% on current study) NR (100% on current study) 732 (94.8%)	772 (100%) 100% DES (sirolimus or paclitaxel) 439 (56.8%) had multi-vessel disease; NR if all received multiple stents	Patients with ACS or CAD undergoing PCI with stenting	All patients received aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance). Loading dose was administered before the procedure	UFH was used during the procedure as the anticoagulant
Gori, 2008 18718420 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	764 NR 563 (75.4%) 68.1	100% NR NR PCI: 22.8%/CABG: 6% 33.4% 39.9% NR 24.5% NR	Hypercholesterolemia: 49.5% 22.8% HTN: 62.3% 20.4%	NR NR NR NR	NR Sirolimus-eluting stent: 54.8%/Paclitaxel-eluting stent: 38.6%/Both stent types: 6.6% NR	Patients with CAD & ACS treated with PCI and stenting	600 mg clopidogrel LD + 75-mg MD Aspirin 325 mg MD	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Gurbel, 2008 19012177 USA None	297 213/293 white (73%) [n=4 had missing data] 193/293 (66%) [n=4 had missing data] 65 +/-12 (mean/SD)	Family history of CAD 140 (47%) NR NR PCI 119 (40%)/CABG 66 (22%) NR NR NR 100 (34%) NR	Hyperlipidemia 244 (82%) 162 (55%) 74+/-16 diastolic/ 143+/-23 systolic/ HTN 221 (74%) 123 (41%)	NR 115 (39%) NR NR	NR DES 56%/BMS 42% NR	patients undergoing nonemergent PCI	On the day of PCI, 113 patients (38%) received 600 mg clopidogrel loading dose and 68 patients (23%) received a 300 mg loading dose. One-hundred fifteen patients (39%) were on maintenance therapy with a 75 mg daily dose at the time of PCI and were not reloaded. All patients received 81–325 mg aspirin daily for at least 1 week prior to PCI and 325 mg on the day of the procedure. Aspirin (325 mg/qd) and clopidogrel (75 mg/qd) were prescribed in all patients at the time of hospital discharge according to ACC/ AHA guidelines.	All patients received bivalirudin (n =94) or heparin therapy (n =203) either with eptifibatide (n =122) or without eptifibatide (n =175). Anticoagulant therapy was discontinued at the completion of the procedure in all patients.
Gurbel, 2004 15154601 USA None	94 Caucasian or African American? 71 (65%) [reporting unclear] 60 (64%) Mean +/- SE 65 +/-17 yr	NR NR NR PTCA 22 (23%)/CABG 18 (19%) NR NR NR 30 (32%) NR	Hypercholesterolemia 65 (70%) <6 mo ago 22 (23%); >6 mo ago 32 (34%); Never 40 (43%) NR 48 (42%)	NR NR 100% NR	100% NR NR	Patients undergoing elective PCI	All patients received 300 mg clopidogrel in the catheterization laboratory after successful coronary artery stent implantation followed by 75 mg daily for 30 days. In addition, all patients had received at least 81 mg aspirin for 7 days prior to the procedure and were administered 325 mg on the day of the procedure and daily thereafter.	Intravenous unfractionated heparin to achieve an activated clotting time >300 s was administered to all patients immediately before stent implantation. GP IIb/IIIa inhibitors were not given as specified by the research protocol.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Hochholzer, 2006 17084243 Germany EXCELSIOR	802 NR 627 (78.2) 66.4±9.1	NR NR NR 112 (14) NR NR NR 184 (22.9) NR	NR 87 (10.8) 660 (82.3) 199 (24.8)	NR 100 100 NR	NR Drug-eluting stents 178 (22.2) NR	Patients undergoing elective coronary stent placement	After PCI, all patients received aspirin (≥100 mg/day) and 75 mg/day clopidogrel for the duration of the study.	
Htun, 2011 21273381 Germany NR	1567 Caucasian 100% 1170 (74.7) 67.4± 0.27	NR NR NR NR NR NR NR NR	943 (60.2) 521 (33.2) 1259 (80.3) 499 (32.4)	70 (4.5) 698 (44.6) NR NR	NR bare metal 1143 (74.1) drug eluting 297 (19.2) NR	patients underwent coronary stenting	600-mg clopidogrel loading dose and 100 mg of aspirin. All of the patients were prescribed clopidogrel (75 mg/d) and aspirin (100 mg/d) treatment for at least 3 months after the index PCI.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
L'Allier 2008 18342223 Canada PREPAIR study	148 NR 116 (78%) 61.7 (9.2) yr mean (SD)	NR NR NR Coronary angioplasty 31 (21%); Coronary bypass 14 (9%) NR NR NR 36 (24%) NR	Hypercholesterolemia 122 (82%) Current smoker 35 (24%) HTN 106 (72%) 37 (25%)	NR NR 144 (97%) NR	NR NR NR	Patients with suspected or documented coronary artery disease admitted to our hospital for elective coronary angiography and PCI when appropriate	Group A, clopidogrel 300 mg the day before (≥ 15 h) plus 75 mg the morning of the procedure; Group B, clopidogrel 600 mg the morning of the procedure (≥ 2 h); and Group C, clopidogrel 600 mg the day before (≥ 15 h) and 600 mg the morning of the procedure (≥ 2 h); All stented patients received 75 mg of clopidogrel daily for at least 30 days as clinically indicated after implantation.	
Liu, 2011 21613806 China None	111 [NB 2 withdrew before 12 hr] Chinese 100% 73 (66%) Mean/SD 66.2/8.9 yr	NR NR NR PCI 13% CABG 4% NR NR NR NR	Hypercholesterolemia 16% 47% HTN 78% 32%	NR 100% 100% 51%	100% NR NR	Patients undergoing elective stenting	A loading dose of 300 mg of clopidogrel was administered on the first day, approximately 12 h before PCI. A maintenance dose (75 mg) was administered daily after PCI. In addition, all patients received 100 mg of aspirin for 7 days before the procedure and 100 mg daily thereafter.	Heparin was administered as a bolus to all patients immediately before stenting.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Muller, 2003 12719773 Germany None	105 NR 65 (71%) 65+/-10 mean +/- SD	100% NR NR NR NR NR NR NR	NR 14% HTN 77% 21%	NR NR NR NR	NR NR NR	patients with stable coronary artery disease undergoing coronary angiography	All patients received regular aspirin therapy with a daily dose of 100 mg. Before coronary angiography, initial dose of 600 mg clopidogrel	
Muller, 2010 20728084 Germany NR	903 NR 673 (75.5%) 68.5±10.7	ACS:56.9% NR NR NR NR NR NR NR NR	Hyperlipidemia (triglycerides ≥175 mg/dl and/or LDL-cholesterol ≥100 mg/dl and/or taking any of lipid lowering drugs): 62.4% Tobacco use: 41.5% HTN:80.7% 32.3	NR NR NR NR	NR NR NR	Patients undergoing percutaneous coronary intervention (PCI) for ACS and CAD	Clopidogrel: 600 mg LD + 75 mg MD Aspirin: 100 mg/d MD	
Obradovic, 2009 19318922 Serbia NR	total 52 NR 42 (80.8) 59.9±9.2	NR NR NR elective PCI 30 (57.7); urgent PCI 22 (42.3) 17 (32.7) 35 (67.3) NR NR NR	NR 15 (28.8) 34 (65.4) 10 (23.1)	NR NR NR NR	100 NR 29 (55.8)	PCI patients	After the angiogram, patients with one or two vessel disease suitable for PCI were scheduled for PCI 3-4 h later, and these patients received a loading dose of clopidogrel of 300 mg.	Patients scheduled for PCI received clopidogrel 75 mg once daily or ticlopidine 250 mg twice daily together with 100 mg of aspirin once daily for at least 5 days before PCI. Patients received nonenteric-coated aspirin (300mg) and subcutaneous enoxaparin (1mg/kg) at admission and had a priority for the angiogram.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Saw, 2008 19038679 Canada ELAPSE trial	33 (but 7 withdrew, so baseline & follow-up data reported for only 26) NR 22 (84.6%) 63.0 +/- 8.6 mean +/- SD	NR NR NR NR NR NR NR	Hyperlipidemia 25 (96.2%) 2 (7.7%) HTN 21 (80.8%) 4 (15.4%)	NR 0% 100% NR	1 DES 18 (69.2%) NR	patients undergoing coronary stenting	Patients were already receiving aspirin. Clopidogrel 600 mg was given before stenting. Clopidogrel 75 mg/day and aspirin 325 mg/day were continued for 1 year	Procedural anticoagulant choice was at the discretion of the interventionalists. Eptifibatide or tirofiban was permitted, but had to be discontinued 10 h before the next day's blood work. Abciximab was not permitted due to its long effective half-life.
Trenk, 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	802 NR 627 (78%) 66.4 ± 9.1 (SD)	NR NR; Left ventricular ejection fraction <55%: 35.8% NR Previous balloon angioplasty:34.2%; Previous CABG: 14% CANADIAN Cardiovascular Society angina class III or IV: 24.8% NR NR 22.9% NR	NR Active smokers: 10.8% arterial hypertension (definition NR): 82.3% 24.8	NR NR 100% NR	36.4 Drug-eluting stents multivessel PCI: 22.2%	Patients undergoing percutaneous coronary intervention (PCI), including those who have undergone PCI with stent implantation, and those who have undergone coronary artery bypass grafting surgery	Pretreatment: with pre-treatment with 600 mg of clopidogrel & aspirin (100 mg per day for at least 5 days); After PCI: All patients received aspirin (≥100 mg per day) lifelong & clopidogrel (75 mg per day) for 30 days after placement of bare-metal stents or for 6 months after placement of at least 1 drug-eluting stent.	During procedure: All patients received an intra-arterial dose of 100 to 140 U/kg heparin;

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Wang, 2010 21171668 China None	154 NR 90 (58%) mean±SD 60±10 yr	NR NR NR NR NR NR NR	97 (63%) 47 (31%) HTN 107 (69%) 56 (36%)	NR NR NR NR	100% DES 100% Single 40 (26%); Dual 74 (48%); Multi 40 (26%)	patients who underwent selective PCI with DES	A 300 mg loading dose of clopidogrel was given to all patients at least 6 hours prior to PCI, followed by a daily dose of 150 mg for 2 weeks and then 75 mg for a minimum of 11.5 mo. In addition, from the first day of the procedure, all patients were administered aspirin 300 mg daily for 1 month and then 100 mg for the lifetime of the patient.	Use of glycoprotein IIb-IIIa inhibitors at discretion of the operator. A weight-adjusted intra-procedural unfractionated heparin (with a goal activated clotting time of 250–300 seconds) was administered during the procedure and was routinely discontinued at the end of the procedure.
Wang, 2009 19041120 China NR	386 NR male 257 (66.6) 68.8±9.2	NR NR NR PCI 49 (12.7); CABG 15 (3.9) NR NR NR 86 (22.3) NR	190 (49.2) 162 (41.9) 262 (67.9) 128 (33.2)	NR 100 100 NR	100 NR NR	Patients for elective coronary intervention in symptomatic stable coronary artery disease (CAD)	A loading dose of 300 mg clopidogrel was given to all patients at least 6 h prior to PCI, followed by a daily dose of 75 mg for a minimum of 12 months. In addition, all patients were administered 300 mg aspirin daily, begun the day of the procedure.	the use of Glycoprotein IIb/IIIa inhibitors at discretion of the operator. Weight adjusted intra-procedural unfractionated heparin (with a goalactivated clotting time 250 s to 300 s) was administered during the procedure andwas routinely discontinued at the end of the procedure.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Yong, 2009 19081397 Australia Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial	256 (all subjects) NR 180 (70.3%) Mean: 62.7	NR NR NR PCI: 11.3%; CABG: 7.4% NR NR NR 18.4 NR	Hypercholesterolemia: 50.4% Current: 30% HTN: 52% 21.5	NR NR 39.8 NR	NR NR Multivessel disease: 53.9%	Patients undergoing percutaneous coronary intervention (PCI) for ACS	An open-label 300-mg LD of clopidogrel and then pts randomized to 300 mg of clopidogrel (clopidogrel 600-mg group) or matching placebo (clopidogrel 300-mg group).	All other treatments were administered at the discretion of the treating physician.
Gurbel, 2003 12714161 USA No	63 NR 60 67±11	NR NR NR CABG 18 NR NR NR 24 NR	hyper 60 NR HTN 72 39	NR 100 100 NR	100 NR NR	elective stenting	all received ± 81 mg of aspirin for 7 days before the procedure. All patients received the same clopidogrel regimen (300 mg in the catheterization laboratory after stent implantation, then 75 mg/day for 30 days) with 325 mg/day aspirin.	Heparin (activated clotting time >300 seconds) was administered to all patients immediately before stent implantation, and per protocol, GP IIb/IIIa inhibitors were not given.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Gurbel, 2005 16286165 USA PREPARE POST-STENTING	182 White: 115 (59%) 108 (56) 65±12	NR NR NR PTCA:39.6/CABG:24.5% NR NR NR 36.9% NR	Hyperlipidemia: 66.7% 43.8% HTN: 66.2% 42.2%	NR 100 NR NR	96% DES: 69.8%/BMS: 28.1% NR	PCI for ACS	Clopidogrel (loading dose of 300 or 600 mg or continuation of pre-enrollment maintenance dose; maintenance dose 75 mg daily) + aspirin (81- to 325-mg daily dose for seven days before the procedure, and 325 mg on day of procedure and daily thereafter)	
Gurbel, 2003 12796140 USA NR	96 NR NR NR	NR NR NR NR NR NR NR NR	NR NR NR NR	NR NR 100% NR	NR NR NR	Patients undergoing PCI with stenting	All patients received aspirin (325 mg). Clopidogrel (300 mg) was administered in the catheterization laboratory and followed by 75 mg daily.	
Kalantzi, 2012 21806493 Greece NR	40 NR 70 57.6±10.8	NR NR NR NR NR NR NR NR	hyper 40 57.5 HTN 60 0	NR NR NR NR	NR NR NR NR	patients with ACS with or without ST elevation for PCI	LD 325 mg aspirin+MD 100mg/day LD 600mg clopidogrel+MD 75 mg/day	heparin 1mg/kg every 12 h atorvastatin 40mg/day

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Angiolillo, 2011 Italy NR	187 Caucasian 100 70.5 64±10	71 NR NR 2 NR NR 10.7 56.7 NR	72.7 14.9 65.2 32.6	NR NR NR 78.6	NR NR NR	CAD for PCI	aspirin 100mg/day indefinitely and clopidogrel 75mg/day for 12 months	NR
Gurbel, 2012 21862113 USA NR	78 Caucasians: 67% 64% 65±10	100% NR NR NR NR NR NR NR	NR 67% NR NR 32%	NR NR 100% NR	NR NR NR	CAD patients and also CAD patients for PCI	325 mg of aspirin and a loading dose of 600 mg of clopidogrel	NR
Saad, 2012 22146578 Egypt NR	90 NR 58% 56.2 y	100% NR NR NR NR NR NR NR	Hypercholesterolemia: 31.1% 67% 19% HTN: 57% 62%	NR NR 100% NR	NR NR NR	CAD patients for PCI	clopidogrel LD: 600 mg; MD: 75 mg/d; aspirin 162 mg/d	nitrates, b-blockers, , lipid-lowering drugs, antihypertensive drugs and oral hypoglycemic drugs

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Aradi 21902692 Hungary NR	200 NR 60.7 61.9	NR NR 3.1 PCI 7.7; CABG 10.2 NR 100 NR NR NR	52.6 36.7 85.2 38.3	NR NR NR 24.5	NR DES 68.4 NR	stable angina patients with de novo stenosis feasible for as hoc coronary stent implantation	LD clopidogrel 600 mg, 300 mg aspirin. MD clopidogrel 75 mg or 150 mg for 4 weeks	NR
Gaglia, 2012 21919956 USA NR	200 69.5 72.5 63.5	NR 17.5 NR PCI=39.9/CABG-23% NR NR 14.6 NR NR	NR 29.5 87.4 34.8	NR NR NR NR	NR NR NR NR	CAD and ACS patients undergoing PCI & stenting	LD: 600 mg loading clopidogrel or 75-mg for 5 days MD: Aspirin + clopidogrel 75 mg for 1 month in patients with BMS and 12 months in patients receiving DES	NR
Marcucci, 2012 22390861 Italy NR	1187 NR 75 69	NR NR NR NR NR NR 100 (ACS) 35	54 37 NR 65 24	NR 100 100 94	100 DES 18%/BMS NR NR	Adults undergoing PCI and stenting for ACS	600 mg clopidogrel loading dose followed by 75 mg daily dose ASA IV 500 mg followed by 100-325 mg daily dose	"Unfractionated" heparin 70 IU/kg during PCI

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Ge, 2012 21602258 China NR	352 NR 190 (54) 55.3 (8.8)	NR NR 118 (34) NR NR NR NR NR NR	156 (44) NR NR 239 (68) 159 (45)	NR NR NR NR	352 (100) DES = 352 (100) NR	PCI for DES implantation	Patients were on aspirin for ≥5 d but not clopidogrel (within 2 w). They received clopidogrel a loading dose of clopidogrel 600 mg pre-PCI and maintenance treatment with clopidogrel 75 mg/d and aspirin 100 mg/d, for 1 yr.	Unfractionated heparin; use of IIb/IIIa inhibitors was at the discretion of the investigator.

*Mean (standard deviation), unless otherwise stated.

Appendix Table E6. Baseline characteristics of patients with peripheral arterial disease in studies assessing the predictive ability of LTA

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medications
Linnemann, 2010 20153859 Germany NR	54 NR 29 (53.7%) Median: 68 (range 53-94)	IHD: 38.9% NR CVD:18.5%;prior cerebral infarction: 5.6% PCI: 24.1%;CABG: 11.1% NR NR 100% 14.8% NR	hyperlipidemia: 81.5% Current: 24.1% HTN: 77.8% 33.3%	NR 100% NR NR	NR NR NR	Patients with Peripheral artery occlusive disease on clopidogrel	Clopidogrel 75 mg daily	

* Mean (standard deviation), unless otherwise stated.

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH=Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors; ACC/AHA=American College of Cardiology/American Heart Association

Appendix Table E7. Baseline characteristics of a mixed patient population of patients with ischemic heart, cerebrovascular and peripheral vascular disease in a single study assessing the predictive ability of LTA

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Reny, 2012 22615340 France and Switzerland ADRIE	771 NR 81 62.9	66 NR 13 NR NR 21 NR NR	36 75 NR 57 22	NR 99 85.5 29	NR NR NR	patients with symptomatic documented ischemic atherothrombotic disease (coronary artery disease, ischemic cerebrovascular disease, and/or peripheral artery disease)	non–enteric-coated aspirin and/or clopidogrel	NR

*Mean (standard deviation), unless otherwise stated.

Appendix Table E8. Design characteristics of studies assessing the predictive ability of LTA in patients with ischemic heart disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Geisler, 2010 20526607 Germany NR	Prospective	NO	Consecutive	Patients with diabetes and symptomatic CAD undergoing PCI	March 2005-May 2008	Total 30 days after PCI	Inpatient and then 30 day followup of outpatients	YES [NR]	NR
Cuisset, 2009 19801028 France NR	prospective Cohort	No	Consecutive	NSTE ACS patients	NR	NR	CHU Timone inpatient	NR	non-industry (grants from the Assistance publique hôpitaux de Marseille, Marseille, France)
Frere, 2007 17938809 France NR	Prospective observational	No	Selected patients with coronary stenting	Patients had undergone successful coronary stenting	March 2005-May 2006	One-month follow up	Department of Cardiology inpatient	NR	NR
Hoshino, 2009 19106460 Japan NR	Prospective observational	NO	NR	Patients undergoing percutaneous coronary intervention (PCI) for ischemic heart disease	NR	Max 30 days	followup after intervention	NR	Non-industry (Health and Labor Sciences Research Grant for Cardiovascular Research and a Grant from the Japan Cardiovascular Research Foundation.)
Breet, 2010 20179285 Netherlands NR	prospective Cohort	No	Patients scheduled for PCI with stent implantation	Patients with PCI and stent implantation	Dec 2005-Dec 2007	1-year	Hospital inpatient	Yes. 80%	NR
Gurbel, 2010 20194878 10 study sites in North America and Europe RESPOND	Prospective cohort derived from an crossover RCT	YES	Consecutive	Patients with CAD on aspirin therapy	May 19, 2008 - March 25, 2009	NR (At least 28 days for completion of period 1 and period 2)	community (non-health care setting)	YES; Accrual >80%	Industry (AstraZeneca)
Kim, 2010 20449634 Korea NR	prospective cohort	no	Consecutively enrolled	unselected patients treated with coronary stenting for symptomatic coronary artery disease, including acute myocardial infarction (AMI) and chronic clopidogrel therapy	December 2007 to June 2009	6 months	Department of Cardiology of the Gyeongsang National University hospital inpatient	NR	NR

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Angiolillo, 2008 18312754 USA OPTIMUS	prospective Cohort	No	Patients underwent PCI and were treated with standard clopidogrel	Patients underwent PCI and were treated with standard clopidogrel	NR	1 months	Hospital inpatient	Yes; Accrual>80%	NR
Blindt, 2007 18064332 Germany NR	prospective Cohort	No	Selected sample?	Patients with an elevated risk to develop ST acute MI within 48 hours undergoing emergency or elective PCI	NR	6 months	Department of cardiology in University Hospital Aachen inpatient	NR	NR
Bliden, 2007 17291930 USA NR	prospective Cohort	no	Consecutive	Patients receiving clopidogrel	NR	12 months	Hospital inpatient	With the sample size calculation from SigmaStat software, it is estimated that the sample size required for 95% power with the alpha of 0.05 is approximately 100 patients.	Partly industry (NIH and Bayer)
Gori, 2008 19132241 Italy RECLOSE	Prospective	NR but probably NO	Consecutive	RECLOSE patients who underwent DES implantation for whom complete AA- and collagen-induced platelet aggregation values were available.	July 2005 to February 2006	Total 6 months	Outpatient followup of cohort at 1, 3, and 6 mo	YES [YES]	Nonindustry
Gurbel, 2010 20691842 USA PREPARE POST- STENTING	Prospective observational study	NO	Consecutive	Patients undergoing percutaneous coronary intervention (PCI)	2004 and 2005	Max of 36 months	Followup after intervention	YES; Accrual>80%	Non-industry (Sinai Hospital, Baltimore & NIH grant R44- HL059753)
Matetzky, 2004 15184279 Israel No	prospective	NR	Consecutive	STEMI patients	NR	total 6 months	Outpatient follow up	NO	NR

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Angiolillo, 2007 17936152 Spain NR	prospective Cohort	No	Type 2 diabetes mellitus patients with coronary artery disease (CAD) on chronic treatment with dual antiplatelet therapy were eligible for this study.	Type 2 diabetes mellitus patients with coronary artery disease (CAD) on chronic treatment with dual antiplatelet	Jan 2003 to Feb 2005	One year	Hospital inpatient	NR	Partly industry
Aradi, 2008 18388039 Hungary NR	Prospective	NR	NR	Patients referred for PCI with stenting	NR	10 mo	Inpatient and then outpatient after PCI, followed till 10 mo	NR	NR
Bellemain-Appaix, 2010 20170822 France ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis)	Substudy of ALBION RCT	YES	Selected sample (Patients with platelet aggregation data from RCT)	Patients with ACS	NR	max: 1 day	Inpatient	NO	NR [Industry funding for authors is reported]
Breet, 2011 21478385 The Netherlands POPular	prospective Observational study	NR	Consecutive	Patients scheduled for PCI with stent implantation	NR	1 year	Hospital inpatient	NR	NR

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Breet, 2010 20695984 Netherlands Substudy of a larger cohort (Breet 2010 PMID: 20179285)	prospective Cohort	No	Patients scheduled for PCI with stent implantation	Patients with PCI and stent implantation	Dec 2005- Dec 2007	1-year	Hospital inpatient	Yes. The study was designed on the basis of the superiority principle to have 80% power to observe an incidence of the primary end point in patients exhibiting high on-treatment platelet reactivity of 10% and 4% in patients without high on-treatment platelet reactivity.	NR [Authors report no COI]
Buonamici, 2007 17572245 Italy NR	prospective Cohort	No	Consecutive patients	Patients received successful drug eluting stent implantation	July 2005 to August 2006	6 months	Academic hospital inpatient	Yes. To have a power of 0.80 to detect the hypothesized effect size with a 1-sided p value <0.05, a sample size of at least 800 was needed.	NR
Campo, 2007 17868803 Italy NR	prospective Cohort	No	Patients undergoing PCI	Patients undergoing PCI	Nov 2005-may 2006	Every 4 months	Hospital inpatient	No	NR
Cuisset, 2009 19736156 France NR	Prospective observational study	NO	Consecutive	Patients admitted with a NSTEMI ACS for coronary angiography/PCI	NR	Total 30 days	followup after intervention	NO	non-inducstry (Assistance Publique Hôpitaux of Marseille)
Cuisset, 2006 16371119 France NR	Prospective	NO	Consecutive	Patients with clinical symptoms compatible with acute myocardial ischemia admitted for PCI and stenting	June-Dec 2004	Total 1 mo	Outpatient after PCI	NR	NR
Cuisset, 2006 17010792 France NR	Prospective; 2 arms of an RCT are separate cohorts	NO	RCT	Patients undergoing percutaneous coronary intervention (PCI) for NSTEMI ACS	June 2004 – Oct 2005	Max 1 month	followup after intervention	NR	Non-industry [Assistance Publique Hôpitaux de Marseille]

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Cuisset, 2007 17264958 France NR	prospective Cohort	No	Consecutive patients	NSTE ACS patients	May 2005-Feb 2006	24 hours after PCI	Hospital inpatient	No	NR
Geisler, 2008 17949474 Germany NR	Prospective	NO	Consecutive	Unselected adults undergoing coronary stenting for symptomatic CAD	March 2005- Dec. 2006	Total 30 days	Inpatient for stenting, then follow up by phone 30 days after discharge	NO	Nonindustry only
Geisler, 2006 17005534 Germany NR	prospective Cohort	No	Consecutive Patients admitted for CAD	CAD patients	March to August 2006	3 months	Hospital inpatient	Yes. With a probability of 80% that the study will detect a minimal hazard ratio (HR) of 2.25% for the primary endpoint at a one-sided 5.0% significance level and a presumed low responder rate of up to 10%, we estimated a sample size of 335 patients.	NR
Geisler, 2010 19812059 Germany NR	Prospective observational	NO	Consecutive	Patients with CAD & ACS for PCI	March 2005- March 2007	max 3 months	followup after intervention	YES; Accrual>80%	non-industry ('Deutsche Forschungsgemeinschaft', 'Sonderforschungsbereich Transregio TR-19', and the Karl&Lore-Klein-Stiftung.)
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Prospective observational study of patients enrolled in the RECLOSE study in a single center	NO (single center recruitment for this study)	Consecutive patients consenting to genetic study identified from the RECLOSE study population	Patients with ACS or CAD undergoing PCI with stenting	July 2005 to August 2006 [recruitment period of the RECLOSE study; information from pmid = 17572245]	6 months (unclear what metric; from the KM curves implied maximum FU)	In hospital (PCI)	NO	Non-industry only

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Gori, 2008 18718420 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis)	Prospective cohort	NO	Consecutive	Patients with CAD & ACS treated with PCI and stenting	NR	6 months	Followup after intervention	NR	NR
Gurbel, 2008 19012177 USA None	Prospective	NO	Consecutive	patients undergoing nonemergent PCI	Jan. 29, 2004, to May 1, 2007	546 days (median)	Inpatient during PCI, then outpatient follow- up	YES (YES)	Non-industry only
Gurbel, 2004 15154601 USA None	Prospective	NR	NR	Patients undergoing elective PCI	NR	Total 30 days	Inpatient with subsequent followup for 30 days as outpatient	NR	Non-industry only
Hochholzer, 2006 17084243 Germany EXCELSIOR	prospective Cohort	No	Patients undergoing elective coronary stent placement	Patients undergoing elective coronary stent placement	NR	30 days	Hospital inpatient	Yes. We intended to have a power of 0.80 to detect an effect size of 0.015 (e.g., 3-fold risk in the fourth quartile) with a 2- sided p value <0.05.	NR
Htun, 2011 21273381 Germany NR	prospective cohort	no	consecutive, unselected patients	patients underwent coronary stenting	NR	365 days	university hospital inpatient	yes. With an estimated prevalence of 35%, a sample size of 1090 was calculated to detect this difference of event rate with a statistical power of 90% at a two- sided alpha level of 5%.	NR
L'Allier 2008 18342223 Canada PREPAIR study	Randomized	NR	Consecutive	Patients with suspected or documented coronary artery disease admitted to our hospital for elective coronary angiography and PCI when appropriate	NR	Total 1 month	Inpatient and followup at 1 mo after discharge	YES (YES—80%)	Nonindustry only

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Liu, 2011 21613806 China None	Prospective	NO	Consecutive	Patients undergoing elective stenting	NR	Total 3 month	Inpatient and then 12 hr, 36 hr, 1 mo, and 3 mo after stenting (most as outpatient visit)	NO	All Industry
Muller, 2003 12719773 Germany None	Prospective	NO	NR	patients with stable coronary artery disease undergoing coronary angiography	NR	NR	Inpatient and then followup as outpatient	NO	Non-industry only
Muller, 2010 20728084 Germany NR	Prospective observational study	NO	Consecutive	Patients undergoing percutaneous coronary intervention (PCI) for ACS and CAD	March 2005 to May 2008	mean : 344 days	Followup after intervention	YES; Accrual>80%	Non-industry [“Deutsche Forschungsgemeinschaft”, the “Sonderforschungsbereich Transregio TR-19”, the Karl&Lore- Klein-Stiftung and a personal grant “Atherothrombosis Grant” of the European Society of Cardiology (TG).]
Obradovic, 2009 19318922 Serbia NR	prospective Cohort	No	Selective patients with PCI	PCI patients	NR	24 h	Catheterization lab of the Military medical Academy inpatient	NR	NR
Saw, 2008 19038679 Canada ELAPSE trial	Prospective	NO	NR	patients undergoing coronary stenting who were on aspirin for 5 days but not previously on clopidogrel	Sept. 2005- Aug. 2006	Total 1 yr	Inpatient for PCI, then outpatient visits for 1 yr of follow-up	YES [YES]	Non-industry only
Trenk, 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	Observational study	NO	Substudy of the EXCELSIOR prospective study	Patients undergoing percutaneous coronary intervention (PCI), including those who have undergone PCI with stent implantation, and those who have undergone coronary artery bypass grafting surgery	NR	30 day follow up for all patients, and 12 month follow up for 795 patients (99.1%)	followup after intervention	YES; Accrual 100%; reported in Hochholzer 2006 17084243	non-industry university Funding (Herz-Zentrum, Bad Krozingen, Germany)

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Wang, 2010 21171668 China None	Prospective	NO	Selected for the same type of DES	patients who underwent selective PCI with DES	January 2006 to January 2008	Total 1 year after discharge	Inpatient and then outpatient followup	NR	No funding
Wang, 2009 19041120 China NR	prospective Cohort	No	Patients for elective coronary intervention in symptomatic stable coronary artery disease (CAD)	Patients for elective coronary intervention in symptomatic stable coronary artery disease (CAD)	Oct 2006- March 2007	One year	Hospital inpatient	Yes. We estimated a sample size of 373 patients would provide 80% power to detect an 70% relative difference in the rate of events using a one-sided 0.05 significance level, with a presumed event rate of 5.0% in normal responders and a resistance rate of up to 15%.	NR
Yong, 2009 19081397 Australia Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial	Pooled data from 2 arms of an RCT	YES	Consecutive	Patients undergoing percutaneous coronary intervention (PCI) for ACS	January 2004 and November 2005	Max 6 months	Followup after intervention	YES (for RCTs main outcome) [Accrual < 80%]	Industry
Gurbel, 2003 12714161 USA No	Prospective	NO	NR	Patients undergoing PCI with stenting	NR	NR	Inpatient and then outpatient visit at 30 days	NR	All Industry
Gurbel, 2005 16286165 USA PREPARE POST- STENTING	Prospective, observational	NO	Consecutive patients	Patients undergoing percutaneous coronary intervention (PCI) for ACS	NR	NR	Hospital, then outpatient	NO	NR

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Gurbel, 2003 12796140 USA NR	Prospective	No	Consecutive	Patients undergoing percutaneous coronary intervention (PCI) with stenting	NR	30 days	Hospital, then outpatient	NO	Industry (Sinai Center for Thrombosis Research and Platelet and Thrombosis Research, LLC)
Kalantzi, 2012 21806493 Greece NR	prospective	no	NR	patients with ACS with or without ST elevation	NR	30 days	single center	NR	NR
Angiolillo, 2011 Italy NR	NR	NR	NR	patients with type 2 DM and stable coronary artery disease	Nov 2003- March 2007	24 months	single center	yes. 89%	NR
Park, 2011 22152948 Korea NR	NR	no	consecutive	patients undergone PCI with at least 1 DES for stable angina or ischemia, or non-ST-segment elevation ACS	March 2006- Dec 2009	2.2 years	Asan Medical Center (Seoul, Korea)	yes, 90%	NR
Gurbel, 2012 21862113 USA NR	Prospective	No	NR	Stable CAD patients and CAD patients undergoing elective stenting	NR	24 hours	Hospital, Sinai Hospital of Baltimore	NR	Industry (Sanofi-Aventis U.S. Bridgewater, NJ)
Saad, 2012 22146578 Egypt NR	Prospective	No	NR	CAD patients undergoing PCI with stenting	NR	6 months	followup after intervention	NR	None reported
Aradi, 2012 21902692 Hungary NR	yes	no	selected patients	stable angina patients	Feb 2008 and Sep 2009	12 months	inpatient then followup	yes (80%)	non-industry
Gaglia, 2012 21919956 USA NR	prospective	no	NR	PCI-STENT for ACS and CAD	October 2009 to September 2010	3 days	inpatient	no	NR
Marcucci, 2012 22390861 Italy NR	Prospective observational	NO	NR	Adults undergoing PCI and stenting for ACS	NR	12 mo	Inpatient	No (NA)	Nonindustry

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Ge, 2012 21602258 China NR	Prospective cohott; unclear if prospective	No	NR	Adults ≥30 years, undergoing PCI for DES implantation	NR	Up to 6 mo	Single academic cardiology department	NR	“No support” was received

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; CAD = coronary artery disease; MI = myocardial infarction; NSTEMI = non-ST-elevation; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; DES=drug eluting stent; CABG=coronary artery bypass grafting; AA= arachidonic acid; SD=standard deviation; RCT=randomized controlled trial; NR=not reported

Appendix Table E9. Design characteristics of studies assessing the predictive ability of LTA in patients with peripheral arterial disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enroment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Linnemann 2010 20153859 Germany NR	Prospective observational study	NO	Consecutive	Patients with peripheral arterial occlusive disease on clopidogrel	July 2003-Jan 2006	Median: 17.5 months (range 10.5-40.4 months)	Outpatient	NO	NR

Appendix Table E10. Design characteristics of a single study assessing the predictive ability of LTA in a mixed patient population with ischemic heart, cerebrovascular and peripheral vascular disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enroment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Reny, 2012 22615340 France and Switzerland ADRIE	prospective Cohort	yes	Consecutive patients	symptomatic documented ischemic atherothrombotic disease (coronary artery disease, ischemic cerebrovascular disease, and/or peripheral artery disease)	June 2006 - December 2008	6 months	inpatient, then followup	yes (yes)	Non- industry only

Appendix Table E11. Phenotypic test details in studies assessing the predictive ability of LTA in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Angiolollo, 2007 17936152 Spain NR	Light transmittance aggregometry ChronoLog 490 Model ChronoLog Corp., Havertown, Pennsylvania	ADP	Blood samples for platelet function assays were collected 2 to 4 h after antiplatelet therapy intake NR 2 to 4 h after antiplatelet therapy intake. NR	HRP (set a cutoff of 62% Aggmax) non HRP	Based on ROC curve	HRP (set a cutoff of 62% Aggmax.): n=45(26) non HRP: n=128 (73)
Aradi, 2008 18388039 Hungary NR	Optical aggregometry Carat TX4 optical aggregometer Carat Diagnostics, Budapest, Hungary	adenosine diphosphate 5 and 10 umol, collagen 2 ug/ml, and adrenaline 10 umol	10 mL blood was drawn by direct venipunc ture for optical aggregometry into a sodium citrate vacuum tube Sodium citrate Clopidogrel given at time of PCI and stenting and platelets tested at 30 ± 5 days after coronary stent implantation 2 hours	Lower 50% of ADP 5 umol Induced Aggregation Upper 50% of ADP 5 umol Induced Aggregation	Not explicitly reported	Lower 50% of ADP 5 umol Induced Aggregation: NR but maybe can ascertain from Fig 1A (distribution of aggregation %s) Upper 50% of ADP 5 umol Induced Aggregation: NR but maybe can ascertain from Fig 1A (distribution of aggregation %s)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Bellemain-Appaix, 2010 20170822 France ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis)	LTA NR NR	20 µmol/l ADP	Samples obtained at baseline and 0.5, 1, 2, 3, 4, 5, 6, and 24 h NR Less than 1 day; Clopidogrel came first NR	Slow responders (maximal platelet aggregation <10% within the first hour after loading) Fast responders (maximal platelet aggregation ≥10% within the first hour after loading) Low response (maximal platelet aggregation <10% over 24 hrs) Responders (maximal platelet aggregation ≥10% over 24 hrs)	Not explicitly reported	Slow responders (maximal platelet aggregation <10% within the first hour after loading): 53 (55%) Fast responders (maximal platelet aggregation ≥10% within the first hour after loading): 46 (45%) Low response (maximal platelet aggregation <10% over 24 hrs): 9 (9.3%) Responders (maximal platelet aggregation ≥10% over 24 hrs): 7 (90.7%)
Bliden, 2007 17291930 USA NR	Platelet aggregation/ Chronolog Lumi- Aggregometer Model 490-4D Chronolog, Havertown, Pennsylvania	5 umol/LADP and 1 mmol/Larachidonic acid (AA)	from patients in a fasting state in the catheterization laboratory through the indwelling femoral vessel sheath. 3.8% trisodium citrate or lithium heparin Baseline samples were obtained before coronary intervention and at 3 h and 18 to 24 h after stenting Within 2h	HPR=high on-treatment platelet reactivity based on LTA-5 umol/L ADP (%)	Based on literature	HPR=high on-treatment platelet reactivity based on LTA-5 umol/L ADP (%) : 22%Gori

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Blindt, 2007 18064332 Germany NR	Platelet aggregation/ Densitometrically-determined measurement of platelet aggregation APACT 4 S Plus platelet aggregometer Rolf Greiner Biochemica, Flacht, Germany	10 µM ADP	The blood samples were obtained 72–96 h after stent placement. Interval at least 8 days 3.2% citrate All patients were given 75 mg clopidogrel and 100 mg aspirin once a day at least five days prior to PCI. The blood samples were obtained 72–96 h after stent placement. Interval at least 8 days Within 1 h	NR	NR	NR
Breet, 2010 20695984 Netherlands Substudy of a larger cohort (Breet 2010 PMID: 20179285)	LTA four-channel APACT 4004 aggregometer LABiTec, Arensburg, Germany	NR	NR 3.2% citrate NR 2h	High on-treatment platelet reactivity with native platelet rich plasma Non-high on-treatment platelet reactivity with native platelet rich plasma (Cutoffs NR) High on-treatment platelet reactivity with adjusted platelet rich plasma (Cutoffs NR) Non-high on-treatment platelet reactivity with adjusted platelet rich plasma (Cutoffs NR)	Not explicitly reported	High on-treatment platelet reactivity with native platelet rich plasma (Cutoffs NR) : 200 (28.9%) Non-high on-treatment platelet reactivity with native platelet rich plasma (Cutoffs NR): 492 (71.1%) High on-treatment platelet reactivity with adjusted platelet rich plasma (Cutoffs NR): 243 (35.1%) Non-high on-treatment platelet reactivity with adjusted platelet rich plasma (Cutoffs NR): 449 (64.9%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Breet, 2010 20179285 Netherlands POPULAR	Light transmittance aggregometry NR NR	5 µmol/L ADP 20 µmol/L ADP	Before Heparinization 3.2% citrate NR Within 2 hours after blood collection.	High on-treatment platelet reactivity ≥42.9% aggregation LTA-ADP 5 µmol/L N=445 Not High on-treatment platelet reactivity <42.9% aggregation LTA- ADP 5 µmol/L N=604 High on-treatment platelet reactivity <64.5% aggregation LTA-ADP 20 µmol/L n=659 Not high on-treatment platelet reactivity ≥64.5% aggregation LTA- ADP 20 µmol/L n=392	Based on ROC curves	High on-treatment platelet reactivity ≥42.9% aggregation LTA-ADP 5 µmol/L: N=445 Not High on-treatment platelet reactivity <42.9% aggregation LTA-ADP 5 µmol/L: N=604 High on-treatment platelet reactivity ≥64.5% aggregation LTA-ADP 20 µmol/L: n=392 Not high on-treatment platelet reactivity <64.5% aggregation LTA-ADP 20 µmol/L: n=659
Breet, 2011 21478385 The Netherlands POPular	Light transmission aggregometry Four-channel APACK 4004 aggregometer LABiTec, Arensburg, Germany	ADP	NR 3.2% Sarstedt citrate NR 2h	No HCPR (LTA5) With HCPR (LTA5) No HCPR (LTA20) With HCPR (LTA20) Cutoff 43% aggregation for LTA5, 65% for LTA20	Based on literature	No HCPR (LTA5): 536 With HCPR (LTA5): 385 No HCPR (LTA20): 588 With HCPR (LTA20): 335
Buonamici, 2007 17572245 Italy NR	LTA APACT 4 light transmittance aggregometer Helena Laboratories, Milan, Italy	ADP	Blood samples anticoagulated with 0.129 mol/l sodium citrate (ratio 9:1) for platelet reactivity assessment was obtained 12 to 18 h from clopidogrel loading 0.129 mol/l sodium citrate 12-18 h from clopidogrel loading NR	Responders Non-responders Patients with platelet aggregation by 10-mol ADP ≥90th percentile of controls (70%) were defined as nonresponders.	Not explicitly reported	Responders 699/804(86.9) Non-responders: 105/804 (13.1)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Campo, 2007 17868803 Italy NR	Platelet aggregation NR NR	ADP	NR NR T0 baseline before thienopyridine; T1, 5-7 days after baseline; T2, 7-10 days after T1 NR	Responder to both thienopyridines Clopidogrel nonresponders Ticlopidine nonresponders Nonresponder to both thienopyridines [Based on thienopyridine responsiveness]	Not explicitly reported	Responder to both thienopyridines: 90 Clopidogrel nonresponders: 30 Ticlopidine nonresponders: 28 Nonresponder to both thienopyridines: 5
Cuisset, 2006 16371119 France NR	light transmittance PAP4 Aggregometer Biodata Corp, Wellcome, Paris, France	ADP 10 umol/L	first blood millimeters discarded to avoid platelet activation induced by needle puncture and blood was immediately collected in vacutainer tube, filled to capacity, and then inverted three to five times for gentle mixing 3.8% Trisodium citrate before the PCI at least 12 h after the loading dose of clopidogrel and the aspirin administration and before administration of tirofiban if needed Immediately	Quartiles of (mean \pm SD) ADP- induced maximal intensity of platelet aggregation (with threshold for low response $\geq 70\%$) Q1, Q2, and Q3: responsive to clopidogrel Q4 ($82 \pm 1.2\%$): nonresponsive to clopidogrel	The quartile data— Q4 range determined the cutoff	Q1, Q2, and Q3: responsive to clopidogrel: 83 Q4 ($82 \pm 1.2\%$): nonresponsive to clopidogrel: 23

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Cuisset, 2006 17010792 France NR	Light transmission PAP4 Aggregometer Biodata Corporation, Wellcome, Paris, France	10 µmol/L ADP	Before PCI after clopidogrel LD 3.8% trisodium citrate 0.5 days (12 hours)Clopidogrel came first NR	high post treatment platelet reactivity (ADP induced platelet aggregation >70%) in 300 mg group normal post treatment platelet reactivity (ADP induced platelet aggregation <70%) in 300 mg group high post treatment platelet reactivity (ADP induced platelet aggregation >70%) in 600 mg group normal post treatment platelet reactivity (ADP induced platelet aggregation <70%) in 600 mg group	Not explicitly reported	high post treatment platelet reactivity (ADP induced platelet aggregation >70%) in 300 mg group: 36 (24.7%) normal post treatment platelet reactivity (ADP induced platelet aggregation <70%) in 300 mg group: 110 (75.3%) high post treatment platelet reactivity (ADP induced platelet aggregation >70%) in 600 mg group: 22 (15.1%) normal post treatment platelet reactivity (ADP induced platelet aggregation <70%) in 600 mg group: 124 (84.9%)
Cuisset, 2007 17264958 France NR	Light transmission PAP4 Aggregometer Biodata Corporation, Wellcome, Paris, France	ADP	Blood samples for testing platelet reactivity were drawn in the catheterization laboratory from a 6- French arterial sheath before the PCI 3.8% trisodium citrate Blood samples were drawn before the PCI, at least 12 h after the loading dose of clopidogrel and aspirin, and before administration of tirofiban if needed NR	HPPR ADP10 >70 No HPPR ADP10 <70 [Based on high post-treatment platelet reactivity (HPPR) defined as >70% by ADP LTA]	Based on literature	HPPR ADP10 >70: 42 (22) No HPPR ADP10 <70: 148 (78)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Cuisset, 2009 19801028 France NR	light transmission aggregometry PAP4 aggregometer Bio data welcome, Paris France	10 umol/L ADP	blood samples were obtained 72–96 h after stent placement Citrate Interval at least 8 days. NR	Non-responder: ADP-Ag of >67% Responder: ADP-Ag of ≤67%	As per the ROC curve created using data from study subjects	Non-responder: ADP-Ag of >67%: 31% Responder: ADP-Ag of ≤67%: 69%
Cuisset, 2009 19736156 France NR	Light transmission aggregometry PAP4 Aggregometer Biodata Corporation, Wellcome, Paris, Francea	ADP	Blood drawn after cardiac catheterization NR 0.5 days (12 hours after the loading dose of clopidogrel and aspirin) NR	Hyper-responder (quartile 1: ADP- induced aggregation <40%) Non hyperresponder (quartile 2-4: ADP-induced aggregation ≥40%)	Not explicitly reported	Hyper-responder (quartile 1: ADP-induced aggregation <40%): 150 (25.1%) Non hyperresponder (quartile 2- 4: ADP-induced aggregation ≥40%): 447 (74.9)
Frere, 2007 17938809 France NR	light transmission aggregometry PAP4 aggregometer Bio data welcome, Paris France	ADP	before the PCI at least 12 h after the loading dose of clopidogrel and aspirin, and before administration of tirofiban if needed. 3.8% trisodium citrate After 12hours after the loading dose of clopidogrel With 1 hour	ADP-Ag ≥ 70% ADP-Ag <70%	As per the ROC curve created using data from study subjects	ADP-Ag ≥ 70%: 11/14 (79%) ADP-Ag <70%: 3/14 (21%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Geisler 2008 17949474 Germany NR	Turbidoaggregometry Chronolog Lumi aggregometer with Aggro-link software NR	20 umol ADP	Venous blood. RPA measured 5 min after ADP addition 3.8% citrate At least 6 hr after loading dose (median, 24.8 hr) if 600 mg; if 300 mg (for those previously on clopidogrel), at least 24 hr after loading dose NR	RPA tertile 1 (lowest) RPA tertile 2 RPA tertile 3 (highest)	Not explicitly reported	RPA tertile 1 (lowest) NR RPA tertile 2 NR RPA tertile 3 (highest) NR
Geisler 2010 20526607 Germany NR	Turbidometry; Chronolog Lumi Aggregometer Chronolog	ADP (20 umol/l)	NR Samples were collected the day following PCI blood was collected at least 6 h (median 23.6 h interquartile range 20.8 h) after first administration of 600 mg clopidogrel NR	Diabetics with ADP-induced aggregation in the top tertile vs. lowest tertile (among n=413 patients followed)	Prestudy data by the authors in a smaller, different patient group (data reported in current paper but not extracted)	NR
Geisler, 2006 17005534 Germany NR	NR Chronolog Lumi aggregometer with Aggro- Link Software NR	ADP	Blood samples were collected in 3.8% citrate plasma 3.8% citrate plasma Patient blood was collected at least 6 h (mean 34.8±25.9 h) after first administration of 600 mg clopidogrel NR	Adequate response (<70%) Low response (>70%) Based on post-treatment aggregation	Based on literature	Adequate response (<70%): 341/363(93.9) Low response (>70%): 22/363 (6.1)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Geisler, 2010 19812059 Germany NR	light transmission aggregometry Chronolog Lumi aggregometer NR	ADP	6 hrs after clopidogrel dose 3.8% citrate 0.25 days (6 hours); Clopidogrel came first NR	Clopidogrel low responders (tertile 3) Clopidogrel responders (tertile 1 & 2)	Not explicitly reported	Clopidogrel low responders (tertile 3): 329 (32.3%) Clopidogrel responders (tertile 1 & 2): 690 (67.7%)
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel- Eluting Stent Thrombosis)	Turbidimetric aggregometry APACT4 (4 channel aggregometer) Helena Laboratories (Milan, Italy)	ADP (10 µM)	Venous blood was obtained Citratated blood Venous blood was obtained 12-18 h from clopidogrel loading; for patients administered IIb/IIIa inhibitors blood was obtained 6 d after catheterization NR	Residual platelet reactivity (RPR) (ADP-induced platelet aggregation ≥70%) No residual platelet reactivity (RPR)	Based on literature	Residual platelet reactivity (RPR) (ADP-induced platelet aggregation ≥70%): 110 (14.2%) No residual platelet reactivity (RPR): 662 (85.8%)
Gori, 2008 19132241 Italy RECLOSE	LTA/NR APACT 4 light transmittance aggregometer Helena Laboratories, Milan, Italy	10 umol ADP or 2 µg/ml collagen	NR 0.109 M sodium citrate Platelet reactivity measured 12 to 18 hr after clopidogrel loading For patients receiving in the catheterization laboratory both the loading dose of clopidogrel and a IIb/IIIa inhibitor, blood samples were obtained after six days while the patient was on the 75-mg maintenance dose of clopidogrel NR	All patients RPR ≥70% by LTA with ADP No RPR RPR by LTA with collagen >90th percentile of patients' distribution No RPR RPR by LTA with ADP+LTA with collagen [NB Fig. 1 says n=32 but Table 3 says n=31) No RPR	LTA-ADP cutoff: Based on literature LTA-collagen cutoff: NR	All patients RPR ≥70% by LTA with ADP: 90/746 (12%) No RPR: 656/746 (88%) RPR by LTA with collagen >90th percentile of patients' distribution (56%): 78/746 (10%) No RPR: 668/746 (90%) RPR by LTA with ADP+LTA with collagen: 32/746 (4%) [NB Fig. 1 says n=32 but Table 3 says n=31) No RPR: 714/746 (96%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Gori, 2008 18718420 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel- Eluting Stent Thrombosis)	light transmission aggregometry APACT4 Helena Laboratories, Milan, Italy	10-μM ADP (clopidogrel) , 1-mM arachidonic acid (aspirin), and 2-μg/ml collagen (clopidogrel)	In catheterization laboratory 0.129 mol/l sodium citrate 0.5-0.75 day (12 to 18 h); 6 days for those pm glycoprotein (GP) IIb/IIIa inhibitor clopidogrel came first NR	Clopidogrel responder (platelet aggregation by ADP <70%; by collagen was defined as platelet aggregation I below 90th percentile of aggregation value distribution that resulted in 56%) and Aspirin responder (platelet aggregation by arachidonic acid ≥20%) Clopidogrel nonresponder (platelet aggregation by ADP ≥70%; by collagen was defined as platelet aggregation above the 90th percentile of aggregation value distribution that resulted in 56%) and aspirin nonresponsiveness (platelet aggregation by arachidonic acid ≥20%) Clopidogrel nonresponder (platelet aggregation by ADP ≥70%; by collagen was defined as platelet aggregation above the 90th percentile of aggregation value distribution that resulted in 56%) and aspirin responder (platelet aggregation by arachidonic acid ≥20%) Clopidogrel responder (platelet aggregation by ADP ≥70%; by collagen was defined as platelet aggregation above the 90th percentile of aggregation value distribution that resulted in 56%) and aspirin nonresponder (platelet aggregation by arachidonic acid ≥20%)	Based on literature	Clopidogrel responder and Aspirin responder : 570 (76.4%) Clopidogrel nonresponder and aspirin nonresponder: 45 (6%) Clopidogrel nonresponder and aspirin responder : 45 (6%) Clopidogrel responder and aspirin nonresponder : 86 (11.6%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Gurbel, 2010 20691842 USA PREPARE POST- STENTING	light transmission aggregometry LumiAggregometer Model 490-4D Chronolog, Havertown, PA	5 µmol/ L ADP (2 mmol/L arachidonic acid (AA) was also used)	Blood; 18 to 24 hours post-PCI or 5 days post-PCI (if eptifibatide used) 3.2% trisodium citrate NR; Clopidogrel came first NR	Quartile of LTA with ADP Quartile 1 <25 % Quartile 2 25-35 % Quartile 3 >35-45 % Quartile 4 >45 %	Quartiles: Not explicitly reported Also by ROC analysis within the same cohort	Quartile of LTA with ADP Quartile 1 <25 %: 56 (25%) Quartile 2 25-35 %: 56 (25%) Quartile 3 >35-45 %: 56 (25%) Quartile 4 >45 %: 57 (25%)
Gurbel, 2003 12796140 USA NR	LTA Chronology Lumi- Aggregometer (Model 490- 4D) Chronology, Havertown, Pennsylvania	5 µm ADP	Response assessed at day 5 3.8% trisodium citrate 2 hours NR	Drug resistance= <10% difference between baseline aggregation and posttreatment aggregation with 5 µmol/L ADP used as the agonist	Based on literature	Resistance Nonresistance
Gurbel, 2003 12714161 USA NR	Platelet aggregation NR NR & P-selectin expression by flow cytometry NR Parmingen, San Diego, California	ADP 5 and 20 umol/liter for LTA & ADP 200 umol/liter for Flow cytometry	Blood was collected in vacutainer tubes 3.8% trisodium citrate Blood was collected immediately before clopidogrel administration (baseline), and at 1, 5, and 30 days after stenting. NR	Nonresponder (change from baseline of <10%) Responder (change from baseline of <10%)	Not explicitly reported	Nonresponder (change from baseline of <10%) Aggregation by ADP 5 umol/liter: 23/63 (37%) Aggregation by ADP 20 umol/liter: 13/38 (34%) Responder (change from baseline of <10%) Aggregation by ADP 5 umol/liter: 40/63 (63%) Aggregation by ADP 20 umol/liter: 25/38 (66%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Gurbel, 2004 15154601 USA None	aggregometry Chronolog Lumi- Aggregometer (model 4902D) with AggroLink software Chronolog, Hawerton [sic], PA	5 and 20 uM ADP	Blood was collected in vacutainer tubes filled to capacity, and then gently inverted 3–5 times for mixing 3.8% trisodium citrate obtained before clopidogrel administration and stenting (baseline); and at 2 h, 24 h, 5 days and 30 days post-stenting NR	heightened reactivity after stenting (post-stent aggregation > baseline aggregation) Non-heightened reactivity	Not explicitly reported	heightened reactivity after stenting (post-stent aggregation > baseline aggregation) : NR Non-heightened reactivity: NR
Gurbel, 2005 16286165 USA PREPARE POST- STENTING	LTA Chronology Lumi- Aggregometer (Model 490- 4D) Chronology, Havertown, Pennsylvania	20um ADP	At discharge 3.8% trisodium citrate 2 hours NR	High LTA (maximum percent change in light transmittance from baseline) >67% Not high LTA (maximum percent change in light transmittance from baseline ≤67%)	Defined by ROC curve in the same study	High LTA : NR Not high LTA : NR
Gurbel, 2008 19012177 USA None	Conventional aggregometry Chronolog LumiAggregometer (Model 490-4D) with the Aggrolink software package Chronolog, Havertown, PA	5 and 20 uM ADP	Post-procedural blood samples were drawn by venipuncture into vacutainer tubes. The tubes were filled to capacity and gently inverted 3–5 times to ensure complete mixing of the anticoagulant 3.2% trisodium citrate Platelet function was measured on the day of hospital discharge in patients not treated with eptifibatide or ≥5 days post-discharge in patients treated with eptifibatide (all after clopidogrel dosing) Within 30 minutes	>46% platelet aggregation after 5 umol ADP stimulation (HPR) ≤46% (no HPR) >59% platelet aggregation after 20 umol ADP stimulation (HPR) ≤59% (no HPR)	ROC analysis in present study	>46% platelet aggregation after 5 umol ADP stimulation (HPR): 88 (30%) ≤46% (no HPR): 209 (70%) >59% platelet aggregation after 20 umol ADP stimulation (HPR):101 (34%) ≤59% (no HPR): 196 (66%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Gurbel, 2010 20194878 10 study sites in North America and Europe RESPOND	light transmission aggregometry Chronolog Optical Aggregometer (model 490– 4D) NR	20 µmol/L ADP	NR 3.2% trisodium citrate 0.25 -0.33 days (6-8 hrs); clopidogrel came first NR	Nonresponder (absolute change in maximum platelet aggregation (MPA) ≤10% between pre-dose and 6-8 hr post-dose measurements) Responder (absolute change in maximum platelet aggregation (MPA) >10% between pre-dose and 6-8 hr post-dose measurements)	Based on literature	Nonresponder (absolute change in maximum platelet aggregation (MPA) ≤10% between pre-dose and 6-8 hr post-dose measurements): 41/98 (41.8%) Responder (absolute change in maximum platelet aggregation (MPA) >10% between pre-dose and 6-8 hr post-dose measurements): 57/98 (58.2%)
Hochholzer, 2006 17084243 Germany EXCELSIOR	turbidimetric aggregometry 4- channel Bio/Data PAP4 aggregometer Mölab, Langenfeld, Germany	ADP	blood was drawn for platelet function assays We obtained the second blood sample at the time of catheterization before administration of heparin or contrast medium. 3.8% sodium citrate NR NR	Quartiles	NR	Quartiles
Hoshino, 2009 19106460 Japan NR	light transmission aggregometry 12-channel light transmission aggregometer MCM HEMA TRACER 313 MC Medical, Japan	5 and 20 µmol/L ADP	1) Baseline; 2) 4 h after loading; 3) 24 h after loading; 4) 48 h after loading; 5) 14 days after loading; 6) 28 days after loading 0.313% sodium citrate. Interval: 0.16 days (4 hrs), 1 day; 2 days; 14 days and 28 days; clopidogrel came first 0.1 days (2 hours)	IPA <10% (clopidogrel non- responders) 10%≤ IPA <30% (hypo-responders) IPA ≥30% (responders)	Based on a previous report	IPA <10% (clopidogrel non- responders): 4 (14.3%) 10%≤ IPA <30% (hypo- responders): 14 (50%) IPA ≥30% (responders): 10 (35.7%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Htun, 2011 21273381 Germany NR	turbidimetric aggregometry two-channel Chronolog aggregometer (Nobis, Germany)	ADP	Blood samples for platelet function analysis were obtained at an earliest time point of 6 hours after administration of 600 mg of clopidogrel NR Blood samples for platelet function analysis were obtained at an earliest time point of 6 hours after administration of 600 mg of clopidogrel, when a minority of patients already on chronic clopidogrel treatment received a loading dose of 300 mg and were measured approximately 24 hours after drug administration.	low responder 326 (20.8) responder 1009 (64.4) cutoff is beyond 75 percentile of all value in platelet aggregation as low responder.	Based on literature	low responder 326 (20.8) responder 1009 (64.4)
Kim, 2010 20449634 Korea NR	LTA ADP AggRam aggregometer Helena Laboratories Corp., Beaumont, TX	5 and 20 µmol/L ADP	Blood samples were drawn into vacutainer tubes containing 0.5 ml of sodium citrate 3.2% and processed within 60 min sodium citrate 3.2% clopidogrel- naïve patients received a 300-mg loading-dose (LD) of clopidogrel at least 12 h before procedure, and blood sampling was performed after insertion of the arterial sheath. In the case of patients who were already on chronic clopidogrel therapy, blood sampling was performed at the catheterization lab without clopidogrel LD 60 minutes	Aggregation <50% Aggregation ≥50%	Based on literature	Aggregation <50%: NR Aggregation ≥50%: NR

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
L'Allier 2008 18342223 Canada PREPAIR study	Aggregometry light transmission aggregometer (Model 570VS) Chrono-Log Corporation, Havertown, Pennsylvania	ADP at concentrations of 5 and 20 umol/l	Blood was collected from the forearm citrate 3.2% Blood samples were obtained at the time of randomization (baseline), immediately before coronary angiography, and the next morning (12 to 24 h) when a PCI was performed (post- PCI) NR	Nonresponders (resistance) to clopidogrel <10% inhibition of peak aggregation <20% inhibition of peak aggregation <40% inhibition of peak aggregation	Based on literature	Nonresponders (resistance) to clopidogrel by 5 umol ADP per liter & 20 umol ADP per liter: <10% inhibition of peak aggregation 9 in Group A (18%), 8 in Group B (16%), 0 in Group C 11 in Group A (22%), 12 in Group B (24%), 3 in Group C (6%) <20% inhibition of peak aggregation 16 in Group A (33%), 18 in Group B (37%), 4 in Group C (8%) 21 in Group A (43%), 25 in Group B (51%), 9 in Group C (18%) <40% inhibition of peak aggregation 30 in Group A (618%), 29 in Group B (59%), 14 in Group C (28%) 38 in Group A (78%), 36 in Group B (73%), 20 in Group C (40%)
Liu, 2011 21613806 China None	Turbidometric method in a 4- channel light transmission aggregometer LBY-BJ4 Precil, China	ADP at concentrations of 5 and 20 umol/l	NR 3.8% trisodium citrate Blood samples were collected before clopidogrel administration (baseline and at 12 h (10-14) and 36 h (34-318) after the loading dose. The 12-hour sample was collected before the daily 75-mg clopidogrel dose, whereas the 36-hour sample was collected afterward NR	inhibition of platelet aggregation (IPA) with 5 umol ADP at 12 hr: <10% [clopidogrel nonresponders] 35 (32%) (IPA) < 30% but >=10% [clopidogrel low responders] 28 (25%) (IPA) >=30% [clopidogrel responders] 46 (41%)	Based on literature	inhibition of platelet aggregation (IPA) with 5 umol ADP at 12 hr: <10% [clopidogrel nonresponders] 35 (32%) (IPA) < 30% but >=10% [clopidogrel low responders] 28 (25%) (IPA) >=30% [clopidogrel responders] 46 (41%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Matetzky, 2004 15184279 Israel No	turbidoaggregometry A routine aggregometer: PACKS-4 Helena Laboratory	ADP, 5 umol/L	NR Citrate Blood sampling done before clopidogrel dose (interval NR) and 6 days after NR	Quartile of % reduction of ADP- induced platelet aggregation at 6 days vs. baseline (before clopidogrel LD) [P<0.01 among the quartiles for both mean % reduction and inhibition of aggregation)	Not explicitly reported	1: mean±SD, 103±8% (low responders): 15 (25%) 2: mean±SD 69±3%: 15 (25%) 3: mean±SD 58±7%: 15 (25%) 4: mean±SD 33±12%: 15 (25%)
Muller, 2003 12719773 Germany None	Lumi-aggregometry NR (article says done as previously described and cites ref 7—I skimmed reference and nothing special specified) NR	5 or 20 umol ADP	NR citrate Prior to, 4 and 24 h after clopidogrel administration, whole blood was collected; in some patients, blood was collected 7 and 14 days after PCI NR	Responder (>30% inhibition of aggregation) Nonresponder (inhibition <10%) Semiresponder (inhibition 10-29%)	Not explicitly reported	Response with 5 umol ADP & 20 umol ADP: Responder (>30% inhibition of aggregation) 90 (86%) 12 (11%) Nonresponder (inhibition <10%) 5 (5%) 27 (26%) Semiresponder (inhibition 10- 29%) 10 (10%) 66 (63%)
Muller, 2010 20728084 Germany NR	light transmission aggregometry Chronolog Lumi aggregometer Chronolog, Havertown, Pennsylvania	ADP	NR 3.8% citrate plasma 0.25 -1 day (6-24 hrs); Clopidogrel came first NR	Stratum I: RPA & CRP <median Stratum II:RPA >median & CRP ≤median Stratum III:RPA ≤ median & CRP >median Stratum IV:RPA & CRP >median	Not explicitly reported	Stratum I: RPA & CRP <median:NR Stratum II:RPA >median & CRP ≤median:NR Stratum III:RPA ≤ median & CRP >median:NR Stratum IV:RPA & CRP >median:NR

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Obradovic, 2009 19318922 Serbia NR	Platelet aggregation BCT-system Dade-Behring, Germany	20 umol/L ADP	Venous blood was sampled in tubes from an antecubital vein under minimal stasis. 3.8% sodium citrate After the angiogram, patients with one or two vessel disease suitable for PCI were scheduled for PCI 3-4 h later, and these patients received a loading dose of clopidogrel of 300 mg. Before PCI, 15 min after PCI, 24 h after PCI	High aggregation Low aggregation Platelet aggregation to ADP above the median was defined as high aggregation and below the median as low aggregation.	not explicitly reported	High aggregation:n=26 Low aggregation:n=26
Saw, 2008 19038679 Canada ELAPSE trial	light-transmittance aggregometry lumi-aggregometer Chronolog Corp, Havertown, Pennsylvania	5 umol/L ADP	Patients were fasting for 4h prior to blood withdrawal. The first 3 ml of blood drawn were discarded. Baseline samples were collected from the arterial sheath. Post-PCI samples were drawn from peripheral venipunctures. EDTA, sodium citrate (3.2%), heparin Clopidogrel 600 mg was given before stenting. Platelet data measured at baseline (before clopidogrel); 1 day (16- 24 hr) after PCI; and 1, 6, and 12 months after 2 h after blood withdrawal in duplicates (means reported as percent aggregation)	Absolute difference between baseline and post-clopidogrel platelet aggregation with LTA using 5.0 umol/l ADP: <10% (resistance) ≥10% or greater (nonresistance)	Based on literature	<10% (resistance):4/26 (16%) 1 day after PCI 10% or greater (nonresistance):22/26 (85%) 1 day after PCI

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Trenk, 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	light transmission aggregometry 4-channel Bio/ Data PAP4 aggregometer Mölab, Langenfeld, Germany	5 and 20 umol ADP	Baseline, cardiac catheterization and at predischarge sample at day 1 3.8% sodium-citrate 0.08 – 0.16 days (2-4 hrs) after clopidogrel 0.04 (1 hour)	high on-treatment platelet reactivity (Residual platelet aggregation >14%) no high on-treatment platelet reactivity (Residual platelet aggregation ≤14%)	Based on literature	high on-treatment platelet reactivity (Residual platelet aggregation >14%) :217 (28.4%) no high on-treatment platelet reactivity (Residual platelet aggregation ≤14%):548 (71.6%)
Wang, 2009 19041120 China NR	Chrono-Log Lume- Aggregometer Chrono-Log Lume- Aggregometer (model 700) and the Aggro/Link software package Chrono-Log Corporation, Havertown, Pennsylvania, USA	20 umol ADP	The first sample was defined as baseline. Blood samples were collected in evacuated container tubes containing 3.8% trisodium citrate. Tubes were filled to capacity and then inverted 3 to 5 times for gentle mixing. 3.8% trisodium citrate Patient blood samples were collected before clopidogrel administration, and at least 24 hours after the first 300 mg clopidogrel dose to make sure maximum platelet inhibition has been achieved. NR	Clopidogrel resistance Normal clopidogrel response Drug resistance was defined as 10% or less absolute difference between aggregation at baseline and 24h after the 300mg loading dose of clopidogrel.	Based on literature	Clopidogrel resistance :65/386=16.8% Normal clopidogrel response :321/386=83.2%
Wang, 2010 21171668 China None	light transmittance aggregometry (LTA) Chrono-Log Lume- Aggregometer (model 700) with Aggro/Link software Chrono-Log Corpor ation, Havertown, PA	20 µmol/L ADP	Blood 3.8 % sodium citrate Before clopidogrel administration (baseline) and at least 24 (24 – 28) hours after loading with clopidogrel 300 mg NR	Clopidogrel resistance was defined as≤10 % absolute difference between baseline aggregation and post- administration aggregation Nonresistance (>10%)	Based on literature	Clopidogrel resistance:32 (21%) Nonresistance (>10%):122 (79%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Yong, 2009 19081397 Australia Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial	light transmission aggregometry 8 sites: Chronolog; 2 sites— Monitor IV Plus Chronolog instruments, Havertown, PA; Monitor IV Plus, Helena, Beaumont, TX	ADP 4, 10, and 20 μmol/L	before angiography (preangiography sample) and the morning after the procedure (morning-after sample) Citrate 2 hours 4 hours	Quartiles	not explicitly reported	Quartile cutoffs: NR
Kalantzi, 2012 21806493 Greece NR	light transmission aggregometry LTA Chronolog Lumi- Aggregometer (model 560- Ca) with the AggroLink software package	ADP 2.5, 5 and 10uM ADP ADP	Citrated blood samples were collected after the patient's presentation at the emergency room before clopidogrel administration (baseline), as well as at 5- and 30-days after clopidogrel loading. citrate 5 days 30 days	nonresponder VASP PRI >50% responder VASP PRI <50%	reference 15, 23	nonresponder n=12 responder n=28
Angiolillo, 2011 Italy NR	light transmittance aggregometry (LTA) NR	ADP 20uM	NR NR NR NR	HPR=upper quartile of ADP induced aggregation (64%)	reference 9, 17, 18	HPR N=47 no HPR N=140

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Park, 2011 Korea NR	VerifyNow P2Y12 NR NR	ADP	NR NR NR NR	HTPR =PRU >235	references 13-15	high n=1660 normal n=1189
Gurbel, 2012 21862113 USA NR	light transmittance aggregometry LTA NR	ADP (5 and 20µM) and 4 µg/ml collagen	blood samples at baseline, 2, 6 and 24 hours post 600 mg clopidogrel 3.2% trisodium citrate 2, 6 and 24 hours (0-6 hr time used to define responsiveness)	Clopidogrel resistance (nonresponse) ≤10% absolute change in 20µM ADP- induced aggregation between baseline and 6 hours post-dose.	NR	Nonresponders=21 (27%) Responders=57 (73%)
Saad, 2012 22146578 Egypt NR	light transmittance aggregometry Chronolog LumiAggregometer (Model 450) Chronolog, Havertown, PA	ADP (5 µM)	Peripheral blood samples before PCI 6 hrs after clopidogrel 3.8% trisodium citrate 0.25 days (6hours) NR	best cutoff value of posttreatment platelet reactivity to predict ischemic events	ROC analysis	NR
Aradi 2012 21902692 Hungary NR	CARAT TX4 four-channel light transmission aggregometer (Carat Diagnostics, Budapest, Hungary)	ADP (5uM)	NR NR NR 2 hours	normal platelet reactivity (NPR) LTA adp <34% n=122 high on-clopidogrel platelet reactivity (HPR) LTAadp≥34% n=78	ref 14 and 15	NPR N=122 HPR N=78
Gaglia, 2012 21919956 USA NR	LTA light transmission aggregometry ChronoLog, Havertown, PA, USA	5 and 20 µM of adenosine disphosphate (ADP)	6 hours following a loading dose of clopidogrel 3.2% sodium citrate 6 hours 6 and 24 hours following PCI	MPA >46% for LTA with 5 µM ADP MPA ≤46% for LTA with 5 µM ADP MPA >60% for LTA with 20 µM ADP MPA ≤60% for LTA with 20 µM ADP	Based on literature	5 µM ADP MPA >46% : 46 MPA ≤46%: 154 20 µM ADP MPA >60% : 32 MPA ≤60%: 168

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Marcucci, 2012 22390861 Italy NR	LTA APACT 4 light transmission aggregometer Helena Laboratories, Milan, Italy	10 µM of ADP	Whole blood NR NR NR	high on-treatment platelet reactivity (HPR) MPA ≥55% for LTA with 10 µM ADP MPA <55% for LTA with 10 µM ADP	Based on literature	Entire cohort MPA ≥55% : 486 MPA <55%: 701 in CYP2C19 carriers MPA ≥55% : 144 MPA <55%: 151 in CYP2C19 noncarriers MPA ≥55% : 342 MPA <55%: 550
Ge, 2012 21602258 China NR	LTA Chrono-Log Lume- Aggregometer (model 700); Aggro/Link software package (Chrono-Log Corporation, Havertown, Pennsylvania)	5 µM of ADP	Whole blood to obtain plasma NR From baseline to “loading” NR	“resistance”: ≤10% drop in reactivity between baseline and post-loading “non-resistance” >10% drop in reactivity between baseline and post- loading	Based on literature	≤10% drop in reactivity between baseline and post-loading: 65 >10% drop in reactivity between baseline and post-loading: 287

*If more than one test, they are presented in separate rows

Abbreviations: ADP= adenosine 5’-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported;

Appendix Table E12. Phenotypic test details in a single study assessing the predictive ability of LTA in patients with peripheral arterial disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Linnemann, 2010 20153859 Germany NR	Light transmittance aggregometry Behring Coagulation Timer (BCT) Dade Behring, Düringen, Switzerland	2 umol/l ADP	venous blood 3.2% citrate 0.04-1 day (1-24 hrs); clopidogrel came first 0.04 – 0.125 days (1-3 hrs)	Non-responsiveness (late aggregation (LateAggr) ≥42.9%) Responsiveness (late aggregation (LateAggr) <42.9%)	Based on guidelines (53rd Annual Scientific and Standardization Committee Meeting of the International Society of Thrombosis and Haemostasis, Geneva 2007)	Non-responsiveness (late aggregation (LateAggr) ≥42.9%): 19/34 (38.2%) Responsiveness (late aggregation (LateAggr) <42.9%): 21/34 (61.8)

*If more than one test, they are presented in separate rows

Abbreviations: ADP= adenosine 5'-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported.

Appendix Table E13. Phenotypic test details in studies assessing the predictive ability of LTA in patients with ischemic heart, cerebrovascular and peripheral vascular disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Reny, 2012 22615340 France and Switzerland ADRIE	8-channel aggregometer (TA- 8V, SD Medical, Heillecourt, France)	ADP 5 and 20 µmol/L	Blood samples collected after antiplatelet therapy intake 0.105 mol/L sodium citrate (1 vol/9 vol) 3 hrs NR	≥55% with ADP 20 µmol/L ≥42% with ADP 5 µmol/L	Based on ROC curve	≥55%:445 <55%: 204 ≥42%: 490 <42%: 159

*If more than one test, they are presented in separate rows

Appendix Table E14. Results of studies assessing the ability of LTA to predict mortality in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80-100mg daily	ADP LTA 5µmol/L	Death	death,	1-year	High OTPR N=445	Death	11 (2.5)	OR=2.53	0.93-6.88	<0.06 (high vs normal) [logistic regression]	No	NR	
						Normal OTPR N=604		6 (1)						
	maintaining Clopidogrel 75 mg daily +aspirin 80-100mg daily	ADP LTA 20 µmol/L	Death	death,	1-year	High OTPR N=392	Death	6(12)	OR=0.92	0.34-2.50	0.86 (high vs normal) [logistic regression]	No	NR	
						Normal OTPR N=659		11 (6.2)						
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	5µmol/L ADP LTA	cardiac death	cardiac death	6 months	<50%	cardiac death	0.2%	OR=9.61	1.15-80.11	0.016 (<50 vs ≥ 50%) [logistic regression]	NR	NR	
						≥50%		1.5%						
Bliden, 2007 17291930 USA NR	clopidogrel 75 mg qd	ADP-induced platelet reactivity	death	death	Day 0-30	HPR n=22	Death	0	OR (calculate)=3.5	NR	P=0.535 (HPR vs NPR) [Chi square]	NR	NR	
					Day 0-30	NPR N=78	death	0	NR	NR	NR	NR	NR	
					Day 31-365	HPR n=22	death	0						
					Day 31-365	NPR N=78	death	0						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA5	Death	Death	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual HPR N=385	Death,	9/385	OR (calculate)=2.1	0.7- 6.0	P=0.19 (HPR vs NPR) [Fishers exact]	NR	NR	
	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA20	Death	Death	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual HPR N=335	Death,	5/335	OR (calculate)=0.86	0.3- 2.5	P=1.0 (HPR vs NPR) [Fishers exact]	NR	NR	
Buonamici, 2007 17572245 Italy NR	Clopidogrel LD 600 mg maintenance dose of 75 mg daily	LTA ADP	Cardic mortality	Cardic mortality	6 months	Responders N=699	Cardic mortality	10 (1.4)	NR	NR	<0.001 (responder vs nonresponder) Chi-square	NR	NR	
						Nonresponders N=105		9 (8.6)						
Campo, 2007 17868803 Italy NR	Clopidogrel 300-mg loading dose, followed by 75 mg/day	LTA ADP	Death	Death	6 months	Responder to both	Death	1/90 (1.1)	OR (calculate)=1.52	0.1- 17.5	P=1.0 (clopidogrel nonresponder +dual nonresponder vs other groups) [Fishers exact]	NR	NR	
						Clopidogrel – Ticlopidine+		0(0)						
						Clopidogrel + Ticlopidine -		1(4.3)						
						Nonresponder to both		1(20)						
Geisler, 2006 17005534 Germany NR	Clopidogrel LD dose of 600 mg followed 75 mg daily	ADP LTA	Death from cardiovascular cause	Death from cardiovascular cause	3-month	Adequate response	Death from cardiovascular cause	10/341 (2.9)	NR	NR	0.006	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Low response		4/22 (18.2)						
	Clopidogrel LD dose of 600 mg followed 75 mg daily	ADP LTA	Death from any cause	Death from any cause	3-month	Adequate response	Death from any cause	14/341 (4.1)	NR	NR	0.003	NR	NR	
						Low response		5/22 (22.7)						
Geisler 2010 19812059 Germany NR	Clopidogrel 300- 600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	cardiovascular death	cardiovascular death	3 months	Low responder (Tertile 3)	cardiovascular death	10 (1.4%)	OR=3.02	1.33- 6.88	p=0.02 (low responder vs responder) [chi square]	NO	NR	Secondary outcome
						Responders (Tertile 1&2)		14 (4.3%)						
Gori 2008 18718420 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel- Eluting Stent Thrombosis)	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	Cardiac death	Cardiac death	6 months	Clopidogrel responder and Aspirin responder	Cardiac death	9 (1.6)	NR	NR	p <0.05 (dual clopidogrel and aspirin nonresponders versus aspirin nonresponders) p <0.0001 (dual clopidogrel and aspirin nonresponders versus aspirin nonresponders)	NO	NR	Secondary endpoint
						Clopidogrel nonresponder and aspirin nonresponder		4 (8.9)	OR (calculate)=4.54	1.6- 12.8	P=0.008 (dual and single clopidogrel nonresponder vs responders) [Fishers exact]			
						Clopidogrel nonresponder and aspirin responder		2 (4.4)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Clopidogrel responder and aspirin nonresponder		1 (1.2)						
Gurbel, 2008 19012177 USA None	Clopidogrel + aspirin	5 uM ADP aggregation	Death		1 mo	>46% platelet aggregation (HPR)		0	OR (calculate)=2.4	0.1- 38.7	P=0.505 (HPR vs NPR over 1-24 months) [Fishers exact]	NR	NR	NR
					2-24 mo			1	NR	NR	NR	NR	NR	NR
					1 mo	<=46%		1	NR	NR	NR	NR	NR	NR
					2-24 mo			0	NR	NR	NR	NR	NR	NR
	Clopidogrel + aspirin	20 uM ADP aggregation	Death		1 mo	>46% platelet aggregation (HPR)		0	OR (calculate)=1.95	0.1- 31.5	P=1.0 (HPR vs NPR over 1-24 months) [Fishers exact]	NR	NR	NR
					2-24 mo			1	NR	NR	NR	NR	NR	NR
					1 mo	<=46%		1	NR	NR	NR	NR	NR	NR
					2-24 mo			0	NR	NR	NR	NR	NR	NR
Hochholzer, 2006 17084243 Germany EXCELSIOR	Clopidogrel 75 mg/day	ADP LTA	Death	death	30-day	1st quartile <4%	Death	0/209	OR (calculate)=7.3	0.4- 141.2	P=0.119 (3rd & 4th quartile vs 1st and 2nd quartile) [Fishers exact]	NR	NR	Cumulative incidence of major adverse cardiac events
						2nd quartile 4- 14%		0/198						
						3rd quartile 15-32%		0/196						
						4th quartile >32%		3/199 (1.5%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Htun, 2011 21273381 Germany NR	clopidogrel LD 600 mg then 75 mg/d and aspirin 100 mg/d	LTA ADP	death	death e	1 year	low-responder group1 (K/DOQI index III –V)	death	17/165 (10.3)	NR	NR	0.04 low responder vs responder)	NR	NR	
						responder group 1 (K/DOQI index III –V)		22/396 (5.6)						
						low-responder group 2 (K/DOQI index I –II)		3/161 (1.9)			0.85 (low responder vs responder)			
						responder group 2 (K/DOQI index I –II)		10/613 (1.6)						
Liu, 2011 21613806 China None	Clopidogrel+aspirin		CV death			Nonresponders		2	OR (calculate)=4.43	0.4- 50.7	P=0.25 (nonresponder vs low + responder) [Fishers exact]			
						Low responders		1						
						Responders		0			0.288 across this and previous 2 rows (chi-square test)			
	Clopidogrel + aspirin	Aggregometry	CV death		1 mo after stenting	Nonresponders		2						
						Low responders		1						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Responders		0			0.288 across this and previous 2 rows (chi-square test)			
Trenk, 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	LTA	Death	Death	1 year	high on- treatment platelet reactivity (RPA>14%)	Death	7/217 (3.2%)	HR= 6	1.5- 23.2	P=0.003 (between high and not high residual platelet reactivity)	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%)	Death	3/548 (0.5%)						
Wang, 2010 21171668 China None	Clopidogrel+aspirin	LTA	Cardiovascular death		1 year	Clopidogrel resistance		2 (6.25%)			0.191 vs. next row (Student's t)	NR		
						nonresistance		2 (1.64%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Wang, 2009 19041120 China NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Cardiovascular death	Cardiovascular death,	One year	Clopidogrel resistance	Cardiovascular death	5/65 (7.7)	NR	NR	0.068 comparing with the following group	NO	NO	
						Normal response		9/321 (2.8)						
						Total		14/386 (3.6)						
Gurbel 2003 12796140 USA NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Death	Death	30 days	Clopidogrel resistance	Death	0	OR (calculate)=1.25	NR	P=0.91 (resistance vs nonresistance) [Chi square]	NO	NO	
						Clopidogrel nonresistance		0						
Aradi 21902692 Hungary NR	LD clopidogrel 600mg and aspirin 300mg MD clopidogrel 75 mg/day 4 weeks	LTA ADP	CV death	cardiovascular death	12 months	NPR	CV death	0/122=0	OR=9.8(calculated)	0.39- 245.63	NR	NR	NR	NR
						HPR+150 mg clopidogrel	CV death	0/36=0			0.31 comparing with the low row log-rank test			
						HPR +75 mg clopidogrel	CV death	1/38=0						
Gaglia, 2012 21919956 USA NR	LD: 600 mg loading clopidogrel or 75- mg for 5 days MD: Aspirin + clopidogrel 75 mg for 1 month in patients with BMS and 12 months in patients receiving DES	LTA 5 µmol/L ADP	death	death	3 days	HPR with 5 µM ADP MPA >46% : n=46	HPR	0	OR (calculated)=3.3	NR	0.6 (HPR vs NPR) [Fishers exact test]	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						NPR with 5 µM ADP MPA >46% : n=154		0						
						HPR with 20 µM ADP MPA >60% n=32	HPR	0	OR (calculated)=5.2	NR	0.4 (HPR vs NPR) [Fishers exact test]	No	NR	
						NPR with 20 µM ADP MPA >60% n=168		0						
Ge, 2012 21602258 China NR	Clopidogrel 600 mg loading; maintenance clopidogrel 75 mg/d + aspirin 100 mg/d	LTA (ADP)	All-cause mortality	NR	6 mo	Resistance (drop in reactivity <10% post-loading)	Deaths	0/65 (0%)	NA	NA	NR	NR	NR	NR
						Non-resistance (drop ≥10% post-loading)		0/287 (0%)						

Appendix Table E15. Results from studies assessing the ability of LTA to predict myocardial infarction in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	ADP LTA 5µmol/L	MI	MI	1-year	High OTPR	MI	37/445 (8.3)	OR=2.19	1.29-3.72	<0.003	No	NR	
						Normal OTPR		24/604 (4)						
	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	ADP LTA 20 µmol/L	MI	MI	1-year	High OTPR	MI	37/392 (9.4)	OR=2.76	1.62-4.68	<0.0001	No	NR	
						Normal OTPR		24/659 (3.6)						
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	5umol/L ADP LTA	non-fatal myocardial infarction	non-fatal myocardial infarction	6 months	<50%	non-fatal myocardial infarction	1.9%	OR=3.15	1.55-6.4	0.001	NR	NR	
						≥50%		5.6%						
Bliden 2007 17291930 USA NR	clopidogrel 75 mg qd	ADP- induced platelet reactivity	Myocardial infarction	Myocardial infarction	Day 0-30	HPR n=22	Myocardial infarction	3/100	OR(calculated)=17.1	1.8-162.4	P=0.003 (HPR vs NPR) [Fishers exact]	NR	NR	
					Day 0-30	NPR N=78	Myocardial infarction	1/100	NR	NR	NR	NR	NR	
					Day 31-365	HPR n=22	Myocardial infarction	1/100						
					Day 31-365	NPR N=78	Myocardial infarction	0/100						
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA5	MI	MI	1 year	HCPR (high on-clopidogrel platelet reactivity) or dual HPR	MI	31/385	NR	NR	0.023comparing with NPR(normal on- treatment platelet reactivity)	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA20	MI	MI	1 year	HCPR (high on-clopidogrel platelet reactivity) or dual HPR	MI	30/335	NR	NR	0.007comparing with NPR(normal on- treatment platelet reactivity)	NR	NR	
Buonamici, 2007 17572245 Italy NR	Clopidogrel LD 600 mg maintenance dose of 75 mg daily	LTA ADP	ST-segment elevation AMI	ST-segment elevation AMI	6 months	Responders	ST-segment elevation AMI	199/699	NR	NR	<0.001 comparing with the following group	NR	NR	
						Non- responders		18/105						
Campo, 2007 17868803 Italy NR	Clopidogrel 300- mg loading dose, followed by 75 mg/day	LTA ADP	Reinfarction	Reinfarction	6 months	Responder to both	Reinfarction	0/25	OR(calculated)=6.41	0.6-74.2	P=0.15 (nonresponder vs responder) [Fishers exact]	NR	NR	
						Clopidogrel – Ticlopidine +		1/25						
						Clopidogrel + Ticlopidine -		1/25						
						Nonresponder to both		1/25						
Cuisset, 2007 17264958 France NR	Clopidogrel loading dose 600 mg	ADP LTA	Periprocedural MI	Periprocedural MI	NR	Non- responders	Periprocedural MI	43%	OR=2.43	1.18-4.97	0.0143 comparing with the following group	NR	NR	
						responders		24%						
Geisler, 2006 17005534 Germany NR	Clopidogrel LD dose of 600 mg followed 75 mg daily	ADP LTA	Myocardial infarction	Myocardial infarction	3-month	Adequate response	Myocardial infarction	4/341 (1.2)	NR	NR	0.29	NR	NR	
						Low response		1/22 (4.5)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Geisler 2010 19812059 Germany NR	Clopidogrel 300- 600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	MI	NR	3 months	Low responder (Terrtile 3)	MI	14 (2%)	OR=2.15	1.01-4.57	p=0.04 (low responder vs responder) [chi square]	NO	NR	Secondary outcome
						Responders (Terrtile 1&2)		14 (4.3%)						
Gurbel 2008 19012177 USA None	Clopidogrel + aspirin	5 uM ADP aggregation	MI		1 mo	>46% platelet aggregation (HPR)		1	OR(calculated)=2.4	0.5-12.2	P=0.37 (HPR vs NPR) [Fishers exact]	NR	NR	NR
					2-24 mo			2	NR	NR	NR	NR	NR	NR
					1 mo	<=46%		0	NR	NR	NR	NR	NR	NR
					2-24 mo			3	NR	NR	NR	NR	NR	NR
	Clopidogrel + aspirin	20 uM ADP aggregation	MI		1 mo	>46% platelet aggregation (HPR)		1	OR(calculated)=10.2	1.2-88.1	P=0.012 (HPR vs NPR) [Fishers exact]	NR	NR	NR
					2-24 mo			4	NR	NR	NR	NR	NR	NR
					1 mo	<=46%		0	NR	NR	NR	NR	NR	NR
					2-24 mo			1	NR	NR	NR	NR	NR	NR
Htun, 2011 21273381 Germany NR	clopidogrel LD 600 mg then 75 mg/d and aspirin 100 mg/d	LTA ADP	myocardial infarction	myocardial infarction	1 year	low-responder group1	myocardial infarction	17/165 (10.2)	NR	NR	0.024 comparing with the lower row	NR	NR	
						responder group 1		20/396 (5.1)			0.2			
						low-responder group 2		9/161 (5.7)			comparing with the lower row			
						responder group 2		21/613 (3.4)						
Saw, 2008 19038679 Canada ELAPSE trial	Clopidogrel+aspirin	LTA	NSTEMI	NR	12 mo	Clopidogrel resistant	YES event	0	OR(calculated)=0.62	0-14.2	P=1.0 (resistant vs onresistant) [chi square]	NR	NR	NR
						Nonresistant		3						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Trenk, 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	LTA	Nonfatal ST elevation MI	Nonfatal ST elevation MI	1 year	high on- treatment platelet reactivity (RPA>14%)	Nonfatal ST elevation MI	2/217 (0.9%)	HR=2. 6	0.4-18.1	P=0.33 (between high and not high residual platelet reactivity)	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%)		2/548 (0.4%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	LTA	Nonfatal non- ST elevation MI	Nonfatal non- ST elevation MI	1 year	high on- treatment platelet reactivity (RPA>14%)	Nonfatal non- ST elevation MI	4/217 (1.8%)	HR=1.7	0.5-6.1	P=0.4 (between high and not high residual platelet reactivity)	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%)		6/548 (1.1%)						
Wang, 2010 21171668 China None	Clopidogrel+aspirin	LTA	MI			Clopidogrel resistance		3 (9.38%)	OR=6.21 (calculated)	0.99-38.9	0.061 vs. next row	NR		
						nonresistance		2 (1.64%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Wang, 2009 19041120 China NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Non fatal-MI	nonfatal-MI	One year	Clopidogrel resistance	nonfatal-MI	4/65 (6.2)	OR=2.56 (calculate)	0.75-8.79)	0.126 comparing with the following group	NO		
						Normal response		8/321 (2.5)						
						Total		12/386 (3.1)						
Yong, 2009 19081397 Australia Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial	300-600 mg LD of clopidogrel	LTA using 4 , 10, 20µmol/L	Post-PCI myonecrosis	Postprocedure troponin I level above the preprocedure troponin I level and greater than 5 times the upper limit of the reference range (0.1 ng/mL).	6 months	Quartile 1	Post-PCI myonecrosis	NR	NR	NR	NR	NR	NR	Data presented in Fig 2A; no pvalues are reporter for all concentrations of ADP
						Quartile 2	NR							
						Quartile 3	NR							
						Quartile 4	NR							
Gurbel, 2003 12796140 USA NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Q wave MI	Q wave MI	30 days	Clopidogrel resistance	Q wave MI	0	NR	OR(calculated)=1.3	NR	P=0.9 (HPR vs NPR) [Fishers exact]	NO	
						Clopidogrel nonresistance		0						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Aradi 2012 21902692 Hungary NR	LD clopidogrel 600mg and aspirin 300mg MD clopidogrel 75 mg/day 4 weeks	LTA ADP	MI	Myocardio infarction	12 months	NPR	MI	1/122=0.8%	OR=10.37(calculate)	1.05-102.85	NR	NR	NR	NR
						HPR+150 mg clopidogrel	MI	0/36=0			0.08 comparing with the low row log-rank test			
						HPR +75 mg clopidogrel	MI	3/38=8.7%						
Ge, 2012 21602258 China NR	Clopidogrel 600 mg loading; maintenance clopidogrel 75 mg/d + aspirin 100 mg/d	LTA (ADP)	MI	Myocardial infarction , including procedural MI requiring TVR	6 mo	Resistance (drop in reactivity <10% post- loading)	MI events	4/65 (6%)	OR (calculated) = 9.34	1.67, 52.17	0.015 [reported; Cox regression]; p = 0.012 [calculated, Fisher's exact test]	Unclear ("relevant prognostic factors")	NR	NR
						Non- resistance (drop ≥10% post-loading)	MI events	2/287 (1%)						

Appendix Table E16. Results from studies assessing the ability of LTA to predict stent thrombosis in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Cuisset, 2009 19801028 France NR	Clopidogrel LD 600 mg	ADP stimulated platelet aggregation	Subacute stent thrombosis	Subacute stent thrombosis	30 days	ADG-Ag >67% as non responders N=NR	Subacute stent thrombosis	31% as nonresponders	OR=5.8	1.9-24.6	0.003 [logistic regression]	NO	NR	
	Clopidogrel LD 600 mg	ADP stimulated platelet aggregation	Subacute stent thrombosis	Subacute stent thrombosis	30 days	ADG-Ag >67% as non responders N=NR	Subacute stent thrombosis	31% as nonresponders	OR=6.24	1.6-24.6	0.009 [logistic regression]	Yes. Age, gender, stent length, left ventricular ejection fraction, diabetes mellitus.	NR	
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	ADP LTA 5µmol/L	Stent thrombosis	Stent thrombosis	1-year	High OTPR N=445	Stent thrombosis	7 (1.6)	OR=1.59	0.53-4.77	<0.40 (high vs normal) [logistic regression]	No	NR	
						Normal OTPR N=604		6 (1)						
	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	ADP LTA 20 µmol/L	Stent thrombosis	Stent thrombosis	1-year	High OTPR N=445	Stent thrombosis	9 (2.3)	OR=3.85	1.18-12.58	<0.017 (high vs normal) [logistic regression]	No	NR	
						Normal OTPR N=604		4 (0.6)						
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	5µmol/L ADP LTA	stent thrombosis	stent thrombosis	6 months	<50%	stent thrombosis	1.2%	OR=2.83	1.18-6.80	0.015 (<50 vs ≥ 50%) [logistic regression]	NR	NR	
						≥50%		3.4%						
Blindt, 2007 18064332 Germany NR	75 mg clopidogrel	ADP-LTA	Stent thrombosis	Stent thrombosis	6 months	NR	NR	NR	OR=1.059	1.00-1.21	0.049 [logistic regression]	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gori, 2008 19132241 Italy RECLOSE	Clopidogrel+aspirin	LTA-ADP	Stent thrombosis	definite or probable: ACS+either angiographic confirmation of thrombosis or pathological confirmation of thrombosis; or unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	6 mo	RPR (n=90)	YES event	6	NR	NR	<0.05 (RPR vs no RPR) [chi square]	NR	NR	NONE
						No RPR (n=656)		14	NR	NR		NR	NR	
		LTA-collagen				RPR (n=78)		8	NR	NR	<0.001 (RPR vs no RPR) [chi square]	NR	NR	
						No RPR (n=668)		11	NR	NR		NR	NR	
		LTA- ADP+LTA- collagen				RPR (n=32)		6	NR	NR	<0.001 (RPR vs no RPR) [chi square]	NR	NR	
						No RPR (n=714)		14	NR	NR		NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		LTA-ADP	Stent thrombosis			RPR (n=90)			AUC 0.65+/-0.06 (cutoff 46%) 30% (11- 54%)sensitivity 88% (86-91%) specificity		NS			For this entire section of data: NR what ranges (e.g., “(11- 54)” to the left) mean for clinical validity data Also ROC curves are in Fig 2 Also bootstrap data re cutoff in text
		LTA-collagen				RPR (n=78)		NA	AUC 0.50+/-0.07 (cutoff 55%) 45% (23-69%) sensitivity 90% (88-92%) specificity		For specificity, “p<0.0001 vs RPR by collagen”	NR	NR	
		LTA- ADP+LTA- collagen				RPR (n=31)			30% (10-50%) sensitivity 97% (95-98%) specificity		For specificity, <0.01vs. LTA- ADP alone and vs. LTA- collagen			
		LTA-ADP among patients at high risk for AEs	Stent thrombosis			RPR (n=352)		NA	70% (50-90%) sensitivity 53% (506-57%) specificity		For specificity, <0.0001 vs. LTA- collagen	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		LTA-collagen among patients at high risk for AEs				RPR (n=78)		NA	50% (28-72%) sensitivity 91% (88-93%) specificity		For specificity, p<0.0001 vs. LTA-ADP	NR	NR	
		LTA- ADP+LTA- collagen among patients at high risk for AEs				RPR (n=61)		NA	45% (23-67%) sensitivity 93% (91-95%) specificity		For specificity, <0.0001 vs. LTA-ADP alone and <0.0001 vs. LTA- collagen alone	NR	NR	
		LTA-ADP	Stent thrombosis			RPR			OR 3.28	1.23-8.75	0.018 Univariate analysis	NR	NR	
		LTA-collagen				RPR			OR 7.79	3.12-19.46	0.0001 Univariate analysis	NR	NR	
		LTA- ADP+LTA- collagen				RPR			OR 12.01	4.26-33.87	0.0001 Univariate analysis	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		LTA-ADP	Stent thrombosis			RPR		NR	OR 2.41	0.99-6.85	0.090 (RPR vs no RPR) [Logistic regression]	Clinical characteristics (age, sex, cardiovascular risk factors, ejection fraction, number of vessel disease, renal failure, total stent length, chronic total occlusion, bifurcation lesion and glycoprotein IIb/IIIa inhibitors) were included in the logistic regression analysis as independent variables in a model in which each RPR was added separately.	NR	
		LTA-collagen				RPR		NR	OR 5.45	2.05-14.53	0.001 Multivariate analysis	YES	NR	
		LTA- ADP+LTA- collagen				RPR		NR	OR 7.50	2.40-23.43	0.001 Multivariate analysis	Yes	NR	
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA5	ST	ST	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual HPR N=385	ST	4	OR (calculated): 1.1	0.3-4.2	P=1.0 (high + dual vs responders + high aspirin) [fishers exact]	NR	NR	
	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA20	ST	ST	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual HPR N=335	ST	5	OR (calculated): 2.2	0.6-8.2	P=0.3 (high + dual vs responders + high aspirin) [fishers exact]	NR	NR	
Buonamici, 2007 17572245 Italy NR	Clopidogrel LD 600 mg maintenance dose of 75 mg daily	LTA ADP	Stent thrombosis	Definite or probable stent thrombosis	6 months	Responders N=699	Stent thrombosis	16 (2.3)	NR	NR	<0.001 (responders vs nonresponders) [chi square]	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Nonresponders N=105		9 (8.6)						
	Clopidogrel LD 600 mg maintenance dose of 75 mg daily	LTA ADP	Stent thrombosis	Stent thrombosis	6 months	Responders	Stent thrombosis	7/699 (3.5)	NR	NR	<0.001 (responders vs nonresponders) [chi square]	NR	NR	
						Non-responders		4/105 (22)						
	Clopidogrel LD 600 mg maintenance dose of 75 mg daily	LTA ADP	Stent thrombosis	Stent thrombosis	6 months	Nonresponsiveness	Stent thrombosis	105	HR=3.85	1.7-8.71	<0.001 [cox regression]	No	NR	
	Clopidogrel LD 600 mg maintenance dose of 75 mg daily	LTA ADP	Stent thrombosis	Stent thrombosis	6 months	Nonresponsiveness	Stent thrombosis	105	HR=3.08	1.32-7.16	0.009 [cox regression]	Yes. Acute myocardial infarction, total stent length, LVEF per 1% increase		
Geisler 2010 19812059 Germany NR	Clopidogrel 300- 600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	Stent Thrombosis	Academic research consortium (ARC) definition	3 months	Low responder (Terrtile 3)	Stent Thrombosis	15 (2%)	NR	NR	p=0.03 (low responder vs responder) [KM survival analysis - log rank test]	NO	NR	primary outcome
						Responders (Terrtile 1&2)		14 (4.6%)						
	Clopidogrel 300- 600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	Early Stent Thrombosis	Academic research consortium (ARC) definition	30 days	Low responder (Terrtile 3)	Early Stent Thrombosis	NR	NR	NR	p=0.02 (low responder vs responder) [KM survival analysis - log rank test]	NO	NR	primary outcome
						Responders (Terrtile 1&2)		NR						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	Late Stent Thrombosis	Academic research consortium (ARC) definition	3 months	Low responder (Terrtile 3)	late Stent Thrombosis	NR	NR	NR	p=0.31 (low responder vs responder) [KM survival analysis - log rank test]	NO	NR	primary outcome
						Responders (Terrtile 1&2)		NR						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	Stent Thrombosis	Academic research consortium (ARC) definition	3 months	Low responder (Terrtile 3)	Stent Thrombosis	15 (2%)	OR=2.31	1.1-4.84	p=0.02 (low responder vs responder) [Chi square]	NO	NR	primary outcome
						Responders (Terrtile 1&2)		14 (4.6%)						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	Definite Stent Thrombosis	Academic research consortium (ARC) definition	3 months	Low responder (Terrtile 3)	definite Stent Thrombosis	7 (1%)	OR=1.2	0.35-4.13	p=0.02 (low responder vs responder) [Chi square]	NO	NR	primary outcome
						Responders (Terrtile 1&2)		4 (1.2%)						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	Probable Stent Thrombosis	Academic research consortium (ARC) definition	3 months	Low responder (Terrtile 3)	Probable Stent Thrombosis	5 (0.7%)	OR=3.85	1.28-11.59	p=0.01 (low responder vs responder) [Chi square]	NO	NR	primary outcome
						Responders (Terrtile 1&2)		9 (2.7%)						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	Possible Stent Thrombosis	Academic research consortium (ARC) definition	3 months	Low responder (Terrtile 3)	Possible Stent Thrombosis	2 (0.3%)	OR=2.1	0.3-15	p=0.45 (low responder vs responder) [Chi square]	NO	NR	primary outcome
						Responders (Terrtile 1&2)		2 (0.6%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel- Eluting Stent Thrombosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	LTA- ADP	Stent thrombosis	Definite or probable stent thrombosis. Definite = ACS + angiographic or pathologic confirmation of thrombosis; probable = unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	Maximum FU of 6 mo	Residual platelet reactivity (RPR) (ADP-induced platelet aggregation ≥70%)	Stent thrombosis present	8 (7.3%)	NR	NR	0.001 across groups (chi square test)	NO	NO	Primary outcome
						No residual platelet reactivity (RPR)		16 (2.4%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	Combination of genotypic and phenotypic tests: CYP2C19*2 + ADP residual platelet reactivity	Stent thrombosis	Definite or probable stent thrombosis. Definite = ACS + angiographic or pathologic confirmation of thrombosis; probable = unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	Maximum FU of 6 mo	*2/*2 + RPR N = 40	Stent thrombosis present	6 (15%)	NR OR=5.79	NR (1.04, 39.01)	<0.0001 across groups (chi square test) 0.033 (logistic regression)	NO Adjusted (“for traditional cardiovascular risk factors and clinical and procedural risk factors for stent thrombosis”)	NO	Primary outcome
						*1/*1 or low RPR N = 732		18 (2.5%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	LTA-ADP	Stent thrombosis	Definite or probable stent thrombosis. Definite = ACS + angiographic or pathologic confirmation of thrombosis; probable = unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	Maximum FU of 6 mo	Residual platelet reactivity (RPR) (ADP-induced platelet aggregation ≥70%)	Stent thrombosis present	8 (7.3%)	OR=3.17 OR=3.08	(1.32, 7.59) (1.23, 7.72)	0.001 (chi square test) 0.016 (logistic regression)	NO (univariate) YES (ADP-RPR, traditional cardiovascular risk factors, clinical and procedural risk factors for ST)	NO	Primary outcome
						No residual platelet reactivity (RPR)		16 (2.4%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gori, 2008 18718420 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel- Eluting Stent Thrombosis)	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	definite or probable stent thrombosis	definite or probable stent thrombosis	6 months	Clopidogrel nonresponder	definite or probable stent thrombosis	NR	HR=1.44	0.54 to 3.82	P=0.463 [Cox regression]	YES; age (years), male gender, family history of CAD, smoker, HTN, hypercholesterolemia, diabetes mellitus, history of myocardial infarction, history of coronary surgery, acute coronary syndrome, acute STEMI, left ventricular ejection fraction (%), multivessel disease, bifurcation lesion, thrombus-containing lesion, chronic total occlusion, and stent length (mm).	NR	Primary endpoint
	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	definite or probable stent thrombosis	definite or probable stent thrombosis ¹	6 months	Clopidogrel & Aspirin nonresponder	definite or probable stent thrombosis	NR	HR=3.18	1.14 to 8.83	P=0.027 [Cox regression]	YES; age (years), male gender, family history of CAD, smoker, HTN, hypercholesterolemia, diabetes mellitus, history of myocardial infarction, history of coronary surgery, acute coronary syndrome, acute STEMI, left ventricular ejection fraction (%), multivessel disease, bifurcation lesion, thrombus-containing lesion, chronic total occlusion, and stent length (mm).	NR	Primary endpoint

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	definite or probable stent thrombosis	definite or probable stent thrombosis	6 months	Clopidogrel non with r without Aspirin responder	definite or probable stent thrombosis	6 /90 (6.7)	HR=3.15	1.21 to 8.20	P=0.019 [Cox regression]	NO	NR	Primary endpoint
	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	definite or probable stent thrombosis	definite or probable stent thrombosis ¹	6 months	Clopidogrel responder and Aspirin responder	definite or probable stent thrombosis	12 (2.1)	NR	NR	p<0.0001; (dual clopidogrel and aspirin nonresponders versus aspirin nonresponders) p<0.05 (dual clopidogrel and aspirin nonresponders versus aspirin nonresponders)	NO	NR	Primary endpoint
						Clopidogrel nonresponder and aspirin nonresponder		5 (11.1)						
						Clopidogrel nonresponder and aspirin responder		1 (2.2)						
						Clopidogrel responder and aspirin nonresponder		2 (2.3)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	definite or probable stent thrombosis	definite or probable stent thrombosis ¹	6 months	Clopidogrel responder and Aspirin responder	definite or probable stent thrombosis	NR	NR	NR	p<0.001; (dual nonresponders vs. dual responders) P=0.036 (dual nonresponders vs. aspirin nonresponders) P=0.096 (dual nonresponders vs. clopidogrel nonresponders)	NO	NR	Primary endpoint
	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	definite stent thrombosis	definite stent thrombosis	6 months	Clopidogrel responder and Aspirin responder	definite stent thrombosis	6 (1.1)	NR	NR		NO	NR	Primary endpoint
						Clopidogrel nonresponder and aspirin nonresponder		2 (4.4)						
						Clopidogrel nonresponder and aspirin responder		0						
						Clopidogrel responder and aspirin nonresponder		1 (1.2)						
	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	probable stent thrombosis	probable stent thrombosis	6 months	Clopidogrel responder and Aspirin responder	probable stent thrombosis	6 (1.1)	NR	NR	p <0.05 (dual clopidogrel and aspirin nonresponders versus clopidogrel and aspirin responders)	NO	NR	Primary endpoint

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Clopidogrel nonresponder and aspirin nonresponder		3 (6.7)						
						Clopidogrel nonresponder and aspirin responder		1 (2.2)						
						Clopidogrel responder and aspirin nonresponder		1 (1.2)						
Gurbel, 2008 19012177 USA None	Clopidogrel + aspirin	5 uM ADP aggregation	Stent thrombosis		1 mo	>46% platelet aggregation (HPR)		1	NR	OR (calculated): 3.7	0.6-22.3	P=0.16 (HPR vs NPR) [fishers exact]	NR	NR
					2-24 mo			2	NR	NR	NR	NR	NR	NR
					1 mo	<=46%		2	NR	NR	NR	NR	NR	NR
					2-24 mo			0	NR	NR	NR	NR	NR	NR
	Clopidogrel + aspirin	20 uM ADP aggregation	Stent thrombosis		1 mo	>64.5% platelet aggregation (HPR)		1	NR	OR (calculated): 3	0.5-18.1	P=0.34 (HPR vs NPR) [fishers exact]	NR	NR
					2-24 mo			2	NR	NR	NR	NR	NR	NR
					1 mo	<=46%		2	NR	NR	NR	NR	NR	NR
					2-24 mo			0	NR	NR	NR	NR	NR	NR
Liu, 2011 21613806 China None	Clopidogrel + aspirin	Aggregometry	Stent thrombosis			Nonresponders	34	0		OR (calculated): 16	0.8-321.2	P=0.03 (HPR vs NPR) [fishers exact]		
						Low responders	28	0						
						Responders	44	0			NR			
	Clopidogrel + aspirin	Aggregometry	Stent thrombosis			Nonresponders	34	0						
						Low responders	28	0						
						Responders	44	0			NR			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Muller, 2003 12719773 Germany None	Clopidogrel + aspirin	Aggregometry	Subacute stent thrombosis	Day 6 or 7 after angiography	Day 6 or 7	Nonresponder (NB authors don't say according to which level of ADP or both)	Yes event	2	OR (calculated): 143	5.7-3586	P=0.001 (nonresp vs others) [fishers exact]	NR	NR	NONE
						Semiresponder		0						
						Responder		0						
Muller, 2010 20728084 Germany NR	Clopidogrel 600 mg LD + 75 mg MD & Aspirin 100 mg/d MD	LTA	Stent thrombosis	Defined according to the Academic Research Consortium criteria	Mean follow up of 344 days	Stratum I: RPA & CRP <median	Stent thrombosis	NR	NR	NR	P=0.02 (Stratum IV vs I) P<0.001 (Stratum IV vs II) P=0.04 (Stratum IV vs III) P>0.05 (Stratum III vs I+II) P>0.05 (Stratum II vs I) [Log Rank]test	YES; age, gender, left ventricular function, acute coronary syndromes, hyperlipidemia and relevant comedication	NR	Primary
						Stratum II:RPA >median & CRP ≤median		NR						
						Stratum III:RPA ≤ median & CRP >median		NR						
						Stratum IV:RPA & CRP >median		NR						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Trenk, 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	LTA	Any stent thrombosis	Any stent thrombosis	1 year	high on-treatment platelet reactivity (RPA>14%) N=217	Any stent thrombosis	10(4.6%)	HR=3.7	1.4-9.6	P=0.008 (between high and not high residual platelet reactivity) [Cox regression]	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%) N=548		7 (1.3%)						
	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	LTA	Definite or probable stent thrombosis	Definite or probable stent thrombosis	1 year	high on-treatment platelet reactivity (RPA>14%) N=217	Definite or probable stent thrombosis	8 (3.7%)	HR=4.1	1.3-12.5	P=0.01 (between high and not high residual platelet reactivity) [Cox regression]	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%) N=548		5 (0.9%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	LTA	Definite stent thrombosis	Definite stent thrombosis	1 year	high on-treatment platelet reactivity (RPA>14%) N=217	Definite stent thrombosis	1(0.5%)	HR=1.3	0.1-14.1	P=0.84 (between high and not high residual platelet reactivity) [cox regression]	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%) N=548		2 (0.4%)						
	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	LTA	Probable stent thrombosis	Probable stent thrombosis	1 year	high on-treatment platelet reactivity (RPA>14%) N=217	Probable stent thrombosis	7 (3.2%)	HR=5.9	1.5-23	P=0.01 (between high and not high residual platelet reactivity) [cox regression]	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%) N=548		3 (0.5%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	LTA	Possible stent thrombosis	Possible stent thrombosis	1 year	high on-treatment platelet reactivity (RPA>14%) N=217	Possible stent thrombosis	2(0.9%)	HR=2.6	0.4-18.4	P=0.34 (between high and not high residual platelet reactivity) [cox regression]	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%) N=548		2(0.4%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Wang, 2010 21171668 China None	Clopidogrel + aspirin	LTA	Definite or probable stent thrombosis	Academic Research Consortium (ARC) definitions: Definite— presence of ACS with angiographic or autopsy evidence of thrombus or occlusion Probable -- unexplained deaths within 1 month after the procedure or acute MI involving target-vessel territory without angiographic confirmation		Clopidogrel resistance		4 (12.5%)	OR=8.6	1.49-49.15	0.017 (resisters vs nonresistant) (Student's t); p=0.025 from multivariate regression (for independent prediction)	YES for multivariate regression P value only (diabetes, BMI, and smoking status)		
						nonresistance		2 (1.64%)						
	Clopidogrel + aspirin	LTA	Definite			Clopidogrel resistance		2 (6.25%)	OR=8.1	0.71-91.95	0.110 (resisters vs nonresistant) (Student's t)	NR		
						nonresistance		1 (0.82%)						
	Clopidogrel + aspirin	LTA	Probable			Clopidogrel resistance		2 (6.25%)	OR=8.1(calculated)	0.71-91.95	0.110 (resisters vs nonresistant) (Student's t)	NR		
						nonresistance		1 (0.82%)						
	Clopidogrel + aspirin	LTA	Acute	within 24 hours		Clopidogrel resistance		0	OR=3.76 (calculated)		NR	NR		
						nonresistance		0						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel + aspirin	LTA	Subacute	1–30 days after		Clopidogrel resistance		1 (3.13%)	OR=3.90 (calculated)	0.24-64.17	0.373 (resisters vs nonresistant) (Student's t)	NR		
						nonresistance		1 (0.82%)						
	Clopidogrel + aspirin	LTA	Late	30 days to 1 year after		Clopidogrel resistance		3 (9.38%)	OR=12.52 (calculated)	1.26-124.75	0.028 (resisters vs nonresistant) (Student's t)	NR		
						nonresistance		1 (0.82%)						
Wang, 2009 19041120 China NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Definite or probable stent thrombosis	Definite or probable stent thrombosis	12-months	Clopidogrel resistance	Definite or probable stent thrombosis	NR	HR=4.46	1.03-20.27	0.031 [cox regression]	Yes, LV dysfunction (EF<30%), Total stent length	NR	
	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Definite or probable stent thrombosis	Definite or probable stent thrombosis	One year	Clopidogrel resistance N=65	Definite or probable stent thrombosis	6 (9.2)	NR	NR	0.018 (resisters vs normal response)	NO	NO	
						Normal response N=321		8(2.5)						
	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Definite stent thrombosis	Definite stent thrombosis	One year	Clopidogrel resistance N=65	Definite stent thrombosis	3 (4.6)	OR=3.8 (calculate)	0.84-17.56	0.096 (resisters vs normal response)	NO	NO	
						Normal response N=321		4(1.2)						
	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Probable stent thrombosis	Probable stent thrombosis	One year	Clopidogrel resistance N=65	Probable stent thrombosis	3 (4.6)	OR=3.83	0.84-17.56	0.096 (resisters vs normal response)	NO	NO	
						Normal response N=321		4 (1.2)						
Gurbel, 2003 12796140 USA NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Stent thrombosis	Stent thrombosis	30 days	Clopidogrel resistance	Stent thrombosis	0/50	OR (calculated): 1.3	NR	P=0.9 (nonresp vs others) [fishers exact]	NO	NO	
						Clopidogrel nonresistance		0/63						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gaglia, 2012 21919956 USA NR	LD: 600 mg loading clopidogrel or 75- mg for 5 days MD: Aspirin + clopidogrel 75 mg for 1 month in patients with BMS and 12 months in patients receiving DES	LTA 5 µmol/L ADP	stent thrombosis	stent thrombosis	3 days	HPR with 5 µM ADP MPA >46% : n=46	HPR	0	OR (calculated)=3.3	NR	0.6 (HPR vs NPR) [Fishers exact test]	No	NR	
						NPR with 5 µM ADP MPA >46% : n=154		0						
						HPR with 20 µM ADP MPA >60% n=32	HPR	0	OR (calculated)=5.2	NR	0.4 (HPR vs NPR) [Fishers exact test]	No	NR	
						NPR with 20 µM ADP MPA >60% n=168		0						

Appendix Table E17. Results from studies assessing the ability of LTA to predict major adverse cardiovascular events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Geisler 2010 20526607 Germany NR	Clopidogrel + aspirin	Lumi- aggregometer	MACE	MI, cardiovascular events, and cardiovascular death	30 days after PCI	Top tertile of platelet aggregation (among the total 413 DM patients followed for 30 days) N=NR	MACE	NR	NR	NR	0.02 (log-rank test) vs. DM patients in lowest tertile	NR	NR	K-M curve in Fig 6
Frere, 2007 17938809 France NR	600 mg loading dose of clopidogrel and maintaining 75mg daily	ADP-induced platelet aggregation (ADP-Ag)	CV event	CV death, acute or subacute stent thrombosis, recurrent ACS and stroke	30 days after PCI	≥70% N=54	CV event	11/54 (20%)	AUC: 0.74±0.08	NR	NR	NR	NR	NR
						<70% N=127	CV event	3/127 (2.5%)	OR (calculate) = 10.6	2.8- 39.7	P value=0.000125 (≥70% vs <70%) [Fisher's exact test]			
Breet 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	ADP LTA 5μmol/L	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR N=445	Death combined	52/445 (11.7)	OR=2.09	1.34- 3.25	<0.001	No	NR	Figure 1 KM curves
						Normal OTPR N=604		36/604 (6)						
	maintaining Clopidogrel 75 mg daily + aspirin 80- 100mg daily	ADP LTA 20 μmol/L	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR N=392	Death combined	47/392 (12)	OR=2.05	1.32- 3.19	<0.001	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal OTPR N=659		41/659 (6.2)						
	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	ADP LTA 5µmol/L	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR ≥42.9% N=445	Death combined	52/445 (11.7)	AUC: 0.63 Sens: 0.602 Spec: 0.591	0.58- 0.68 0.498– 0.698 0.56- 0.622	NR	No	NR	
	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	ADP LTA 20µmol/L	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR ≥64.5% N=392	Death combined	47/392 (12)	AUC: 0.62 Sens: 0.546 Spec: 0.639	0.56- 0.67 0.442- 0.645 0.608- 0.668	NR	No	NR	
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	5umol/L ADP LTA	composite	composite	6 months	<50%	composite	2.2%	OR=2.69	1.37- 5.29	0.003	NR	NR	
						≥50%		5.6%						
Bliden, 2007 17291930 USA NR	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Total patients with ischemic events	Total patients with ischemic events	Day 0- 30	HPR n=22	Total patients with ischemic events	5/22	OR (calculated) = 27.0	8-91.4	P value<0.0001 (HPR vs NPR) [Fisher's exact test]	NR	NR	
					Day 0- 30	NPR N=78	Total patients with ischemic events	1/78	NR	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
					Day 31- 365	HPR n=22	Total patients with ischemic events	11/22						
					Day 31- 365	NPR N=78	Total patients with ischemic events	6/78						
	clopidogrel 75 mg qd	LTA	Ischemic events	Ischemic events	NR	HPR	Ischemic event	NR	OR=34.6	8.3- 144.2	<0.001	Yes, age, presentation, diabetes, hypertension, current smoking, BMS (bare-metal stents)	NR	
Gori, 2008 19132241 Italy RECLOSE	Clopidogrel+asp irin	LTA-ADP	Stent thrombosis or cardiac death (composite)			RPR (n=90)		8	OR (calculated) = 3.67	NR	P value = 0.006 (RPR vs no RPR) [Fisher's exact test]	NR	NR	
						No RPR (n=656)		17	NR	NR		NR	NR	
		LTA-collagen				RPR (n=78)		11	OR (calculated) = 7.67	NR	P value = 0.00001 (RPR vs no RPR) [Fisher's exact test]	NR	NR	
						No RPR (n=668)		14	NR	NR		NR	NR	
		LTA-ADP	Stent thrombosis or cardiac death (composite)			RPR (n=90)			32% (15-54%) sensitivity 89% (86-91%) specificity		NS			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
		LTA-collagen				RPR (n=78)			44% (25-63%) sensitivity 91% (88-93%) specificity		For specificity, “p<0.0001 vs RPR by collagen			
		LTA-ADP+LTA- collagen				RPR (n=31)		NA	28% (10-46%) sensitivity 97% (95-98%) specificity		For specificity, <0.01vs. LTA-ADP alone and vs. LTA- collagen	NR	NR	
		LTA-ADP among patients at high risk for AEs	Stent thrombosis or cardiac death (composite)			RPR (n=352)		NA	64% (45-83%) sensitivity 53% (50-57%) specificity		NS	NR	NR	
		LTA-collagen among patients at high risk for AEs				RPR (n=78)		NA	48% (28-68%) sensitivity 91% (89-93%) specificity			NR	NR	
		LTA-ADP+LTA- collagen among patients at high risk for AEs				RPR (n=61)			40% (21-59%) sensitivity 93% (91-95%) specificity		For sensitivity, p<0.01 vs. LTA-ADP For specificity, p<0.0001 vs. LTA- ADP	NR	NR	
		LTA-ADP	Stent thrombosis or cardiac death (composite)			RPR			OR 3.67	1.53- 8.76	0.003 Univariate analysis	NR	NR	
		LTA-collagen				RPR			OR 7.67	3.35- 17.57	0.0001 Univariate analysis	NR	NR	
		LTA-ADP+LTA- collagen				RPR			OR 11.29	4.31- 25.59	0.0001 Univariate analysis	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gurbel, 2010 20691842 USA PREPARE POST- STENTING	Clopidogrel 300- 600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	LTA-ADP	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascular- ization	First event over f/u of 36 months	LTA-ADP >34%	MACE	NR	Sensitivity: 0.8 Specificity: 0.59 AUC: 0.75	0.68- 0.8	P<0.001	NO	NR	Primary endpoint; 14/59 (24%) of first events occurred after clopidogrel stopped (mean duration of Tx=of 6.4 ± 3 months)
						LTA-ADP ≤34%		NR						
	Clopidogrel 300- 600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	LTA-ADP	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascular- ization	First event over f/u of 36 months	LTA-ADP >34%	MACE	NR	HR=4.8	2.4-9.6	P<0.001	NO	NR	Primary endpoint
						LTA-ADP ≤34%		NR						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 300- 600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	LTA-ADP	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascular- ization ¹	First event over f/u of 36 months	LTA-ADP >34%	MACE	NR	HR=5.6	2.7- 11.6	P<0.001	YES; History of prior PTCA and calcium-channel blockers	NR	Primary endpoint
						LTA-ADP ≤34%		NR						
	Clopidogrel 300- 600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	LTA-ADP	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascular- ization ¹	First event over f/u of 36 months	Quartile 1 <65 mm	MACE	6 (11%)	NR	NR	NR	NR	NR	Primary endpoint
						Quartile 2 65-69 mm		8 (15%)						
						Quartile 3 >69-72 mm		16 (30%)						
						Quartile 4 >72 mm		29 (52%)						
Matetzky, 2004 15184279 Israel No	Clopidogrel	Aggregometer (not cone and platelet device)	Recurrent major adverse cardiovascular event	NR	6 months after PCI	Q1	Yes event	6 (40%)	NR	NR	0.007 for trend of Q1 through Q2, Q3 and Q4	NR	NR	NO
						Q2		1 (6.7%)						
						Q3		0						
						Q4		0						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Angiolollo, 2007 17936152 Spain NR	clopidogrel (75 mg/day)	LTA-ADP	MACE	Major adverse cardiovascular events	2 years	HPR cutoff 62%	MACE	37.7%	OR=3.96	1.8-8.7	<0.001 comparing no-HPR	NR	NR	
						No HPR	MACE	13.3%						
						HPR cutoff 62%	MACE	37.7%	OR=3.35	1.68- 6.66	0.0013 comparing no-HPR	Yes, renal failure, New York Heart Assocaition functional class III to IV	NR	
						No HPR	MACE	13.3%						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Aradi 2008 18388039 Hungary NR	Clopidogrel + aspirin	Platelet aggregometry	Cumulative event-free survival (events were cardiovascular death, myocardial infarction, revascularizati on, in-stent restenosis, stent thrombosis, or de novo lesion)	All deaths regarded as cardiovascular unless clear evidence of any other non- cardiovascular cause. MI defined as presence of at least 2 of the 3 criteria: typical chest pain, new ECG changes compatible with MI (Q-wave duration >0.04 sec or >1/4 of the corresponding R-wave's amplitude, ST segment elevation in >2 relevant leads over 0.1 mV), elevation of CK and CK-MB >2xULN in at least 2 different samples. Revascularizati ons included repeated PCI and CABG.	10 mo after stenting	Below 50th percentile of maximal ADP 5 mcmol aggregation	~60% eyeballed estimate	NR	NR	NR	<0.01 vs. next row (Kaplan-Meier test)	NR	NR	Fig 2A has survival curves

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Above 50th percentile of ADP 5 mcmol aggregation	~93% eyeball estimate							
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA5	Death, MI, ST, stroke	Death, MI, ST, stroke	1 year	HCPR (high on- clopidogrel platelet reactivity) or dual HPR	Death, MI, ST, stroke	43/385	NR	NR	0.009 (HCPR vs NPR)	NR	NR	Kalpak- Meier curves (figure 1)
	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA20	Death, MI, ST, stroke	Death, MI, ST, stroke	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual HPR	Death, MI, ST, stroke	37/355	NR	NR	0.006 (HCPR vs NPR)	NR	NR	
	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA5	Death, MI, ST, stroke	Death, MI, ST, stroke	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual HPR	Death, MI, ST, stroke	NR	OR=2.63	1.17- 5.92	0.02 (HCPR vs NPR) [Logistic regression]	Yes, age, impaired ejection fraction, LTA5: HAPR, LTA20 HAPR, hypertension, LTA20 HCPR, LTA5 DAPR, LTA20 DAPR, graft-stenting, bifurcation lesion, verifynow DAPR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA20	Death, MI, ST, stroke	Death, MI, ST, stroke	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual HPR	Death, MI, ST, stroke	NR	OR=3.31	1.47- 7.5	0.004 (HCPR vs NPR) [Logistic regression]	Yes, age, impaired ejection fraction, LTA5: HAPR, LTA20 HAPR, hypertension, LTA5 HCPR, LTA5 DAPR, LTA20 DAPR, graft-stenting, bifurcation lesion, verifynow DAPR	NR	
Breet 2010 20695984 Netherlands Substudy of a larger cohort (Breet 2010 PMID: 20179285)	Clopidogrel 300- 900 LD + 75 mg MD	LTA with 20 µmol/L	MACE	All-cause death, nonfatal MI, definite stent thrombosis and ischemic stroke	1-year	High on- treatment platelet reactivity with native platelet rich plasma	MACE	30	OR=2.45	1.45- 4.15	P=0.001	No	NR	
						Normal on- treatment platelet reactivity with native platelet rich plasma		33						
	Clopidogrel 300- 900 LD + 75 mg MD	LTA with 20 µmol/L	MACE	All-cause death, nonfatal MI, definite stent thrombosis and ischemic stroke	1-year	High on- treatment platelet reactivity with adjusted platelet rich plasma	MACE	30	OR=1.78	1.05- 2.99	P=0.04	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal on- treatment platelet reactivity with adjusted platelet rich plasma		33						
	Clopidogrel 300- 900 LD + 75 mg MD	LTA with 20 μmol/L	MACE	All-cause death, nonfatal MI, definite stent thrombosis and ischemic stroke	1-year	High on- treatment platelet reactivity with native platelet rich plasma	MACE	30	AUC=0.59	0.52- 0.66	NR	No	NR	
	Clopidogrel 300- 900 LD + 75 mg MD	LTA with 20 μmol/L	MACE	All-cause death, nonfatal MI, definite stent thrombosis and ischemic stroke	1-year	High on- treatment platelet reactivity with adjusted platelet rich plasma	MACE	30	AUC=0.59	0.52- 0.66	NR	No	NR	
Buonamici, 2007 17572245 Italy NR	Clopidogre I LD 600 mg maintenance dose of 75 mg daily	LTA ADP	Composite of cardiac death and stent thrombosis	Composite of cardiac death and stent thrombosis	6 months	Responders	Composite of cardiac death and stent thrombosis	19/699 (2.7)	NR	NR	<0.001 comparing with the following group	NR	NR	
						Non- responders		11/105 (11)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Campo, 2007 17868803 Italy NR	Clopidogrel 300- mg loading dose, followed by 75 mg/day	LTA ADP	MACE	MACE	6 months	Responder to both	MACE	2(2.2)	OR (calculated)=2. 43	0.7-8.5	P value=0.169 (clopidogrel and dual nonresponders vs other groups) [Fisher's exact test]	NO	NR	
						Clopidogrel – Ticlopidine +		3(12)						
						Clopidogrel + Ticlopidine -		5(22)						
						Non- responder to both		2(40)						
Cuisset 2006 16371119 France NR	Clopidogrel + aspirin	PAP4 aggregometer	Cardiovascular event	CV death, acute or subacute stent t hrombosis, ischemic stroke and recurrent ACS	1 month	Q1-Q3 (responder)	Yes event	3 (4%)	NR	NR	NR	NO	NR	NO
							No event	80 (96%)	NR	NR	NR	NO		
						Q4 (non- responder)	Yes event	9 (39%)	OR vs Q1-3: 22.4	4.6-109	<0.05 (l ogistic regression) vs. Q1-3 yes event	NO		
									OR vs Q1-3: 19.6	4.24- 90.3	<0.001 (l ogistic regression) vs. Q1-3 yes event	YES age, sex		

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
									OR vs Q1-3: 35	4.81- 248	<0.001 (l ogistic regression) vs. Q1-3 yes event	YES age, sex, (hypertension, diabetes, dyslipidemia, smoking, ejection fraction), heart rate, systolic blood pressure and treatments.		
									OR vs Q1-3: 41.6	4.74- 364	0.003 (l ogistic regression) vs. Q1-3 yes event	YES age, sex, (hypertension, diabetes, dyslipidemia, smoking, ejection fraction), heart rate, systolic blood pressure and treatments + P- selectin and CRP		
							No event	14 (61%)						
Cuisset 2006 17010792 France NR	Clopidogrel 300 mg LD	LTA	CV events	CV death, acute or subacute stent thrombosis, recurrent ACS, and stroke.	1 month	high post treatment platelet reactivity	CV events	12	OR=9.93	3.19- 30.9	NR [logistic regression]	YES; Age, gender	NR	
						normal post treatment platelet reactivity		6						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 600 mg LD	LTA	CV events	CV death, acute or subacute stent thrombosis, recurrent ACS, and stroke.	1 month	high post treatment platelet reactivity	CV events	6	OR=43.16	4.89- 381.1	NR [logistic regression]	YES; Age, gender	NR	
						normal post treatment platelet reactivity		1						
Geisler 2008 17949474 Germany NR	Clopidogrel	Turbidoaggregom etry	Major adverse events (MI, ischemic stroke, death, or cardiovascular death		30 days	RPA tertile 1 (lowest)	Yes event	5 (1.5%)	OR (calculated)=2. 37	1.1-5	P value=0.026 (highest tertile vs tertile 1&2) [Fisher's exact test]	NO (not for these data)	NR	These data are for 950 patients (87% of the 1092) with 30-day followup data
						RPA tertile 2		8 (2.5%)						
						RPA tertile 3 (highest)		15 (4.8%)						
Geisler, 2006 17005534 Germany NR	Clopidogrel LD dose of 600 mg followed 75 mg daily	ADP LTA	Composite CV endpoints	Composite CV endpoints	3-month	Adequate response	Composite CV endpoints	19/341 (5.6)	NR	NR	0.01	NR	NR	
						Low response		5/22 (22.7)						
	Clopidogrel LD dose of 600 mg followed 75 mg daily	ADP LTA	Cumulative events	Cumulative events	3-month	Adequate response	Cumulative events	23/341 (6.7)	NR	NR	0.005	NR	NR	
						Low response		6/22 (27.3)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel LD dose of 600 mg followed 75 mg daily	ADP LTA	Composite cardiovascular endpoints	Composite cardiovascular endpoints	3 months	Low response	Composite cardiovascular endpoints	N=22	HR=3.71	1.08- 12.69	0.04	Yes, factors influencing cardiovascular outcome	NR	
Geisler 2010 19812059 Germany NR	Clopidogrel 300- 600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	MACE	MI, ischemic stroke, cardiovascular death	3 months	Low responder (Terrtile 3)	MACE	30 (4.2%)	OR=2.21	1.31- 3.73	p=0.002 (low responder vs responder) [chi square]	NO	NR	Secondary outcome
						Responders (Terrtile 1&2)		30 (9.1%)						
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiven ess to Clopidogrel and Sirolimus- or Paclitaxel- Eluting Stent Thrombosis)	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	LTA- ADP	MACE	Composite of cardiac mortality and stent thrombosis (definite or probable)	Maximu m FU of 6 mo	Residual platelet reactivity (RPR) (ADP- induced platelet aggregation ≥70%)	Cardiac death or stent thrombosis	10 (9.1%)	NR	NR	0.001 across groups (chi square test)	NO	NO	Secondary outcome
						No residual platelet reactivity (RPR)		19 (2.1%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	Combination of genotypic and phenotypic tests: CYP2C19*2 + ADP residual platelet reactivity (see also KQ1b extraction form)	MACE	Composite of cardiac mortality and stent thrombosis (definite or probable)	Maximum FU of 6 mo	*2/*2 + RPR N = 40	Cardiac death or stent thrombosis	7 (17.5%)	NR OR=11.45	NR (1.84, 71.27)	<0.0001 (chi square test) 0.009 (logistic regression)	NO Adjusted (“for traditional cardiovascular risk factors and clinical and procedural risk factors for stent thrombosis”)	NO	Secondary outcome
						*1/*1 or low RPR N = 732		22 (3%)						
	Aspirin (loading dose = 325 mg; maintenance dose = 325 mg per day) and clopidogrel (loading dose = 600 mg; 75 mg maintenance).	LTA-ADP	MACE	Composite of cardiac mortality and stent thrombosis (definite or probable)	Maximum FU of 6 mo	Residual platelet reactivity (RPR) (ADP-induced platelet aggregation ≥70%)	Cardiac death or stent thrombosis	10 (9.1%)	OR=3.38 OR=2.9	(1.53, 7.49) (1.08, 12.98)	0.003 (chi square test) 0.019 (logistic regression)	NO (univariate) YES (ADP-RPR, traditional cardiovascular risk factors, clinical and procedural risk factors for ST)	NO	Secondary outcome
						No residual platelet reactivity (RPR)		19 (2.1%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gori 2008 18718420 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel- Eluting Stent Thrombosis)	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	MACE	Cardiac death & stent thrombosis	6 months	Clopidogrel non- responder	Cardiac death & stent thrombosis	NR	HR=2.23	0.85 to 5.82	P=0.101	YES; age (years), male gender, family history of CAD, smoker, HTN, hypercholesterole mia, diabetes mellitus, history of myocardial infarction, history of coronary surgery, acute coronary syndrome, acute STEMI, left ventricular ejection fraction (%), multivessel disease, bifurcation lesion, thrombus- containing lesion, chronic total occlusion, and stent length (mm).	NR	Secondary endpoint

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	MACE	Cardiac death & stent thrombosis	6 months	Clopidogrel & Aspirin non- responder	Cardiac death & stent thrombosis	NR	HR=2.94	1.17 to 7.41	P=0.022	YES; age (years), male gender, family history of CAD, smoker, HTN, hypercholesterole mia, diabetes mellitus, history of myocardial infarction, history of coronary surgery, acute coronary syndrome, acute STEMI, left ventricular ejection fraction (%), multivessel disease, bifurcation lesion, thrombus- containing lesion, chronic total occlusion, and stent length (mm).	NR	Secondary endpoint

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	MACE	Cardiac death & stent thrombosis	6 months	Clopidogrel responder and Aspirin responder	Cardiac death & stent thrombosis	15 (2.6)	NR	NR	P<0.0001; (dual clopidogrel and aspirin nonresponders versus aspirin nonresponders) P<0.05; (dual clopidogrel and aspirin nonresponders versus aspirin nonresponders)	NO	NR	Secondary endpoint
						Clopidogrel non- responder and aspirin non- responder		6 (13.3)			p <0.05 (dual clopidogrel and aspirin nonresponders versus aspirin nonresponders) p <0.0001 (dual clopidogrel and aspirin nonresponders versus aspirin nonresponders)			
						Clopidogrel non- responder and aspirin responder		2 (4.4)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Clopidogrel responder and aspirin non- responder		2 (2.3)						
	600 mg clopidogrel LD + 75-mg MD & Aspirin 325 mg MD	LTA	MACE	Cardiac death & stent thrombosis	6 months	Clopidogrel responder and Aspirin responder	Cardiac death & stent thrombosis	NR	NR	NR	P<0.0001; (dual nonresponders vs. dual responder) P=0.011 (dual nonresponders vs. aspirin nonresponders) P=0.127 (dual nonresponders vs. clopidogrel nonresponders)	NO	NR	Secondary endpoint
Gurbel, 2008 19012177 USA None	Clopidogrel + aspirin	5 mcM ADP aggregation	Any first ischemic event	Death, MI, stent thrombosis, revascular- ization (target or nontarget vessel), stroke, rehospitalization for ischemia without revascular- ization	1 mo	>46% platelet aggregation (HPR)	YES event	4 (5%)	NR	NR	NR	NR	NR	NR
					2-24 mo			47 (53%)	NR	NR	NR	NR	NR	NR
					1 mo	<=46%		5 (2%)	NR	NR	NR	NR	NR	NR
					2-24 mo			25 (12%)	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
									AUC 0.77; Also sensitivity 63%, specificity 82%	NR	0.0001			95% CIs are in Fig 3
	Clopidogrel+asp irin	5 mcM ADP aggregation	Any first ischemic event		0-24 mo	>46% platelet aggregation (HPR)		51 (58%)	HR vs. next row, 3.9	1.9-8.4	0.001 vs. next row (Fisher's exact and also multivariate Cox regression for HR)	NR	NR	NR
						<=46%		30 (14%)	NR	NR	NR	NR	NR	NR
	Clopidogrel+asp irin	20 mcM ADP aggregation	Any first ischemic event	Death, MI, stent thrombosis, revascular- ization (target or nontarget vessel), stroke, rehospitalization for ischemia without revascular- ization	1 mo	>59% platelet aggregation (HPR)	YES event	4 (4%)	NR	NR	NR	NR	NR	NR
					2-24 mo			50 (50%)	NR	NR	NR	NR	NR	NR
					1 mo	<=59%		5 (3%)	NR	NR	NR	NR	NR	NR
					2-24 mo			22 (11%)	NR	NR	NR	NR	NR	NR
									AUC 0.78; Also sensitivity 68%, specificity 78%	NR	0.0001			95% CIs are in Fig 4
	Clopidogrel + aspirin	20 mcM ADP aggregation	Any first ischemic event			>59% platelet aggregation (HPR)		54 (54%)	HR vs. next row, 3.8	1.8-7.9	0.001 vs. next row (Fisher's exact and also multivariate Cox regression for HR)	NR	NR	NR

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gurbel, 2004 15154601 USA None	Clopidogrel + aspirin	Aggregometry	Stent thrombosis, target vessel revascularizati on, cerebro- vascular ischemic event, or death	NR	Within 30 days after PCI	Heightened reactivity	Yes event	0	NR	NR	NR	NR	NR	NO
						No heightened reactivity		0						
Hochholzer, 2006 17084243 Germany EXCELSIOR	Clopidogrel 75 mg/day	ADP LTA	Any MACE	Any MACE	30-day	1st quartile <4%	Any MACE	209	Mean 1(0.5)	NR	0.03	NR	NR	
						2nd quartile 4-14%		198	1(0.5)					
						3rd quartile 15-32%		196	6 (3.1)					
						4th quartile >32%		199	7(3.5)					
	Clopidogrel 75 mg/day	ADP LTA	Any MACE or major bleeding	Any MACE or major bleeding	30-day	1st quartile <4%	Any MACE or major bleeding	209	Mean 4(1.9)	NR	0.44	NR	NR	
						2nd quartile 4-14%		198	3(1.5)					
						3rd quartile 15-32%		196	7(3.6)					
						4th quartile >32%		199	7(3.5)					

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 75 mg/day	Platelet aggregation(PA)	MACE	Major adverse cardiac event	30 days	10% increase in ADP- induced PA	MACE	NR	OR=1.32	1.04- 1.61	0.026	Yes. Demographic, clinical and angiographic variables, time from clopidogrel loading and baseline platelet aggregation	NR	
									OR=1.31	1.03- 1.67	0.026	No		
Htun, 2011 21273381 Germany NR	clopidogrel LD 600 mg then 75 mg/d and aspirin 100 mg/d	LTA ADP	combined major event within follow- up	myocardial infarction, ischemic stroke, and death	1 year	low- responder group	combined major event within follow- up	326/1567	HR=2.08	1.42- 3.03	<0.001 comparing with responder	no	NR	
	clopidogrel LD 600 mg then 75 mg/d and aspirin 100 mg/d	LTA ADP	combined major event within follow- up	myocardial infarction, ischemic stroke, and death	1 year	low- responder group	combined major event within follow- up	326/1567	HR=1.64	1.06- 2.54	0.026 comparing with responder	yes, diabetes mellitus, acute coronary syndromes, impaired left ventricular, gender arterial hypertension, tobacco use, age, cardiovascular comedication, antiplatelet pretreatment, clopidogrel low response, and age.	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
L'Allier 2008 18342223 Canada PREPAIR study	clopidogrel LD 600 mg then 75 mg/d and aspirin 100 mg/d	LTA ADP	combined major event within follow- up	myocardial infarction, ischemic stroke, and death	1 year	low- responder group 1	combined major event within follow- up	30/165 (18.2)	NR	NR	0.038 comparing with the lower row	NR	NR	
						responder group 1		46/396 (11.6)						
						low- responder group 2		11/161 (6.8)			0.59 comparing with the lower row			
						responder group 2		35/613 (5.7)						
	Clopidogrel: Group A, B, and C (differing clopidogrel regimens)	Aggregometry	Major bleeding, death, rehospitali- zation for MI, or repeat target-vessel revasculari- zation	Major bleeding defined as intracranial or clinically relevant bleeding with decrease in hemoglobin of >5 g/dl	within 1 mo after dis- charge	All non- responder groups as listed above	Yes event	0 in each group	NR	NR	NR	NO	NO	Each outcome here reporter independ- ently in paper
Liu 2011 21613806 China None	Clopidogrel + aspirin	Aggregometry	Any CV event	NR	1 mo after stenting	Non- responders	34	6	NR	NR	NR	NR	NR	For all clinical data, n=106 patients because 3 more were lost to followup
						Low responders	28	2						
						Responders	44	0			0.014 across this and previous 2 rows (chi-square test)			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel + aspirin	Aggregometry	Any CV event		3 mo after stenting	Non- responders	34	11						
						Low responders	28	2						
						Responders	44	0			<0.0001 across this and previous 2 rows (chi-square test)			
Muller, 2010 20728084 Germany NR	Clopidogrel 600 mg LD + 75 mg MD & Aspirin 100 mg/d MD	LTA	MACE	composite of myocardial infarction and death	Mean follow up of 344 days	Stratum I: RPA & CRP <median	MACE	NR	NR	NR	P<0.001 (Stratum IV vs I) P<0.001 (Stratum IV vs II) P=0.06 (Stratum IV vs III) P=0.01 (Stratum III vs I) P>0.05 (Stratum III vs I) P>0.05 (Stratum II vs I) [Log Rank] test	YES; age, gender, left ventricular function, acute coronary syndromes, hyperlipidemia and relevant comedication	NR	Primary
						Stratum II:RPA >median & CRP ≤median		NR						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Stratum III:RPA ≤ median & CRP >median		NR						
						Stratum IV:RPA & CRP >median		NR						
	Clopidogrel 600 mg LD + 75 mg MD & Aspirin 100 mg/d MD	LTA	MACE	composite of myocardial infarction and death	Mean follow up of 344 days	By Quartiles (not defined)	MACE	NR	NR	NR	NR	NO	NR	“Most events occurred in patients with a platelet aggregation in the upper quartile of the collective”

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Trenk, 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ atleast 1 drug-eluting stent	LTA	Composite of death and MI	MI: new rise in troponin T ≥0.03 mg/l associated with typical symptoms and/or typical electrocardiogra m changes and/or typical angiographic finding Death: as reported in phone interview	1 year	high on- treatment platelet reactivity (RPA>14%)	MI or death	13/217 (6%)	HR= 3	1.4-6.8	P=0.004 (between high and not high residual platelet reactivity)	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%)		11/548 (2%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Wang, 2010 21171668 China None	Clopidogrel + aspirin	LTA	composite of cardiovascular death, MI and revascularizati on	death of acute MI, coronary artery disease, or heart failure; any typical increase or decrease of cardiac biomarker along with clinical symptoms consis ent with cardia c ischemia, following the American College of Cardiology definition; or bypass surgery and PCI	Within 1 yr after dis- charge	Clopidogrel resistance	YES event	7 (21.88%)	NR	NR	0.006 vs. next row (Student's t); P=0.008 from multivariate regression (for independent prediction)	YES for multivariate regression P value only (diabetes, BMI, and smoking status)	NR	NONE
						Non- resistance		6 (4.92%)						
Wang, 2009 19041120 China NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Composite thrombotic events	Cardiovascular death, confatal- MI stent thrombosis or CVA	12- months	Clopidogrel resistancce	Cardio- vascular death, confatal-MI stent thrombosis or CVA	NR	HR=2.44	1.09- 5.45	0.031	Yes, diabetes, LV dysfunction (EF<30%)	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	Composite end points	Cardiovascular death, confatal- MI stent thrombosis or CVA	One year	Clopidogrel resistance	Composite end points	11/65 (16.9)	NR	NR	0.01comparing with the following group	NO	NO	2 Kaplan- Meier curves for 12-month event-freee survival from composite thrombotic events
						Normal response		20/321 (6.2)						
						Total		31/386 (8.0)						
Yong, 2009 19081397 Australia Platelet Responsiven ess to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial	300-600 mg LD of clopidogrel	LTA using 4 , 10, 20µmol/L	MACE	death, nonfatal MI, nonfatal stroke, hospitalization for recurrent ischemia	6 months	Quartile 1	Post-PCI myonecrosis	NR	NR	NR	NR	NR	NR	Data presented in Fig 2B; no pvalues are reporter for all concentratio ns of ADP
						Quartile 2	NR							
						Quartile 3	NR							

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gurbel, 2005 16286165 USA PREPARE POST- STENTING	Clopidogrel (300- 600 mg LD+75 mg daily MD) + aspirin (81- to 325-mg/d x 7 days LD + 325 md/f MD)	LTA	Ischemic events	Cardiovascular death, MI, unstable angina and stroke requiring rehospitalization	6 months	Quartile 4 High LTA - Quartile 4 (>67%)	Ischemic events	NR	OR=2.7	0.565- 12.964	P=0.2129 (Multiple logistic regression)	NO	YES; Low TEG- R (reaction time<3.9 mins), High TEG-MA (Max amplitude >72 mm) and combinati on of High TEG-MA and low R	Tab 4; it's not clear if all predictor were in the same model
	Clopidogrel (300- 600 mg LD+75 mg daily MD) + aspirin (81- to 325-mg/d x 7 days LD + 325 md/f MD)	LTA	Ischemic events	Cardiovascular death, MI, unstable angina and stroke requiring rehospitalization	6 months	High LTA - Quartile 4 (>67%)	Ischemic events	NR	Sens=0.37 Spec=0.79	NR	NR	NO	No	
	Clopidogrel (300- 600 mg LD+75 mg daily MD) + aspirin (81- to 325-mg/d x 7 days LD + 325 md/f MD)	LTA	Ischemic events	Cardiovascular death, MI, unstable angina and stroke requiring rehospitalization	6 months	Quartile 1 (<50%)	Ischemic events	10%	NR	NR	P=0.02 (Q1 vs Q4) P=0.35 (Q2 vs Q4) P=0.37 (Q3 vs Q4) Logistic regression with appropriate contrasts	NO	NR	Fig 4

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Quartile 2 (50-61%)		24%						
						Quartile 3 (62-67%)		22%						
						Quartile 4 (>67%)		32%						
Angiolillo, 2011 Italy NR	aspirin 100mg/day indefinitely and clopidogrel 75mg/day for 12 months	LTA-ADP	MACE	composite of cardiovascular death, ACS leading to hospital stay, nonfatal stroke	24 months	HPR N=47	MACE	13 (28%)	HR=2.9	1.38- 6.11	0.005 (HRP vs no HPR) [Cox regression]	No	NR	
						No HPR N=140		15 (10.9%)						
						HPR N=47	MACE	13 (28%)	HR=3.1	1.47- 6.52	0.003 (HRP vs no HPR) [Cox regression]	yes, variable from table 1	NR	
						No HPR N=140		15 (10.9%)						
Saad, 2012 22146578 Egypt NR	clopidogrel LD: 600 mg; MD: 75 mg/d; aspirin 162 mg/d	LTA-ADP	MACE	CV death, recurrent acute coronary syndrome (ACS), and acute, subacute, and late stent thromboses	6 months	≥12.5% N=NR	MACE	NR	AUC=0.793	0.674- 0.913	P<0.001	No	NR	
						<12.5% N=NR		NR						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Aradi 2012 21902692 Hungary NR	LD clopidogrel 600mg and aspirin 300mg MD clopidogrel 75 mg/day 4 weeks	LTA ADP	CV death and MI	CV death and MI	12 months	NPR	CV death and MI	9/122=9.5 %	NR	NR	NR	NR	NR	NR
						HPR+150 mg clopidogrel	CV death and MI	1/36=3.1 %	OR=14.2 (calculated)	1.54- 131.61	0.09 comparing with the low row log-rank test			
						HPR +75 mg clopidogrel	CV death and MI	5/38=16.4 %						
Aradi 2012 21902692 Hungary NR	LD clopidogrel 600mg and aspirin 300mg MD clopidogrel 75 mg/day 4 weeks	LTA ADP	CV death , MI or TVR	CV death , MI or TVR	12 months	NPR	CV death , MI or TVR	9/122=9.5 %	OR=3.35 (calculated)	1.19- 9.42	NR	NR	NR	NR
						HPR+150 mg clopidogrel	CV death, MI or TVR	1/36=3.1 %			0.09 comparing with the low row log-rank test			
						HPR +75 mg clopidogrel	CV death, MI or TVR	5/38=16.4 %						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
Marcucci, 2012 22390861 Italy NR	600 mg clopidogrel loading dose followed by 75 mg daily dose ASA IV 500 mg followed by 100- 325 mg daily dose	LTA ADP	MACE	CV death , non- fatal MI	6 months	HPR N=486	CV death , non-fatal MI	NR	HR=2	1.2-3.4	P=0.01 (HPR vs no HPR) [Cox regression]	Yes (CV risk factors, renal failure, reduced ejection fraction, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, type of stent and use of GpIIb/IIIa inhibitors)	NR	
						No HPR N=701	CV death, MI or TVR	NR						
			MACE	CV death , non- fatal MI	7-12 months	HPR N=486	CV death , non-fatal MI	NR	HR=2.7	1.4-5.3	P=0.003 (HPR vs no HPR) [Cox regression]	Yes (CV risk factors, renal failure, reduced ejection fraction, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, type of stent and use of GpIIb/IIIa inhibitors)	NR	
						No HPR N=701	CV death, MI or TVR	NR						
			MACE	CV death , non- fatal MI	12 months	HPR N=486	CV death , non-fatal MI	NR	NR	NR	P<0.0001 (HPR vs no HPR) [log rank test]	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
						No HPR N=701	CV death, MI or TVR	NR						
			MACE in CYP2C19 carriers	CV death , non- fatal MI	12 months	HPR N=144	CV death , non-fatal MI	NR	NR	NR	P<0.0001 (HPR vs no HPR) [log rank test]	No	NR	
						No HPR N=151	CV death, MI or TVR	NR						
			MACE in CYP2C19 noncarriers	CV death , non- fatal MI	12 months	HPR N=342	CV death , non-fatal MI	NR	NR	NR	P<0.0001 (HPR vs no HPR) [log rank test]	No	NR	
						No HPR N=550	CV death, MI or TVR	NR						
			MACE	CV death , non- fatal MI	6 months	HPR N=486	CV death , non-fatal MI	NR	NR	NR	P<0.0001 (HPR vs no HPR) [log rank test]	No	NR	
						No HPR N=701	CV death, MI or TVR	NR						
			MACE in CYP2C19 carriers	CV death , non- fatal MI	6 months	HPR N=144	CV death , non-fatal MI	NR	NR	NR	P<0.006 (HPR vs no HPR) [log rank test]	No	NR	
						No HPR N=151	CV death, MI or TVR	NR						
			MACE in CYP2C19 noncarriers	CV death , non- fatal MI	6 months	HPR N=342	CV death , non-fatal MI	NR	NR	NR	P<0.007 (HPR vs no HPR) [log rank test]	No	NR	
						No HPR N=550	CV death, MI or TVR	NR						
			MACE	CV death , non- fatal MI	7-12 months	HPR N=486	CV death , non-fatal MI	NR	NR	NR	P=0.002 (HPR vs no HPR) [log rank test]	No	NR	
						No HPR N=701	CV death, MI or TVR	NR						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of meas- ure- ment	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within pheno- type group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Proce- dures for multiple compar- isons [YES, NO, NR]	Comments (e.g., additional data in figures)
			MACE in CYP2C19 carriers	CV death , non- fatal MI	7-12 months	HPR N=144	CV death , non-fatal MI	NR	NR	NR	P=0.28 (HPR vs no HPR) [log rank test]	No	NR	
						No HPR N=151	CV death, MI or TVR	NR						
			MACE in CYP2C19 noncarriers	CV death , non- fatal MI	7-12 months	HPR N=342	CV death , non-fatal MI	NR	NR	NR	P<0.001 (HPR vs no HPR) [log rank test]	No	NR	
						No HPR N=550	CV death, MI or TVR	NR						
			MACE	CV death , non- fatal MI	12 months	HPR N=486	CV death , non-fatal MI	NR	AUC=0.66	0.6- 0.71	P<0.0001	No	NR	
						No HPR N=701	CV death, MI or TVR	NR						
			MACE in CYP2C19 carriers	CV death , non- fatal MI	12 months	HPR N=144	CV death , non-fatal MI	NR	AUC=0.64	0.57- 0.71	P<0.0001	No	NR	
						No HPR N=151	CV death, MI or TVR	NR						
			MACE in CYP2C19 noncarriers	CV death , non- fatal MI	12 months	HPR N=342	CV death , non-fatal MI	NR	AUC=0.64	0.57- 0.71	P<0.0001	No	NR	
						No HPR N=550	CV death, MI or TVR	NR						

Appendix Table E18. Results from studies assessing the ability of LTA to predict bleeding events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	5umol ADP- induced PRmax≥50%	TIMI bleeding	TIMI bleeding (major, minor)	6 months	HPPR - 5umol ADP-induced PRmax≥50% N=NR	TIMI bleeding	6.8% (major 4.6%, minor 2.2%)	NR	NR	0.381 (HPPR vs no HPPR)	NR	NR	
						no HPPR N=NR		4.5% (major 1.9%, minor 2.6%)						
Bliden 2007 17291930 USA NR	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Major bleeding	Major bleeding	Day 0-30	HPR n=22	Major bleeding	1	OR (calculated) = 10.95	0.4- 278.6	P= 0.15 (HPR vs NPR) [Fisher's exact]	NR	NR	
						NPR N=78		0	NR	NR	NR	NR	NR	
				Major bleeding	Day 31-365	HPR n=22		0	OR (calculated) = 3.5	NR	P=0.54 (HPR vs NPR) [Fisher's exact]			
						NPR N=78		0						
	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Minor bleeding	Minor bleeding	Day 0-30	HPR n=22	Minor bleeding	1	OR (calculated) = 3.67	0.2- 61.1	P= 0.37 (HPR vs NPR) [Fisher's exact]	NR	NR	
						NPR N=78		1	NR	NR	NR	NR	NR	
					Day 31-365	HPR n=22		0	OR (calculated) = 3.5	NR	P=0.54 (HPR vs NPR) [Fisher's exact]			
						NPR N=78		0						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 75 mg qd	ADP-induced platelet reactivity	bleeding events	bleeding events	Day 0-30	HPR n=22	bleeding events	2	OR (calculated): 7.7	0.7- 89.3	P=0.120 (HPR vs NPR at 1 year) [Fishers exact]]	NR	NR	
						NPR N=78		1						
					Day 31-365	HPR n=22	Bleeding events	0	OR (calculated): 3.5	NR	P=0.54 (HPR vs NPR at 1 year) [Fishers exact]]			
						NPR N=78		0						
Cuisset 2009 19736156 FranceNR	Clopidogrel 600 mg LD + Aspirin 250 mg LD	LTA	Bleeding composite	non-CABG related TIM I major and minor bleeding	30 days	Hyper-responder (quartile 1: ADP- induced aggregation <40%) N=151	Major and minor bleeding +	10 (6.6%)	NR	NR	P=0.001 (hyper- responder versus non hyper- responder) Chi square	NO	NR	Primary
						Non hyperresponder (quartile 2-4: ADP-induced aggregation ≥40%) N=429		6 (1.4%)						
Cuisset 2006 17010792 FranceNR	Clopidogrel 300 mg LD	LTA	Bleeding	major bleeding defined as intracranial bleeding or clinically overt bleeding associated with a decrease in hemoglobin of 5 g/dL	1 month	high post treatment platelet reactivity	bleeding	0	OR = 3.02 (calculated)	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						normal post treatment platelet reactivity		0						
	Clopidogrel 600 mg LD	LTA	Bleeding		1 month	high post treatment platelet reactivity	bleeding	0	OR = 5.53 (calculated)	NR	NR	NR	NR	
						normal post treatment platelet reactivity		0						
Hochholzer, 2006 17084243 Germany EXCELSIOR	Clopidogrel 75 mg/day	ADP LTA	TIMI major bleeding	TIMI major bleeding	30-day	1 st quartile <4% N=209	TIMI major bleeding	3/209 (1.4%)	OR (calculated): 0.615	0.1- 2.6	P= 0.73 (3rd & 4th quartile vs 1st and second quartiles) [Fishers exact]	NR	NR	
						2nd quartile 4- 14% N=198	2/198 (1%)							
						3rd quartile 15-32% N=196	2/196(1%)							
						4th quartile >32% N=199	1/199(0.5%)							
Liu, 2011 21613806 China None	Clopidogrel + aspirin	Aggregometry	Any bleeding event	BleedScore classifications	1 month	Nonresponders N=34	Any bleeding event	0						
						Low responders N=28		0						
						Responders N=44		6			0.011 (responder, nonresponders and low responders) (chi- square test)			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel + aspirin	Aggregometry	Alarming bleeding event	Requiring transfusion, intracranial bleeding or any life-threatening event	1 month	Nonresponders N=34	Alarming bleeding event	0						
						Low responders N=28		0						
						Responders N=44		0						
	Clopidogrel + aspirin	Aggregometry	Internal bleeding event	Hematoma, epistaxis, blood loss from mouth or vagina, melena, eye bleed, hematuria, or hematemesis	1 month	Nonresponders N=34	Internal bleeding event	0						
						Low responders N=28		0						
						Responders N=44		1			0.491 (responder, nonresponders and low responders) (chi- square test)			
	Clopidogrel + aspirin	Aggregometry	Superficial bleeding event	Easy bruising, bleeding from small cuts, petechia, or ecchymosis	1 month	Nonresponders N=34	Superficial bleeding event	0						
						Low responders N=28		0						
						Responders N=44		5			0.025 (responder, nonresponders and low responders) (chi- square test)			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel + aspirin	Aggregometry	Any bleeding event	BleedScore classifications	3 month	Nonresponders N=34	Any bleeding event	1						
						Low responders N=28		1						
						Responders N=44		14			0.1 (responder, nonresponders and low responders) (chi- square test)			
	Clopidogrel + aspirin	Aggregometry	Alarming bleeding event	Requiring transfusion, intracranial bleeding or any life-threatening event	3 month	Nonresponders N=34	Alarming bleeding event	0						
						Low responders N=28		0						
						Responders N=44		0						
	Clopidogrel + aspirin	Aggregometry	Internal bleeding event	Hematoma, epistaxis, blood loss from mouth or vagina, melena, eye bleed, hematuria, or hematemesis	3 month	Nonresponders N=34	Internal bleeding event	0						
						Low responders N=28		1						
						Responders N=44		3			0.292 (responder, nonresponders and low responders) (chi- square test)			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel + aspirin	Aggregometry	Superficial bleeding event	Easy bruising, bleeding from small cuts, petechia, or ecchymosis	3 month	Nonresponders N=34	Superficial bleeding event	01						
						Low responders N=28		0						
						Responders N=44		11			0.001 (responder, nonresponders and low responders) (chi- square test)			

Appendix Table E19. Results from studies assessing the ability of LTA to predict stroke in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80-100mg daily	ADP LTA 5µmol/L	stroke	Stroke	1-year	High OTPR N=445	Stroke	6 (1.3)	OR=1.17	0.39-3.49	<0.78 (high vs normal) [logistic regression]	No	NR	
						Normal OTPR N=604		7 (1.2)						
	maintaining Clopidogrel 75 mg daily +aspirin 80-100mg daily	ADP LTA 20 µmol/L	stroke	Stroke	1-year	High OTPR N=392	Stroke	5 (1.3)	OR=1.05	0.34-3.24	<0.93 (high vs normal) [logistic regression]	No	NR	
						Normal OTPR N=659		8 (1.2)						
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	5µmol/L ADP LTA	ischemic stroke	ischemic stroke	6 months	<50%	ischemic stroke	0.2%	OR=1.58	0.10-25.36	1.000 (<50 vs ≥ 50%) [logistic regression]	NR	NR	
						≥50%		1.2%						
Bliden, 2007 17291930 USA NR	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Stroke	Stroke	Day 0-30	HPR n=22	Stroke	0	OR (calculated)=16.1	NR	P=0.535 (HPR vs NPR at 1 year) [chi square]	NR	NR	
					Day 0-30	NPR N=78	Stroke	0						
					Day 31-365	HPR n=22	Stroke	0	OR=3.5	NR	NR	NR	NR	
					Day 31-365	NPR N=78	Stroke	0						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA5	Stroke	Stroke	1 year	HCPR(high on-clopidogrel platelet reactivity) or dual HPR N=385	Stroke	5	NR	NR	NR	NR	NR	
	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	LTA20	Stroke	Stroke	1 year	HCPR(high on-clopidogrel platelet reactivity) or dual HPR N=335	Stroke	3	NR	NR	0.045 comparing with NPR(normal on-treatment platelet reactivity)	NR	NR	
Geisler, 2006 17005534 Germany NR	Clopidogrel LD dose of 600 mg followed 75 mg daily	ADP LTA	Stroke	Stroke	3-month	Adequate response N=341	Stroke	5 (1.5)	NR	NR	0.43 (adequate vs low response) [Chi square]	NR	NR	
						Low response N=22		0						
Geisler, 2010 19812059 Germany NR	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 500 mg LD + 100 mg MD	LTA	ischemic stroke	NR	3 months	Low responder (Tertile 3)	ischemic stroke	6 (0.9%)	OR=0.7	0.14-3.48	p=0.66 (low responder vs responder) [chi square]	NO	NR	Secondary outcome
						Responders (Tertile 1&2)		2 (0.6%)						
Gurbel, 2008 19012177 USA None	Clopidogrel + aspirin	5 uM ADP aggregation	Stroke		1 mo	>46% platelet aggregation (HPR)		0	OR (calculated) = 12.1	0.6-254.9	P=0.09 (HPR vs NPR at 2 year) [Fishers exact]	NR	NR	NR
					2-24 mo			2	NR	NR	NR	NR	NR	NR
					1 mo	<=46%		0	NR	NR	NR	NR	NR	NR
					2-24 mo			0	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel + aspirin	20 uM ADP aggregation	Stroke		1 mo	>46% platelet aggregation (HPR)		0	OR (calculated) = 9.9	0.5-207.7	P=0.12 (HPR vs NPR at 2 year) [Fishers exact]	NR	NR	NR
					2-24 mo			2	NR	NR	NR	NR	NR	NR
					1 mo	<=46%		0	NR	NR	NR	NR	NR	NR
					2-24 mo			0	NR	NR	NR	NR	NR	NR
Htun, 2011 21273381 Germany NR	clopidogrel LD 600 mg then 75 mg/d and aspirin 100 mg/d	LTA ADP	ischemic stroke	ischemic stroke	1 year	low-responder group1 (K/DOQI index III-V) N=165	ischemic stroke	2(1.2)	NR	NR	0.08 (low responder vs responder)	NR	NR	
						responder group 1 (K/DOQI index III-V) N=396		16 (4.1)						
						low-responder group 2 (K/DOQI index I-II) N=161		1 (0.6)			0.67 (low responder vs responder)			
						responder group 2 (K/DOQI index I-II) N=613		6 (1.0)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Liu, 2011 21613806 China None	Clopidogrel + aspirin	Aggregometry	Ischemic stroke	New focal neurologic deficit without bleeding on tomodesitoemtry confirmed by a neurologist to have occurred within the time frame (1 or 3 mo after PCI)	1 month	Non-responders	34	3	OR (calculated) = 16.1	0.8-321.2	P=0.03 (nonresponder vs resp + low resp at 1month) [Fishers exact]	NR		
						Low responders	28	0						
						Responders	44	0			0.38 across this and previous 2 rows (chi-square test)			
Wang, 2009 19041120 China NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	CVA	Cerebrovascular ischemia accident (CVA)	One year	Clopidogrel resistance	CVA	2/65 (3.1)	OR=3.37	0.55-20.55	0.199 comparing with the following group	NO	NO	
						Normal response		3/321 (0.9)						
Gurbel, 2003 12796140 USA NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	cerebrovascular ischemic events	cerebrovascular ischemic events	30 days	Clopidogrel resistance	cerebrovascular ischemic events	0/50	OR (calculated) = 1.25	NR	P=0.91 (nonresponder vs resp + low resp at 1month) [Fishers exact]	NR	NO	
						Clopidogrel nonresistance		0/63						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Ge, 2012 21602258 China NR	Clopidogrel 600 mg loading; maintenance clopidogrel 75 mg/d + aspirin 100 mg/d	LTA (ADP)	stroke	NR	6 mo	Resistance (drop in reactivity <10% post-loading)	Stroke events	0/65 (0%)	NA	NA	NR	NR	NR	NR
						Non-resistance (drop ≥10% post-loading)		0/287 (0%)						

Appendix Table E20. Results from studies assessing the ability of LTA to predict other clinical events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple compari- sons [YES, NO, NR]	Comments (e.g., additional data in figures)
Bliden, 2007 17291930 USA NR	clopidogrel 75 mg qd	ADP- induced platelet reactivity	Target vessel revascularization	Target vessel revascularization	Day 0-30	HPR n=22	Target vessel revascularization	0/22	OR (calculated) = 14.25	2.6-77.1	P=0.001 (HPR vs NPR) [Fisher's exact test]	NR	NR	
					Day 0-30	NPR N=78	Target vessel revascularization	0/78	NR	NR	NR	NR	NR	
					Day 31-365	HPR n=22	Target vessel revascularization	6/22						
					Day 31-365	NPR N=78	Target vessel revascularization	2/78						
	clopidogrel 75 mg qd	ADP- induced platelet reactivity	Nontarget vessel revascularization	Nontarget vessel revascularization	Day 0-30	HPR n=22	Nontarget vessel revascularization	0/22	OR (calculated) = 7.7	0.7-89.3	P=0.12 (HPR vs NPR) [Fisher's exact test]	NR	NR	
					Day 0-30	NPR N=78	Nontarget vessel revascularization	0/78	NR	NR	NR	NR	NR	
					Day 31-365	HPR n=22	Nontarget vessel revascularization	2/22						
					Day 31-365	NPR N=78	Nontarget vessel revascularization	1/78						
	clopidogrel 75 mg qd	ADP- induced platelet reactivity	Rehospitalization for ischemia	Rehospitalization for ischemia	Day 0-30	HPR n=22	Rehospitalization for ischemia	2/100	OR (calculated) = 5.6	1.1-27	P=0.04 (HPR vs NPR) [Fisher's exact test]	NR	NR	
					Day 0-30	NPR N=78	Rehospitalization for ischemia	0/100	NR	NR	NR	NR	NR	
					Day 31-365	HPR n=22	Rehospitalization for ischemia	2/100						
					Day 31-365	NPR N=78	Rehospitalization for ischemia	3/100						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple compari- sons [YES, NO, NR]	Comments (e.g., additional data in figures)
Campo, 2007 17868803 Italy NR	Clopidogrel 300-mg loading dose, followed by 75 mg/day	LTA ADP	TVR	TVR	6 months	Responder to both	TVR	23	1/90(1.1)	OR (calculated) = 1.95	0.3-11.2	P=0.605 (clopidogrel + dual non- responder vs responder) [Fisher's exact test]	NR	
						Clopidogrel non- responders Ticlopidine responders			2/25(8)					
						Clopidogrel responders Ticlopidine non- responders			3/23(13)					
						Non- responder to both			0/5					
Gurbel, 2008 19012177 USA None	Clopidogrel + aspirin	5 uM ADP aggregation	revascularization (target vessel)		1 mo	>46% platelet aggregation (HPR)		1	NR	OR(calculated) = 7.39	3.1-17.5	P<0.0001 (HPR vs NPR) [Fisher's exact test]	NR	NR
						<=46%		0	NR	NR	NR	NR	NR	NR
					2-24 mo	>46% platelet aggregation (HPR)		19	NR	NR	NR	NR	NR	NR
						<=46%		8	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple compari- sons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
	Clopidogrel + aspirin	5 uM ADP aggregation	revascularization (nontarget vessel)		1 mo	>46% platelet aggregation (HPR)		0	NR	OR (calculated) = 4.34	1.5-12.3	P=0.008 (HPR vs NPR) [Fisher's exact test]	NR	NR
						<=46%		1	NR	NR	NR	NR	NR	NR
					2-24 mo	>46% platelet aggregation (HPR)		10	NR	NR	NR	NR	NR	NR
						<=46%		5	NR	NR	NR	NR	NR	NR
	Clopidogrel + aspirin	5 uM ADP aggregation	rehospitalization for ischemia, no revascularization		1 mo	>46% platelet aggregation (HPR)		1	NR	OR (calculated) = 3.14	1.3-7.6	P=0.01 (HPR vs NPR) [Fisher's exact test]	NR	NR
						<=46%		1	NR	NR	NR	NR	NR	NR
					2-24 mo	>46% platelet aggregation (HPR)		11	NR	NR	NR	NR	NR	NR
						<=46%		9	NR	NR	NR	NR	NR	NR
	Clopidogrel + aspirin	20 uM ADP aggregation	revascularization (target vessel)		1 mo	>46% platelet aggregation (HPR)		1	NR	OR (calculated) = 3.17	1.4-7.1	P=0.005 (HPR vs NPR) [Fisher's exact test]	NR	NR
						<=46%		0	NR	NR	NR	NR	NR	NR
					2-24 mo	>46% platelet aggregation (HPR)		16	NR	NR	NR	NR	NR	NR
						<=46%		11	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple compari- sons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel + aspirin	20 uM ADP aggregation	revascularization (nontarget vessel)		1 mo	>46% platelet aggregation (HPR)		0	NR	OR(calculated) = 4.66	NR	P=0.004 (HPR vs NPR) [Fisher's exact test]	NR	NR
						<=46%		1	NR	NR	NR	NR	NR	NR
					2-24 mo	>46% platelet aggregation (HPR)		11	NR	NR	NR	NR	NR	NR
						<=46%		4	NR	NR	NR	NR	NR	NR
	Clopidogrel + aspirin	20 uM ADP aggregation	Rehospitalization for ischemia, no revascularization		1 mo	>46% platelet aggregation (HPR)		1	NR	OR (calculated) = 4.71	1.9-12	P=0.0007 (HPR vs NPR) [Fisher's exact test]	NR	NR
						<=46%		1	NR	NR	NR	NR	NR	NR
					2-24 mo	>46% platelet aggregation (HPR)		14	NR	NR	NR	NR	NR	NR
						<=46%		6	NR	NR	NR	NR	NR	NR
Liu, 2011 21613806 China None	Clopidogrel + aspirin	Aggrego- metry	Acute coronary syndrome	presence of symptoms compatible with recurrent ischemia requiring hospitalization and angiocoronaro- graphy	1 month	Non- responders	34	1		OR (calculated) = 15.2	1.8-132.2	P=0.004 (HPR vs NPR) [Fisher's exact test]		
						Low responders	28	1						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple compari- sons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Responders	44	0			0.447 across this and previous 2 rows (chi- square test)			
	Clopidogrel + aspirin	Aggrego- metry	Acute coronary syndrome	presence of symptoms compatible with recurrent ischemia requiring hospitalization and angiocoronaro- graphy	3 month	Non- responders	34	6						
						Low responders	28	1						
						Responders	44	0			0.006 across this and previous 2 rows (chi- square test)			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple compari- sons [YES, NO, NR]	Comments (e.g., additional data in figures)
Trenk, 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	600 mg clopidogrel LD + 75 mg/day MD (for 30 d w/ bare-metal stents or 6 mth w/ at least 1 drug-eluting stent	LTA	target lesion intervention	target lesion intervention	1 year	high on- treatment platelet reactivity (RPA>14%)	target lesion intervention	26/217 (12%)	HR=1.1	0.7-1.8	P=0.67 (between high and not high residual platelet reactivity)	YES; Age, HTN, DM, BMI, platelet count, verapamil, insulin and antidiabetic medication use, previous angioplasty and CABG, LV function, angina class, PCI, stent implantation, LAD affected, stenosis length ad diameter of stenosis	NR	Primary outcome
						no high on- treatment platelet reactivity (RPA≤ 14%)		60/548 (10.9%)						
Wang, 2010 21171668 China None	Clopidogrel + aspirin	LTA	Revascularization		1 year	Clopidogrel resistance		2 (6.25%)	OR = 4.0 (calculated)	0.5-29.6	0.191 vs. next row (Student's t)	NR		
						nonresistance		2 (1.64%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENO- TYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple compari- sons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Gurbel, 2003 12796140 USA NR	LD 300 mg clopidogrel and maintaining 75 mg daily	ADP-LTA	target-vessel revascularization	target-vessel revascularization	30 days	Clopidogrel resistance	target-vessel revascularization	0	NR	OR (calculated) = 1.25	P=0.91 (resistant vs nonresistant) [Chisquare test]	NR	NO	
						Clopidogrel nonresistance		0						
Aradi 2012 21902692 Hungary NR	LD clopidogrel 600mg and aspirin 300mg MD clopidogrel 75 mg/day 4 weeks	LTA ADP	TVR	target vessel revascularization	12 months	NPR	TVR	9/122 = 9.5%	OR=1.9	0.60-6.07	NR	NR	NR	NR
						HPR+150 mg clopidogrel	TVR	1/36 = 3.1%			0.09 comparing with the low row log-rank test			
						HPR +75 mg clopidogrel	TVR	5/38 = 16.4%						

Appendix Table E21. Results from studies assessing the ability of LTA to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Hoshino, 2009 19106460 Japan NR	300 mg clopidogrel LD + 74 mg MD	12-channel light transmission aggregometer	Responder	based on the the inhibition of platelet aggregation (IPA)	28 days	IPA <10% (clopidogrel non-responders)	In Fig 2	In Fig 2	In Fig 2	In Fig 2	In Fig 2	NR	NR	NR	Data is presented in Fig 2 which can be digitized to obtain the change in status within the three phenotype groups
						10%≤ IPA <30% (hypo-responders)	In Fig 2	In Fig 2	In Fig 2	In Fig 2	In Fig 2	NR	NR	NR	
						IPA ≥30% (responders)	In Fig 2	In Fig 2	In Fig 2	In Fig 2	In Fig 2	NR	NR	NR	
Gurbel, 2010 20194878 10 study sites in North America and Europe RESPOND	600-mg clopidogrel LD + 75-mg daily MD	LTA	On treatment high platelet reactivity (HPR) by LTA associated with long-term ischemic event occurrence	Platelet aggregation (20 mol/L ADP, maximum extent) ≤59%	30 days	Nonresponder (absolute change in maximum platelet aggregation (MPA) ≤10% between pre-dose and 6-8 hr post-dose measurements)	On treatment high platelet reactivity (HPR) +	20/33 (61%, 95% CI: 44–77)	≤10	NR	NR	0.15 (fisher's exact calculated from data)	NO	NR	NR

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Responder (absolute change in maximum platelet aggregation (MPA) >10% between pre-dose and 6-8 hr post-dose measurements)	On treatment high platelet reactivity (HPR) +	41/54 (76%, 95% CI: 65–87)	≤10						
	600-mg clopidogrel LD + 75-mg daily MD	LTA	On treatment high platelet reactivity (HPR) by VerifyNow P2Y12 associated with long-term ischemic event occurrence	VerifyNow P2Y12-PRU ≤235	30 days	Nonresponder (absolute change in maximum platelet aggregation (MPA) ≤10% between pre-dose and 6-8 hr post-dose measurements)	On treatment high platelet reactivity (HPR) +	17/32 (53%, 95% CI: 36–70)	≤10	NR	NR	0.258 (fisher's exact calculated from data)	NO	NR	NR
						Responder (absolute change in maximum platelet aggregation (MPA) >10% between pre-dose and 6-8 hr post-dose measurements)	On treatment high platelet reactivity (HPR) +	35/53 (66%, 95% CI: 53–79)	≤10						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600-mg clopidogrel LD + 75-mg daily MD	LTA	On treatment high platelet reactivity (HPR) by VASP associated with long-term ischemic event occurrence	VASP-PRI ≤50%	30 days	Nonresponder (absolute change in maximum platelet aggregation (MPA) ≤10% between pre-dose and 6-8 hr post-dose measurements)	On treatment high platelet reactivity (HPR) +	10/34 (29% , 95% CI: 14-45)	≤10	NR	NR	0.00458 (fisher's exact calculated from data)	NO	NR	NR
						Responder (absolute change in maximum platelet aggregation (MPA) >10% between pre-dose and 6-8 hr post-dose measurements)	On treatment high platelet reactivity (HPR) +	28/53 (53%, 95% CI: 39–66)	≤10						
Gurbel, 2003 12714161 USA No	Clopidogrel + aspirin	Platelet aggregation ADP 5 mcmol/liter	Continued nonresponse since baseline	NR	5 days	Nonresponders at baseline (n=23)	Nonresponders at 5 days	15/23 (66%)	<10% change from baseline	NR	NR	<0.0001 (fisher's exact calculated from data)	NR	NR	NONE
						Responders at baseline (n=40)	Responders at 5 days	38/40 (95%)							
					30 days	Nonresponders at baseline (n=23)	Nonresponders at 30 days	7/13 (54%) with data (10 were not measured at 30 days)				0.013 (fisher's exact calculated from data)			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Responders at baseline (n=40)	Responders at 30 days	18/20 (90%) with data (20 were not measured at 30 days)							
		Platelet aggregation ADP 20 mcmol/liter	Continued nonresponse since baseline		5 days	Nonresponders at baseline (n=13)	Nonresponders at 5 days	9/13 (69%)				0.003 (fisher's exact calculated from data)			
						Responders at baseline (n=25)	Responders at 5 days	22/25 (88%)							
					30 days	Nonresponders at baseline (n=13)	Nonresponders at 30 days	3/8 (38%) with data (5 were not measured at 30 days)				0.25 (fisher's exact calculated from data)			
						Responders at baseline (n=25)	Responders at 30 days	12/13 (92%) with data (12 were not measured at 30 days)							

Appendix Table E22. Results from the single study assessing the ability of LTA to predict platelet reactivity during followup (discrete outcome) in patients with peripheral artery disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Linnemann, 2010 20153859 GermanyNR	Clopidogrel 75 mg MD	LTA	Non- responsiveness	Late aggregation ≥ 42.9%	median 17.5 months	Non- responsiveness	Non- responsiveness	5	≥42.5%	NR	NR	0.02 (fisher's exact calculated from data)	NO	NR	
						Non- responsiveness	Responsiveness	8							
						Responsiveness	Non- responsiveness	1							
						Responsiveness	Responsiveness	20							

Appendix Table E23. Results from studies assessing the ability of LTA to predict platelet reactivity during followup (continuous outcome) in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measure- ment for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean differ- ence (state if other metric)	95% CI of mean differ- ence (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Matetzky, 2004 15184279 Israel No	Clopidogrel	Aggrego- meter (not cone and platelet device)	% Change from baseline in ADP- induced platelet aggregation	NR	6 days vs. baseline	Q1	15	-9%	NR	NR	NR	NR	<0.05 (P for trend") [2-tailed Fisher's exact test]	NR	NR	NO
						Q2	15	-22%								
						Q3	15	-28%								
						Q4	15	-45%								
Angiolollo, 2007 17936152 Spain NR	clopidogrel (75 mg/day)	LTA-ADP	Platelet aggre- gation (late)	Platelet aggregation (late)	1 year	HPR +	First quartile	Mean 24.7	11.3	ANOVA	NR	NR	<0.0001	NR	NR	
						HPR +	Second quartile	Mean 36.8	11.4							
						HPR +	Third quartile	Mean 48.2	7							
						HPR +	Fourth quartile	Mean 65.1	8.4							
	clopidogrel (75 mg/day)	LTA-ADP	Platelet disaggre- gation	Platelet disaggre- gation	1 year	HPR +	First quartile	Mean 30.5	26.2	ANOVA	NR	NR	<0.0001	NR	NR	
						HPR +	Second quartile	Mean 22.9	23.3							
						HPR +	Third quartile	Mean 15.4	10.3							
						HPR +	Fourth quartile	Mean 5.4	7							

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measure- ment for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean differ- ence (state if other metric)	95% CI of mean differ- ence (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
Bellemain- Appaix 2010 20170822 France ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis)	Clopidogrel LD= 300 mg or 600 mg or 900 mg)	LTA	VASP Index	VASP index was calculated from the median fluorescence intensity (MFI)	6 hrs	Slow responders	50	76.4	15.8 (SD)	Linear regresssion	NR	NR	0.0192 (slow vs fast)	YES; NR	NR	
							38	66.4	20.3 (SD)							
	Clopidogrel LD= 300 mg or 600 mg or 900 mg)	LTA	VASP index	VASP index was calculated from the median fluorescence intensity (MFI)	24 hrs	Slow responders	50	70.2	22.2 (SD)	Linear regresssion	NR	NR	0.0192 (slow vs fast)	YES; NR	NR	
							38	61.5	19.1 (SD)							
Cuisset, 2006 16371119 France NR	Clopidogrel + aspirin	PAP4 aggrego- meter	P-selection expression after ADP stimulation	Measured in mean channel fluorescence intensity (MFI)	NR	Q1 (highest responder)	NR	0.44 mean MFI	0.38	NR	NR	NR	0.04 for Q1 vs. Q4 (general linear model with ADP- induced aggregation as depe ndent variable)	NR	NR	NO

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measure- ment for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean differ- ence (state if other metric)	95% CI of mean differ- ence (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Q4 (nonresponder)	23	0.57 mean MFI	0.29							
Liu, 2011 21613806 China None	Clopidogrel + aspirin	Aggregometry	Mean maximal aggregation rate, 5 mcmol ADP	NR	36 hr after stenting	Non- responders	35 (32%)	48.65%	15.46%	NR	NR	NR	NR	NR	NR	NONE
						Low responders	28 (25%)	45.20%	14.70%							
						Responders	46 (41%)	30.31%	16.04%				<0.0001 vs. two rows above and <0.05 vs. previous row (ANOVA)			
	Clopidogrel + aspirin	Aggregometry	Mean maximal aggregation rate, 20 mcmol ADP		36 hr after stenting	Non- responders	35 (32%)	63.54%	14.81%							
						Low responders	28 (25%)	62.53%	17.64%							
						Responders	46 (41%)	45.74%	19.94%				<0.0001 vs. two rows above and <0.05 vs. previous row (ANOVA)			
Obradovic, 2009 19318922 Serbia NR	Clopidogrel LD 300 mg	ADP-PA	ADP-PA	ADP-PA	Before PCI	PA>20%	26	47.35(34.95- 68.8)	NR	NR	NR	NR	<0.001 comparing with the lower row	NR	NR	NR
					Before PCI	PA<20%	26	8.5 (2.3- 14.15)	NR	NR	NR	NR		NR	NR	NR
	Clopidogrel LD 300 mg	ADP-PA	ADP-PA	ADP-PA	24 h after PCI	PA>20%	26	23.4 (12.97- 48.35)	NR	NR	NR	NR	<0.001 comparing with the lower row	NR	NR	NR

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measure- ment for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean differ- ence (state if other metric)	95% CI of mean differ- ence (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
					24 h after PCI	PA<20%	26	7.5 (0.8-16.75)	NR	NR	NR	NR		NR	NR	NR
Kalantzi, 2012 21806493 Greece	LD 600mg clopidogrel + MD 75 mg/day	LTA-ADP	LTA -ADP	platelet aggregation	30 days	responder	12	2.5uMADP 23 (12-35) 5uM ADP 32 (17-50) 10uM ADP 50(31-65)	NR NR	t-test	NR	NR	p<0.001 p<0.001 p<0.001	NR	NR	
Kalantzi, 2012 21806493 Greece	LD 600mg clopidogrel + MD 75 mg/day	LTA-ADP	LTA -ADP	platelet aggregation	30 days	non-responder	28	2.5uMADP 24(10-30) 5uM ADP 37 (20-55) 10uM ADP 53(33-62)	NR NR	t-test	NR	NR	p<0.01 p<0.01 p<0.01	NR	NR	
Gurbel, 2012 21862113 USA NR	LD 600mg clopidogrel + Aspirin 325 mg/day	LTA with 20 µM ADP	LTA ADP & collagen	platelet aggregation	24 hours	non-responder (≤ 10% absolute change in 20uMADP- induced PA in 0-6 hrs) (n=21)	21	5 µM ADP mean= 15.2 % (estimate from Fig 1) 20 µM ADP mean= 6.5% (estimate from Fig 1) 4 µg/mL collagen = 8.8% (estimate from Fig 1)	NR	NR	NR	NR	P<0.001 (responder vs nonresponder) for 5 µM ADP, 20 µM ADP & 4 µg/mL collagen	NR	NR	Data obtained from digitizng fig 1

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measure- ment for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean differ- ence (state if other metric)	95% CI of mean differ- ence (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/ NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Com- ments (e.g., additional data in figures)
						Responder (>10% absolute change in 20uMADP- induced PA in 0-6 hrs) (n=57)	57	5 µM ADP mean= 34.9% (estimate from Fig 1) 20 µM ADP mean=37.2% (estimate from Fig 1) 4 µg/mL collagen = 18.5 (estimate from Fig 1)								

Appendix Table E24. Quality assessment of studies assessing the predictive ability of LTA in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	1	2	3	Patients selection ROB (selection)	Applicability (selection)	4	5	Index test ROB (index)	Applicability (index)	6	7	Reference standard ROB (reference)	Applicability (reference)	8	9	10	11	Flow and timing ROB (flow & timing)
Geisler, 2010 20526607 Germany NR	yes	yes	yes	low	low	NR	yes	unclear	low	yes	NR	unclear	low	no	yes	yes	no	high
Cuisset, 2009 19801028 France NR	yes	No	yes	low	low	NR	No	unclear	high	yes	NR	Low	low	no [30 days]	yes	yes	yes	low
Frere, 2007 17938809 France NR	yes	No	yes	low	low	NR	No	High	Low	yes	NR	Unclear	low	no [30 days]	yes	yes	yes	low
Hoshino, 2009 19106460 Japan NR	No	Yes	yes	low	low	NR	Yes	unclear	high	No	NR	high	high	NO [28 days]	yes	yes	yes	low
Breet, 2010 20179285 Netherlands POPULAR	yes	yes	yes	low	low	NR	no	high	low	yes	yes	low	low	yes	yes	yes	yes	low
Gurbel, 2010 20194878 10 study sites in North America and Europe RESPOND	yes	yes	yes	low	low	Yes	Yes	Low	High	No	Yes	high	high	NO [30 days]	yes	yes	No	High
Kim, 2010 20449634 Korea NR	yes	yes	yes	low	low	NR	yes	unclear	high	Yes	NR	unclear	Low	no [6 months]	yes	yes	yes	low
Angiolillo, 2007 18312754 USA OPTIMUS	NO	yes	yes	low	low	NR	NR	unclear	unclear	No	NR	unclear	high	no [1 month]	yes	yes	yes	low
Blindt, 2007 18064332 Germany NR	NO	NO	yes	HIGH	LOW	NR	No	unclear	high	yes	NR	Unclear	low	no [6 months]	yes	yes	yes	low

Author, year [ref] UID Country Study Name	1	2	3	Patients selection ROB (selection)	Applicability (selection)	4	5	Index test ROB (index)	Applicability (index)	6	7	Reference standard ROB (reference)	Applicability (reference)	8	9	10	11	Flow and timing ROB (flow & timing)
Bliden, 2007 17291930 USA NR	yes	yes	yes	low	low	NR	yes	unclear	high	yes	NR	unclear	low	yes	yes	yes	yes	low
Gori, 2008 19132241 Italy RECLOSE	yes	yes	yes	low	low	NR	yes	unclear	low	yes	NR	unclear	low	no	yes	yes	yes	low
Gurbel, 2010 20691842 USA PREPARE POST- STENTING	yes	yes	yes	low	low	NR	NO	high	high	yes	yes	low	low	yes	yes	yes	yes	low
Matetzky, 2004 15184279 Israel No	yes	yes	yes	low	low	NR	no	high	low	no	yes	low	low	no	yes	yes	yes	low
Angiolollo, 2007 17936152 Spain NR	NO	yes	yes	low	low	NR	NR	unclear	low	Yes	NR	Unclear	low	Yes [2 years]	yes	yes	yes	low
Aradi, 2008 18388039 Hungary NR	NO	yes	yes	low	low	NR	No	High	High	Yes	NR	Unclear	low	No [~9 months]	yes	yes	yes	low
Bellemain-Appaix 2010 20170822 France ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis)	Yes [RCT substudy]	yes	yes	low	low	NR	No	High	High	No	NR	High	High	No [24 hrs]	yes	yes	yes	low

Author, year [ref] UID Country Study Name	1	2	3	Patients selection ROB (selection)	Applicability (selection)	4	5	Index test ROB (index)	Applicability (index)	6	7	Reference standard ROB (reference)	Applicability (reference)	8	9	10	11	Flow and timing ROB (flow & timing)
Breet, 2011 21478385 The Netherlands POPular	Yes	yes	yes	low	low	NR	Yes	Unclear	Unclear	Yes	Yes	Low	low	Yes [1 year]	yes	yes	yes	low
Breet, 2010 20695984 Netherlands Substudy of a larger cohort (Breet 2010 PMID: 20179285)	Yes	yes	yes	low	low	NR	No	Unclear	Low	Yes	Yes	Low	low	Yes [1 year]	yes	yes	yes	low
Buonamici, 2007 17572245 Italy NR	Yes	yes	yes	low	low	NR	No	Unclear	High	Yes	Yes	Low	low	No [6 months]	yes	yes	yes	low
Campo, 2007 17868803 Italy NR	No	yes	yes	low	low	NR	No	Unclear	Unclear	Yes	NR	Unclear	low	No [6 months]	yes	yes	yes	low
Cuisset, 2009 19736156 France NR	Yes	yes	yes	low	low	Yes	No	High	High	Yes	NR	Unclear	low	No [30 days]	yes	yes	yes	low
Cuisset, 2006 16371119 France NR	Yes	yes	yes	low	low	NR	No	High	Low	Yes	Yes	Low	low	No [1 month]	yes	yes	yes	low
Cuisset, 2006 17010792 France NR	Yes	yes	yes	low	low	NR	No	High	Low	Yes	Yes	Low	low	No [1 month]	yes	yes	yes	low
Cuisset, 2007 17264958 France NR	Yes	yes	No	low	low	NR	Yes	Unclear	High	Yes	NR	Unclear	low	No [12 hrs]	yes	yes	No [20 patients who did not receive successful angioplasty were excluded from the study]	low

Author, year [ref] UID Country Study Name	1	2	3	Patients selection ROB (selection)	Applicability (selection)	4	5	Index test ROB (index)	Applicability (index)	6	7	Reference standard ROB (reference)	Applicability (reference)	8	9	10	11	Flow and timing ROB (flow & timing)
Geisler, 2008 17949474 Germany NR	Yes	yes	yes	low	low	NR	No	High	High	Yes	Yes	Low	low	NO (30 days)	yes	yes	NO (~13% of patients were lost to followup)	High
Geisler, 2006 17005534 Germany NR	Yes	yes	yes	low	low	NR	Yes	Unclear	High	Yes	Yes	Low	low	No [3 months]	yes	yes	yes	low
Geisler, 2010 19812059 Germany NR	Yes	yes	yes	low	low	Yes	No	High	High	Yes	Yes	Low	low	No [3 months]	yes	yes	yes	low
Giusti, 2009 19268736 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel- Eluting Stent Thrombosis)	Yes	yes	yes	low	low	NR	No	High	High	Yes	YES (states that event adjudication was blind to laboratory results)	Low	low	No [6 months]	yes	yes	yes	low
Gori, 2008 18718420 Italy RECLOSE study (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel- Eluting Stent Thrombosis)	Yes	yes	yes	low	low	Yes	Yes	Low	High	Yes	Yes	Low	low	No [6 months]	yes	yes	yes	low
Gurbel, 2008 19012177 USA None	Yes	yes	yes	low	low	NR	Yes	Unclear	Low	Yes	Yes	Low	low	Yes [2 years]	yes	yes	yes	low
Gurbel, 2004 15154601 USA None	NR	yes	yes	low	low	NR	No	High	Low	Yes	NR	Unclear	low	NO (30 days)	yes	yes	yes	High

Author, year [ref] UID Country Study Name	1	2	3	Patients selection ROB (selection)	Applicability (selection)	4	5	Index test ROB (index)	Applicability (index)	6	7	Reference standard ROB (reference)	Applicability (reference)	8	9	10	11	Flow and timing ROB (flow & timing)
Hochholzer, 2006 17084243 Germany EXCELSIOR	No	yes	yes	low	low	NR	NR	Unclear	High	Yes	NR	Unclear	low	NO (30 days)	yes	yes	yes	Low
Htun, 2011 21273381 Germany NR	Yes	yes	No [232 of 1567 patients excluded in final analysis]	low	low	NR	Yes	Unclear	High	Yes	NR	Unclear	low	Yes [1 year]	yes	yes	No [15% excluded in final analysis]	low
L'Allier, 2008 18342223 Canada PREPAIR study	Yes	yes	yes	low	low	Yes	Yes	Low	High	Yes	NR	Unclear	low	NO (1 month)	yes	yes	yes	Low
Liu, 2011 21613806 China None	Yes	yes	yes	low	low	NR	Yes	Unclear	Unclear	Yes	NR	Unclear	low	NO (3 months)	yes	yes	YES (~2% [2 patients] withdrew before 12 hr and three more [!3%] were lost to followup later)	Low
Muller, 2003 12719773 Germany None	NR	yes	yes	low	low	NR	NR	Unclear	Low	Yes	NR	Unclear	low	NO [latest date mentioned is a 9-mo measurement, only in 1 pt]	yes	yes	yes	Low
Muller, 2010 20728084 Germany NR	Yes	yes	yes	low	low	Yes	No	Unclear	High	Yes	Yes	Low	low	No [mean 344 days]	yes	yes	yes	Low
Obradovic, 2009 19318922 Serbia NR	No	yes	yes	low	low	NR	No	High	High	No	NR	High	High	No [24 hours]	yes	yes	yes	Low

Author, year [ref] UID Country Study Name	1	2	3	Patients selection ROB (selection)	Applicability (selection)	4	5	Index test ROB (index)	Applicability (index)	6	7	Reference standard ROB (reference)	Applicability (reference)	8	9	10	11	Flow and timing ROB (flow & timing)
Saw, 2008 19038679 Canada ELAPSE trial	NR	yes	yes	low	low	NR	Yes	Unclear	Low	Yes	NR	Unclear	low	Yes [12 months]	yes	yes	NO (22% withdrew [7 of 33 enrolled])	Low
Trenk, 2008 18482659 Germany EXCELSIOR (Impact of Extent of Clopidogrel- Induced Platelet Inhibition During Elective Stent Implantation on Clinical Event Rate)	NO (included all patients in the prospective EXCELSIOR cohort that had genotypic information)	yes	No	high	low	Yes	Yes	Low	Low	No	No	High	Low	Yes [1 year]	yes	yes	yes	Low
Wang, 2010 21171668 China None	No	yes	yes	low	low	NR	Yes	Unclear	Low	Yes	Yes	Low	low	Yes [1 year]	yes	yes	yes	Low
Wang, 2009 19041120 China NR	No	yes	yes	low	low	NR	Yes	Unclear	High	Yes	NR	Unclear	low	Yes [12 months]	yes	yes	yes	Low
Yong, 2009 19081397 Australia Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial	Yes	yes	yes	low	low	Yes	NR	Unclear	High	Yes	Yes	Low	low	No [6 months]	yes	yes	yes	low
Gurbel, 2003 12714161 USA No	NR	yes	yes	low	low	NR	no	high	unclear	No	NR	high	yes	No (30 days)	yes	yes	No (many had no data at 30 days)	high

Author, year [ref] UID Country Study Name	1	2	3	Patients selection ROB (selection)	Applicability (selection)	4	5	Index test ROB (index)	Applicability (index)	6	7	Reference standard ROB (reference)	Applicability (reference)	8	9	10	11	Flow and timing ROB (flow & timing)
Gurbel 2005 16286165 USA PREPARE POST- STENTING	Yes	No	No	High	Low	NR	NR	Unclear	High	Yes	Yes	Low	Low	No [6 months]	yes	yes	yes	low
Gurbel 2003 12796140 USA NR	Yes	YES	Yes	Low	Low	Yes	Yes	Low	Low	Yes	NR	Unclear	Low	No [30 days]	Yes	Yes	Yes	Low
Kalantzi, 2012 21806493 Greece NR	NR	yes	yes	low	low	NR	yes	unclear	low	no	NR	unclear	high	no	yes	yes	yes	low
Angiolillo, 2011 Italy NR	NR	yes	yes	low	low	NR	yes	unclear	low	yes	NR	unclear	low	yes	yes	yes	yes	low
Parodi, 2011 21934054 Italy NR	yes	yes	yes	low	low	NR	yes	unclear	high	yes	yes	low	low	yes	yes	yes	yes	low
Gurbel, 2012 21862113 USA NR	NR	yes	yes	low	low	NR	No	High	High	No	NR	High	High	No [1 day]	yes	yes	yes	low
Saad, 2012 22146578 Egypt NR	NR	yes	yes	low	low	NR	No	High	High	yes	yes	low	low	No [6 months]	yes	yes	yes	low
Tselepis, 2011 22008470 Greece NR	yes	yes	yes	low	low	NR	yes	unclear	high	no	NR	high	high	no	yes	yes	yes	low
Gaglia, 2012 21919956 USA NR	Yes	Yes	Yes	Low	Low	Yes	Yes	Low	high	Yes	Yes	Low	Low	No [in-hospital]	yes	yes	yes	Low

Author, year [ref] UID Country Study Name	1	2	3	Patients selection ROB (selection)	Applicability (selection)	4	5	Index test ROB (index)	Applicability (index)	6	7	Reference standard ROB (reference)	Applicability (reference)	8	9	10	11	Flow and timing ROB (flow & timing)
Aradi 21902692 Hungary NR	no	yes	yes	low	low	NR	yes	unclear	high	yes	NR	unclean	low	yes	yes	yes	yes	low
Marcucci, 2012 22390861 Italy NR	NR	YES	YES	LOW	LOW	NR	Yes	UNCLEAR	High	NR	NR	UNCLEAR	LOW	YES	YES	YES	YES	LOW
Ge, 2012 21602258 China NR	NR	YES	YES	LOW	LOW	NR	YES	UNCLEAR	LOW	YES	NR	UNCLEAR	LOW	NO	YES	YES	YES	LOW

1. Consecutive or random sample of patients enrolled.
 2. Case-control design avoided
 3. Study avoided inappropriate exclusions
- Risk of bias: could the selection of patients have introduced bias (If ≥ 2 of the above 3 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)
- Concerns that the included patients do not match the review question?
4. Index test results interpreted without knowledge of results of reference standard?
 5. If a threshold used, was it prespecified?
- Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
- Concerns that the index test, its conduct, or its interpretation differ from the review question?
6. Reference standard likely to correctly classify the target condition?
 7. Reference standard results interpreted without knowledge of index test results?
- Could the reference standard, its conduct, or its interpretation have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
- Are there concerns that the target condition as defined by the reference standard does not match the review question?
8. Appropriate interval between index test and reference standard?
 9. All patients received a reference standard?
 10. All patients received the same reference standard?
 11. Were all patients included in the analysis?
- Could the patient flow have introduced bias? (If ≥ 3 of the above 4 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix Table E25. Quality assessment of the single study assessing the predictive ability of LTA in patients with peripheral arterial disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Linnemann 2010 20153859 Germany NR	Yes	yes	yes	low	low	NR	Yes	Unclear	High	No	NR	High	High	YES [median 17.5 months]	No	yes	No	High

1. Consecutive or random sample of patients enrolled.
2. Case-control design avoided
3. Study avoided inappropriate exclusions
- Risk of bias: could the selection of patients have introduced bias (If ≥2 of the above 3 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)
- Concerns that the included patients do not match the review question?
4. Index test results interpreted without knowledge of results of reference standard?
5. If a threshold used, was it prespecified?
- Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
- (If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
- Concerns that the index test, its conduct, or its interpretation differ from the review question?
6. Reference standard likely to correctly classify the target condition?
7. Reference standard results interpreted without knowledge of index test results?
- Could the reference standard, its conduct, or its interpretation have introduced bias?
- (If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
- Are there concerns that the target condition as defined by the reference standard does not match the review question?
8. Appropriate interval between index test and reference standard?
9. All patients received a reference standard?
10. All patients received the same reference standard?
11. Were all patients included in the analysis?
- Could the patient flow have introduced bias? (If ≥3 of the above 4 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix Table E26. Quality assessment of the single study assessing the predictive ability of LTA in a mixed population of patients with ischemic heart disease and peripheral vascular disease

Author, year [ref] UID Country Study Name	1	2	3	Patients selection ROB (selection)	Applicability (selection)	4	5	Index test ROB (index)	Applicability (index)	6	7	Reference standard ROB (reference)	Applicability (reference)	8	9	10	11	Flow and timing ROB (flow & timing)
Reny, 2012 22615340 France and Switzerland ADRIE	yes	yes	yes	Low	low	yes	yes	low	high	yes	yes	low	low	No [3 months]	yes	yes	yes	low

1. Consecutive or random sample of patients enrolled.
2. Case-control design avoided
3. Study avoided inappropriate exclusions
- Risk of bias: could the selection of patients have introduced bias (If ≥2 of the above 3 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)
- Concerns that the included patients do not match the review question?
4. Index test results interpreted without knowledge of results of reference standard?
5. If a threshold used, was it prespecified?
- Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
- (If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
- Concerns that the index test, its conduct, or its interpretation differ from the review question?
6. Reference standard likely to correctly classify the target condition?
7. Reference standard results interpreted without knowledge of index test results?
- Could the reference standard, its conduct, or its interpretation have introduced bias?
- (If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
- Are there concerns that the target condition as defined by the reference standard does not match the review question?
8. Appropriate interval between index test and reference standard?
9. All patients received a reference standard?
10. All patients received the same reference standard?
11. Were all patients included in the analysis?
- Could the patient flow have introduced bias? (If ≥3 of the above 4 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix Table E27. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of VerifyNow

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Cotton, 2010 20406238 UK NR	49 NR 67 63±11	NR NR 0 CABG 6 NR NR 29 NR	hyper 59 Ex-smoker 29 current 31 HTN 61 24	NR 100 94 39	NR NR one vessel 45 two vessel 10 three vessel 0	ACS	at least 300 mg clopidogrel loading dose if >12 prior to angiography followed by 75 mg daily as maintenance, or 600 mg loading if <12 h prior to angiography with 75 mg daily maintenance	NR
Angiolillo, 2007 18312754 USA OPTIMUS	34 NR 22 (64.7) 64.5±9	NR NR NR CABG 6(17.6) NR NR NR 14 (41.2) NR	31 (91.2) 10 (29.4) 31 (91.2) 100	NR 100 100 NR	NR NR 27(79.4)	Patients underwent PCI and were treated with standard clopidogrel	Clopidogrel 75 mg/day, and 1 month after clopidogrel 150 mg/day. Thereafter, all patients resumed the standard 75 mg/day maintenance dose.	None
Breet, 2010 20179285 Netherlands POPULAR	1069 NR 75 64±10.6	NR NR NR NR NR NR 54.5 NR	80.3 11.1 HTN 76.9 18.6	NR 100 89.4 27.8	100 DES 63.5 NR	coronary artery disease scheduled for elective PCI with stent	clopidogrel treatment (a maintenance of 75 mg/d therapy for>5 days or a loading dose of 300 mg ≥24 hours before PCI or 600 mg ≥4 hours before PCI) and aspirin (80-100 mg/d ≥10 days).	unless they were receiving long-term anticoagulation with warfarins

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Kim, 2010 20449634 Korea NR	1058 NR 70.1 62.2±11.2	62.2±11.2 NR 3.6% PCI 30.4% NR NR 20.9% NR	19% 39.8% 52% 29%	NR 25.3% NR NR	NR NR 27.6%	Patients treated with coronary stenting for symptomatic coronary artery disease, including acute myocardial infarction (AMI) and on chronic clopidogrel therapy	scheduled coronary stenting procedures, 300-mg loading-dose (LD) of clopidogrel at least 12 h before procedure. In AMI patients, all received a 600-mg LD of clopidogrel immediately after emergency room arrival, followed by a maintenance dose of 75 mg daily.	If use of glycoprotein IIb/IIIa inhibitor (GPI) was deemed necessary, only tirofiban, which has a short half-life, was administered.
Ko, 2011 21315223 Korea NR	222 ?Asian 152 (69) 63.3 ± 10	100 NR CVA: 14.9PCI: 37 (16.7); CABG: 1 (0.5) NR NR NR 5.9 NSTEMI: 10.1	Hypercholesterolemia: 46.8 Current: 12.2 HTN: 72.1 32	NR 72.1 89.6 NR	100 Drug eluting Multi-vessel; Stents/pt: 1.8±1	Patients undergoing percutaneous coronary intervention (PCI) for CAD	All patients were pretreated with aspirin (100 mg/d) and clopidogrel (75 mg/d) at least 5 days before PCI or received oral loading doses of 250 mg aspirin and 300 mg clopidogrel 12 to 24 hours before PCI. Maintenance doses of 100 mg aspirin and 75 mg clopidogrel after PCI After PCI, dual antiplatelet therapy with 100 mg/d aspirin and 75 mg/d clopidogrel was continued for at least 6 months	NR

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	total 468 NR 349 (74.6) 67±10.5	NR NR NR PCI 195 (41.7); CABG 44 (9.4) 152 (32.5) NR NR 196 (41.9) NR	268 (57.3) 120 (25.6) 346 (73.9) 111 (23.7)	NR 396 (84.6) NR NR	NR 362 (77.4) multi 301 (64.3)	Patients scheduled for coronary angiography or PCI	clopidogrel 600 mg at least 2 h before or 300 mg at least 6 h before or 75 mg/day for at least 7 days. Aspirin (100 mg/day) was given to all patients indefinitely. Clopidogrel (75 mg/day) was given for at least 1 month to patients with stable disease as an indication for PCI and receiving bare metal stent implantation, whereas it was given for at least 1 year to patients with unstable angina and/or who were receiving drug-eluting stent implantation.	In poor responders, which were included in the 3T/2R main study, the use of tirofiban was randomized as previously reported . Conversely, in other patients, the use and type of glycoprotein (GP) IIb/IIIa inhibitors were according to the operator's choice.
Campo, 2011 21679849 Italy NR	300 NR 231 (77%) 66 ± 13 mean±SD	NR NR NR PCI, 47 (16%); CABG, 34 (11%) NR NR NR 81 (27%) Non-STEMI ACS 184 (61%)	Hyperlipidemia 153 (51%) 71 (24%) HTN 215 (72%) 71 (24%)	NR 100%; at 6 mo, 290 (97%) 100%; at 6 mo, 298 (99%) 158 (53%)	NR DES 214 (71) Multivessel PCI 109 (36)	Patients undergoing PCI for ischemic heart disease	All patients were treated with aspirin (300 mg as loading dose [LD] at hospital admission, followed by 100 mg daily, independently to previous or not chronic use). Clopidogrel 600 mg was given as LD at least 12 h before PCI. After intervention, clopidogrel 75 mg/day was continued for 12 months.	Anticoagulant and glycoprotein IIb/IIIa inhibitors treatment was administered at the interventionalist's discretion.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Cuisset, 2008 18549843 Belgium NR	122 NR 95 (77.9%) 67.2	NR NR NR Previous PCI/MI: 37% NR NR NR Previous PCI/MI: 37% NR	65.6% 29% HTN: 61.5% 30.3%	NR NR NR NR	NR NR NR	Patients undergoing PCI for ACS	loading doses of clopidogrel 600 mg and aspirin 500 mg the day before the procedure	All pts: received intravenous heparin to achieve a target activated clotting time of 250 to 350 seconds.
De Miguel Castro, 2009 19232185 Spain NR	161 NR 120 (75%) 67.6 ± 1.9	NR NR NR PCI: 12%; CABG: 7% NR NR NR 21% NR	53 Current: 19% HTN: 59% 27%	NR 14% NR NR	NR NR LAD: 2% Multivessel: 54%	Patients with acute NSTEMI ACS undergoing coronary angiography	clopidogrel 300 mg LD + followed by 75 mg/d MD for 9 -12 months Aspirin: 250 mg LD followed by 100 mg/d MD.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Gladding, 2008 19463375 New Zealand Secondary (but not subgroup) analysis of PRINC (Plavix Response in Coronary Intervention) Trial	60 Caucasian: 57 (95%) 50 (83%) 68 (10) mean (SD)	NR CHF 2 (3%) NR Prior PCI: 12 (20%); Prior CABG: 6 (10%) NR NR NR NR 3 (5%)/4 (7%)	NR 6 (10%) HTN 34 (57%) 11 (18%)	NR 0% [exclusion criterion] 59 (98%) NR	NR Multiple stents 9 (15%); DES 21 (35%) NR	Patients undergoing elective PCI	All patients: 600-mg clopidogrel at the start of the PCI procedure. At 2 hours after, 37 patients received 600 mg clopidogrel and 23 received placebo. Starting the next day, all patients were separately randomized to receive clopidogrel 75 or 150 mg once daily for 1 week, followed by 75 mg once daily thereafter.	
Huczek, 2011 21443410 Poland NR	374 NR 230 (61.5%) 66.6 ± 11.3	NR NR Ejection fraction: 47.5±10.1; Killip>I: 65 (17.4) NR NR NR NR NR STEMI: 44.9	222 (59.4) 48.1% HTN: 67.1% 19.8%	NR NR NR 69.5%	NR; No. of stents 1.47±0.8 Drug-eluting stents: 16 (4.3%) Multi-vessel disease: 83 (22.2%)	Patients undergoing PCI for ACS	Clopidogrel: 600mg loading dose before PCI and 75mg daily for 30 days after PCI Aspirin: 300mg oral dose before PCI and 75mg daily after PCI	Unfractionated heparin was administered as weight adjusted bolus (70 IU/kg) and if needed additional boluses were given under the guidance of activated clotting time (ACT) in order to reach the range of 300–350

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Kim, 2011 21786434 South Korea Cilostazol administration before percutaneous coronary intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial)	110 NR 53 (48%) Mean +/-SD 66+/-9 yr	NR NR Previous stroke 3% PCI 5%/CABG 0% NR NR NR 2% NR	Hyperlipidemia 21.8 14% HTN 68% 42%	NR 100% 99% NR	100% DES 100% NR but no. of diseased vessels, 1—45% 2—31% 3—24%	patients with typical angina, not on statins and without elevated levels of cardiac enzymes scheduled for drug-eluting stent (DES) implantation in de novo coronary artery lesions	All patients received daily aspirin 100-200 mg and clopidogrel 75 mg starting from 7 days before the elective PCI. Patients were randomized to also receive cilostazol 200 mg/day for 7 days (Cilostazol group) or no pretreatment (control). All patients received clopidogrel 75 mg/day for at least 6 months in addition to continued aspirin (100 mg/day).	Before PCI, all patients received a 60 IU/kg intravenous bolus of unfractionated heparin. Glycoprotein IIb/IIIa inhibitors were administered at the operator's discretion.
Lee, 2009 20049136 South Korea NR	237 NR 160 (68%) 65.2±10.3 years mean±SD	NR NR NR PCI 10% NR 162 (68%) NR 8% NSTEMI 75 (32%)	NR Current smoker 21% HTN 51% 29%	NR 100% 100% NR	100% DES 100% NR	ACS patients undergoing DES stenting	Prior to stent insertion, all the patients received a pre-treatment using 600 mg clopidogrel and 300 mg aspirin. In patients who received a DES, 100 mg aspirin was administered for life and 75 mg clopidogrel was administered for at least 6 months in principle.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Mangiacapra, 2010 20298992 Italy NR	250 NR 200 (80%) 65.6	NR NR NR PCI:40.4%;CABG: 5% 16% 84% NR 27.2% NR	hyperlipidemia: 73.6% Current: 21.2% HTN: 75.2% 33.2%	NR 11.2% 100% 28%	NR NR NR	Patients undergoing elective PCI	600-mg clopidogrel LD or were on therapy with clopidogrel 75 mg/day for at least 5 days. Chronic aspirin treatment (dose NR)	Procedural anticoagulation with unfractionated heparin (100 U/kg)
Mangiacapra, 2010 20129566 Belgium NR	338 NR 274 (81%) 67±10	NR NR NR multivessel PCI: 18% NR NR NR 25% NR	74% 19% HTN: 72% 37%	NR NR 100% 26%	Direct stenting: 37% Drug eluting: 43% NR	Patients undergoing angiography for stable angina or have stenotic coronary artery	clopidogrel 600 mg and aspirin 500 mg loading doses at least 12 h before PCI	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Mangiacapra, 2010 20723634 Italy NR	285 NR 224 (78.5%) 66.4	NR NR NR PCI: 38.6%/CABG: 5.6% NR NR NR 30.9% NSTEMI: 54%	hypercholesterolemia: 75.4% Current: 18.9% HTN (>140/90 mm Hg): 79.3% NR	NR 24.9% 100% 30.2%	NR NR NR	Patients undergoing elective PCI for stable angina or non–ST-elevation acute coronary syndromes	clopidogrel 600 mg LD + 75 mg MD Aspirin 100 md LD + 100 mg MD	Procedural anticoagulation: unfractionated heparin (100 U/kg)
Marcucci, 2009 19118249 Italy NR	683 NR 517 (75.6) 69 (range 29-94)	NR LVEF <40%: 25.5% NR NR NR NR NR STEMI: 28%	52.3% 30.8% HTN: 67.3% 26%	NR NR NR 92.9%	NR DES: 17.7% NR	Patients with ACS who underwent PCI	clopidogrel 600 mg LD + daily dose of 75 mg MD ASA 500 mg IV LD + daily dose of 100 to 325 mg PO MD	unfractionated heparin 70 IU/kg during the procedure

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Patti, 2008 18804738 Italy ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome)	160 NR 129 (81) 66 ± 9	NR NR;Left ventricular ejection fraction (%): 56± 7 NR Previous coronary intervention: 39% NR NR NR 28% ACS/NSTEMI: 54%	Hypercholesterolemia: 74% NR NR NR	NR Chronic clopidogrel therapy: 40 (25%); everyone received clopidogrel before PCI 100 NR	149 (93%) Drug eluting: 41 (26%) Multivessel: 28 (18%)	Patients undergoing PCI for ACS, including those who have had a myocardial infarction	Clopidogrel before PCI: 600 mg loading dose approximately 6 h before intervention (n=120); 75 mg/day for ≥ 5 days (n=40) Post PCI: continued for 1 month after PCI (dose NR, presumable 75 mg/day) Aspirin: Dose NR	
Patti, 2011 21256470 Italy Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty (ARMYDA)—Bleeding Study (ARMYDA-BLEEDS)	310 NR 243 (78%) 67+/-10 (mean SD)	NR NR 10 (3%) PCI 123 (40%) 210 (68%) UA or non-STEMI 100 (32%) NR 91 (29%) NR	Hypercholesterolemia (>200 mg/dl) : 220 (71%) NR NR 115 (37%)	0% (exclusion criterion) 100% NR NR	NR DES 95 (31%) NR	clopidogrel-treated patients who underwent PCI	Patients receiving long-term clopidogrel therapy were not reloaded in the catheterization laboratory. Clopidogrel was continued (75 mg/day) for 1 month after PCI, except in patients receiving drug-eluting stents or treated for ACS, in whom the drug was discontinued 1 year after intervention. Aspirin was given to all patients and continued indefinitely.	All interventions were performed using the femoral approach, with weight-adjusted intravenous unfractionated heparin (70 IU/kg body weight). During PCI, bivalirudin was used instead of unfractionated heparin in patients considered at high bleeding risk (age >75 years, history of previous bleeding, renal failure, low body weight); periprocedural use of glycoprotein IIb/IIIa inhibitors was left to the operator's discretion according to the presence of thrombus at the site of the index stenosis, occurrence of no reflow, or vessel closure.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Price, 2011 21406646 USA Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	1691 White race: 1652 (97.7%) 1193 (70.1%) Mean: 63.1	NR NR NR PCI: 45.5%;CABG: 20.7% 58.5% UA without ST-segment depression or elevated biomarker levels: 25.5% NR 29.8% NR	Hyperlipidemia: 85.9% Current (smoker within previous 7 days): 16% HTN: 82.4% 40.7%	NR 600-mg loading dose: 52.5%; 75 mg/d >7 d: 37.3%; Loading dose ≥300 mg, followed by 75 mg/d >7 d: 10.2% 88.4% 26.2%	NR NR NR	PCI for ACS and MI	Before randomization: If not exposure before, clopidogrel 300-600 mg LD given Only Standard dose subjects included for KQ2b: loading dose of placebo followed by a dose of 75 mg and placebo tablet daily. Aspirin: 75 to 162 mg daily	
Price, 2008 18263931 USA NR	380 NR 292 (76.8) 68±11	NR NR NR NR 356 (93.7) NR NR 120 (31.6) NR	NR 34 (8.9) 335 (88.2) 110 (28.9)	NR 100 328 (86.3) NR	NR NR NR	Patients with one lesion ≥50% diameter stenosis requiring PCI.	All patients received aspirin 325 mg on the day of the procedure. Patients not previously on clopidogrel: 600 mg loading dose at the conclusion of the procedure. Patients were instructed to take aspirin 325 mg indefinitely and clopidogrel 75 mg daily for a minimum of 3 months post-procedure.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Saw, 2008 19463380 Canada BRIEF-PCI	209 NR 169 (80.9) NR	NR NR NR PCI: 47 (22.5)/CABG: 10 (4.8) NR NR 11(5.2) 64 (30.6) NR	165 (78.9) 48 (23%) 120 (57.4) 31 (14.8)	NR 100 100 NR	NR DES 77(36.8) NR	Patients underwent PCI	aspirin (≥81 to 325 mg daily for at least 5 days) and clopidogrel (received 75 mg/day for ≥5 days or 300-mg loading dose ≥6 h prior or 600-mg loading dose ≥2 h prior)	
Valgimigli, 2009 19528337 10 sites in Europe (Italy, Belgium, France, Spain) Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) study	263 (including aspirin nonresponders, who are not of interest) NR 193 (73%) 68+/-10 yr	NR NR 14 (5%) PCI 103 (39%)/CABG 17 (6%) 110 (42%) 86 (33%) NR 113 (43%)	Hyperlipidemia 161 (61%) Current cigarette use 40 (15%) HTN 188 (71%) 69 (26%)	NR 81 (31%) 248 (94%) NR	NR NR NR	Adults with stable or troponin-negative non-STEMI ACS undergoing coronary angiography or PCI	Clopidogrel loading dose (300 or 600 mg) 2-6 hr before PCI except in those who'd been on clopidogrel for at least 7 days previously at a dose of 75 mg/day. IV aspirin was permitted at the time of angioplasty.	Patients were randomized to tirofiban (50 ml) or placebo. Heparin or bivalirudin was permitted.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Vavuranakis, 2011 21712606 Greece NR	74 NR 60 (81.1%) 60.9 ± 11.9	27% Impaired Killip class (≥ III): 20.3% NR Previous PCI: 13.5%/Previous CABG: 4.1% NR NR NR NR STEMI: 100%	47.3% 73% HTN: 45.9% 21.6%	NR 10.8% 24.3% NR	NR NR NR	Patients undergoing PCI for ACS (NSTEMI)	600 mg clopidogrel LD (300 mg LD in those already receiving it >1 week) + 75 mg MD 325 mg of acetylsalicylic acid from day 1-7 + 100 mg MD from day 7	glycoprotein IIb/IIIa inhibitor only in patients with total occlusion after successful crossing of the lesion with the guide wire Intravenous bolus unfractionated heparin (100 IU/kg) was given during PCI β-blockers and statins were given to all patients after PCI
Breet, 2011 21478385 The Netherlands POPular	951 NR 717 (75.4) 64±10.6	NR NR NR NR NR NR 519 (54.6) NR	Hyper 769 (80.9) 107 (11.3) 737 (77.5) 175 (18.4)	NR 489 (51.4) NR 270 (28.4)	Total length 28.3±17.1 DES 604 (63.8) NR	Patients scheduled for PCI with stent implantation	All patients on aspirin 80-100 mg daily for >0 days unless they were on long-term anticoagulation with coumarin derivatives; clopidogrel - chronic maintenance therapy of 75 mg for >5 days or a clopidogrel loading dose of 300 mg at least 24 h before PCI or 600 mg at least 4 h before PCI. Aspirin 80-100 mg daily for ≥10 days unless they were on long-term anticoagulation with coumarin derivatives.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Suh, 2011 21232664 Korea CILON-T	915 NR 68.5 64.4±13	NR NR NR PCI 7.5; CABG 2.3 39.2 45.2 NR 10.2 NR	173/915 (18.9%) 25.3 SBP 128; DBP 78.8; HTN 65.7% 33.8	NR NR 98.4 2.3	NR TAXUS 50.4; ENDEAVOR 45 34.9	patients had angina pectoris or native coronary artery lesions	All patients were given aspirin and clopidogrel before coronary intervention. Loading doses of aspirin (300 mg) and clopidogrel (300 to 600 mg) were given to patients who had not taken aspirin or clopidogrel before. Aspirin (100 mg daily) and clopidogrel (75 mg daily) were given for at least 6 months.	The decision of pre-dilation or direct stenting was made by the operator, as was the use of glycoprotein IIb/IIIa inhibitor.
Price, 2011 21875913 USA Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	2553 NR NR NR	NR NR NR NR NR NR NR NR	NR NR NR NR NR	NR NR NR NR	NR NR NR	PCI for ACS and MI	Highdose clopidogrel : 600 mg LD + 150 mg daily MD Standard-dose Clopidogrel: 75 mg/day MD Aspirin: 75 to 162 mg daily	
Park, 2011 22152948 Korea NR	900 NR 71.1 61.7±9.7	NR NR 4.9 18 55.6 NR NR 5.9 NR	hyper 61 25 HTN 58.9 28.5	NR 65.5 NR 2.6	100 NR 51.6	patients undergone PCI with at least 1 DES for stable angina or ischemia, or non-ST-segment elevation ACS	clopidogrel LD 300 or 600 mg>=12h before PCI, MD 75mg/day aspirin LD 200mg, MD 100-200 mg/day	NR

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Park, 2011 21880289 Korea CROSS-VERIFY	809 NR (?Asian-100%) 67% 63.9y	NR NR Previous CVD: 6% NR 63.9% NR 7% NR	46% Current: 18% HTN: 66% 31%	NR NR NR 1.7%	98% DES:100% 3 vessels: 32%	PCI with stenting for CAD	Clopidogrel LD: 300 mg / 600 mg (if PCI < 6 hrs); MD: 75 mg/day x 6 months; Aspirin 100 mg/day x 6 months	
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA-PROVE	732 NR 73% 66±10	100% NR NR PCI:33% 100% NR NR 30%NR	Hyperlipidemia: 75% Current smoker: 20% HTN: 78% 30%	NR 12% 100% 34%	NR NR Multivessel: 43%	PCI with stenting for CAD	Clopidogrel LD: 600 mg loading dose ≥6 h before PCI or 75 mg/d x 5 days Clopidogrel MD: 75 mg/d from 4 weeks to 12 months Aspirin 80-100 mg/day	Unfractionated heparin till activated clotting time of 250-300 secs
Jin, 2012 22682702 Korea NR	181 NR 83.4 61.3	NR NR NR NR NR NR 3.9 NR	NR 51.4 38.1 24.9	NR NR NR 7.7	NR 1st generation 53.6 2nd generation 46.4 multi vessel 12.2	ST-segment elevation MI for PCI	600 mg 600 mg clopidogrel and 300 mg aspirin LD, 75 mg clopidogrel was continued for at least 12 months and 100 mg aspirin was prescribed as MD	heparin during the procedure to maintain an activated clotting time of ≥250 s.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Yu, 2012 22787468 Korea NR	186 NR 66.1 62.7	NR NR 5.4 23.7 9.7 62.4 NR 21.5 8.6/19.4	hyper 21.5 32.8 HTN52.7 38.2	NR NR NR 1.1	1 VD 30.6 2 VD 41.4 3 VD 28.0 NR	CAD patients undergone PCI with drug-eluting stent implantation	LD 300mg aspirin and 300 mg clopidogrel,	NR
Saraf, 2010 20447533 UK NR	NR NR NR NR	NR NR NR NR NR NR NR NR	NR NR NR NR	NR NR NR NR	NR NR NR NR	ACS patients undergoing PCI, CABG or medical treatment	LD 300mg aspirin and 300 mg clopidogrel, MD 75 mg aspirin and 75 mg clopidogrel for 1 year	unfractionated or low molecular weight heparin (LMWH)
Ari, 2011 21239075 Turkey EFFICIENT	192 NR 79.7 57.6	NR NR NR NR NR NR NR NR	NR 69.3 NR 24.5	NR NR NR 25	NR NR 1 vessel 88 2 vessels 11.9	PCI	clopidogrel 75mg/day or 150 mg/day for 1 month	NR

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Aradi, 2012 21902692 Hungary NR	200 NR 60.7 61.9	NR NR 3.1 PCI 7.7; CABG 10.2 NR 100 NR NR NR	52.6 36.7 85.2 38.3	NR NR NR 24.5	NR DES 68.4 NR	stable angina patients with de novo stenosis feasible for as hoc coronary stent implantation	LD clopidogrel 600 mg, 300 mg aspirin. MD clopidogrel 75 mg or 150 mg for 4 weeks	NR
Gaglia, 2012 21919956 USA NR	200 69.5 72.5 63.5	NR 17.5 NR PCI=39.9/CABG-23% NR NR 14.6 NR NR	NR 29.5 87.4 34.8	NR NR NR NR	NR NR NR NR	CAD and ACS patients undergoing PCI & stenting	LD: 600 mg loading clopidogrel or 75-mg for 5 days MD: Aspirin + clopidogrel 75 mg for 1 month in patients with BMS and 12 months in patients receiving DES	NR

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Codner, 2012 22534051 Israel NR	57 NR 91 54.5	7 NR NR PCI-16/CABG-7% NR NR NR 18 NR	58 39 45 19	NR NR NR NR	NR NR NR	PCI for ACS	LD: clopidogrel 600 mg and aspirin 100 mg MD: clopidogrel 75 mg/d and aspirin 100 mg/d	heparin, bivalirudin, and/or glycoprotein IIb/IIIa inhibitors

*Mean (standard deviation), unless otherwise stated.

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; VD, vessel disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH= Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors

Appendix Table E28. Baseline characteristics of patients with cerebrovascular disease in studies assessing the predictive ability of VerifyNow

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%): Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation (%) Type of stent (%) Multi- or single-vessel (%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medications
Ryu, 2010 21113358 South Korea NR	57 NR 24 (42%) Mean +/-SD 60.3 ± 12 years	NR NR NR NR NR NR NR NR	Hypercholesterolemia 10 (18%) NR NR 13 (23%)	NR 100% 100% NR	81% NR NR	Patients receiving a neurointervention	All patients were pre-medicated with 100mg of aspirin and 75 mg of clopidogrel for at least 72 hours before the procedure.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%): Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation (%) Type of stent (%) Multi- or single-vessel (%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medications
Kang, 2010 20223886 South Korea NR	186 NR (?100% Asian) 57 (31%) 58.3±10.2	NR NR NR NR NR NR NR NR	NR; Total cholesterol level (mg/dL): 181.1 ± 36.8; Triglyceride level (mg/dL): 150.3 ± 85.6; HDL cholesterol level (mg/dL): 51.1 ± 17.5; LDL cholesterol level (mg/dL): 109.0 ± 32.5 Smoker (current and past smokers who have ever smoked 10 cigarettes per day for at least 1 year): 19% HTN: 51% 8%	NR Clopidogrel loading (300 mg) only: 136 (73%); Previous other antiplatelet medication plus clopidogrel loading: 29 (16%); Continued clopidogrel medication without loading: 21 (11%) NR NR	NR NR NR	patients undergoing coil embolization for intracranial aneurysms	Clopidogrel: 300-mg LD day before procedure with 89% of patients getting additional 75 mg of CPG on the morning of the procedure ; after procedure, an antiplatelet agent was administered for ≥1 week Aspirin dose/regimen: NR	Heparin during procedure: 3000-IU IV bolus, followed by 1000 IU/h

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure (%) Previous TIA/stroke (%) History of PCI or CABG (%): Stable angina (%) Unstable angina (%) Previous PAD (%) History of MI (%) STEMI/non-STEMI (%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation (%) Type of stent (%) Multi- or single-vessel (%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medications
Drazin 2011 21990814 US NR	52 NR 20 (38%) 62.6+/-14.0 yr (mean/SD)	NR NR NR NR NR NR 54.5 NR	NR 3 (6%) NR 15 (29%)	NR 100% 100% 29%	100% NR NR	Patients undergoing neurovascular stenting	Loading dose of 600 mg of clopidogrel and 81 mg of aspirin at least 12 hr before stenting (except in 3 patients with ruptured aneurysm, who received clopidogrel on the day of stenting) and maintenance dose thereafter of 75 mg/day for clopidogrel and 81 mg/day for aspirin. Patients with initial clopidogrel-induced inhibition of 10-19% were given 300 mg more of clopidogrel; those with initial inhibition <10% were given 600 mg more.	Heparin also given but regimen NR, and abciximab given in at least 1 patient.

*Mean (standard deviation), unless otherwise stated.

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH=Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors

Appendix Table E29. Study design characteristics of studies assessing the predictive ability of VerifyNow in patients with ischemic heart disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Cotton, 2010 20406238 UK NR	prospective cohort	No	Patients with ACS history	Patients with ACS history	Jan-June 2008	6 months	Hospital inpatient	NR	NR
Angiolillo, 2007 18312754 USA OPTIMUS	prospective cohort	No	Patients underwent PCI and were treated with standard clopidogrel	Patients underwent PCI and were treated with standard clopidogrel	NR	1 months	Hospital inpatient	Yes; Accrual>80%	NR
Breet, 2010 20179285 Netherlands POPULAR	prospective cohort	No	Patients scheduled for PCI with stent implantation	Patients with PCI and stent implantation	Dec 2005- Dec 2007	1-year	Hospital inpatient	Yes. 80%	NR
Kim, 2010 20449634 Korea NR	prospective cohort	no	Consecutively enrolled	unselected patients treated with coronary stenting for symptomatic coronary artery disease, including acute myocardial infarction (AMI) and chronic clopidogrel therapy	December 2007 to June 2009	6 months	Department of Cardiology of the Gyeongsang National University hospital inpatient	NR	NR
Ko, 2011 21315223 Korea NR	observational study	YES	Consecutive patients	Patients undergoing percutaneous coronary intervention (PCI) for CAD	Aug-Oct 2009	30 days for all patients	followup after intervention	NO	Non-industry only - grant from Government & non- profit foundation
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	Sub-study of RCT	Yes	Patients scheduled for coronary angiography or PCI	Patients scheduled for coronary angiography or PCI	Feb, 2006- June, 2008	1-year	Hospitals inpatient	NR	Partly industry

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Campo, 2011 21679849 Italy NR	Prospective cohort	No	Consecutive	Patients undergoing PCI for ischemic heart disease who had a baseline and 1 month PRU evaluation and a baseline blood sample for genotyping	December 2008 to May 2009	Max, 1 year	Inpatient followed by outpatient followup	NO	NR but authors have COIs with drug companies
Cuisset, 2008 18549843 Belgium NR	Prospective observational study	NO	Consecutive patients	Patients undergoing percutaneous coronary intervention (PCI) for ACS	May – Oct 2007	NR	Followup after intervention	YES; Accrual >80%	NR
De Miguel Castro, 2009 19232185 Spain NR	Prospective observational study	NO	NR	Patients with acute NSTEMI undergoing coronary angiography	Jan 2005 – Feb 2006	12 month followup	Followup	YES; Accrual = 161/175 (92%)	non-industry (grant from the Fundación Investigación Sanitaria (Health Research Foundation) in León, Spain.)
Gladding, 2008 19463375 New Zealand Secondary (but not subgroup) analysis of PRINC (Plavix Response in Coronary Intervention) Trial	2 by 2 factorial, randomized, placebo-controlled, double-blind study over the first 24 h, followed by a 1-week randomized, placebo-controlled, double-blind study	NR	Consecutive	Patients undergoing elective PCI	NR	7 Days total	Inpatient, with outpatient followup after the inpatient procedure	YES [YES (“~80%”)]	Non-industry only except the VerifyNow platelet function analyzer was provided by Sanofi Aventis, New Zealand.
Huczek, 2011 21443410 Poland NR	Prospective	NO	NR	Patients undergoing percutaneous coronary intervention (PCI) for ACS	July 2008 until December 2009	Max: 30 day followup	followup after intervention	NO	Non-industry (Polish Ministry of Science and Higher Education [No. N402 4400 33])

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Kim, 2011 21786434 South Korea CiLostazol administration before pErcutaneous coronAry intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial)	RCT	NO	Consecutive	patients with typical angina, not on statins and without elevated levels of cardiac enzymes scheduled for drug- eluting stent (DES) implantation in de novo coronary artery lesions	June 2007- May 2009	Total 6 mo	Outpatient visits and inpatient during PCI	YES [YES]	Partly industry
Lee, 2009 20049136 South Korea NR	Prospective	NO	Consecutive	ACS patients undergoing DES stenting	Jan. 2006- Dec. 2007	Total 6 mo	In hospital for those who were continually hospitalized or outpatient followup for those who were discharged	NO	NR
Mangiacapra, 2010 20298992 Italy NR	Prospective observational study	NO	NR	Patients undergoing elective PCI	NR	NR	followup after intervention	YES; Accrual >80%	NR
Mangiacapra, 2010 20129566 Belgium NR	Prospective observational study	NO	NR	Patients undergoing angiography for stable angina or have stenotic coronary artery	NR	NR	Followup after intervention	YES Accrual > 80%	NR
Mangiacapra, 2010 20723634 Italy NR	Prospective observational study	NO	NR	Patients undergoing elective PCI for stable angina or non-ST- elevation acute coronary syndromes	NR	NR	followup after intervention	YES; Accrual >80%	NR
Marcucci, 2009 19118249 Italy NR	Prospective cohort	NO	NR	Patients with ACS who underwent PCI	January 2005 to March 2006	12 months	Followup after intervention	NO	Non-industry (grant to the FiorGen Foundation by Ente Cassa di Risparmio Florence, Italy)

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Patti, 2008 18804738 Italy ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome)	Prospective observational study	NO	NR (appears to be a consecutive study)	Patients undergoing PCI for ACS, including those who have had a myocardial infarction	NR	6 month followup for each patient	Followup after intervention	YES; accrual >80%	Not supported by external sources of funding
Patti, 2011 21256470 Italy Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty (ARMYDA)– Bleeding Study (ARMYDA-BLEEDS)	Prospective	NO	Consecutive	clopidogrel-treated patients who underwent PCI	April 1-Dec. 31, 2009	Total 1 month	Inpatient for PCI, then followup for 1 mo as outpatient	NO	NR
Price, 2011 21406646 USA Gauging Responsiveness with A VerifyNow assay— Impact on Thrombosis And Safety (GRAVITAS)	Prospective cohort with comparison being made between one of the randomized arm of an RCT and a parallel observation cohort	YES	Consecutive	PCI for ACS and MI	July 2008 – Apr 2010	6 months	Followup after intervention	Yes; Accrual>80%	Industry (Accumetrics & study drug was provided by an investigator-initiated grant from Bristol-Myers Squibb/ sanofi-aventis)
Price, 2008 18263931 USA NR	prospective Cohort	No	Patients with one lesion ≥50% diameter stenosis requiring PCI.	Patients with one lesion ≥50% diameter stenosis requiring PCI.	July 2005- Aug 2006	6 months	Hospital inpatient	YES	Industry

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Saw, 2008 19463380 Canada BRIEF-PCI	Sub-study of RCT	No	Sub-study of RCT	Patients underwent PCI	March 2005- May 2007	24 hours	Vancouver General Hospital	Yes. A sample size of 204 was determined to be required— assuming clopidogrel low- responder prevalence of 25% and myonecrosis prevalence of 40% after PCI in responders—to detect an absolute difference of 20% from low-responders, with 5% alpha and 80% power.	Non-industry only
Valgimigli, 2009 19528337 10 sites in Europe (Italy, Belgium, France, Spain) Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) study	Prospective	YES	Consecutive	Adults with stable or troponin-negative non- STEMI ACS undergoing (elective?) coronary angiography or PCI	Feb. 2006- June 2008	Total 30 days	Inpatient and then followup after discharge for 30 days	YES (YES—90%)	Partly industry
Vavuranakis, 2011 21712606 Greece NR	Prospective observational study	NO	NR	Patients undergoing PCI for ACS (NSTEMI)	NR	Mean ± sd: 203±152 days	followup after intervention	YES [accrual > 80%; Min required: 64; recruited 74]	Reported as None
Breet, 2011 21478385 The Netherlands POPular	Observational study	NR	Consecutive	Patients scheduled for PCI with stent implantation	NR	1 year	Hospital	NR	NR
Suh, 2011 21232664 Korea CILON-T	prospective RCT	yes	patients had angina pectoris or native coronary artery lesions	patients had angina pectoris or native coronary artery lesions	Sep 2006 and June 2009	6 months	5 hospitals	yes. 80%	Non-industry

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Price, 2011 21875913 USA Gauging Responsiveness with A VerifyNow assay— Impact on Thrombosis And Safety (GRAVITAS)	Prospective cohort	YES	Consecutive	PCI for ACS and MI	July 2008 – Apr 2010	6 months	Followup after intervention	Yes; Accrual>80%	Industry (Accumetrics & study drug was provided by an investigator-initiated grant from Bristol-Myers Squibb/ sanofi-aventis)
Park, 2011 22152948 Korea NR	prospective	no	consecutive	ACS patients with PCI and stent	March 2006- Dec 2009	2.2 years	follow up after intervention	yes, 90%	NR
Park, 2011 21880289 Korea CROSS-VERIFY	prospective	no	NR	CAD patients with PCI and stent	June 2006- July 2008	12 months	follow up after intervention	Yes, 100%	Government & nongovernment (Clinical Research Center for Ischemic Heart Disease, Korean Society of Interventional Cardiology; Ministry of Health, Welfare & Family
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA-PROVE	Prospective	Yes	yes	CAD patients with PCI and stent	April 2010- February 2011	30 days	follow up after intervention	Yes, 100%	NR
Yu, 2012 Korea NR	prospective cohort	no	Consecutive	CAD patients undergone PCI with drug-eluting stent	Nov 2007- Oct 2009	12 months	followup after intervention	yes, 80%	non-industry
Jin, 2012 Korea NR	prospective cohort	yes	NR	patients underwent PCI with DES and who were compliant with dual antiplatelet therapy	July 2007- Oct 2009	12 months	inpatient and then follow-up	yes (80%)	NR
Saraf, 2010 20447533 UK NR	Prospective Cohort	NR	NR	Patients hospitalized for ACS undergoing PCI, CABG or medical treatment	NR	1 year	Followup after intervention	No	NR

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Ari, 2011 21239075 Turkey EFFICIENT	prospective RCT	yes	NR	PCI patients	Sep 2008- July 2009	6 months	inpatients then followup	yes (80%)	NR
Gaglia, 2012 21919956 USA NR	prospective	no	NR	PCI-STENT for ACS and CAD	October 2009 to September 2010	3 days	inpatient	no	NR
Codner, 2012 22534051 Israel NR	prospective	no	NR	PCI for ACS	NR	6 months	followup after intervention	No	NR

Appendix Table E30. Study design characteristics of studies assessing the predictive ability of VerifyNow in patients with cerebrovascular disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enroment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Ryu, 2010 21113358 South Korea NR	Prospective	NO	NR	Patients receiving a neurointervention	Jan. 2007 to July 2008	18.2 ± 7.84 months mean/SD	In hospital at baseline, outpatient followup at 6 mo	NR	Non-industry only
Drazin, 2011 21990814 US NR	Prospective	NR	Consecutive	Patients undergoing neurovascular stenting and receiving clopidogrel and aspirin	2007-2009	Mean 12 mo (range, 0-34 mo)	Intraoperative + in- and outpatient followup	NO	NR but one author has consulting fees, and one has grants, from industry
Kang, 2010 20223886 South Korea NR	observational study	NO	NR	patients undergoing coil embolization for intracranial aneurysms	Since Mar 2008	Max 60 days	followup after intervention	NO	NR

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; CAD = coronary artery disease; MI = myocardial infarction; NSTE = non-ST-elevation; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; DES=drug eluting stent; CABG=coronary artery bypass grafting; AA= arachidonic acid; SD=standard deviation; RCT=randomized controlled trial; NR=not reported;

Appendix Table E31. Phenotypic test details in studies assessing the predictive ability of VerifyNow in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Cotton, 2010 20406238 UK NR	VerifyNow VerifyNow Accumetrics, San Diego, CA, USA)	ADP	After discarding 5 mL, arterial sheath blood was drawn into vacutainer R tubes and analyzed using the Verify-Now system containing sodium citrate 0.109 M NR NR	PRU≤240 PRU >240	Based on previous literature	PRU≤240 PRU >240
Angiolillo, 2007 18312754 USA OPTIMUS	VerifyNow P2Y12 VerifyNow P2Y12	ADP	2 to 4 hours after antiplatelet therapy intake NR 2 to 4 hours after antiplatelet therapy intake NR	P2Y12 inhibition ≥50% P2Y12 inhibition <50%	Not explicitly reported.	P2Y12 inhibition ≥50%: n=17 (50%) P2Y12 inhibition <50%: n=17 (50%)
Breet, 2010 20179285 Netherlands POPULAR	VerifyNowP2Y12assay Accumetrics, SanDiego,California	ADP	NR Greiner tubes NR Within 2 hours after blood collection.	Verify now P2Y12 <236 Verify now P2Y12 ≥ 236	Based on ROC curves	Verify now P2Y12 <236: n=646 Verify now P2Y12 ≥236: n=406

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Kim, 2010 20449634 Korea NR	turbidimetry-based optical detection device VerifyNow P2Y12assay NR	20 µmol/L ADP	Blood was drawn into a Greiner Bio-One 3.2% citrate Vacuette tube sodium citrate 3.2% clopidogrel- naïve patients received a 300- mg loading-dose (LD) of clopidogrel at least 12 h before procedure, and blood sampling was performed after insertion of the arterial sheath. In the case of patients who were already on chronic clopidogrel therapy, blood sampling was performed at the catheterization lab without clopidogrel LD 60 minutes	PRU<240 PRU≥240	Based on literature	PRU<240 n=512 PRU≥240 n=546
Ko, 2011 21315223 Korea NR	turbidimetric-based optical detection system VerifyNow P2Y12 Assay Accumetrics	ADP	Before PCI; 8 and 24 hrs after PCI lepirudin (25 µg/mL) 5 days (clopidogrel came first) 0.125 days (Within 3 hrs)	Hyporesponsiveness to clopidogrel (PRU≥ 274) Normal responsiveness to clopidogrel (PRU<274)	For identification of PRU cutoff, ROC curve analysis that presented the highest sum of sensitivity and specificity was used	Hyporesponsiveness to clopidogrel (PRU≥ 274): 121 (54.5) Normal responsiveness to clopidogrel (PRU<274): 101 (45.5)
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	VerifyNow P2Y12assay NR Accumetrics, SanDiego,California	NR	NR NR NR NR	Full responder (%PI≥40% full responder) Poor responder (%PI<40 poor responder)	Based on literature	Full responder (%PI≥40% full responder): N=289 Poor responder (%PI<40 poor responder): N=179

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Campo, 2011 21679849 Italy NR	VerifyNowP2Y12assay NR Accumetrics, SanDiego,California	NR	NR NR All samples obtained after clopidogrel started; Blood samples were drawn at baseline (just before PCI and administration of interventional therapy) and at 1 and 6 months after PCI. NR	Clopidogrel poor response (PRU value ≥ 235) at baseline Clopidogrel full response (PRU < 235) at baseline Enhanced response (PRU ≤ 85) at 1 mo Normal response (PRU 86- 238) at 1 mo Poor response (≥ 239) at 1 month	For PRU ≥ 235 vs < 235 : Based on literature For enhanced, normal, poor: best cutoffs from ROC curves done in current study	Clopidogrel poor response (PRU value ≥ 235) at baseline, 107 (36%) Clopidogrel full response (PRU < 235) at baseline, 193 (64%) Enhanced response (PRU ≤ 85) at 1 mo, 75 (25%) Normal response (PRU 86-238) at 1 mo, 185 (62%) Poor response (≥ 239) at 1 mo, 40 (13%)
Cuisset, 2008 18549843 Belgium NR	VerifyNow P2Y12 VerifyNow P2Y12 NR	PGE1+ADP	Before PCI NR 0.5 days (≥ 12 hrs) Clopidogrel came first NR	Quartile 1 (nonresponders) percent inhibition P2Y12 $< 15\%$ Quartile 2-4 (responders) percent inhibition P2Y12 $\geq 15\%$	Not explicitly reported.	Quartile 1 (nonresponders) percent inhibition P2Y12 $< 15\%$: 32 (25%) Quartile 2-4 (responders) percent inhibition P2Y12 $\geq 15\%$: 90 (75%)
De Miguel Castro, 2009 19232185 Spain NR	VerifyNow VerifyNow® analyzer Accumetrics Inc., San Diego, California	NR	Before angiography 3.2% sodium citrate NR [clopidogrel came first] 0.04 (1 hr)	Post treatment platelet reactivity ≤ 175 Post treatment platelet reactivity > 175 Quartile 1 (< 115 PRU) Quartile 2 (115 -164 PRU) Quartile 3 (165 -206 PRU) Quartile 4 (> 206 PRU)	Not explicitly reported.	Post treatment platelet reactivity \leq 175: 97 (60.2%) Post treatment platelet reactivity > 175 : 64 (39.8%) Quartile 1 (< 115 PRU): 40 (25%) Quartile 2 (115 -164 PRU): 40 (25%) Quartile 3 (165 -206 PRU): 40 (25%) Quartile 4 (> 206 PRU):41 (25%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Gladding, 2008 19463375 New Zealand Secondary (but not subgroup) analysis of PRINC (Plavix Response in Coronary Intervention) Trial	Agglutination plus light transmittance VerifyNow point-of-care rapid platelet function analyzer (RPFA) and its P2Y12 cartridge Accumetrics Ltd., San Diego, California	ADP, 20 mmol/l [published as mmol but must be umol?]	Arterial blood was sampled through a 6-F femoral sheath and transferred immediately; collection tubes were inverted 4 times to mix the anticoagulant and left at ambient temperature (24°C) 3.2% citrate Platelet function was tested at baseline, 2, 4, and 7 h from 10 mins	600 mg Clopidogrel: Nonresponse (inhibition <10%) at 7 hr Response (inhibition >=10%) at 7 hr 1200 mg Clopidogrel Nonresponse (inhibition <10%) at 7 hr Response (inhibition >=10%) at 7 hr	Not explicitly reported.	600 mg Clopidogrel Nonresponse (inhibition <10%) at 7 hr: 6/26 (26%) Response (inhibition >=10%) at 7 hr: 20/26 (77%) 1200 mg Clopidogrel Nonresponse (inhibition <10%) at 7 hr: 2/37 (5%) Response (inhibition >=10%) at 7 hr: 35/37 (95%)
Huczek, 2011 21443410 Poland NR	VerifyNow/ turbidoaggregometry VerifyNow P2Y12 assay Accumetrics Inc., San Diego, CA	ADP (with prostaglandin E1 to reduce the nonspecific binding for ADP to P2Y1 receptor)	Venous blood sample after clopidogrel 3.2% sodium citrate 0.5 ± 0.1 days (12± 2 hours); Clopidogrel came first NR	low platelet reactivity (PRU≤150) - first Medium platelet reactivity (PRU = 151-209 High platelet reactivity (PRU ≥210) – Third tertile	Not explicitly reported.	low platelet reactivity (PRU≤150) - first tertile -124 (33.2%) Medium platelet reactivity (PRU = 151-209) - Second tertile - 124 (33.2%) High platelet reactivity (PRU ≥210) – Third tertile-124 (33.2%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Kim, 2011 21786434 South Korea Cilostazol administration before percutaneous coronary intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial)	VerifyNow P2Y12 NR Accumetrics Inc., San Diego, CA	NR	Samples were obtained by antecubital venipuncture using a 23-gauge syringe, and the initial 3 to 4 mm of blood was discarded. The second samples were collected in 4.5- mL plastic tubes for rapid platelet-function assay 3.2% citrate Venous blood samples were drawn immediately after randomization (baseline, before clopidogrel), before PCI (7 days later after pre-treatment with clopidogrel), and 6 and 24 hours after PCI. NR	clopidogrel resistance (% inhibition <20%) normal response to clopidogrel (% inhibition ≥20%)	Based on literature	clopidogrel resistance (% inhibition <20%): 37/110 (34%) normal response to clopidogrel (% inhibition ≥20%): 73/110 (66%)
Lee, 2009 20049136 South Korea NR	VerifyNow P2Y12 assay NR NR	NR	samples were collected from the vein following PCI. Sampling was done in the hospital for patients who were continually hospitalized during this period or during the first follow-up for patients who had been discharged. 3.2% citrate samples were collected after PCI and 5 days after initiating regular administration of clopidogrel (75 mg) Within 8 hours	Clopidogrel low response (<20% inhibition) Clopidogrel normal response (≥20% inhibition)	Based on literature	Clopidogrel low response (<20% inhibition): 95 (40%) Clopidogrel normal response (≥20% inhibition):142 (60%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Mangiacapra, 2010 20298992 Italy NR	VerifyNow/optical turbidimetry VerifyNow P2Y12 assay Accumetrics, San Diego, California	20-μmol adenosine diphosphate,	Before PCI 3.2% sodium citrate NR [Clopidogrel came first] NR	high platelet reactivity PRU value ≥240 not high platelet reactivity	Based on literature	high platelet reactivity PRU value ≥240: 78 (31.2%) Not high platelet reactivity: 172 (68.8%)
Mangiacapra, 2010 20129566 Belgium NR	VerifyNow/optical turbidimetry VerifyNow P2Y12 assay Accumetrics, San Diego, California	20-μmol adenosine diphosphate,	Before PCI 3.2% sodium citrate NR [Clopidogrel came first] NR	High platelet reactivity (HPR) - PRU value ≥240 units Normal platelet reactivity - PRU value <240 units	Not explicitly reported.	High platelet reactivity (HPR) - PRU value ≥240 units: 101 (30%) Normal platelet reactivity - PRU value <240 units: 237 (70%)
Mangiacapra, 2010 20723634 Italy NR	VerifyNow/optical turbidimetry VerifyNow P2Y12 assay Accumetrics, San Diego, California	20-μmol adenosine diphosphate,	Before PCI 3.2% sodium citrate NR [Clopidogrel came first] NR	high platelet reactivity PRU value ≥240 not high platelet reactivity	Based on literature	high platelet reactivity PRU value ≥240: 77 (27%) not high platelet reactivity: 208 (73%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Marcucci, 2009 19118249 Italy NR	VerifyNow/optical turbidimetry VerifyNow P2Y12 assay Accumetrics, San Diego, California	ADP	24 hours after 600-mg clopidogrel loading sodium citrate 0.109 mol/L 1 day [clopidogrel came first] NR	high residual platelet reactivity (PRU ≥ 240) No residual platelet reactivity (PRU < 240) high residual platelet reactivity (PRU ≥ 235) No residual platelet reactivity (PRU < 235) PRU quartiles Quartile 1 ≤129 Quartile 2 130-195 Quartile 3 196-257 Quartile 4 ≥258	ROC analysis; posttreatment PRU that provided the greatest sum of sensitivity and specificity.	high residual platelet reactivity (PRU ≥ 240): 219 (32.1%) No residual platelet reactivity (PRU < 240): 464 (67.9%) high residual platelet reactivity (PRU ≥ 235): 231 (33.8%) No residual platelet reactivity (PRU < 235): 452 (66.2%) PRU quartiles Quartile 1 ≤129: 171 (25%) Quartile 2 130-195: 171 (25%) Quartile 3 196-257: 171 (25%) Quartile 4 ≥258: 170 (25%)
Patti, 2008 18804738 Italy ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome)	VerifyNow/optical turbidimetry VerifyNow P2Y12 assay Accumetrics, San Diego, California	NR (ADP and PGE1 as per Ref 8)	Before PCI & 8 and 24 hrs after intervention NR 0.25 days between clopidogrel dose & sampling in 120 pts; the other 40 were on chronic clopidogrel therapy NR	First Quartile Second Quartile Third Quartile Fourth Quartile	Not explicitly reported for quartile classification; For identification of PRU cutoff, ROC curve analysis that presented the highest sum of sensitivity and specificity was used.	First Quartile: 40 (25) Second Quartile:40 (25) Third Quartile: 40 (25) Fourth Quartile: 40 (25)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Patti, 2011 21256470 Italy Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty (ARMYDA)– Bleeding Study (ARMYDA- BLEEDS)	VerifyNow P2Y12 assay NR Accumetrics, Inc., San Diego, California	NR	NR NR Dose came first; reactivity tested immediately before PCI and at 8 and 24 hours after intervention NR	PRU quartiles at baseline (before PCI): 1 (lowest PRU, which = highest inhibition) 2 3 4 Also ROC-curve-based threshold PRU>189 (low inhibition) PRU< or = 189 (high inhibition)	Not explicitly reported for quartiles; for cutoff at 187, authors did an ROC analysis in this study	PRU quartiles at baseline (before PCI): 1 (lowest PRU, which = highest inhibition): 77 (25%) 2: 77 (25%) 3: 77 (25%) 4: 79 (25%) Also ROC-curve-based threshold PRU>189 (low inhibition): NR PRU< or = 189 (high inhibition): NR
Price, 2011 21406646 USA Gauging Responsiveness with A VerifyNow assay— Impact on Thrombosis And Safety (GRAVITAS)	VerifyNow P2Y12 test/turbidoaggregometry VerifyNow P2Y12 test Accumetrics, San Diego, California	NR	12 to 24 hours after PCI; outcomes and repeat measurements at 30 days and 6 months NR 0.5-1 day (12-24 hrs) Clopidogrel came first NR	High on-treatment reactivity (PRU≥230) Not High On-Treatment Reactivity (PRU<230)	Based on literature	High on-treatment reactivity (PRU≥230): 1105 (65.3%) Not High On-Treatment Reactivity (PRU<230): 586 (34.7%)
Price, 2008 18263931 USA NR	VerifyNow P2Y12 assay NR Accumetrics Inc	20-μmol adenosine diphosphate,	Whole blood was obtained at the time of catheterization prior to anticoagulant therapy in patients on previous clopidogrel therapy and by phlebotomy 12 h after PCI 3.2% sodium Whole blood was obtained by phlebotomy 12 h after PCI and a 600 mg clopidogrel loading dose in patients who were clopidogrel naive NR	Low reactivity (PRU<235) High reactivity (PRU≥235)	ROC analysis	Low reactivity (PRU<235): 258 High reactivity (PRU≥235): 122

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Saw, 2008 19463380 Canada BRIEF-PCI	VerifyNow P2Y12 assay NR Accumetrics Inc	ADP	Whole blood samples 3.2% sodium citrate NR NR	Low-responder (Clopidogrel low-responders were defined as those belonging to the lowest quartile of platelet inhibition)- <19% Responder ≥19%	Not explicitly reported.	Low-responder (Clopidogrel low- responders were defined as those belonging to the lowest quartile of platelet inhibition): 51 (24.4) responder: 147 (70.3)
Valgimigli, 2009 19528337 10 sites in Europe (Italy, Belgium, France, Spain) Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) study	VerifyNow P2Y12 assay NR Accumetrics Inc	NR	NR NR Clopidogrel loading dose (300 or 600 mg) 2- 6 hr before PCI except in those who'd been on clopidogrel for at least 7 days previously at a dose of 75 mg/day NR	Clopidogrel nonresponders (<40% inhibition) Dual (clopidogrel and aspirin) nonresponders Aspirin nonresponder	Not explicitly reported	Clopidogrel nonresponders (<40% inhibition): 147 Dual (clopidogrel and aspirin) nonresponders: 26 Aspirin nonresponder: 136 For groups above, denominator unclear no % not given. The Ns sum to 309 patients but 54 were withdrawn—group affiliation not given. Total of 263 enrolled in the end.
Vavuranakis, 2011 21712606 Greece NR	VerifyNow system/turbidoaggregometry VerifyNow P2Y12 system Accumetrics, SanDiego, CA, USA	NR	Whole blood ; prior to catheterization 0.2 ml buffered 3.2% sodium citrate solution NR[clopidogrel came first] 0.01 ± 0.007 (15±1 min after collection)	NR	ROC analysis to predicts the presence of Large Thrombus Burden	NR
Breet, 2011 21478385 The Netherlands POPular	VerifyNow NR NR	ADP	NR K3-EDTA NR 2h	No HCPR (VerifyNow) With HCPR and Dual HCPR (VerifyNow) Cutoff: 236 P2Y12 reaction units	Based on literature	No HCPR (VerifyNow): 280 With HCPR and dual HPR (VerifyNow): 168

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Suh, 2011 21232664 Korea CILON-T	VerifyNow/ turbidometric aggregation NR NR	20uM ADP and 22nM PGE1	NR NR 2h	low PRU 0-164 Middle PRU 165-264 High PRU ≥ 265	ROC analysis	low PRU 0-164:<16% Middle PRU 165-264:16-36% High PRU ≥ 265:>36%
Price, 2011 21875913 USA Gauging Responsiveness with A VerifyNow assay— Impact on Thrombosis And Safety (GRAVITAS)	VerifyNow P2Y12 test/turbidoaggregometry VerifyNow P2Y12 test Accumetrics, San Diego, California	NR	12 to 24 hours after PCI; outcomes and repeat measurements at 30 days and 6 months NR 0.5-1 day (12-24 hrs) Clopidogrel came first NR	High on-treatment reactivity at 30 days (PRU≥208) Not high on-treatment reactivity at 30 days (PRU<208) High on-treatment reactivity at 30 days (PRU≥230) Not high on-treatment reactivity at 30 days (PRU<230)	Based on literature	Not high on-treatment reactivity (PRU<208): 1156(45.3%) High On-Treatment Reactivity (PRU≥208): 1397 (54.7%) Not high on-treatment reactivity (PRU<230): 1105 (56.7%) High On-Treatment Reactivity (PRU≥230): 586 (43.3%)
Park, 2011 Korea NR	VerifyNow P2Y12 NR NR	ADP	NR NR NR 24 to 48 h post-PCI	HTPR was defined by a PRU value>235 and/or a % inhibition <15%.	Based on literature	High n=1660 normal n=1189
Park, 2011 21880289 Korea CROSS-VERIFY	VerifyNow P2Y12 NR NR	NR	NR NR NR NR	high OPR (HOPR) : ≥235 PRU	Based on literature	HOPR: n=407 No HOPR: n=402

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA-PROVE	VerifyNow system/ turbidoaggregometry VerifyNow P2Y12 system Accumetrics, SanDiego, CA, USA	NR	Whole blood; prior to catheterization 3.2% sodium citrate NR[clopidogrel came first] NR	Low platelet reactivity (LPR) (PRU ≤178) to predict bleeding events Normal platelet reactivity NPR (PRU between ≥179 and ≤238) High platelet reactivity (HPR) (PRU ≥239) to predict ischemic events	ROC analysis	LPR (PRU ≤178) : n = 248 [33.9%] NPR (PRU between ≥179 and ≤238): n = 244 [33.3%] HPR (PRU ≥239: n = 240 [32.8%])
Yu, 2012 22787468 Korea NR	VerifyNow NR (Accumetrics Inc., San Diego, CA, USA	ADP	12 to 24 hours post- PCI 3.2% sodium citrate clopidogrel received at least 6 hours before PCI NR	responder (PRU>235-240) low responder	Ref 11, 21, 22	responder n=186 low responder n=77
Jin, 2012 Korea NR	VerifyNow P2Y12 point-of care assay NR (Accumetrics Inc., San Diego, CA, USA	20 µmol of ADP	NR NR blood sample obtained at the time of discharge and run with 60 minutes while patients was taking MD clopidogrel	no HPR HPR	Not explicitly reported.	no HPR N=127 HPR N=54
Saraf, 2010 20447533 UK NR	VerifyNow P2Y12 point-of care assay NR (Accumetrics Inc., San Diego, CA, USA	ADP	NR sodium citrate 0.109 mol/L NR NR	PRU≥240 PRU<240	Based on literature	PRU≥240 = NR PRU<240 = NR

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Ari, 2011 21239075 Turkey EFFICIENT	VerifyNow P2Y12	20mM ADP	blood samples were drawn before PCI 3.2% sodium citrate 3 days 30 min to 4 hours	clopidogrel resistance inhibition <40%	NR	platelet inhibition <40%=94 platelet inhibition ≥40%=98
Gaglia, 2012 21919956 USA NR	VerifyNow P2Y12	20 µM ADP	6 hours following a loading dose of clopidogrel 3.2% sodium citrate 6 hours 6 and 24 hours following PCI	PRU>235 PRI≤235	Based on literature	PRU>235: 54 PRI≤235: 146
Codner, 2012 22534051 Israel NR	VerifyNow P2Y12	20 µM ADP & prostaglandin E1 22 nmol	NR 3.2% citrate NR 1 hr	PRU>235 PRI≤235	Based on literature	PRU>235: 22 PRI≤235: 35

*If more than one test, use separate rows

**e.g., nonresponsive vs. responsive to clopidogrel, high vs. low platelet reactivity

Appendix Table E32. Phenotypic test details in studies assessing the predictive ability of VerifyNow in patients with cerebrovascular disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Ryu, 2010 21113358 South Korea NR	VerifyNow P2Y12 assay NR Accumetrics Inc	NR	NR NR Test conducted after taking the medicine for 3 days NR	platelet inhibition < 40% (clopidogrel resistance) platelet inhibition >= 40% (clopidogrel nonresistance)	Not explicitly reported.	platelet inhibition < 40% (clopidogrel resistance): 33/53 (62.3%) platelet inhibition >= 40% (clopidogrel nonresistance): 20/53 (37.7%)
Kang, 2010 20223886 South Korea NR	VerifyNow P2Y12 assay/Turbidimetric based optical detection system VerifyNow P2Y12 assay Accumetrics, San Diego, California	20 µmol of ADP	Whole blood was obtained before the coil embolization 3.2% sodium citrate NR [Clopidogrel came first] NR	First quartile (<240 PRU) Second quartile (240-284 PRU) Third quartile (285-332 PRU) Fourth quartile (>332 PRU)	Not explicitly reported.	First quartile (<240 PRU): 47 (25.3%) Second quartile (240-284 PRU): 46 (24.7%) Third quartile (285-332 PRU): 46 (24.7%) Fourth quartile (>332 PRU): 47 (25.3%)
Drazin, 2011 21990814 US NR	VerifyNowP2Y12assay NR Accumetrics	ADP	NR Heparin Clopidogrel given at least 12 hr before stenting and measurements taken intraoperatively NR	Suboptimal clopidogrel response (<20% P2Y12 platelet inhibition), measured intraoperatively Optimal responders, measured intraoperatively	Not explicitly reported.	Suboptimal clopidogrel response (<20% P2Y12 platelet inhibition), measured intraoperatively: 19/52 (37%) Optimal responders, measured intraoperatively: 33/52 (63%)

Abbreviations: ADP= adenosine 5'-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported

**If more than one test, use separate rows

Appendix Table E33. Results from studies assessing the ability of VerifyNow to predict death in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	VerifyNow P2Y12	Death	death,	1-year	High OTPR	Death	9/406 (2.2)	OR=1.60	0.63- 4.08	0.32 (high OTPR vs Normal OTPR) [logistic regression]	No	NR	
						Normal OTPR		9/646 (1.4)						
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	VerifyNow P2Y12 (PRU)	cardiac death	cardiac death	6 months	<240	cardiac death	0.2%	OR=3.85	0.46- 32.12	0.258 (≥240 vs <240) [logistic regression]	NR	NR	
						≥240		0.9%						
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNowP2Y12	Death	Death	1-year	Full responder	Death	5/289 (1.7)	NR	NR	0.4 (poor vs full responder) [log rank]	NR	NR	Figure 4 and figure 5, KM curve for 1-year primary end point
						Poor responder		4/179 (2.2)	OR (calculate)=1.30	0.3- 4.9	P=0.737 (poor responder vs full responder) [Fisher's exact test]			
Campo, 2011 21679849 Italy NR	Clopidogrel + aspirin	VerifyNow	Death	NR	1 yr	Poor response at baseline (N=107)	Death	3	OR (calculated)=1.83	0.4- 9.2	P=0.67 (poor responder at baseline vs full responder) [Fisher's exact test]	NR	NR	NO
						Full response at baseline (n=193)		3						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel + aspirin	VerifyNow	Death	Death	1 yr	Poor response at 1 mo (n=40)		5	OR (calculated)=37	4.2- 326	P=0.0002 (poor responder at 1 month vs full responder) [Fisher's exact test]	NR	NR	NR
						Full response at 1 mo (n=260)		1						
Kim, 2011 21786434 South Korea Clopidogrel + aspirin administration before percutaneous coronary intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial)	Clopidogrel+ aspirin	VerifyNow	Cardiac death		6 months	Clopidogrel resistance		0/37 (0%)			NS (resistance vs normal response) [chi-square statistics or Fisher's exact test]			
						Normal response		1/73 (1%)						
Lee, 2009 20049136 South Korea NR	600 mg clopidogrel + 300 mg aspirinLD & in pts with DES, 100 mg aspirin +75 mg clopidogrel	VerifyNow	Cardiac death	Cardiac death		Normal response		1 (0.7%)			0.344 (low vs normal response) [chi-square or Fisher's exact]			
						Low response		2 (2.1%)						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Marcucci, 2009 19118249 Italy NR	clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100- 325 mg MD	VerifyNow	Cardiovascular death	Cardiovascular death	12 months	high residual platelet reactivity (PRU≥240)	Cardiovascular death	13 (5.9)	HR=2.38	1.15– 5.2	P=0.031 (RPR vs no RPR) [cox regression]	NO	NR	
						No residual platelet reactivity (PRU<240)		11 (2.4)						
					12 months	high residual platelet reactivity (PRU≥240)	Cardiovascular death	13 (5.9)	HR=2.55	1.08– 6.07	P=0.034 (RPR vs no RPR) [cos regression]	YES; cardiovascular risk factors, renal failure, left ventricular ejection fraction <40%, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, type of stent used, and use of glycoprotein IIb/IIIa inhibitors	NR	
						No residual platelet reactivity (PRU<240)		11 (2.4)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Survival free from Cardiovascular death	Survival free from Cardiovascular death	12 months	high residual platelet reactivity (PRU≥240)	Survival free from Cardiovascular death	NR	NR	NR	P=0.02 (RPR vs no RPR) Log rank test	NO	NR	
						No residual platelet reactivity (PRU<240)		NR						
			Cardiovascular death	Cardiovascular death	12 months	high residual platelet reactivity (PRU≥235)	Cardiovascular death	NR	HR=2.37	1.06– 5.3	P=0.035 (RPR vs no RPR) [cox regression]	NO	NR	
						No residual platelet reactivity (PRU<235)		NR						
			Cardiovascular death	Cardiovascular death	12 months	high residual platelet reactivity (PRU≥235)	Cardiovascular death	NR	HR=2.41	1.01– 5.72	P=0.046 (RPR vs no RPR) [cox regression]	YES; cardiovascular risk factors, renal failure, left ventricular ejection fraction <40%, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, type of stent used, and use of glycoprotein IIb/IIIa inhibitors	NR	

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						No residual platelet reactivity (PRU<235)		NR						
Price, 2011 21406646 USA Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	Clopidogrel 75 mg/d MD+ Aspirin 75- 162 mg/d MD	VerifyNow	Cardiovascular death	Cardiovascular death	6 months	High on- treatment reactivity was defined (PRU≥230)	Cardiovascular death	8 (0.7%)	HR=1.42	0.38- 5.36	P=0.60 (high vs not high) [log-rank test stratified by acute coronary syndromes status]	NO	NR	Secondary analysis
						Not High On- Treatment Reactivity (PRU<230)		3 (0.5%)						
	Clopidogrel 75 mg/d MD+ Aspirin 75- 162 mg/d MD	VerifyNow	All cause death	All cause death	6 months	High on- treatment reactivity was defined (PRU≥230)	All cause death	10 (0.9%)	HR=1.34	0.42- 4.28	P=0.62 (high vs not high) [log-rank test stratified by acute coronary syndromes status]	NO	NR	Secondary analysis
						Not High On- Treatment Reactivity (PRU<230)		4 (0.7%)						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Price, 2008 18263931 USA NR	Clopidogrel LD 600 mg and maintaining 75mg daily	VerifyNow P2Y12 assay	CV death	Cardiovascular death	6-months	Lower reactivity	CV death	0/209	NR	NR	0.04 comparing with the following row	NR	NR	
						High reactivity		3/108 (2.8)						
	Clopidogrel LD 600 mg and maintaining 75mg daily	VerifyNow P2Y12 assay	CV death	Cardiovascular death	6-months follow-up with a minimal of 3 months post- procedure	Lower reactivity	CV death	0/252	NR	NR	0.04 comparing with the following row	NR	NR	
						High reactivity		3/121 (2.5)						
						Total		3/373 (0.8)						
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	VerifyNow	Death	Death	1 year	HCPR(high on-clopidogrel platelet reactivity) or dual HPR	Death,	6/168	OR (calculate)=3.6	0.9- 14.6	P=0.07 (HCPR(high on- clopidogrel platelet reactivity) or dual HPR vsLow CPR+ or low PR) [Fisher's exact test]	NR	NR	
						Low CPR + Low PR		3/280						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Park, 2011 22152948 Korea NR	clopidogrel LD 300 or 600 mg>=12h before PCI, MD 75mg/day aspirin LD 200mg, MD 100-200 mg/day	VerifyNow	death	death	2-year	HTPR (PRU >235 and/or a % inhibition <15%)	death	high 40/1660 (2)	HR=1.10	0.69- 1.75	0.71 comparing with normal cox proportional model	NR	NR	
								normal 32/1189 (2)						
Park, 2011 21880289 Korea CROSS-VERIFY	clopidogrel LD 300 or 600 mg, MD 75mg/day; aspirin MD 100 mg/day	VerifyNow	Cardiac death	Cardiac death	1 year	high OPR (HOPR) ≥275 PRU n=247	Cardiac death	3 (1.2%)	NR	NR	P=0.299 (HOPR vs no HOPR) [log rank test]	NR	NR	
						No HOPR <275 PRU n=562		3 (0.5%)						
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA- PROVE	Clopidogrel LD: 600 mg loading dose ≥6 h before PCI or 75 mg/d x 5 days Clopidogrel MD: 75 mg/d from 4 weeks to 12 months Aspirin 80- 100 mg/day	VerifyNow	Death	Death	30 days	Low PR (PRU ≤178) n = 248	Death	1 (0.4%)	NR	NR	NS [Fisher's exact test]	No	NR	

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal PR (PRU between ≥179 and ≤238) n = 244		1 (0.4%)						
						High PR (PRU ≥239) n = 240		1 (0.4%)						
Jin, 2012 Korea NR	600mg clopidogrel and 300 mg aspirin LD, 75 mg clopidogrel and 100 mg aspirin as MD	VerifyNow P2Y12	cardiovascular death	cardiovascular death,	12 months	no HPR (<282PRU)	cardiovascular death,	4/127=3.1%	HR=3.84	1.04- 14.22	0.044comparing with HPR cox-model	yes	No	
						HPR (≥282PRU)	cardiovascular death,	6/54=11.1%						
Yu, 2012 22787468 Korea NR	LD 300mg aspirin and 300 mg clopidogrel,	VerifyNow P2Y12	cardiac death	cardiac death	12 months	responder n=109	cardiac death	2/109=1.8%	OR=3.6	0.17- 76.14	0.234 comparing with low responder chi square test or Fisher's exact test	No	No	no
						low responder n=77		0/77=0						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gaglia, 2012 21919956 USA NR	LD: 600 mg loading clopidogrel or 75-mg for 5 days MD: Aspirin + clopidogrel 75 mg for 1 month in patients with BMS and 12 months in patients receiving DES	VerifyNow	death	death	3 days	HPR with PRU>235 n=54	HPR	0	OR (calculated)=2.7	NR	0.6 (HPR vs NPR) [Fishers exact test]	No	NR	
						NPR with PRU>235 n=146		0						

Appendix Table E34. Results from studies assessing the ability of VerifyNow to predict myocardial infarction in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	VerifyNow P2Y12	MI	MI	1-year	High OTPR	MI	40/406 (9.9)	OR=2.96	1.74-5.02	<0.001	No	NR	
						Normal OTPR		23/646 (3.6)						
Kim, 2010 20449634 Korea NR	300-600 mg LD and 75 mg maintain dose clopidogrel	VerifyNow P2Y12 (PRU)	non-fatal myocardial infarction	non-fatal myocardial infarction	6 months	<240	non-fatal myocardial infarction	1.7%	OR=2.62	1.13-6.06	0.019	NR	NR	
						≥240		4.3%						
Ko, 2011 21315223 Korea NR	75 mg/d clopidogrel & 100 mg/d aspirin	VerifyNow P2Y12 Assay	Periprocedural MI	Postprocedural ↑ of troponin or CK-MB >3 times the 99th percentile of the ULN in patients with normal baseline levels (or >3 times in pts with elevated baseline levels)	From PCI to 30 days	Hyporesponsiveness (PRU>274)	MI+	NR	Sens = 0.923 Spec = 0.479	NR	NR	NR	NR	Prev. of CKMB>3x and moderate/ severe bleeding were reported by clopidogrel response; These were not extracted

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	75 mg/d clopidogrel & 100 mg/d aspirin	VerifyNow P2Y12 Assay	Periprocedural MI	Postprocedural ↑ of troponin or CK-MB >3 times the 99th percentile of the ULN in patients with normal baseline levels (or >3 times in pts with elevated baseline levels).	From PCI to 30 days	NR	MI+	NR	NR	NR	NR	NR	NR	AUC = 0.680; P= 0.024 (Fig2d)
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	Myocardial infarction	Myocardial infarction	1-year	Full responder	Myocardial infarction	13/289 (4.5)	NR	NR	0.001	NR	NR	
						Poor responder		29/179 (16.2)						
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	MI by CK-MB	55 MIs, 6.6% using ≥ 3xULN of CK-MB definition	0-3 days	Full responder	MI by CK-MB	55	HR=1.19	1.09-1.28	<0.01	NR	NR	
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	MI by CK-MB	55 MIs, 6.6% using ≥ 3xULN of CK-MB definition	0-3 days	Full responder	MI by CK-MB	NR	HR=1.15	1.05-1.35	0.01	Yes, variables with p- value>0.2	NR	
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	MI by troponin I/T	114 MIs, 6.6% using ≥ 3xULN of troponin I/T definition	0-3 days	Full responder	MI by troponin I/T	NR	HR=1.39	1.28-1.5	<0.01	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	MI by troponin I/T	114 MIs, 6.6% using ≥ 3xULN of troponin I/T definition	0-3 days	Full responder	MI by troponin I/T	NR	HR=1.30	1.07-1.56	0.01	Yes, variables with p- value>0.2	NR	
Cuisset, 2008 18549843 Belgium NR	clopidogrel 600 mg + aspirin 500 mg LD	VerifyNow P2Y12	Periprocedural MI	postprocedural increase in troponin T 3 times the 99th percentile (>0.03 ng/ml).	NR	nonresponder (Quartile 1)	Periprocedural MI	14/32 (44%)	OR=4.6 OR=3.9	1.9-11.5 1.6-8.7	P=0.001 (Q1 vs Q2-4) P<0.01 (Q1 vs Q2-4)	NO YES; For confounding variable (list NR)	NR NR	
						responder (Quartile 2)		4/30 (13%)						
						responder (Quartile 3)		5/30 (17%)						
						responder (Quartile 4)		4/30 (13%)						
Kim, 2011 21786434 South Korea Clopidogrel administration before percutaneous coronary intervention for Reduction of periprocedural myocardial infarction (CLEAR trial)	Clopidogrel + aspirin	VerifyNow	MI		6 mo	Clopidogrel resistance		1/37 (1%)			NS vs. next row (chi-square statistics or Fisher's exact test)			
						Normal response		0/73 (0%)						
			periprocedural MI	CK-MK elevation ≥3 times UNL	6 mo	Clopidogrel resistance	YES event	2/37 (5%)	NR	NR	NS vs. next row (chi-square statistics or Fisher's exact test)	NR	NR	NONE
						Normal response		4/73 (5%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			large periprocedural MI	CK-MK elevation >=10 times UNL		Clopidogrel resistance		1/37 (3%)			NS vs. next row (chi-square statistics or Fisher 's exact test)			
						Normal response		2/73 (3%)						
			cTnl elevation >=3 times UNL			Clopidogrel resistance		5/37 (14%)			NS vs. next row (chi-square statistics or Fisher 's exact test)			
						Normal response		14/73 (19%)						
			cTnl elevation >=10 times UNL			Clopidogrel resistance		3/37 (8%)			NS vs. next row (chi-square statistics or Fisher 's exact test)			
						Normal response		7/73 (10%)						
Mangiacapra 2010 20298992 Italy NR	Clopidogrel 300 mg LD, 75 mg MD with aspirin	verifyNow	Periprocedural myocardial infarction	periprocedural myocardial infarction as per CPK-MB: increases of biomarkers >3x ULN	NR	HPR	periprocedural MI by CK-MB	10/78 (13%)	OR= 3.47	1.27-9.48	p=0.011 (HPR vs no HPR) [logistic regression]	No	NR	Secondary outcome
						No HPR		7/172 (4%)						
	Clopidogrel 300 mg LD, 75 mg MD with aspirin	verifyNow	Periprocedural myocardial infarction	periprocedural myocardial infarction as per Troponin I increases of biomarkers >3x ULN	NR	HPR	periprocedural MI by Troponin I	25/78 (32%)	OR= 2.06	1.12- 3.80	p=0.019 (HPR vs no HPR) [logistic regression]	No	NR	Secondary outcome
						No HPR		33/172 (19%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 300 mg LD, 75 mg MD with aspirin	verifyNow	Periprocedural myocardial infarction	periprocedural myocardial infarction as per CPK-MB: increases of biomarkers >3x ULN	NR	HPR	periprocedural MI by CK-MB	10/78 (13%)	OR= 3.21	1.11-9.32	p=0.032 (HPR vs no HPR) [logistic regression]	YES; multivessel intervention, lesion type B2/C, multivessel disease, diabetes, total stent length, left ventricle ejection fraction <40%	NR	Secondary outcome
						No HPR		7/172 (4%)						
	Clopidogrel 300 mg LD, 75 mg MD with aspirin	verifyNow	Periprocedural myocardial infarction	periprocedural myocardial infarction as per Troponin I increases of biomarkers >3x ULN	NR	HPR	periprocedural MI by Troponin I	25/78 (32%)	OR= 2.25	1.24- 4.13	p=0.019 (HPR vs no HPR) [logistic regression]	YES; multivessel intervention, lesion type B2/C, multivessel disease, diabetes, total stent length, left ventricle ejection fraction <40%	NR	Secondary outcome
						No HPR		33/172 (19%)						
Mangiacapra, 2010 20129566 Belgium NR	clopidogrel 600 mg and aspirin 500 mg	VerifyNow	Periprocedural MI	post-procedural Troponin-T increase more than 3 times the 99th percentile of the upper reference limit	NR	HPR	Periprocedural MI	42 (41.2%)	1.92	1.18-3.13	P=0.008	NO	Bonferroni	
						Normal platelet reactivity		63 (26.7%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 600 mg and aspirin 500 mg	VerifyNow	Periprocedural MI	post-procedural Troponin-T increase more than 3 times the 99th percentile of the upper reference limit	NR	HPR	Periprocedural MI	42 (41.2%)	1.684	1.016-2.789	P=0.043 (high PR vs normal PR) [multivariable logistic regression model]	YES; All clinical and procedural variables that showed a significant univariate association with periprocedural MI (p<0.05)	Bonferroni	
Mangiacapra, 2010 20723634 Italy NR	Clopidogrel 600 mg LD + 75 mg MD + aspirin 100 mg LD & MD	VerifyNow	Periprocedural MI	postprocedural increase in creatinine kinase- MB x3 times the 99th percentile of the upper reference limit (with baseline negative myocardial necrosis markers) or subsequent increase ≥50% the baseline value (in patients with increased baseline levels of creatine kinase MB)	NR	HPR	Periprocedural MI	11/77 (14%)	NR	NR	P=0.0008 (P for trend) [chi square test]	NO	NR	Data calculated from Fig 3 and Fig 1
						No HPR		16/208 (7.7%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 600 mg LD + 75 mg MD + aspirin 100 mg LD & MD	VerifyNow	Periprocedural MI	postprocedural increase in creatinine kinase- MB x3 times the 99th percentile of the upper reference limit (with baseline negative myocardial necrosis markers) or subsequent increase ≥50% the baseline value (in patients with increased baseline levels of creatine kinase MB)	NR	HPR	Periprocedural MI	11/77 (14%)	OR=8.34	2.6-26.76	P=0.0003 (HPR vs no HPR) [multivariate logistic regression]	YES; All variables listed in Tables 1 and 2 showing a significant univariate association with periprocedural MI (p<0.05) and HPR	NR	Data calculated from Fig 3 and Fig 1
Marcucci, 2009 19118249 Italy NR	clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100- 325 mg MD	VerifyNow	Nonfatal MI	Nonfatal MI	12 months	high residual platelet reactivity (PRU≥240)	Nonfatal MI	16 (7.3)	HR=2.73	1.54–5.01	P=0.006 (RPR vs no RPR)	NO	NR	
						No residual platelet reactivity (PRU<240)		11 (2.4)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100- 325 mg MD	VerifyNow	Nonfatal MI	Nonfatal MI	12 months	high residual platelet reactivity (PRU≥240)	Nonfatal MI	16 (7.3)	HR=3.36	1.49–7.58	P=0.034 (RPR vs no RPR)	YES; cardiovascular risk factors, renal failure, left ventricular ejection fraction <40%, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, type of stent used, and use of glycoprotein IIb/IIIa inhibitors	NR	
						No residual platelet reactivity (PRU<240)		11 (2.4)						
	clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100- 325 mg MD	VerifyNow	Nonfatal MI	Nonfatal MI	12 months	high residual platelet reactivity (PRU≥235)	Nonfatal MI	NR	HR=2.94	1.37–6.34	P=0.006 (RPR vs no RPR)	NO	NR	
						No residual platelet reactivity (PRU<235)		NR						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100- 325 mg MD	VerifyNow	Nonfatal MI	Nonfatal MI	12 months	high residual platelet reactivity (PRU≥235)	Nonfatal MI	NR	HR=3.12	1.38–7.02	P=0.006 (RPR vs no RPR)	YES; cardiovascular risk factors, renal failure, left ventricular ejection fraction <40%, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, type of stent used, and use of glycoprotein IIb/IIIa inhibitors	NR	
						No residual platelet reactivity (PRU<235)		NR						
Price, 2011 21406646 USA Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	Clopidogrel 75 mg/d MD+ Aspirin 75- 162 mg/d MD	VerifyNow	Nonfatal MI	Nonfatal MI	6 months	High on-treatment reactivity was defined (PRU≥230)	Nonfatal MI	18 (1.6%)	HR=1.93	0.72-5.21	P=0.19 (high vs not high) [log-rank test stratified by acute coronary syndromes status]	NO	NR	Secondary analysis
						Not High On- Treatment Reactivity (PRU<230)		5 (0.9%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Price, 2008 18263931 USA NR	Clopidogrel LD 600 mg and maintaining 75mg daily	VerifyNow P2Y12 assay	Non-fatal MI	Non-fatal MI	6-months	Lower reactivity	Non-fatal MI	2/209 (1.0)	NR	NR	0.6 comparing with the following row	NR	NR	
						High reactivity		2/108 (1.9)						
						Total		4/317 (1.3)						
	Clopidogrel LD 600 mg and maintaining 75mg daily	VerifyNow P2Y12 assay	Non-fatal MI	Non-fatal MI	6-months follow-up with a minimal of 3 months post- procedure	Lower reactivity	Non-fatal MI	2/252 (0.8)	NR	NR	0.6 comparing with the following row	NR	NR	
						High reactivity		2/121 (1.7)						
						Total		4/373 (1.1)						
Valgimigli , 2009 19528337 10 sites in Europe (Italy, Belgium, France, Spain) Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) study	Clopidogrel	VerifyNow	periprocedural MI	elevation of troponin I/T ratio ≥/3x ULN	48 hr after PCI	Clopidogrel nonresponders, 21% to <40% inhibition		NR	NR	NR	0.35 for interaction between tirofiban or placebo for this and next row	NR	NR	Risk ratios and CIs are in Fig. 4 (all are <1)
						Clopidogrel nonresponders, <21% inhibition		NR	NR	NR	0.78 for interaction between tirofiban and placebo and clopidogrel vs. aspirin nonresponder	NR	NR	Risk ratios and CIs are in Fig. 4 (all are <1)

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Dual (clopidogrel and aspirin) nonresponders		NR	NR	NR	NR	NR	NR	Risk ratios and CIs are in Fig. 4 (all are <1)
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	VerifyNow	MI	MI	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual PR	MI	12/168	NR	NR	0.0033comparing with NPR(normal on-treatment platelet reactivity)	NR	NR	
Saw, 2008 19463380 Canada BRIEF-PCI	Clopidogrel LD 600 mg and maintaining 75mg daily	VerifyNow P2Y12	MI	Tr-I > 3x ULN with normal baseline Tr-I	30 day	Low-responder (n=51)	30-day death, MI, urgent TVR	12 (24%)	NR	NR	0.433 (low vs normal responder) [Fisher's exact]	NR	NR	
						Responder (n=147)		43 (29.3%)	NR					
			MI	CK-MB > 3x ULN with high baseline Tr-I	30 day	Low-responder (n=51)	30-day death, MI, urgent TVR	2 (3.9%)	NR	NR	0.467 (low vs normal responder) [Fisher's exact]	NR	NR	
						Responder (n=147)		3 (2%)	NR					
Park, 2011 22152948 Korea NR	clopidogrel LD 300 or 600 mg >= 12h before PCI, MD 75mg/day aspirin LD 200mg, MD 100-200 mg/day	VerifyNow	MI	MI	2-year	HTPR (PRU >235 and/or a % inhibition <15%)	MI	high 6/1660 (0.3)	HR=1.34	0.37-4.83	0.66 comparing with normal cox proportional model	NR	NR	
								normal 4/1189 (0.3)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Park, 2011 21880289 Korea CROSS-VERIFY	clopidogrel LD 300 or 600 mg, MD 75mg/day; aspirin MD 100 mg/day	VerifyNow	Periproedural MI	cardiac enzyme (creatine kinase-MB or troponin I) elevation >3 times the 99th percentile upper limit	1 year	high OPR (HOPR) ≥235 PRU n=407	Periprocedural MI	NR	NR	NR	P=0.435 (HOPR vs no HOPR) [Log rank test]	NR	NR	
						No HOPR <235 PRU n=402		NR						
						high OPR (HOPR) ≥275 PRU n=247	Periprocedural MI	42(17%)	OR=1.23	0.82-1.86	P=0.311 (HOPR vs no HOPR) [Chi-square test]	NR	NR	
						No HOPR <275 PRU n=562		80 (14.2%)						
			Nonfatal MI	Nonfatal MI	1 year	high OPR (HOPR) ≥275 PRU n=247	MI	4(1.6%)	OR=3.07	0.68-13.81	P=0.124 (HOPR vs no HOPR) [Log rank test]	NR	NR	
						No HOPR <275 PRU n=562		3 (0.5%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA- PROVE	Clopidogrel LD: 600 mg loading dose ≥6 h before PCI or 75 mg/d x 5 days Clopidogrel MD: 75 mg/d from 4 weeks to 12 months Aspirin 80- 100 mg/day	VerifyNow	MI	MI (including periprocedural MI)	30 days	Low PR (PRU ≤178) n = 248	MI	9 (3.6%)			P<0.001 P for trend	No	NR	
						Normal PR (PRU between ≥179 and ≤238) n = 244		11 (4.5%)	OR=0.48	0.24-0.94	normal vs other			
						High PR (PRU ≥239) n = 240		35 (14.6%)						
			Periprocedural MI	Periprocedural MI	30 days	Low PR (PRU ≤178) n = 248	Periprocedural M	8 (3.2%)			P<0.001 P for trend	No	NR	
						Normal PR (PRU between ≥179 and ≤238) n = 244		11 (4.5%)	OR=0.53 (calculated)	0.27-1.05	normal vs other			
						High PR (PRU ≥239) n = 240		32 (13.3%)						
Jin, 2012 Korea NR	600mg clopidogrel and 300 mg aspirin LD, 75 mg clopidogrel and 100 mg aspirin as MD	VerifyNow P2Y12	nonfatal MI	nonfatal MI	12 months	no HPR	nonfatal MI	1/127=0.8%	HR=10.08	1.11-92.40	0.041comparing with HPR cox-model	yes	No	
						HPR	nonfatal MI	4/54=7.4%						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Yu, 2012 22787468 Korea NR	LD 300mg aspirin and 300 mg clopidogrel,	VerifyNow P2Y12	non-fatal MI	non-fatal MI	12 months	responder n=109	non-fatal MI	5/109=4.6%	OR=1.8	0.34-9.54	0.515 comparing with low responder chi square test or Fisher's exact test	No	No	no
						low responder n=77		2/77=2.6%						

Appendix Table E35. Results from studies assessing the ability of VerifyNow to predict stent thrombosis in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily + aspirin 80- 100mg daily	VerifyNow P2Y12	Stent thrombosis	Stent thrombosis	1-year	High OTPR	Stent thrombosis	8/406 (2.0)	OR=2.58	0.84- 7.93	<0.09	No	NR	
						Normal OTPR		5/646 (0.8)						
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	VerifyNow P2Y12 (PRU)	stent thrombosis	stent thrombosis	6 months	<240	stent thrombosis	1.0%	OR=2.92	0.98- 8.7	0.044	NR	NR	
						≥240		2.8%						
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	Definite ST	Definite ST	1-year	Full responder	Definite ST	2/289 (0.6)	NR	NR	0.3	NR	NR	
						Poor responder		3/179 (1.7)						
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	Definite/probable ST	Definite/ probable ST	1-year	Full responder	Definite/ probable ST	3/289 (1)	NR	NR	0.1	NR	NR	
						Poor responder		5/179 (2.8)						
Campo, 2011 21679849 Italy NR	Clopidogrel + aspirin	VerifyNow	Stent thrombosis			Poor response at baseline (N=107)		2	OR (calculate)= 1.82	NR	P=0.62 (poor response vs full response) [Fisher's exact test]			
						Full response at baseline (n=193)		2						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel + aspirin	VerifyNow	Stent thrombosis	xx		Poor response at 1 mo (n=40)		3	OR (calculate) = 21	NR	P=0.008 (poor response vs full response) [Fisher's exact test]			
						Full response at 1 mo (n=260)		1						
Kim, 2011 21786434 South Korea Clopidogrel administration before percutaneous coronary intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial)	Clopidogrel+aspirin	VerifyNow	Stent thrombosis		6 mo	Clopidogrel resistance		1/37 (3%)			NS vs. next row (chi- square statistics or Fisher's exact test)			
						Normal response		1/73 (1%)						
Lee, 2009 20049136 South Korea NR	600 mg clopidogrel + 300 mg aspirinLD & in pts with DES, 100 mg aspirin +75 mg clopidogrel	VerifyNow	Definitive stent thrombosis	in-stent thrombosis on coronary angiography	6 mo after stenting	Normal response	YES event	0 (0%)	NR	NR	0.014 vs. next row (chi-square or Fisher's exact)	NR	NR	NONE
						Low response		4 (4.2%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Probable stent thrombosis	MI confirmed around the area of stent insertion or in cases in which death due to an unknown cause occurred within 30 days post- PCI		Normal response		0 (0%)						
						Low response		0 (0%)						
			Possible stent thrombosis	idiopathic sudden death within 30 days post- PCI		Normal response		0 (0%)						
						Low response		0 (0%)						
			Acute stent thrombosis		within 24 hours after stenting	Normal response		0 (0%)						
						Low response		1 (1.0%)						
			Subacute stent thrombosis		Within 1 day after stenting	Normal response		0 (0%)						
						Low response		1 (1.0%)						
			Late stent thrombosis		Within 1 mo after stenting	Normal response		0 (0%)						
						Low response		2 (2.1%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Price, 2011 21406646 USA Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	Clopidogrel 75 mg/d MD+ Aspirin 75-162 mg/d MD	VerifyNow	Stent thrombosis	Stent thrombosis	6 months	High on- treatment reactivity was defined (PRU≥230)	Stent thrombosis	8 (0.7%)	HR=2.16	0.46- 10.19	P=0.31 (high vs not high) [log-rank test stratified by acute coronary syndromes status]	NO	NR	Secondary analysis
						Not High On- Treatment Reactivity (PRU<230)		2 (0.3%)						
Price, 2008 18263931 USA NR	Clopidogrel LD 600 mg and maintaining 75mg daily	VerifyNow P2Y12 assay	Stent thrombosis	Stent thrombosis	6-months	Lower reactivity	Stent thrombosis	0/209	NR	NR	0.004 comparing with the following row	NR	NR	
						High reactivity		5/108 (4.6)						
						Total		5/317 (1.6)						
	Clopidogrel LD 600 mg and maintaining 75mg daily	VerifyNow P2Y12 assay	Stent thrombosis	Stent thrombosis	6-months follow-up with a minimal of 3 months post- procedure	Lower reactivity	Stent thrombosis	0/252	NR	NR	0.004 comparing with the following row	NR	NR	
						High reactivity		5/121 (4.1)						
						Total		5/373 (1.3)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	VerifyNow	ST	ST	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual HPR	ST	2/168	OR (calculate)= 3.53	NR	P=0.3 (HCPR(high on- clopidogrel platelet reactivity) or dual HPR vsLow CPR+ or low PR) [Fisher's exact test]	NR	NR	
						Low CPR + normal PR		1/280						
Park, 2011 22152948 Korea NR	clopidogrel LD 300 or 600 mg>=12h before PCI, MD 75mg/day aspirin LD 200mg, MD 100-200 mg/day	VerifyNow	stent thrombosis	definite, probable, or possible	2-year	HTPR (PRU >235 and/or a % inhibition <15%)	stent thrombosis	high 13/1660 (0.8)	HR=0.72	0.34- 1.51	0.38 comparing with normal Cox proportional model	NR	NR	
								normal 15/1189 (0.8)						
Park, 2011 21880289 Korea CROSS-VERIFY	clopidogrel LD 300 or 600 mg, MD 75mg/day; aspirin MD 100 mg/day	VerifyNow	stent thrombosis	Definite or probable	1 year	high OPR (HOPR) ≥235 PRU n=407	stent thrombosis	NR	NR	NR	P=0.060 (HOPR vs no HOPR) Log rank test	NR	NR	
						No HOPR <235 PRU n=402		NR						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel LD 300 or 600 mg, MD 75mg/day; aspirin MD 100 mg/day	VerifyNow	stent thrombosis	Definite or probable	1 year	high OPR (HOPR) ≥275 PRU n=247	stent thrombosis	5(2%)	OR=5.79 (calculated)	1.11- 30.0	P=0.018 (HOPR vs no HOPR) Log rank test	NR	NR	
						No HOPR <275 PRU n=562		2 (0.4%)						
			Definite stent thrombosis	Definite stent thrombosis	1 year	high OPR (HOPR) ≥275 PRU n=247	Definite stent thrombosis	2 (0.8%)	OR=2.29 (calculated)	0.32- 16.32	P=0.395 (HOPR vs no HOPR) Log rank test	NR	NR	
						No HOPR <275 PRU n=562		2 (0.4%)						
			Probable stent thrombosis	probable stent thrombosis	1 year	high OPR (HOPR) ≥275 PRU n=247	Probable stent thrombosis	3(1.2%)	OR=16.1 (calculated)	0.83- 312.96	P=0.009 (HOPR vs no HOPR) Log rank test	NR	NR	
						No HOPR <275 PRU n=562		0 (0%)						
			stent thrombosis	Definite or probable	1 year	Hyporesponders <5% inhibition of platelet aggregation n=195	stent thrombosis	5(2.6%)	OR=8.05 (calculated)	1.55- 41.84	P=0.003 (hypo-vs normal responders) Log rank test	NR	NR	Supp fig 5 has incorrect information on N at risk

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						responders ≥5% inhibition of platelet aggregation n=614		2 (0.3%)						
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA- PROVE	Clopidogrel LD: 600 mg loading dose ≥6 h before PCI or 75 mg/d x 5 days Clopidogrel MD: 75 mg/d from 4 weeks to 12 months Aspirin 80-100 mg/day	VerifyNow	Stent thrombosis	Stent thrombosis	30 days	Low PR (PRU ≤178) n = 248	Stent thrombosis	0(0%)	NR	NR	P=0.013 [Fisher's exact test]	No	NR	
						Normal PR (PRU between ≥179 and ≤238) n = 244		0(0%)	OR=0.22 (calculated)	0.012- 4.11	normal vs others			
						High PR (PRU ≥239) n = 240		4 (1.7%)						
Jin, 2012 22682702 Korea NR	600mg clopidogrel and 300 mg aspirin LD, 75 mg clopidogrel and 100 mg aspirin as MD	VerifyNow P2Y12	stent thrombosis	stent thrombosis	12 months	no HPR	stent thrombosis	3/127=2.4%	HR=2.43	0.48- 12.45	0.286 comparing with HPR cox-model	yes	No	
						HPR	stent thrombosis	3/54=5.6%						
Yu, 2012 22787468 Korea NR	LD 300mg aspirin and 300 mg clopidogrel,	VerifyNow P2Y12	stent thrombosis	stent thrombosis	12 months	responder n=109	stent thrombosis	4/109=3.7%	OR=1.43 (calculated)	0.26- 8.0	0.68 comparing with low responder chi square test or Fisher's exact test	No	No	No

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						low responder n=77		2/77=2.6%						
Gaglia, 2012 21919956 USA NR	LD: 600 mg loading clopidogrel or 75- mg for 5 days MD: Aspirin + clopidogrel 75 mg for 1 month in patients with BMS and 12 months in patients receiving DES	VerifyNow	stent thrombosis	stent thrombosis	3 days	HPR with PRU>235 n=54	HPR	0	OR (calculated) = 2.7	NR	0.6 (HPR vs NPR) [Fishers exact test]	No	NR	
						NPR with PRU>235 n=146		0						

Appendix Table E36. Results from studies assessing the ability of VerifyNow to predict major adverse cardiovascular events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Cotton, 2010 20406238 UK NR	300 mg or 600 mg LD Clopidogrel and maintaining 75 mg + Aspirin	Verify Now	MACE	MI + revasculari- zation + cardio- vascular admissions	1 year	PRU<240 (n=19)	MACE	0	NR	NR	P<0.02 (high PRU vs low PRU) [Fisher's exact]	NR	NR	
						PRU>240 (n=29)		5						
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily + aspirin 80- 100mg daily	Verify Now P2Y12	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR >236 PRU (n=406)	Death combined	54 (13.3)	OR=2.53	1.63- 3.91	<0.001 (high OTPR vs low OTPR) [Fisher's exact]	No	NR	
						Normal OTPR ≤236 PRU (n=646)		37 (5.7)						
	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	Verify Now P2Y12	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR >236 PRU (n=406)	Death combined	54(406) (13.3)	AUC: 0.62 Sens: 0.604 Spec: 0.631	0.57- 0.67 0.502- 0.699 0.6- 0.661	NR	No	NR	
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	Verify Now P2Y12 (PRU)	composite	composite	6 months	<240 (n=512)	composite	1.7%	OR=2.82	1.23- 6.48	0.011	NR	NR	
						≥240 (n=546)		4.6%						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Ko, 2011 21315223 Korea NR	75 mg/d clopidogrel & 100 mg/d aspirin	Verify Now P2Y12 Assay	Major adverse cardio- vascular events (MACE)	Death, MI, stroke, and target vessel revasculari- zation	30 days	Hyporespon- siveness (PRU>274) (n=121)	MACE+	NR	OR=5.95	1.26- 28.1)	P=0.024 between hyporesponsive vs normal responsive	YES; All Only variables with p <0.15 were entered into final model; final list is NR; only reported variables include: total stent length, hyporesponsive- ness to clopidogrel, and no previous use of statin	NR	
	75 mg/d clopidogrel & 100 mg/d aspirin	Verify Now P2Y12 Assay	Major adverse cardio- vascular events (MACE)	Death, MI, stroke, and target vessel revasculari- zation	From PCI to 30 days	Hyporespon- siveness (PRU>274) (n=101)	MACE +	NR	Sens=0.833 Spec=0.481	NR	NR	NR	NR	NR
	75 mg/d clopidogrel & 100 mg/d aspirin	Verify Now P2Y12 Assay	Major adverse cardio- vascular events (MACE)	Death, MI, stroke, and target vessel revasculari- zation	From PCI to 30 days	NR	MACE +	NR	NR	NR	NR	NR	NR	AUC = 0.649; P=0.032 (Fig2b)
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	Verify Now P2Y12 Assay	Composite primary end point	death, MI, and stroke	1-year	Full responder (n=289)	Composite primary end point	17 (5.9)	HR=1.20	1.1-1.3	<0.01	NR	NR	
						Poor responder (n=179)		31 (17.3)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	Verify Now P2Y12	Composite primary end point	death, MI, and stroke	1-year	Full responder (n=289)	death, MI, and stroke	17 (5.9)	HR=1.3	1.07- 1.56	0.01	Yes, variables with p-value>0.2	NR	
						Poor responder (n=179)		31 (17.3)						
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	Verify Now P2Y12	Composite primary end point	death, MI, and stroke	0-3 days	Full responder (n=289)	death, MI, and stroke	8 (2.8)	NR	NR	0.004	NR	NR	
						Poor responder (n=179)		20 (11.1)						
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	Verify Now P2Y12	Composite primary end point	death, MI, and stroke	3-365 days	Full responder (n=289)	death, MI, and stroke	11 (3.8)	HR=1.15	1.05- 1.29	0.01	NR	NR	
						Poor responder (n=179)		17 (9.5)						
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	Verify Now P2Y12	Composite primary end point	death, MI, and stroke	3-365 days	Full responder (n=289)	death, MI, and stroke		HR=1.12	1.06- 1.25	0.03	Yes, variables with p-value>0.2	NR	
						Poor responder (n=179)								
Campo, 2011 21679849 Italy NR	Clopidogrel + aspirin	Verify Now	Death, MI, or stroke			Poor response at baseline (N=107)		14	HR 3.1	1.3-7.3	Table 3 gives <0.01 but text gives 0.02 vs. next row (t-test)			Maybe HR not for composite end point but rather any AE? Text unclear

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Full response at baseline (n=193)		7						
	Clopidogrel + aspirin	Verify Now	Death, MI, or stroke			Poor response at 1 mo (n=40)		17	HR 28.5	8-104	<0.01 vs. next row (t-test)			
						Full response at 1 mo (n=260)		4						
	Clopidogrel + aspirin	Verify Now	Death, MI, or stroke			Full response at baseline but poor response at 1 mo (n=8)					<0.01 vs. next row (1-way ANOVA)			Kaplan- Meier curves given in Fig 3
						Poor response at baseline and at 1 mo (n=32)								
						Poor response at baseline but full response at 1 mo (n=75)								
						Full response at baseline but poor response at 1 mo (n=185)								
	Clopidogrel + aspirin	Verify Now	Death, MI, or stroke			Enhanced response (PRU ≤85) at 1 mo (n=75)		1						This and rest of data in table from Fig 5

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal response (PRU 86-238) at 1 mo (N=185)		3						
						Poor response (PRU ≥239) at 1 mo (n=40)		17						
	Clopidogrel + aspirin	Verify Now	Ischemic endpoints (details NR)						Difference in AUC for 1 mo vs baseline, 0.21	0.05- 0.33	<0.01			
					Baseline	≥214 PRU cutoff			AUC 0.69	0.63- 0.74				
									Sensitivity 78%, specificity 63%, PPV 14%, NPV 97%					
					1 mo	≥239 PRU cutoff			AUC 0.87	0.63- 0.74				
									Sensitivity 81%, specificity 92%, PPV 43%, NPV 98%					

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
De Miguel Castro, 2009 19232185 Spain NR	clopidogrel 300 mg LD + 75 mg/d MD w/ aspirin250 mg LD + 100 mg MD	Verify Now	MACE	Death from any cause, nonfatal acute myocardial infarction, new revasculari- zation (CABG or PCI) after readmission for NSTEMACS, and ischemic stroke	1 year	PRU>175	MACE	13 (20%)	Sensitivity 0.75 Specificity 0.64	NR	NR	NR	NR	
						PRU≤175		5 (5%)						
	clopidogrel 300 mg LD + 75 mg/d MD w/ aspirin 250 mg LD + 100 mg MD	Verify Now	MACE	Death from any cause, nonfatal acute myocardial infarction, new revasculari- zation (CABG or PCI) after readmission for NSTEMACS, and ischemic stroke	1 year	PRU>175	MACE	13 (20%)			P=0.0013 (Between PRU>175 and PRU ≤175) [Event free survival by kaplan meir method and Log rank test]	NR	NR	
						PRU≤175		5 (5%)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 300 mg LD + 75 mg/d MD w/ aspirin 250 mg LD + 100 mg MD	Verify Now	MACE	Death from any cause, nonfatal acute myocardial infarction, new revasculari- zation (CABG or PCI) after readmission for NSTEMACS, and ischemic stroke	1 year	PRU>175	MACE	13 (20%)	OR=3.9	1.2- 15.4	P=0.024 (Between PRU>175 and PRU ≤175) [logistic regression]	Yes; not listed - All variables (demographic, clinical, and angiographic) that had shown an association with PPR, percentage of IPA, or MACE with a probability value of P≤.20 in the univariate models	NR	
	clopidogrel 300 mg LD + 75 mg/d MD w/ aspirin 250 mg LD + 100 mg MD	Verify Now	MACE	Death from any cause, nonfatal acute myocardial infarction, new revasculari- zation (CABG or PCI) after readmission for NSTEMACS, and ischemic stroke	1 year	Quartile 1 (<115 PRU)	MACE	1 (2.7%)			P=0.009 (Between quartiles) [Chi square or Fishers exact test]	NO	NR	
						Quartile 2 (115 -164 PRU)		3 (7.9%)						
						Quartile 3 (165 -206 PRU)		4 (10.5%)						
						Quartile 4 (>206 PRU)		9 (21.6%)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Huczek, 2011 21443410 Poland NR	Clopidogrel 600mg LD and 75mg MD Aspirin: 300 mg LD & 75 mg MD	Verify Now P2Y12 assay	Composite ischemic end point	CV death (defined as death from cardiac causes or stroke) and non-fatal myocardial infarction (defined as rise in CK-MB of at least twice the upper limit of normal with either ischemic symptoms or typical ECG changes);	30 days	Low PR	Ischemic events	7 (Non-fatal MI:4 Cardio- vascular death: 3 Early stent thrombosis*: 2)	Ref group vs high	Ref group vs high	Ref group vs high			
						Medium PR	Ischemic events	2 (Non-fatal MI:1 Cardiovascular death:1 Early stent thrombosis: 0)	Ref group vs high	Ref group vs high	Ref group vs high			
						High PR	Ischemic events	17 (Non-fatal MI:8 Cardio- vascular death: 9 Early stent thrombosis: 5)	7.26 1.51	1.67-31 .6 0.96-2. 36	0.008 (High vs medium) 0.074 (High vs Low)	YES female sex, BMI, diabetes, ejection fraction	NR	Kaplan– Meier time- to-event curves in Fig 4

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 600mg LD and 75mg MD Aspirin: 300 mg LD & 75 mg MD	Verify Now P2Y12 assay	Composite ischemic end point	CV death (defined as death from cardiac causes or stroke) and non-fatal myocardial infarction (defined as rise in CK-MB of at least twice the upper limit of normal with either ischemic symptoms or typical ECG changes);	30 days	PRU ≥225	Ischemic events	NR	Sensitivity: 61.5% specificity: 77% Area under the curve (AUC): 0.64	Sensiti v-ity of (40.6- 79.8) specifi- city (72.3- 81.3) 0.59– 0.69	P=0.038	NR	NR	ROC curve Fig 5

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 600mg LD and 75mg MD Aspirin: 300 mg LD & 75 mg MD	Verify Now P2Y12 assay	Combined end point of ischemic events and bleeding	CV death (defined as death from cardiac causes or stroke) and non-fatal myocardial infarction (defined as rise in CK-MB of at least twice the upper limit of normal with either ischemic symptoms or typical ECG changes)	30 days	Low PR	Ischemic events + bleeding	20	Ref group vs medium	Ref group vs mediu m	Ref group vs medium			
						Medium PR	Ischemic events	6	0.3 0.31	0.12- 0.75 0.12- 0.77	0.01 (Medium vs low) 0.012 (Medium vs High)	YES female sex, BMI, diabetes, ejection fraction	NR	Kaplan– Meier time- to-event curves in Fig 6
						High PR	Ischemic events	19	Ref group vs medium	Ref group vs mediu m	Ref group vs medium			

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 600mg LD and 75mg MD Aspirin: 300 mg LD & 75 mg MD	Verify Now P2Y12 assay	Composite ischemic end point	CV death (defined as death from cardiac causes or stroke) and non-fatal myocardial infarction (defined as rise in CK-MB of at least twice the upper limit of normal with either ischemic symptoms or typical ECG changes)	30 days	Medium PR defined with a different range than before (≥161 to <225 PRU)	Ischemic events + bleeding	NR	0.14 0.42	0.05- 0.4 0.24- 0.73	0.0003 (Medium vs low) 0.002 (Medium vs High)	YES female sex, BMI, diabetes, ejection fraction	NR	Kaplan– Meier time- to-event curves in Fig 6
Kim, 2011 21786434 South Korea Cilostazol administration before percutaneous coronary intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial)	Clopidogrel + aspirin	Verify Now	Cardiac death, MI, target- lesion revascu- larization, or cerebro- vascular accident		6 mo	Clopidogrel resistance		4/37 (11%)			NS vs. next row (chi-square statistics or Fisher's exact test)			
						Normal response		2/73 (3%)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Lee, 2009 20049136 South Korea NR	600 mg clopidogrel + 300 mg aspirinLD & in pts with DES, 100 mg aspirin +75 mg clopidogrel	Verify Now	Any stent thrombosis or cardiac death		6 months	Normal response		1 (0.7%)			0.012 vs. next row (chi-square or Fisher's exact)			
						Low response		6 (6.3%)	vs previous row: OR (also stated as relative risk), 12.074 (multi- variate logistic regression) Relative risk, 9.646 (univariate logistic regression)	1.205- 120.99 2 for multi- variate OR 1.139- 81.679 for uni- variate RR	0.034 for multivariate OR 0.038 for univariate RR	YES age and sex for OR/RR		
Marcucci, 2009 19118249 Italy NR	clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100- 325 mg MD	Verify Now	MACE	Cardiovascula r death and nonfatal MI	12 months	high residual platelet reactivity (PRU≥240)	MACE	27 (12.3)	HR=2.52	1.30– 5.13	P=0.011 (RPR vs no RPR)	NO	NR	
						No residual platelet reactivity (PRU<240)		17 (3.6)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100- 325 mg MD	Verify Now	MACE	Cardio- vascular death and nonfatal MI	12 months	high residual platelet reactivity (PRU≥240)	MACE	27 (12.3)	Sens: 0.61 Spec: 0.7 AUC 0.66	0.47- 0.758 0.664- 0.735 0.57- 0.78	P<0.001	NO	NR	
						No residual platelet reactivity (PRU<240)		17 (3.6)						
	clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100- 325 mg MD	Verify Now	MACE	Cardio- vascular death and nonfatal MI	12 months	Quartile 1 ≤129	MACE	NR	HR=1.1 HR=1.6 HR=3.6	0.4-3.4 0.6-4.5 1.5-9.1	P>0.05 (Quartile II vs 1) P>0.05 (Quartile III vs 1) P<0.05 (Quartile IV vs 1)	NO	NR	
						Quartile 2 130-195		NR						
						Quartile 3 196-257		NR						
						Quartile 4 ≥258		NR						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Patti, 2008 18804738 Italy ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty- Platelet Reactivity Predicts Outcome)	Clopidogrel 75 mg/day	Verify Now P2Y12	major adverse cardiac events (MACE)	Cardiac death, myocardial infarction (MI)†, target vessel revasculari- zation§	30 days	1st quartile	MACE+	1 (3 %)	Ref group	Ref Group	Ref group	NO	NR	
						2nd quartile	MACE+	2 (5%)	NR	NR	NR	NR	NR	
						3rd quartile	MACE+	4 (10%)	NR	NR	NR	NR	NR	
						4th quartile	MACE+	8 (20%)	OR=12.67 (4th vs. 1st)**	1.49- 107.7	P=0.034 (between 4th and 1st quartile); Fisher's exact/ Chi square	NO	NR	
					6 months	1st quartile	MACE+	4 (10%)	Ref group	Ref Group	Ref group	NO	NR	
						2nd quartile	MACE+	5 (13%)	NR	NR	NR	NR	NR	
						3rd quartile	MACE+	7 (17%)	NR	NR	NR	NR	NR	
						4th quartile	MACE+	12 (30%)	OR=6 (4th vs. 1st)02**	1.67- 21.6	P=0.05 (between 4th and 1st quartile); Fisher's exact/Chi square	NO	NR	
					30 days	1st quartile	MACE+	1 (3 %)	Ref group	Ref Group	Ref group	YES	NR	
						2nd quartile	MACE+	2 (5%)			P=0.71 (between 1st and 2nd quartile); Logistic regression	YES		

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						3rd quartile	MACE+	4 (10%)			P=0.68 (between 1st and 3rd quartile); Logistic regression	YES		
						4th quartile	MACE+	8 (20%)	OR=6.1 (4th vs. 1st)	1.1- 18.3	P=0.033 (between 4th and 1st quartile); Logistic regression	YES; All Only variables with p <0.15 were entered into final model; final list is NR; only reported variables include: Age >70 years, left ventricular dysfunction, and use of glycoprotein IIb/IIIa inhibitors, statin therapy		
	Clopidogrel 75 mg/day	Verify Now P2Y12	major adverse cardiac events (MACE)	Cardiac death, myocardial infarction (MI)†, target vessel revasculari- zation§	30 days	PRU≥ 240 units	MACE+	NR	Sens=0.81; spec=0.53	NR	NR	NR	NR	AUC= 0.69 (95% CI: 0.56 to 0.81; p= 0.016)

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Price, 2011 21406646 USA Gauging Responsive- ness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	Clopidogrel 75 mg/d MD+ Aspirin 75-162 mg/d MD	Verify Now	MACE	Death from cardio- vascular causes, nonfatal myocardial infarction, or stent thrombosis‡	6 months	High on- treatment reactivity was defined (PRU≥230) n=586	MACE	25 (2.3%)	HR=1.68	0.76- 3.72	P=0.20 (high vs not high) [log-rank test stratified by acute coronary syndromes status]	NO	NR	Secondary analysis
						Not High On- Treatment Reactivity (PRU<230) n=1109		8 (1.4%)						
	Clopidogrel 75 mg/d MD+ Aspirin 75-162 mg/d MD	Verify Now	MACE	Death from cardio- vascular causes, nonfatal myocardial infarction, or stent thrombosis‡	30 days	High on- treatment reactivity was defined (PRU≥230) n=586	MACE	17 (1.6%)	HR=2.27	0.76- 6.74	P=0.13 (high vs not high) [log-rank test stratified by acute coronary syndromes status]	NO	NR	Landmark analysis
						Not High On- Treatment Reactivity (PRU<230) n=1109		4 (0.7%)						
Price, 2008 18263931 USA NR	Clopidogrel LD 600 mg and maintaining 75mg daily	Verify Now P2Y12 assay	CV death, non-fatal MI, Stent thrombosis	CV death, non-fatal MI, Stent thrombosis	6-months	Lower reactivity	CV death, non-fatal MI, Stent thrombosis	2/209 (1)	NR	NR	0.008 comparing with the following row	NR	NR	
						High reactivity		7/108 (6.5)						
						Total		9/317 (2.8)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel LD 600 mg and maintaining 75mg daily	Verify Now P2Y12 assay	CV death, non-fatal MI, Stent thrombosis	CV death, non-fatal MI, Stent thrombosis	6-months follow-up with a minimal of 3 months post- procedure	Lower reactivity	CV death, non-fatal MI, Stent thrombosis	2/252 (2)	NR	NR	0.008 comparing with the following row	NR	NR	
						High reactivity		7/121 (5.8)						
						Total		9/373 (2.4)						
Saw, 2008 19463380 Canada BRIEF-PCI	Clopidogrel LD 600 mg and maintaining 75mg daily	Verify Now P2Y12	30-day death, MI, urgent TVR	30-day death, MI, urgent TVR	30 day	Low- responder (n=51)	30-day death, MI, urgent TVR	1 (2%)	NR	NR	0.766 (low vs normal responder) [Fisher's exact]	NR	NR	
						Responder (n=147)		4 (2.7%)	NR					
Vavuranakis, 2011 21712606 Greece NR	300-600 mg LD + 75 mg MD; Aspirin 325 mg X 7 days then 100 mg MD	Verify Now P2Y12	MACE	death; myocardial infarction; stroke	Mean followup: 203±152	NR	MACE	4 (death: 2; myocardial infarction: 2; stroke: 0)	NR	NR	NR [Cox regression (stepwise backward conditional method)]	NR	NR	"Multi- variate analysis did not revealed any significant relation- ship between PRU and MACE."
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	Verify Now	Death, MI, ST, stroke	Death, MI, ST, stroke	1 year	HCPR (high on-clopidogrel platelet reactivity or dual HPR) N=168	Death, MI, ST, stroke	21	OR (calculate)= 3.16	1.5-6.7	P=0.003 (HCPR or Dual HPR vs NPR) [Fisher's exact]	NR	NR	

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						NPR (normal on-clopidogrel platelet reactivity or only high aspirin PR) N=254		11						
Suh, 2011 21232664 Korea CILON-T	Aspirin (100 mg daily) and clopidogrel (75 mg daily	VerifyNo w	primary end point	composite of cardiac death, non fatal MI, ischemic stroke and TLR	6 months	PRU 0-184	primary end point	NR	NR	NR	0.077	NR	NR	figure 4 A showed bar graphs
						PRU 185-264								
						PRU 265-438								
	Aspirin (100 mg daily) and clopidogrel (75 mg daily	Verify Now	Athero- thrombotic complica- tions	composite of cardiac death, non fatal MI, ischemic stroke	6 months	PRU 0-184	Athero- thrombotic complica- tions	0%	NR	NR	0.037	NR	NR	figure 4 A showed bar graphs
						PRU 185-264		2%						
						PRU 265-438		2.9%						
	Aspirin (100 mg daily) and clopidogrel (75 mg daily	Verify Now	target lesion revasculari- zation	composite of cardiac death, non fatal MI, ischemic stroke	6 months	PRU 0-184	target lesion revasculari- zation	NR	NR	NR	0.486	NR	NR	figure 4 A showed bar graphs
						PRU 185-264								
						PRU 265-438								
	Aspirin (100 mg daily) and clopidogrel (75 mg daily	Verify Now	composite clinical outcomes	composite of cardiac death, non fatal MI, ischemic stroke	6 months	high PRU level (every increase of tertile)	composite clinical outcomes	NR	HR=1.42	1.04- 1.93	NR	NR	NR	

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Aspirin (100 mg daily) and clopidogrel (75 mg daily)	VerifyNow	composite clinical outcomes	composite of cardiac death, non fatal MI, ischemic stroke	6 months	high PRU level (every increase of tertile)	composite clinical outcomes	NR	HR=1.61	1.16-2.25	NR	yes (age, sex, Diabetes, HTN, hypercholesterolemia, previous MI, clinical diagnosis, lesion length, reference vessel diameter, multivessel intervention, type of DES, the use of cilostazol, PRU level at discharge)	NR	
Price, 2011 21875913 USA Gauging Responsive- ness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	Highdose clopidogrel : 600 mg LD + 150 mg daily MD Standard-dose Clopidogrel: 75 mg/day MD Aspirin: 75 to 162 mg daily	VerifyNow	MACE	Cardiovas- cular death, nonfatal myocardial infarction, and stent thrombosis	60 days	Platelet reactivity <208 (n=1156)	MACE	12	HR=0.18	0.04-0.79	P=0.02 (PRU<208 vs PRU ≥208) [Cox regression]	No	NR	
						Platelet reactivity ≥208 (n=1397)	MACE	46						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					60 days	Platelet reactivity <208 (n=1156)	MACE	12	HR=0.23	0.05- 0.98	P=0.047 (PRU<208 vs PRU ≥208) [Cox regression]	Yes; ACS presentation, Diabetes mellitus, Prior myocardial infarction, Prior CABG, Prior PCI, creatinine clearance, beta- Blocker at discharg, Total stented length in mm	NR	
						Platelet reactivity ≥208 (n=1397)	MACE	46						
					60 days	Platelet reactivity <230 (n=1448)	MACE	NR	HR=0.62	0.25- 1.51	P=0.3 (PRU<230 vs PRU ≥230) [Cox regression]	No	NR	
						Platelet reactivity ≥230 (n=1105)	MACE	NR						
					6 months	Platelet reactivity <208 (n=1156)	MACE	12	HR=0.43	0.23- 0.82	P=0.047(PRU<20 8 vs PRU ≥208) [Cox regression]	No	NR	
						Platelet reactivity ≥208 (n=1397)	MACE	46						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					6 months	Platelet reactivity <208 (n=1156)	MACE	12	HR=0.54	0.28- 1.04	P=0.065 (PRU<208 vs PRU ≥208) [Cox regression]	Yes; ACS presentation, Diabetes mellitus, Prior myocardial infarction, Prior CABG, Prior PCI, creatinine clearance, beta- Blocker at discharge, Total stented length in mm	NR	
						Platelet reactivity ≥208 (n=1397)	MACE	46						
					6 months	Platelet reactivity <230 (n=1448)	MACE	NR	HR=0.71	0.41- 1.23	P=0.22 (PRU<230 vs PRU ≥230) [Cox regression]	No	NR	
						Platelet reactivity ≥230 (n=1105)	MACE	NR						
Park, 2011 22152948 Korea NR	clopidogrel LD 300 or 600 mg>=12h before PCI, MD 75mg/day aspirin LD 200mg, MD 100-200 mg/day	Verify Now	composite	death, MI, stent thrombosis, or stroke	2-year	HTPR (PRU >235 and/or a % inhibition <15%) N=1660	composite	58 (2.8%)	HR=1.33	0.88- 2.01	0.18 (HTPR vs normal PR) [cox regression]	NR	NR	
						Normal PR N=1189		38 (2.4%)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Park, 2011 21880289 Korea CROSS- VERIFY	clopidogrel LD 300 or 600 mg, MD 75mg/day; aspirin MD 100 mg/day	Verify Now	MACE	Cardiac death and nonfatal spontaneous MI	1 year	high OPR (HOPR) ≥235 PRU n=407	MACE	10 (2.5%)	NR	NR	P=0.022 (HOPR vs no HOPR) Log rank test	NR	NR	
						No HOPR <235 PRU n=402		2 (0.5%)						
						high OPR (HOPR) ≥235 PRU n=407	MACE	10 (2.5%)	OR=6.64	1.27- 34.84	P=0.025 (HOPR vs no HOPR) Logistic regression	YES; age, gender, clinical diagnosis, smoking status, hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, body mass index, left ventricular ejection fraction, extent of involved vessels, target vessel location, use of a drug-eluting stent, implanted stent number, stent diameter, stent length	NR	
						No HOPR <235 PRU n=402		2 (0.5%)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						HTN+ & high OPR (HOPR) ≥235 PRU	MACE	1.7%	NR	NR	P=0.374 (HOPR vs no HOPR) Log rank test NS (HTN+ vs HTN -)	NR	NR	
						HTN+ & No HOPR <235 PRU		0.8%						
						HTN- & high OPR (HOPR) ≥235 PRU	MACE	4.4%	NR	NR	P=0.007 (HOPR vs no HOPR) Log rank test	NR	NR	
						HTN- & No HOPR <235 PRU		0%						
						DYSLIPIDE- MIA+ & high OPR (HOPR) ≥235 PRU	MACE	2.6%	NR	NR	P=0.288 (HOPR vs no HOPR) Log rank test NS (DYSLIPIDEMIA+ vs DYSLIPIDEMIA-)	NR	NR	
						DYSLIPIDE- MIA+ & No HOPR <235 PRU		1.1%						
						DYSLIPIDE- MIA- & high OPR (HOPR) ≥235 PRU	MACE	2.3%	NR	NR	P=0.023 (HOPR vs no HOPR) Log rank test	NR	NR	

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						DYSLIPIDE- MIA- & No HOPR <235 PRU		0%						
						DM+ & high OPR (HOPR) ≥235 PRU	MACE	0.7%	NR	NR	P=0.374 (HOPR vs no HOPR) Log rank test NS (DM+ vs DM-)	NR	NR	
						DM+ & No HOPR <235 PRU		0%						
						DM- & high OPR (HOPR) ≥235 PRU	MACE	3.3%	NR	NR	P=0.023 (HOPR vs no HOPR) Log rank test	NR	NR	
						DM- & No HOPR <235 PRU		0.7%						
						high OPR (HOPR) ≥275 PRU n=247	MACE	7(2.8%)	NR	NR	P=0.035 (HOPR vs no HOPR) Log rank test	NR	NR	
						No HOPR <275 PRU n=562		5 (0.9%)						
						Hyporespon- ders <5% inhibition of platelet aggregation n=195	MACE	6(3.1%)	NR	NR	P=0.035 (hypo- vs normal responders) Log rank test	NR	NR	Supp fig 5 has incorrect info on N at risk

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						responders ≥5% inhibition of platelet aggregation n=614		6 (1%)						
						≥ 275 PRU & Hyporespon- ders <5% inhibition of platelet aggregation n=126	MACE	5 (4%)	NR	NR	P=0.035 (hypo- vs normal responders) Log rank test	NR	NR	
						≥ 275 PRU & normal responders ≥5% inhibition of platelet aggregation n=121		2 (1.7%)						
						< 275 PRU & Hyporespon- ders <5% inhibition of platelet aggregation n=69		1 (1.4%)						
						< 275 PRU & normal responders ≥5% inhibition of platelet aggregation n=493		4 (0.8%)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA- PROVE	Clopidogrel LD: 600 mg loading dose ≥6 h before PCI or 75 mg/d x 5 days Clopidogrel MD: 75 mg/d from 4 weeks to 12 months Aspirin 80-100 mg/day	Verify Now	MACE	Death, MI, target vessel revasculari- zation, bleeding events, hematoma	30 days	Normal PR (PRU between ≥179 and ≤238) n = 244	MACE	35 (14.1%)	OR=0.49	0.29- 0.83	P=0.008 (NPR vs HPR+LPR) [logistic regression]	No	NR	
						Low PR (PRU ≤178) or High PR (PRU ≥239) n = 488		72 (14.8%)						
			MACE	Death, MI, target vessel revasculari- zation, bleeding events, hematoma	30 days	Normal PR (PRU between ≥179 and ≤238) n = 244	MACE	35 (14.1%)	OR=0.47	0.27- 0.81	P<0.001 (NPR vs HPR+LPR) [logistic regression]	Yes; Diabetes mellitus, multivessel disease, chronic renal failure, total stent length, glycoprotein IIb/IIIa inhibitors	NR	
						Low PR (PRU ≤178) or High PR (PRU ≥239) n = 488		72 (14.8%)						

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			MACE	Death, MI, target vessel revasculari- zation, bleeding events, hematoma	30 days	Low PR (PRU ≤178) n = 248	MACE	35 (14.1%)	NR	NR	P=0.034 [log rank test] P=0.007 (NPR vs HPR+LPR) P=0.025 (NPR vs LPR) P=0.005 (NPR vs HPR) [chi square test]	No	NR	
						Normal PR (PRU between ≥179 and ≤238) n = 244		19 (7.8%)						
						High PR (PRU ≥239) n = 240		37 (15.4%)						
			MACE- free survival	MACE-free survival	30 days	Low PR (PRU ≤178) n = 248	MACE-free survival	213 (85.9%)	NR	NR	P=0.034 [log rank test]	No	NR	
						Normal PR (PRU between ≥179 and ≤238) n = 244		225 (92.2%)						
						High PR (PRU ≥239) n = 240		203 (84.6%)						
			Ischemic events	Death, MI, target vessel revasculari- zation	30 days	Low PR (PRU ≤178) n = 248	MACE	10 (4%)	NR	NR	P for trend <0.001 [chi square test]	No	NR	

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal PR (PRU between ≥179 and ≤238) n = 244		12 (4.9%)						
						High PR (PRU ≥239) n = 240		36 (15%)						
Jin, 2012 Korea NR	600mg clopidogrel and 300 mg aspirin LD, 75 mg clopidogrel and 100 mg aspirin as MD	VerifyNow P2Y12	MACE	cardiovas- cular death, nonfatal MI and ischemic stroke	12 months	no HPR	MACE	5/127=3.9%	HR=6.24	2.05- 18.99	0.001comparing with HPR cox-model	yes	No	
Saraf, 2010 20447533 UK NR	Clopidogrel LD 300 mg, MD 75 mg; Aspirin LD 300 mg, MD 75 mg	VerifyNow P2Y12	MACE	CV death, nonfatal MI, stroke	12 months	HPR PRU≥ 240	MACE	11/54=20.4% NR	NR	NR	NR	NR	NR	“no relationship between VerifyNow results and MACE in our population”
						PRU<240		NR						
Ari, 2011 21239075 Turkey EFFICIENT	clopidogrel 75 mg/day	VerifyNow P2Y12	MACCE	major adverse cardiac and cerebral events	1 month	group 1 platelet inhibition >40%	MACCE	3/98=3.1%	absolute risk difference 3.3%	-14.5 to 14.2	0.34 group 1 comparing with group 2	NR	NR	no
	clopidogrel 75 mg/day	VerifyNow P2Y12	MACCE	major adverse cardiac and cerebral events	1 month	group 2 platelet inhibition <40%	MACCE	3/47=6.4%	absolute risk difference 1.2%	-5.1 to 11.3	0.71 group 1 comparing with group 3	NR	NR	no

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 150 mg/day	Verify Now P2Y12	MACCE	major adverse cardiac and cerebral events	1 month	group 3 platelet inhibition <40%	MACCE	2/47=4.3%	absolute risk difference 2.1%	-8.7 to 3.3	0.64 group 2 comparing with group 3	NR	NR	no
	clopidogrel 75 mg/day	Verify Now P2Y12	MACCE	major adverse cardiac and cerebral events	2-6 month	group 1 platelet inhibition >40%	MACCE	2/98=2%	absolute risk difference 8.6%	1.7- 20.8	0.02 group 1 comparing with group 2	NR	NR	no
	clopidogrel 75 mg/day	Verify Now P2Y12	MACCE	major adverse cardiac and cerebral events	2-6 month	group 2 platelet inhibition <40%	MACCE	5/47=10.6%	absolute risk difference 2.0%	-19 to 7.1	0.32 group 1 comparing with group 3	NR	NR	no
	clopidogrel 150 mg/day	Verify Now P2Y12	MACCE	major adverse cardiac and cerebral events	2-6 month	group 3 platelet inhibition <40%	MACCE	47	absolute risk difference 10.6%	0.8 to 30	0.02 group 2 comparing with group 3	NR	NR	no
	clopidogrel 75 mg/day	Verify Now P2Y12	total MACCE	major adverse cardiac and cerebral events	6 month	group 1 platelet inhibition >40%	total MACCE	5/98=5.1%	absolute risk difference 11.9%	-1.4 to 22.2	0.019 group 1 comparing with group 2	NR	NR	no
	clopidogrel 75 mg/day	Verify Now P2Y12	total MACCE	major adverse cardiac and cerebral events	6 month	group 2 platelet inhibition <40%	total MACCE	8/47=17%	absolute risk difference 0.8%	-9.5 to 7.7	0.82 group 1 comparing with group 3	NR	NR	no
	clopidogrel 150 mg/day	Verify Now P2Y12	total MACCE	major adverse cardiac and cerebral events	6 month	group 3 platelet inhibition <40%	total MACCE	2/47=4.3%	absolute risk difference 12.7%	7.5 to 39.7	0.045 group 2 comparing with group 3	NR	NR	no
	clopidogrel 75 mg/day	Verify Now P2Y12	NACE	TIMI major or minor bleeding, or total MACCE	6 month	group 1 platelet inhibition >40%	NACE	9/98=9.2%	absolute risk difference 9.9%	-4.1 to 21.2	0.08 group 1 comparing with group 2	NR	NR	no
	clopidogrel 75 mg/day	Verify Now P2Y12	NACE	TIMI major or minor bleeding, or total MACCE	6 month	group 2 platelet inhibition <40%	NACE	9/47=19.1%	absolute risk difference 3.6%	-9.4 to 13.5	0.50 group 1 comparing with group 3	NR	NR	no

Author, year UID Country Study name	Treatment	Pheno- typic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 150 mg/day	Verify Now P2Y12	NACE	TIMI major or minor bleeding, or total MACCE	6 month	group 3 platelet inhibition <40%	NACE	6/47=12.8%	absolute risk difference 6.3%	-8.7 to 21.3	0.39 group 2 comparing with group 3	NR	NR	no

*Each case of stent thrombosis resulted in MI.

†Myocardial infarction was defined as post-procedural increase of cardiac biomarkers (Tn or CK-MB) >3 × 99th percentile of the upper reference limit.

§Target vessel revascularization included by-pass surgery or repeat PCI of the target vessel(s).

**Calculated; P value only reported for 1st vs 4th.

‡All deaths were considered cardiovascular unless an unequivocal noncardiovascular cause could be established; hemorrhagic deaths were also considered to be cardiovascular. Myocardial infarction followed the American College of Cardiology definition. Stent thrombosis was defined as definite or probable according to the Academic Research Consortium definitions.

Appendix Table E37. Results from studies assessing the ability of VerifyNow to predict bleeding events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	PRU≥240	TIMI bleeding	TIMI bleeding (major, minor)	6 months	HPPR- PRU≥240 (n=546)	TIMI bleeding	5.6% (major 3.7%, minor 1.9%)	NR	NR	0.628 (HPPR vs no HPPR) [chi-square test]	NR	NR	
						no HPPR (n=512)		5.1% (major 1.7%, minor 3.4%)						
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	TIMI major bleeding	TIMI major bleeding	1-year	Full responder (n=289)	TIMI major bleeding	2 (0.6)	NR	NR	0.8 (full vs poor responder) [chi-square test]	NR	NR	
						Poor responder (n=179)		1 (0.5)						
	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	TIMI minor bleeding	TIMI minor bleeding	1-year	Full responder (n=289)	TIMI minor bleeding	9 (3.1)	NR	NR	0.4 (full vs poor responder) [chi-square test]	NR	NR	
						Poor responder (n=179)		4 (2.2)						
Campo, 2011 21679849 Italy NR	Clopidogrel + aspirin	VerifyNow	Major or minor TIMI bleeding		1 year	Poor response at baseline (N=107)		6			0.8 (poor vs full responders) [Fisher's exact]			
						Full response at baseline (n=193)		13						
	Clopidogrel + aspirin	VerifyNow	Superficial bleeding according to BleedScore			Poor response at baseline (N=107)		9	OR (calculated) = 0.75		P= 0.495 (poor vs full responder) [Fisher's exact]			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Full response at baseline (n=193)		21						
	Clopidogrel + aspirin	VerifyNow	Internal or alarming bleeding according to BleedScore	intracranial, needing transfusion, melema, hematuria, hematemesis, or epistaxis		Poor response at baseline (N=107)		8			0.3 (poor vs full responder) [Fisher's exact]			
						Full response at baseline (n=193)		18						
	Clopidogrel + aspirin	VerifyNow	Major or minor TIMI bleeding			Poor response at 1 mo (n=40)		1			0.5 (poor vs full responder) [Fisher's exact]			
						Full response at 1 mo (n=260)		18						
	Clopidogrel + aspirin	VerifyNow	Superficial bleeding according to BleedScore			Poor response at 1 mo (n=40)		3			NR			
						Full response at 1 mo (n=260)		27						
	Clopidogrel + aspirin	VerifyNow	Internal or alarming bleeding according to BleedScore	intracranial, needing transfusion, melema, hematuria, hematemesis, or epistaxis		Poor response at 1 mo (n=40)		1			0.2 (poor vs full responder) [Fisher's exact]			
						Full response at 1 mo (n=260)		25						
	Clopidogrel + aspirin	VerifyNow	Bleeding			Enhanced response (PRU ≤85) at 1 mo (n=75)		15			?			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal response (PRU 86-238) at 1 mo (N=185)		3						
						Poor response (PRU ≥239) at 1 mo (n=40)		1						
	Clopidogrel + aspirin	VerifyNow	Bleeding endpoints (details NR)						Difference in AUC for 1 mo vs baseline, 0.2	0.1-0.3	<0.01			
					Baseline	<=95 PRU cutoff (n=NR)			AUC 0.63	0.58-0.69				
									Sensitivity 46%, specificity 85%, PPV 17%, NPV 96%					
					1 mo	<=85 PRU cutoff (n=NR)			AUC 0.84	0.79-0.88				
									Sensitivity 81%, specificity 80%, PPV 21%, NPV 98%					
Huczek, 2011 21443410 Poland NR	Clopidogrel 600mg LD and 75mg MD Aspirin: 300 mg LD & 75 mg MD	VerifyNow P2Y12 assay	Bleeding events	Bleeding defined as the occurrence of either TIMI major or TIMI minor bleeding	30 days	Low PR (n=124)	Bleeding	18	3.5 2.78	1.3-9.42 1.5-5.15	0.014 (Low vs medium) 0.001 (Low vs High)	YES female sex, BMI, diabetes, ejection fraction	NR	Kaplan– Meier time- to-event curves in Fig 2
						Medium PR (n=124)	Bleeding	5	Ref group vs low	Ref group vs low	Ref group vs low			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						High PR (n=126)	Bleeding	3	Ref group vs low	Ref group vs low	Ref group vs low			
	Clopidogrel 600mg LD and 75mg MD Aspirin: 300 mg LD & 75 mg MD	VerifyNow P2Y12 assay	Bleeding events	Bleeding defined as the occurrence of either TIMI major or TIMI minor bleeding	30 days	PRU ≤161 (n=NR)	Bleeding	NR	Sensitivity: 88.5% specificity: 65.8% Area under the curve (AUC): 0.77	sensitivity of (69.8– 97.6) specificity (60.6– 70.8) 0.72–0.81	P<0.0001	NR	NR	ROC curve Fig 3
Mangiacapra 2010 20298992 Italy NR	Clopidogrel 300 mg LD, 75 mg MD with aspirin	verifyNow	major bleeding	NR	NR	HPR (n=78)	major bleeding	0 (0%)	NR	NR	NR	NO	NR	Secondary outcome
						No HPR (n=172)		0 (0%)						
Patti 2011 21256470 Italy Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty (ARMYDA)– Bleeding Study (ARMYDA- BLEEDS)	Clopidogrel + aspirin	VerifyNow	30-day incidence of major TIMI bleeding			PRU ≤189 (high inhibition) (n=NR)		11.6%	AUC 0.76 Sensitivity 87% Specificity 70%	For AUC, 0.66-0.87	For AUC, P=0.001 For incidence, <0.001 vs. next row	NR	NR	
						PRU >189 (low inhibition) (n=NR)		1.9%	NR	NR	NR	NR	NR	
			30-day incidence of minor TIMI bleeding			PRU ≤189 (high inhibition) (n=NR)		13.7%	NR	NR	<0.001 (high vs low inhibition)	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						PRU>189 (low inhibition) (n=NR)		5.1%	NR	NR	NR	NR	NR	
Price, 2011 21406646 USA Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	Clopidogrel 75 mg/d MD+ Aspirin 75-162 mg/d MD	VerifyNow	Severe or moderate bleeding	As per Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) definition	6 months	High on- treatment reactivity was defined (PRU≥230) (n= 1092)	Severe or moderate bleeding	25 (2.3%)	HR=0.51	0.22-1.19	P=0.12 (high vs not high) [log-rank test stratified by acute coronary syndromes status]	NO	NR	Secondary analysis
						Not High On- Treatment Reactivity (PRU<230) (n=586)		7 (1.2%)						
	Clopidogrel 75 mg/d MD+ Aspirin 75-162 mg/d MD	VerifyNow	Any bleeding	As per Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) definition	6 months	High on- treatment reactivity was defined (PRU≥230) (n=1105)	Any bleeding	113/1105 (10.2%)	HR=1.02	0.75-1.39	P=0.87 (high vs not high) [log-rank test stratified by acute coronary syndromes status]	NO	NR	Secondary analysis
						Not High On- Treatment Reactivity (PRU<230) (n=586)		62/586 (10.6%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Saw, 2008 19463380 Canada BRIEF-PCI	Clopidogrel 300 or 600 mg LD and maintaining 75 mg daily	VerifyNow P2Y12	Major bleeding	REPLACE-2 major bleeding	30 day	Low-responder (n=51)	Major bleeding	2 (3.9%)	NR	NR	0.667 (low vs normal responder) [chi square]	NR	NR	
						responder (n=147)		4 (2.7)	NR					
	Clopidogrel 300 or 600 mg LD and maintaining 75 mg daily	VerifyNow P2Y12	Minor bleeding	REPLACE-2 minor bleeding	30 day	Low-responder (n=51)	Minor bleeding	9 (17.6)	NR	NR	0.125 (low vs normal responder) [chi square]	NR	NR	
						responder (n=147)		43 (29.3)	NR					
Valgimigli 2009 19528337 10 sites in Europe (Italy, Belgium, France, Spain) Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) study	Clopidogrel	VerifyNow	Major TIMI bleeding	NR	30 days	Clopidogrel nonresponders (<40% inhibition) (n=147)	Major bleeding	0	OR (calculated)= 0.18	NR	P= 0.39 (<40% vs ≥ 40%) [Fisher's exact]	NR	NR	NONE
						Dual (clopidogrel and aspirin) nonresponders (n=26)		0	NR	NR	NR	NR	NR	NONE

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Park, 2011 22152948 Korea NR	clopidogrel LD 300 or 600 mg≥12h before PCI, MD 75mg/day aspirin LD 200mg, MD 100-200 mg/day	VerifyNow	bleeding	all type bleeding according to TIMI criteria	2-year	HTPR (PRU >235 and/or a % inhibition <15%)	bleeding	high 62/1660 (3.3)	HR=1.31	0.87-1.98	0.20 comparing with normal cox proportional model	NR	NR	
								normal 36/1189 (2.6)						
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA-PROVE	Clopidogrel LD: 600 mg loading dose ≥6 h before PCI or 75 mg/d x 5 days Clopidogrel MD: 75 mg/d from 4 weeks to 12 months Aspirin 80- 100 mg/day	VerifyNow	All bleeding events	Major bleed, & hematoma >10 cms	30 days	Low PR (PRU ≤178) n = 248	All bleeding events	26 (10.5%)	NR	NR	P for trend <0.0001	No	NR	
						Normal PR (PRU between ≥179 and ≤238) n = 244		7 (2.9%)	OR=0.53 (calculate)	0.21-1.33	normal vs other			
						High PR (PRU ≥239) n = 240		3 (1.3%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Major bleed	Major bleed	30 days	Low PR (PRU ≤178) n = 248	Major bleed	7 (2.8%)	NR	NR	P for trend =0.003 [fishers exact test]	No	NR	
						Normal PR (PRU between ≥179 and ≤238) n = 244		1 (0.4%)						
						High PR (PRU ≥239) n = 240		3 (0%)						
Yu, 2012 22787468 Korea NR	LD 300mg aspirin and 300 mg clopidogrel,	VerifyNow P2Y12	major bleeding	major bleeding	12 months	responder n=109	major bleeding	1/109=0.9%	OR=0.70	0.04- 11.42	0.802 comparing with low responder chi square test or Fisher's exact test	No	No	no
						low responder n=77		1/77=1.3%						
Ari, 2011 21239075 Turkey EFFICIENT	clopidogrel 75 mg/day	VerifyNow P2Y12	TIMI major bleeding	TIMI major bleeding	6 month	group 1 platelet inhibition >40%	TIMI major bleeding	98	absolute risk difference 0	-14.5 to 14.2	1 group 1 comparing with group 2	NR	NR	no
	clopidogrel 75 mg/day	VerifyNow P2Y12	TIMI major bleeding	TIMI major bleeding	6 month	group 2 platelet inhibition <40%	TIMI major bleeding	47	absolute risk difference 2.1%	-1.9 to 11.0	0.32 group 1 comparing with group 3	NR	NR	no
	clopidogrel 150 mg/day	VerifyNow P2Y12	TIMI major bleeding	TIMI major bleeding	6 month	group 3 platelet inhibition <40%	TIMI major bleeding	1/47=2.1%	absolute risk difference 2.1 %	-5.5 to 11.1	0.32 group 2 comparing with group 3	NR	NR	no
	clopidogrel 75 mg/day	VerifyNow P2Y12	TIMI minor bleeding	TIMI minor bleeding	6 month	group 1 platelet inhibition >40%	TIMI minor bleeding	4/98=4.1%	absolute risk difference 2%	-7.2 to 8.0	0.54 group 1 comparing with group 2	NR	NR	no

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 75 mg/day	VerifyNow P2Y12	TIMI minor bleeding	TIMI minor bleeding	6 month	group 2 platelet inhibition <40%	TIMI minor bleeding	1/47=2.1%	absolute risk difference 2.3%	-4.3 to 13.2	0.54 group 1 comparing with group 3	NR	NR	no
	clopidogrel 150 mg/day	VerifyNow P2Y12	TIMI minor bleeding	TIMI minor bleeding	6 month	group 3 platelet inhibition <40%	TIMI minor bleeding	3/47=6.4%	absolute risk difference 4.3 %	-2.0 to 15.1	0.30 group 2 comparing with group 3	NR	NR	no
	clopidogrel 75 mg/day	VerifyNow P2Y12	total bleeding	TIMI major or minor bleeding	6 month	group 1 platelet inhibition >40%	TIMI minor bleeding	4/98=4.1%	absolute risk difference 2%	1.0 to 11.8	0.54 group 1 comparing with group 2	NR	NR	no
	clopidogrel 75 mg/day	VerifyNow P2Y12	total bleeding	TIMI major or minor bleeding	6 month	group 2 platelet inhibition <40%	TIMI minor bleeding	1/47=2.1%	absolute risk difference 4%	-6 to 16.1	0.27 group 1 comparing with group 3	NR	NR	no
	clopidogrel 150 mg/day	VerifyNow P2Y12	total bleeding	TIMI major or minor bleeding	6 month	group 3 platelet inhibition <40%	TIMI minor bleeding	4/47=8.1%	absolute risk difference 6 %	-3.6 to 17.9	0.16 group 2 comparing with group 3	NR	NR	no

Appendix Table E38. Results from studies assessing the ability of VerifyNow to predict stroke in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	VerifyNow P2Y12	stroke	Stroke	1-year	High OTPR	Stroke	7/406 (1.7)	OR=1.87	0.62- 5.61	<0.26	No	NR	
						Normal OTPR		6/646 (0.9)						
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	VerifyNow P2Y12 (PRU)	ischemic stroke	ischemic stroke	6 months	<240	ischemic stroke	0%	OR=1.0	0.99- 1.01	0.524	NR	NR	
						≥240		0.3%						
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	Clopidogrel LD 300 or 600 mg or maintaining 75mg daily	VerifyNow P2Y12	Stroke	Stroke	1-year	Full responder	Stroke	0/289 (0)	NR	NR	0.2	NR	NR	
						Poor responder		2/179 (1.1)						
Kim, 2011 21786434 South Korea CiLostazol administration before pErcutaneous coronAry intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial)	Clopidogrel + aspirin	VerifyNow	Cerebrovascular accident		6 months	Clopidogrel resistance		1/37 (1%)			NS vs. next row (chi- square statistics or Fisher 's exact test)			
						Normal response		0/73 (0%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2011 21478385 The Netherlands POPular	Clopidogrel LD 300 or 600mg or maintaining 75 mg daily	VerifyNow	Stroke	Stroke	1 year	HCPR(high on- clopidogrel platelet reactivity) or dual HPR	Stroke	3/168	NR	NR	NR	NR	NR	
Park, 2011 22152948 Korea NR	clopidogrel LD 300 or 600 mg>=12h before PCI, MD 75mg/day aspirin LD 200mg, MD 100-200 mg/day	VerifyNow	stroke	stroke	2-year	HTPR (PRU >235 and/or a % inhibition <15%)	stroke	high 17/1660 (0.9)	HR=1.54	0.68- 3.47	0.30 comparing with normal cox proportional model	NR	NR	
								normal 9/1189 (0.7)						
Jin, 2012 Korea NR	600mg clopidogrel and 300 mg aspirin LD, 75 mg clopidogrel and 100 mg aspirin as MD	VerifyNow P2Y12	ischemic stroke	ischemic stroke	12 months	no HPR	ischemic stroke	1/127=1.0%	HR=2	0.12- 32.32	0.627 comparing with HPR cox-model	yes	No	
						HPR	ischemic stroke	1/54=1.9%						
Yu, 2012 22787468 Korea NR	LD 300mg aspirin and 300 mg clopidogrel	VerifyNow P2Y12	stroke	stroke	12 months	responder n=109	stroke	3/109=2.6%	OR = 2.15 (calculated)	0.22- 21.08)	0.519 comparing with low responder chi square test or Fisher's exact test	No	No	no
						low responder n=77		1/77=1.3%						

Appendix Table E39. Results from studies assessing the ability of VerifyNow to predict other clinical events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Kim, 2011 21786434 South Korea CiLostazol administration before pErcutaneous coronAry intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial)	Clopidogrel + aspirin	VerifyNow	Target-lesion revasculari-zation		6 months	Clopidogrel resistance		2/37 (5%)			NS vs. next row (chi- square statistics or Fisher 's exact test)			
						Normal response		1/73 (1%)						
Marcucci, 2009 19118249 Italy NR	clopidogrel 600 mg LD + 75 mg MD & ASA 500 mg IV LD + 100- 325 mg MD	VerifyNow	Target-lesion revasculari-zation	by repeat PCI or CABG	12 months	high residual platelet reactivity (PRU≥240)	Target-lesion revasculari- zation	16 (7.3)	HR=1.48	0.78– 2.78	P=0.225 (RPR vs no RPR)	NO	NR	
						No residual platelet reactivity (PRU<240)		24 (5.2)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Patti, 2011 21256470 Italy Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty (ARMYDA)– Bleeding Study (ARMYDA- BLEEDS)	Clopidogrel + aspirin	VerifyNow	30-day incidence of major TIMI bleeding or significant entry- site complications (hematoma > 10 cm in diameter, pseudo-aneurysm, or arteriovenous fistula)	NR	Within 1 mo	PRU Q1 (highest inhibition) (n=77)	Yes bleeding	10.1%	OR, 4.5 (NR whether this is vs. Q4 or vs. Q2-4)	1.9- 25.9	For incidence, 0.043 vs. next row (Fisher's exact or chi- square) For OR, 0.01	NR for incidence YES for OR: age, sex, BMI, DM, stable angina vs ACS, chronic renal failure, hemoglobin levels, previous TIA or stroke, previous major bleeding, use of bivalirudin vs. unfraction- ated heparin, and use of glycoprotein IIb/IIIa inhibitors	NR	NONE
						PRUQ4 (n=79)		1.3%	NR	NR	NR	NR	NR	
						PRU Q3 (n=77)		1.4%	NR	NR	0.05 vs. first row (Fisher's exact or chi- square)	NR	NR	
						PRU Q2 (n=77)		6.3%	NR	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Park, 2011 22152948 Korea NR	clopidogrel LD 300 or 600 mg>=12h before PCI, MD 75mg/day aspirin LD 200mg, MD 100-200 mg/day	VerifyNow	revascularization	revascularization	2-year	HTPR (PRU >235 and/or a % inhibition <15%)	revascularization	high 78/1660 (4.3)	HR=0.94	0.67- 1.31	0.71 comparing with normal cox proportional model	NR	NR	
								normal 62/1189 (5.1)						
Park, 2011 21880289 Korea CROSS- VERIFY	clopidogrel LD 300 or 600 mg, MD 75mg/day; aspirin MD 100 mg/day	VerifyNow	Target vessel revascularization	any repeat percutaneous intervention or surgical bypass of any segment of the target vessel	1 year	high OPR (HOPR) ≥235 PRU n=407	MACE	10 (2.6%)	NR	NR	P=0.861 (HOPR vs no HOPR) Log rank test	NR	NR	
						No HOPR <235 PRU n=402		1 (0.3%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA- PROVE	Clopidogrel LD: 600 mg loading dose ≥6 h before PCI or 75 mg/d x 5 days Clopidogrel MD: 75 mg/d from 4 weeks to 12 months Aspirin 80- 100 mg/day	VerifyNow	Target vessel revascularization	Target vessel revascularization	30 days	Low PR (PRU ≤178) n = 248	Target vessel revascularization	1 (0.4%)	NR	NR	P for trend =0.041	No	NR	
						Normal PR (PRU between ≥179 and ≤238) n = 244		0 (0%)	OR = 0.15 (calculated)	0.009- 2.71	normal vs other			
						High PR (PRU ≥239) n = 240		5 (2.1%)						
			Hematoma > 10 cms	Hematoma > 10 cms	30 days	Low PR (PRU ≤178) n = 248	Hematoma > 10 cms	19 (7.7%)	NR	NR	P for trend <0.001	No	NR	
						Normal PR (PRU between ≥179 and ≤238) n = 244		6 (2.5%)						
						High PR (PRU ≥239) n = 240		3 (1.3%)						

Appendix Table E40. Results from studies assessing the ability of VerifyNow to predict other clinical events in patients with cerebrovascular disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Drazin, 2011 21990814 US NR	Clopidogrel + aspirin	VerifyNow	Intraprocedural thrombosis	NR	Intraprocedural	Suboptimal response	Yes event	1 (2%)	NR	NR	NR	NR	NR	NONE
						Optimal response		0 (0%)	NR	NR	NR	NR	NR	NONE
			Thromboembolic event		At followup	Suboptimal response		0 (0%)	NR	NR	NR	NR	NR	NONE
						Optimal response		0 (0%)	NR	NR	NR	NR	NR	NONE
			Good function score on modified Ranking Scale	score \leq 2	At discharge	Suboptimal response	Yes good function	16/19	OR for poor function among suboptimals vs. optimals, 1.55	0.54-4.44	0.41 Ordinal repeated measures model (GEEs)	YES age, sex, DM status, smoking, PPI)	NR	Table 2 has raw data
						Optimal response		32/33 (97%)	NR	NR	NR	NR	NR	Table 2 has raw data
					At followup	Suboptimal response		16/19 (84%)	NR	NR	NR	NR	NR	Table 2 has raw data
						Optimal response		31/33 (94%)	NR	NR	NR	NR	NR	Table 2 has raw data
			Good function Glasgow Outcome Score	Score \geq 4	At discharge	Suboptimal response		17/19 (89%)	OR for poor function among suboptimals vs. optimals, 1.19	0.25-5.67	0.83 Ordinal repeated measures model (GEEs)	YES age, sex, DM status, smoking, PPI)		Table 2 has raw data
						Optimal response		33/33 (100%)	NR	NR	NR	NR	NR	Table 2 has raw data
					At followup	Suboptimal response		17/19 (89%)	NR	NR	NR	NR	NR	Table 2 has raw data
						Optimal response		31/33 (94%)	NR	NR	NR	NR	NR	Table 2 has raw data

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Kang, 2010 20223886 South Korea NR	Clopidogrel 300 mg LD	VerifyNow P2Y12 assay	procedure-related thromboembolism	Thrombus formation and/or a distal embolism observed during procedure or clinically recognized ischemic deficits that occurred within 60 days of the procedure	60 days	PRU>295	Thromboembolic event	NR	Sensitivity: 75% Specificity: 57% AUC: 0.675	0.526-0.825	P=0.043	NO	NR	
	Clopidogrel 300 mg LD	VerifyNow P2Y12 assay	procedure-related thromboembolism	Thrombus formation and/or a distal embolism observed during procedure or clinically recognized ischemic deficits that occurred within 60 days of the procedure	60 days	1st quartile	Thromboembolic event	2	NR	NR	0.013 (between quartiles, Chi-square for trends)	NO	Tukey-Kramer multiple comparison test	
						2nd quartile		1						
						3rd quartile		3						
						4th quartile		8						
	Clopidogrel 300 mg LD	VerifyNow P2Y12 assay	procedure-related aneurysm perforation	Perforation (“leak” [demonstration of extra-aneurysmal contrast material] and “nonleak” [device extrusion from an aneurysm without contrast leakage])	60 days	1st quartile	Perforation	1	NR	NR	0.605 (between quartiles, Chi-square for trends)	NO	Tukey-Kramer multiple comparison test	
						2nd quartile		0						
						3rd quartile		0						
						4th quartile		2						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 300 mg LD	VerifyNow P2Y12 assay	All procedure related adverse events	Combination of thromboembolic and perforation events	60 days	1st quartile	thromboembolic and perforation events	3	NR	NR	0.605 (between quartiles, Chi-square for trends)	NO	Tukey-Kramer multiple comparison test	
						2nd quartile		1						
						3rd quartile		3						
						4th quartile		10						
Ryu, 2010 21113358 South Korea NR	Clopidogrel + aspirin	VerifyNow	thromboembolic complications	Embolic or thrombotic	6 mo after stenting/clinical intervention	Resistance	YES event	5	NR	NR	NR	NR	NR	NONE
						Nonresistance		0						
Jin, 2012 Korea NR	600mg clopidogrel and 300 mg aspirin LD, 75 mg clopidogrel and 100 mg aspirin as MD	VerifyNow P2Y12	target revascularization	target revascularization	12 months	no HPR	target revascularization	5/127=3.9%	HR=1.95	0.5-7.57	0.333 comparing with HPR cox-model	yes	No	
						HPR	target revascularization	4/54=7.4%						

Appendix Table 41. Results from studies assessing the ability of VerifyNow to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut- off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Campo, 2011 21679849 Italy NR	Clopidogrel + aspirin	VerifyNow	Clopidogrel response category	NR	1 mo after PCI	Poor at baseline (n=107)	Poor (no change)	32	>=235 PRU (poor)	NR	NR	< 0.01 across this and next 4 rows (exact version of McNemar test	NR	NR	NO
							Full (change)	75							
						Full at baseline (n=196)	Poor (change)	8							
							Full (no change)	185							
Gladding, 2008 19463375 New Zealand Secondary (but not subgroup) analysis of PRINC (Plavix Response in Coronary Intervention) Trial	Clopidogrel	VerifyNow	Nonresponse at 7 hr			<2% at 2 hr				AUC 0.90, sensitivity 100%, specificity 88%		0.02			Scatterplots are in Fig 2
Codner, 2012 22534051 Israel NR	LD: clopidogrel 600 mg and aspirin 100 mg MD: clopidogrel 75 mg/d and aspirin 100 mg/d	VerifyNow	HTPR	PRU≥235	6 months	HTPR at baseline	HTPR at 6 months	12	≥235	OR (calculated) 4.87	1.48- 15.6	P = 0.0091 [Chi square]			
						HTPR at baseline	responder at 6 months	10							

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut- off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						responder at baseline	HTPR at 6 months	7							
						responder at baseline	responder at 6 months	28							

Appendix Table E42. Results from the single study assessing the ability of VerifyNow to predict platelet reactivity during followup (continuous measurement) in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Cotton, 2010 20406238 UK NR	300 mg or 600 mg LD Clopidogrel and maintaining 75 mg+ Aspirin	VerifyNow	PRU	PRU mean AUC15	NR	PRU≤240	19	Mean 493	SD 238	t-test	NR	NR	0.0001 comparing the lower group	NR	NR	
						PRU>240	29	Mean 911	SD195							

Appendix Table E43. Quality assessment of studies assessing the predictive ability of VerifyNow in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Cotton, 2010 20406238 UK NR	no	yes	yes	low	low	NR	No	high	low	yes	NR	yes	low	yes	yes	yes	yes	low
Angiolillo, 2007 18312754 USA OPTIMUS	NO	yes	yes	low	low	NR	NR	unclear	unclear	No	NR	unclear	high	no [1 month]	yes	yes	yes	low
Breet, 2010 20179285 Netherlands POPULAR	yes	yes	yes	low	low	NR	no	high	low	yes	yes	low	low	yes	yes	yes	yes	low
Kim, 2010 20449634 Korea NR	yes	yes	yes	low	low	NR	yes	unclear	Low	Yes	NR	unclean	Low	no [6 months]	yes	yes	yes	low
Ko, 2011 21315223 Korea NR	YES	YES	YES	LOW	LOW	YES	NO	HIGH	LOW	YES	NR	UNCLEAR	LOW	NO [30 days]	YES	YES	YES	LOW
Campo, 2010 20951320 10 sites in Italy, Belgium, France, Spain 3T/2R trial	No	YES	YES	LOW	LOW	NR	yes	unclear	Low	YES	NR	UNCLEAR	LOW	yes [1 year]	yes	yes	yes	low
Campo, 2011 21679849 Italy NR	Yes	YES	YES	LOW	LOW	NR	yes	Low	Low	YES	NR	UNCLEAR	LOW	yes [12 months]	yes	yes	yes	low
Cuisset, 2008 18549843 Belgium NR	Yes	YES	YES	LOW	LOW	NR	No	High	Low	YES	Yes	Low	LOW	NO [followup NR]	yes	yes	yes	low

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard					Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)	
De Miguel Castro, 2009 19232185 Spain NR	No	YES	YES	LOW	LOW	Yes	No	High	Low	YES	Yes	Low	LOW	yes [1 year]	yes	yes	yes	low	
Gladding, 2008 19463375 New Zealand Secondary (but not subgroup) analysis of PRINC (Plavix Response in Coronary Intervention) Trial	Yes	YES	YES	LOW	LOW	NR [double-blind trial but details related to genotyping unclear]	yes	Unclear	Low	No	NR [double-blind trial but details related to genotyping unclear]	High	Low	No [7 days]	yes	yes	yes	low	
Huczek, 2011 21443410 Poland NR	NR	YES	No	Unclear	LOW	NR	No	High	Low	YES	NR	UNCLEAR	LOW	NO [30 days]	YES	YES	YES	LOW	
Kim, 2011 21786434 South Korea CiLostazol administration before pErcutaneous coronAry intervention for Reduction of periprocedural myonecrosis trial (CLEAR trial)	Ye (RCT)s	YES	YES	LOW	LOW	NR	yes	Unclear	Low	YES	NR	UNCLEAR	LOW	NO [6 months]	YES	YES	YES	LOW	
Lee, 2009 20049136 South Korea NR	Yes	YES	YES	LOW	LOW	NR	yes	Unclear	Low	YES	NR	UNCLEAR	LOW	NO [6 months]	YES	YES	YES	LOW	
Mangiacapra, 2010 20298992 Italy NR	No	YES	YES	LOW	LOW	NR	yes	Unclear	Low	YES	NR	UNCLEAR	LOW	NO [followup NR]	yes	yes	yes	low	
Mangiacapra, 2010 20129566 Belgium NR	No	YES	YES	LOW	LOW	NR	No	High	Low	YES	NR	UNCLEAR	LOW	NO [followup NR]	yes	yes	yes	low	

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Mangiacapra, 2010 20723634 Italy NR	Yes	YES	YES	LOW	LOW	NR	yes	Unclear	Low	YES	NR	UNCLEAR	LOW	NO [followup NR]	yes	yes	yes	low
Marcucci, 2009 19118249 Italy NR	No	YES	YES	LOW	LOW	Yes	No	Unclear	Low	YES	NR	UNCLEAR	LOW	yes [12 months]	yes	yes	yes	low
Patti, 2008 18804738 Italy ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome)	NR	YES	YES	LOW	LOW	NR	No	High	Low	YES	NR	UNCLEAR	LOW	NO; 1 MONTH & 6 MONTH	yes	yes	yes	low
Patti, 2011 21256470 Italy Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty (ARMYDA)– Bleeding Study (ARMYDA- BLEEDS)	Yes	YES	YES	LOW	LOW	NR	yes	Unclear	Low	YES	NR	UNCLEAR	LOW	NO (1 month)	yes	yes	yes	low
Price, 2011 21406646 USA Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	Yes	YES	YES	LOW	LOW	Yes	yes	Low	Low	Yes	yes	Low	Low	NO (6 months)	yes	yes	yes	low
Price, 2008 18263931 USA NR	No	YES	YES	LOW	LOW	NR	NR	Unclear	Low	YES	NR	UNCLEAR	LOW	NO (6 months)	yes	yes	yes	low

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Saw, 2008 19463380 Canada BRIEF-PCI	No	YES	YES	LOW	LOW	Yes	No	Unclear	Low	YES	NR	UNCLEAR	LOW	NO (6 months)	yes	yes	yes	low
Valgimigli, 2009 19528337 10 sites in Europe (Italy, Belgium, France, Spain) Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) study	No	YES	YES	LOW	LOW	NR	No	High	Low	YES	NR	UNCLEAR	LOW	NO (2-30 days)	yes	yes	yes	low
Vavuranakis, 2011 21712606 Greece NR	No	YES	No	High	LOW	NR	No	High	Low	Yes	yes	Low	Low	NO (Mean 203 days)	yes	yes	yes	low
Breet, 2011 21478385 The Netherlands POPular	Yes	yes	yes	low	low	NR	Yes	Unclear	Unclear	Yes	Yes	Low	low	Yes [1 year]	yes	yes	yes	low
Suh, 2011 21232664 Korea CILON-T	NR	YES	YES	LOW	LOW	Yes	No	High	Low	Yes	NR	Unclear	low	NO (6 months)	yes	yes	yes	low
Park, 2011 22152948 Korea NR	yes	yes	yes	low	low	yes	yes	low	low	yes	yes	low	low	yes (median 2.2 years)	Yes	yes	yes	low
Price, 2011 21875913 USA Gauging Responsiveness with A VerifyNow assay—Impact on Thrombosis And Safety (GRAVITAS)	Yes	YES	YES	LOW	LOW	Yes	yes	Low	Low	Yes	yes	Low	Low	NO (6 months)	yes	yes	yes	low

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Park, 2011 21880289 Korea CROSS-VERIFY	NR	yes	yes	low	low	yes	yes	Low	Low	Yes	yes	Low	Low	Yes (12 months)	yes	yes	yes	low
Mangiacapra, 2012 22440493 Italy & Belgium ARMYDA-PROVE	Yes	yes	yes	low	low	yes	No	High	Low	Yes	yes	Low	Low	No (30 days)	yes	yes	yes	low
Yu, 2012 Korea NR	yes	yes	yes	low	low	NR	yes	unclear	low	yes	NR	unclear	yes	yes	yes	yes	yes	low
Jin, 2012 Korea NR	NR	yes	no	unclear	low	NR	no	High	low	yes	NR	unclear	low	yes	yes	yes	no	low
Saraf, 2010 20447533 UK NR	NR	Yes	Yes	Low	Low	Yes	Yes	Low	Low	Yes	NR	Unclear	Low	Yes [1 year]	Yes	Yes	Yes	Low
Codner, 2012 22534051 Israel NR	NR	Yes	yes	Low	Low	NR	Yes	unclear	Low	No	Yes	High	High	No [6 months]	Yes	yes	Yes	Low
Gaglia, 2012 21919956 USA NR	Yes	Yes	Yes	Low	Low	Yes	Yes	Low	low	Yes	Yes	Low	Low	No [in- hospital]	yes	yes	yes	Low

- Consecutive or random sample of patients enrolled.
- Case-control design avoided
- Study avoided inappropriate exclusions
Risk of bias: could the selection of patients have introduced bias (If ≥ 2 of the above 3 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)
Concerns that the included patients do not match the review question?
- Index test results interpreted without knowledge of results of reference standard?
- If a threshold used, was it prespecified?
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Concerns that the index test, its conduct, or its interpretation differ from the review question?

6. Reference standard likely to correctly classify the target condition?
7. Reference standard results interpreted without knowledge of index test results?
Could the reference standard, its conduct, or its interpretation have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Are there concerns that the target condition as defined by the reference standard does not match the review question?
8. Appropriate interval between index test and reference standard?
9. All patients received a reference standard?
10. All patients received the same reference standard?
11. Were all patients included in the analysis?
Could the patient flow have introduced bias? (If ≥ 3 of the above 4 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix Table E44. Quality assessment of studies assessing the predictive ability of VerifyNow in patients with cerebrovascular disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard					Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)	
Drazin 2011 21990814 US NR	Yes	YES	YES	LOW	LOW	NR	No	High	Low	YES	NR	UNCLEAR	LOW	yes [12 months]	yes	yes	yes	low	
Kang 2010 20223886 South Korea NR	NR	YES	No	Unclear	LOW	NR	No	High	Low	YES	NR	UNCLEAR	LOW	NO [60 days]	YES	YES	YES	LOW	
Ryu 2010 21113358 South Korea NR	NR	YES	YES	LOW	LOW	NR	No	High	Low	YES	NR	UNCLEAR	LOW	NO (6 months)	yes	yes	YES (but 4 pts [7%] did not have data available and reason NR)	low	
Ari, 2011 21239075 Turkey EFFICIENT	NR	yes	yes	low	low	NR	NR	unclear	low	yes	NR	unclear	low	no	yes	yes	yes	low	

1. Consecutive or random sample of patients enrolled.
2. Case-control design avoided
3. Study avoided inappropriate exclusions
Risk of bias: could the selection of patients have introduced bias (If ≥2 of the above 3 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)
Concerns that the included patients do not match the review question?
4. Index test results interpreted without knowledge of results of reference standard?
5. If a threshold used, was it prespecified?
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Concerns that the index test, its conduct, or its interpretation differ from the review question?
6. Reference standard likely to correctly classify the target condition?
7. Reference standard results interpreted without knowledge of index test results?
Could the reference standard, its conduct, or its interpretation have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Are there concerns that the target condition as defined by the reference standard does not match the review question?
8. Appropriate interval between index test and reference standard?
9. All patients received a reference standard?

- 10. All patients received the same reference standard?
 - 11. Were all patients included in the analysis?
- Could the patient flow have introduced bias? (If ≥ 3 of the above 4 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix Table E45. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of VASP

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Freyenhofer, 2011 21614416 Austria NR	300 NR 205 62±16	43.3 NR NR PCI 24.3 NR see UA/NSTEMI 10 22.7 29.7/34.3	hyper 69.3 27.3 HTN 74.7 27.3	NR 100 100 81.3	100 DES 65.3 multi-vessel 58.7	PCI and coronary stenting	Clopidogrel-naïve patients received a 300 or 600 mg loading dose (LD). Patients on chronic clopidogrel therapy with 75 mg clopidogrel of at least seven consecutive days did not receive an additional LD.	According to actual evidence, all patients received in parallel ASA (100 mg daily dose). The use of GP-IIb/IIIa-blockers during PCI as well as the choice of the anticoagulant depended on the individual situation and the thrombus load at angiography, and was left to the discretion of the operator

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Siller-Matula, 2009 19135705 Austria NR	30 NR 63±10	100 NR CVD 7 PCI 43 NR NR 10 37 NR	hyper 77 57 HTN 77 33	NR 100 100 NR	NR NR NR	Patients undergoing PCI for coronary artery disease	Patients had been on chronic aspirin (100 mg/day) and clopidogrel (75 mg/day) treatment for three months on average.	All patients received unfractionated heparin and 250 mg of injectable acetyl-salicylic acid during PCI
Blindt, 2007 18064332 Germany NR	99 NR 74 (74.7) 63.7±11.2	NR NR NR PCI 47 (47.5) 35 (35.4) NR NR 47 (47.5) 22(22.2)/29 (29.3)	58 (58.6) 42 (42.4) 70 (70.1) 16 (16.2)	NR 100 100 NR	NR DES 65 (65.7); BMS 34 (34.3) NR	Patients with an elevated risk to develop ST acute MI within 48 hours undergoing emergency or elective PCI	All patients were given 75 mg clopidogrel and 100 mg aspirin once a day at least five days prior to PCI. Only in case of emergency PCI, patients received a loading dose of 600 mg before the intervention. Dual antiplatelets for 6 months.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Kalantzi,2011 21255245 Greece NR	61 NR 47 (77) 58.8 ± 11.5	NR NR NR NR NR NR NR	NR NR NR NR	NR NR NR	NR NR NR	Patients with acute coronary syndromes (ACS), including those who have had a NSTEMI or have unstable angina)	Loading dose of 325 mg aspirin followed by 100 mg per day Loading dose of 600 mg clopidogrel, followed by 75 mg per day	Low-molecular-weight heparin (enoxaparin) given sc at 1 mg/kg x12 h until discharge Atorvastatin (40 mg/d) started at admission & continued on discharge
Siller-Matula, 2010 19943879 Austria NR	416 NR 76 64±12	100 NR NR 47 NR NR 13 33 NR	hyper 76 55 85 32	NR 100 100 77	99 NR NR	PCI with stenting	Clopidogrel loading dose at least 2 hr before PCI (600 mg); thereafter, a daily dose of 75 mg, with planned treatment with clopidogrel and aspirin for at least 6 months.	Also all patients received unfractionated heparin (100 IU per kg) during PCI and 250 mg aspirin intravenously immediately after stent placement (and daily dose of 100 mg thereafter).

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Bjelland, 2010 20727659 Norway NR	25 NR 19 (76%) 59.7 ± 14.6	8% 8% NR PCI: 52% NR NR NR 56% STEMI: 40%; NSTEMI: 16%	NR NR NR 8%	NR 0% 88% 64%	NR NR NR	Patients with suspected ACS treated with therapeutic hypothermia	Clopidogrel: enteral LD 300mg (600mg if urgent coronary angiography planned); MD of 75 mg/day	NR
Bonello, 2007 17488353 France NR	144 NR 114 (79) 68±10	56 (39) NR NR NR NR NR NR NR NR	76 (53) 94 (50) 72 (50) 58 (40)	NR 100 100 NR	NR NR NR	Patients admitted for PCI	pretreatment with a loading dose of clopidogrel (300-mg initial oral bolus) 24 h before the procedure, followed by 75 mg per day for at least 6 months + aspirin 160 mg daily, starting at least 12 h before stenting.	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Djukanovic, 2008 18719318 Serbia NR	32 (only 17 included in final analysis as others were not given clopidogrel) NR 27 (84.3%) 57.1 ±8.5	Previous vascular event: 81.3% NR NR NR NR 68.8% NR	NR NR NR NR	NR NR NR NR	NR NR NR	Patients with ischemic heart disease, undergoing elective PCI	Aspirin 100 mg x 3 days followed by aspirin (100 mg/day) + clopidogrel (75 mg/day) from 7 days before stent implantation up to 12 months after the intervention	All patients received unfractionated heparin (5000 – 6000 IU or 700 IU/kg, i.v.) and antibiotic (1 g ceftazidim or 1.5 g cefuroxim, i.v.) before PCI The use of other cardiovascular drugs (beta-blockers, ACE inhibitors, Ca2+-channel blockers, diuretics) was allowed.

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
El Ghannudi, 2011 21524751 France NR	436 NR NR Mean/SD 65.0/12.4 yr	NR NR Prior stroke 4.6% Prior CABG 8.3% Stable angina or silent ischemia, 25.5% 8.5% Peripheral vascular disease 6.9% NR 32.8%/33.3%	Hyperlipidemia 51.6% 48.9 HTN 54.6% 32.4%	NR 100% 100% 72.2%	100% DES 47.9% Three vessel 31.0%	Patients undergoing PCI with stenting	Everyone received a loading dose (300 or 600 mg) of clopidogrel and aspirin	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
El Ghannudi, 2010 20630458 France NR	461 NR NR 65.4(55.8-75.4)	NR NR Stroke 20 (4.3) CABG 40 (8.7); PCI 130 (28.2) NR NR NR NR 81 (17.6) / 27 (5.9)	NR NR Stroke 20 (4.3) CABG 40 (8.7); PCI 130 (28.2) NR NR NR NR 81 (17.6) / 27 (5.9)	NR 100 100 314 (83.7)	NR NR NR	Patients undergoing PCI for ACS or stable CAD	loading dose (300 or 600 mg) of clopidogrel.	
Morel, 2011 21251579 France NR	440 NR 333 (75.7%) mean: 65.3	NR NR Stroke: 4.5% NR NR 9.3 NR NR STEMI: 16.8%	Hyperlipidemia: 52.5% Current: 40.3% HTN: 54.3% 37.5%	oral anticoagulants: 6.1% clopidogrel & aspirin: 100% clopidogrel & aspirin: 100% 69.8%	NR NR NR	Patients undergoing percutaneous coronary intervention (PCI) for ACS & CAD	clopidogrel. loading dose (300 or 600 mg)	

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Palmerini, 2010 19604542 Italy DOUBLE	48 NR 43 (90%) 63	NR NR NR NR NR 100% STEMI: 100%	hyperlipidemia: 44% present or previous: 67% HTN: 48% 17%	NR NR 100% 46%	NR NR Multivessel; 59%	Patients with STEMI	Clopidogrel: LD 300 mg; MD – 75 or 150 mg	Abciximab in the periprocedural period

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Schafer, 2011 21655677 Germany NR	54 NR 46 (85%) 64 ± 1 years (mean/SD)	NR NR NR NR NR 100% AMI; Family history of MI, 28% NR	NR 37% HTN 64% 17%	NR NR NR	93% DES 13%; BMS 80% NR	patients with acute STEMI admitted for coronary intervention	loading dose, 600 mg clopidogrel	
Frere, 2007 17938809 France NR	195 NR 158 (81) 63.4±11.1	NR NR NR NR NR NR NR	107 (54.9) 96 (49.2) 111(56.9) 68 (34.9)	NR 100 100 NR	NR NR NR	Patients had undergone successful coronary stenting	All patients received a 600 mg loading dose of clopidogrel and a 250 mg loading dose of aspirin administered at least 12 h before stenting. After PCI, patients received clopidogrel and aspirin 75 mg daily during one-month follow-up.	Anticoagulation was performed with low-molecular-weight heparin (enoxaparin), or unfractionated heparin if age over 75 years or in case of renal insufficiency (creatinin clearance < 60 ml/min).

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Kalantzi, 2012 21806493 Greece NR	40 NR 70 57.6±10.8	NR NR NR NR NR NR	hyper 40 57.5 HTN 60 0	NR NR NR NR	NR NR NR NR	patients with ACS with or without ST elevation	LD 325 mg aspirin+MD 100mg/day heparin 1mg/kg every 12 h LD 600mg clopidogrel+MD 75 mg/day	atorvastatin 40mg/day
Siller-Matula, 2012 22260716 Austria PEGASUS-PCI	416 NR 76 64±12	NR NR NR PCI 47 NR NR 13 31 18/NR	hyper 76 55 htn 84 32	NR 100 100 76	100 DES 99 NR	CAD patients undergoing PCI	clopidogrel LD 600mg, MD 75mg	NR

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Tselepis, 2011 22008470 Greece NR	74 NR 70 63.3±8.6	NR NR NR NR NR NR NR	NR NR NR NR	NR NR NR NR	NR NR NR	patients with ACS	aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day.	low-molecular-weight heparin (enoxaparin) was given subcutaneously (s.c) at a dose of 1mg/kg every 12 h until hospital discharge.
Gaglia, 2012 21919956 USA NR	200 69.5 72.5 63.5	NR 17.5 NR PCI=39.9/CABG-23% NR NR 14.6 NR NR	NR 29.5 87.4 34.8	NR NR NR NR	NR NR NR	CAD and ACS patients undergoing PCI & stenting	LD: 600 mg loading clopidogrel or 75-mg for 5 days MD: Aspirin + clopidogrel 75 mg for 1 month in patients with BMS and 12 months in patients receiving DES	NR

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Cuisset, 2011 21872198 France NR	689 NR 80.6 64.9	NR NR NR NR NR NR NR NR	55.9 37.2 57.9 28.4	NR NR NR 87.2	NR DES: 46.5 3 vessel: 20.8	PCI-STENT for ACS	LD: 250 mg aspirin and 600 mg clopidogrel MD: aspirin 75 mg and clopidogrel 150 mg/day	unfractionated heparin or 2.5 mg/day fondaparinux subcutaneously plus additional unfractionated heparin during PCI; glycoprotein IIb/IIIa antagonist

*Mean (standard deviation), unless otherwise stated.

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH= Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors

Appendix Table E46. Baseline characteristics of a mixed patient population with ischemic heart, cerebrovascular and peripheral vascular disease in studies assessing the predictive ability of VASP

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Reny, 2012 22615340 France and Switzerland ADRIE	771 NR 81 62.9	66 NR 13 NR NR 21 NR NR	36 75 NR 57 22	NR 99 85.5 29	NR NR NR	patients with symptomatic documented ischemic atherothrombotic disease (coronary artery disease, ischemic cerebrovascular disease, and/or peripheral artery disease)	non-enteric-coated aspirin and/or clopidogrel	NR

*Mean (standard deviation), unless otherwise stated

Appendix Table E47. Study design characteristics of studies assessing the predictive ability of VASP in patients with ischemic heart disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Freynhofer 2011 21614416 Austria NR	Prospective, registry data	NO	Consecutive	Adults undergoing PCI and coronary stenting with no contraindication for dual antiplatelet therapy for up to one year	May 2009 to February 2010	Total 6 month, mean/SD 189/68 days	Inpatient, then outpatient visits after discharge, at 1 mo and 6 mo	YES [YES]	Non-industry only
Siller- Matula, 2009 19135705 Austria NR	Prospective observational study	NO	NR	Patients undergoing PCI for coronary artery disease	Aug 2007-Apr 2008	1 day	followup after intervention	YES Accrual=100%	Non-industry [grant from the Jubiläumsfond of the Austrian National Bank (Nr. 12565)]
Blindt, 2007 18064332 Germany NR	prospective Cohort	No	Selected sample?	Patients with an elevated risk to develop ST acute MI within 48 hours undergoing emergency or elective PCI	NR	6 months	Department of cardiology in University Hospital Aachen inpatient	NR	NR
Kalantzi, 2011 21255245 Greece NR	prospective observational study	NO	NR	Patients with acute coronary syndromes (ACS), including those who have had a NSTEMI or have unstable angina)	NR	30 days f/u after discharge	Inpatient	NO	NR
Siller- Matula, 2010 19943879 Austria NR	Prospective observational	NO	Consecutive	Adults with CAD undergoing PCI with stenting (most elective) with clopidogrel and aspirin therapy	NR	Total, 6 months	Inpatient with followup after discharge (contacted patients at 3 and 6 mo after)	YES (YES—80%)	Nonindustry only
Bjelland, 2010 20727659 Norway NR	Prospective observational study	YES	Other (Patients were recruited through screening for participation in an RCT comparing two protocols for sedation analgesia in patients treated with therapeutic hypothermia)	Patients with suspected ACS treated with therapeutic hypothermia	Apr 2008 – May 2009	Max 3 days	Inpatient (Emergency room)	NO	Non-industry (Grant from the medical student research programme at the Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Norway & grant from Trondheim University Hospital, Trondheim, Norway.)

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Bonello, 2007 17488353 France NR	prospective cohort	No	Consecutive	Patients admitted for PCI	Nov 2004- Nov 2005	6-month	Cardiology department of the university hospital	NR	NR
Djukanovic, 2008 18719318 Serbia NR	Prospective observational study	NO	NR	Patients with ischemic heart disease, undergoing elective PCI	NR	1 year	NR	NR	non-industry (Ministry of Science, Republic of Serbia)
EI Ghannudi, 2011 21524751 France NR	Prospective	NO	Consecutive	Patients undergoing PCI with stenting	Sept 2007- Dec 2008	Mean/SD 9/2 mo Range 6-14 mo (end of study June 30, 2009)	Inpatient for stenting and then outpatient followup via questionnaire and phone	NR	NR
EI Ghannudi, 2010 20630458 France NR	prospective Cohort	No	Consecutive patients	Patients undergoing PCI for ACS or stable CAD	Sep 2007, Dec 2008	Mean 9 months	Hospital inpatient	NR	NR
Morel, 2011 21251579 France NR	Prospective	NO	Consecutive	Patients undergoing percutaneous coronary intervention (PCI) for ACS & CAD	Sep 2007 – dec 2008	mean:9± 2 months	followup after intervention	NR	NR [Authors report no conflict]
Palmerini, 2010 19604542 Italy DOUBLE	Prospective; 2 arms of an RCT are separate cohorts	NO	RCT	Patients with STEMI	NR	Max 1 month	Followup after intervention	YES; Accrual > 80%	Non-industry [Fondazione Fanti Melloni, Bologna, Italy]
Schafer, 2011 21655677 Germany NR	Prospective	NO	Consecutive	patients with acute STEMI admitted for coronary intervention	November 2008 and May 2009	Total 12 months	Inpatient for PCI; outpatient followup for 1 yr afterward	NO	NR but one author has a COI from funding from industry

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Frere, 2007 17938809 France NR	Prospective observational	No	Selected patients with coronary stenting	Patients had undergone successful coronary stenting	March 2005- may 2006	1 month follow up	Department of Cardiology	NR	NR
Kalantzi, 2012 21806493 Greece NR	prospective	no	NR	patients with ACS with or without ST elevation	NR	30 days	single center	NR	NR
Siller- Matula, 2012 22260716 Austria PEGASUS- PCI	prospective cohort	no	consecutive	patients undergoing PCI	March 2007- Nov, 2009	12 months	inpatient and then followup	yes, 80%	Austrian National Bank
Tselepis, 2011 22008470 Greece NR	NR	no	consecutive	ACS patients underwent PCI	NR	30 days	NR	NR	NR
Gaglia, 2012 21919956 USA NR	prospective	no	NR	PCI-STENT for ACS and CAD	October 2009 to September 2010	3 days	inpatient	no	NR
Cuisset, 2011 21872198 France NR	prospective	no	consecutive	PCI-STENT for ACS	June 2008 to January 2011	1 month	followup after intervention	no	NR

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; CAD = coronary artery disease; MI = myocardial infarction; NSTE = non-ST-elevation; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; DES=drug eluting stent; CABG=coronary artery bypass grafting; AA= arachidonic acid; SD=standard deviation; RCT=randomized controlled trial; NR=not reported

Appendix Table E48. Study design characteristics of studies assessing the predictive ability of VASP in a mixed patient population with ischemic heart, cerebrovascular and peripheral vascular disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enroment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Reny, 2012 22615340 France and Switzerland ADRIE	prospective Cohort	yes	Consecutive patients	symptomatic documented ischemic atherothrombotic disease (coronary artery disease, ischemic cerebrovascular disease, and/or peripheral artery disease)	June 2006 - December 2008	6 months	inpatient, then followup	yes (yes)	Non-industry only

Appendix Table E49. Phenotypic test details in studies assessing the predictive ability of VASP in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Freyenhofer, 2011 21614416 Austria NR	Flow cytometric analysis of VASP phosphorylation Platelet VASP kit Biocytex, Marseille, France	ADP	Venous blood samples along with the routine blood samples were collected via atraumatic venipuncture of the forearm into coagulation tubes buffered sodium citrate 3.2% 6-24 h (morning) after PCI 48 hours after blood collection	VASP result: PRI≤60.2% (low reactivity, good response) VASP result: PRI>60.2% (high reactivity, poor response)	ROC curve (area under the ROC-curve was 0.683 (p=0.014) for the platelet reactivity index (PRI) calculated from median fluorescence intensities (FI) with an optimal cut-off at 60.2% PRI.)	VASP result: PRI≤60.2% (low reactivity, good response): 114/300 (38%) VASP result: PRI>60.2% (high reactivity, poor response): 186/300 (62%)
Siller-Matula, 2009 19135705 Austria NR	Flow cytometric analysis of VASP phosphorylation Platelet VASP kit Biocytex, Marseille, France	Adenosine diphosphate (ADP), prostaglandin (PGE1)	1st blood sample: in catheterization laboratory, after PCI and after 250 mg IV aspirin ; 2nd blood sample: 20-24 hours after PCI 3.8% citrate NR; Clopidogrel came first 0.04 days (1 hour)	Platelet reactivity index ≥ 69% by VASP (? Low efficiency) Platelet reactivity index <69% by VASP	Based on normal ranges as reported by manufacturer	Platelet reactivity index ≥ 69% by VASP (? Low efficiency): 8 (27%) Platelet reactivity index <69% by VASP: 22 (63%)
Blindt, 2007 18064332 Germany NR	Flow cytometric analysis of VASP phosphorylation NR Biocytex, Marseille, France	10 µM ADP	blood samples were obtained 72–96 h after stent placement Citrate Interval at least 8 days. NR	VASP-platelet reactivity indices (VASP-PRI) > 48% VASP-platelet reactivity indices (VASP-PRI) < 48%	ROC curve revealed VASP PRI <48% be the best cut-off	VASP-platelet reactivity indices (VASP-PRI) > 48%: NR VASP-platelet reactivity indices (VASP-PRI) < 48%: NR

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Kalantzi, 2011 21255245 Greece NR	Flow cytometric analysis of VASP phosphorylation NR Biocytex, Marseille, France	ADP	Pre-clopidogrel, 5 days after clopidogrel, 30 days after clopidogrel Citrate 5 days; the pre-clopidogrel sampling was not used for estimation of responder status NR	Non-responders (VASP platelet reactivity index [PRI] ≥50%) Responders (VASP PRI < 50%)	Based on literature; Proposed previously [Ref #6] and also associated with adverse clinical outcome [ref #4]	Non-responders (VASP platelet reactivity index [PRI] ≥50%): 46 (75.4%) Responders (VASP PRI < 50%): 15 (24.6%)
Siller-Matula, 2010 19943879 Austria NR	Flow cytometric analysis of VASP phosphorylation NR Biocytex, Marseille, France	ADP	Blood samples obtained from arterial sheath 3.8% citrate Dose first (clopidogrel loading dose given at least 2 hr before PCI); Samples taken directly after PCI and at least 5 min after IV aspirin dose (250 mg). NR	Clopidogrel responders (PRI<42%) Clopidogrel nonresponders (PRI≥42%)	ROC optimal cutoffs for prediction of definite stent thrombosis at 6 m, as done in this study	Clopidogrel responders (PRI<42%): 154 (37%) Clopidogrel nonresponders (PRI≥42%): 262 (64%)
Bjelland, 2010 20727659 Norway NR	Dual flow cytometry PLT VASP/P2Y12 Biocytex, France	ADP	Whole blood; Day 1 and Day 3 after clopidogrel administration citrate Day 1: Median 21 hrs [IQR: 17.5-27.5] Day 1: Median 68 hrs [IQR: 63-72] NR	Satisfactory clopidogrel effect (Platelet reactivity index <0.5) Unsatisfactory clopidogrel effect (Platelet reactivity index ≥0.5)	Based on literature	Satisfactory clopidogrel effect (Platelet reactivity index <0.5): 0 (0%) Unsatisfactory clopidogrel effect (Platelet reactivity index ≥0.5): 25 (100%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Bonello, 2007 17488353 France NR	VASP Platelet VASP kits Diagnostica Stago,Asnieres, France	ADP and/or prostaglandin E1 (PGE1)	Blood samples for PRI testing were drawn before PCI and at least 24 h after clopidogrel loading dose and aspirin 3.8% trisodium citrate 24 hours 24 hours	Quintile 1 (<47%) vs Quintile 2-4	70% is normal range using ROC curve.	Quintile 1 (<47%) : 29 vs Quintile 2-4: 115
Djukanovic, 2008 18719318 Serbia NR	Flow cytometric analysis of VASP phosphorylation Platelet VASP kit Diagnostica Stago (Biocytex), Asnières, France	PGE1 and ADP	Whole blood; Collection time NR 0.129 M sodium citrate NR NR	At Day 2: Rapid response (Platelet reactivity index ≤50% at 2 days) Not rapid response (Platelet reactivity index >50% at 2 days) At Day 7: Good responders (Platelet reactivity index ≤50% at Day 7): NR (Difficult to extract from Fig 2B) Bad responders (Platelet reactivity index >50% at Day 7)	Based on literature	Rapid response (Platelet reactivity index ≤50% at 2 days): 7/17 (41.2%) Not rapid response (Platelet reactivity index >50% at 2 days): 10/17 (58.8%) Good responders (Platelet reactivity index ≤50% at Day 7): NR (Difficult to extract from Fig 2B) Bad responders (Platelet reactivity index >50% at Day 7): NR (Difficult to extract from Fig 2B)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
El Ghannudi, 2011 21524751 France NR	Flow cytometric analysis of VASP phosphorylation Platelet VASP kit Diagnostica Stago (Biocytex), Asnières, France	ADP	Whole blood samples were drawn by venous puncture 0.129 M sodium citrate Blood taken at least 6 h after clopidogrel, mean interval ~24 h, and range 12-120 h Sent to Alsace laboratory for VASP immediately after sample obtained but interval NR	Non-diabetic responders (NDM- R) (PRI <61%) Non-diabetic low responders (NDM-LR) (PRI≥61%) Diabetic responders (DM-R) (PRI<61%) Diabetic low responders (DM- LR) (PRI≥61%) [NB outcome data available for only 429 of the 436 (98.4%) but NR why] Also some data reported for groups with cutoff at 60%, not 61%, but no explanation given	Based on literature (Ref 7)	Non-diabetic responders (NDM-R) (PRI <61%) 177 (64.8%) Non-diabetic low responders (NDM-LR) (PRI≥61%) 96 (35.2%) Diabetic responders (DM-R) (PRI<61%) 85 (52.1%) Diabetic low responders (DM- LR) (PRI≥61%) 78 (47.9%)
El Ghannudi, 2010 20630458 France NR	Flow cytometric analysis of VASP phosphorylation Platelet VASP kit Diagnostica Stago (Biocytex), Asnières, France	ADP	Blood samples drawn at least 6 h after a loading dose (300 or 600 mg) of clopidogrel. 0.129 mol/L sodium Citrate 6 h after a loading dose (300 or 600 mg) of clopidogrel. NR	Low responder (PRI≥61%) Responder (PRI≥61%)	Based on an ROC curve from data on subjects in this study	Low responder (PRI≥61%): N=184 Responder (PRI≥61%): N=277

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Morel, 2011 21251579 France NR	Flow cytometric analysis of VASP phosphorylation Platelet VASP kit Diagnostica Stago (Biocytex), Asnières, France	prostaglandin E1 (PGE1) or ADP	after PCI 0.129 M sodium citrate 0.25 (6 hours after loading dose) NR [It is reported that the samples were sent off immediately for analysis]	Low responders (PRI≥ 61%) Normal responders (PRI<61%) By Quartile: Quartile 1 (<40.30%) Quartile 2 (40.30%–55.83%) Quartile 3 (55.84%–70.25%) Quartile 4 (>70.25%)	Single PRI cutoff based on literature; quartile cutoffs not explicitly reported	Low responders (PRI≥ 61%): 173 (40%) Normal responders (PRI<61%): 260 (60%) Quartile 1 (<40.30%): 108 (25%) Quartile 2 (40.30%–55.83%): 108 (25%) Quartile 3 (55.84%– 70.25%):108 (25%) Quartile 4 (>70.25%): 109 (25%)
Palmerini, 2010 19604542 Italy DOUBLE	VASP Phosprylation VASP kit Biocytex, Marseille, France	ADP 20 µmol/L	1-2 hrs after ingestion of last clopidogrel dose done at baseline, 1 week and 1 month Citrate NR [clopidogrel] 0.02 [30 minutes]	Poor responders (PRI>50%) in clopidogrel 75 mg group Normal responders (PRI between 30-50%) in clopidogrel 75 mg group Poor responders (PRI>50%) in clopidogrel 150 mg group Normal responders (PRI between 30-50%) in clopidogrel 150 mg group	Based on literature	Poor responders (PRI>50%) in clopidogrel 75 mg group: 21 (87.5%) Normal responders (PRI between 30-50%) in clopidogrel 75 mg group : 3 (12.5%) Poor responders (PRI>50%) in clopidogrel 150 mg group: 20 (83.3%) Normal responders (PRI between 30-50%) in clopidogrel 150 mg group: 4 (16.7%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Schafer, 2011 21655677 Germany NR	Flow cytometric analysis of VASP phosphorylation Platelet VASP/P2Y12 kit Biocytex, Marseille, France	ADP	NR NR 24 hours after loading with 600 mg clopidogrel NR	PRI >50% (suboptimal inhibition; impaired clopidogrel responsiveness) PRI ≤ 50% 14 (26%) PRI quartiles: <51%, 51-58%, 59-71%, and >71% PRI >57% PRI ≤57%	>50% vs. ≤50% was based on literature 57% threshold based on ROC analysis in present study	PRI >50% (suboptimal inhibition; impaired clopidogrel responsiveness): 40 (74%) PRI ≤50%: 14 (26%) PRI quartiles: <51%, 51-58%, 59-71%, and >71%: FrequencyNR PRI >57%: 40 (74%) PRI ≤57%: 14 (26%)
Frere, 2007 17938809 France NR	Flow cytometric analysis of VASP phosphorylation Platelet VASP/P2Y12 kit Biocytex, Marseille, France	PGE1 and ADP	before the PCI at least 12 h after the loading dose of clopidogrel and aspirin, and before administration of tirofiban if needed. 3.8% trisodium citrate After 12hours after the loading dose of clopidogrel With 1 hour	VASP PRI ≥ 53% VASP PRI < 53%	As per the ROC curve created using data from study subjects	VASP PRI ≥ 53%: 13/106 (12.3%) VASP PRI < 53%: 1/89 (1.1%)
Kalantzi, 2012 21806493 Greece NR	VASP VASP/P2Y12 kit (BioCytex, Marseille, France)	ADP 2.5, 5 and 10uM ADP ADP	Citrated blood samples were collected after the patient's presentation at the emergency room before clopidogrel administration (baseline), as well as at 5- and 30-days after clopidogrel loading. citrate 5 days 30 days	nonresponder VASP PRI >50% responder VASP PRI <50%	reference 15, 23	nonresponder n=12 responder n=28

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Siller-Matula, 2012 22260716 Austria PEGASUS-PCI	VASP Platelet VASP; BioCytex, Marseille, France	ADP	Blood samples from patients were obtained from the arterial sheath (6F) in the catheterization laboratory directly post-PCI and at least 5 min after intravenous infusion of aspirin. 3.8% sodium citrate NR performed up to 24 h after blood sampling	Clopidogrel non-responder according to MEA (≥ 48 U) Clopidogrel responder according to MEA (< 48 U) n = 321 (80%)	ref 16, 28	non-responder n = 81 (20%) responder n = 321 (80%)
Tselepis, 2011 22008470 Greece NR	VASP FACS Calibur flow cytometer Becton Dickinson, san Jose, CA, USA VASP/P2Y12 kit (BioCytex, Marseille,France)	ADP+PGE1 (prostaglandin E1)	Blood samples were obtained from all patients before clopidogrel loading (baseline) as well as at 5 and 30 days afterwards. NR 0, 5 and 30 days 3h after blood sampling	clopidogrel responders PRI 50% as cutoff	reference 21	clopidogrel responder n=57 non-responder n=17
Gaglia, 2012 21919956 USA NR	VASP FACS Calibur flow cytometer Becton Dickinson, san Jose, CA, USA VASP/P2Y12 kit (BioCytex, Marseille,France)	ADP+PGE1 (prostaglandin E1)	6 hours following a loading dose of clopidogrel 3.2% sodium citrate 6 hours 6 and 24 hours following PCI	PRI>50% PRI≤50%	Based on literature	PRI>50%: 79 PRI≤50%: 121

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Cuisset, 2011 21872198 France NR	VASP Platelet VASP; BioCytex, Marseille, France	ADP	≥12 hours after the loading dose of aspirin and clopidogrel 3.8% trisodium citrate 12 hrs NR	PRI>50% PRI≤50%	NR	PRI>50%: 331 PRI≤50%: 358

*If more than one test, use separate rows

**E.g., nonresponsive vs. responsive to clopidogrel, high vs. low platelet reactivity

Abbreviations: ADP= adenosine 5’-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported

Appendix Table E50. Phenotypic test details in a single study assessing the predictive ability of VASP in patients with ischemic heart, cerebrovascular and peripheral vascular disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Reny, 2012 22615340 France and Switzerland ADRIE	VASP FACS Calibur flow cytometer Becton Dickinson, san Jose, CA, USA VASP/P2Y12 kit (BioCytex, Marseille, France)	ADP+PGE1 (prostaglandin E1)	Blood samples collected after antiplatelet therapy intake 0.105 mol/L sodium citrate (1 vol/9 vol) 3 hrs NR	PRI ≥50% PRI <50%	Based on literature	≥50%: 226 <50%: 221

Appendix Table E51. Results from studies assessing the ability of VASP to predict death in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Freyenhofer, 2011 21614416 Austria NR	Clopidogrel+aspirin	VASP	CV death		6-month	PRI>60.2% (high reactivity, poor response) N=186		7	OR (calculated)=4.41	0.5-36.4	P=0.167 (poor vs good response) [Fisher's exact]	NR	NR	Get n's from Fig 1 (pasted in on last page of this form)
						VASP result: PRI≤60.2% (low reactivity, good response) N=114		1						Get n's from Fig 1 (pasted in on last page of this form)
Bonello, 2007 17488353 France NR	clopidogrel LD 300-mg followed by 75 mg daily	VASP	Death of cardiovascular origin	Death of cardiovascular origin	6-month	Quintile 1 N=28	Death of cardiovascular origin	0	OR (calculated)=0.57	0-11.3	P=0.711 (Q1 vs Q2-5) [Fisher's exact]	NR	NR	
						Quintiles 2-4 N=116		3(2.6%)						
Ei Ghannudi, 2011 21524751 France NR	Clopidogrel + aspirin	VASP	Cardiac death	any death with a demonstrable cardiovascular cause or any death which was not clearly attributable to a non-cardiovascular cause	Any point during study period	non-diabetic responders (NDM-R) (PRI <61%)	Cardiac death	4 (4.2%)	HR 1.74	0.43–7.00)	0.43 (univariate analysis) 0.004 across all 4 phenotypic groups with 61% cutoff (log-rank test)	NR	NR	Get survival curves from Fig 2 for each of the 4 phenotypic groups

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						non-diabetic low responders (NDM-LR) (PRI≥61%)		4 (2.3%)						
						PRI > 50% (LR to clopidogrel) in patients without diabetes			HR 1.38	0.33–5.81	0.66 (univariate analysis)			
						diabetic responders (DM-R) (PRI<61%)		2 (2.4%)						
						diabetic low responders (DM-LR) (PRI≥61%)		9 (12.2%)	HR 5.798	1.25–26.86	0.025 (univariate analysis)			
						Same as just above except multivariate			HR 6.09	1.27–29.08	0.02 (MULTIvariate analysis)			
						PRI > 50% (LR to clopidogrel) in patients with diabetes			HR 2.81	0.60–13.02	0.19 (univariate analysis)			
			Total death			non-diabetic responders (NDM-R) (PRI <61%)		5 (5.3%)			0.003 across all 4 phenotypic groups with 61% cutoff (log-rank test)			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						non-diabetic low responders (NDM-LR) (PRI≥61%)		6 (3.4%)	HR 1.53	0.47–5.04	0.48 (univariate analysis)			
						diabetic responders (DM-R) (PRI<61%)		3 (3.5%)						
						diabetic low responders (DM-LR) (PRI≥61%)		11 (14.9%)	HR 3.84	1.04–14.23	0.04 (univariate analysis)			
						Same as just above but multivariate analysis			4.42	1.12–17.40	0.03 (MULTIvariate analysis)			
						PRI > 50% (LR to clopidogrel) in patients without diabetes			HR 1.56	0.45–5.37	0.48 (univariate analysis)			
						PRI > 50% (LR to clopidogrel) in patients with diabetes			HR 1.86	0.50–6.89	0.35 (univariate analysis)			
EI Ghannudi, 2010 20630458 France NR	Clopidogrel LD 300 or 600mg	VASP	Total death	Total death	9 months	Low responders N=178	Total death	17 (9.6%)	NR	NR	0.005 (low responder vs responder)	NR	NR	
						Responders N=275		9 (3.3%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel LD 300 or 600mg	VASP	Cardiac death	Cardiac death	9 months	Low responders N=178	Cardiac death	14 (7.9%)	NR	NR	0.004 (low responder vs responder)	NR	NR	
						Responders N=275		6 (2.2%)						
	Clopidogrel LD 300 or 600mg	VASP PRI	Cardiac death	Cardiac death	9 months	PRI≥61%	Cardiac death	NR	HR=3.65	1.40-9.50	0.008 (≥61% vs <61%) [Cox regression]	No	NR	Figure 2 and figure 3Kaplan-Meier analysis for cardiac survival
						PRI≥50%	Cardiac death	NR	HR=2.22	0.80-6.12	0.12 (≥50% vs <50%) [Cox regression]	No	NR	
						PRI≥69%	Cardiac death	NR	HR=2.42	1.00-5.85	0.049 (≥69% vs <69%) [Cox regression]	No	NR	
	Clopidogrel LD 300 or 600mg	VASP PRI	Cardiac death	Cardiac death	9 months	PRI≥61%	Cardiac death	NR	HR=4.0	1.08-14.8	0.037 (≥61% vs <61%) [Cox regression]	Yes, variables with p<0.1 in univariate analysis were entered into a stepwise ascending multivariate analysis	NR	
	Clopidogrel LD 300 or 600mg	VASP PRI	Total death	Total death	9 months	PRI≥61%	Total death	NR	HR=2.71	1.18-6.2	0.02 (≥61% vs <61%) [Cox regression]	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					9 months	PRI≥50%	Total death	NR	HR=1.86	0.77-4.51	0.17	No	NR	
					9 months	PRI≥69%	Total death	NR	HR=1.85	0.8-4.24	0.15	No	NR	
Morel, 2011 21251579 France NR	clopidogrel 300-600 mg LD	VASP	Cardiac death	any death with demonstrable cardiovascular cause or any death that was not clearly attributable to a noncardiovascular cause	mean 9±2 months	low responders (PRI≥ 61%)	Cardiac death	14 (8.1%)	HR=3.66	1.4-9.53	P=0.008 (low vs normal) [Cox regression]	NO	NR	Primary
						normal responders (PRI<61%)		6 (2.3%)						
	clopidogrel 300-600 mg LD	VASP	Cardiac death	any death with demonstrable cardiovascular cause or any death that was not clearly attributable to a noncardiovascular cause	mean 9±2 months	low responders (PRI≥ 61%)	Cardiac death	14 (8.1%)	HR=11.96	1.22-116.82	P=0.033 (low vs normal) [Cox regression]	YES; Killip class III–IV; Drug-eluting stent; PRI ≥61%; CKD	NR	Primary PRI>61% is entered twice in the model; could explain the large se
					mean 9±2 months	normal responders (PRI<61%)		6 (2.3%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 300-600 mg LD	VASP	Cardiac death	any death with demonstrable cardiovascular cause or any death that was not clearly attributable to a noncardiovascular cause		Quartile 1 (<40.30%)	Cardiac death	1 (3%)	NR	NR	P=0.023 (Q4 vs Q1-3) fishers exact	NO	NR	primary
						Quartile 2 (40.30%–55.83%)		1 (3.3%)						
						Quartile 3 (55.84%–70.25%)		5 (15.6%)						
						Quartile 4 (>70.25%)		7 (24.1%)						
	clopidogrel 300-600 mg LD	VASP	all-cause mortality	all-cause mortality	mean 9±2 months	low responders (PRI≥ 61%)	all-cause mortality	16 (9.2%)	NR	NR	P=0.019 (low vs normal) chi square	NO	NR	primary
						normal responders (PRI<61%)		9 (3.5%)						
	clopidogrel 300-600 mg LD	VASP	all-cause mortality	all-cause mortality	mean 9±2 months	Quartile 1 (<40.30%)	all-cause mortality	1 (3%)	NR	NR	P=0.019 (low vs normal) fishers exact	NO	NR	primary
						Quartile 2 (40.30%–55.83%)		1 (3.3%)						
						Quartile 3 (55.84%–70.25%)		5 (15.6%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Quartile 4 (>70.25%)		8 (27.6%)						
Schafer, 2011 21655677 Germany NR	Clopidogrel	VASP	cardiac death			>57% N=40		1	OR (calculated)=1.1	0-28.6	P=0.95 (>57 vs ≤ 57%) [Fisher's exact]	NR	NR	NR
						≤57% N=14		0	NR	NR	NR	NR	NR	NR
Gaglia, 2012 21919956 USA NR	LD: 600 mg loading clopidogrel or 75-mg for 5 days MD: Aspirin + clopidogrel 75 mg for 1 month in patients with BMS and 12 months in patients receiving DES	VASP	death	death	3 days	HPR with PRI>50% n=79	HPR	0	OR (calculated)=3.3	NR	0.6 (HPR vs NPR) [Fishers exact test]	No	NR	
						NPR with PRI>50% n=121		0						

Appendix Table E52. Results from studies assessing the ability of VASP to predict myocardial infarction in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Freyenhofer, 2011 21614416 Austria NR	Clopidogrel+aspirin	VASP	STEMI	STEMI	6 months	PRI>60.2% (high reactivity, poor response) N=186	STEMI	3	OR (calculated)=4.37	0.2- 85.3	P=0.33 (>60.2 vs ≤ 60.2) [Fisher's exact]			Get n's from Fig 1 (pasted in on last page of this form)
						VASP result: PRI≤60.2% (low reactivity, good response) N=114		0						Get n's from Fig 1 (pasted in on last page of this form)
Djukanovic, 2008 18719318 Serbia NR	clopidogrel 75 mg + Aspirin 100 mg	VASP phosphorylation	Periprocedural MI	NR	1 year	Bad responder N=17	Periprocedural MI	0	OR(calculated)= 1	NR	P= 1.0 (bad vs good responder) [Fisher's exact]	NR	NR	NR
						Good responder N=17		0	NR	NR	NR	NR	NR	NR
	clopidogrel 75 mg + Aspirin 100 mg	VASP phosphorylation	Myocardial Infarction	NR	1 year	Bad responder N=17	Myocardial Infarction	0	OR(calculated)= 1	NR	P= 1.0 (bad vs good responder) [Fisher's exact]	NR	NR	NR
						Good responder N=17		0	NR	NR	NR	NR	NR	NR

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
El Ghannudii, 2011 21524751 France NR	Clopidogrel + aspirin	VASP	STEMI			non-diabetic responders (NDM-R) (PRI <61%)		1 (1.1%)			0.86 across this and next 3 rows (log rank)			
						non-diabetic low responders (NDM-LR) (PRI≥61%)		3 (1.7%)						
						diabetic responders (DM-R) (PRI<61%)		2 (2.4%)						
						diabetic low responders (DM-LR) (PRI≥61%)		2 (2.7%)						
			NSTEMI			non-diabetic responders (NDM-R) (PRI <61%)		6 (6.3%)			0.41 across this and next three rows (log rank)			
						non-diabetic low responders (NDM-LR) (PRI≥61%)		5 (2.9%)						
						diabetic responders (DM-R) (PRI<61%)		6 (7.1%)						
						diabetic low responders (DM-LR) (PRI≥61%)		5 (5.4%)						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
El Ghannudi, 2010 20630458 France NR	Clopidogrel LD 300 or 600mg	VASP	STEMI	STEMI	9 months	Low responders N=178	STEMI	3 (1.7%)	NR	NR	1.00 (low responder vs responder)	NR	NR	
						Responders N=275		5 (1.8%)						
	Clopidogrel LD 300 or 600mg	VASP	NSTEMI	NSTEMI	9 months	Low responders N=178	NSTEMI	11(6.2%)	NR	NR	0.39 (low responder vs responder)	NR	NR	
						Responders N=275		12 (4.4%)						
Morel, 2011 21251579 France NR	clopidogrel 300- 600 mg LD	VASP	STEMI	new or presumably new ST- segment elevation in 2 consecutive leads associated with an increase in biochemical markers of myocardial necrosis	mean 9±2 months	low responders (PRI≥ 61%)	STEMI	3 (1.7%)	NR	NR	P=1 (low vs normal) chi square	NO	NR	primary
						normal responders (PRI<61%)		5 (1.9%)						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 300- 600 mg LD	VASP	STEMI	new or presumably new ST- segment elevation in 2 consecutive leads associated with an increase in biochemical markers of myocardial necrosis	mean 9±2 months	Quartile 1 (<40.30%)	STEMI	1 (3%)	NR	NR	P=1 (low vs normal) fishers exact	NO	NR	primary
						Quartile 2 (40.30%– 55.83%)		1 (3.3%)						
						Quartile 3 (55.84%– 70.25%)		1 (3.1%)						
						Quartile 4 (>70.25%)		1 (3.4%)						
	clopidogrel 300- 600 mg LD	VASP	NSTEMI	occurrence of ischemic symptoms, STsegment depression and/or T- wave abnormalities, and an increase of biochemical markers of myocardial necrosis	mean 9±2 months	low responders (PRI≥ 61%)	NSTEMI	11 (6.4%)	NR	NR	P=0.513 (low vs normal) chi square	NO	NR	primary

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						normal responders (PRI<61%)		12 (4.6%)						
	clopidogrel 300- 600 mg LD	VASP	NSTEMI	occurrence of ischemic symptoms, STsegment depression and/or T- wave abnormalities, and an increase of biochemical markers of myocardial necrosis	mean 9±2 months	Quartile 1 (<40.30%)	NSTEMI	1 (3%)	NR	NR	P=0.906 (low vs normal) fishers exact	NO	NR	primary
						Quartile 2 (40.30%– 55.83%)		1 (3.3%)						
						Quartile 3 (55.84%– 70.25%)		2 (6.3%)						
						Quartile 4 (>70.25%)		1 (3.4%)						
Schafer, 2011 21655677 Germany NR	Clopidogrel	VASP	nonfatal myocardial infarction			>57%		3	OR (calculate)= 2.71	0.1- 55.7	P=0.52 (>57% vs ≤57%) [Fisher's exact]	NR	NR	NR
						<=57%		0	NR	NR	NR	NR	NR	NR

Appendix Table E53. Results from studies assessing the ability of VASP to predict stent thrombosis in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Freyenhofer, 2011 21614416 Austria NR	Clopidogrel + aspirin	VASP	Definite or probable stent thrombosis	Definite or probable stent thrombosis		PRI>60.2% (high reactivity, poor response) n=186	Stent thrombosis	5	OR (calculated)= 6.94	0.4-136.7	P=0.19 (>60.2% vs ≤60.2) [Fisher's exact]			Get n's from Fig 1 (pasted in on last page of this form)
						VASP result: PRI≤60.2% (low reactivity, good response) n=114		0						Get n's from Fig 1 (pasted in on last page of this form)
Blindt, 2007 18064332 Germany NR	75 mg clopidogrel	VASP-PRI	Stent thrombosis	Stent thrombosis	6 months	NR	Stent thrombosis	NR	OR=1.112	1.041-1.188	0.002	No	NR	
	75 mg clopidogrel	VASP-PRI	Stent thrombosis	Stent thrombosis	6 months	NR	Stent thrombosis	NR	OR=1.164	1.008-1.334	0.039	Yes, variables with P<0.01 in the univariable analysis	NR	
Siller-Matula, 2010 19943879 Austria NR	Clopidogrel + aspirin	VASP	Definite stent thrombosis	Defined by ARC as ACS with angiographic or pathologic confirmation of thrombosis	Within 6 mo after stenting	Response vs. nonresponse to clopidogrel	Definite Stent thrombosis	NR	AUC, 0 .60 (SE 0.10) ROC cutoff, 42% Sensitivity 100% and specificity 37%; PPV 1%, NPV 100%; positive likelihood ratio,.1.6	For AUC, 0.39-0.80	0.547	NR	NR	NONE

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Response to clopidogrel N=145	Definite Stent thrombosis	0	OR (calculated)=4.00	NR	P=0.36 (nonresponse vs response) [Fisher's exact test]]	NR	NR	Data also given for MEA+VASP in Fig 3
						Nonresponse to clopidogrel N=257		3						Data also given for MEA+VASP in Fig 3
Siller-Matula, 2010 19943879 Austria NR	Clopidogrel+aspirin	VASP	Composite of definite or probable stent thrombosis	Probable defined any unexplained death within 30 days or target vessel MI without angiographic confirmation of thrombosis or other identified culprit lesion		Response vs. nonresponse to clopidogrel	Composite of definite or probable stent thrombosis	--	AUC, 0.53 (SE 0.94) ROC cutoff, 23% Sensitivity 100% and specificity 17%; PPV 2%, NPV 100%; positive likelihood ratio, 1.2	For AUC, 0.34-0.71	0.811	NR	NR	NONE
						Response to clopidogrel N=145	Composite of definite or probable stent thrombosis	2	OR (calculated)=1.42	0.3-7.4	P=0.68 (nonresponse vs response) [Fisher's exact test]]	NR	NR	Data also given for MEA+VASP in Fig 3
						Nonresponse to clopidogrel N=257		5	NR	NR	NR	NR	NR	Data also given for MEA+VASP in Fig 3
Siller-Matula, 2010 19943879 Austria NR	Clopidogrel+aspirin	VASP	Probable stent thrombosis	Probable stent thrombosis		Response to clopidogrel N=145	Probable stent thrombosis	2	OR (calculated)=0.56	0.1-4.0	P=0.57 (nonresponse vs response) [Fisher's exact test]]	NR	NR	Data also given for MEA+VASP in Fig 3

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Nonresponse to clopidogrel N=257		2	NR	NR	NR	NR	NR	Data also given for MEA+VASP in Fig 3
El Ghannudi, 2011 21524751 France NR	Clopidogrel + aspirin	VASP	Stent thrombosis definite	Stent thrombosis definite	9 months	non-diabetic responders (NDM-R) (PRI <61%)		2 (2.1%)	OR=1 (calculated)	0.5-2.0	0.09 across this and next 3 rows (log rank)			
						non-diabetic low responders (NDM-LR) (PRI ≥61%)		0 (0%)						
						diabetic responders (DM-R) (PRI <61%)		3 (3.5%)						
						diabetic low responders (DM-LR) (PRI ≥61%)		3 (3.9%)						
			Stent thrombosis probable			non-diabetic responders (NDM-R) (PRI <61%)		3 (3.2%)			0.61 across this and next 3 rows (log rank)			
						non-diabetic low responders (NDM-LR) (PRI ≥61%)		2 (1.1%)						
						diabetic responders (DM-R) (PRI <61%)		1 (1.2%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						diabetic low responders (DM-LR) (PRI≥61%)		2 (2.6%)						
			Stent thrombosis possible			non-diabetic responders (NDM-R) (PRI <61%)		0 (0%)			0.0001 across this and next 3 rows (log rank)			
						non-diabetic low responders (NDM-LR) (PRI≥61%)		0 (0%)						
						diabetic responders (DM-R) (PRI<61%)		1 (1.2%)						
						diabetic low responders (DM-LR) (PRI≥61%)		5 (6.6%)						
			Stent thrombosis any			non-diabetic responders (NDM-R) (PRI <61%)		4 (4.2%)			0.002 across this and next 3 rows (log rank)			
						non-diabetic low responders (NDM-LR) (PRI≥61%)		3 (1.7%)						
						diabetic responders (DM-R) (PRI<61%)		5 (5.9%)						
						diabetic low responders (DM-LR) (PRI≥61%)		10 (13.3%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
El Ghannudi, 2010 20630458 France NR	Clopidogrel LD 300 or 600mg	VASP	Definite stent thrombosis	Definite stent thrombosis	9 months	Low responders N=178	Definite stent thrombosis	5 (2.8%)	NR	NR	0.49 (low responder vs responder) [chi square]	NR	NR	
						Responders N=275		4 (1.5%)						
	Clopidogrel LD 300 or 600mg I	VASP	Probable stent thrombosis	Probable stent thrombosis	9 months	Low responders N=178	Probable stent thrombosis	5 (2.8%)	NR	NR	0.27 (low responder vs responder) [chi square]	NR	NR	
						Responders N=275		3 (1.1%)						
	Clopidogrel LD 300 or 600mg	VASP	Possible stent thrombosis	Possible stent thrombosis	9 months	Low responders N=178	Possible stent thrombosis	6 (3.3%)	NR	NR	0.017 (low responder vs responder) [chi square]	NR	NR	
						Responders N=275		1 (0.4%)						
	Clopidogrel LD 300 or 600mg	VASP	All stent thrombosis	All stent thrombosis	9 months	Low responders N=178	All stent thrombosis	15 (8.3%)	NR	NR	0.018 (low responder vs responder) [chi square]	NR	NR	
						Responders N=275		9 (3.3%)						
Morel, 2011 21251579 France NR	clopidogrel 300-600 mg LD	VASP	All stent thrombosis	According to the Academic Research Consortium criteria	mean 9±2 months	low responders (PRI≥ 61%)	All stent thrombosis	15 (8.7%)	NR	NR	P=0.086 (low vs normal) chi square	NO	NR	Secondary
						normal responders (PRI<61%)		8 (3.1%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 300-600 mg LD	VASP	All stent thrombosis	According to the Academic Research Consortium criteria	mean 9±2 months	Quartile 1 (<40.30%)	All stent thrombosis	1 (3%)	NR	NR	P=0.906 (low vs normal) fishers exact	NO	NR	Secondary
						Quartile 2 (40.30%–55.83%)		1 (3.3%)						
						Quartile 3 (55.84%–70.25%)		4 (12.6%)						
						Quartile 4 (>70.25%)		6 (20.6%)						
	clopidogrel 300-600 mg LD	VASP	Definite stent thrombosis	acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis	mean 9±2 months	low responders (PRI≥ 61%)	Definite stent thrombosis	5 (2.9%)	NR	NR	P=0.494 (low vs normal) chi square	NO	NR	Secondary
						normal responders (PRI<61%)		4 (1.5%)						
	clopidogrel 300-600 mg LD	VASP	Definite stent thrombosis	acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis	mean 9±2 months	Quartile 1 (<40.30%)	Definite stent thrombosis	1 (3%)	NR	NR	P=0.562 (low vs normal) fishers exact	NO	NR	Secondary
						Quartile 2 (40.30%–55.83%)		0						
						Quartile 3 (55.84%–70.25%)		0						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Quartile 4 (>70.25%)		1 (3.4%)						
	clopidogrel 300-600 mg LD	VASP	Probable stent thrombosis	unexplained death within 30 days or target vessel infarction without angiographic information	mean 9±2 months	low responders (PRI≥ 61%)	Probable stent thrombosis	5 (2.9%)	NR	NR	P=0.275 (low vs normal) chi square	NO	NR	Secondary
						normal responders (PRI<61%)		3 (1.2%)						
	clopidogrel 300-600 mg LD	VASP	Probable stent thrombosis	unexplained death within 30 days or target vessel infarction without angiographic information	mean 9±2 months	Quartile 1 (<40.30%)	Probable stent thrombosis	0	NR	NR	P=0.04 (low vs normal) fishers exact	NO	NR	Secondary
						Quartile 2 (40.30%–55.83%)		1 (3.3%)						
						Quartile 3 (55.84%–70.25%)		2 (6.3%)						
						Quartile 4 (>70.25%)		2 (6.9%)						
	clopidogrel 300-600 mg LD	VASP	Possible stent thrombosis	unexplained death within 30 days or target vessel infarction without angiographic information	mean 9±2 months	low responders (PRI≥ 61%)	Possible stent thrombosis	5 (2.9%)	NR	NR	P=0.110 (low vs normal) chi square	NO	NR	Secondary

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						normal responders (PRI<61%)		1 (0.4%)						
	clopidogrel 300-600 mg LD	VASP	Possible stent thrombosis	unexplained death within 30 days or target vessel infarction without angiographic information	mean 9±2 months	Quartile 1 (<40.30%)	Possible stent thrombosis	0	NR	NR	P=0.485 (low vs normal) fishers exact	NO	NR	Secondary
						Quartile 2 (40.30%–55.83%)		0						
						Quartile 3 (55.84%–70.25%)		2 (6.3%)						
						Quartile 4 (>70.25%)		3 (10.3%)						
Schafer, 2011 21655677 Germany NR	Clopidogrel	VASP	stent thrombosis	stent thrombosis	12 months	>57% N=40		0	OR (calculated)=0.35	NR	P=0.61 (>57% vs ≤ 57%)) [Fisher's exact]	NR	NR	NR
						≤57% N=14		0	NR	NR	NR	NR	NR	NR
Gaglia, 2012 21919956 USA NR	LD: 600 mg loading clopidogrel or 75-mg for 5 days MD: Aspirin + clopidogrel 75 mg for 1 month in patients with BMS and 12 months in patients receiving DES	VASP	stent thrombosis	stent thrombosis	3 days	HPR with PRI>50% n=79	HPR	0	OR (calculated)=3.3	NR	0.6 (HPR vs NPR) [Fishers exact test]	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						NPR with PRI>50% n=121		0						

Appendix Table E54. Results from studies assessing the ability of VASP to predict major adverse cardiovascular events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Freyrhofer, 2011 21614416 Austria NR	Clopidogrel+aspirin	VASP	MACE	MACE included: 1) definite and probable ST according to the ARC-definition; 2) cardiovascular death, defined as death associated with ACS, significant arrhythmia, or congestive heart failure; and 3) non-fatal STEMI (STEMI: acute onset of prolonged typical ischaemic chest pains, ST-segment elevation of at least 1 mm in 2 or more contiguous electrocardiogram leads and increased biomarkers of myocardial necrosis)	6 mo	PRI>60.2% (high reactivity, poor response) N=186	MACE	8.1%	NR	NR	NR	NR	NR	Get n's from Fig 1 (pasted in on last page of this form)
						VASP result: PRI≤60.2% (low reactivity, good response) N=114		0.9%	Relative risk reduction= 89%		0.007 (>60.2 vs ≤60.2)			Get n's from Fig 1 (pasted in on last page of this form)
						Cutoff 60.2%			AUC 0.683	NR	0.014			ROC curves in Fig 2

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Bonello, 2007 17488353 France NR	clopidogrel LD 300- mg followed by 75 mg daily	VASP	MACE	Cardiovascular death, ischemic stroke, recurrent ACS, and repeated revascularization either by coronary angioplasty or bypass surgery	6-month	Quintile 1 N=28	MACE	0	NR	NR	NR	NR	NR	
						Quintiles 2-5 N=144		21 (14.5)	OR (calculated)= 0.1	NR	P= 0.11 (Q2-5 vs Q1) [Fisher's exact]	NR	NR	
El Ghannudi 2011 21524751 France NR	Clopidogrel + aspirin	VASP	MACE	Not explicitly defined	9 months	non-diabetic responders (NDM-R) (PRI <61%)		15 (15.8%)			0.26 across all 4 phenotypic groups with 61% cutoff (log-rank test)			
						non-diabetic low responders (NDM-LR) (PRI≥61%)		23 (13.1%)	HR 1.06	0.55– 2.03	0.87 (univariate analysis)			
						PRI > 50% (LR to clopidogrel) in patients without diabetes			HR 1.15	0.60– 2.21	0.67 (univariate analysis)			
						diabetic responders (DM-R) (PRI<61%)		12 (14.1%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						diabetic low responders (DM-LR) (PRI≥61%)		17 (23%)	HR 2.01	0.96– 4.23	0.06 (univariate analysis)			
						Same as just above			HR 2.44	1.10– 5.39	0.027 (multivariate analysis)			
						PRI > 50% (LR to clopidogrel) in patients with diabetes			HR 1.28	0.59– 2.77	0.52 (univariate analysis)			
El Ghannudi, 2010 20630458 France NR	Clopidogrel LD 300 or 600mg	VASP	MACE	MACE	9 months	Low responders	MACE	35/178 (19.7)	NR	NR	0.06 (low responders vs responders)	NR	NR	
						responders		22/275 (13.1)						
	Clopidogrel LD 300 or 600mg	VASP PRI	MACE	MACE	9 months	PRI≥61%	MACE	NR	HR=1.54	0.97– 2.46	0.07 (low responders vs responders) [Cox regression]	No	NR	
						PRI≥50%	MACE	NR	HR=1.36	0.83– 2.22	0.22 (low responders vs responders) [Cox regression]	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						PRI≥69%	MACE	NR	HR=1.14	0.67- 1.92	0.64 (low responders vs responders) [Cox regression]	No	NR	
Morel, 2011 21251579 France NR	clopidogrel 300-600 mg LD	VASP	MACE	all-cause mortality, nonfatal myocardial infarction, or target lesion revascularization	mean 9±2 months	low responders (PRI≥ 61%)	MACE	35 (20.2%)	HR=1.54	0.96- 2.45	P=0.069 (low vs normal) [Cox regression]	NO	NR	Secondary
						normal responders (PRI<61%)		36 (13.8%)						
	clopidogrel 300-600 mg LD	VASP	MACE	all-cause mortality, nonfatal myocardial infarction, or target lesion revascularization	mean 9±2 months	low responders (PRI≥ 61%)	MACE	35 (20.2%)	HR=2.36	1.35- 4.15	P=0.003 (low vs normal) [Cox regression]	YES; Planned PCI; Drug-eluting stent;	NR	Secondary
						normal responders (PRI<61%)		36 (13.8%)						
	clopidogrel 300-600 mg LD	VASP	MACE	all-cause mortality, nonfatal myocardial infarction, or target lesion revascularization	mean 9±2 months	Quartile 1 (<40.30%)	MACE	5 (15.2%)	NR	NR	P=0.019 (low vs normal) fishers exact	NO	NR	Secondary
						Quartile 2 (40.30%– 55.83%)		3 (10%)						
						Quartile 3 (55.84%– 70.25%)		9 (31%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Quartile 4 (>70.25%)		7 (24.1%)						
Schafer,2011 21655677 Germany NR	Clopidogrel	VASP	combined cardiovascular endpoint consisting of cardiac death, nonfatal myocardial infarction, stent thrombosis, ischaemic stroke, and urgent target vessel revascularisation	NR	12 mo	<51% PRI (n is NR)	YES event	2	NR	NR	NR	NR	NR	NR
						51-58% PRI (n is NR)		2	NR	NR	NR	NR	NR	NR
						59-71% PRI (n is NR)		6	NR	NR	NR	NR	NR	NR
						>71% PRI (n is NR)		5	NR	NR	NR	NR	NR	NR
						>57%		5/40 (12%) [per data in rest of table, s/b 12, not 5 [see Table 2 in paper]]	HR = 4.3	1.3- 9.9	0.0136 (>57% vs ≤ 57%) [log rank]	NR	NR	K-M curve given in Fig. 2B
						≤57%		6/14 (41.4%) [per data in rest of table, s/b 3, not 6 [see Table 2 in paper]]	NR	NR	NR	NR	NR	K-M curve given in Fig. 2B

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
									AUC 0.69	0.53- 0.86	0.027			ROC curve in Fig. 2A
Frere, 2007 17938809 France NR	600 mg loading dose of clopidogrel and maintaining 75mg daily	VASP	CV event	CV death, acute or subacute stent thrombosis, recurrent ACS and stroke	30 days after PCI	≥53% N=106	CV event	13 (12.3%)	AUC: 0.73±0.08 OR (calculated)= 12.3	NR	P= 0.017 (>53 vs ≤ 53%) [Fisher's exact]	NR	NR	NR
						<53% N=89	CV event	1 (1.1%)						

Appendix Table E55. Results from studies assessing the ability of VASP to predict major adverse cardiovascular events in patients with ischemic heart, cerebrovascular and peripheral vascular disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Reny, 2012 22615340 France and Switzerland ADRIE	Clopidogrel+aspirin	VASP	MACE	acute MI, unstable angina, hospitalization for revascularization, acute limb ischemia, ischemic stroke, TIA, or CV death	6 months	HOPR n=226	MACE	44	HR=1.06	0.73-1.53	0.77 (HOPR vs normal PR) [cox regression]	NR	NR	K-M curve in Fig 2
						normal PR n=221		43						

Appendix Table E56. Results from studies assessing the ability of VASP to predict stroke in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Schafer, 2011 21655677 Germany NR	Clopidogrel	VASP	ischaemic stroke	Ischemic stroke	1 year	>57% (n=40)	Suboptima inhibition	1	OR(calculated)=1.1	NR	P=0.953 (>57% vs ≤ 57%) [Fisher's exact]	NR	NR	NR
						≤57% (n=14)		0	NR	NR	NR	NR	NR	NR

Appendix Table E57. Results from studies assessing the ability of VASP to predict other clinical events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Djukanovic, 2008 18719318 Serbia NR	clopidogrel 75 mg + Aspirin 100 mg	VASP phosphorylation	Revascularization	NR	1 year	Bad responder	Revascularization	0	OR (calculate)=1	NR	P=1.0 (bad vs good responder) [Fisher's exact test]	NR	NR	NR
						Good responder		0	NR	NR	NR	NR	NR	NR
Bonello, 2007 17488353 France NR	clopidogrel LD 300-mg followed by 75 mg daily	VASP	ACS	defined according to the ACC/AHA guidelines	6-month	Quintile 1	ACS	0	OR (calculate)=410	23.1-7306.8	P<0.0001 (Q1 vs Q2-5) [Fisher's exact test]	NR	NR	
						Quintiles 2-4		18(15.6)						
	clopidogrel LD 300-mg followed by 75 mg daily	VASP	PCI	PCI	6-month	Quintile 1	PCI	0	OR (calculate)=410	NR	P<0.0001 (Q1 vs Q2-5) [Fisher's exact test]	NR	NR	
						Quintiles 2-5		16(13.9)						
	clopidogrel LD 300-mg followed by 75 mg daily	VASP	Bypass surgery	Bypass surgery	6-month	Quintile 1	Bypass surgery	0	OR (calculate)=307	NR	P<0.0001 (Q1 vs Q2-5) [Fisher's exact test]	NR	NR	
						Quintiles 2-5		2(1.7)						
Ei Ghannudi, 2011 21524751 France NR	Clopidogrel + aspirin	VASP	Target lesion revascularization		9 months	non-diabetic responders (NDM-R) (PRI <61%)		9 (9.5%)	OR (calculate)=22	NR	P=0.04 (nonresponders vs responder) [Fisher's exact test]			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						non-diabetic low responders (NDM-LR) (PRI≥61%)		17 (9.7%)						
						diabetic responders (DM-R) (PRI<61%)		6 (7.1%)	OR=1 (calculated)	0.5-2	>=61% vs others			
						diabetic low responders (DM-LR) (PRI≥61%)		4 (5.4%)						
Schafer, 2011 21655677 Germany NR	Clopidogrel	VASP	urgent target vessel revascularisation		1 year	>57%		7/40	OR (calculate)=0.78	0.2- 3.5	P=0.71 (>57% vs ≤57%) [Fisher's exact test]	NR	NR	NR
						</=57%		3/14						

Appendix Table E58. Results from studies assessing the ability of VASP to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Siller-Matula, 2009 19135705 Austria NR	Clopidogrel 75 mg MD	VASP	VASP	PRI as measured by VASP	24 hrs after PCI	Platelet reactivity index \geq 69% by VASP (? Low efficiency)	Platelet reactivity index \geq 69% by VASP (? Low efficiency)	1	NR	NR	NR	0.27 (fisher's exact calculated from data)	NR	NR	Fig 1B
						Platelet reactivity index \geq 69% by VASP (? Low efficiency)	Platelet reactivity index $<$ 69%	7	NR	NR	NR	NR	NR	NR	
						Platelet reactivity index $<$ 69% by VASP	Platelet reactivity index \geq 69%	0	NR	NR	NR	NR	NR	NR	
						Platelet reactivity index $<$ 69% by VASP	Platelet reactivity index $<$ 69% by VASP	22	NR	NR	NR	NR	NR	NR	
Kalantzi 2011 21255245 Greece NR	Clopidogrel 300 mg loading & 75 mg/d	VASP at Day 5	Nonresponder by VASP	PRI \geq 50%	30 days	Nonresponder	Nonresponder	3	PRI \leq 50%	NR	NR	0.01264 (fisher's exact calculated from data)	N	NO	
						Nonresponder	Responder	12	NR	NR	NR	NR	NR	NR	NR
						Responder	Nonresponder	0	NR	NR	NR	NR	NR	NR	NR
						Responder	Responder	46	NR	NR	NR	NR	NR	NR	NR
Bjelland, 2010 20727659 Norway NR	Clopidogrel 300-600 mg LD + 75 mg MD	VASP Platelet reactivity index $<$ 0.5 at Day 1	Satisfactory Clopidogrel effect	Platelet reactivity index $<$ 0.5	Day 3	Satisfactory (PRI $<$ 0.5) at day 1	Satisfactory (PRI $<$ 0.5) at day 3	0	0.5	NR	NR	Not calculable as no patients had PRI $<$ 50% at baseline	NR	NR	
						Satisfactory (PRI \geq 0.5) at day 1	Unsatisfactory (PRI \geq 0.5 at day 3)	0							

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Unsatisfactory (PRI ≥0.5) at day 1	Unsatisfactory (PRI ≥0.5) at day 3	20							
						Unsatisfactory (PRI ≥0.5) at day 1	Satisfactory (PRI <0.5 at day 3)	5							
Djukanovic, 2008 18719318 Serbia NR	clopidogrel 75 mg + Aspirin 100 mg	VASP phosphorylation	Good response	PRI≤50%	7 days	Rapid response	Good response	NR	NR	NR	NR	NR	NR	NR	Text mentions that “all the patients with rapid response still had PRI ≤50% (good responders) on day 7” but actual numbers in each outcome group can only be obtained from digitized Fig 2B which is not clear
							Bad response	NR	NR	NR	NR	NR	NR	NR	
						Not Rapid response	Good response	NR	NR	NR	NR	NR	NR	NR	
							Bad response	NR	NR	NR	NR	NR	NR	NR	
Palmerini , 2010 19604542 Italy DOUBLE	Clopidogrel 300 mg LD + 75 mg MD	VASP	VASP	PRI>50% at 1 month	1 month	Poor responder	Poor responder	10	NR	NR	NR	1.0 (fisher's exact calculated from data)	NR	NR	
						Poor responder	Normal responder	11	NR	NR	NR	NR	NR	NR	
						Normal responder	Poor responder	2	NR	NR	NR	NR	NR	NR	
						Normal responder	Normal responder	1	NR	NR	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 300 mg LD + 150 mg MD	VASP	VASP	PI>50% at 1 month	1 month	Poor responder	Poor responder	3	NR	NR	NR	0.54 (fisher's exact calculated from data)	NR	NR	
						Poor responder	Normal responder	17	NR	NR	NR	NR	NR	NR	
						Normal responder	Poor responder	1	NR	NR	NR	NR	NR	NR	
						Normal responder	Normal responder	3	NR	NR	NR	NR	NR	NR	

Appendix Table E59. Results from studies assessing the ability of VASP to predict platelet reactivity during followup (when used as a continuous measurement) in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Kalantzi, 2011 21255245 Greece NR	Clopidogrel 300 mg loading & 75 mg/d	VASP at Day 5	Percent inhibition of maximum platelet aggregation (IPA,%)	Light transmittance aggregometry in platelet-rich plasma using 2.5 µM ADP & IPA achieved within 3 min	30 days	Non-responder	15	51.8%	NR	NR	NR	NR	NR	NR	NR	Value obtained from digitizing Fig1 One P value of 0.01 is reported between IPA values of 30 days vs 5 days but not specified for which ADP conc
					30 days	Responder	46	56.2%	NR	NR	NR	NR	NR	NR	NR	
			Percent inhibition of maximum platelet aggregation (IPA,%)	Light transmittance aggregometry in platelet-rich plasma using 5 µM ADP & IPA achieved within 3 min	30 days	Non-responder	15	40.9%	NR	NR	NR	NR	NR	NR	NR	
					30 days	Responder	46	50.6%	NR	NR	NR	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Percent inhibition of maximum platelet aggregation (IPA,%)	Light transmittance aggregometry in platelet-rich plasma using 10 µM ADP & IPA achieved within 3 min	30 days	Non-responder	15	30.4%	NR	NR	NR	NR	NR	NR	NR	
					30 days	Responder	46	35.5%	NR	NR	NR	NR	NR	NR	NR	
			P-selection expression (% positive cells)	Flow cytometry, using anti-CD62P-PE after activation with 100 µM of ADP (10 min, in static conditions at 37 °C)	30 days	Non-responder who underwent PCI	8	Median= 29	Range= 24,35	NR	NR	NR	NR	NR	NR	
					30 days	Non-responder who underwent conservative treatment	7	Median= 27	Range= 22,32	NR	NR	NR	NR	NR	NR	
					30 days	Responder	46	Median= 27	Range= 24,34	NR	NR	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Platelet/ monocyte conjugates (% positive particles)	Flow cytometry, using anti-CD61-PerCP and anti-CD14-FITC after activation with 100 µM of ADP (10 min, in static conditions at 37 °C)	30 days	Non-responder who underwent PCI	8	Median= 49	Range= 42,57	NR	NR	NR	NR	NR	NR	
					30 days	Non-responder who underwent conservative treatment	7	Median= 51	Range= 45,60	NR	NR	NR	NR	NR	NR	
					30 days	Responder	46	Median= 44	Range= 37,49	NR	NR	NR	NR	NR	NR	
			Platelet/ neutrophil conjugates (% positive particles)	Flow cytometry, using anti-CD41a-FITC and anti-CD45-PE after activation with 100 µM of ADP (10 min, in static conditions at 37 °C)	30 days	Non-responder who underwent PCI	8	Median= 25	Range= 21,32	NR	NR	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					30 days	Non-responder who underwent conservative treatment	7	Median= 26	Range= 21,32	NR	NR	NR	NR	NR	NR	
					30 days	Responder	46	Median= 23	Range= 17,28	NR	NR	NR	NR	NR	NR	
Tselepis, 2011 22008470 Greece NR	aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day.	VASP	VASP-ADP PRI	VASP-ADP	30 days	non-responder	17	mean 41.2	SD 16.1	NR	NR	NR	<0.01 comparing with 5 days values t-test	NR	NR	
						responder	NR	NR	NR	NR	NR	NR	NR	NR	NR	
Tselepis, 2011 22008470 Greece NR	aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day.	VASP	LTA-ADP 5uM	platelet aggregation	30 days	responder	57	5uMADP mean36	13	NR	NR	NR	<0.001comparing with baseline values t-test	NR	NR	
						non-responder	17	5uM ADP mean 40	14				<0.001 comparing with baseline values <0.01 comparing with 5 days results t-test			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Tselepis, 2011 22008470 Greece NR	aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day.	VASP	LTA-ADP 10uM	platelet aggregation	30 days	responder	57	10uM ADP mean 52	11	NR	NR	NR	<0.001 comparing with baseline values t-test	NR	NR	
						non-responder	17	10uM ADP mean 55	10				<0.001 comparing with baseline values <0.01 comparing with 5 days results t-test			
Tselepis, 2011 22008470 Greece NR	aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day.	VASP	LTA- TRAP	platelet aggregation	30 days	responder	57	trap 10uM mean 61	15	NR	NR	NR	<0.001 comparing with baseline values t-test	NR	NR	
						non-responder	17	trap 10uM mean 60	9				<0.001 comparing with baseline values t-test			
Tselepis, 2011 22008470 Greece NR	aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day.	VASP	p-selection expression (MFI)	p-selection expression (MFI)	30 days	responder	57	mean 26	SD 10	NR	NR	NR	<0.001 comparing with baseline values t-test	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	No. with given phenotype	Platelet reactivity measurement for the phenotype group [metric]	SD/SE (report value and metric)	Statistical method	Mean difference (state if other metric)	95% CI of mean difference (state if other metric)	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						non-responder	17	mean 23	SD 8				<0.001 comparing with baseline values t-test			
Tselepis, 2011 22008470 Greece NR	aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day.	VASP	platelet/monocyte conjugates	platelet/monocyte conjugates (% positive particles)	30 days	responder	57	mean 40	SD 10	NR	NR	NR	<0.001 comparing with baseline values t-test	NR	NR	
						non-responder	17	mean 44	SD 12				<0.001 comparing with baseline values t-test			
Tselepis, 2011 22008470 Greece NR	aspirin LD 325 mg, MD 100mg per day; clopidogrel LD 600mg, MD 75mg per day.	VASP	platelet/monocyte conjugates	platelet/neutrophil conjugates (% positive particles)	30 days	responder	57	mean 22	SD 9	NR	NR	NR	<0.001 comparing with baseline values t-test	NR	NR	
						non-responder	17	mean 27	SD 10				<0.001 comparing with baseline values t-test			

Appendix Table E60. Quality assessment of studies assessing the predictive ability of VASP in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Freyrhofer, 2011 21614416 Austria NR	yes	yes	yes	low	low	NR	yes	unclear	low	yes	yes	low	low	no	yes	yes	yes	low
Siller-Matula, 2009 19135705 Austria NR	NR	yes	yes	low	low	NR	yes	unclear	high	No	NR	high	high	no	yes	yes	yes	low
Blindt, 2007 18064332 Germany NR	NO	NO	yes	HIGH	LOW	NR	No	unclear	high	yes	NR	Unclear	low	no [6 months]	yes	yes	yes	low
Kalantzi 2011 21255245 Greece NR	NR	Yes	No	UNCLEAR	LOW	NR	Yes	unclear	Low	No	NR	High	High	no [30 days]	yes	yes	yes	low
Siller-Matula 2010 19943879 Austria NR	yes	yes	yes	low	low	NR	Yes	unclear	Low	yes	NR	Unclear	low	no [6 months]	yes	yes	yes	low
Bjelland, 2010 20727659 Norway NR	NO	Yes	No	HIGH	High	NR	Yes	unclear	Low	No	NR	High	High	no [2 days]	yes	yes	yes	low
Bonello, 2007 17488353 France NR	yes	yes	yes	low	low	NR	NR	unclear	Low	yes	NR	Unclear	low	no [6 months]	yes	yes	yes	low

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Djukanovic, 2008 18719318 Serbia NR	No	yes	yes	low	low	NR	Yes	unclear	Low	yes	NR	Unclear	low	Yes [1 year]	yes	yes	yes	low
Ei Ghannudi, 2011 21524751 France NR	yes	yes	yes	low	low	NR	Yes	unclear	Low	yes	yes	low	low	No [Mean 9 months]	yes	yes	yes (<2% loss though it isn't explained)	low
Ei Ghannudi, 2010 20630458 France NR	yes	yes	yes	low	low	NR	NR	unclear	Low	yes	NR	Unclear	low	No [9 months]	yes	yes	Yes	low
Morel, 2011 21251579 France NR	yes	yes	yes	low	low	Yes	Yes	Low	Low	yes	yes	low	low	No [Mean 9±2 months]	yes	yes	Yes	low
Palmerini, 2010 19604542 Italy DOUBLE	yes	yes	yes	low	low	NR	Yes	unclear	Low	NO	NR	High	High	No [1 month]	yes	yes	Yes	low
Schafer, 2011 21655677 Germany NR	yes	YES (for clinicial; controls were included but not germane to data of interest)	yes	low	low	NR	Yes	unclear	Low	Yes	NR	unclear	Low	Yes [12 months]	yes	yes	yes	Low
Frere, 2007 17938809 France NR	yes	No	yes	low	low	NR	No	High	Low	yes	NR	Unclear	low	no [30 days]	yes	yes	yes	low

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Siller-Matula, 2012 22260716 Austria PEGASUS-PCI	yes	yes	yes	low	low	yes	yes	low	low	yes	NR	unclear	low	yes	yes	yes	yes	low
Tselepis, 2011 22008470 Greece NR	yes	yes	yes	low	low	NR	yes	unclear	high	no	NR	high	high	no	yes	yes	yes	low
Cuisset, 2011 21872198 France NR	NR	Yes	Yes	Low	Low	NR	Yes	Unclear	Low	Yes	Yes	Low	Low	No [30 days]	Yes	Yes	Yes	Low
Gaglia, 2012 21919956 USA NR	Yes	Yes	Yes	Low	Low	Yes	Yes	Low	low	Yes	Yes	Low	Low	No [in-hospital]	yes	yes	yes	Low

1. Consecutive or random sample of patients enrolled.
2. Case-control design avoided
3. Study avoided inappropriate exclusions
Risk of bias: could the selection of patients have introduced bias (If ≥2 of the above 3 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)
Concerns that the included patients do not match the review question?
4. Index test results interpreted without knowledge of results of reference standard?
5. If a threshold used, was it prespecified?
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Concerns that the index test, its conduct, or its interpretation differ from the review question?
6. Reference standard likely to correctly classify the target condition?
7. Reference standard results interpreted without knowledge of index test results?
Could the reference standard, its conduct, or its interpretation have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)

Are there concerns that the target condition as defined by the reference standard does not match the review question?

- 8. Appropriate interval between index test and reference standard?
 - 9. All patients received a reference standard?
 - 10. All patients received the same reference standard?
 - 11. Were all patients included in the analysis?
- Could the patient flow have introduced bias? (If ≥ 3 of the above 4 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix Table E61. Quality assessment of studies assessing the predictive ability of VASP in a mixed patient population with Ischemic heart, cerebrovascular and peripheral vascular disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Reny, 2012 22615340 France and Switzerland ADRIE	yes	yes	yes	Low	low	yes	yes	low	low	yes	yes	low	low	No [3 months]	yes	yes	yes	low

Appendix Table E62. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of Multiplate Analyzer

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Siller-Matula, 2009 19135705 Austria NR	30 NR 84 63±10	100 NR CVD 7 PCI 43 NR NR 10 37 NR	hyper 77 57 HTN 77 33	NR 100 100 NR	NR NR NR	not used	Patients had been on chronic aspirin (100 mg/day) and clopidogrel (75 mg/day) treatment for three months on average.	All patients received unfractionated heparin and 250 mg of injectable acetyl-salicylic acid during PCI

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Ko, 2011 21315223 Korea NR	222 ?Asian 152 (69) 63.3 ± 10	100 NR CVA: 14.9 PCI: 37 (16.7); CABG: 1 (0.5) NR NR NR 5.9 NSTEMI: 10.1	Hypercholesterolemia: 46.8 Current: 12.2 HTN: 72.1 32	NR 72.1 89.6 NR	100 Drug eluting Multi-vessel; Stents/pt: 1.8±1	Patients undergoing percutaneous coronary intervention (PCI) for CAD	All patients were pretreated with aspirin (100 mg/d) and clopidogrel (75 mg/d) at least 5 days before PCI or received oral loading doses of 250 mg aspirin and 300 mg clopidogrel 12 to 24 hours before PCI. Maintenance doses of 100 mg aspirin and 75 mg clopidogrel after PCI. After PCI, dual antiplatelet therapy with 100 mg/d aspirin and 75 mg/d clopidogrel was continued for at least 6 months	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Sibbing, 2010 19943882 Sibbing, 2010 20633826 Germany NR	2533 NR 2034 (80.3%) mean: 67.8	NR NR NR CABG: 14.3% NR NR NR 31.4 NSTEMI/STEMI: 14.5%	Hypercholesterolemia: 68.4% Active: 13.2% Arterial HTN:90.6% 28.6%	10.9% Thienopyridine: 41.3% 74.3 NR	Stents per lesion: 1.3; Lesions per patient: 1.9 NR Multivessel disease: 85.5%	Patients undergoing PCI with stenting for ACS and CAD	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	PCI: Intravenous anticoagulant: unfractionated heparin or bivalirudin (140 U/kg body weight for unfractionated heparin and for bivalirudin with a dosing regimen of 0.75 mg/kg body weight for bivalirudin before PCI, followed by an infusion of 1.75 mg/kg/h bivalirudin for the procedure); Some pts received glycoprotein IIb/IIIa inhibitor abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/min infusion for 12 h) with reduced heparin dose

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Sibbing, 2009 19264241 Sibbing, 2010 20062919 Germany NR	1608 NR 1234 (77%) 67.5±40.5	NR NR NR CABG: 14% NR NR NR 32 NR	Hypercholesterolemia: 70% Active: 13% HTN: 91.6% 29	NR NR 99.1 NR	NR NR NR	Patients undergoing PCI with stenting for ACS and CAD	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	PCI: Intravenous anticoagulant: unfractionated heparin or bivalirudin (140 U/kg body weight for unfractionated heparin and for bivalirudin with a dosing regimen of 0.75 mg/kg body weight for bivalirudin before PCI, followed by an infusion of 1.75 mg/kg/h bivalirudin for the procedure); Some pts received glycoprotein IIb/IIIa inhibitor abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/min infusion for 12 h) with reduced heparin dose

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Schulz, 2010 20691843 Germany NR	1608 NR 1234 (76.7%) 67.4	NR NR NR CABG: 14.4% 66.9 22.2 NR 31.5 STEMI: 2.5%; NSTEMI: 8.4%	Hypercholesterolemia: 69.8% Active: 13.4% HTN: 91% 28.7	NR NR NR NR	94.8% BMS: 2.2%; DES: 92.6% Multivessel: 85.1%	patients undergoing PCI	600 mg clopidogrel before PCI and 500 mg aspirin LD directly before the intervention; Postinterventional therapy : clopidogrel 75 mg twice daily for 3 days, then 75 mg per day for 6 months with aspirin 100 mg twice daily	Periprocedural therapy: unfractionated heparin (as a bolus of 140 U/kg bodyweight) or bivalirudin (0.75 mg per kg bodyweight bolus, followed by an infusion of 1.75 mg per kg bodyweight per hour for the duration of the procedure) or abciximab (0.25-mg/kg bodyweight bolus, followed by an infusion of 0.125 µg/kg bodyweight per min for 12 hours) along with 70 U/kg bodyweight unfractionated heparin

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Freyenhofer, 2011 21614416 Austria NR	300 NR 205 62±16	43.3 NR NR PCI 24.3 NR see UA/NSTEMI 10 22.7 29.7/34.3	hyper 69.3 27.3 HTN 74.7 27.3	NR 100 100 81.3	100 DES 65.3 multi-vessel 58.7	PCI and coronary stenting	Clopidogrel-naïve patients received a 300 or 600 mg loading dose (LD). Patients on chronic clopidogrel therapy with 75 mg clopidogrel of at least seven consecutive days did not receive an additional LD.	According to actual evidence, all patients received in parallel ASA (100 mg daily dose). The use of GP-IIb/IIIa-blockers during PCI as well as the choice of the anticoagulant depended on the individual situation and the thrombus load at angiography, and was left to the discretion of the operator
Siller-Matula, 2010 19943879 Austria NR	416 NR 76 64±12	100 NR NR 47 NR NR 13 33 NR	hyper 76 55 85 32	NR 100 100 77	99 NR NR	PCI with stenting	Clopidogrel loading dose at least 2 hr before PCI (600 mg); thereafter, a daily dose of 75 mg, with planned treatment with clopidogrel and aspirin for at least 6 months.	Also all patients received unfractionated heparin (100 IU per kg) during PCI and 250 mg aspirin intravenously immediately after stent placement (and daily dose of 100 mg thereafter).

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Eshtehardi, 2010 20435201 Switzerland NR	219 NR 168 (77%) Mean/SD 66+/-9 yr	NR ACS 82 (37%) [not sure ACS=heart failure] NR PCI 70 (32%); CABG 26 (12%) 137 (63%) NR NR 60 (27%) NR	155 (71%) Current 57 (26%) Atrial HTN 163 (74%) 43 (20%)	NR 100%; (pretreatment in study) 100% (pretreatment in study) NR	NR 1 DES 164 (75%); BMS 55 (25%) Multi 77 (34%)	Patients with stable angina or ACS with an indication for PCI, undergoing PCI with stenting	500 mg ASA intravenously (unless if already on 100 mg daily); then 600 mg clopidogrel loading dose (unless already on 75 mg daily)	unfractionated heparin (70-100 U/kg body weight) before or at time of PCI

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Ivandic, 2009 19359538 Germany NR	182 (163 full responders, 19 dual nonresponders) NR 130 (71%) Median age (95% CI); Nonresponders 68 (59–72); Responders 65 (67–72)	NR NR NR 78 (43%) 14 (8%) NR NR 40 (22%)/52 (29%)	Hypercholesterolemia 113 (82%) 61 (34%) HTN (arterial) 146 (80%) 57 (31%)	NR 100% 100% NR	100% DES only 77 (42%); BMS only 75 (41%); Both 23 (13%) 3-vessel 90 (49%)	CAD patients who underwent PCI	Emergency patients with ACS received 0.5 g ASA intravenously and an oral loading dose of 600 mg clopidogrel before PCI. Electively hospitalized patients with suspected CAD or suspected progression of CAD received 0.5 g ASA intravenously before and loading dose of 600 mg clopidogrel immediately after PCI and stenting. After PCI, all patients received maintenance doses of 100 mg ASA and 75 mg clopidogrel once daily.	A single bolus of unfractionated heparin (10 000 U) was given immediately before PCI. The type of stent used for PCI was left at the discretion of the operator.

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Siller-Matula, 2012 22260716 PEGASUS-PCI	416 NR 76 64±12	NR NR NR PCI 47 NR NR 13 31 18/NR	hyper 76 55 84 32	NR 100 100 76	100 DES 99 NR	patients undergoing PCI	clopidogrel LD 600mg, MD 75mg	NR
Codner, 2012 22534051 Israel NR	57 NR 91 54.5	7 NR NR PCI-16/CABG-7% NR NR NR 18 NR	58 39 45 19	NR NR NR NR	NR NR NR NR	PCI for ACS	LD: clopidogrel 600 mg and aspirin 100 mg MD: clopidogrel 75 mg/d and aspirin 100 mg/d	heparin, bivalirudin, and/or glycoprotein IIb/IIIa inhibitors
Gerotziakas, 2012 22311629 Greece NR	106 NR 84.9 63.3	NR NR NR PCI - 71% NR NR NR NR NR	53.8 17.9 84.9 18.9	NR 100 100 NR	NR NR NR NR	PCI for ACS	aspirin 100 mg and clopidogrel 75 mg once daily	NR

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Johnston, 2012 22465351 New Zealand NR	250 European 81.2 77.7 67.6	77.7 67.6 NR NR NR PCI=38.3/CABG-14% NR NR NR 19.1 NR	70.6 22 89.4 31.2	NR 100 100 NR	NR NR NR	PCI for ACS	aspirin ≥300 mg at and clopidogrel ≥300 mg and/or aspirin (≥75 mg) and clopidogrel (≥75 mg)	NR
Sibbing, 2012 22682553 Germany ISAR-REACT 4	564 81.2 74.8 62	NR NR NR PCI-18/CABG-8 NR NR NR 22.4 NR	54.8 26 58 20.8	NR NR NR 26	NR NR NR	PCI for ACS	LD: 600 mg of clopidogrel and 500 mg aspirin MD: clopidogrel 75 mg x 12 months and aspirin 100 mg twice daily for an indefinite period	Abciximab plus UFH group: bolus of 0.25 mg abciximab and 70 units UFH per kilogram body weight; then continuous infusion of 0.125 µg abciximab per kilogram body weight per minute x 12 h. Bivalirudin group: bolus of 0.75 mg per kilogram bivalirudin, followed by a continuous infusion of 1.75 mg per kilogram per hour during PCI.

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Siller-Matula, 2012 22305813 Austria NR	403 NR 75.9 64.3	100 NR 10.2 PCI=46.9 NR NR 12.4 32 NR	76.4 55.1 NR 85 24	NR NR 100 78.4	100 DES-99% NR	Elective PCI for CAD	LD clopidogrel 600 mg 2 h pre PCI, 100 mg aspirin intake ; Additionally 250 mg acetylsalicylic acid i.v. directly before stent placement MD: 75 mg clopidogrel; 100 mg aspirin for 12 months	unfractionated heparin 100 IU/kg before PCI

*Mean (standard deviation), unless otherwise stated.

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DES=Drug eluting stent; HTN = hypertension, MI = myocardial infarction; NSTEMI = non-ST-elevation MI; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack

Appendix Table E63. Baseline characteristics of patients with cerebrovascular disease in studies assessing the predictive ability of Multiplate Analyzer

	Demographics	Vascular disease history	Vascular risk factors	Prior medications (pre-study)	Procedural data	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)			
Muller-Schunk, 2008 18223094 Germany NR	50 NR 36(72) 65±8	NR NR Stroke 31 (63); TIA 19 (38) NR NR NR NR NR	NR NR NR NR	NR 100% NR NR	NR NR NR	Patients with extracranial or intracranial stenosis	All 50 of the patients received a loading dose of 300 mg of clopidogrel at least 12 hours before the intervention and after loading were treated with 75 mg/day continuously. All of the patients received 100 mg of aspirin per day according to the usual protocol.	None

* Mean (standard deviation), unless otherwise stated.

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH=Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors

Appendix Table E64. Study design characteristics of studies assessing the predictive ability of Multiplate Analyzer in patients with ischemic heart disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enroment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Siller-Matula, 2009 19135705 Austria NR	Prospective observational study	NO	NR	Patients undergoing PCI for coronary artery disease	Aug 2007-Apr 2008	1 day	followup after intervention	YES Accrual=100%	Non-industry [grant from the Jubiläumsfond of the Austrian National Bank (Nr. 12565)]
Ko, 2011 21315223 Korea NR	observational study	YES	Consecutive patients	Patients undergoing percutaneous coronary intervention (PCI) for CAD	Aug-Oct 2009	30 days for all patients	followup after intervention	NO	Non-industry only - grant from Government & non-profit foundation
Sibbing, 2010 19943882 Sibbing, 2010 20633826 Germany NR	Prospective cohort	YES	Consecutive	Patients undergoing PCI with stenting for ACS and CAD	February 2007 to December 2008	30 days	followup after intervention	NR	partly industry (Material for platelet function analysis on the Multiplate device were provided free of charge from Dynabyte, Munich, Germany)
Sibbing, 2009 19264241 Sibbing, 2010 20062919 Germany NR	Prospective observational study	YES	Consecutive	Patients undergoing PCI with stenting for ACS and CAD	February 2007 to April 2008	30 day and 6 months day followup	Followup after intervention	YES; Accrual>80%	partly industry (Material for platelet function analysis on the Multiplate device were provided free of charge from Dynabyte, Munich, Germany)
Schulz, 2010 20691843 Germany NR	Prospective observational study	YES	Consecutive	patients undergoing PCI	NR	1 year	Followup after intervention	NR	Partial industry [Material for platelet function analysis on the Multiplate device was provided free of charge by Dynabyte (Munich, Germany)]
Freynhofer, 2011 21614416 Austria NR	Prospective, registry data	NO	Consecutive	Adults undergoing PCI and coronary stenting with no contraindication for dual antiplatelet therapy for up to one year	May 2009 to February 2010	Total 6 month, mean/SD 189/68 days	Inpatient, then outpatient visits after discharge, at 1 mo and 6 mo	YES [YES]	Non-industry only

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enroment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Siller-Matula, 2010 19943879 Austria NR	Prospective observational	NO	Consecutive	Adults with CAD undergoing PCI with stenting (most elective) with clopidogrel and aspirin therapy	NR	Total, 6 month	Inpatient with followup after discharge (contacted patients at 3 and 6 mo after)	YES (YES—80%)	Nonindustry only
Eshtehardi, 2010 20435201 Switzerland NR	Prospective	NO	Consecutive	Patients with stable angina or ACS with an indication for PCI, undergoing PCI with stenting	Jan 2007- March 2008	Total 30 days after PCI	Inpatient and then 30- day followup as outpatient	NO	Non-industry only
Ivancic, 2009 19359538 Germany NR	Prospective	NO	Consecutive	CAD patients who underwent PCI and received standard therapy including ASA and clopidogrel	June 2006 to August 2006	Median follow-up was 419 days (95% CI 414–420 days)	Inpatient and then followup 30 days after PCI	NR	NR
Codner, 2012 22534051 Israel NR	prospective	no	NR	PCI for ACS	NR	6 months	followup after intervention	No	NR
Gerotziapas, 2012 22311629 Greece NR	prospective	no	NR	Adults undergoing PCI for ACS	Oct 2007 – Jan 2008	3 months	Inpatient and followup after intervention	No	Industry provided assays
Johnston, 2012 22465351 New Zealand NR	prospective	no	NR	Adults undergoing PCI for ACS	Oct 2010 – march 2011	3 days	Inpatient and followup after intervention	No	Non profit (Wellington Cardiology Trust)
Siller-Matula, 2012 22260716 USA PEGASUS- PCI	prospective cohort	no	Consecutive	patients undergoing PCI	March 2007- Nov, 2009	12 months	medical university of vienna	yes, 80%	Austrian National Bank

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enroment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Siller-Matula, 2012 22305813 Austria NR	prospective cohort	no	NR	patients undergoing PCI for CAD	March 2007- September 2008	12 months	Inpatient and followup after intervention	yes	Non-industry - Jubiläumsfond of the Austrian National Bank

Appendix Table E65. Study design characteristics of studies assessing the predictive ability of Multiplate Analyzer in patients with cerebrovascular disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enroment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Muller-Schunk, 2008 18223094 Germany NR	prospective Cohort	No	Consecutive	Patients with extracranial or intracranial stenosis	NR	NR	Hospital inpatient	NR	NR

Abbreviation: NR=not reported.

Appendix Table E66. Phenotypic test details in studies assessing the predictive ability of Multiplate Analyzer in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Siller-Matula, 2009 19135705 Austria NR	Multiplate Analyzer Impedance aggregometry Dynabyte Medical, Munich, Germany	Adenosine diphosphate (ADP), prostaglandin (PGE1)	1 st blood sample: in catheterization laboratory, after PCI and after 250 mg IV aspirin 2 nd blood sample: 20-24 hours after PCI 3.8% citrate, 3.2% citrate and recombinant hirudin NR Clopidogrel came first 0.04 days (1 hour)	Impedence between 16-88 units Impedence between <16 units	Based on Normal ranges as reported by manufacturer	Impedence between 16-88 units: 20 (67%) Impedence between <16 units:10 (33%)
Ko, 2011 21315223 Korea NR	Multiple Electrode Platelet Aggregometry Whole blood impedence aggregometry Multiplate analyzer Dynabyte	ADP	Before PCI; 8 and 24 hrs after PCI Ilepirudin (25 µg/mL) 5 days (clopidogrel came first) 0.125 days (Within 3 hrs)	Multiple electrode aggregometry with ADP was not used to classify clopidogrel response in patients	NR	NR

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Sibbing, 2010 19943882 Sibbing, 2010 20633826 Germany NR	multiple electrode aggregometry Multiplate analyzer Dynabyte, Munich, Germany	6.4 µmol/l ADP	Whole blood; after diagnostic angiography, before PCI lepirudin (25 µg/ml) 0.08 days (2 hours) NR	Enhanced Responders (<188 aggregation units*min) Remaining patients - Not enhanced responders (≥188 aggregation units*min) From Sibbing 2010 PMID: 20633826 Enhanced responder (AUC≤188) Normal responder (AUC189-467) Low responder (AUC≥468) For Stent thrombosis >468 aggregation units*min ≤468 aggregation units*min	ROC curve of all participants in the study	Enhanced Responders (<188 aggregation units*min): 975 (38.5%) Remaining patients - Not enhanced responders (≥188 aggregation units*min): 1558 (61.5%) From Sibbing 2010 PMID: 20633826 Enhanced responder (AUC≤188): 975 (38%) Normal responder (AUC189-467): 1130 (45%) Low responder (AUC≥468): 428 (17%) For Stent thrombosis >468 aggregation units*min: 428 (17%) ≤468 aggregation units*min: 1180 (83%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Sibbing, 2009 19264241 Sibbing, 2010 20062919 Germany NR	multiple electrode platelet aggregometry multiple electrode platelet aggregometry Multiplate Dynabyte, Munich, Germany	6.4 µmol/l ADP	Whole blood; after diagnostic angiography, before PCI, and at least 2 min after administration of intravenous aspirin. lepirudin (25 µg/ml) 0.08 days (2 hours) 0.02 days (30 mins)	Low Responders (Quintile 5: >416 aggregation units*min) Normal Responders (Quintile 1-4 ≤416 aggregation units*min) By other quintiles High Responders (Quintile 1 ≤124 AU*min) Normal Responders (Quintile 2 >124- ≤192 AU*min) Normal Responders (Quintile 3 >192- ≤261 AU*min) Normal Responders (Quintile 4 >261- ≤416 AU*min) Low Responders (Quintile 5: >416 AU*min)	Based on literature	Low Responders (Quintile 5: >416 aggregation units*min): 323 (20.1%) Normal Responders (Quintile 1-4 ≤416 aggregation units*min): 1285 (79.9%) By other quintiles High Responders (Quintile 1 ≤124 AU*min): 318 (19.8%) Normal Responders (Quintile 2 >124- ≤192 AU*min): 322 (20%) Normal Responders (Quintile 3 >192- ≤261 AU*min): 322 (20%) Normal Responders (Quintile 4 >261- ≤416 AU*min): 323 (20.1%) Low Responders (Quintile 5: >416 AU*min): 323 (20.1%)
Schulz, 2010 20691843 Germany NR	multiple electrode platelet aggregometry multiple electrode platelet aggregometry Multiplate Dynabyte, Munich, Germany	ADP	After diagnostic angiography lepirudin NR NR	Low response (Upper quintile of MEA measurements [>416 AU*min]) Normal response (Lower 4 quintiles of MEA measurements [≤416 AU*min])	Based on literature – a previous study	Low response (Upper quintile of MEA measurements [>416 AU*min]): 323 (20%) Normal response (Lower 4 quintiles of MEA measurements [≤416 AU*min]): 1285 (80%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Freynhofer, 2011 21614416 Austria NR	MEA/Impedence aggregometry Multiple Platelet Function Analyzer Dynabyte Medical, Munich, Germany	ADP 6.5 umol	Samples were incubated and stirred at 37°C for 3 min in the test cuvettes. Agonists were added and the increase in electrical impedance was recorded for 6 min Lithium-heparin + 0.9% sodium chloride 6-24 h (morning) after PCI Within 30 min to 3 hr after blood collection	MEA result <47 U (high on-treatment platelet reactivity, poor response) MEA result >47 U (low reactivity, good response)	previous published literature	MEA result <47 U (high on-treatment platelet reactivity, poor response); 57/196 (29%) MEA result >47 U (low reactivity, good response); 139/196 (71%)
Siller-Matula, 2010 19943879 Austria NR	Multiple electrode aggregometry Multiplate analyzer Dynabyte Medical, Munich, Germany	ADP (6.4 uM) + PGE ₁ (9.4 nM)	Samples taken directly after PCI and at least 5 min after IV aspirin dose (250 mg). Hirudin and 0.9% NaCl Dose first (clopidogrel loading dose given at least 2 hr before PCI). NR	MEA (n=402; 14 pts not tested because of glycoprotein IIb/IIIa): No platelet hyperreactivity (<54U) Platelet hyperreactivity (≥54U)	ROC curve analysis	MEA (n=402; 14 pts not tested because of glycoprotein IIb/IIIa): 346 (86%) No platelet hyperreactivity (<54U) Platelet hyperreactivity (≥54U) 56 (14%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Eshtehardi, 2010 20435201 Switzerland NR	whole blood impedance platelet aggregometry the multiple electrode aggregometry Multiplate analyzer Dynabyte, Munich, Germany	ADP 6.4 umol/L	peripheral venous blood samples were drawn from an antecubital vein using a 21-gauge needle and collected in a polyethylene tube containing a stabilized direct thrombin inhibitor (melagatran 15 µg/mL). Sample was diluted with NaCl 0.9% in a 1:1 ratio Melagatran 12 to 18 hr after PCI within 30 to 60 minutes after the blood sampling	Low response to clopidogrel only= results of ADP test AUC within the upper quartile and results of aspirin test AUC below the upper quartile. Low response to ASA and clopidogrel (dual low response) = results of aspirin test AUC and ADP test AUC within the upper quartile. Controls (dual normal response)= results of aspirin test AUC and ADP test AUC below the upper quartile. [Also low response to aspirin; this group ignored re data extraction since not relevant]	AUC plots in present study (see Fig. 4 and previous publications and findings [refs 7,14,16,17,27-30]	Low response to clopidogrel only= results of ADP test AUC within the upper quartile and results of aspirin test AUC below the upper quartile.: 33 (15%) Low response to ASA and clopidogrel (dual low response) =results of aspirin test AUC and ADP test AUC within the upper quartile: 19 (9%) Controls (dual normal response)= results of aspirin test AUC and ADP test AUC below the upper quartile: 133 (60%) [Also low response to aspirin; this group ignored re data extraction since not relevant]: 34 (16%)
Ivandic, 2009 19359538 Germany NR	whole-blood impedance aggregometry CA560 lumi- aggregometer ChronoLog	6.4 µmol/l ADP	NR NR NR the day after clopidogrel loading NR	Nonresponse, defined as impedance exceeded 5 ohms after 6 min of aggregation, to clopidogrel Full response (to aspirin and clopidogrel) Dual nonresponse (to aspirin and clopidogrel) Nonresponse to clopidogrel but full response to aspirin	Not explicitly reported	Nonresponse, defined as impedance exceeded 5 ohms after 6 min of aggregation, to clopidogrel: 34 (18.7%) Full response (to aspirin and clopidogrel):163 (73.6%) Dual nonresponse (to aspirin and clopidogrel): 19 (10.4%) Nonresponse to clopidogrel but full response to aspirin: 15 (8%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Siller-Matula, 2012 22260716 PEGASUS- PCI	multiple electrode aggregometry (MEA) impedance aggregometer Multiplate Analyzer; Verum Diagnostica GmbH, Munich, Germany	6.4 uM ADP	Blood samples from patients were obtained from the arterial sheath (6F) in the catheterization laboratory directly post-PCI and at least 5 min after intravenous infusion of aspirin. 3.8% sodium citrate NR performed up to 24 h after blood sampling	Clopidogrel non-responder according to MEA (≥ 48 U) Clopidogrel responder according to MEA (< 48 U) n = 321 (80%)	ref 16, 28	non-responder n = 81 (20%) responder n = 321 (80%)
Codner, 2012 22534051 Israel NR	multiple electrode aggregometry (MEA) impedance aggregometer Multiplate Analyzer; Verum Diagnostica GmbH, Munich, Germany	6.4 uM ADP	NR 3.2% citrate NR 1 hr	HTPR MEA (≥ 47 AU) Clopidogrel responder (< 47 U)	Based on literature	HTPR : 13 Clopidogrel responder: 44
Gerotziakas, 2012 22311629 France NR	multiple electrode aggregometry (MEA) impedance aggregometer Multiplate Analyzer; Verum Diagnostica GmbH, Munich, Germany	6.4 uM ADP	NR r-hirudin 25µg/mL NR 2 hrs	HTPR MEA (≥ 50 AU) Clopidogrel responder (< 50 U)	Based on ROC curve	HTPR MEA (≥ 50 AU): 3 Clopidogrel responder (< 50 U): 103

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Johnston, 2012 22465351 New Zealand NR	multiple electrode aggregometry (MEA) impedance aggregometer Multiplate Analyzer; Verum Diagnostica GmbH, Munich, Germany	6.4 uM ADP	2 hrs after loading dose r-hirudin 2 hrs 30-60 minutes	HTPR MEA (≥ 468 AU*min) Clopidogrel responder (< 468 AU*min)	Based on literature	HTPR MEA (≥ 468 AU*min): 95 Clopidogrel responder (< 468 AU*min): 155
Sibbing, 2012 22682553 Germany ISAR- REACT 4	multiple electrode aggregometry (MEA) impedance aggregometer Multiplate Analyzer; Verum Diagnostica GmbH, Munich, Germany	6.4 uM ADP	Before PCI r-hirudin 25µg/mL NR NR	HTPR MEA (≥ 468 AU*min) Clopidogrel responder (< 468 AU*min)	Based on literature	Pts on Abciximab Plus UFH: HTPR MEA (≥ 468 AU*min): 96 Clopidogrel responder (< 468 AU*min): 178 Pts on Bivaluridin: HTPR MEA (≥ 468 AU*min): 109 Clopidogrel responder (< 468 AU*min): 181
Siller-Matula, 2012 22305813 Austria NR	multiple electrode aggregometry (MEA) impedance aggregometer Multiplate Analyzer; Verum Diagnostica GmbH, Munich, Germany	ADP: 6.4 µM or AA: 0.5 mM	Before PCI r-hirudin 25µg/mL NR Immediately after sampling	With only ADP high platelet reactivity (HPR) to ADP (ADP \geq 48U) No HPR to ADP (ADP $<$ 48U) With ADP & AA HPR to AA and ADP (ADP \geq 48U; AA \geq 14U) HPR to ADP(ADP \geq 48U;) HPR to AA (AA \geq 14U) No HPR (ADP $<$ 48U; AA $<$ 14U)	Based on ROC curve	high platelet reactivity (HPR) to ADP (ADP \geq 48U): 75 (19%) No HPR to ADP (ADP $<$ 47U): 328 (81%) With ADP & AA HPR to AA and ADP: 32(8%) HPR to ADP: 44 (11%) HPR to AA: 77 (19%) No HPR: 250 (62%)

Abbreviations: ADP= adenosine 5'-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported

Appendix Table E67. Phenotypic test details in studies assessing the predictive ability of Multiplate Analyzer in patients with cerebrovascular disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Muller-Schunk, 2008 18223094 Germany NR	Impedance aggregometry Multiplate analyzer Dynabyte Medical, Munich, Germany	6.4 uM ADP	300 microL of saline and 300microL of patient blood are pipetted into the test cell. Pipetting is performed by an attached electronic pipette. Hirudin, 25microg/mL NR 6 minutes	Non –responder >52U Responder ≤ 52U	Not explicitly reported	Non –responder >52U: 14 (28%) Responder ≤ 52U: 36 (72%)

Abbreviations: ADP= adenosine 5’-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported

Appendix Table E68. Results from studies assessing the ability of Multiplate Analyzer to predict death in patients with ischemic heart disease

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing, 2009 19264241 Sibbing 2010 20062919 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Death	Death	30 days	Low Responders (>416 aggregation units*min)	Death	4 (1.2%)	OR=3.2	0.92- 11.1	P=0.07 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		5 (0.4%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Mortality	Death	6 months	Low Responders (>416 aggregation units*min)	Mortality	10 (3.2%)	OR=1.6	0.8- 3.3	P=0.20 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		25 (2%)						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Cardiac Death	Cardiac Death	6 months	Low Responders (>416 aggregation units*min)	Cardiac Death	8 (2.5%)	OR=2.5	1.1- 5.8	P=0.037 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		13 (1%)						
Schulz, 2010 20691843 Germany NR	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	Death	Death	1 year	Low responder	Death	16 (5%)	HR=1.5	0.9- 2.7	0. 144 (low vs normal) cox proportional hazard model	NO	NR	Secondary outcome
						Normal responder		42 (3.3%)						
	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	Cardiac Death	Cardiac Death	1 year	Low responder	Cardiac Death	9 (2.8%)	HR=1.8	0.8-4	0. 139 (low vs normal) cox proportional hazard model	NO	NR	Secondary outcome
						Normal responder		20 (1.6%)						
Freyenhofer 2011 21614416 Austria NR	300 or 600mg LD Clopidogrel and maintain dose 75 mg + aspirin 100mg	MEA	CV death	CV death	6 months	High reactivity/poor response	CV death	4/57	OR (calculate) = 23	1.2- 443.3	P=0.006 (High vs low reactivity) [Fisher's exact test]			Fig 1

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Low reactivity/good response		0/139						Fig 1
Eshtehardi, 2010 20435201 Switzerland NR	600 mg LD Clopidogrel + 500 mg aspirin	Aggregometry	Death	Death	30 days	Clopidogrel low response	Death	0	OR (calculate) = 9.8	0.4- 243.2	P=0.023 (High vs low reactivity) [Fisher's exact test]			
						Aspirin low response		0						
						Dual low response		1 (5.3%)						
						Normal response		0						
Ivandic, 2009 19359538 Germany NR	Clopidogrel 600mg LD+aspires 0.5g	Aggregometry	Cardiac death	Cardiac death	14 months	Responders (n=163)	Cardiac death	4 (2.4%)	OR (calculate) = 0.91	0- 17.5	P=1.0 (dual nonresponder + clopidogrel nonresponder vs responder) [Fisher's exact test]			
						Dual nonresponders (n=19)		0 (0%)						
Siller- Matula, 2012 22260716 PEGASUS- PCI	clopidogrel LD 600mg, MD 75mg	MEA	cardiac death	Stent thrombosis (definite and probable)	12-month	non-responder	stent thrombosis	6/81 (8)	HR=2.1	0.7- 6.2	NR	yes,CY P2C19*2 carrier status,BMI, CRP levels,DM, age, renal failure(creatin e clearance<60mg mL,MI,sex,PPI	NR	
						responder		14/321(5)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Johnston, 2012 22465351 New Zealand NR	aspirin ≥300 mg at and clopidogrel ≥300 mg and/or aspirin (≥75 mg) and clopidogrel (≥75 mg)	MEA	Death		3 days	High on treatment platelet reactivity >468 AU*min n=95	HTPR	0	OR (calculated) = 1.63	NR	P=0.81 (HTPR vs normal) [Fisher's exact]	No	NR	
						normal platelet reactivity ≤468 AU*min n=155		0						
Sibbing, 2012 22682553 Germany ISAR- REACT 4	LD: 600 mg of clopidogrel and 500 mg aspirin MD: clopidogrel 75 mg x 12 months and aspirin 100 mg twice daily for an indefinite period	MEA	Death in pts on Abciximab Plus UFH	death	30 days	high on- treatment platelet reactivity >468 AU*min n=96	death	1	OR=0.6	0.1- 5.6	P=0.64 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=178		3						
			Death in pts on Bivalirudin	death	30 days	high on- treatment platelet reactivity >468 AU*min n=109	death	1	OR=1.9	0.1- 30.1	P=0.66 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=181		1						

Appendix Table E69. Results from studies assessing the ability of Multiplate Analyzer to predict myocardial infarction in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Ko, 2011 21315223 Korea NR	Multiple Electrode Platelet Aggregometry (MEA-ADP)	Periprocedural MI	Postprocedural ↑ of troponin or CK-MB >3 times the 99th percentile of the ULN in patients with normal baseline levels (or >3 times in pts with elevated baseline levels).	From PCI to 30 days	30 days	MI+	NR	NR	NR	NR	NR	NR	AUC=0.419; P=0.310 (Fig2d)	Multiple Electrode Platelet Aggregometry (MEA-ADP)
Sibbing, 2009 19264241 Sibbing, 2010 20062919 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Myocardial infarction	according to TIMI criteria	30 days	Low Responders (>416 aggregation units*min)	Myocardial infarction	12 (3.7%)	OR=1.16	0.61-2.21	P=0.64 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		41 (3.2%)						
			Myocardial infarction	according to TIMI criteria	6 months	Low Responders (>416 aggregation units*min)	Myocardial infarction	17 (5.2%)	OR=1.4	0.8-2.4	P=0.25 (low vs normal responder) [log rank]	NO	NR	Secondary

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal Responders (≤416 aggregation units*min)		49 (3.8%)						
			MI >24 h post- PCI	according to TIMI criteria	30 days	Low Responders (>416 aggregation units*min)	MI >24 h post-PCI	5 (1.5%)	OR=4.02	1.28- 12.63	P=0.02 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		5 (0.4%)						
			Q-wave MI	according to TIMI criteria	30 days	Low Responders (>416 aggregation units*min)	Q-wave MI	5 (1.5%)	OR=4.99	1.53- 16.29	P=0.008 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		4 (0.3%)						
Schulz, 2010 20691843 Germany NR	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	MI	according to Thrombolysis in Myocardial Infarction criteria	1 year	Low responder	MI	17 (5.3%)	HR=1.3	0.7-2.2	0.378 (low vs normal) Chi square	NO	NR	Secondary outcome
						Normal responder		43 (4.1%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Q-wave MI	according to Thrombolysis in Myocardial Infarction criteria	1 year	Low responder	Q-wave MI	8 (2.5%)	HR=4	1.5- 10.7	0.005 (low vs normal) Chisquare	NO	NR	Secondary outcome
						Normal responder		8 (0.6%)						
Freyenhofer, 2011 21614416 Austria NR	300 or 600mg LDClopidogrel and maintain dose 75 mg+aspirin 100mg	MEA	STEMI			High reactivity/poor response		0	OR=0.3 (calculate)	0-6.7	NR	NR	NR	Fig 1
						Low reactivity/good response		3						Fig 1
Eshtehardi 2010 20435201 Switzerland NR	600 mg LD Clopidogrel+500 mg aspirin	Aggregometry	PCI-related MI	peak CK-MB >3x ULN if baseline troponin was normal, and >20% increase of CK or CK-MB postprocedure in case of elevated baseline Troponin [ref 25]	Within 30 days after PCI	Clopidogrel low response	PCI-related MI	2 (6.1%)	NR	NR	0.039 across this and next 3 rows (Fisher's exact or chi-square)	NR	NR	NONE
						Aspirin low response		3 (8.8%)						
						Dual low response		5 (26.3%)						
						Normal response		9 (6.8%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			MI	new Q waves ≥0.4-sec duration in at least 2 contiguous leads on ECG with or without elevate CK or CK-MB; In the absence of pathologic Q waves, an elevation of CK levels >3x ULN with elevated CK- MB or troponin I or T level	after the periprocedural period	Clopidogrel low response		0			0.004 across this and next three rows (Fisher's exact or chi-square)			
						Aspirin low response		0						
						Dual low response		2 (10.5%)	OR=6.6 (calculated)	0.6- 74.8				
						Normal response		1 (0.8%)						
Ivandic, 2009 19359538 Germany NR	Clopidogrel600mg LD+aspires 0.5g	Aggregometry	STEMI	ST-elevation myocardial infarction	30days or later after PCI	Responders (n=163)	ST- elevation myocardial infarction	1 (0.6%)	Relative risk vs. previous row, 8.58	0.56- 131.65	NR	NR	NR	
						Dual nonresponders (n=19)		1 (5.3%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Johnston, 2012 22465351 New Zealand NR	aspirin ≥300 mg at and clopidogrel ≥300 mg and/or aspirin (≥75 mg) and clopidogrel (≥75 mg)	MEA	Periprocedural MI	Increase in hs-TnT to >three times the upper reference limit (>39 ng/L) for those with preprocedural hs-TnT levels within the normal range In those with elevated preprocedural hs-TnT, a further elevation of hs-TnT >39 ng/L	3 days	High on treatment platelet reactivity >468 AU*min n=95	HTPR	13	OR (calculated)= 1.13	0.53-2.42	P=0.23 (HTPR vs normal) [Fisher's exact]	No	NR	
						normal platelet reactivity ≤468 AU*min n=155		19						
Sibbing, 2012 22682553 Germany ISAR-REACT 4	LD: 600 mg of clopidogrel and 500 mg aspirin MD: clopidogrel 75 mg x 12 months and aspirin 100 mg twice daily for an indefinite period	MEA	Any recurring MI in pts on Abciximab Plus UFH	Any recurring MI	30 days	high on-treatment platelet reactivity >468 AU*min n=96	Any recurring MI	8	OR(calculated)=1.4	0.53-3.6	P=0.5 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=178		11						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Any recurring MI in pts on Bivalirudin	Any recurring MI	30 days	high on- treatment platelet reactivity >468 AU*min n=109	Any recurring MI	22	OR (calculated) = 5.5	2.3- 12.8	P<0.001 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=181		8						
			Large MI in pts on Abciximab Plus UFH	Large	30 days	high on- treatment platelet reactivity >468 AU*min n=96	large MI	4	OR (calculated) = 1.5	0.4-5.7	P=0.55 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=178		5						
			Large MI in pts on Bivalirudin	Large MI	30 days	high on- treatment platelet reactivity >468 AU*min n=109	large mi	12	OR (calculated) = 7.3	2.1- 26.6	P<0.001 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=181		3						

Appendix Table E70. Results from studies assessing the ability of Multiplate Analyzer to predict stent thrombosis in patients with ischemic heart disease

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing, 2010 19943882 Sibbing, 2010 20633826 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	definite ST	Occurrence of an acute coronary syndrome with either angiographic or pathological confirmation of thrombosis.	30 days	>468 aggregation units*min	definite ST	9/428 (2.1%)	OR=3.6 (calculated)	1.3- 9.7	P<0.001 (>468 AU*min vs ≤ 468 AU*min) [chi square]	NO	NR	Secondary
						≤468 aggregation units*min		7/1180 (0.3)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	Multiplate analyzer	Definite or probable stent thrombosis	Definite or probable stent thrombosis	30 days (all outcomes)	Enhanced responder (AUC≤188) (N=975)	Yes thrombosis	NR	NR	NR	0.38 enhanced responder vs. the remaining			Fig. 2
						Normal responder (AUC189-467) (N=1130)	Yes thrombosis	NR						
						Low responder (AUC≥468) (N=428)	Yes thrombosis	NR (2.8%)			<0.001 low responder vs the remaining two rows			

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing, 2009 19264241 Sibbing, 2010 20062919 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	definite ST	Occurrence of an acute coronary syndrome with either angiographic or pathological confirmation of thrombosis.	30 days	Low Responders (>416 aggregation units*min) n=323	definite ST	7 (2.2%)	OR=9.4	3.1- 28.4	P<0.0001 (low vs normal responder) [log rank]	NO	NR	Primary
						Normal Responders (≤416 aggregation units*min) n=1285		3 (0.2%)						
Sibbing, 2010 20062919 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	definite ST	Occurrence of an acute coronary syndrome with either angiographic or pathological confirmation of thrombosis.	6 months	Low Responders (>416 aggregation units*min) n=323	definite ST	8 (2.5%)	OR=6.5	2.4- 17	P<0.0001 (low vs normal responder) [log rank]	NO	NR	Primary
						Normal Responders (≤416 aggregation units*min) n=1285		6 (0.4%)						

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing, 2009 19264241	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	definite ST	Occurrence of an acute coronary syndrome with either angiographic or pathological confirmation of thrombosis.	30 days	Low Responders (>416 aggregation units*min) n=323	definite ST	7 (2.2%)	HR=10.95	2.31- 51.99	P=0.003 (low vs normal responder) [cox proportional hazards regression]	YES; Diabetes mellitus, active smoking, body mass index, ejection fraction, platelet count, time from clopidogrel loading to blood sampling, and CAD presentation (including STEMI, NSTEMI, stable angina, and unstable angina)	NR	Primary
						Normal Responders (≤416 aggregation units*min) n=1285		3 (0.2%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	definite ST	Occurrence of an acute coronary syndrome with either angiographic or pathological confirmation of thrombosis.	6 months	Low Responders (>416 aggregation units*min)	definite ST	8 (2.5%)	HR=5.3	2.3- 13.7	P=0.0006 (low vs normal responder) [cox proportional hazards regression]	YES; Diabetes mellitus, active smoking, body mass index, ejection fraction, platelet count, time from clopidogrel loading to blood sampling, and CAD presentation (including STEMI, NSTEMI, stable angina, and unstable angina)	NR	Primary

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal Responders (≤416 aggregation units*min)		6 (0.4%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Probable Stent thrombosis	As per Academic Research Consortium criteria	30 days	Low Responders (>416 aggregation units*min)	Probable Stent thrombosis	2 (0.6%)	OR=4	0.65- 24.47	P=0.13 (low vs normal responder) [log rank]	NO	NR	Primary
						Normal Responders (≤416 aggregation units*min)		2 (0.2%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Probable Stent thrombosis	As per Academic Research Consortium criteria	6 months	Low Responders (>416 aggregation units*min)	Probable Stent thrombosis	5 (1.6%)	OR=5	1.5- 16.3	P=0.008 (low vs normal responder) [log rank]	NO	NR	Primary

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal Responders (≤416 aggregation units*min)		4 (0.3%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Possible stent thrombosis	As per Academic Research Consortium criteria	6 months	Low Responders (>416 aggregation units*min)	Possible stent thrombosis	0/323	OR=0.4 (calculated)	0-6.5	P=0.26 (low vs normal responder) [log rank]	NO	NR	Primary
						Normal Responders (≤416 aggregation units*min)		5/1285 (0.4%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Stent thrombosis	Occurrence of an acute coronary syndrome with either angiographic or pathological confirmation of thrombosis.	30 days	Low Responders (>416 aggregation units*min)	Stent thrombosis	9 (2.8%)	Sensitivity: 0.7 Specificity: 0.84 AUC=0.78	0.60- 0.96	P<0.001	NR	NR	Primary

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal Responders (≤416 aggregation units*min)		5 (0.4%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Stent thrombosis	Occurrence of an acute coronary syndrome with either angiographic or pathological confirmation of thrombosis.	6 months	Low Responders (>425 aggregation units*min)	Stent thrombosis	13 (4.1%)	Sensitivity: 0.59 Specificity: 0.81 AUC=0.74	0.62- 0.86	P<0.0001	NR	NR	Primary
						Normal Responders (≤425 aggregation units*min)		9 (0.7%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	definite ST	Occurrence of an acute coronary syndrome with either angiographic or pathological confirmation of thrombosis.	30 days	High Responders (Quintile 1 ≤124 AU*min)	definite ST	1 (0.3%)	NR	NR	P=0.003 [Chi square]	NO	NR	Primary

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal Responders (Quintile 2 >124-≤192 AU*min)		0						
						Normal Responders (Quintile 3 >192-≤261 AU*min)		1 (0.3%)						
						Normal Responders (Quintile 4 >261-≤416 AU*min)		1 (0.3%)						
						Low Responders (Quintile 5: >416 AU*min)		7 (2.2%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Probable/definite ST	Occurrence of an acute coronary syndrome with either angiographic or pathological confirmation of thrombosis.	30 days	High Responders (Quintile 1 ≤124 AU*min)	Probable/definite ST	1 (0.3%)	NR	NR	P=0.001 [Chi square]	NO	NR	Primary
						Normal Responders (Quintile 2 >124-≤192 AU*min)		0						

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal Responders (Quintile 3 >192-≤261 AU*min)		2 (0.6%)						
						Normal Responders (Quintile 4 >261-≤416 AU*min)		2 (0.6%)						
						Low Responders (Quintile 5: >416 AU*min)		9 (2.8%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Combined probable/ definite stent thrombosis	As per Academic Research Consortium criteria	30 days	Low Responders (>416 aggregation units*min)	Combined probable/ definite stent thrombosis	9 (2.8%)	OR=7.26	2.86- 18.46	P<0.0001 (low vs normal responder) [log rank]	NO	NR	Landmark
						Normal Responders (≤416 aggregation units*min)		5 (0.4%)						

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Combined probable/definite stent thrombosis	As per Academic Research Consortium criteria	6 months	Low Responders (>416 aggregation units*min)	Combined probable/definite stent thrombosis	13 (4.1%)	OR=5.8	2.8-12.3	P<0.0001 (low vs normal responder) [log rank]	NO	NR	Landmark
						Normal Responders (≤416 aggregation units*min)		9 (0.7%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Combined probable/definite stent thrombosis	As per Academic Research Consortium criteria	30 days to 6 months	Low Responders (>416 aggregation units*min)	Combined probable/definite stent thrombosis	4 (1.2%)	OR=4.1	1.1-14.7	P=0.03 (low vs normal responder) [log rank]	NO	NR	Landmark
						Normal Responders (≤416 aggregation units*min)		4 (0.3%)						

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Schulz, 2010 20691843 Germany NR	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	Definite stent thrombosis	Based on definition of the Academic Research Consortium (ARC)	1 year	Low responder	Definite stent thrombosis	8 (2.5%)	HR=5.4	1.9- 15.6	0.02 (low vs normal) cox proportional hazard model	NO	NR	Secondary outcome
						Normal responder		6 (0.5%)						
	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	Probable stent thrombosis	Based on definition of the Academic Research Consortium (ARC)	1 year	Low responder	Probable stent thrombosis	5 (1.6%)	HR=3.4	1-11	0.046 (low vs normal) cox proportional hazard model	NO	NR	Secondary outcome
						Normal responder		6 (0.5%)						
Siller- Matula 2010 19943879 Austria NR	600 mg LD Clopidogrel followed by MD 75 mg daily+250 mg LD aspirin followed by 100 mg daily	MEA	Definite stent thrombosis	Defined by ARC as ACS with angiographic or pathologic confirmation of thrombosis	Within 6 mo after stenting	Platelet hyperreactivity vs. no hyperreactivity	Definite stent thrombosis	--	AUC, 0.92 (SE 0.04) ROC cutoff, 54U Sensitivity 100% and specificity 86%;	For AUC, 0.85- 0.99	0.012 from ROC	NR	NR	NONE
						No platelet hyperreactivity	Definite stent thrombosis	0/341	NR	NR	NR	NR	NR	Data also given for MEA+VASP in Fig 3

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Platelet hyperreactivity		3/61	NR	NR	NR	NR	NR	Data also given for MEA+VASP in Fig 3
	600 mg LD Clopidogrel followed by MD 75 mg daily+250 mg LD aspirin followed by 100 mg daily	MEA	Composite of definite or probable stent thrombosis	Probable defined any unexplained death within 30 days or target vessel MI without angiographic confirmation of thrombosis or other identified culprit lesion		Platelet hyperreactivity vs. no hyperreactivity	Composite of definite or probable stent thrombosis	--	AUC, 0.81 (SE 0.10) ROC cutoff, 54U Sensitivity 86% and specificity 87%	For AUC, 0.61-1.02	0.004 from ROC	NR	NR	NONE
						No platelet hyperreactivity		1/341	NR	NR	NR	NR	NR	Data also given for MEA+VASP in Fig 3
						Platelet hyperreactivity		6/61	NR	NR	NR	NR	NR	Data also given for MEA+VASP in Fig 3
	600 mg LD Clopidogrel followed by MD 75 mg daily+250 mg LD aspirin followed by 100 mg daily	MEA	Probable stent thrombosis	Probable stent thrombosis		No platelet hyperreactivity	Probable stent thrombosis	0/341	NR	NR	NR	NR	NR	Data also given for MEA+VASP in Fig 3
						Platelet hyperreactivity		3/61	NR	NR	NR	NR	NR	Data also given for MEA+VASP in Fig 3

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Eshtehardi, 2010 20435201 Switzerland NR	600 mg LD Clopidogrel+500 mg aspirin	Aggregometry	Stent thrombosis (early definite)	Defined according to the Academic Research Consortium Definitions [ref 26]		Clopidogrel low response		0	OR=6.6 (calculated)	0.6- 74.8	0.004 across this and next three rows (Fisher's exact or chi- square)			
						Aspirin low response		0						
						Dual low response		2 (10.5%)						
						Normal response		1 (0.8%)						
Siller- Matula, 2012 22260716 PEGASUS- PCI	clopidogrel LD 600mg, MD 75mg	MEA	stent thrombosis	stent thrombosis (definite and probable)	12-month	non-responder	stent thrombosis	9/81 (12.5)	HR=36.9	4.3- 31.9	<0.001 between non- responder and responder cox regression	yes,CY P2C19*2 carrier status,BMI, CRP levels,DM, age, renal failure(creatin e clearance<60mg mL,MI,sex,PPI	NR	
						responder		1/321(0.3)						
	clopidogrel LD 600mg, MD 75mg	MEA-ADP- PGE1	stent thrombosis	stent thrombosis	12-month	NR	stent thrombosis	NR	sensitivity 0.9 specificity 0.83 AUC 0.90 cut-off 48	AUC 0.86- 0.95	<0.001	NR	NR	
	clopidogrel LD 600mg, MD 75mg	MEA-ADP	stent thrombosis	stent thrombosis	12-month	NR	stent thrombosis	NR	sensitivity 0.7 specificity 0.67 AUC 0.78 cut-off 46	AUC 0.63- 0.94	0.002	NR	NR	

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel LD 600mg, MD 75mg	VASP (%PRI)	stent thrombosis	stent thrombosis	12-month	NR	stent thrombosis	NR	sensitivity 0.7 specificity 0.38 AUC 0.62 cut-off 42	AUC 0.46- 0.79	0.204	NR	NR	
	clopidogrel LD 600mg, MD 75mg	PFA100:CADP- CT(s)	stent thrombosis	stent thrombosis	12-month	NR	stent thrombosis	NR	sensitivity 0.70 specificity 0.61 AUC 0.66 cut-off 105	AUC 0.48- 0.84	0.084	NR	NR	
	clopidogrel LD 600mg, MD 75mg	CPA:ADP (SC%)	stent thrombosis	stent thrombosis	12-month	NR	stent thrombosis	NR	sensitivity 0.90 specificity 0.36 AUC 0.62 cut-off 4.6	AUC 0.47- 76	0.205	NR	NR	
	clopidogrel LD 600mg, MD 75mg	CPA: ADP (ASum2)	stent thrombosis	stent thrombosis	12-month	NR	stent thrombosis	NR	sensitivity 0.6 specificity 0.42 AUC 0.45 cut-off 43	AUC 0.25- 0.65	0.606	NR	NR	
Johnston, 2012 22465351 New Zealand NR	aspirin ≥300 mg at and clopidogrel ≥300 mg and/or aspirin (≥75 mg) and clopidogrel (≥75 mg)	MEA	stent thrombosis	stent thrombosis	3 days	High on treatment platelet reactivity >468 AU*min n=95	HTPR	0	OR (calculated) = 1.63	NR	P=0.81 (HTPR vs normal) [Fisher's exact]	No	NR	
						normal platelet reactivity ≤468 AU*min n=155		0						

Author year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing, 2012 22682553 Germany ISAR- REACT 4	LD: 600 mg of clopidogrel and 500 mg aspirin MD: clopidogrel 75 mg x 12 months and aspirin 100 mg twice daily for an indefinite period	MEA	stent thrombosis in pts on Abciximab Plus UFH	definite stent thrombosis	30 days	high on- treatment platelet reactivity >468 AU*min n=96	definite stent thrombosis	0	OR (calculated) = 0.6	0.02- 15.2	P=0.46 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=178		1						
			stent thrombosis in pts on Bivalirudin	definite stent thrombosis	30 days	high on- treatment platelet reactivity >468 AU*min n=109	definite stent thrombosis	1	OR (calculated) = 5.02	0.2- 124.3	P=0.2 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=181		0						

Appendix Table E71. Results from the studies assessing the ability of Multiplate Analyzer to predict major adverse cardiovascular events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Ko, 2011 21315223 Korea NR	75 mg/d clopidogrel & 100 mg/d aspirin	Multiple Electrode Platelet Aggregometry (MEA-ADP)	Major adverse cardio-vascular events (MACE)	Death, MI, stroke, and target vessel revascularization	From PCI to 30 days	NR	MACE +	NR	NR	NR	NR	NR	NR	AUC = 0.443; P = 0.415 (Fig2b)
Sibbing 2010 19943882 Sibbing 2010 20633826 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	Mutliplate analyzer	adverse event	Definite or probable stent thrombosis or in-hospital TIMI major bleeding	30 days	AUC≤ 188 Enhanced responder (N=975)	adverse event	NR	incidence of adverse events	NR	0.008 across all 3 groups chi square test	NR	NR	Fig 1
						AUC 189-467 normal responders n=1130								
						AUC ≥468 low responders n=428								

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing 2010 20633826 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	Mutliplate analyzer	adverse event	Definite or probable stent thrombosis or in-hospital TIMI major bleeding	30 days	Normal responder (N=1130)	adverse event	NR	OR=0.40	0.22-0.75	0.003 between normal responder and remaining patients NR	NR	NR	
						Enhanced or low responder (N=1403)								
Sibbing 2009 19264241 Sibbing 2010 20062919 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	MACE	Death or Stent thrombosis	30 days	Low Responders (>416 aggregation units*min)	MACE	10 (3.1%)	OR=5.1	2.2- 11.6	P<0.001 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		8 (0.6%)						
Sibbing 2010 20062919 Germany NR		MEA	MACE	Death or Stent thrombosis	6 months	Low Responders (>416 aggregation units*min)	MACE	16 (5%)	OR=5.1	2.2- 11.6	P<0.001 (low vs normal responder) [log rank]	NO	NR	Secondary

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal Responders (≤416 aggregation units*min)		30 (2.3%)						
			MACE	Cardiac Death + Definite ST	6 months	Low Responders (>416 aggregation units*min)	MACE	14 (4.4%)	OR=3.3	1.7- 6.5	P<0.001 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		17 (1.3%)						
			MACE	Death + ST As per Academic Research Consortium criteria	30 days	Low Responders (>416 aggregation units*min)	Combined death/ definite ST	10 (3.1%)	OR=5.05	2.19- 11.64	P<0.001 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		8 (0.6%)						
			MACE	Death or definite Stent thrombosis	6 months	Low Responders (>416 aggregation units*min)	MACE	16 (5%)	OR=2.2	1.2- 4.1	P=0.008 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		29 (2.3%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Schulz 2010 20691843 Germany NR	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	MACE	Death or MI	1 year	Low responder	MACE	27 (8.4%)	HR=1.3	0.8-1.9	0.298 (low vs normal) cox proportional hazard model	NO	NR	Secondary outcome
						Normal responder		86 (6.7%)						
Freyenhofer 2011 21614416 Austria NR	300 or 600mg LD Clopidogrel and maintain dose 75 mg + aspirin 100mg	MEA	MACE	MACE included: 1) definite and probable ST according to the ARC-definition; 2) cardiovascular death, defined as death associated with ACS, significant arrhythmia, or congestive heart failure; and 3) non-fatal STEMI (STEMI: acute onset of prolonged typical ischaemic chest pains, ST-segment elevation of at least 1 mm in 2 or more contiguous electrocardiogram leads and increased biomarkers of myocardial necrosis)	6 months	High reactivity/poor response n=59	MACE	3 (5.4%)	OR=23.5 (calculate)	NR	0.670 high vs. low reactivity chi square	NR	NR	Fig 1

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Low reactivity/ good response n=137		4 (2.9%)						Get n's from Fig 1 (pasted in on last page of this form)
Eshtehardi 2010 20435201 Switzerland NR	600 mg LD Clopidogrel + 500 mg aspirin	Aggregometry	MACE	Composite of PCI-related MI, stent thrombosis, death, or MI	30 days	Clopidogrel low response n=33	MACE	2 (6.1%)	OR = 8.0 dual vs normal (calculate) OR= 9.0 dual vs clopidogrel low response (calculated)	2.5-25.4 1.6-49.8	<0.001 across this and next three rows; <0.001 for dual vs normal; 0.005 for dual vs clopidogrel (Fisher's exact or chi-square)	NR	NR	none
						Aspirin low response n=34		3 (8.8%)						
						Dual low response n=19		7 (36.8%)	odds 7.35	2.21-24.42	<0.001 (Multivariable logistic regression analysis)			
						Normal response n=133		9 (6.8%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Ivancic 2009 19359538 Germany NR	Clopidogrel 600mg LD + aspirin 0.5g	Aggregometry	Combined end point:	Combined end point: first occurrence of any of the following cardiovascular events: cardiovascular death, myocardial infarction, target vessel revascularization, or stent thrombosis occurring 30 days or later after PCI.	>= 30 days after PCI	Clopidogrel nonresponder (n=34)	Combined end point	8 (23.5%)	HR= 1.04	0.24-4.44	NS non-responder vs. full (cox proportional hazard model) Also NS vs full responders below	NR	NR	NONE
						Nonresponse to clopidogrel but response to aspirin (n=15)		2 (13.3%)						
						Full responders (n=134)		18 (13.4%)						
						Dual nonresponder (n=19)		6 (31.6%)	HR 2.57 HR in multivariate analysis, 2.9	1.18-5.61 In multivariate, 1.17-7.2	0.03 dual non-responder vs. any responders In multivariate, 0.02 (Cox regression)			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 600 mg LD + aspirin 0.5g	Aggregometry	Cardio-vascular events	Freedom from combined end point myocardial infarction, target vessel revascularization, late stent thrombosis, or cardiac death in KM curve	>= 30 days after PCI	Responders (n=163)	cardiovascular events	40/163	OR=5.3 (calculated)	1.9-14.3	0.03 dual nonresponder vs. responder (log rank)	NR	NR	K-M curves are in Fig. 1
						Dual nonresponders (n=19)		12/19						K-M curves are in Fig. 1
	Clopidogrel 600 mg LD + aspirin 0.5g	Aggregometry	Any cardio-vascular event	Any cardiovascular event	>= 30 days after PCI	Responders (n=163)	Any cardiovascular event	20 (12.2%)	Relative risk 2.57 dual non-responder vs. responder	1.18-5.61	NR	NR	NR	
						Dual nonresponders (n=19)		6 (31.5%)						
Siller-Matula, 2012 22260716 PEGASUS-PCI	clopidogrel LD 600 mg, MD 75mg	MEA	MACE	major adverse cardiac events	12-month	non-responder	MACE	15/81 (21)	HR=1.67	0.86-3.2	NR	yes,CY P2C19*2 carrier status, BMI, CRP levels,DM, age, renal failure (creatinine clearance <60mg mL, MI, sex, PPI	NR	
						responder		37/321(12)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel LD 600mg, MD 75mg	MEA	MACE	major adverse cardiac events	12-month	non-responder	MACE	15/81 (21)	HR=1.67	0.86-3.2	NR	yes,CY P2C19*2 carrier status, BMI, CRP levels, DM, age, renal failure (creatinine clearance <60mg mL, MI, sex, PPI	NR	
						responder		37/321(12)						
	clopidogrel LD 600 mg, MD 75 mg	MEA-ADP-PGE1	MACE	major adverse cardiac events	12-month	NR	MACE	NR	sensitivity 0.3 specificity 0.81 AUC 0.63 cut-off 48	AUC 0.55-0.71	0.042	NR	NR	
	clopidogrel LD 600mg, MD 75mg	MEA-ADP	MACE	major adverse cardiac events	12-month	NR	MACE	NR	sensitivity 0.5 specificity 0.64 AUC 0.62 cut-off 46	AUC 0.54-0.70	0.039	NR	NR	
	clopidogrel LD 600 mg, MD 75 mg	VASP (%PRI)	MACE	major adverse cardiac events	12-month	NR	MACE	NR	sensitivity 0.68 specificity 0.37 AUC 0.54 cut-off 42	AUC0.45-0.63	0.039	NR	NR	
	clopidogrel LD 600mg, MD 75mg	PFA100:CADP-CT(s)	MACE	major adverse cardiac events	12-month	NR	MACE	NR	sensitivity 0.44 specificity 0.62 AUC 0.56 cut-off 105	AUC0.48-0.64	0.062	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel LD 600mg, MD 75mg	CPA:ADP (SC%)	MACE	major adverse cardiac events	12-month	NR	MACE	NR	sensitivity 0.72 specificity 0.36 AUC 0.54 cut-off 4.6	AUC0.38-0.62	0.38	NR	NR	
	clopidogrel LD 600mg, MD 75mg	CPA: ADP (ASum2)	MACE	major adverse cardiac events	12-month	NR	MACE	NR	sensitivity 0.43 specificity 0.60 AUC 0.53 cut-off 43	AUC 0.45-0.61	0.47	NR	NR	
Gerotziakas, 2012 22311629 Greece NR	aspirin 100 mg and clopidogrel 75 mg once daily	MEA	MACE	acute coronary syndrome, ischemic stroke, and death from cardiovascular cause	90 days	High platelet reactivity MEA >50U n=3	HPR	0	OR (calculated) = 29.6	NR	P=0.1 (HPR vs normal) [Fisher's exact]	No	NR	
						normal platelet reactivity n=103		0						
Sibbing, 2012 22682553 Germany ISAR-REACT 4	LD: 600 mg of clopidogrel and 500 mg aspirin MD: clopidogrel 75 mg x 12 months and aspirin 100 mg twice daily for an indefinite period	MEA	MACE	death, MI, or urgent TVR at 30 days after PCI	30 days	high on-treatment platelet reactivity >468 AU*min n=205	MACE	33	OR=3.1	1.73-5.5	P<0.0001 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=359		31						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			MACE in pts on Abciximab Plus UFH	death, MI, or urgent TVR at 30 days after PCI	30 days	high on-treatment platelet reactivity >468 AU*min n=96	MACE	9	OR=1.43	0.6-3.5	P=0.43 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=178		12						
			MACE in pts on Bivalirudin	death, MI, or urgent TVR at 30 days after PCI	30 days	high on-treatment platelet reactivity >468 AU*min n=109	MACE	24	OR=1.4	0.4-2.3	P<0.001 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=181		9						
			MACE in pts on Abciximab Plus UFH	death or any recurrent MI	30 days	high on-treatment platelet reactivity >468 AU*min n=96	MACE	9	OR=1.43	0.6-3.5	P=0.43 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=178		12						
			MACE in pts on Bivalirudin	death or any recurrent MI	30 days	high on-treatment platelet reactivity >468 AU*min n=109	MACE	23	OR=5.5	2.3-12.8	P<0.001 (HTPR vs normal) [Cox regression]	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						normal platelet reactivity ≤ 468 AU*min n=181		9						
Siller-Matula, 2012 22305813 Austria NR	LD clopidogrel 600 mg 2 h pre PCI, 100 mg aspirin intake ; Additionally 250 mg acetylsalicylic acid i.v. directly before stent placement MD: 75 mg clopidogrel; 100 mg aspirin for 12 months	MEA	MACE	stent thrombosis, acute coronary syndrome, death, stroke, repeated revascularization: percutaneous coronary intervention or coronary artery bypass surgery	12 monhts	high platelet reactivity (HPR) to ADP (ADP \geq 48U): 75 (19%)	MACE	NR	AUC=0.6	0.53-0.66	P=0.033	No	NR	
						No HPR to ADP (ADP<47U): 328 (81%)		NR						
			MACE	stent thrombosis, acute coronary syndrome, death, stroke, repeated revascularization: percutaneous coronary intervention or coronary artery bypass surgery	12 monhts	HPR to AA and ADP: 32(8%)	MACE	K-M estimates: 12 (37.5%)	NR	NR	P=0.003 (dual nonresponders vs any or both responders) [log rank test]	yes	Bonferroni correction	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						HPR to ADP: 44 (11%)		K-M estimates: 15 (33.3%)						
						HPR to AA: 77 (19%)		K-M estimates: 20 (25.6%)						
						No HPR: 250 (62%)		K-M estimates: 47 (18.6%)						
			MACE	stent thrombosis, acute coronary syndrome, death, stroke, repeated revascularization: percutaneous coronary intervention or coronary artery bypass surgery	12 monhts	Any HPR (ADP≥48U and/or AA>14U): n=153	MACE	48	OR=1.75	1.1-2.9	P=0.029 (Any HPR vs no HPR) [Chi-squared Automatic Interaction Detection (CHAID) analysis]	No	NR	
						No HPR to ADP or AA (ADP<48U, AA<14U): 250		47						
			MACE in diabetic patients	stent thrombosis, acute coronary syndrome, death, stroke, repeated revascularization: percutaneous coronary intervention or coronary artery bypass surgery	12 monhts	Any HPR (ADP≥48U and/or AA>14U):	MACE	37%	OR=2.18	1.2-3.95	P=0.04 (Any HPR vs no HPR) [Chi-squared Automatic Interaction Detection (CHAID) analysis]	No	NR	
						No HPR to ADP or AA (ADP<48U, AA<14U):		21%						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			MACE in non-diabetic patients	stent thrombosis, acute coronary syndrome, death, stroke, repeated revascularization: percutaneous coronary intervention or coronary artery bypass surgery	12 monhts	Any HPR (ADP≥48U and/or AA>14U):	MACE	29%	OR=1.86	1.03-3.37	P=0.048 (Any HPR vs no HPR) [Chi-squared Automatic Interaction Detection (CHAID) analysis]	No	NR	
						No HPR to ADP or AA (ADP<48U, AA<14U):		18%						

Appendix Table E72. Results from studies assessing the ability of Multiplate Analyzer to predict major adverse cardiovascular events in patients with cerebrovascular disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Muller-Schunk, 2008 18223094 Germany NR	LD 300 mg of clopidogrel 75 mg/day continuously	Impedance aggregometry	Adverse event	Transient intrainterventional thrombosis, TIA or infarction	NR	Non-responder	Adverse event	5/14	OR=42.3 (calculated)	2.1-833.5	0.001 non-responder vs. responder Fisher exact test	NR	NR	
						Responder		0/36						
	LD 300 mg of clopidogrel 75 mg/day continuously	Impedance aggregometry	Adverse event	Transient intrainterventional thrombosis, TIA or infarction	NR	1 Aggregation unit	Adverse event	NR	OR=1.15	NR	0.032 1U increase of aggregation logistic regression	NR	NR	

Appendix Table E73. Results from studies assessing the ability of Multiplate Analyzer to predict bleeding events in patients with ischemic heart disease

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing 2010 19943882 Sibbing 2010 20633826 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	in-hospital major bleed	As per Thrombolysis in Myocardial Infarction (TIMI) criteria -TIMI major bleeding	30 days	Enhanced Responders (<188 aggregation units*min)	in-hospital major bleed	21/975 (2.2%)	Sensitivity: 0.62 Specificity: 0.62 AUC=0.61	0.51- 0.7	P=0.017 for ROC	NR	NR	Primary
						Remaining patients - Not enhanced responders (≥188 aggregation units*min)		13/1558 (0.8%)						
			in-hospital major bleed	As per Thrombolysis in Myocardial Infarction (TIMI) criteria -TIMI major bleeding	30 days	Enhanced Responders (<188 aggregation units*min)	in-hospital major bleed	21/975 (2.2%)	OR=2.6	1.3- 5.2	P=0.005 (enhanced vs remaining responder) [logistic regression]	NO	NR	Primary
						Remaining patients - Not enhanced responders (≥188 aggregation units*min)		13/1558 (0.8%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			in-hospital major bleed	As per Thrombolysis in Myocardial Infarction (TIMI) criteria -TIMI major bleeding	30 days	Enhanced Responders (<188 aggregation units*min)	in-hospital major bleed	21/975 (2.2%)	OR=3.5	1.6- 7.3	P=0.001 (enhanced vs remaining responder) [multiple logistic regression]	YES; age, body mass index, diabetes, renal failure, presence of an MI at admission, treatment at admission with aspirin, a thienopyridine, a statin or a coumarin derivate, use of abciximab, use of intra-aortic balloon pumping, number of lesions treated and complex lesions (defined as type B2/C lesions according to AHA/ACC lesions morphology).	NR	Primary
						Remaining patients - Not enhanced responders (≥188 aggregation units*min)		13/1558 (0.8%)						
			in-hospital major bleed	As per Thrombolysis in Myocardial Infarction (TIMI) criteria -TIMI major bleeding	30 days	Enhanced responder (AUC≤188) (N=975)	Yes bleeding	NR /975(2.2%)	NR	NR	0.018 across this and next two rows of enhanced, normal and low responders			Data for this outcome are %s in Fig. 1—can be obtained by digitizing

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal responder (AUC189-467) (N=1130)	Yes bleeding	NR/1130			0.72 between normal and low responder			
						Low responder (AUC≥468) (N=428)	Yes bleeding	NR/428						
			in-hospital minor bleed	As per Thrombolysis in Myocardial Infarction (TIMI) criteria -TIMI minor bleeding	30 days	Enhanced Responders (<188 aggregation units*min)	in-hospital minor bleed	55/975 (5.6%)	OR=1.1	0.8- 1.5	P=0.68 (enhanced vs remaining responder) [logistic regression	NO	NR	Primary
						Remaining patients - Not enhanced responders (≥188 aggregation units*min)		82/1558 (5.3%)						
			Bleeding Composite	TIMI major and minor bleeding	30 days	Enhanced Responders (<188 aggregation units*min)	in-hospital major and minor bleed	76/975 (7.8%)	OR=1.3	0.95- 1.8	P=0.1 (enhanced vs remaining responder) [logistic regression]	NO	NR	Primary
						Remaining patients - Not enhanced responders (≥188 aggregation units*min)		95/1558 (6.1%)						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing 2009 19264241 Sibbing 2010 20062919 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Thrombolysis In Myocardial Infarction (TIMI) major bleeding	TIMI criteria	30 days	High Responders (Quintile 1 ≤124 AU*min)	Thrombolysis In Myocardial Infarction (TIMI) major bleeding	4/318 (1.3%)	OR=1.8 (calculated)	0.6- 5.9	P=0.32 between quintile 1 and 2-5 [Chi square]	NO	NR	Safety
						Normal Responders and low responders (Quintile 2 -5)		9/1290 (0.7%)						
			Thrombolysis In Myocardial Infarction (TIMI) minor bleeding	TIMI criteria	30 days	High Responders (Quintile 1 ≤124 AU*min)	Thrombolysis In Myocardial Infarction (TIMI) minor bleeding	10/318 (3.1%)	OR=1.3 (calculated)	0.6- 2.7	P=0.45 between high responder and remaining [Chi square]	NO	NR	Safety
						Normal Responders and low responders (Quintile 2 -5)		31/1290 (2.4%)						

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Schulz 2010 20691843 Germany NR	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	In-hospital TIMI major bleeding	defined according to Thrombolysis in Myocardial Infarction criteria	1 year	Low responder	In-hospital TIMI major bleeding	1 (0.3%)	HR=0.3	0.01- 2.4	0. 460 (low vs normal) Cox proportional hazards model	NO	NR	Secondary outcome
						Normal responder		12 (0.9%)						
Siller- Matula, 2012 22260716 PEGASUS- PCI	clopidogrel LD 600mg, MD 75mg	MEA	TIMI major bleeding	TIMI major bleeding	12-month	non-responder	TIMI major bleeding	0/81 (0)	HR=0 OR=1.17(calculated)	0-33 0.009- 2.84	NR	yes,CY P2C19*2 carrier status,BMI, CRP levels,DM, age, renal failure (creatine clearance <60mg mL, MI, sex, PPI	NR	
						responder		11/321(4)						
Gerotziafas, 2012 22311629 Greece NR	aspirin 100 mg and clopidogrel 75 mg once daily	MEA	Bleeding		90 days	High platelet reactivity MEA >50U n=3	HPR	0	OR (calculated)= 29.6	NR	P=0.1 (HPR vs normal) [Fisher's exact]	No	NR	
						normal platelet reactivity n=103		0						
Johnston, 2012 22465351 New Zealand NR	aspirin ≥300 mg at and clopidogrel ≥300 mg and/or aspirin (≥75 mg) and clopidogrel (≥75 mg)	MEA	Bleeding		3 days	High on treatment platelet reactivity >468 AU*min n=95	HTPR	0	OR (calculated) = 1.63	NR	P=0.81 (HTPR vs normal) [Fisher's exact]	No	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						normal platelet reactivity ≤468 AU*min n=155		0						

Appendix Table E74. Results from studies assessing the ability of Multiplate Analyzer to predict stroke in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing, 2009 19264241 Sibbing 2010 20062919 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Ischemic stroke	confirmation by CT/MRI imaging of the head.	30 days	Low Responders (>416 aggregation units*min)	Ischemic stroke	3 (0.9%)	OR=6.01	1.25-28.88	P=0.03 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		2 (0.2%)						
	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Ischemic stroke	confirmation by CT/MRI imaging of the head.	6 months	Low Responders (>416 aggregation units*min)	Ischemic stroke	3 (0.9%)	OR=4	0.9-17.6	P=0.07 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		3 (0.2%)						
Schulz, 2010 20691843 Germany NR	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	Stroke	By CT/MRI	1 year	Low responder	Stroke	4 (1.3%)	HR=2.3	0.7-7.8	0.185 (low vs normal) Chisquare	NO	NR	Secondary outcome

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal responder		7 (0.6%)						
	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	Hemorrhagic Stroke	By CT/MRI	1 year	Low responder	Hemorrhagic Stroke	0/323	OR=0.4 (calculated)	0-8.2	0. 853 (low vs normal) Chi square	NO	NR	Secondary outcome
						Normal responder		4/1285(0.3%)						
	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	Ischemic Stroke	By CT/MRI	1 year	Low responder	Ischemic Stroke	4 (1.3%)	HR=5.4	1.2-24	0. 028 (low vs normal) Chisquare	NO	NR	Secondary outcome
						Normal responder		3 (0.2%)						

Appendix Table E75. Results from studies assessing the ability of Multiplate Analyzer to predict other clinical events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Sibbing, 2009 19264241 Sibbing, 2010 20062919 Germany NR	Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MD & Aspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD	MEA	Target lesion reintervention	NR	30 days	Low Responders (>416 aggregation units*min)	Target lesion reintervention	7 (2.2%)	OR=4.02	1.53-10.58	P=0.005 (low vs normal responder) [log rank]	NO	NR	Secondary
						Normal Responders (≤416 aggregation units*min)		7 (0.5%)						
Schulz, 2010 20691843 Germany NR	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	Clinical restenosis defined as target lesion revascularization (TLR)	repeat PCI of the target lesion or bypass surgery of the target vessel	1 year	Low responder	Clinical restenosis	34 (10.9%)	HR=1.2	0.8-1.7	0.441 (low vs normal) cox proportional hazard model	NO	NR	Primary outcome
						Normal responder		119 (9.5)						
	Clopidogrel 75 mg/d + Aspirin 100 mg/d	MEA by Multiplate analyzer	Clinical restenosis defined as target lesion revascularization (TLR)	repeat PCI of the target lesion or bypass surgery of the target vessel	1 year	Low responder	Clinical restenosis	34 (10.9%)	HR=1	0.9-1.1	0.717 (low vs normal) Cox regression	YES; chronic occlusions, complex lesions, lesion length, and diameter stenosis before PCI	NR	Secondary outcome

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal responder		119 (9.5)						
Ivancic, 2009 19359538 Germany NR	Clopidogrel 600mg LD+aspirin 0.5g	Aggregometry	Target vessel revascularization	Target vessel revascularization	30 days or later after PCI	Responders (n=163)	Target vessel revascularization	7 (4.3%)	Relative risk 3.68	1.03-13.04	NR	NR	NR	
						Dual nonresponders (n=19)		3 (15.8%)						
Johnston, 2012 22465351 New Zealand NR	aspirin ≥300 mg at and clopidogrel ≥300 mg and/or aspirin (≥75 mg) and clopidogrel (≥75 mg)	MEA	Target vessel revascularization		3 days	High on treatment platelet reactivity >468 AU*min n=95	HTPR	0	OR (calculated) = 1.63	NR	P=0.81 (HTPR vs normal) [Fisher's exact]	No	NR	
						normal platelet reactivity ≤468 AU*min n=155		0						
Sibbing, 2012 22682553 Germany ISAR-REACT 4	LD: 600 mg of clopidogrel and 500 mg aspirin MD: clopidogrel 75 mg x 12 months and aspirin 100 mg twice daily for an indefinite period	MEA	Target vessel revascularization in pts on Abciximab Plus UFH	Target vessel revascularization	30 days	high on-treatment platelet reactivity >468 AU*min n=96	Target vessel revascularization	0	OR (calculated) = 0.6	0.02-15.2	P=0.46 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=178		1						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Target vessel revascularization in pts on Bivalirudin	Target vessel revascularization	30 days	high on-treatment platelet reactivity >468 AU*min n=109	Target vessel revascularization	2	OR(calculated)=8.4	0.4-177.5	P=0.07 (HTPR vs normal) [Cox regression]	No	NR	
						normal platelet reactivity ≤468 AU*min n=181		0						

Appendix Table E76. Results from studies assessing the ability of Multiplate Analyzer to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Siller-Matula, 2009 19135705 Austria NR	Clopidogrel 75 mg MD	Impedence aggregometry	Impedence aggregometry	Aggregation measured with PGE1 and ADP	24 hrs after PCI	Impedence between 16-88 units	Impedence between 16-88 units	In Fig 1D; difficult to interpret	NR	NR	NR	NR	NR	NR	Fig 1D shows shaded area greater than normal range reported in the text
						Impedence between 16-88 units	Impedence between <16 units	In Fig 1D; difficult to interpret	NR	NR	NR	NR	NR	NR	
						Impedence between <16 units	Impedence between 16-88 units	In Fig 1D; difficult to interpret	NR	NR	NR	NR	NR	NR	
						Impedence between <16 units	Impedence between <16 units	In Fig 1D; difficult to interpret	NR	NR	NR	NR	NR	NR	
Codner, 2012 22534051 Israel NR	LD: clopidogrel 600 mg and aspirin 100 mg MD: clopidogrel 75 mg/d and aspirin 100 mg/d	MEA	HTPR	MEA>47 AU	6 months	HTPR at baseline	HTPR at 6 months	5	≥47	OR (calculated)= 3.3	0.8-13.1	P = 0.0894 [Chi square]			
						HTPR at baseline	responder at 6 months	8							
						responder at baseline	HTPR at 6 months	7							
						responder at baseline	responder at 6 months	37							

Appendix Table E77. Quality assessment of studies assessing the predictive ability of Multiplate Analyzer in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Siller- Matula, 2009 19135705 Austria NR	NR	yes	yes	low	low	NR	yes	unclear	high	No	NR	high	high	no	yes	yes	yes	low
Ko, 2011 21315223 Korea NR	YES	YES	YES	LOW	LOW	YES	NO	HIGH	LOW	YES	NR	UNCLEAR	LOW	NO [30 days]	YES	YES	YES	LOW
Sibbing, 2010 19943882 Sibbing, 2010 20633826 Germany NR	YES	YES	YES	LOW	LOW	YES	NO;(Sibbing 19943882 was used as reference for Sibbing 20638826))	UNCLEAR	HIGH	YES	YES; (NR in Sibbing 20638826)	LOW; (Unclear in Sibbing 20638826)	LOW	NO	YES	YES	YES	LOW
Sibbing, 2009 19264241 Sibbing, 2010 20062919 Germany NR	YES	YES	YES	LOW	LOW	YES	NO	UNCLEAR	HIGH	YES	YES	LOW	LOW	NO	YES	YES	YES	LOW
Schulz, 2010 20691843 Germany NR	YES	YES	YES	LOW	LOW	NR	YES	UNCLEAR	HIGH	YES	YES	LOW	LOW	YES [1 year]	YES	YES	YES	LOW

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Freynhofer, 2011 21614416 Austria NR	yes	yes	yes	low	low	NR	yes	unclear	low	yes	yes	low	low	no	yes	yes	yes	low
Siller- Matula, 2010 19943879 Austria NR	yes	yes	yes	low	low	NR	yes	unclear	Low	yes	NR	unclear	low	no (6 months)	yes	yes	yes	low
Eshtehardi, 2010 20435201 Switzerland NR	YES	YES	YES	low	low	YES ("The operators	YES	low	low	YES	YES ("All events were independently adjudicated by a	low	low	NO (30 days)	YES	YES	YES	LOW
Ivandic, 2009 19359538 Germany NR	YES	YES	YES	LOW	LOW	NR	NO	HIGH	UNCLEAR	YES	NR	UNCLEAR	LOW	NO (30 days)	YES	YES	YES	LOW
Siller- matula, 2012 22260716 PEGASUS- PCI	yes	yes	yes	low	low	yes	yes	low	low	yes	NR	unclear	Low	yes	yes	yes	yes	low
Codner, 2012 22534051 Israel NR	NR	Yes	yes	Low	Low	NR	Yes	unclear	Low	No	Yes	High	High	No [6 months]	Yes	yes	Yes	Low

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Gerotziafas, 2012 22311629 Greece NR	NR	Yes	Yes	Low	Low	Yes	Yes	Low	Low	Yes	Yes	Low	Low	No [3 months]	yes	Yes	Yes	Low
Sibbing, 2012 22682553 Germany ISAR- REACT 4	Yes	Yes	Yes	Low	Low	Yes	Yes	Low	Low	Yes	Yes	Low	Low	No [1 month]	yes	Yes	Yes	Low
Johnston, 2012 22465351 New Zealand NR	NR	Yes	Yes	Low	Low	Yes	Yes	Low	Low	Yes	Yes	low	Low	No [3 days]	yes	Yes	Yes	Low
Siller- Matula, 2012 22305813 Austria NR	NR	Yes	Yes	Low	Low	Yes	Yes	Low	Low	Yes	Yes	Low	Low	Yes [12 months]	Yes	Yes	Yes	Low

- Consecutive or random sample of patients enrolled.
- Case-control design avoided
- Study avoided inappropriate exclusions
Risk of bias: could the selection of patients have introduced bias (If ≥2 of the above 3 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)
Concerns that the included patients do not match the review question?
- Index test results interpreted without knowledge of results of reference standard?
- If a threshold used, was it prespecified?
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Concerns that the index test, its conduct, or its interpretation differ from the review question?
- Reference standard likely to correctly classify the target condition?
- Reference standard results interpreted without knowledge of index test results?

Could the reference standard, its conduct, or its interpretation have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Are there concerns that the target condition as defined by the reference standard does not match the review question?

- 8. Appropriate interval between index test and reference standard?
- 9. All patients received a reference standard?
- 10. All patients received the same reference standard?
- 11. Were all patients included in the analysis?

Could the patient flow have introduced bias? (If ≥ 3 of the above 4 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix Table E78. Quality assessment of studies assessing the predictive ability of Multiplate Analyzer in patients with cerebrovascular disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Muller- Schunk, 2008 18223094 Germany NR	Yes	No	Yes	Low	Low	NR	NO	HIGH	LOW	YES	NR	UNCLEAR	LOW	NO (30 days)	YES	YES	YES	LOW

Appendix Table E79. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of TEG

Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Bliden, 2006 17291930 USA NR	100 Caucasian male 60 African-American male 12 66±11	NR NR CABG 31 NR 13 NR 40 NR	83 56 HTN 74; systolic 145±22; diastolic 76±16 44	NR 100 100 NR	100 DES 75 BMS 24 NR	Non-emergent coronary stenting	Clopidogrel therapy (75 mg qd) for ≥1 month before undergoing non-emergent coronary stenting were enrolled after giving informed consent. A clopidogrel loading dose was not administered. All patients had received at least 81 mg aspirin for 7 days before the procedure.	Eptifibatide was administered at the discretion of the treating physician with the ESPRIT study protocol as a double bolus (180 ug/kg) followed by an infusion (2 ug/kg/min) for 18 to 24 h after procedure. Unfractionated heparin was administered according to the ESPRIT dosing regimen (60 U/kg) as a bolus to all patients in the catheterization laboratory immediately before stenting.
Cotton, 2010 20406238 UK NR	49 NR 67 63±11	NR NR 0 CABG 6 NR NR 29 NR	hyper 59 Ex-smoker 29 current 31 HTN 61 24	NR 100 94 39	NR NR one vessel 45 two vessel 10 three vessel 0	ACS	at least 300 mg clopidogrel loading dose if >12 prior to angiography followed by 75 mg daily as maintenance, or 600 mg loading if <12 h prior to angiography with 75 mg daily maintenance	NR
Kwak, 2010 211266640 Korea OPCABG	99 NR 72 65±7	NR NR 3 NR NR NR 6 NR	NR NR 65 41	NR NR NR NR	NR NR NR NR	patients scheduled for CABG	Dual antiplatelet therapy consisting of aspirin 100 mg and clopidogrel 75 mg was started 24 h after the surgery as adequate.	NR

Author, year [ref] UID Country Study Name	Total N Enrolled Race (% by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Gurbel, 2010 20691842 USA PREPARE POST-STENTING	225 White male: 54 African American male: 13 66±12	NR NR CVA 12 PTCA 35;CABG 24 NR NR 8 33 NR	hyper 80 55 Systolic BP, mm Hg: 144 ± 25 Diastolic BP, mm Hg 75 ± 17;HTN: 74 41	NR NR NR 34	NR NR NR	Patients undergoing percutaneous coronary intervention (PCI) from ACS	Clopidogrel: 300 (n=73) to 600 mg (n=75) LD + 75 mg/d MD; no LD for pts on clopidogrel (n=77) Aspirin: 325 mg LD + 81-325 mg MD	Eptifibatide (n=123) Unfractionated heparin to achieve a clotting time of 200 to 250 seconds (for those given GPIIb/IIIa inhibitor) and >300 seconds (all other patients)
Gurbel, 2005 16286165 USA PREPARE POST-STENTING	182 White: 115 (59%) 108 (56) 65±12	NR NR NR PTCA:39.6/CABG:24.5% NR NR 36.9% NR	Hyperlipidemia: 66.7% 43.8% HTN: 66.2% 42.2%	NR 100 NR NR	96% DES: 69.8%/BMS: 28.1% NR	PCI for ACS	Clopidogrel (loading dose of 300 or 600 mg or continuation of pre-enrollment maintenance dose; maintenance dose 75 mg daily) + aspirin (81- to 325-mg daily dose for seven days before the procedure, and 325 mg on day of procedure and daily thereafter)	
Tang, 2012 China NR	90 NR 48.9 63	NR NR 1.1 PCI 10/CABG 0 36.7 35.6 NR 11.1 16.7/8.9	hyper 22.2 63.3 47.8 21.1	NR NR NR NR	NR NR NR	PCI	LD 300 mg of clopidogrel and aspirin; MD 100 mg aspirin plus 75 mg clopidogrel or LD 200 mg aspirin and 150 mg clopidogrel	NR

* Mean (standard deviation), unless otherwise stated

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH= Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors

Add headings for additional subgroups. Data are means unless otherwise indicated; estimated is noted if reported as an estimate.

Appendix Table E80. Design characteristics of studies assessing the predictive ability of TEG in patients with ischemic heart disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enroment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Bliden, 2006 17291930 USA NR	prospective Cohort	no	Consecutive	Patients receiving clopidogrel	NR	12 months	Hospital inpatient	With the sample size calculation from SigmaStat software, it is estimated that the sample size required for 95% power with the alpha of 0.05 is approximately 100 patients.	Partly industry (NIH and Bayer)
Cotton, 2010 20406238 UK NR	prospective Cohort	No	Patients with ACS history	Patients with ACS history	Jan-June , 2008	6 months	Hospital inpatient	NR	NR
Preisman, 2010 20181490 Israel None	Prospective observational	NO	NR	Patients undergoing first CABG and receiving either or both aspirin and clopidogrel	13 May 2008 to 24 November 2008	NR	Inpatient	YES [YES]	Nonindustry (except PlateletMapping kits donated by manufacturer)
Kwak, 2010 21126640 Korea OPCABG	prospective cohort	no	patients scheduled for CABG	patients scheduled for CABG	Dec 2007- March 2009	5 days	hospital inpatient	yes. 80%	non-industry
Gurbel, 2010 20691842 USA PREPARE POST- STENTING	Prospective observational study	NO	Consecutive	Patients undergoing percutaneous coronary intervention (PCI) for ACS	2004 and 2005	Max of 36 months	Follwoup after intervention	YES; Accrual>80%	Non-industry (Sinai Hospital, Baltimore & NIH grant R44-HL059753)
Gurbel, 2005 16286165 USA PREPARE POST- STENTING	Prospective, observational	NO	Consecutive patients	Patients undergoing percutaneous coronary intervention (PCI) for ACS	NR	NR	Hospital, then outpatient	NO	NR
Tang, 2012 China NR	prospective cohort	no	NR	PCI patients	Jan 2009- March 2010	6 months	inpatient the followup	NR	non-industry

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; CAD = coronary artery disease; MI = myocardial infarction; NSTEMI = non-ST-elevation; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; DES=drug eluting stent; CABG=coronary artery bypass grafting; AA= arachidonic acid; SD=standard deviation; RCT=randomized controlled trial; NR=not reported

Appendix Table E81. Phenotypic test details in studies assessing the predictive ability of TEG in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Bliden, 2006 17291930 USA NR	Thrombelastograph Hemostasis Analyzer With Platelet-Mapping. Thrombelastograph Hemostasis Analyzer With Platelet-Mapping assay (Haemoscope Corp., Niles, Illinois)	ADP and AA	Baseline samples were obtained before coronary intervention and at 3 h and 18 to 24 h after stenting. Heparin at 3 h and 18 to 24 h within 2h	High on-treatment platelet reactivity (HPR): ≥70% ADP-induced aggregation with 2-μmol ADP at baseline as measured by TEG Normal on-treatment platelet reactivity (NPR): <70% ADP-induced aggregation with 2-μmol ADP at baseline as measured by TEG	based on previous literature	HPR: 22/100 (22%) NPR: 78/100 (22%)
Kwak, 2010 211266640 Korea OPCABG	TEG/ thromboelastography platelet mapping assay NR Haemoscope Corp., Niles, Illinois	ADP	Blood sampling and TEG platelet mapping assay were performed immediately before the induction of anesthesia Heparin NR NR	platelet inhibitory response 70%	ROC curve	platelet inhibitory response 70% n=33

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Gurbel, 2010 20691842 USA PREPARE POST- STENTING	Thromboelastography TEG Hemostasis System Haemoscope Corporation, Niles, IL	Thrombin & ADP	Blood; 18 to 24 hours post-PCI or 5 days post-PCI (if eptifibatide used) 40 USP lithium heparin Clopidogrel came first NR	Quartile of TEG Maximum amplitude with Thrombin Quartile 1 <65 mm Quartile 2 65-69 mm Quartile 3 >69-72 mm Quartile 4 >72 mm Quartile of TEG Maximum amplitude with ADP Quartile 1 <29 mm Quartile 2 29-39 mm Quartile 3 >39-72 mm Quartile 4 >72 mm	ROC curve analysis	Quartile of TEG Maximum amplitude with Thrombin Quartile 1 <65 mm 56 (25%) Quartile 2 65-69 mm56 (25%) Quartile 3 >69-72 mm56 (25%) Quartile 4 >72 mm57 (25%) Quartile of TEG Maximum amplitude with ADP Quartile 1 <29 mm 56 (25%) Quartile 2 29-39 mm 56 (25%) Quartile 3 >39-72 mm 56 (25%) Quartile 4 >72 mm 57 (25%)
Cotton, 2010 20406238 UK NR	Clot strength and speed of clot formation TEG R _ platelet mapping kit Haemoscope Corp	ADP	Study sample drawn into a 6 mL Lithium Heparin Vacutainer Lithium Heparin NR NR	sTEG <800 mm/min sTEG >800 mm/min	Based on literature	sTEG <800 mm/min: NR sTEG >800 mm/min: NR

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Gurbel, 2005 16286165 USA PREPARE POST- STENTING	Thromboelastography TEG Hemostasis System NR	20um ADP	At discharge 40 USP lithium heparin 2 hrs NR	TEG: Low reaction time R (time to initial thrombin- generated fibrin formation) <3.9 minutes TEG: Normal reaction time R(time to initial thrombin- generated fibrin formation) ≥3.9 minutes TEG: High maximum amplitude of thrombin-generated clot (MA) >72 mm TEG: Not High maximum amplitude of thrombin- generated clot (MA) ≤72 mm	Defined by ROC curve in the same study	TEG: Low reaction time R: NR TEG: Normal reaction time R: NR TEG: High maximum amplitude : NR TEG: Not High maximum amplitude : NR
Tang, 2012 China NR	thrombelastograph TEG Haemoscope Corporation, Niles, Illinois, USA	3.8% trisodium citrate	1 week, 1 month, 3 months, 6 months, 9 months, 12 months 3.8% trisodium citrate and lithium heparin 3 days NR	inhibition >50% n=30 resistence n=60	NR	inhibition >50% n=30 resistence n=60

*If more than one test, use separate rows

**E.g., nonresponsive vs. responsive to clopidogrel, high vs. low platelet reactivity

Abbreviations: ADP= adenosine 5'-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported

Appendix Table E82. Results from studies assessing the ability of TEG to predict death in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Bliden, 2006 17291930 USA NR	clopidogrel 75 mg qd	ADP-induced platelet reactivity	death	death	Day 0-30	Total n=100	death	0/100	NR	NR	NR	NR	NR	Figure 2 with dotted box plot for association of ADP inducing light transmittance aggregometry
					Day 31-365	Total n=100	death	0/100						
	clopidogrel 75 mg qd	ADP-induced platelet reactivity	death)	death	Day 0-30	HPR n=22	death	0/22	OR=3.5 (calculated)	NR	p=0.54 HPR vs NPR Fisher's exact test	NR	NR	
					Day 0-30	NPR N=78	death	0/78						
	clopidogrel 75 mg qd	ADP-induced platelet reactivity	death	death	Day 31-365	HPR n=22	death	0/22	OR=3.5 (calculated)	NR	p=0.54 HPR vs NPR Fisher's exact test	NR	NR	
					Day 31-365	NPR N=78	death	0/78						
Tang, 2012 22490487 China NR	100mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	cardiovascular death	cardiovascular death	6 months	control group	cardiovascular death	0/30=0	OR=3.10(calculated)	0.12-79.23	>0.05	NR	NR	from table 4

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	100 mg aspirin and 75 mg clopidogrel (R+R)		cardiovascular death	cardiovascular death	6 months	resistance plus routine	cardiovascular death	1/30=3%						
	200 mg aspirin and 150 mg clopidogrel (R+L)		cardiovascular death	cardiovascular death	6 months	resistance plus loading dose	cardiovascular death	0/30=0						
	100mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	cardiovascular death	cardiovascular death	12 months	control group	cardiovascular death	0/30=0	OR=3.10(calculated)	0.12-79.23	>0.05	NR	NR	from table 5
	100mg aspirin and 75 mg clopidogrel (R+R)		cardiovascular death	cardiovascular death	12 months	resistance plus routine	cardiovascular death	1/30=3%						
	200mg aspirin and 150 mg clopidogrel (R+L)		cardiovascular death	cardiovascular death	12 months	resistance plus loading dose	cardiovascular death	0/30=0						

Appendix Table E83. Results from studies assessing the ability of TEG to predict myocardial infarction in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Bliden, 2006 17291930 USA NR	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Myocardial infarction	Myocardial infarction	Day 0-30	HPR n=22	Myocardial infarction	3/22	OR=12.2 (calculated)	1.2- 123.5	p=0.03 HPR vs NPR Fisher's exact test	NR	NR	
	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Myocardial infarction	Myocardial infarction	Day 0-30	NPR N=78	Myocardial infarction	1/78						
	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Myocardial infarction	Myocardial infarction	Day 31-365	HPR n=22	Myocardial infarction	1/22	OR=10.95 (calculate)	0.4- 278.6	P=0.15 HPR vs NPR Fisher's exact test	NR	NR	
	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Myocardial infarction	Myocardial infarction	Day 31-365	NPR N=78	Myocardial infarction	0/78						
Tang, 2012 22490487 China NR	100mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	MI	myocardial infarction	6 months	control group	MI	0/30=0	OR=13.16 (calculate)	0.69- 249.48	<0.05 con vs R+R ANOVA	NR	NR	from table 4
	100mg aspirin and 75 mg clopidogrel (R+R)				6 months	resistance plus routine		5/30=17%			<0.05 R+R vs R+L ANOVA			
	200mg aspirin and 150 mg clopidogrel (R+L)				6 months	resistance plus loading dose		2/30=6%			<0.05 con vs R+L ANOVA			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	100mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	MI	myocardial infarction	12 months	control group	MI	0/30=0	OR=16. 18(calculated)	0.87- 301.62	<0.05 con vs R+R ANOVA	NR	NR	from table 5
	100mg aspirin and 75 mg clopidogrel (R+R)				12months	resistance plus routine		6/30=20%			<0.05 R+R vs R+L ANOVA			
	200mg aspirin and 150 mg clopidogrel (R+L)				12 months	resistance plus loading dose		3/30=6%			<0.05 con vs R+L ANOVA			

Appendix Table E84. Results from studies assessing the ability of TEG to predict stent thrombosis in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Tang, 2012 22490487 China NR	100mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	ST	stent thrombosis	12 months	control group	ST	1/30=3%	OR=7.25(calculated)	0.82-64.46	<0.05 con vs R+R ANOVA	NR	NR	from table 4
	100 mg aspirin and 75 mg clopidogrel (R+R)					resistance plus routine		6/30=20%			<0.05 R+R vs R+L ANOVA			
	200 mg aspirin and 150 mg clopidogrel (R+L)					resistance plus loading dose		3/30=10%			<0.05 con vs R+L ANOVA			
	100 mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	ST	stent thrombosis	12 months	control group	ST	2/30=6%	OR=4.26	0.81-22.53	<0.05 con vs R+R ANOVA	NR	NR	from table 5
	100 mg aspirin and 75 mg clopidogrel (R+R)					resistance plus routine		7/30=23%			<0.05 R+R vs R+L ANOVA			
	200 mg aspirin and 150 mg clopidogrel (R+L)					resistance plus loading dose		3/30=10%			<0.05 con vs R+L ANOVA			

Appendix Table E85. Results from studies assessing the ability of TEG to predict major adverse cardiovascular events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gurbel, 2010 20691842 USA PREPARE POST-STENTING	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	TEG-ADP	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascularization	First event over f/u of 36 months	TEG MA-ADP >47mm	MACE	NR	Sensitivity: 0.76 Specificity: 0.85 AUC: 0.84	0.78-0.89	P<0.001 from ROC	NO	NR	Primary endpoint; 14/59 (24%) of first events occurred after clopidogrel stopped (mean duration of Tx=of 6.4 ± 3 months)
						TEG MA-ADP ≤47mm		NR						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	TEG-Thrombin	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascularization	First event over f/u of 36 months	TEG MA-Thrombin >69mm	MACE	NR	Sensitivity: 0.76 Specificity: 0.60 AUC: 0.70	0.64-0.76	P<0.001 from ROC	NO	NR	Primary endpoint; 14/59 (24%) of first events occurred after clopidogrel stopped (mean duration of Tx=of 6.4 ± 3 months)
						TEG MA-Thrombin≤47mm		NR						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	TEG-ADP	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascularization	First event over f/u of 36 months	TEG MA-ADP >47mm	MACE	NR	HR=10.3	5.4-20	P<0.001 cox proportional hazard model	NO	NR	Primary endpoint
						TEG MA-ADP ≤47mm		NR						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	TEG-Thrombin	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascularization	First event over f/u of 36 months	TEG MA-Thrombin >69mm	MACE	NR	HR=3.8	2.1-7.0	P<0.001 cox proportional hazard model	NO	NR	Primary endpoint
						TEG MA-Thrombin≤47mm		NR						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	TEG-ADP	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascularization	First event over f/u of 36 months	TEG MA-ADP >47mm	MACE	NR	HR=10.9	5.6-21.3	P<0.001 cox proportional hazard model	YES; MA-THROMBIN >69 mm and calcium-channel blockers	NR	Primary endpoint
						TEG MA-ADP ≤47mm		NR						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	TEG-Thrombin	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascularization ¹	First event over f/u of 36 months	TEG MA-Thrombin >69mm	MACE	NR	HR=3.5	1.9-6.4	P<0.001 cox proportional hazard model	YES; MA-ADP>47 mm and calcium-channel blockers	NR	Primary endpoint
						TEG MA-Thrombin≤47mm		NR						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	TEG-ADP	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascularization	First event over f/u of 36 months	Quartile 1 <29 mm	MACE	3 (6%)	NR	NR	NR	NR	NR	Primary endpoint
						Quartile 2 29-39 mm		4 (8%)						
						Quartile 3 >39-72 mm		16 (29%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Quartile 4 >72 mm		36 (65%)						
	Clopidogrel 300-600 mg LD + 75 mg MD & Aspirin 325 mg LD + 81-325 mg MD	TEG-THROMBIN	MACE	Cardiac death, stent thrombosis, myocardial infarction, ischemic stroke, and unplanned revascularization	First event over f/u of 36 months	Quartile 1 <65 mm	MACE	5 (10%)	NR	NR	NR	NR	NR	Primary endpoint
						Quartile 2 65-69 mm		8 (15%)						
						Quartile 3 >69-72 mm		21 (38%)						
						Quartile 4 >72 mm		25 (43%)						
Cotton, 2010 20406238 UK NR	300 mg or 600 mg LD Clopidogrel and maintaining 75 mg+ Aspirin	sTEG AUC 15	Adverse event	MI + revascularization + cardiovascular admissions	1 year	sTEG <800 mm/min	Adverse event	0/NR	NR	NR	<0.02 sTEG <800 vs >800mm/min	NR	NR	
						sTEG AUC>800mm/min		5/NR						
Gurbel, 2005 16286165 USA PREPARE POST-STENTING	Clopidogrel (300- 600 mg LD+75 mg daily MD) + aspirin (81- to 325-mg/d x 7 days LD + 325 md/f MD)	TEG-MA	Ischemic events	Cardiovascular death, MI, unstable angina and stroke requiring rehospitalization	6 months	High TEG- MA- Quartile 4 (>72mm%)	Ischemic events	NR	OR=22.6	6.202-82.604	P<0.0001 (Multiple logistic regression)	YES; Low TEG-R (reaction time<3.9 mins), High LTA(Max agg>67%) and combination of High TEG-MA and low R	NR	Tab 4; it's not clear if all predictor were in the same model

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel (300- 600 mg LD+75 mg daily MD) + aspirin (81- to 325-mg/d x 7 days LD + 325 md/f MD)	TEG-R	Ischemic events	Cardiovascular death, MI, unstable angina and stroke requiring rehospitalization	6 months	Low-R Quartile 1 (<3.9 mins)	Ischemic events	NR	OR=4.4	1.002-19.051	P=0.0498 (Multiple logistic regression)	YES; High TEG-MA (ma amplitude >72mm), High LTA(Max agg>67%) and combination of High TEG-MA and low R	NR	Tab 4; it's not clear if all predictor were in the same model
	Clopidogrel (300- 600 mg LD+75 mg daily MD) + aspirin (81- to 325-mg/d x 7 days LD + 325 md/f MD)	TEG-MA	Ischemic events	Cardiovascular death, MI, unstable angina and stroke requiring rehospitalization	6 months	High TEG- MA- Quartile 4 (>72mm%)	Ischemic events	NR	Sens=0.74 Spec=0.89	NR	NR	NO	No	Tab 4; it's not clear if all predictor were in the same model
	Clopidogrel (300- 600 mg LD+75 mg daily MD) + aspirin (81- to 325-mg/d x 7 days LD + 325 md/f MD)	TEG-R	Ischemic events	Cardiovascular death, MI, unstable angina and stroke requiring rehospitalization	6 months	Low-R Quartile 1 (>3.9 mins)	Ischemic events	NR	Sens=0.42 Spec=0.79	NR	NR	NO	No	Tab 4; it's not clear if all predictor were in the same model

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel (300- 600 mg LD+75 mg daily MD) + aspirin (81- to 325-mg/d x 7 days LD + 325 md/f MD)	TEG-MA	Ischemic events	Cardiovascular death, MI, unstable angina and stroke requiring rehospitalization	6 months	Quartile 1 (<65 mm)	Ischemic events	2%	NR	NR	P<0.001 (Q1 vs Q4) P<0.001 (Q2 vs Q4) P<0.001 (Q3 vs Q4) Logistic regression with appropriate contrasts	NO	NR	Fig 7
						Quartile 2 (65-68 mm)		8%						
						Quartile 3 (69-72 mm)		9%						
						High TEG-MA - Quartile 4 (>72 mm)		58%						
	Clopidogrel (300- 600 mg LD+75 mg daily MD) + aspirin (81- to 325-mg/d x 7 days LD + 325 md/f MD)	TEG-R	Ischemic events	Cardiovascular death, MI, unstable angina and stroke requiring rehospitalization	6 months	Quartile 1 (<3.9 mins)	Ischemic events	33%	NR	NR	P=0.41 (Q1 vs Q2) P=0.006 (Q1 vs Q3) P=0.004 (Q1 vs Q4) Logistic regression with appropriate contrasts	NO	NR	Fig 8
						Quartile 2 (3.9-5.1 min)		26%						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Quartile 3 (5.2-6.1 min)		9%						
						Quartile 4 (6.1-14 min)		7%						
Bliden, 2006 17291930 USA NR	clopidogrel 75 mg qd	TEG	Ischemic events	Ischemic events	1 year	HPR	Ischemic event	NR	OR=26.8	6.7- 107.5	<0.001 cox regression	Yes, age, presentation, diabetes, hypertension, current smoking, BMS(bare-metal stents)	NR	

Appendix Table E86. Results from studies assessing the ability of TEG to predict bleeding events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Blinden, 2006 17291930 USA NR	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Major bleeding	Major bleeding	Day 0-30	HPR n=22	Major bleeding	1/22	OR=10.95 (calculated)	0.4-278.6	p=0.15 HPR vs NPR Fisher's exact test	NR	NR	
						NPR N=78	Major bleeding	0/78						
					Day 31-365	HPR n=22	Major bleeding	0/22	OR=3.5 (calculated)	NR	p=0.53 HPR vs NPR Fisher's exact test	NR	NR	
						NPR N=78	Major bleeding	0/78						
	clopidogrel 75 mg qd	ADP-induced platelet reactivity	Minor bleeding	Minor bleeding	Day 0-30	HPR n=22	Minor bleeding	1/22	OR=3.7 (calculated)	0.2-61.1	P=0.37 HPR vs NPR Fisher's exact test	NR	NR	
						NPR N=78	Minor bleeding	1/100						
					Day 31-365	HPR n=22	Minor bleeding	0/22	OR=3.5	NR	p=0.54 HPR vs NPR Fisher's exact test	NR	NR	
						NPR N=78	Minor bleeding	0/100						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 75 mg qd	ADP-induced platelet reactivity	bleeding events	bleeding events	Day 0-30	HPR n=22	bleeding events	2/22	OR=7.7 (calculated)	0.7-89.3	p=0.10 HPR vs NPR Fisher's exact test	NR	NR	
						NPR N=78	bleeding events	1/78						
					Day 31-365	HPR n=22	Bleeding events	0/22	OR=3.5 (calculated)	NR	p=0.54 HPR vs NPR Fisher's exact test	NR	NR	
						NPR N=78	Bleeding events	0/78						
Kwak, 2010 211266640 Korea OPCABG	aspirin 100 mg and clopidogrel 75 mg	TEG platelet inhibitory response to clopidogrel	post-operative transfusion requirement	post-operative transfusion requirement	5 days	Third tertile of platelet inhibitory response (>76.5%)	post-operative transfusion requirement	2/33	OR=10.63	2.7-41.78	0.001 comparing first and second tertile logistic regression model	No	NR	
						First & Second tertile of platelet inhibitory response (<76.5%)		4/66						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	aspirin 100 mg and clopidogrel 75 mg	TEG platelet inhibitory response to clopidogrel	post-operative transfusion requirement	post-operative transfusion requirement	5 days	Third tertile of platelet inhibitory response (>76.5%)	post-operative transfusion requirement	2/33	OR=11.44	2.77-47.3	0.001 comparing first and second tertile logistic regression model	yes (variable with p<0.2 the discontinuation date of clopidogrel, tertile distribution of the percentage of the platelet inhibitory response, the number of grafts performed)	NR	
						First & Second tertile of platelet inhibitory response (<76.5%)		4/66						
	aspirin 100 mg and clopidogrel 75 mg	TEG platelet inhibitory response to clopidogrel	post-operative transfusion requirement	post-operative transfusion requirement	5 days	platelet inhibitory response ≥70%	post-operative transfusion requirement	NR	AUC= 0.771 Sensitivity= 0.778 Specificity= 0.75	0.674- 0.868	<0.001 from ROC	No	NR	
						platelet inhibitory response <70%		NR						
Tang, 2012 22490487 China NR	100mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	intracranial hemorrhage	intracranial hemorrhage	12 months	control group	intracranial hemorrhage	0/30=0	OR = 1 (calculated)		<0.05 con vs R+R ANOVA	NR	NR	from table 5
	100mg aspirin and 75 mg clopidogrel (R+R)				12months	resistance plus routine		0/30=0			<0.05 R+R vs R+L ANOVA			

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	200mg aspirin and 150 mg clopidogrel (R+L)				12 months	resistance plus loading dose		0/30=0			<0.05 con vs R+L ANOVA			

Appendix Table E87. Results from studies assessing the ability of TEG to predict stroke in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Tang, 2012 22490487 China NR	100mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	stroke	stroke	12 months	control group	stroke	0/30=0	OR = 1 (calculated)		<0.05 con vs R+R ANOVA	NR	NR	from table 5
	100mg aspirin and 75 mg clopidogrel (R+R)				12 months	resistance plus routine		0/30=0			<0.05 R+R vs R+L ANOVA			
	200mg aspirin and 150 mg clopidogrel (R+L)				12 months	resistance plus loading dose		0/30=0			<0.05 con vs R+L ANOVA			

Appendix Table E88. Results from studies assessing the ability of TEG to predict other clinical events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Tang, 2012 22490487 China NR	100 mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	unstable angina	unstable angina	6months	control group	unstable angina	4/30=12%	OR=5.21(calculated)	1.28- 21.24	<0.05 con vs R+R ANOVA	NR	NR	from table 5
	100 mg aspirin and 75 mg clopidogrel (R+R)				6 months	resistance plus routine		12/30=42%			<0.05 R+R vs R+L ANOVA			
	200 mg aspirin and 150 mg clopidogrel (R+L)				6 months	resistance plus loading dose		7/30=23%			<0.05 con vs R+L ANOVA			
Tang, 2012 22490487 China NR	100mg aspirin and 75 mg clopidogrel (con)	ADP-induced platelet reactivity	unstable angina	unstable angina	12 months	control group	unstable angina	4/30=12%	OR=4.97(calculated)	1.39- 17.82	<0.05 con vs R+R ANOVA	NR	NR	from table 5
	100mg aspirin and 75 mg clopidogrel (R+R)				12months	resistance plus routine		13/30=42%			<0.05 R+R vs R+L ANOVA			
	200mg aspirin and 150 mg clopidogrel (R+L)				12 months	resistance plus loading dose		7/30=23%			<0.05 con vs R+L ANOVA			

Appendix Table E89. Quality assessment of studies assessing the predictive ability of TEG in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Bliden, 2006 17291930 USA NR	yes	yes	yes	low	low	NR	yes	unclear	high	yes	NR	unclean	low	yes	yes	yes	yes	low
Cotton, 2010 20406238 UK NR	no	yes	yes	low	low	NR	No	high	low	yes	NR	yes	low	yes	yes	yes	yes	low
Gurbel, 2010 20691842 USA PREPARE POST-STENTING	yes	yes	yes	low	low	NR	NO	high	high	yes	yes	low	low	yes	yes	yes	yes	low
Kwak, 2010 211266640 Korea OPCABG	no	yes	yes	low	low	NR	no	high	low	yes	yes	low	low	no	yes	yes	yes	low
Gurbel, 2005 16286165 USA PREPARE POST-STENTING	Yes	No	No	High	Low	NR	NR	Unclear	High	Yes	Yes	Low	Low	No [6 months]	yes	yes	yes	low
Tang, 2012 China NR	yes	yes	yes	low	low	NR	NR	unclear	high	yes	NR	unclear	yes	yes	yes	yes	yes	low

1. Consecutive or random sample of patients enrolled.
2. Case-control design avoided
3. Study avoided inappropriate exclusions
Risk of bias: could the selection of patients have introduced bias (If ≥2 of the above 3 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)
Concerns that the included patients do not match the review question?
4. Index test results interpreted without knowledge of results of reference standard?
5. If a threshold used, was it prespecified?
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Concerns that the index test, its conduct, or its interpretation differ from the review question?
6. Reference standard likely to correctly classify the target condition?
7. Reference standard results interpreted without knowledge of index test results?
Could the reference standard, its conduct, or its interpretation have introduced bias?

(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)

Are there concerns that the target condition as defined by the reference standard does not match the review question?

- 8. Appropriate interval between index test and reference standard?
- 9. All patients received a reference standard?
- 10. All patients received the same reference standard?
- 11. Were all patients included in the analysis?

Could the patient flow have introduced bias? (If ≥ 3 of the above 4 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix Table E90. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of the PFA-100 System

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%) Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medications
Malek, 2007 17295159 Poland NR	91 NR 68 median age Group1 66 (38, 85) Group 2 59 (51, 82) Group 3 54.5 (48, 71) Controls 58 (35, 86)	NR NR NR NR NR NR 17.6 NR	34.1 48.4 HTN 50.5 15.4	NR 98.9 100 NR	NR NR NR	underwent PCI with stent implantation	All patients received a loading dose of 300 mg of aspirin followed by daily regimen of 75 mg and a loading dose of either 300 or 600 mg of clopidogrel followed by 75 mg daily.	NR
Breet, 2011 20179285 Netherlands NR	1069 NR 75 64±10.6	NR NR NR NR NR NR 54.5 NR	80.3 11.1 HTN 76.9 18.6	NR 100 89.4 27.8	100 DES 63.5 NR	coronary artery disease scheduled for elective PCI with stent	clopidogrel treatment (a maintenance of 75 mg/d therapy for>5 days or a loading dose of 300 mg ≥24 hours before PCI or 600 mg ≥4 hours before PCI) and aspirin (80-100 mg/d ≥10 days).	unless they were receiving long-term anticoagulation with warfarins

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medications
Foussas, 2007 17892990 Greece None	612 NR 81.7 62±10.8	NR NR NR CABG 4.7 23.5 NR NR 17.7 STEMI 36.3	Hyper 67.3 51 HTN 48.6 28.7	NR 100 100 NR	100 BMS 79.8 Sirolimus eluting 20.2 55.5	PCI with stenting	aspirin (100-325 mg/d) and clopidogrel (300 or 600 mg as loading dose and then 75 mg/d).	Unfractionated heparin (70 IU/kg) was given at the start of the procedure.
Smit, 2010 20889993 Netherlands ON-TIME-2	648 NR 75.8 62.3	NR NR CVA 1.7 PCI 7.4; CABG 2.5 15.2 NR NR 7.8 STEMI 100	18.8 44.9 HTN 29.6; systolic 132.8 mmHg; diastolic 79.8 mmHg 9.9	NR NR NR NR	NR NR NR	Patients with ACS (STEMI)	Clopidogrel: (600 mg LD + 75 mg MD daily for 1 year);	acetylsalicylic acid 500 mg IV; unfractionated heparin 5000 IU IV ± tirofiban (25 mg/kg bolus + MD infusion of 0.15 mg/kg/min of tirofiban or placebo)

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medications
Huczek, 2008 18301358 Poland NR	125 NR 66 Mean 62 (range 60- 63)	22 NR CV event 3 NR NR NR 15 NR	37 48 HTN 52 24	NR NR NR NR	NR NR NR	Patients undergoing percutaneous coronary intervention (PCI) for ACS	Clopidogrel: 600-mg LD + 75 mg daily MD for of 30 days Aspirin: 300 mg before angiography + 75 mg daily MD	Abciximab - at the discretion of the operator as a 0.25 mg/kg bolus or a 0.125 µg/kg/min 12-hour infusion.
Moerenhout, 2010 20211306 Belgium NR	250 NR NR 66.1	post ACS 30.1 NR NR NR 72 NR NR NR NR	cholesterol 190.2 (mean) 27.7 HTN 59.9 22.6	NR NR NR NR	NR NR 56.2	Patients undergoing percutaneous coronary intervention (PCI)	aspirin 160 mg LD + 450 mg LD of clopidogrel (300-mg clopidogrel 12 hours before PCI and 150 mg the day of PCI) Clopidogrel 75 mg MD x 6 weeks (bare metal stents) to 6 months (drug-eluting stent)	Unfractionated heparin was administered at the beginning of the procedure and titrated to obtain activated clotted time (ACT) levels between 300 and 350 seconds.
Siller-Matula, 2009 19135705 Austria NR	30 NR 63±10	100 NR CVD 7 PCI 43 NR NR 10 37 NR	hyper 77 57 HTN 77 33	NR 100 100 NR	NR NR NR	Patients undergoing PCI for coronary artery disease	Patients had been on chronic aspirin (100 mg/day) and clopidogrel (75 mg/day) treatment for three months on average.	All patients received unfractionated heparin and 250 mg of injectable acetyl-salicylic acid during PCI

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medications
Gori, 2008 19132241 Italy RECLOSE	746 NR 75 68±12	NR NR NR PCI 23; coronary artery surgery 6 33 40 NR 25 26	hyper 49 23 HTN 61 20	NR NR NR NR	100 DES 93 multi 57	RECLOSE patients who underwent DES implantation for whom complete AA- and collagen-induced platelet aggregation values were available.	All patients received aspirin (325 mg) and a loading dose of 600 mg of clopidogrel followed by a maintenance dose of 75 mg daily.	Patients on a maintenance dose of ticlopidine or clopidogrel at the time of admission received a loading dose of clopidogrel (600 mg).
Siller-Matula, 2012 22260716 Austria PEGASUS- PCI	416 NR 76 64±12	NR NR NR PCI 47 NR NR 13 31 18/NR	hyper 76 55 84 32	NR 100 100 76	100 DES 99 NR	patients undergoing PCI	clopidogrel LD 600mg, MD 75mg	NR

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medications
Chiu 2011 21925055 Taiwan NR	144 NR 76.4% 64.8	NR NR 6% NR 55.6% NR NR 18% NR	50% Active smoker: 32% NR HTN: 69% 47%	NR NR NR 9%	NR BMS: 54%; DES: 34% 3 vessels: 8%	PCI for ACS	Clopidogrel (300 mg LD + 75 mg/d MD) Aspirin 100 mg/day for 7 days prior to (stable angina) or 300 mg LD + 100 mg/day (ACS patients)	NR

* Mean (standard deviation), unless otherwise stated.

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH= Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors

Add headings for additional subgroups. Data are means unless otherwise indicated; estimated is noted if reported as an estimate.

Appendix Table E91. Baseline characteristics of a mixed patient population with ischemic heart, cerebrovascular and peripheral vascular disease in studies assessing the predictive ability of PFA-100

Author, year [ref] UID Country Study Name	Demographics Total N Enrolled Race (% by group) Male (%) Age*	Vascular disease history Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Vascular risk factors Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic) HTN (%) Diabetes (%)	Prior medications (pre-study) Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Procedural data Stent implantation (%) Type of stent (%) Multi- or single vessel (%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Reny, 2012 22615340 France and Switzerland ADRIE	771 NR 81 62.9	66 NR 13 NR NR 21 NR NR	36 75 NR 57 22	NR 99 85.5 29	NR NR NR	patients with symptomatic documented ischemic atherothrombotic disease (coronary artery disease, ischemic cerebrovascular disease, and/or peripheral artery disease)	non–enteric-coated aspirin and/or clopidogrel	NR

*Mean (standard deviation), unless otherwise stated.

Appendix Table E92. Study design characteristics of studies assessing the predictive ability of PFA-100 System in patients with ischemic heart disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Malek, 2007 17295159 Poland NR	prospective Cohort	No	Consecutive patients	Patients who underwent PCI with stent implantation in the course of ACS	NR	In hospital stay Median 6 days (min 3, max 12)	Hospital inpatient	NR	NR
Breet, 2010 20179285 Netherlands POPULAR	prospective Cohort	No	Patients scheduled for PCI with stent implantation	Patients with PCI and stent implantation	Dec 2005- Dec 2007	1-year	Hospital inpatient	Yes. 80%	NR
Foussas, 2007 17892990 Greece None	Prospective	NO	Consecutive	Patients undergoing coronary artery stenting	April 2003-Jan. 2005	Total 1 yr	Inpatient and then outpatient followup for 1 yr	NR	NR
Smit, 2010 20889993 Netherlands ON-TIME-2	Substudy of the Ongoing Tirofiban in Myocardial Infarction Evaluation 2 (On-TIME-2) trial	yes	Selected sample (For whom Platelet aggregation inhibition data was available)	Patients with ACS (STEMI)	June 2004 until November 2007	Max 30 days	follow up after intervention	NR	NR
Huczek, 2008 18301358 Poland NR	Prospective observational	NO	Consecutive	Patients undergoing percutaneous coronary intervention (PCI) for ACS	NR	6 months	Followup after intervention	NO	NR
Moerenhout, 2010 20211306 Belgium NR	Prospective observational	NO	NR	Patients undergoing percutaneous coronary intervention (PCI)	Jan 2006-June 2007	6 months followup	followup after intervention	YES; Accrual >80%	non-industry
Siller-Matula, 2009 19135705 Austria NR	Prospective observational study	NO	NR	Patients undergoing PCI for coronary artery disease	Aug 2007-Apr 2008	1 day	followup after intervention	YES Accrual=100%	Non-industry [grant from the Jubiläumsfond of the Austrian National Bank (Nr. 12565)]
Gori, 2008 19132241 Italy RECLOSE	Prospective	NR but probably NO	Consecutive	RECLOSE patients who underwent DES implantation for whom complete AA- and collagen- induced platelet aggregation values were available.	July 2005 to February 2006	Total 6 mo	Outpatient followup of cohort at 1, 3, and 6 mo	YES [YES]	Nonindustry

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Siller-Matula, 2012 22260716 Austria PEGASUS- PCI	prospective cohort	no	consecutive	patients undergoing PCI	March 2007- Nov, 2009	12 months	medical university of vienna	yes, 80%	Austrian National Bank
Chiu 2011 21925055 Taiwan NR	Prospective	no	NR	patients undergoing PCI for ACS	January 2005 – January 2006	24 months	National Taiwan University Hospital	Yes (yes)	Government (National Science Council, Republic of China.)

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; CAD = coronary artery disease; MI = myocardial infarction; NSTEMI = non-ST-elevation; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; DES=drug eluting stent; CABG=coronary artery bypass grafting; AA= arachidonic acid; SD=standard deviation; RCT=randomized controlled trial; NR=not reported

Appendix Table E93. Study design characteristics of studies assessing the predictive ability of PFA-100 System in a mixed patient population with ischemic heart, cerebrovascular and peripheral vascular disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Reny, 2012 22615340 France and Switzerland ADRIE	prospective Cohort	yes	Consecutive patients	symptomatic documented ischemic atherothrombotic disease (coronary artery disease, ischemic cerebrovascular disease, and/or peripheral artery disease)	June 2006 - December 2008	6 months	inpatient, then followup	yes (yes)	Non- industry only

Appendix Table E94. Phenotypic test details in studies assessing the predictive ability of PFA-100 in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Malek, 2007 17295159 Poland NR	Platelet function analysis PFA-100 point-of-care device – PFA-100; Dade Behring, Germany	ADP	sample collected after the acute phase of ACS (2-9 days after admission) 3.2% sodium citrate NR NR	Group 1 with CADP-CT<104 s group 2 with CEPI-CT <190 s group 3 with CADP CT <104 s and CEPI-CT <190 s both CT values above the cut-off limits	not explicitly reported.	Group 1 (n=10, 11%), group 2 (n=10, 11%), group 3 (n=9, 9.9%) a control group (n=62, 68.1%).
Breet, 2010 20179285 Netherlands POPULAR	PFA 100 the Dade PFA collagen/ADP test cartridge(PFA- 100system) Siemens Healthcare Diagnostics Products GmbH,Marburg, Germany	ADP	NR 3.8% buffered citrated blood NR 2 hours	PFA ≤147 seconds	Based on ROC curve	NR
Breet, 2010 20179285 Netherlands POPULAR	INNOVANCE® PFA P2Y* NR NR	ADP, PGE1, calcium	NR 3.8% buffered citrated blood NR 2 hours	PFA ≤59 seconds	Based on ROC curve	NR

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Foussas, 2007 17892990 Greece None	PFA-100 Closure time Dade-Behring, Collagen+ADP or epiephrine Marburg, Germany	Collagen+ADP or epiephrine	Blood samples obtained after femoral or brachial arterial sheath insertion in the catheterization laboratory. After rejection of the first few milliliters, blood for PFA-100 analysis was collected into tubes. The time required to occlude the aperture is automatically reported as the closure time (CT). Measurements are terminated after ≤300 seconds. citrate Aspirin+clopidogrel loading done >12 hr before stenting; mean/SD 37.4/23.5 hr within 1 hour	CEPI-CT >193 sec (responders) CEPI-CT ≤193 sec (nonresponders)	Based on literature	CEPI-CT >193 sec 489 (79.9%) (responders) CEPI-CT ≤193 sec (nonresponders) 123 (20.1%)
Smit, 2010 20889993 Netherlands ON-TIME-2	PFA Platelet function analyser PFA-100/ Dade Behring, Marburg, Germany	2 mg type I collagen with either 50 mg epinephrine bi-tartrate (col-EPI) or 50 mg ADP (col-ADP)	Whole blood; collected before PCI NR NR Clopidogrel came first NR	quartiles 1-4	Not explicitly reported	quartiles 1 162 (25%) quartiles 2 162 (25%) quartiles 3 162 (25%) quartiles 4 162 (25%)
Huczek, 2008 18301358 Poland NR	PFA-100 PFA-100 Dade Behring, Newark, Delaware	epinephrine and collagen (for Thromboxane A2 pathway) and ADP and collagen (for ADP- dependent pathway)	Venous blood; day 3 & 30 after stenting 3.8% buffered sodium citrate 0.08 days (2 hours) Clopidogrel came first 0.02-0.04 days (0.5-1 hr)	group I (CEPI-CT ≥193 seconds and CADP-CT ≥130 seconds, i.e. complete platelet function inhibition) Group II (either CEPI-CT<193 seconds or CADP-CT<130 seconds, i.e. partial platelet function inhibition) Group III (CEPI-CT<193 seconds and CADP-CT<130 seconds, i.e. no platelet function inhibition).	Previously published information	group I 67 (53.6%) Group II 21(16.8%) Group III 37 (29.6%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Moerenhout, 2010 20211306 Belgium NR	PFA-100 platelet function analyzer (PFA-100 C/ADP) NR	Collagen and ADP	blood before PCI NR 0.5 days (12 hrs) Clopidogrel came first NR	nonresponder (PFA value <71 seconds) responder (PFA value >71 seconds)	Based on literature	nonresponder (PFA value <71 seconds) 17 (7%) responder (PFA value >71 seconds) 225 (93%)
Siller-Matula, 2009 19135705 Austria NR	PFA-100 PFA-100 Dade Behring, Marburg, Germany	collagen and adenosine diphosphate (ADP)	1st blood sample: in catheterization laboratory, after PCI and after 250 mg IV aspirin 2nd blood sample: 20-24 hours after PCI 3.8% citrate NR Clopidogrel came first 0.04 days (1 hour)	Collagen ADP closure time between 65-120 s by PFA-100 Collagen ADP closure time between <65 s & >120 s by PFA-100	Normal ranges as reported by manufacturer	Collagen ADP closure time between 65-120 s by PFA-100 ; 20 (67%) Collagen ADP closure time between <65 s & >120 s by PFA-100; 10 (33%)
Gori, 2008 19132241 Italy RECLOSE	PFA-100 system NR Dade-Behring, Marburg, Germany	Collagen/epinephrine or collage/ADP	Platelet reactivity measured 12 to 18 hr after clopidogrel loading citrate For patients receiving in the catheterization laboratory both the loading dose of clopidogrel and a IIb/IIIa inhibitor, blood samples were obtained after six days while the patient was on the 75-mg maintenance dose of clopidogrel. NR	RPR by CEPI PFA-100 (<203 sec) No RPR Patients at high risk for adverse events: RPR by CEPI PFA-100 (<238 sec) RPR by CADP PFA-100.(<105 sec)	previous literature	RPR by CEPI PFA-100 (<203 sec);133/746 (18%) No RPR; 613/746 (82%) RPR by CEPI PFA-100 (<238 sec) :238/746 (32%) RPR by CADP PFA- 100.(<105 sec) :196/398 (49%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Siller-Matula, 2012 22260716 Austria PEGASUS- PCI	PFA-100 platelet function analyzer The PFA-100 (Dade Behring, Marburg, Germany)	ADP	Blood samples from patients were obtained from the arterial sheath (6F) in the catheterization laboratory directly post-PCI and at least 5 min after intravenous infusion of aspirin. 3.8% sodium citrate NR performed up to 24 h after blood sampling	Clopidogrel non-responder according to MEA (≥ 48 U) Clopidogrel responder according to MEA (< 48 U) n = 321 (80%)	ref 16, 28	non-responder n = 81 (20%) responder n = 321 (80%)
Chiu 2011 21925055 Taiwan NR	PFA-100 platelet function analyzer The PFA-100 (Dade Behring, Marburg, Germany)	Collagen and ADP	Blood samples prior to cardiac catheterization 3.8% sodium citrate NR; clopidogrel came first 0.08 days (2 hours)	CADP-CT <95 s CADP-CT ≥ 95 s	Based on ROC curve (to predict primary endpoint [MACE])	CADP-CT <95 s = 29 (27%) CADP-CT ≥ 95 s = 105 (73%)

Abbreviations: ADP= adenosine 5'-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported

Appendix Table E95. Phenotypic test details in studies assessing the predictive ability of PFA-100 in patients with ischemic heart, cerebrovascular and peripheral vascular disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Reny, 2012 22615340 France and Switzerland ADRIE	PFA-100 platelet function analyzer The PFA-100 (Dade Behring, Marburg, Germany)	Collagen and ADP	Blood samples collected after antiplatelet therapy intake 0.105 mol/L sodium citrate (1 vol/9 vol) 3 hrs NR	CT<190s: CT>190s	based on literature	<190s: 310 ≥190: 339

Appendix Table E96. Results from studies assessing the ability of PFA-100 to predict death in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily + aspirin 80-100 mg daily	PFA 100 collagen/ ADP	Death	death,	1-year	High OTPR	Death	10/506 (2)	OR=1.21	0.41-3.58	0.73	No	NR	
						Normal OTPR		5/306 (1.6)						
	maintaining Clopidogrel 75 mg daily + aspirin 80-100 mg daily	Innovance PFA P2Y	Death	death,	1-year	High OTPR	Death	6/147 (4.1)	OR=4.65	1.29-16.7	0.01	No	NR	
						Normal OTPR		4/441 (0.9)						
Foussas, 2007 17892990 Greece None	300 or 600 mg LD and 75mg MD Clopidogrel + 100-325 mg/day aspirin	PFA-100	Cardiac death	Cardiac death	1 yr	Nonresponder	Cardiac death	6.5%	HR 2.5	1.1-6.1	0.04 (non-responder vs. responder, Cox regression)			
						Responder		2.7%						
	300 or 600 mg LD and 75mg MD Clopidogrel + 100-325 mg/day aspirin	PFA-100	In-hospital death	In-hospital death		Responder	In-hospital death	0.8%			0.13 non-responder vs. responder			
						Nonresponder		2.4%	HR 3.1	0.7-8.3				
	300 or 600 mg LD and 75mg MD Clopidogrel + 100-325 mg/day aspirin	PFA-100	Cardiac death	Cardiac death	1 yr	Q1 of CEPI-CT (shortest time, least responsive)	Cardiac death	6.5%	HR 4.1	1.2-13.9	0.02 for HR Q1 vs. Q4, 0.03 across Q1-Q4			
						Q2		5.6%						
						Q3		1.6%						
						Q4 (most responsive)		1.7%						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Huczek, 2008 18301358 Poland NR	Clopidogrel 75 mg	Combination of CT-EPI and CT-ADP by PFA-100	Cardiac death	cardiac death	6 months	Group I (complete platelet function inhibition)	cardiac death	1	NR	NR	P=0.038 P for trend [ANOVA]	NO	NR	
						Group II (partial platelet function inhibition)		1						
						Group III (no platelet function inhibition).		5						

Appendix Table E97. Results from studies assessing the ability of PFA-100 to predict myocardial infarction in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2011 20179285 Netherlands NR	maintaining Clopidogrel 75 mg daily + aspirin 80-100 mg daily	PFA 100 collagen/ADP	MI	MI	1-year	High OTPR	MI	4/506 (6.7)	OR=1.31	0.71-2.41	0.39 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		16/306 (5.2)						
	maintaining Clopidogrel 75 mg daily + aspirin 80-100 mg daily	Innovance PFA P2Y	MI	MI	1-year	High OTPR	MI	11/147 (7.5)	OR=1.7	0.8-3.64	0.17 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		20/441 (4.5)						
Foussas, 2007 17892990 Greece None	300 or 600 mg LD and 75mg MD Clopidogrel + 100-325 mg/day aspirin	PFA-100	Rehospitalization for MI	Rehospitalization for MI		Nonresponder	Rehospitalization for MI	12.2%	HR 2.7	1.4-5.2	0.002 non-responder vs. responder (Cox regression)			
						Responder		4.9%						
	300 or 600 mg LD and 75mg MD Clopidogrel + 100-325 mg/day aspirin	PFA-100	MI	MI	1 yr	Q1 of CEPI-CT (shortest time, least responsive)	MI	12.2%	HR, 3.2	1.4-7.3	0.006 Q1 vs Q4 for HR 0.02 across Q1-Q4			
						Q2		7.1%						
						Q3		4%						
						Q4 (most responsive)		4.2%						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Huczek, 2008 18301358 Poland NR	Clopidogrel 75 mg	Combination of CT-EPI and CT-ADP by PFA-100	nonfatal reinfarction	nonfatal reinfarction	6 months	Group I (complete platelet function inhibition)	nonfatal reinfarction	0	NR	NR	P=0.026 P for trend [ANOVA]	NO	NR	
						Group II (partial platelet function inhibition)		1						
						Group III (no platelet function inhibition).		4						
Moerenhout, 2010 20211306 Belgium NR	aspirin 160 mg LD + 450 mg LD of clopidogrel + Clopidogrel 75 mg MD x 6 weeks to 6 months	PFA-100	Myocardial infarction post PCI	CK-MB increase of >3x ULN post-PCI	6 months	nonresponder (PFA value <71 seconds)	MI post PCI	2/17 (12%)	OR=3.2 (calculate)	0.6-16.2	P=0.2 (between nonresponder and responder) Chi Square test	NO	NR	Secondary endpoint
						responder (PFA value >71 seconds)		9/225 (4%)						
Malek, 2007 17295159 Poland NR	Clopidogrel LD 300 or 600mg and maintaining 75mg daily	PFA-100	Re-infarction	Re-infarction	In-hospital 6 days	Groups 1-3	Re-infarction	2/29 (6.9)	OR=4.5 (calculate)	0.4-52	p=0.23	NR	NR	Bar graph showed cardiovascular events by group. Figure 1
						Control		1/62 (1.6)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	Clopidogrel LD 300 or 600mg and maintaining 75mg daily	PFA-100	Cardiac arrest	Cardiac arrest	In-hospital 6 days	Groups 1-3	Cardiac arrest	2/29 (6.9)	OR=1.5 (calculate)	0.2- 9.2	p=0.69 groups 1-3 vs control Fisher's exact test	NR	NR	
						Control		3/62 (4.8)						

Appendix Table E98. Results from studies assessing the ability of PFA-100 to predict stent thrombosis in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2011 20179285 Netherlands NR	maintaining Clopidogrel 75 mg daily + aspirin 80-100mg daily	PFA 100 collagen/ADP	Stent thrombosis	Stent thrombosis	1-year	High OTPR	Stent thrombosis	5/506 (1)	OR=0.75	0.20-2.83	0.67high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		4/306 (1.3)						
	maintaining Clopidogrel 75 mg daily + aspirin 80-100mg daily	Innovance PFA P2Y	Stent thrombosis	Stent thrombosis	1-year	High OTPR	Stent thrombosis	1/147 (0.7)	OR=0.75	0.08-6.75	0.8 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		4/441 (0.9)						
Gori, 2008 19132241 Italy RECLOSE	600mg LD and 75mg/day MD Clopidogrel+325 mg aspirin	CADP PFA-100 among patients at high risk for AEs	Stent thrombosis	definite or probable: ACS + either angiographic confirmation of thrombosis or pathological confirmation of thrombosis; or unexplained death or MI in the territory supplied by a stented vessel without angiographic confirmation	6 mo	residual platelet reactivity RPR (n=196)	Stent thrombosis	NA	100% sensitivity 52% (47-57%) specificity		For sensitivity and specificity, <0.001 vs CEPI-PFA-100	NR	NR	
	600mg LD and 75mg/day MD Clopidogrel+325 mg aspirin	CEPI PFA-100	Stent thrombosis	see above	6 -month	residual platelet reactivity RPR	Stent thrombosis		OR 3.97	1.61-9.79	0.003 logistic regression Univariate analysis	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	600mg LD and 75mg/day MD Clopidogrel+325 mg aspirin	CEPI PFA-100	Stent thrombosis	see above	6-month	residual platelet reactivity RPR	Stent thrombosis	NR	OR 3.25	1.26-8.39	0.025 logistic regression Multivariate analysis		NR	
	600mg LD and 75mg/day MD Clopidogrel + 325 mg aspirin	CEPI PFA-100	Stent thrombosis	see above	6-month	residual platelet reactivity RPR (n=133)	Stent thrombosis	9	OR=3.97 (calculated)	1.6-9.8	p=0.002RPR vs. no RPR Fisher's exact test	NR	NR	
						No RPR (n=613)		11				NR	NR	
	600mg LD and 75mg/day MD Clopidogrel + 325 mg aspirin	CEPI PFA-100	Stent thrombosis	see above	6 -month	residual platelet reactivity RPR (n=133)	Stent thrombosis	NA	Cutoff from AUC 238 sec 45% (23-69%) sensitivity 83% (80-86%) specificity		For specificity, <0.01 vs. LTA-ADP and <0.0001 vs. LTA-collagen	NR	NR	
	600mg LD and 75mg/day MD Clopidogrel + 325 mg aspirin	CEPI PFA-100 among patients at high risk for AEs	Stent thrombosis	see above	6-month	residual platelet reactivity RPR (n=238)	Stent thrombosis	NA	40% (19-61%) sensitivity 81% (78-89%) specificity		For specificity, <0.0001 vs. LTA-ADP	NR	NR	

Appendix Table E99. Results from studies assessing the ability of PFA-100 to predict major adverse cardiovascular events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Foussas, 2007 17892990 Greece None	300 or 600 mg LD and 75mg MD Clopidogrel + 100-325 mg/day aspirin	PFA-100	Composite of cardiac death and rehospitalization for nonfatal MI	Composite of cardiac death and rehospitalization for nonfatal MI	1 yr	Nonresponder	Composite of cardiac death and rehospitalization for nonfatal MI	18.7%	HR= 2.7	1.6-4.5	<0.001 non-responder vs. responder (Cox regression)	No	NR	NONE
						Responder		7.6%						
	300 or 600 mg LD and 75mg MD Clopidogrel + 100-325 mg/day aspirin	PFA-100	Composite of cardiac death and rehospitalization for nonfatal MI	Composite of cardiac death and rehospitalization for nonfatal MI	1 yr	Q1 of CEPI-CT (shortest time, least responsive)	Composite of cardiac death and rehospitalization for nonfatal MI	18.7%	HR= 3.7	1.8-7.5	<0.001 Q1 vs. Q4, for HR and for trend across this and next 3 rows			
						Q2		12.7%						
						Q3		5.6%						
						Q4 (most responsive)		5.9%						
	300 or 600 mg LD and 75mg MD Clopidogrel + 100-325 mg/day aspirin	PFA-100	Composite endpoint	Composite endpoint		Nonresponders	Composite endpoint		HR =2.9	1.7-3.9	<0.001 among pts with CK-MB data, (multivariate regression)	YES; Table 4		
									HR= 2.5	1.6-3.8	<0.001 among all pts, (multivariate 2.5 regression)	YES; Table 5		

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Smit, 2010 20889993 Netherlands ON-TIME-2	Clopidogrel 300 mg LD + 75 mg MD	PFA-ADP	MACE	mortality, urgent target vessel revascularisation or recurrent myocardial infarction	30 days	Quartile 1	MACE	NR	NR	NR	0.035; between all quartiles [Chi-square]	NO	NR	Data in figures only shows percentages; needs to be digitized to obtain accurate values
						Quartile 2		NR						
						Quartile 3		NR						
						Quartile 4		NR						
Malek, 2007 17295159 Poland NR	Clopidogrel LD 300 or 600mg and maintaining 75mg daily	PFA-100	Early cardiovascular events	in-hospital re-infarction, cardiac arrest, recurrent angina with changes in electrocardiogram characteristic for acute ischaemia, stroke, ventricular and supraventricular arrhythmias requiring electrical cardioversion or intravenous infusion of antiarrhythmic drugs, pulmonary oedema, cardiogenic shock or major bleeding	Early cardiovascular events	Group 3 vs control	Early cardiovascular events	RR=9.0	2.4-33.9	NR	<0.005 comparing group 3 vs control	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Huczek, 2008 18301358 Poland NR	Clopidogrel 75 mg	Combination of CT-EPI and CT-ADP by PFA-100	MACE	cardiovascular death, nonfatal reinfarction, stroke, and rehospitalization for congestive heart failure	6 months	Group I (complete platelet function inhibition)	MACE	2	HR=3.8 HR=1.6	2.2-6.8 0.9-4.1	P<0.0001 Groups II & III vs I [Cox regression] P=0.082 (group III vs II) [Cox regression]	YES; age, sex, treatment delay, diabetes, previous MI, chronic aspirin therapy, acute heart failure (Killip >I), anterior STEMI, culprit lesion located in the left anterior descending (LAD) artery, threevessel disease in angiography, abciximab administration, and baseline ejection fraction	NR	
						Group II (partial platelet function inhibition)		5						
						Group III (no platelet function inhibition).		20						
Moerenhout, 2010 20211306 Belgium NR	aspirin 160 mg LD + 450 mg LD of clopidogrel + Clopidogrel 75 mg MD x 6 weeks to 6 months	PFA-100	major thrombotic adverse cardiac events (MACE)	death, nonfatal myocardial infarction (MI), and stent thrombosis*	6 months	nonresponder (PFA value <71 seconds)	MACE	2/17 (12%)	OR=2.6 (calculate)	0.5-12.8	P=0.2 (between nonresponder and responder) Chi Square test	NO	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						responder (PFA value >71 seconds)		11/225 (5%)						
	aspirin 160 mg LD + 450 mg LD of clopidogrel + Clopidogrel 75 mg MD x 6 weeks to 6 months	PFA-100	major thrombotic adverse cardiac events (MACE)	death, nonfatal myocardial infarction (MI), and stent thrombosis	6 months	nonresponder (PFA value <71 seconds)	MACE	2/17 (12%)	OR=13	0.9-183	P=0.057 (between nonresponder and responder) [Logistic regression]	YES; sex, age, height, weight, cholesterol level, arterial hypertension, diabetes status, use of statins, use of angiotensin converting enzyme inhibitors, multivessel disease, lesion length, total stent length, number of stents, balloon to reference ratio, post-PCI diameter stenosis, contrast dose, maximum balloon inflation pressure, balloon inflation duration, platelet count, procedural ACT, and clopidogrel nonresponsiveness.	NR	
						responder (PFA value >71 seconds)		11/225 (5%)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet , 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80-100mg daily	PFA-100	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR ≤147 s	Death combined	33/262 (12.6)	AUC: 0.5 Sens: 0.7 Spec: 0.384	0.46-0.55 0.585-0.795 0.35-0.42	NR	No	NR	
			Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR ≤147s	Death combined	49/506 (9.7)	OR=1.46	0.85-2.48	0.17 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR >147		21/306 (6.9)						
		Innovance PFA P2Y	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR ≤159 secs	Death combined	33/262 (12.6)	AUC: 0.56 Sens: 0.391 Spec: 0.762	0.5-0.62 0.264-0.535 0.724-0.796	NR	No	NR	
			Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR ≤159 secs	Death combined	18/147 (12.2)	OR=2.06	1.1-3.84	0.02 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR >159 secs		28/441 (6.3)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gori, 2008 19132241 Italy RECLOSE	600mg LD and 75mg/day MD Clopidogrel + 325 mg aspirin	CEPI PFA-100	Stent thrombosis or cardiac death (composite)			residual platelet reactivity RPR (n=133)		10	NR	NR	NS RPR vs. no RPR	NR	NR	
						No RPR (n=613)		15	NR	NR		NR	NR	
Gori, 2008 19132241 Italy RECLOSE	600mg LD and 75mg/day MD Clopidogrel + 325 mg aspirin	CEPI PFA-100	Stent thrombosis or cardiac death (composite)			residual platelet reactivity RPR (n=133)			40% (21-61%) sensitivity 83% (80-86%) specificity		For specificity, <0.01 vs. LTA-ADP and <0.0001 vs. LTA-collagen			
Gori, 2008 19132241 Italy RECLOSE	600mg LD and 75 mg/day MD Clopidogrel + 325 mg aspirin	CEPI PFA-100 among patients at high risk for AEs	Stent thrombosis or cardiac death (composite)			residual platelet reactivity RPR (n=238)		NA	36% (17-55%) sensitivity 83% (80-86%) specificity		For sensitivity, p<0.01 vs. LTA-ADP For specificity, p<0.0001 vs. LTA-ADP and p<0.0001 vs. LTA-collagen	NR	NR	
Gori, 2008 19132241 Italy RECLOSE	600mg LD and 75mg/day MD Clopidogrel + 325 mg aspirin	CADP PFA-100 among patients at high risk for AEs	Stent thrombosis or cardiac death (composite)			residual platelet reactivity RPR (n=196)		NA	80% (55-100%) sensitivity 52% (46 ^a - 57%) specificity		For specificity, p<0.001 vs CEPI-PFA-100	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Gori, 2008 19132241 Italy RECLOSE	600mg LD and 75mg/day MD Clopidogrel + 325 mg aspirin	CEPI PFA-100	Stent thrombosis or cardiac death (composite)			residual platelet reactivity RPR			OR 3.24	1.42-7.38	0.003 logistic regression Univariate analysis	NR	NR	
Gori, 2008 19132241 Italy RECLOSE	600mg LD and 75mg/day MD Clopidogrel + 325 mg aspirin	CEPI PFA-100	Stent thrombosis or cardiac death (composite)			residual platelet reactivity RPR		NR	OR 2.60	1.08-6.21	0.031 logistic regression Multivariate analysis		NR	
Chiu 2011 21925055 Taiwan NR	Clopidogrel (300 mg LD + 75 mg/d MD); Aspirin 100 mg/day or 300 mg LD + 100 mg/day	CADP PFA-100	CV death, non-fatal MI, or non-fatal stroke		24 months	CADP-CT<95s (n=29)	MACE+	11	HR =7.8	2.2-28.3	0.002 (<95s vs ≥ 95s Log rank test	No	NR	
						CADP-CT≥95s (n=105)	MACE+	3						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES, NO, NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						CADP-CT<95s (n=29)	MACE+	11	HR =5.28	1.37-20.08	0.015 (<95s vs ≥ 95s_ Log rank test	Yes; Age, Male gender, CEPI-CT <193 s, diabetes mellitus, Hypertension, LV ejection fraction (%), creatinine (mg/dl), statins use, von williebrand aggregation % (natural log-transformed), acute coronary syndrome at admission	NR	
						CADP-CT≥95s (n=105)	MACE+	3						
			CV death, non-fatal MI, or non-fatal stroke plus hospitalization due to a cardiac ischemic event, including unstable angina and urgent target vessel revascularization (TVR)		24 months	CADP-CT <95s (n=29)	MACE+	27			P<0.001 (<95s vs ≥ 95s Log rank test			
						CADP-CT≥95s (n=105)	MACE+	6						

*Myocardial infarction was defined as any typical rise and fall of cardiac markers in the setting of clinical signs or symptoms consistent with the new definitions of MI as described by the European Society of Cardiology. The academic research consortium definitions were used for stent thrombosis (definite, probable, and possible).

Appendix Table E100. Results from studies assessing the ability of PFA-100 to predict major adverse cardiovascular events in patients with ischemic heart, cerebrovascular and peripheral vascular disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Reny, 2012 22615340 France and Switzerland ADRIE	Clopidogrel + aspirin	PFA-100	MACE	acute MI, unstable angina, hospitalization for revascularization, acute limb ischemia, ischemic stroke, TIA, or CV death	6 months	HOPR n=310	MACE	63	HR=0.82	0.57-1.19	0.3 (HOPR vs normal PR) [cox regression]	NR	NR	K-M curve in Fig 2
						normal PR n=339		56						

Appendix Table E101. Results from studies assessing the ability of PFA-100 to predict bleeding events in patients with ischemic heart disease

Author,year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Malek, 2007 17295159 Poland NR	Clopidogrel LD 300 or 600mg and maintaining 75mg daily	PFA-100	Major bleeding	Major bleeding	Early cardiovascular events	Groups 1-3	Major bleeding	0/29 (0)	OR=2.1 (calculate)d	NR	p=0.71 groups 1-3 vs. control Fisher's exact test	NR	NR	
						Control		0/62 (0)						

Appendix Table E102. Results from studies assessing the ability of PFA-100 to predict stroke in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands NR	maintaining Clopidogrel 75 mg daily + aspirin 80-100 mg daily	PFA 100 collagen/ ADP	stroke	Stroke	1-year	High OTPR	Stroke	7/506 (1.4)	OR=4.28	0.52-34.9	0.14 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		1/306 (0.3)						
	maintaining Clopidogrel 75 mg daily + aspirin 80-100 mg daily	Innovance PFA P2Y	stroke	Stroke	1-year	High OTPR	Stroke	1/147 (0.7)	OR=0.60	0.07-5.15	0.65 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		5/441 (1.1)						
Huczek, 2008 18301358 Poland NR	Clopidogrel 75 mg	Combination of CT-EPI and CT-ADP by PFA-100	stroke	stroke	6 months	Group I (complete platelet function inhibition)	stroke	0	NR	NR	NR	NO	NR	
						Group II (partial platelet function inhibition)		0						
						Group III (no platelet function inhibition).		1						

Appendix Table E103. Results from studies assessing the ability of PFA-100 to predict other clinical events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Malek, 2007 17295159 Poland NR	Clopidogrel LD 300 or 600mg and maintaining 75mg daily	PFA-100	Recurrent angina	Recurrent angina	In-hospital 6 days	Groups 1-3	Recurrent angina	2/29 (6.9)	OR=4.5 (calculated)	0.4-52	p=0.23 groups 1-3 vs control Fisher's exact test	NR	NR	
						Control		1/62 (1.6)						
	Clopidogrel LD 300 or 600mg and maintaining 75mg daily	PFA-100	Arrhythmia	Arrhythmia	In-hospital 6 days	Groups 1-3	Arrhythmia	3/29 (10.3)	OR=3.5 (calculated)	0.5-22	p=0.19 groups 1-3 vs control Fisher's exact test	NR	NR	
						Control		2/62 (3.2)						
	Clopidogrel LD 300 or 600mg and maintaining 75mg daily	PFA-100	Pulmonary oedema	Pulmonary oedema	In-hospital 6 days	Groups 1-3	Pulmonary oedema	1/29 (3.4)	OR=2.2 (calculated)	0.1-36.1	p=0.59 groups 1-3 vs control Fisher's exact test	NR	NR	
						Control		1/62 (1.6)						
	Clopidogrel LD 300 or 600mg and maintaining 75mg daily	PFA-100	Cardiogenic shock	Cardiogenic shock	In-hospital 6 days	Groups 1-3	Cardiogenic shock	3/29 (10.3)	OR=16.5(calculated)	0.8-330.9	p=0.07 groups 1-3 vs control Fisher's exact test	NR	NR	
						Control		0/62 (0)						
Huczek, 2008 18301358 Poland NR	Clopidogrel 75 mg	Combination of CT-EPI and CT-ADP by PFA-100	rehospitalization for CHF	rehospitalization for CHF	6 months	Group I (complete platelet function inhibition)	rehospitalization for CHF	2	NR	NR	P<0.001 P for trend [ANOVA]	NO	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Group II (partial platelet function inhibition)		3						
						Group III (no platelet function inhibition).		12						

Appendix Table E104. Results from studies assessing the ability of PFA-100 to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR-)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Siller-Matula, 2009 19135705 Austria NR	Clopidogrel 75 mg MD	PFA-100	PFA-100	Closure time with collage and ADP using PFA-100	24 hrs after PCI	Collagen ADP closure time between 65-120 s by PFA-100	Collagen ADP closure time between 65-120 s by PFA-100	18	NR	NR	NR	0.141 (fisher's exact calculated from data)	NR	NR	Fig 2B
						Collagen ADP closure time between 65-120 s by PFA-100	Collagen ADP closure time between <65 s & >120 s by PFA-100	2	NR	NR	NR	NR	NR	NR	
						Collagen ADP closure time between <65 s & >120 s by PFA-100	Collagen ADP closure time between 65-120 s by PFA-100	6	NR	NR	NR	NR	NR	NR	
						Collagen ADP closure time between <65 s & >120 s by PFA-100	Collagen ADP closure time between <65 s & >120 s by PFA-100	4	NR	NR	NR	NR	NR	NR	

Appendix Table E105. Quality assessment of studies assessing the predictive ability of PFA-100 in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard					Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)	
Malek, 2007 17295159 Poland NR	yes	yes	yes	low	low	NR	no	high	low	yes	NR	unclear	low	no	yes	yes	yes	low	
Breet, 2011 20179285 Netherlands POPULAR	yes	yes	yes	low	low	NR	NO	high	low	yes	yes	low	low	yes	yes	yes	yes	low	
Foussas, 2007 17892990 Greece None	yes	yes	yes	low	low	yes	yes	low	low	yes	yes	low	low	yes	yes	yes	yes	low	
Smit, 2010 20889993 Netherlands ON-TIME-2	yes	yes	yes	low	low	NR	NO	high	low	yes	NR	unclear	low	no	yes	yes	yes	low	
Huczek, 2008 18301358 Poland NR	yes	yes	yes	low	low	NR	yes	unclear	low	yes	NR	unclear	low	no	yes	yes	yes	low	
Moerenhout, 2010 20211306 Belgium NR	NR	yes	yes	low	low	NR	yes	unclear	high	yes	NR	unclear	low	no	yes	yes	yes	low	
Siller-Matula, 2009 19135705 Austria NR	NR	yes	yes	low	low	NR	yes	unclear	high	No	NR	high	high	no	yes	yes	yes	low	
Gori, 2008 19132241 Italy RECLOSE	yes	yes	yes	low	low	NR	yes	unclear	low	yes	NR	unclear	low	no	yes	yes	yes	low	
Siller-Matula, 2012 22260716 Austria PEGASUS-PCI	yes	yes	yes	low	low	yes	yes	low	low	yes	NR	unclear	low	yes	yes	yes	yes	low	

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Chiu 2011 21925055 Taiwan NR	NR	yes	yes	low	low	yes	no	high	high	Yes	Yes	Low	Low	Yes[24 months]	yes	yes	yes	low

1. Consecutive or random sample of patients enrolled.
2. Case-control design avoided
3. Study avoided inappropriate exclusions
Risk of bias: could the selection of patients have introduced bias (If ≥2 of the above 3 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)
Concerns that the included patients do not match the review question?
4. Index test results interpreted without knowledge of results of reference standard?
5. If a threshold used, was it prespecified?
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Concerns that the index test, its conduct, or its interpretation differ from the review question?
6. Reference standard likely to correctly classify the target condition?
7. Reference standard results interpreted without knowledge of index test results?
Could the reference standard, its conduct, or its interpretation have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Are there concerns that the target condition as defined by the reference standard does not match the review question?
8. Appropriate interval between index test and reference standard?
9. All patients received a reference standard?
10. All patients received the same reference standard?
11. Were all patients included in the analysis?
Could the patient flow have introduced bias? (If ≥3 of the above 4 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix Table E106. Quality assessment of studies assessing the predictive ability of PFA-100 in patients with ischemic heart, cerebrovascular and peripheral vascular disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard					Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)	
Reny, 2012 22615340 France and Switzerland ADRIE	yes	yes	yes	Low	low	yes	yes	low	low	yes	yes	low	low	No [3 months]	yes	yes	yes	low	

Appendix Table E107. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of miscellaneous platelet function tests

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Smit, 2010 20889993 Netherlands ON-TIME-2	648 NR 75.8 62.3	NR NR CVA 1.7 PCI 7.4; CABG 2.5 15.2 NR NR 7.8 STEMI 100	18.8 44.9 HTN 29.6; systolic 132.8 mmHg; diastolic 79.8 mmHg 9.9	NR NR NR NR	NR NR NR	Patients with ACS (STEMI)	Clopidogrel: (600 mg LD + 75 mg MD daily for 1 year);	acetylsalicylic acid 500 mg IV; unfractionated heparin 5000 IU IV ± tirofiban (25 mg/kg bolus + MD infusion of 0.15 mg/kg/min of tirofiban or placebo)
Dziewierze, 2005 15815794 Poland NR	31 NR 77.4 54.3±9.9	NR NR NR PCI 19.4; CABG 0; 100 NR NR 61.3 NR	74.2 25.8 58.1 12.9	NR NR 100	NR NR multi 70.9	Patients with stable angina selected for PCI	Loading dose 300 mg with 75 mg per day until PCI was performed or 28 days until stent had been implanted.	The use of GP IIb/IIIa inhibitors and heparin titration during PCI were left to the discretion of the operator.

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Breet, 2010 20179285 Netherlands POPULAR	1069 NR 75 64±10.6	NR NR NR NR NR 54.5 NR	80.3 11.1 HTN 76.9 18.6	NR 100 89.4 27.8	100 DES 63.5 NR	coronary artery disease scheduled for elective PCI with stent	clopidogrel treatment (a maintenance of 75 mg/d therapy for>5 days or a loading dose of 300 mg ≥24 hours before PCI or 600 mg ≥4 hours before PCI) and aspirin (80-100 mg/d ≥10 days).	unless they were receiving long-term anticoagulation with warfarins
Mobley, 2004 14969622 USA NONE	50 NR NR NR	NR NR NR NR NR NR NR	NR NR NR NR	NR NR NR(most to be) NR	NR NR NR	Candidates for cardiac catheterization with clinical suspicion of PCI who were on aspirin and clopidogrel	75 mg clopidogrel per day after 300-mg loading dose (if physician judges the loading dose to be necessary); most patients already on aspirin	NR

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Lindvall, 2009 19477870 Sweden None	15 NR 80 61.8±11.6	NR NR NR NR NR NR NR	NR NR NR NR	NR NR NR NR	NR NR NR	Patients with ACS undergoing CABG	loading dose of 300 – 600 mg of clopidogel orally, followed by 75 mg daily; oral aspirin, 75 mg per day,	subcutaneous low molecular weight heparin. At the time of the study, aprotinin was routinely administered according to the Hammersmith regime: consisting of 2 million KIU before start of surgery, 2 million KIU in the CPB prime, and 500,00- KIU per hr during surgery . Aspirin and low molecular weight heparin treatment was continued until the day of surgery, but not given on the day of surgery. ACE inhibitors were omitted on the day of surgery.
Gurbel, 2003 12714161 USA No	63 NR 60 67±11	NR NR NR CABG 18 NR NR 24 NR	hyper 60 NR HTN 72 39	NR 100 100 NR	100 NR NR	Patients undergoing PCI with stenting	all received ± 81 mg of aspirin for 7 days before the procedure. All patients received the same clopidogrel regimen (300 mg in the catheterization laboratory after stent implantation, then 75 mg/day for 30 days) with 325 mg/day aspirin.	Heparin (activated clotting time >300 seconds) was administered to all patients immediately before stent implantation, and per protocol, GP IIb/IIIa inhibitors were not given.

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non-STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Kim, 2010 20449634 Korea NR	1058 NR 70.1 62.2±11.2	62.2±11.2 NR 3.6% PCI 30.4% NR NR NR 20.9% NR	19% 39.8% 52% 29%	NR 25.3% NR NR	NR NR 27.6%	Patients treated with coronary stenting for symptomatic coronary artery disease, including acute myocardial infarction (AMI) and on chronic clopidogrel therapy	scheduled coronary stenting procedures, 300-mg loading-dose (LD) of clopidogrel at least 12 h before procedure. In AMI patients, all received a 600-mg LD of clopidogrel immediately after emergency room arrival, followed by a maintenance dose of 75 mg daily.	If use of glycoprotein IIb/IIIa inhibitor (GPI) was deemed necessary, only tirofiban, which has a short half-life, was administered.
Kalantzi, 2012 21806493 Greece NR	40 NR 70 57.6±10.8	NR NR NR NR NR NR NR NR	hyper 40 57.5 HTN 60 0	NR NR NR NR	NR NR NR NR	patients with ACS with or without ST elevation	LD 325 mg aspirin+MD 100mg/day heparin 1mg/kg every 12 h LD 600mg clopidogrel+MD 75 mg/day	atorvastatin 40mg/day

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Siller- Matula, 2012 22260716 PEGASUS- PCI	416 NR 76 64±12	NR NR NR PCI 47 NR NR 13 31 18/NR	hyper 76 55 84 32	NR 100 100 76	100 DES 99 NR	patients undergoing PCI	clopidogrel LD 600mg, MD 75mg	NR
Saad, 2012 22146578 Egypt NR	90 NR 58% 56.2 y	100% NR NR NR NR NR NR NR	Hypercholesterolemia: 31.1% 67% 19% HTN: 57% 62%	NR NR 100% NR	NR NR NR	CAD patients for PCI	clopidogrel LD: 600 mg; MD: 75 mg/d; aspirin 162 mg/d	nitrites, b-blockers, lipid-lowering drugs, antihypertensive drugs and oral hypoglycemic drugs

Author, year [ref] UID Country Study Name	Total N Enrolled Race (%) by group) Male (%) Age*	Previous CAD (%) Previous heart failure(%) Previous TIA/stroke(%) History of PCI or CABG(%): Stable angina(%) Unstable angina(%) Previous PAD(%) History of MI(%) STEMI/non- STEMI(%)	Dyslipidemia (%) Smokers (%) BP(mmHg diastolic/systolic HTN (%) Diabetes (%)	Vitamin K antagonist(%) Clopidogrel(%) Aspirin(%) PPI(%)	Stent implantation(%) Type of stent(%) Multi-or single vessel(%)	Current indication for clopidogrel treatment	Current antiplatelet regimen	Co-medication
Lakkis, 2001 11458412 USA NR	30 NR NR 53	NR NR NR NR NR NR NR	Hyper 66.7 NR HTN 60 33.3	NR NR NR NR	100 NR NR	ACS patients with PCI	clopidogrel 300 mg and aspirin 325 mg	GP IIb/IIIa inhibitors

* Mean (standard deviation), unless otherwise stated.

Abbreviations: NACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH= Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors.

Appendix Table E108. Study design characteristics of studies assessing the predictive ability of miscellaneous platelet function tests in patients with ischemic heart disease

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Smit, 2010 20889993 Netherlands ON-TIME-2	Substudy of the Ongoing Tirofiban in Myocardial Infarction Evaluation 2 (On-TIME-2) trial	yes	Selected sample (For whom Platelet aggregation inhibition data was available)	Patients with ACS (STEMI)	June 2004 until November 2007	Max 30 days	follow up after intervention	NR	NR
Dziewierze, 2005 15815794 Poland NR	prospective Cohort	No	Consecutive	Patients with stable angina selected for PCI	NR	24 hours-28 days	Hospital inpatient	NR	NR
Breet, 2010 20179285 Netherlands POPULAR	prospective Cohort	No	Patients scheduled for PCI with stent implantation	Patients with PCI and stent implantation	Dec 2005- Dec 2007	1-year	Hospital inpatient	Yes. 80%	NR
Mobley, 2004 14969622 USA NONE	Prospective	NR	NR	Candidates for cardiac catheterization with clinical suspicion of PCI who were on aspirin and clopidogrel	NR	NR	Hospital and then outpatient	NO	Partly industry
Lindvall, 2009 19477870 Sweden None	Prospective observational	NR	Consecutive	Patients with ACS undergoing CABG	NR	NR	Inpatient	NO	Partly industry
Gurbel, 2003 12714161 USA No	Prospective	NO	NR	Patients undergoing PCI with stenting	NR	NR	Inpatient and then outpatient visit at 30 days	NR	All Industry
Kim, 2010 20449634 Korea NR	prospective cohort	no	consecutively enrolled	unselected patients treated with coronary stenting for symptomatic coronary artery disease, including acute myocardial infarction (AMI) and chronic clopidogrel therapy	December 2007 to June 2009	6 months	Department of Cardiology of the Gyeongsang National University hospital inpatient	NR	NR

Author Year PMID Country Study Name	Study design	Multicenter (yes/no)	Recruitment method	Sampling population	Enrollment period	Mean or median (state which follow up duration)	Setting	A Priori power analysis performed? (if yes, was accrual 80% of target or higher)	Funding
Kalantzi, 2012 21806493 Greece NR	prospective	no	NR	patients with ACS with or without ST elevation	NR	30 days	single center	NR	NR
Siller-Matula, 2012 22260716 PEGASUS- PCI	prospective cohort	no	consecutive	patients undergoing PCI	March 2007- Nov, 2009	12 months	medical university if vienna	yes, 80%	Austrian National Bank
Saad, 2012 22146578 Egypt NR	Prospective	No	NR	CAD patients undergoing PCI with stenting	NR	6 months	followup after intervention	NR	None reported
Lakkis, 2001 11458412 USA NR	cohort	no	NR	ACS patients undergoing PCI with stent	NR	24 h	inpatient	NR	NR

Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; CAD = coronary artery disease; MI = myocardial infarction; NSTEMI = non-ST-elevation; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; DES=drug eluting stent; CABG=coronary artery bypass grafting; AA= arachidonic acid; SD=standard deviation; RCT=randomized controlled trial; NR=not reported

Appendix Table E109. Phenotypic test details in studies assessing the predictive ability of miscellaneous platelet function tests in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Smit, 2010 20889993 Netherlands ON-TIME-2	Fe induced platelet aggregation (FIPA) Sysmex K4500 Sysmex, Kobe, Japan	AISI 434 low carbon stainless steel	whole blood; collected before PCI Citrate (0.109 M) NR Clopidogrel came first NR	quartiles 1-4	Not explicitly reported	quartiles 1 162 (25%) quartiles 2 162 (25%) quartiles 3 162 (25%) quartiles 4 162 (25%)
Dziewierze, 2005 15815794 Poland NR	Platelet aggregation inhibition Plateletworks with Sysmex K800 Helena Laboratory	ADP	blood samples were collected at baseline and 3, 6, 12 , 24 hours from the initial loading dose of clopidogrel 3.2% natrium citrate baseline and 3, 6, 12 , 24 hours 15 minutes	DPAI≤10% non-responder DPAI>10% responder	not explicitly reported.	DPAI≤10% non- responder; N=7 DPAI>10% responder; N=24
Breet, 2010 20179285 Netherlands POPULAR	Plateletworks NR (Helena Laboratories, Beaumont, Texas).	ADP	NR K3-EDTA and tubes containing diphenylalanyl-L-prolyl- L-arginine chloromethyl ketone (PPACK[50 µmol/L] NR 2 hours	plateletworks <80.5 plateletworks >=80.5	Based on ROC curves	plateletworks <80.5; n=344 plateletworks >=80.5; n=262
Breet, 2010 20179285 Netherlands POPULAR	IMPACT-R IMPACT-R Matis Medical Inc, Beersel, Belgium	ADP	Before heparinization 3.2% citrate NR 2 hours	High OTPR ≤2 Normal OTPR >2	Based on ROC curves	High OTPR ≤2 (n = 296) Normal OTPR >2 (n = 609)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Mobley, 2004 14969622 USA NONE	NR/Optical platelet aggregation Dual Channel Aggregometer Chrono-Log Corp., Havertown, Pennsylvania & Thromboelastograph Hemoscope Corporation, Niles, Illinois & Optical platelet aggregation Ichor Plateletworks Helena Laboratories, Beaumont, Texas	ADP	NR Heparin for Chronolog; Reptilase and factor XIIIa for TEG; Citrate for Ichor Sampling done before and after clopidogrel (but interval NR) NR	Nonresponders (failure of clopidogrel inhibition) defined as <10% reduction from baseline averaging results from all 3 analyzers Responders ≥10% reduction from baseline averaging results from all 3 analyzers	Not explicitly stated	Nonresponders 15/50 (30%) Responders 35/50 (70%)
Mobley, 2004 14969622 USA NONE	Optical platelet aggregation Ichor Plateletworks Helena Laboratories, Beaumont, Texas	ADP	NR citrate Sampling done before and after clopidogrel (but interval NR) NR	Nonresponders Responders	Not explicitly stated	Nonresponders 15/50 (30%) Responders 35/50 (70%)

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Lindvall, 2009 19477870 Sweden None	Aggregometry NR Plateletworks Helena Lab, Beaumont, TX, USA	20 uM ADP	Blood samples were drawn from the radial arterial cannula before and after administration of a bolus of two million kallikrein inhibiting units (KIU) [of aprotinin]; measurements done just before and just after aprotinin given, with both measurements taken long after clopidogrel given EDTA Mean (SD) interval between last clopidogrel dose and surgery (with blood sampling occurring just before start of surgery) 63.7± 28 hours; median, 72 hours; IQR, 29.5-78 hours Testing done immediately after sampling	Clopidogrel nonresponse (>90% aggregation) Clopidogrel response (≤90% aggregation)	literature published	Clopidogrel nonresponse (>90% aggregation); 4 (27%) Clopidogrel response (≤90% aggregation); 11 (73%)
Gurbel, 2003 12714161 USA No	P-selectin expression Flow cytometry Parminggen, San Diego, California	ADP 200 umol/liter	Blood was collected immediately before clopidogrel administration (baseline), and at 1, 5, and 30 days after stenting. 3.8% trisodium citrate at 0, 1, 5, 30 days NR	Nonresponder (change from baseline of <10%) Responder (change from baseline of <10%)	Not explicitly reported	Nonresponder (change from baseline of <10%): P-selectin expression: 9/38 (24%) P-selectin expression: 29 of 38 (76%)
Kim, 2010 20449634 Korea NR	turbidimetry-based optical detection device VerifyNowP2Y12 assay NR & LTA ADP AggRam aggregometer Helena Laboratories Corp., Beaumont, TX	20 µmol/L ADP for VerifyNow & 5 and 20 µmol/L ADP	Blood was drawn into a Greiner Bio-One 3.2% citrate Vacuette tube sodium citrate 3.2% clopidogrel- naïve patients received a 300-mg loading-dose (LD) of clopidogrel at least 12 h before procedure, and blood sampling was performed after insertion of the arterial sheath. In the case of patients who were already on chronic clopidogrel therapy, blood sampling was performed at the catheterization lab without clopidogrel LD 60 minutes	VerifyNow PRU<240 PRU≥240 LTA: Aggregation <50% Aggregation ≥50%	Based on literature	VerifyNow PRU<240 n=512 PRU≥240 n=546 Aggregation <50%: NR Aggregation ≥50%: NR

Author, year [ref] UID Country Study Name	Test/Device name Device category Device name & manufacturer*	Agonist used	Sample Collection and Procurement Anticoagulant used Interval between clopidogrel doses and blood sampling (in days) Interval between sampling and testing (in days):	Grouping of Phenotypes** [Definition]	Rational for the grouping of phenotypes reported (Yes/No) [short description]	Frequency of phenotypes
Kalantzi, 2012 21806493 Greece NR	CD40L, PMP, FACS Calibur flow cytometer (Becton-Dickinson, San Jose, CA)	ADP	Citrated blood samples were collected after the patient's presentation at the emergency room before clopidogrel administration (baseline), as well as at 5- and 30-days after clopidogrel loading. citrate 5 days 30 days	nonresponder VASP PRI >50% responder VASP PRI <50%	reference 15, 23	non-responder n=12 responder n=28
Siller-Matula, 2012 22260716 PEGASUS- PCI	CPA, Impact R Cone and platelet analyzer DiaMed, Cressier, Switzerland	2uM ADP	Blood samples from patients were obtained from the arterial sheath (6F) in the catheterization laboratory directly post-PCI and at least 5 min after intravenous infusion of aspirin. 3.8% sodium citrate NR performed up to 24 h after blood sampling	Clopidogrel non-responder according to MEA (≥ 48 U) Clopidogrel responder according to MEA (< 48 U) n = 321 (80%)	ref 16, 28	non-responder n = 81 (20%) responder n = 321 (80%)
Saad, 2012 22146578 Egypt NR	Flow Cytometry EPICS-XL PROFILE II Coulter flow cytometer Beckman Coulter, Inc., Fullerton, CA	ADP (5 μ M/L)	Peripheral blood samples before PCI 6 hrs after clopidogrel 3.8% trisodium citrate 0.25 days (6hours) NR	best cutoff value of posttreatment platelet reactivity to predict ischemic events	ROC analysis	NR
Lakkis, 2001 11458412 USA NR	ICHOR platelet works	ADP 20uM	Blood samples were collected 5 min before tirofiban or abciximab was started, and at 30 min, 4 hr, 12 hr during the infusion, and 2 hr after termination of either infusion. EDTA 30 mins, 3h, 12h,2h NR	NR (continuous)	NR	NR

Abbreviations: ADP= adenosine 5'-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP=

glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported

Appendix Table E110. Results from studies assessing the ability of miscellaneous platelet function tests to predict death in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Dziewierze, 2005 15815794 Poland NR	Clopidogrel LD 300 mg, 75mg maintain dose	Platelet aggregation inhibition	Death	Death	In hospital stay	Non-responder	Death	0/7	OR=3.3 (calculated)	NR	p=0.56 nonresponder vs. responder Fisher's exact test	NR	NR	
						Responder		0/24						
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily + aspirin 80-100 mg daily	Plateletworks ADP	Death	death	1-year	High OTPR	Death	4/262 (1.5)	OR=0.58	0.18- 1.89	0.36 high OTPR vs normal logistic regression model	No	NR	
						Normal OTPR		9/344 (2.6)						
		IMPACT-R ADP	Death	death	1-year	High OTPR	Death	6/296 (2)	OR=1.38	0.49- 3.91	0.54 high OTPR vs normal logistic regression model	No	NR	
						Normal OTPR		9/609 (1.5)						
Lakkis, 2001 11458412 USA NR	clopidogrel 300 mg and aspirin 325 mg and tirofiban	ICHOR platelet works	Death	death, Q-wave myocardial infarction, or rehospitalization for ischemia	30 days	High reactivity <80% IPA N=1	death	0	NR	NR	NR	NR	NR	
						Normal reactivity <80% IPA N=19		0						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	clopidogrel 300 mg and aspirin 325 mg and Abciximab	ICHOR platelet works	MACE	death, Q-wave myocardial infarction, or rehospitalization for ischemia	30 days	High reactivity <80% IPA N=2	MACE	0	NR	NR	NR	NR	NR	
						Normal reactivity <80% IPA N=8		0						

Appendix Table E111. Results from studies assessing the ability of miscellaneous platelet function tests to predict myocardial infarction in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Dziewierze, 2005 15815794 Poland NR	Clopidogrel LD 300 mg, 75mg maintain dose	Platelet aggregation inhibition	MI	Myocardial infarction	In hospital stay	Non-responder	MI	0/7	OR=3.2 (calculated)	NR	p=0.56 nonresponder vs. responder Fisher's exact test	NR	NR	
						Responder		0/24						
Breet, 2011 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80-100 mg daily	Plateletworks ADP	MI	MI	1-year	High OTPR	MI	25/262 (9.5)	OR=3.52	1.66-7.47	<0.001 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		10/344 (2.9)						
	maintaining Clopidogrel 75 mg daily +aspirin 80-100 mg daily	IMPACT-R ADP	MI	MI	1-year	High OTPR	MI	22/296 (7.4)	OR=1.61	(0.91-2.85)	0.10 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		29/609 (4.8)						
Lakkis, 2001 11458412 USA NR	clopidogrel 300 mg and aspirin 325 mg and tirofiban	ICHOR platelet works	Q wave MI	death, Q-wave myocardial infarction, or rehospitalization for ischemia	30 days	High reactivity <80% IPA N=1	Q wave MI	0	NR	NR	NR	NR	NR	
						Normal reactivity <80% IPA N=19		0						
	clopidogrel 300 mg and aspirin 325 mg and Abciximab	ICHOR platelet works	Q wave MI	death, Q-wave myocardial infarction, or rehospitalization for ischemia	30 days	High reactivity <80% IPA N=1	Q wave MI	0	NR	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal reactivity <80% IPA N=8		0						

Appendix Table E112. Results from studies assessing the ability of miscellaneous platelet function tests to predict stent thrombosis in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	Plateletworks ADP	Stent thrombosis	Stent thrombosis	1-year	High OTPR	Stent thrombosis	6/262 (2.3)	OR=2.66	0.66- 10.75	<0.09 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		3/344 (0.9)						
Breet, 2010 20179285 Netherlands NR	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	IMPACT-R ADP	Stent thrombosis	Stent thrombosis	1-year	High OTPR	Stent thrombosis	3/296 (1.0)	OR=0.88	0.23- 3.43	0.85 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		7/609 (1.1)						

Appendix Table E113. Results from studies assessing the ability of miscellaneous platelet function tests to predict major adverse cardiovascular events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Smit, 2010 20889993 Netherlands ON-TIME-2	Clopidogrel 300 mg LD + 75 mg MD	FIPA	MACE	mortality, urgent target vessel revascularisation or recurrent myocardial infarction	30 days	Quartile 1	MACE	NR	NR	NR	0.281; between all quartiles [Chi-square]	NO	NR	Data in figures only shows percentages; needs to be digitized to obtain accurate values
						Quartile 2		NR						
						Quartile 3		NR						
						Quartile 4		NR						
	Clopidogrel 300 mg LD + 75 mg MD	Plateletworks	MACE	mortality, urgent target vessel revascularisation or recurrent myocardial infarction	30 days	Quartile 1	MACE	NR	NR	NR	0.358; between all quartiles [Chi-square]	NO	NR	Data in figures only shows percentages; needs to be digitized to obtain accurate values
						Quartile 2		NR						
						Quartile 3		NR						
						Quartile 4		NR						
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80- 100mg daily	IMPACT-R ADP	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR	Death combined	32/296 (10.8)	OR=1.6	0.99- 2.58	0.05 high OTPR vs normal	No	NR	
						Normal OTPR		43/609 (7.1)						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
		IMPACT-R ADP	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1 year	High OTPR ≥93% surface coverage	Death combined	33/262 (12.6)	AUC: 0.53 Sens: 0.44 Spec: 0.669	0.47-0.59 0.333-0.553 0.636-0.7		No	NR	
		Plateletworks ADP	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR ≥80.5%	Death combined	33/262 (12.6)	AUC: 0.61 Sens: 0.63 Spec: 0.585	0.53-0.69 0.496-0.746 0.544-0.626	0.001 regression model	No	NR	
		Plateletworks ADP	Death combined	All-cause death, nonfatal MI, stent thrombosis and stroke	1-year	High OTPR	Death combined	33/262 (12.6)	OR=2.22	1.25-3.93	0.005 high OTPR vs normal logistic regression analysis	No	NR	
						Normal OTPR		21/344 (6.1)						
Kim, 2010 20449634 Korea NR	300-600mg LD and 75 mg maintain dose clopidogrel	5umol ADP-induced PRmax≥50%	ischemic events	ischemic events	6 months	5umol ADP-induced PRmax≥50%	PRmax≥50%	2.2%	OR=1.33	0.16-11.33	0.299 PR≥50 vs <50%	NR	NR	NR
		5umol ADP-induced LTA and VerifyNowP2Y12				5umol ADP-induced LTA and VerifyNowP2Y12	PRmax<50% and PRmax<240	1.6%						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
	300-600mg LD and 75 mg maintain dose clopidogrel	5umol ADP- induced PRmax≥50%	ischemic events	ischemic events	6 months	5umol ADP- induced PRmax≥50%	PRmax≥50%	2.2%	OR=1.33	0.16- 11.33	0.299 HPPR vs no- HPPR	NR	NR	NR
		5umol ADP- induced LTA and VerifyNowP2Y12				5umol ADP- induced LTA and VerifyNowP2Y12	no-HPPR (PRmax<50% and PRU<240)	1.6%						
	300-600mg LD and 75 mg maintain dose clopidogrel	5umol ADP- induced LTA and VerifyNowP2Y12	ischemic events	ischemic events	6 months	5umol ADP- induced PRmax≥50% and PRU≥240	5umol ADP- induced PRmax≥50% and PRU≥240	6.0%	OR=3.86	1.55- 9.63	0.002 HPPR vs no- HPPR	NR	NR	NR
		5umol ADP- induced LTA and VerifyNowP2Y12				5umol ADP- induced LTA and VerifyNowP2Y12	no-HPPR (PRmax<50% and PRU<240)	1.6%						
Mobley, 2004 14969622 USA NONE	300mg LD Clopidogrel and 75mg MD	Combination of LTA, TEG & Ichor PlateletWorks	Major adverse coronary events	death due to cardiovascular or unknown causes, rehospitalization for angina pectoris, rehospitalization for myocardial infarction, or need for target vessel revascularization	1 month	Nonresponder	Yes	0/15	OR=0.74 (calculated)	NR	p=0.85 nonresponder vs. responder Fisher's exact test	NR	NR	
						Responder	Yes	1/35						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Major adverse coronary events	death due to cardiovascular or unknown causes, rehospitalization for angina pectoris, rehospitalization for myocardial infarction, or need for target vessel revascularization	6 months	Nonresponder	Yes	1/15	OR=0.76 (calculate)	NR	p=0.82 nonresponder vs. responder Fisher's exact test	NR	NR	
						Responder	Yes	3/35						
Saad, 2012 22146578 Egypt NR	clopidogrel LD: 600 mg; MD: 75 mg/d; aspirin 162 mg/d	P-selectin by flow cytometry	MACE	CV death, recurrent acute coronary syndrome (ACS), and acute, subacute, and late stent thromboses	6 months	≥18.5% N=NR	MACE	NR	AUC=0.831	0.736-0.926	P<0.001	No	NR	
						<18.5% N=NR		NR						
Lakkis, 2001 11458412 USA NR	clopidogrel 300 mg and aspirin 325 mg and tirofiban	ICHOR platelet works	MACE	death, Q-wave myocardial infarction, or rehospitalization for ischemia	30 days	High reactivity <80% IPA N=1	MACE	0	NR	NR	NR	NR	NR	
						Normal reactivity <80% IPA N=19		0						
	clopidogrel 300 mg and aspirin 325 mg and Abciximab	ICHOR platelet works	MACE	death, Q-wave myocardial infarction, or rehospitalization for ischemia	30 days	High reactivity <80% IPA N=2	MACE	0	NR	NR	NR	NR	NR	

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
						Normal reactivity <80% IPA N=8		0						

Appendix Table E114. Results from studies assessing the ability of miscellaneous platelet function tests to predict bleeding events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Dziewierze, 2005 15815794 Poland NR	Clopidogrel LD 300 mg, 75mg maintain dose	Platelet aggregation inhibition	Haematoma	Haematoma	In hospital stay	Non-responder	Haematoma	1/7 (14.3)	OR=3.8 (calculate)	NR	NS (>0.05) non-responder vs. responder	NR	NR	
						Responder		1/24 (4.2)						
Mobley, 2004 14969622 USA NONE	300mg LD Clopidogrel and 75mg MD	Combination of LTA, TEG & Ichor Platelet Works	Moderate bleeding perioperatively after CABG	5.7 g/dl decrease in hemoglobin plus 600 ml of total chest tube drainage in one patient, and the other had a 3.8 g/dl decrease in hemoglobin plus 840 ml of total chest tube drainage	During procedure	Nonresponder	Yes	2/2	NR	NR	NR	NR	NR	
						Responder	Yes	NA						
			Life-threatening bleeding complications	Fatal hemorrhage, reduction in hemoglobin of 5 g/dl, hypotension requiring inotropic support, symptomatic intracranial hemorrhage, or transfusion of >4 U of packed red blood cells occurred	During procedure	Nonresponder	Yes	0/15	OR=2.3 (calculated)	NR	p=0.68 nonresponder vs. responder Fisher's exact test	NR	NR	
						Responder	Yes	0/35						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
			Major bleeding	intraocular hemorrhage causing visual impairment, a decrease in hemoglobin concentration of 2 to 5 g/dl, hemorrhage requiring transfusion of 2 to 4 U of packed red blood cells, and bleeding requiring surgical intervention, including elective pseudoaneurysm repair	During procedure	Nonresponder	Yes	0/15	OR=0.4 (calculate)	NR	p=0.59 nonresponder vs. responder Fisher's exact test	NR	NR	
						Responder	Yes	2/35						
			Minor bleeding	bleeding, not otherwise classified, that necessitated discontinuation of the study drug, a decrease in hemoglobin of <2 g/dl, hemorrhage requiring transfusion of <2 U of packed red blood cells, or development of a groin hematoma requiring prolonged hospitalization, surgical drainage, or a blood transfusion	During procedure	Nonresponder	Yes	1/15	OR=2.4 (calculate)	NR	p=0.54 nonresponder vs. responder Fisher's exact test	NR	NR	
						Responder	Yes	1/35						

Appendix Table E115. Results from studies assessing the ability of miscellaneous platelet function tests to predict stroke in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80-100mg daily	Plateletworks ADP	stroke	Stroke	1-year	High OTPR	Stroke	4/262 (1.5)	OR=1.76	0.39-7.94	<0.45 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		3/344 (0.9)						
Breet, 2010 20179285 Netherlands POPULAR	maintaining Clopidogrel 75 mg daily +aspirin 80-100mg daily	IMPACT-R ADP	stroke	Stroke	1-year	High OTPR	Stroke	4/296 (1.4)	OR=1.18	0.34-4.06	0.79 high OTPR vs. normal logistic regression	No	NR	
						Normal OTPR		7/609 (1.1)						

Appendix Table E116. Results from studies assessing the ability of miscellaneous platelet function tests to predict other clinical events in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [Y/N/NR]	Comments (e.g., additional data in figures)
Dziewierze, 2005 15815794 Poland NR	Clopidogrel LD 300 mg, 75mg maintain dose	Platelet aggregation inhibition	Angina recurrence	Angina recurrence	In hospital stay	Non-responder	Angina recurrence	0/7	OR=3.3(calculated)	NR	p=0.56 nonresponder vs. responder Fisher's exact test	NR	NR	
						Responder		0/24						
Mobley, 2004 14969622 USA NONE	300mg LD Clopidogrel and 75mg MD	Combination of LTA, TEG & Ichor PlateletWorks	PCI	NA	NA	Nonresponder	PCI	4/15	OR=0.5 (calculated)	NR	p=0.28 nonresponder vs. responder Fisher's exact test	NR	NR	NR
						Responder	PCI	15/35						
	300mg LD Clopidogrel and 75mg MD	Combination of LTA, TEG & Ichor PlateletWorks	Unsuccessful PCI	Unsuccessful PCI	NA	Nonresponder	unsuccessful PCI	0/4	OR=1.1 (calculated)	NR	p=0.97 nonresponder vs. responder Fisher's exact test	NR	NR	NR
						Responder	unsuccessful PCI	1/15						
	300mg LD Clopidogrel and 75mg MD	Combination of LTA, TEG & Ichor PlateletWorks	CABG	CABG	NA	Nonresponder	CABG	2/15	OR=13.1	NR	p=0.1 nonresponder vs. responder Fisher's exact test	NR	NR	NR
						Responder	CABG	0/35						
Lakkis, 2001 11458412 USA NR	clopidogrel 300 mg and aspirin 325 mg and tirofiban	ICHOR platelet works	Rehospitalization for ischemia	death, Q-wave myocardial infarction, or rehospitalization for ischemia	30 days	High reactivity <80% IPA N=1	Rehospitalization for ischemia	0	NR	NR	NR	NR	NR	
						Normal reactivity <80% IPA N=19		0						

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Clinical Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., bleeding or no bleeding)	No. with outcome status within phenotype group	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [Y/N/NR]	Comments (e.g., additional data in figures)
	clopidogrel 300 mg and aspirin 325 mg and Abciximab	ICHOR platelet works	Rehospitalization for ischemia	death, Q-wave myocardial infarction, or rehospitalization for ischemia	30 days	High reactivity <80% IPA N=1	Rehospitalization for ischemia	0	NR	NR	NR	NR	NR	
						Normal reactivity <80% IPA N=8		0						

Appendix Table E117. Results from studies assessing the ability of miscellaneous platelet function tests to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR–)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
Dziewierz, 2005 15815794 Poland NR	Clopidogrel LD 300 mg, 75mg maintain dose	Platelet aggregation	DPAI	The degree of platelet aggregation	3h	Non-responder	Non-responder	15/31 (48.4)	10%	NR	NR	NR	NR	NR	
						responder	responder	16/31 (51.6)							
	Clopidogrel LD 300 mg, 75mg maintain dose	Platelet aggregation	DPAI	The degree of platelet aggregation	6h	Non-responder	Non-responder	8/31 (25.8)	10%	NR	NR	NR	NR	NR	
						responder	responder	23/31 (74.2)							
	Clopidogrel LD 300 mg, 75mg maintain dose	Platelet aggregation	DPAI	The degree of platelet aggregation	12h	Non-responder	Non-responder	8/31 (25.8)	10%	NR	NR	NR	NR	NR	
						responder	responder	23/31 (74.2)							
	Clopidogrel LD 300 mg, 75mg maintain dose	Platelet aggregation	DPAI	The degree of platelet aggregation	24h	Non-responder	Non-responder	7/31 (22.6)	10%	NR	NR	1.0 (fishers exact between categories)	NR	NR	
						responder	responder	24/31 (77.4)							
Lindvall, 2009 19477870 Sweden None	300-600mg LD Clopidogrel and MD 75 mg/day+75mg daily aspirin	ADP-induced aggregation	Clopidogrel response vs nonresponse	Response defined as >90% aggregation	Repeat measurement immediately after aprotinin	Baseline HPR+ N = 4	HPR-	1	>90%	NR	NR	0.07(fishers exact between categories)	NR	NR	
						Baseline HPR- N = 11	HPR+	2							
Gurbel , 2003 12714161 USA No	300mg LD clopidogrel and 75mg daily MD with 325 mg/day aspirin	Flow cytometry for P-selectin expression	Continued nonresponse since baseline	NR	5 days	Nonresponders at baseline (n=9)	Nonresponders at 5 days	5/9 (56%)	<10% change from baseline	NR	NR	0.144 (fishers exact between categories)	NR	NR	NONE
					5 days	Responders at baseline (n=29)	Responders at 5 days	29/29 (100%)							

Author, year UID Country Study name	Treatment	Phenotypic Test Used [index test]	Reactivity Outcome	Outcome Definition	Timing of measurement	Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP	Outcome status (e.g., HPR+ or HPR–)	No. with outcome status within phenotype group	Cut-off	Comparative metric (OR, RR, HR)	95% CI	P (between which groups?) [statistical test]	Adjusted? [YES/NO/NR] If YES, for what factors?	Procedures for multiple comparisons [YES, NO, NR]	Comments (e.g., additional data in figures)
					30 days	Nonresponders at baseline (n=9)	Nonresponders at 30 days	3/6 (50%) with data (3 were not measured at 30 days)							
					30 days	Responders at baseline (n=29)	Responders at 30 days	14/18 (78%) with data (11 were not measured at 30 days)							
Kalantzi, 2012 21806493 Greece	LD 600mg clopidogrel+MD 75 mg/day	CD40L, PMP, FACS Calibur flow cytometer	CD40L, PMP, FACS Calibur flow cytometer	CD40L, PMP, FACS Calibur flow cytometer	30 days	responder	responder by PRI >50%	12	NR	NR	NR	NR	NR	NR	figure 1, 2
					30 days	non-responder		28							

Appendix Table E118. Quality assessment of studies assessing the predictive ability of miscellaneous platelet function tests in patients with ischemic heart disease

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard					Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)	
Smit , 2010 20889993 Netherlands ON-TIME-2	yes	yes	yes	low	low	NR	NO	high	low	yes	NR	unclear	low	no	yes	yes	yes	low	
Dziewierze, 2005 15815794 Poland NR	yes	yes	yes	low	low	NR	no	high	high	yes	NR	unclear	low	no	yes	yes	yes	low	
Breet, 2010 20179285 Netherlands POPULAR	yes	yes	yes	low	low	NR	no	high	low	yes	yes	low	low	yes	yes	yes	yes	low	
Lindvall, 2009 19477870 Sweden None	yes	yes	yes	low	low	NR	yes	unclear	low	no	NR	high	high	no	yes	yes	yes	low	
Gurbel, 2003 12714161 USA No	NR	yes	yes	low	low	NR	no	high	unclear	No	NR	high	yes	No (30 days)	yes	yes	No (many had no data at 30 days)	high	
Kim, 2010 20449634 Korea NR	yes	yes	yes	low	low	NR	yes	unclear	high	Yes	NR	unclear	Low	no [6 months]	yes	yes	yes	Low	
Mobley, 2004 14969622 USA NONE	NR	yes	yes	low	low	NR	No	high	low	yes	NR	unclear	low	no	yes	yes	yes	low	
Siller-Matula, 2012 22260716 PEGASUS-PCI	yes	yes	yes	low	low	yes	yes	low	low	yes	NR	unclear	low	yes	yes	yes	yes	low	

Author, year [ref] UID Country Study Name	Patients selection					Index test				Reference standard				Flow and timing				
	1	2	3	ROB (selection)	Applicability (selection)	4	5	ROB (index)	Applicability (index)	6	7	ROB (reference)	Applicability (reference)	8	9	10	11	ROB (flow & timing)
Saad, 2012 22146578 Egypt NR	NR	yes	yes	low	low	NR	No	High	High	yes	yes	low	low	No [6 months]	yes	yes	yes	low
Lakkis, 2001 11458412 USA NR	NR	yes	yes	low	low	NR	no	high	high	no	NR	high	high	no	yes	yes	yes	low

- Consecutive or random sample of patients enrolled.
- Case-control design avoided
- Study avoided inappropriate exclusions
Risk of bias: could the selection of patients have introduced bias (If ≥2 of the above 3 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)
Concerns that the included patients do not match the review question?
- Index test results interpreted without knowledge of results of reference standard?
- If a threshold used, was it prespecified?
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Concerns that the index test, its conduct, or its interpretation differ from the review question?
- Reference standard likely to correctly classify the target condition?
- Reference standard results interpreted without knowledge of index test results?
Could the reference standard, its conduct, or its interpretation have introduced bias?
(If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)
Are there concerns that the target condition as defined by the reference standard does not match the review question?
- Appropriate interval between index test and reference standard?
- All patients received a reference standard?
- All patients received the same reference standard?
- Were all patients included in the analysis?
Could the patient flow have introduced bias? (If ≥3 of the above 4 questions are YES, give LOW here; if ≥2 are NO give HIGH; otherwise, give UNCLEAR)

Risk of Bias and Applicability Assessment Key

1. Consecutive or random sample of patients enrolled.
2. Case-control design avoided
3. Study avoided inappropriate exclusions

Risk of bias: could the selection of patients have introduced bias (if ≥ 2 of the above 3 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)

Applicability: Concerns that the included patients do not match the review question?

4. Index test results interpreted without knowledge of results of reference standard?
5. If a threshold used, was it prespecified?

Risk of bias: Could the conduct or interpretation of the index test have introduced bias? (if both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)

Applicability: Concerns that the index test, its conduct, or its interpretation differ from the review question?

6. Reference standard likely to correctly classify the target condition?
7. Reference standard results interpreted without knowledge of index test results?

Risk of bias: Could the reference standard, its conduct, or its interpretation have introduced bias? (If both of the above questions are YES, give LOW here; if one or both are NO, give HIGH; otherwise, give UNCLEAR)

Applicability: Are there concerns that the target condition as defined by the reference standard does not match the review question?

8. Appropriate interval between index test and reference standard?
9. All patients received a reference standard?
10. All patients received the same reference standard?
11. Were all patients included in the analysis?

Risk of bias: Could the patient flow have introduced bias? (If ≥ 3 of the above 4 questions are YES, give LOW here; if ≥ 2 are NO give HIGH; otherwise, give UNCLEAR)

Appendix F. Appendix Tables for Key Questions 3 and 4

Appendix Table F1. Assessment of risk of bias in comparative studies of test-and-treat strategies using genetic testing for CYP2C19 variants

Author Year Country PMID Study name (if available)	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
Roberts 2012 Canada 22464343 RAPID- GENE	Unclear	Low	High (6.5% of enrolled patients were not included in analyses)	Low (prospective assessment of genotype)	Unclear	Low	Unclear	High (maximum followup was 30 d)	Low	Low	Low (computer generated; block randomization)	Low (opaque, serially numbered, sealed envelopes)	High (patients were not masked to treatment allocation; cardiologists and data analysts were masked to genotype and subsequent treatment for the duration of the study)	Unclear	Low	Low	Low

Quality items

- Q1: Consecutive sample of patients enrolled
Q2: Case-control design avoided
Q3: Study avoided inappropriate exclusions and post-hoc exclusions were <5%
Q4: Index test results interpreted without knowledge of outcomes?
Q5: If a test threshold was used, was it prespecified?
Q6: Reference standard likely to correctly classify the target condition (low if at least one clinical outcome assessed)?
Q7: Reference standard results interpreted without knowledge of index test results?
Q8: Appropriate interval between index test and reference standard (at least 12 mo of followup)?
Q9: All patients received a reference standard (outcome data for >90% of patients)?
Q10: All patients received the same reference standard?
Q11: Random sequence generation
Q12: Allocation concealment
Q13: Blinding of participants and personnel
Q14: Blinding of outcome assessment
Q15: Incomplete outcome data (do they report enough data to estimate uncertainty for the primary outcome)
Q16: Selective reporting bias (do they report numerical results on the primary and secondary outcome; and are these identified in the methods)
Q17: Other bias (e.g., extreme numerical errors and inconsistencies)

Appendix Table F2. Assessment of risk of bias in studies of CYP2C19 genetic testing assessing treatment effect modification

Author Year Country PMID Study name (if available)	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
Pare* 2010 Multinational 20979470 CURE	High (selected patients from an RCT)	Low	High (included patients ~40% of the CURE trial population)	Unclear	Low (genotype grouping based on prior literature)	Low	Unclear	Unclear	Low	Low	Low (central, 24h, computerized randomization service)	Low (centralized computer generated randomization)	Low	Low (independent blind ascertainment)	Low	Low	Low
Pare† 2010 Multinational 20979470 ACTIVE-A	High (selected patients from an RCT)	Low	High (included patients ~15% of the ACTIVE-A population)	Unclear	Low (genotype grouping based on prior literature)	Low	Unclear	Unclear	Low	Low	Low (interactive phone system, varying blocks sizes)	Low (centralized, phone-based randomization)	Low	Low (independent blind ascertainment)	Low	Low	Low
Mega‡ 2009 Multinational 19106084§ 19414633 TRITON TIMI – 38	High (selected patients from an RCT)	Low	High (included patients ~22% of the TRITON TIMI – 38 population)	Unclear	Low (genotype grouping based on prior literature)	Low	Unclear	Low	Low	Low	Unclear	Unclear	Low	Low (independent blind ascertainment)	Low	Low	Low
Mega** 2010 Multinational 20801494 TRITON TIMI – 38	High (selected patients from an RCT)	Low	High (included patients ~22% of the TRITON TIMI – 38 population)	Unclear	Low (genotype grouping based on prior literature)	Low	Unclear	Low	Low	Low	Unclear	Unclear	Low	Low (independent blind ascertainment)	High (incomplete reporting in analyses relevant to this KQ)	High (missing numerical results for this KQ)	Low
Varenhorst†† 2009 Sweden 19429918 TABR	Unclear	Low	High (included ~90% of eligible patients)	Unclear	Low (genotype grouping based on prior literature)	High (no clinical outcomes)	Unclear	High (30 d)	Unclear	Low	Low (Interactive voice-response system; random permuted block randomization)	Low (centralized randomization)	Low	Unclear	High (inadequate data reported)	Low	Low

Author Year Country PMID Study name (if available)	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
Tantry†† 2010 USA and UK 21079055 ONSET/OFFSET and RESPOND Genotype Studies	Unclear	Low	High (included ~79% of the patients in the parent trial were included)	Unclear	High (multiple groupings of genotypes were evaluated)	High (no clinical outcomes)	Unclear	High (2-4 w)	Low	Low	Low (centralized, balanced block randomization)	Low (random allocation was performed as patients were entered in the study)	Low	Unclear	High (data only in graphical form)	High (incomplete reporting)	Low
Kim§§ 2011 S. Korea 21511217 ACCELAMI2C19	Unclear	Low	High (included ~90% of patients in the parent trial)	Unclear	Unclear (rationale for genotype grouping NR)	Low	Unclear	High (30d)	Low	Low	Low (computer- generated randomization sequence)	Unclear	Unclear	Unclear (study personnel assessed reactivity "blinded to the study protocol")	Low	Low	Low
Hwang*** 2010 S. Korea 20823393 ACCEL- RESISTANCE, DM, and COMPLEX trials (ACEL- POLYMORPHISM)	Unclear	Low	High (included ~89% of patients in the parent trial)	Unclear	Unclear (the authors cited a previous publication from their team)	High (no clinical outcomes)	Unclear	High (30 d)	Low	Low	Low (computer- generated randomization sequence)	High (randomization sequence was provided in envelopes)	Unclear	Low (study personnel assessed reactivity "blinded to group assignment")	Low	Low	Low
Gladding††† 2008 New Zealand 19463375 PRINC	Unclear	Low	Low (included 100% of patients in the parent trial)	Unclear	High (no rationale reported; data on some genotypes not presented)	High (no clinical outcomes)	Unclear	High (7 d)	Low	Low	Low (computer- generated randomized sequence)	Unclear	Low	Low	High (some data only in graphical form)	Low	High (results not reported for all genotypes observed)
Wallentin 2010 Multinational 20801498 PLATO	Unclear	Low	High (included ~55% of patients in the parent trial)	Unclear	Low (genotype grouping based on prior literature)	Low	Unclear	Low	Low	Low	Unclear	Unclear	Low	Low	Low	Low	High (results not reported for all genotypes observed)

Author Year Country PMID Study name (if available)	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
Park 2011 S. Korea 21345843 CILON-T	Unclear	Low	High (included ~85% of patients in the parent trial)	Unclear	Low (genotype and phenotypic grouping based on prior literature)	High (no clinical outcomes)	Unclear	High (until discharge)	Low	Low	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Low
Bhatt††† 2012 Multinational 22450429 CHARISMA	High (selected patients from an RCT)	Low	High (included ~45% of patients in the parent trial)	Unclear	Unclear	Low	Unclear	Low	Low	Low	Low (preestablished randomization scheme, stratified according to site)	Low (central; interactive voice-response system)	Low	Low	Low	Low	High (significant differences between patients enrolled in the parent trial and the genetic substudy)
Collet 2011 France 21511218 CLOVIS-2	Unclear	Low	Low (reported results on 96% of the enrolled patients)	Unclear	Low (enrollment in trial was stratified by baseline genotype status)	High (no clinical outcomes)	Low (reactivity measurement was blinded to genotype)	High (2 periods of 21 d)	Low	Low	Low (web- based, centralized randomization procedure)	Low (web- based, centralized randomization procedure)	High (open- label)	High (open- label)	Low	Low	Low

*Some information extracted from Yusuf et al. 2001 [PMID = 11519503].

†Some information extracted from Connolly et al. 2009 [PMID = 19336502].

‡Some information extracted from Wiviott et al. 2007 [PMID = 17982182]

§Detailed information on the clopidogrel treated arm of the TRITON TIMI 38 trial was provided in Mega et al. 2009 [PMID = 19106084]; detailed information on the prasugrel treated arm was provided in Mega et al. 2009 [PMID = 19414633]. Additional information was extracted from Wiviott et al. 2006 [PMID = 16996826] and Wiviott et al. 2007 [PMID = 17982182].

**Some information on the patient selection criteria and the treatments compared in the parent trial were extracted from Wiviott et al. 2007 [PMID = 17982182] and Wiviott et al. 2006 [PMID = 16996826].

††Some information extracted from Wallentin et al. 2008 [PMID = 18055486].

‡‡Some information extracted from Gurbel et al. 2008 [PMID = 19923168] and Gurbel et al. 2010 [PMID = 20194878].

§§Some information extracted from Jeong et al. 2010 [PMID = 20118150].

***Some information extracted from Jeong et al. 2009 [PMID = 19324253].

†††Some information extracted from Gladding et al. 2008 [PMID = 19463374].

‡‡‡Some information extracted from Bhatt et al. 2006 [PMID = 16531616].

Abbreviation: RCT = randomized controlled trial.

Quality items

Q1: Consecutive sample of patients enrolled

Q2: Case-control design avoided

Q3: Study avoided inappropriate exclusions and post-hoc exclusions were <5%

Q4: Index test results interpreted without knowledge of outcomes?

Q5: If a test threshold was used, was it prespecified?

Q6: Reference standard likely to correctly classify the target condition (low if at least one clinical outcome assessed)?

Q7: Reference standard results interpreted without knowledge of index test results?

Q8: Appropriate interval between index test and reference standard (at least 12 mo of followup)?

Q9: All patients received a reference standard (outcome data for >90% of patients)?

Q10: All patients received the same reference standard?

Q11: Random sequence generation

Q12: Allocation concealment

Q13: Blinding of participants and personnel

Q14: Blinding of outcome assessment

Q15: Incomplete outcome data (do they report enough data to estimate uncertainty for the primary outcome)

Q16: Selective reporting bias (do they report numerical results on the primary and secondary outcome; and are these identified in the methods)

Q17: Other bias (e.g., extreme numerical errors and inconsistencies)

Appendix Table F3. Assessment of risk of bias in the study of genetic test–based selection of patients

Author Year Country PMID Study name (if available)	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
Mega 2011 USA 22088980 ELEVATE-TIMI 56	Unclear	Low	Low (4% excluded after randomization)	Low	Low (enrollment in trial was stratified by baseline genotype status)	Low	Low	High (4 periods of 14 d)	Low	Low	Low (central; reports randomization system)	Low (central; interactive voice-response system)	Low	Low	Low	Low	Low

Quality items

- Q1: Consecutive sample of patients enrolled
- Q2: Case-control design avoided
- Q3: Study avoided inappropriate exclusions and post-hoc exclusions were <5%
- Q4: Index test results interpreted without knowledge of outcomes?
- Q5: If a test threshold was used, was it prespecified?
- Q6: Reference standard likely to correctly classify the target condition (low if at least one clinical outcome assessed)?
- Q7: Reference standard results interpreted without knowledge of index test results?
- Q8: Appropriate interval between index test and reference standard (at least 12 mo of followup)?
- Q9: All patients received a reference standard (outcome data for >90% of patients)?
- Q10: All patients received the same reference standard?
- Q11: Random sequence generation
- Q12: Allocation concealment
- Q13: Blinding of participants and personnel
- Q14: Blinding of outcome assessment
- Q15: Incomplete outcome data (do they report enough data to estimate uncertainty for the primary outcome)
- Q16: Selective reporting bias (do they report numerical results on the primary and secondary outcome; and are these identified in the methods)
- Q17: Other bias (e.g., extreme numerical errors and inconsistencies)

Appendix Table F4. Baseline and final (longest followup) values of laboratory outcomes (platelet reactivity) in comparative studies assessing test-and-treat strategies using phenotypic testing for platelet reactivity

Author Year Country PMID Study Name (if available)	Treatment Group	Outcome Measure	Baseline: N Mean SE/SD	Final: N Mean SE/SD	Within-Group Comparison P Value [statistical test]	Between-Group Comparison P Value [statistical test]
Wang 2011 China 21538380	VASP-guided treatment Control	VASP PRI	150 72.1% SD = 11.4% (1 mo post-PCI) 156 69.3% SD = 18% (1 mo post-PCI)	147 27.7% SD = 8.4% (12 mo post-PCI) 151 66.4% SD = 18.6% (12 mo post-PCI)	P = 0.001 across all time points [ANOVA] P>0.05 across all time points [ANOVA]	P = 0.4 at baseline [ANOVA] P < 0.001 at 12 mo [ANOVA]
Bonello 2009 France 19101221	VASP-guided treatment Control	VASP PRI	215 67% SD = 10% (6-24 h post loading) 214 66% SD = 11% (6-24 h post loading)	215 37% SD = 12% 30 d 214 NR NR 30 d	P<0.0001 compared to baseline [ANOVA] NR	P = 0.3 at baseline [ANOVA] P = NR at 30 d [ANOVA]

Author Year Country PMID Study Name (if available)	Treatment Group	Outcome Measure	Baseline: N Mean SE/SD	Final: N Mean SE/SD	Within-Group Comparison P Value [statistical test]	Between-Group Comparison P Value [statistical test]
Bonello 2008 France 18387444	VASP-guided treatment Control	VASP PRI	78 69.3% SD = 10.0% (24 h post loading) 84 67.8% SD = 10.5 (24 h post loading)	78 37.6 SD = 13.8% (30 d) 84 NR NR	P < 0.0001 compared to baseline [ANOVA]	P = 0.4 at baseline [ANOVA] P = NR at 30 d
Tousek 2011 Czech Republic 21663983	VerifyNow-guided treatment N = 30 Control N = 30	VerifyNow	30 297 SD = 37 (24–48 h post-PCI) 30 306 SD = 45 (24–48 h post-PCI)	30 201 SD = 56 (30 d post-PCI) 30 277 SD = 36 (30 d post-PCI)	P<0.001 compared to baseline [unclear] % change from baseline = –31.6 (SD = –17.1) P<0.01 (reported in graph) or P<0.001 (reported in text) [unclear] % change from baseline = –13.2 (SD = –9.4)	Mean difference between guided group and control group in % within-group change from baseline = –18.4 (95% CI –25.5 to –11.3); P<0.001 [unclear]

Abbreviations: ANOVA=analysis of variance, CI=confidence interval, d=days, mo=months, NA=not applicable, NR=not reported, OR=odds ratio, PRI=platelet reactivity index, SD=standard deviation, SE=standard error, VASP=vasodilator-stimulated phosphoprotein, yr=year.

Appendix Table F5. Assessment of risk of bias for comparative studies assessing test-and-treat strategies using phenotypic testing for platelet reactivity

Author Year Country PMID Study Name (if available)	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
Wang 2011 China 21538380	Low	Low	Low	Low	Low	Low	Unclear	Low	Low	Low	Unclear	Unclear	High	Low	Low	Low	High (numerous discrepancies between results and reported methods)
Bonello 2009 Italy 19101221	Unclear	Low	Low	Low	Low	Low	Unclear	High	Low	Low	Unclear	Unclear	High	Low	Low	Low	Unclear
Bonello 2008 Italy 18387444	Low	Low	Low	Low	Low	Low	Unclear	High	Low	Low	Unclear	Unclear	High	Low	Low	Low	High (statistically significant difference between groups in time-to-PCI may impact results)
Tousek 2011 Czech Republic 21663983	Low	Low	Low	Low	Low	Low	Unclear	High	Low	Low	Unclear	Unclear	Unclear	Unclear	Low	Low	Unclear
Aleil 2008 France 19463377 VASP-02	Unclear	Low	Low	Unclear (timing of outcomes and testing NR)	Low	Low	Unclear	High	Low	Low	Low (sequence provided by central lab)	Unclear (no details reported on how the random assignment information was provided to investigators)	High ("open")	High ("open")	High	High	Unclear
Hazarbasanov 2012 Bulgaria 22249353	Low	Low	Low	Low	Low (literature based; consensus recommendations)	Low	Unclear	High (6 mo)	Low	Low	Unclear	Low ("sealed envelopes")	High ("open- label")	High ("open- label")	Low	Low	Unclear
Siller-Matula 2012 Austria 22656044 MADONNA	Unclear	Low	Low	Low ("technicians" were blinded to outcomes)	Low (based on published literature)	Low	Unclear	High (30d)	Low	Low	High (not randomized)	High (not randomized; assignment based on treating center)	High (not blinded)	High (not blinded)	Low	Low	High (each intervention was used at a different research center)

Abbreviations: NR=not reported, PCI=percutaneous coronary intervention.

Quality items

Q1: Consecutive sample of patients enrolled

Q2: Case-control design avoided

Q3: Study avoided inappropriate exclusions and post-hoc exclusions were <5%

Q4: Index test results interpreted without knowledge of outcomes?
Q5: If a test threshold was used, was it prespecified?
Q6: Reference standard likely to correctly classify the target condition (low if at least one clinical outcome assessed)?
Q7: Reference standard results interpreted without knowledge of index test results?
Q8: Appropriate interval between index test and reference standard (at least 12 mo of followup)?
Q9: All patients received a reference standard (outcome data for >90% of patients)?
Q10: All patients received the same reference standard?
Q11: Random sequence generation
Q12: Allocation concealment
Q13: Blinding of participants and personnel
Q14: Blinding of outcome assessment
Q15: Incomplete outcome data (do they report enough data to estimate uncertainty for the primary outcome)
Q16: Selective reporting bias (do they report numerical results on the primary and secondary outcome; and are these identified in the methods)
Q17: Other bias (e.g., extreme numerical errors and inconsistencies)

Appendix Table F6. Assessment of risk of bias for studies assessing effect modification by platelet reactivity status

Author Year Country PMID Study name (if available)	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
Montalescot 2009 France 20062936 ACAPULCO	Unclear	Low	Low (93% of eligible patients received baseline testing)	Low	Low	Low	Unclear	High (2 w on each treatment)	High (only 73% of patients completed the trial)	Low	Unclear	Unclear	Low	Low	High (incomplete outcome reporting for items relevant to this review)	High	High (study terminated early with unequal number of terminated subjects in each arm)
Capranzano* 2012 USA 22431415	High (selected patients from an RCT)	Low	High (23% of patients in the parent trial withdrew after randomization and were not included in the analysis of reactivity)	Low	Low (literature based; consensus recommendations)	High	Unclear	High (2 periods of 14 d)	Low (among those included in reactivity substudy)	Low	Unclear	Unclear	Low	Low	Low	Low	Low
Sibbing† Germany 2012 22682553 ISAR-REACT 4	High (selected patients from an RCT)	Low	High (only included 33% of the patients in the parent trial)	Low	Low (literature based; consensus recommendations)	Low	Unclear	High (30 d)	Low	Low	Unclear	Low ("sealed opaque envelopes")	Low	Low	Low	Low	Unclear (patients for the platelet substudy were enrolled "at the core times of the central laboratory" and not at night or outside the core times)

*Some information extracted from Angiolillo et al. 2011 [PMID = 21614414].

†Some information extracted from Sibbing et al. 2011 [PMID = 22077909]

Quality items

Q1: Consecutive sample of patients enrolled

Q2: Case-control design avoided

Q3: Study avoided inappropriate exclusions and post-hoc exclusions were <5%

Q4: Index test results interpreted without knowledge of outcomes?

Q5: If a test threshold was used, was it prespecified?

Q6: Reference standard likely to correctly classify the target condition (low if at least one clinical outcome assessed)?

Q7: Reference standard results interpreted without knowledge of index test results?

Q8: Appropriate interval between index test and reference standard (at least 12 mo of followup)?

Q9: All patients received a reference standard (outcome data for >90% of patients)?

Q10: All patients received the same reference standard?

Q11: Random sequence generation

Q12: Allocation concealment

Q13: Blinding of participants and personnel

Q14: Blinding of outcome assessment

Q15: Incomplete outcome data (do they report enough data to estimate uncertainty for the primary outcome)

Q16: Selective reporting bias (do they report numerical results on the primary and secondary outcome; and are these identified in the methods)

Q17: Other bias (e.g., extreme numerical errors and inconsistencies)

Appendix Table F7. Assessment of risk of bias for studies of patients selected on the basis of platelet reactivity testing and then randomized into alternative antiplatelet

Author Year Country UID Study name (if available)	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17
Price 2011 Multinational 21406646 GRAVITAS	Unclear	Low	Low	Low	Low (protocol-specified)	Low	Low	High (6 mo)	Low	Low	Low (centralized, interactive voice-response system)	Low (encrypted reactivity values; central randomization)	Low (encrypted reactivity values and placebo- controlled design)	Low (blinded clinical events committee)	Low	Low	Low
Palmerini 2010 Italy 19604542 DOUBLE	Unclear	Low	High	Unclear	High (cut-off for response was based on prior literature; unclear choice of cut-off for selection of patients)	High (patients with AEs were excluded from analyses of reactivity; no other clinical outcomes assessed)	Unclear	High (1 mo)	Low	Low	Low (computer-generated random sequence)	Unclear	Unclear	Unclear	Low	Low	Low
Valgimigli 2009 Italy 19528337 3T/2R	Low (“all patients”)	Low	Low	Low	Low (threshold based on prior literature)	Low	Low	High (1 mo)	Low	Low	Low (block of 6, stratified (stable or unstable CAD; and response status) by a local nurse using sealed envelopes)	High (local randomization using envelopes)	Low	Low	Low (uncertainty in estimates was reported)	High (only limited outcomes were reported in the clopidogrel non- responsive patients)	Low
Cuisset 2008 France 19463379	Unclear	Low	Low	Unclear	Low (threshold based on prior literature)	Low	Unclear	High (1 mo)	Low	Low	Unclear	Unclear	Unclear	Unclear	Low	Low	Low
Gurbel 2010 Multinational (N. America and Europe) 20194878 RESPOND	Unclear	Low	High (>5% dropout)	Low	Low (single threshold used for stratification; unclear rationale)	High (no clinical outcomes)	Unclear	High (30 d)	Low	Low	Low (centralized block randomization)	Unclear	Low	Unclear	Low	Low	Low

*Despite including both responders and non-responders, this study was categorized as a study of randomized treatment after test-based selection because patients were assigned to different treatments during the course of the study based on their original response status.

Abbreviations: AE = adverse event; CAD = coronary artery disease; mo = month; PMID = PubMed identification number.

Quality items

Q1: Consecutive sample of patients enrolled

Q2: Case-control design avoided
Q3: Study avoided inappropriate exclusions and post-hoc exclusions were <5%
Q4: Index test results interpreted without knowledge of outcomes?
Q5: If a test threshold was used, was it prespecified?
Q6: Reference standard likely to correctly classify the target condition (low if at least one clinical outcome assessed)?
Q7: Reference standard results interpreted without knowledge of index test results?
Q8: Appropriate interval between index test and reference standard (at least 12 mo of followup)?
Q9: All patients received a reference standard (outcome data for >90% of patients)?
Q10: All patients received the same reference standard?
Q11: Random sequence generation
Q12: Allocation concealment
Q13: Blinding of participants and personnel
Q14: Blinding of outcome assessment
Q15: Incomplete outcome data (do they report enough data to estimate uncertainty for the primary outcome)
Q16: Selective reporting bias (do they report numerical results on the primary and secondary outcome; and are these identified in the methods)
Q17: Other bias (e.g., extreme numerical errors and inconsistencies)

Appendix G. Detailed Assessment of the Strength of Evidence

Appendix Table G1. Assessment of strength of evidence domains

Key Question	Population	Test/Assay	Outcome	Risk of bias	Directness	Consistency	Precision	Reporting bias	Other Issues/Notes	SOE and additional information
1a: What is the analytic validity of tests for genotyping CYP2C19 variants?	NA	Genotyping for any CYP2C19 variant		NA	NA	NA	NA	NA	Few studies provided information on analytic validity specifically using samples obtained from patient populations relevant to this review. When available, data were limited to test–retest reliability or inter-assay agreement.	SOE was not evaluated.
1b: What is the predictive value of genetic testing for CYP2C19 variants?	Ischemic heart disease	Genotyping for LOF CYP2C19 variants	Stent thrombosis	Intermediate	Direct	Consistent	Somewhat imprecise; but the lower bound of the confidence interval of the summary effect indicated a 17% increase in risk	Suspected (publication bias and selective outcome reporting)	None	Moderate
			MACE	Intermediate	Direct	Consistent	Precise	Suspected (publication bias)	None	Moderate
			Cardiovascular mortality	Intermediate	Direct	Consistent	Imprecise	Suspected (selective outcome reporting)	None	Low
			All other clinical outcomes	Intermediate	Direct	Consistent or not enough data to assess (single study)	Imprecise	Suspected (selective outcome reporting; in some cases publication bias)	None	Insufficient
		Genotyping for GOF CYP2C19 variants	MACE	Intermediate	Direct	Consistent	Somewhat imprecise	Suspected (selective outcome reporting)	None	Low
			All other clinical outcomes	Intermediate	Direct	Somewhat inconsistent for bleeding events; consistent for all other outcomes	Imprecise	Suspected (selective outcome reporting)	None	Insufficient

Key Question	Population	Test/Assay	Outcome	Risk of bias	Directness	Consistency	Precision	Reporting bias	Other Issues/Notes	SOE and additional information
	Other patient groups who are candidates for clopidogrel therapy	Genotyping for any CYP2C19 variants	All clinical outcomes	Intermediate	Direct	It was not possible to evaluate consistency because studies were conducted in diverse populations and reported information on different outcomes	Imprecise	Suspected (selective outcome reporting)	None	Insufficient

Key Question	Population	Test/Assay	Outcome	Risk of bias	Directness	Consistency	Precision	Reporting bias	Other Issues/Notes	SOE and additional information
1c: What factors affect the predictive value of genetic testing for CYP2C19 variants?	All patient populations	Genotyping for any CYP2C19 variants	All clinical outcomes	Intermediate	Direct	Inconsistent	Imprecise	Suspected (selective outcome reporting)	In meta-regression analyses we found some evidence of effect modification by ethnicity (East Asians vs. White) for MACE and stent thrombosis. However, this result was based on comparisons across studies, which may be confounded by other study characteristics, and was not corroborated by within-study analyses.	Insufficient
2a: What is the analytic validity of tests for on-clopidogrel platelet reactivity?	NA	All assays used to measure on-clopidogrel platelet reactivity	NA	NA	NA	NA	NA	NA	Few studies reported information on analytic sensitivity and specificity, possibly reflecting the research community's belief that there is no good reference standard assay for platelet reactivity. Agreement ranged from poor to moderate and was variable between tests. The highest agreement was observed between applications of the same assay with different concentrations of agonists, rather than between different assays.	SOE was not evaluated.
2b: What is the predictive ability of phenotypic testing for platelet reactivity?	Ischemic heart disease	LTA	All-cause mortality	Intermediate	Direct	It was not possible to evaluate consistency with respect to the effect size of the association because studies used different metrics and cut-offs for platelet reactivity. Qualitatively, studies were consistent in demonstrating an association between platelet reactivity and the outcomes of interest.	Study-level findings were generally imprecise	Suspected (selective outcome reporting)	Studies used heterogeneous methods to define increased reactivity	Low

Key Question	Population	Test/Assay	Outcome	Risk of bias	Directness	Consistency	Precision	Reporting bias	Other Issues/Notes	SOE and additional information
			Cardiovascular mortality	Intermediate	Direct	It was not possible to evaluate consistency with respect to the effect size of the association because studies used different metrics and cut-offs for platelet reactivity. Qualitatively, studies were consistent in demonstrating an association between platelet reactivity and the outcomes of interest.	Study-level findings were generally imprecise	Suspected (selective outcome reporting)	Studies used heterogeneous methods to define increased reactivity.	Low
			Acute coronary syndromes	Intermediate	Direct	It was not possible to evaluate consistency with respect to the effect size of the association because studies used different metrics and cut-offs for platelet reactivity. Qualitatively, studies were consistent in demonstrating an association between platelet reactivity and the outcomes of interest.	Study-level findings were generally imprecise	Suspected (selective outcome reporting)	Studies used heterogeneous methods to define increased reactivity	Low
			Stent thrombosis	Intermediate	Direct	It was not possible to evaluate consistency with respect to the effect size of the association because studies used different metrics and cut-offs for platelet reactivity. Qualitatively, studies were consistent in demonstrating an association between platelet reactivity and the outcomes of interest.	Study-level findings were generally imprecise	Suspected (selective outcome reporting)	Studies used heterogeneous methods to define increased reactivity	Low
			Stroke	Intermediate	Direct	It was not possible to evaluate consistency with respect to the effect size of the association because studies used different metrics and cut-offs for platelet reactivity. Qualitatively, studies were consistent in demonstrating an association between platelet reactivity and the outcomes of interest.	Study-level findings were generally imprecise	Suspected (selective outcome reporting)	Studies used heterogeneous methods to define increased reactivity	Low (for lack of association)

Key Question	Population	Test/Assay	Outcome	Risk of bias	Directness	Consistency	Precision	Reporting bias	Other Issues/Notes	SOE and additional information
			MACE	Intermediate	Direct	It was not possible to evaluate consistency with respect to the effect size of the association because studies used different metrics and cut-offs for platelet reactivity. Qualitatively, studies were consistent in demonstrating an association between platelet reactivity and the outcomes of interest.	Study-level findings were generally imprecise	Suspected (selective outcome reporting)	Studies used heterogeneous methods to define increased reactivity	Low
			All other clinical outcomes	Intermediate	Direct	It was not possible to evaluate consistency with respect to the effect size of the association because studies used different metrics and cut-offs for platelet reactivity. Qualitatively, studies were consistent in demonstrating an association between platelet reactivity and the outcomes of interest.	Study-level findings were generally imprecise	Suspected (selective outcome reporting)	Clinical and population heterogeneity or small number of studies limited our ability to draw conclusions. Studies used heterogeneous methods to define increased reactivity.	Insufficient
		VerifyNow	All-cause mortality	Intermediate	Direct	Consistent	Somewhat imprecise	Suspected (selective outcome reporting)	None	Low (for lack of association)
			Cardiovascular mortality	Intermediate	Direct	Consistent	Imprecise	Suspected (selective outcome reporting)	None	Moderate
			Acute coronary syndromes	Intermediate	Direct	Qualitatively consistent	Imprecise	Suspected (selective outcome reporting)	None	Low
			Stent thrombosis	Intermediate	Direct	Consistent	Imprecise	Suspected (publication bias and selective outcome reporting)	None	Low (for lack of association)

Key Question	Population	Test/Assay	Outcome	Risk of bias	Directness	Consistency	Precision	Reporting bias	Other Issues/Notes	SOE and additional information
			MACE	Intermediate	Direct	Somewhat inconsistent with regards to the magnitude of the effect size, but consistent with regards to the direction of effects	Imprecise	Suspected (publication bias and selective outcome reporting)	None	Moderate
			Bleeding events (major and all levels of severity combined)	Intermediate	Direct	Inconsistent for major events; consistent for all events	Imprecise for major events; precise for all events	Suspected (mainly selective outcome reporting)	None	Low (for lack of association)
			All other clinical outcomes	Intermediate	Direct	Few studies were available for each outcome of interest; results were somewhat inconsistent (when 2 or more studies were available)	Imprecise	Suspected (mainly selective outcome reporting)	Clinical heterogeneity and small number of studies limited our ability to draw conclusions	Insufficient
		VASP assay	Cardiovascular mortality	Intermediate	Direct	Somewhat inconsistent (estimates from individual studies indicated different directions of effect)	Imprecise	Suspected (mainly selective outcome reporting)	None	Insufficient
			Acute coronary syndromes	Intermediate	Direct	Consistent	Imprecise	Suspected (mainly selective outcome reporting)	None	Low (for lack of association)
			Stent thrombosis	Intermediate	Direct	Consistent	Imprecise	Suspected (mainly selective outcome reporting)	None	Low
			MACE	Intermediate	Direct	Inconsistent	Somewhat imprecise; but the lower bound of the confidence interval of the summary effect indicated a 21% increase in risk	Suspected (mainly selective outcome reporting)	None	Low

Key Question	Population	Test/Assay	Outcome	Risk of bias	Directness	Consistency	Precision	Reporting bias	Other Issues/Notes	SOE and additional information
			All other clinical outcomes	Intermediate	Direct	Few studies were available for each outcome of interest; results were somewhat inconsistent (when ≥2 studies were available)	Imprecise	Suspected (mainly selective outcome reporting)	Few studies reported information. Clinical heterogeneity or small number of studies limited our ability to draw conclusions.	Insufficient
		PFA-100	MACE	Intermediate	Direct	Qualitatively consistent	Imprecise	Not suspected	Heterogeneity in the methods used to define increased reactivity precluded definitive conclusions. Studies generally indicated an association between increase platelet reactivity and composite clinical outcomes.	Low
			All other clinical outcomes	Intermediate	Direct	Few studies were available for other outcomes; results were somewhat inconsistent when ≥2 studies were available for the same outcome	Imprecise	Suspected (mainly selective outcome reporting)	Few of the available studies reported information on other outcomes	Insufficient
		All other assays	All clinical outcomes	Intermediate	Direct	Qualitatively inconsistent	Imprecise	Suspected (mainly selective outcome reporting)	Few studies were available for each assay; when ≥2 studies were available for the same outcome they used heterogeneous metrics or thresholds to define increased reactivity or used different agonists for ex vivo stimulation of platelets	Insufficient
		Other patient groups who are candidates for clopidogrel therapy	All assays used to measure on-clopidogrel platelet reactivity	All clinical outcomes	Intermediate	Direct	NA (single study available for each population)	Imprecise	Suspected (mainly selective outcome reporting)	6 studies, using diverse assays to measure reactivity, were available in clinically heterogeneous populations. Studies were fairly small.
2c: What factors affect the predictive value of phenotypic testing for platelet reactivity?	All patient populations	All assays used to measure on-clopidogrel platelet reactivity	All clinical outcomes	Intermediate	Direct	Inconsistent (for factors evaluated by ≥2 studies)	Imprecise	Suspected (mainly selective outcome reporting)	7 studies provided information on effect modification; no factor was assessed by more than 3 studies. Effect modification by study-level factors could not be assessed for most assays–outcome pairs; when such analysis was possible (for VerifyNow MACE), results indicated substantial uncertainty.	Insufficient

Key Question	Population	Test/Assay	Outcome	Risk of bias	Directness	Consistency	Precision	Reporting bias	Other Issues/Notes	SOE and additional information
3a: What is the comparative effectiveness of alternative test-and-treat strategies	Ischemic heart disease	Genetic testing for CYP2C19 variants or phenotypic testing for platelet reactivity (all assays assessed)	All clinical outcomes	Low-Intermediate	Direct	NA (single study was available for each population/treatment strategy of interest)	Imprecise	Not suspected	Repurposed RCTs reported on non-random subsets of the populations included in the parent trials and were not specifically designed to assess effect modification; a single well-conducted RCT directly comparing test-based vs. non-test-based treatment had short followup and did not report any major clinical events.	Insufficient
		Phenotypic testing for platelet reactivity	All clinical outcomes	Intermediate - High	Direct	Generally qualitatively consistent (RCTs produced consistent results between them; the NRCS produced inconsistent results with those of RCTs for cardiovascular mortality)	Imprecise	Suspected (mainly selective outcome reporting)	None	Insufficient
	Atrial fibrillation	Genetic testing for CYP2C19 variants or phenotypic testing for platelet reactivity (all assays assessed)	All clinical outcomes	Intermediate	Direct	NA (single study)	Imprecise	Not suspected	1 study providing information on effect modification by CYP2C19 status was identified	Insufficient
		Phenotypic testing for platelet reactivity	All clinical outcomes	NA	NA	NA	NA	NA	No studies were identified	Insufficient
	Other patient populations	Genetic testing for CYP2C19 variants or phenotypic testing for platelet reactivity (all assays assessed)	All clinical outcomes	Intermediate	Direct	NA (single study)	Imprecise	Not suspected	1 study provided information on treatment effect modification in a mixed population of patients with atherothrombotic disease (cardiovascular, cerebrovascular, or peripheral arterial) along with asymptomatic individuals at risk for atherothrombotic disease	Insufficient

Key Question	Population	Test/Assay	Outcome	Risk of bias	Directness	Consistency	Precision	Reporting bias	Other Issues/Notes	SOE and additional information
		Phenotypic testing for platelet reactivity	All clinical outcomes	NA	NA	NA	NA	NA	No studies were identified	Insufficient
3b: What factors modify the comparative effectiveness of alternative test-and-treat strategies?	All patient populations	Genetic testing for CYP2C19 variants or phenotypic testing for platelet reactivity (all assays assessed)	All clinical outcomes	Intermediate	Direct	NA (each study assessed different effect modifiers)	Imprecise	Suspected (mainly selective outcome reporting)	None	Insufficient
4: What are the harms of testing? What are the harms of test-directed treatment?	All patient populations	Genetic testing for CYP2C19 variants	All clinical outcomes	Low-Intermediate (for the harms of test-directed treatment)	Direct (for the harms of test-directed treatment)	A single study was available for each population/treatment strategy of interest	Imprecise	Not suspected	No studies provided direct information on the harms of testing per se	Insufficient, both for harms of test-directed treatment and for harms of testing per se
		Phenotypic testing for platelet reactivity (all assays assessed)	All clinical outcomes	Intermediate - High	Indirect	NA (single study)	Imprecise	Suspected (mainly selective outcome reporting)	1 study reported delays in PCI due to repeat testing. No studies provided direct information on the harms of testing per se.	Insufficient, both for harms of test-directed treatment and for harms of testing per se

Abbreviations: CI = confidence interval; GOF = gain-of-function; LOF = loss-of-function; MACE = major adverse cardiovascular events; NA = not applicable; PCI = percutaneous coronary intervention; RR = relative risk; SOE = strength of evidence.